25763772|t|DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis
25763772|a|Pseudomonas aeruginosa (Pa) infection in cystic fibrosis (CF) patients is associated with worse long-term pulmonary disease and shorter survival, and chronic Pa infection (CPA) is associated with reduced lung function, faster rate of lung decline, increased rates of exacerbations and shorter survival. By using exome sequencing and extreme phenotype design, it was recently shown that isoforms of dynactin 4 (DCTN4) may influence Pa infection in CF, leading to worse respiratory disease. The purpose of this study was to investigate the role of DCTN4 missense variants on Pa infection incidence, age at first Pa infection and chronic Pa infection incidence in a cohort of adult CF patients from a single centre. Polymerase chain reaction and direct sequencing were used to screen DNA samples for DCTN4 variants. A total of 121 adult CF patients from the Cochin Hospital CF centre have been included, all of them carrying two CFTR defects: 103 developed at least 1 pulmonary infection with Pa, and 68 patients of them had CPA. DCTN4 variants were identified in 24% (29/121) CF patients with Pa infection and in only 17% (3/18) CF patients with no Pa infection. Of the patients with CPA, 29% (20/68) had DCTN4 missense variants vs 23% (8/35) in patients without CPA. Interestingly, p.Tyr263Cys tend to be more frequently observed in CF patients with CPA than in patients without CPA (4/68 vs 0/35), and DCTN4 missense variants tend to be more frequent in male CF patients with CPA bearing two class II mutations than in male CF patients without CPA bearing two class II mutations (P = 0.06). Our observations reinforce that DCTN4 missense variants, especially p.Tyr263Cys, may be involved in the pathogenesis of CPA in male CF.
25763772	0	5	DCTN4	T116,T123	C4308010
25763772	23	63	chronic Pseudomonas aeruginosa infection	T047	C0854135
25763772	67	82	cystic fibrosis	T047	C0010674
25763772	83	120	Pseudomonas aeruginosa (Pa) infection	T047	C0854135
25763772	124	139	cystic fibrosis	T047	C0010674
25763772	141	143	CF	T047	C0010674
25763772	145	153	patients	T101	C0030705
25763772	179	188	long-term	T079	C0443252
25763772	189	206	pulmonary disease	T047	C0024115
25763772	211	227	shorter survival	T169	C0220921
25763772	233	253	chronic Pa infection	T047	C0854135
25763772	255	258	CPA	T047	C0854135
25763772	279	300	reduced lung function	T033	C0847557
25763772	302	329	faster rate of lung decline	T033	C3160731
25763772	341	346	rates	T081	C1521828
25763772	350	363	exacerbations	T033	C4086268
25763772	368	384	shorter survival	T169	C0220921
25763772	395	411	exome sequencing	T063	C3640077
25763772	416	440	extreme phenotype design	T052	C1707689
25763772	469	477	isoforms	T116	C0597298
25763772	481	491	dynactin 4	T116,T123	C4308010
25763772	493	498	DCTN4	T116,T123	C4308010
25763772	514	526	Pa infection	T047	C0854135
25763772	530	532	CF	T047	C0010674
25763772	551	570	respiratory disease	T047	C0035204
25763772	592	597	study	T062	C2603343
25763772	605	616	investigate	T169	C1292732
25763772	629	634	DCTN4	T116,T123	C4308010
25763772	635	643	missense	T033	C3845273
25763772	644	652	variants	T116	C0597298
25763772	656	668	Pa infection	T047	C0854135
25763772	669	678	incidence	T081	C0021149
25763772	680	683	age	T032	C0001779
25763772	693	705	Pa infection	T047	C0854135
25763772	710	730	chronic Pa infection	T047	C0854135
25763772	731	740	incidence	T081	C0021149
25763772	746	752	cohort	T098	C0599755
25763772	756	761	adult	T100	C0001675
25763772	762	764	CF	T047	C0010674
25763772	765	773	patients	T101	C0030705
25763772	788	794	centre	T073,T093	C0475309
25763772	796	821	Polymerase chain reaction	T063	C0032520
25763772	826	843	direct sequencing	T063	C3899368
25763772	864	875	DNA samples	T026	C0444245
25763772	880	885	DCTN4	T116,T123	C4308010
25763772	886	894	variants	T116	C0597298
25763772	911	916	adult	T100	C0001675
25763772	917	919	CF	T047	C0010674
25763772	920	928	patients	T101	C0030705
25763772	938	963	Cochin Hospital CF centre	T073,T093	C0019994
25763772	1009	1013	CFTR	T028	C1413365
25763772	1014	1021	defects	T169	C0243067
25763772	1048	1067	pulmonary infection	T047	C0876973
25763772	1073	1075	Pa	T007	C0033809
25763772	1084	1092	patients	T101	C0030705
25763772	1105	1108	CPA	T047	C0854135
25763772	1110	1115	DCTN4	T116,T123	C4308010
25763772	1116	1124	variants	T116	C0597298
25763772	1157	1159	CF	T047	C0010674
25763772	1160	1168	patients	T101	C0030705
25763772	1174	1186	Pa infection	T047	C0854135
25763772	1210	1212	CF	T047	C0010674
25763772	1213	1221	patients	T101	C0030705
25763772	1230	1242	Pa infection	T047	C0854135
25763772	1251	1259	patients	T101	C0030705
25763772	1265	1268	CPA	T047	C0854135
25763772	1286	1291	DCTN4	T116,T123	C4308010
25763772	1292	1300	missense	T033	C3845273
25763772	1301	1309	variants	T116	C0597298
25763772	1327	1335	patients	T101	C0030705
25763772	1344	1347	CPA	T047	C0854135
25763772	1364	1375	p.Tyr263Cys	T116	C0597298
25763772	1415	1417	CF	T047	C0010674
25763772	1418	1426	patients	T101	C0030705
25763772	1432	1435	CPA	T047	C0854135
25763772	1444	1452	patients	T101	C0030705
25763772	1461	1464	CPA	T047	C0854135
25763772	1485	1490	DCTN4	T116,T123	C4308010
25763772	1491	1499	missense	T033	C3845273
25763772	1500	1508	variants	T116	C0597298
25763772	1537	1541	male	T032	C0086582
25763772	1542	1544	CF	T047	C0010674
25763772	1545	1553	patients	T101	C0030705
25763772	1559	1562	CPA	T047	C0854135
25763772	1575	1593	class II mutations	T045	C0026882
25763772	1602	1606	male	T032	C0086582
25763772	1607	1609	CF	T047	C0010674
25763772	1610	1618	patients	T101	C0030705
25763772	1627	1630	CPA	T047	C0854135
25763772	1643	1661	class II mutations	T045	C0026882
25763772	1706	1711	DCTN4	T116,T123	C4308010
25763772	1712	1720	missense	T033	C3845273
25763772	1721	1729	variants	T116	C0597298
25763772	1742	1753	p.Tyr263Cys	T116	C0597298
25763772	1778	1790	pathogenesis	T046	C0699748
25763772	1794	1797	CPA	T047	C0854135
25763772	1801	1805	male	T032	C0086582
25763772	1806	1808	CF	T047	C0010674

25847295|t|Nonylphenol diethoxylate inhibits apoptosis induced in PC12 cells
25847295|a|Nonylphenol and short-chain nonylphenol ethoxylates such as NP2 EO are present in aquatic environment as wastewater contaminants, and their toxic effects on aquatic species have been reported. Apoptosis has been shown to be induced by serum deprivation or copper treatment. To understand the toxicity of nonylphenol diethoxylate, we investigated the effects of NP2 EO on apoptosis induced by serum deprivation and copper by using PC12 cell system. Nonylphenol diethoxylate itself showed no toxicity and recovered cell viability from apoptosis. In addition, nonylphenol diethoxylate decreased DNA fragmentation caused by apoptosis in PC12 cells. This phenomenon was confirmed after treating apoptotic PC12 cells with nonylphenol diethoxylate, whereas the cytochrome c release into the cytosol decreased as compared to that in apoptotic cells not treated with nonylphenol diethoxylate s. Furthermore, Bax contents in apoptotic cells were reduced after exposure to nonylphenol diethoxylate. Thus, nonylphenol diethoxylate has the opposite effect on apoptosis in PC12 cells compared to nonylphenol, which enhances apoptosis induced by serum deprivation. The difference in structure of the two compounds is hypothesized to be responsible for this phenomenon. These results indicated that nonylphenol diethoxylate has capability to affect cell differentiation and development and has potentially harmful effect on organisms because of its unexpected impact on apoptosis. Â© 2015 Wiley Periodicals, Inc. Environ Toxicol 31: 1389-1398, 2016.
25847295	0	24	Nonylphenol diethoxylate	T131	C1254354
25847295	25	33	inhibits	T052	C3463820
25847295	34	43	apoptosis	T043	C0162638
25847295	44	51	induced	T169	C0205263
25847295	55	65	PC12 cells	T025	C0085262
25847295	66	77	Nonylphenol	T131	C1254354
25847295	82	117	short-chain nonylphenol ethoxylates	T131	C1254354
25847295	126	132	NP2 EO	T131	C1254354
25847295	137	144	present	T033	C0150312
25847295	148	167	aquatic environment	T067	C0563034
25847295	171	181	wastewater	T069	C3494254
25847295	182	194	contaminants	T167	C2827365
25847295	206	219	toxic effects	T037	C0600688
25847295	223	238	aquatic species	T001	C0596121
25847295	259	268	Apoptosis	T043	C0162638
25847295	290	297	induced	T169	C0205263
25847295	301	306	serum	T031	C0229671
25847295	307	318	deprivation	T080	C0871712
25847295	322	328	copper	T121,T123,T196	C0009968
25847295	329	338	treatment	T169	C1522326
25847295	358	366	toxicity	T080	C0040539
25847295	370	394	nonylphenol diethoxylate	T131	C1254354
25847295	416	426	effects of	T080	C1704420
25847295	427	433	NP2 EO	T131	C1254354
25847295	437	446	apoptosis	T043	C0162638
25847295	447	454	induced	T169	C0205263
25847295	458	463	serum	T031	C0229671
25847295	464	475	deprivation	T080	C0871712
25847295	480	486	copper	T121,T123,T196	C0009968
25847295	496	512	PC12 cell system	T025	C0085262
25847295	514	538	Nonylphenol diethoxylate	T131	C1254354
25847295	579	593	cell viability	T043	C0007620
25847295	599	608	apoptosis	T043	C0162638
25847295	623	647	nonylphenol diethoxylate	T131	C1254354
25847295	648	657	decreased	T081	C0205216
25847295	658	675	DNA fragmentation	T044	C0376669
25847295	686	695	apoptosis	T043	C0162638
25847295	699	709	PC12 cells	T025	C0085262
25847295	716	726	phenomenon	T067	C1882365
25847295	747	755	treating	T169	C1522326
25847295	756	765	apoptotic	T080	C1516044
25847295	766	776	PC12 cells	T025	C0085262
25847295	782	806	nonylphenol diethoxylate	T131	C1254354
25847295	820	832	cytochrome c	T116,T126	C0010749
25847295	850	857	cytosol	T026	C1383501
25847295	858	867	decreased	T081	C0205216
25847295	891	906	apoptotic cells	T025	C0007634
25847295	911	918	treated	T169	C1522326
25847295	924	948	nonylphenol diethoxylate	T131	C1254354
25847295	965	968	Bax	T116,T123	C0219474
25847295	969	977	contents	T077	C0456205
25847295	981	996	apoptotic cells	T025	C0007634
25847295	1002	1009	reduced	T080	C0392756
25847295	1016	1027	exposure to	T080	C0332157
25847295	1028	1052	nonylphenol diethoxylate	T131	C1254354
25847295	1060	1084	nonylphenol diethoxylate	T131	C1254354
25847295	1093	1108	opposite effect	T080	C1280500
25847295	1112	1121	apoptosis	T043	C0162638
25847295	1125	1135	PC12 cells	T025	C0085262
25847295	1148	1159	nonylphenol	T131	C1254354
25847295	1167	1175	enhances	T052	C2349975
25847295	1176	1185	apoptosis	T043	C0162638
25847295	1186	1193	induced	T169	C0205263
25847295	1197	1202	serum	T031	C0229671
25847295	1203	1214	deprivation	T080	C0871712
25847295	1220	1230	difference	T080	C1705242
25847295	1234	1243	structure	T082	C0678594
25847295	1255	1264	compounds	T103	C0220806
25847295	1268	1280	hypothesized	T078	C1512571
25847295	1308	1318	phenomenon	T067	C1882365
25847295	1326	1333	results	T033	C2825142
25847295	1349	1373	nonylphenol diethoxylate	T131	C1254354
25847295	1378	1388	capability	T080	C2698977
25847295	1399	1419	cell differentiation	T043	C0007589
25847295	1424	1435	development	T039	C0243107
25847295	1444	1455	potentially	T080	C3245505
25847295	1456	1470	harmful effect	T037	C0600688
25847295	1474	1483	organisms	T001	C0029235
25847295	1510	1516	impact	T080	C4049986
25847295	1520	1529	apoptosis	T043	C0162638

26316050|t|Prevascularized silicon membranes for the enhancement of transport to implanted medical devices
26316050|a|Recent advances in drug delivery and sensing devices for in situ applications are limited by the diffusion -limiting foreign body response of fibrous encapsulation. In this study, we fabricated prevascularized synthetic device ports to help mitigate this limitation. Membranes with rectilinear arrays of square pores with widths ranging from 40 to 200 Î¼m were created using materials (50 Î¼m thick double-sided polished silicon) and processes (photolithography and directed reactive ion etching) common in the manufacturing of microfabricated sensors. Vascular endothelial cells responded to membrane geometry by either forming vascular tubes that extended through the pore or completely filling membrane pores after 4 days in culture. Although tube formation began to predominate overgrowth around 75 Î¼m and continued to increase at even larger pore sizes, tubes formed at these large pore sizes were not completely round and had relatively thin walls. Thus, the optimum range of pore size for prevascularization of these membranes was estimated to be 75-100 Î¼m. This study lays the foundation for creating a prevascularized port that can be used to reduce fibrous encapsulation and thus enhance diffusion to implanted medical devices and sensors. Â© 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 104B: 1602-1609, 2016.
26316050	0	15	Prevascularized	T169	C0042382
26316050	16	23	silicon	T109,T122	C0037114
26316050	24	33	membranes	T073	C1706182
26316050	42	53	enhancement	T052	C2349975
26316050	57	66	transport	T169	C1705822
26316050	70	95	implanted medical devices	T033	C2828363
26316050	115	128	drug delivery	T074	C0085104
26316050	133	148	sensing devices	T073	C0183210
26316050	153	160	in situ	T082	C0444498
26316050	161	173	applications	T058	C0185125
26316050	178	185	limited	T169	C0439801
26316050	193	202	diffusion	T070	C0012222
26316050	213	234	foreign body response	T033	C1708386
26316050	238	245	fibrous	T080	C0439709
26316050	246	259	encapsulation	T067	C2348438
26316050	290	305	prevascularized	T169	C0042382
26316050	306	328	synthetic device ports	T073	C1706409
26316050	337	345	mitigate	T067	C1553901
26316050	351	361	limitation	T169	C0449295
26316050	363	372	Membranes	T073	C1706182
26316050	378	396	rectilinear arrays	T082	C1254362
26316050	400	406	square	T082	C0205120
26316050	407	412	pores	T082	C1254362
26316050	418	424	widths	T081	C0487742
26316050	470	479	materials	T167	C0520510
26316050	487	492	thick	T080	C1280412
26316050	493	505	double-sided	T082	C1254362
26316050	506	522	polished silicon	T109,T122	C0037114
26316050	528	537	processes	T067	C1522240
26316050	539	555	photolithography	T057	C0599199
26316050	560	589	directed reactive ion etching	T067	C1254366
26316050	605	618	manufacturing	T057	C0870840
26316050	622	645	microfabricated sensors	T073	C0183210
26316050	647	673	Vascular endothelial cells	T025	C1257792
26316050	687	704	membrane geometry	T073	C1706182
26316050	723	737	vascular tubes	T023	C0005847
26316050	743	751	extended	T082	C0231449
26316050	764	768	pore	T082	C1254362
26316050	772	782	completely	T080	C0205197
26316050	783	790	filling	T052	C0441655
26316050	783	790	filling	T052	C0441655
26316050	791	799	membrane	T073	C1706182
26316050	800	805	pores	T082	C1254362
26316050	822	829	culture	T059	C1331092
26316050	840	854	tube formation	T169	C0042382
26316050	864	875	predominate	T080	C0332251
26316050	876	886	overgrowth	T033	C1849265
26316050	917	925	increase	T169	C0442805
26316050	934	940	larger	T081	C0549177
26316050	941	951	pore sizes	T081	C3829176
26316050	953	965	tubes formed	T169	C0042382
26316050	975	980	large	T081	C0549177
26316050	981	991	pore sizes	T081	C3829176
26316050	1001	1011	completely	T080	C0205197
26316050	1012	1017	round	T082	C0332490
26316050	1037	1041	thin	T080	C0205168
26316050	1042	1047	walls	T082	C0442069
26316050	1059	1066	optimum	T080	C2698651
26316050	1067	1072	range	T081	C1514721
26316050	1076	1085	pore size	T081	C3829176
26316050	1090	1108	prevascularization	T169	C0042382
26316050	1118	1127	membranes	T073	C1706182
26316050	1132	1141	estimated	T081	C0750572
26316050	1164	1169	study	T062	C2603343
26316050	1205	1220	prevascularized	T169	C0042382
26316050	1221	1225	port	T073	C1706409
26316050	1253	1260	fibrous	T080	C0439709
26316050	1261	1274	encapsulation	T067	C2348438
26316050	1284	1291	enhance	T052	C2349975
26316050	1292	1301	diffusion	T070	C0012222
26316050	1305	1330	implanted medical devices	T033	C2828363
26316050	1335	1342	sensors	T073	C0183210

26406200|t|Seated maximum flexion: An alternative to standing maximum flexion for determining presence of flexion - relaxation?
26406200|a|The flexion - relaxation phenomenon (FRP) in standing is a specific and sensitive diagnostic tool for low back pain. Seated flexion as an alternative could be beneficial for certain populations, yet the behavior of the trunk extensors during seated maximum flexion compared to standing flexion remains unclear. Compare FRP occurrences and spine angles between seated and standing flexion postures in three levels of the erector spinae muscles. Thirty-one participants free of back pain performed seated and standing maximum trunk flexion. Electromyographical signals were recorded from the bilateral lumbar (L3), lower-thoracic (T9), and upper-thoracic (T4) erector spinae and assessed for the occurrence of FRP. Spine angles corresponding to FRP onset and cessation were determined, and FRP occurrences and angles were compared between posture and muscle. FRP occurrence was similar in standing and seated maximum flexion across all muscles, with the lumbar muscles showing the greatest consistency. Standing FRP onset and cessation angles were consistently greater than the corresponding seated FRP angles. Considering the similar number of FRP occurrences, seated maximum flexion may constitute an objective criterion for low back pain diagnosis. Future work should seek to confirm the utility of this test in individuals with low back pain.
26406200	0	6	Seated	T033	C0277814
26406200	7	14	maximum	T081	C0806909
26406200	15	22	flexion	T042	C0231452
26406200	27	38	alternative	T077	C1523987
26406200	42	50	standing	T082	C0231472
26406200	51	58	maximum	T081	C0806909
26406200	59	66	flexion	T042	C0231452
26406200	95	102	flexion	T042	C0231452
26406200	105	115	relaxation	T052	C0035028
26406200	121	128	flexion	T042	C0231452
26406200	131	141	relaxation	T052	C0035028
26406200	142	152	phenomenon	T067	C1882365
26406200	154	157	FRP	T067	C1882365
26406200	162	170	standing	T082	C0231472
26406200	176	184	specific	T080	C0205369
26406200	189	198	sensitive	T169	C0332324
26406200	199	214	diagnostic tool	T060	C0430022
26406200	219	232	low back pain	T184	C0024031
26406200	234	248	Seated flexion	T042	C0231452
26406200	255	266	alternative	T077	C1523987
26406200	299	310	populations	T098	C1257890
26406200	336	351	trunk extensors	T024	C0026845
26406200	359	365	seated	T033	C0277814
26406200	366	373	maximum	T081	C0806909
26406200	374	381	flexion	T042	C0231452
26406200	394	402	standing	T082	C0231472
26406200	403	410	flexion	T042	C0231452
26406200	436	439	FRP	T067	C1882365
26406200	456	461	spine	T023	C0037949
26406200	462	468	angles	T082	C0205143
26406200	477	483	seated	T033	C0277814
26406200	488	496	standing	T082	C0231472
26406200	497	504	flexion	T042	C0231452
26406200	505	513	postures	T032	C0231476
26406200	523	529	levels	T080	C0441889
26406200	537	559	erector spinae muscles	T023	C0224301
26406200	572	584	participants	T098	C0679646
26406200	593	602	back pain	T184	C0004604
26406200	613	619	seated	T033	C0277814
26406200	624	632	standing	T082	C0231472
26406200	633	640	maximum	T081	C0806909
26406200	641	646	trunk	T029	C0460005
26406200	647	654	flexion	T042	C0231452
26406200	656	683	Electromyographical signals	T067	C1710082
26406200	707	728	bilateral lumbar (L3)	T023	C0223522
26406200	730	749	lower-thoracic (T9)	T023	C0459954
26406200	755	774	upper-thoracic (T4)	T023	C1180431
26406200	775	789	erector spinae	T023	C0224301
26406200	794	802	assessed	T052	C1516048
26406200	825	828	FRP	T067	C1882365
26406200	830	842	Spine angles	T082	C0205143
26406200	860	863	FRP	T067	C1882365
26406200	874	883	cessation	T052	C1880019
26406200	905	908	FRP	T067	C1882365
26406200	925	931	angles	T082	C0205143
26406200	937	945	compared	T052	C1707455
26406200	954	961	posture	T032	C0231476
26406200	966	972	muscle	T024	C0026845
26406200	974	977	FRP	T067	C1882365
26406200	1004	1012	standing	T082	C0231472
26406200	1017	1023	seated	T033	C0277814
26406200	1024	1031	maximum	T081	C0806909
26406200	1032	1039	flexion	T042	C0231452
26406200	1051	1058	muscles	T024	C0026845
26406200	1069	1083	lumbar muscles	T024	C0026845
26406200	1105	1116	consistency	T080	C0332529
26406200	1118	1126	Standing	T082	C0231472
26406200	1127	1130	FRP	T067	C1882365
26406200	1141	1150	cessation	T052	C1880019
26406200	1207	1213	seated	T033	C0277814
26406200	1214	1217	FRP	T067	C1882365
26406200	1260	1263	FRP	T067	C1882365
26406200	1277	1283	seated	T033	C0277814
26406200	1284	1291	maximum	T081	C0806909
26406200	1292	1299	flexion	T042	C0231452
26406200	1328	1337	criterion	T078	C0243161
26406200	1342	1355	low back pain	T184	C0024031
26406200	1356	1365	diagnosis	T033	C0011900
26406200	1422	1426	test	T169	C0039593
26406200	1430	1441	individuals	T098	C0027361
26406200	1447	1460	low back pain	T184	C0024031

26424709|t|The Relationship Between Distance and Post-operative Visit Attendance Following Medical Male Circumcision in Nyanza Province, Kenya
26424709|a|To date, there is no research on voluntary medical male circumcision (VMMC) catchment areas or the relationship between distance to a VMMC facility and attendance at a post-operative follow-up visit. We analyzed data from a randomly selected subset of males self-seeking circumcision at one of 16 participating facilities in Nyanza Province, Kenya between 2008 and 2010. Among 1437 participants, 46.7 % attended follow-up. The median distance from residence to utilized facility was 2.98 km (IQR 1.31-5.38). Nearly all participants (98.8 %) lived within 5 km from a facility, however, 26.3 % visited a facility more than 5 km away. Stratified results demonstrated that among those utilizing fixed facilities, greater distance was associated with higher odds of follow-up non-attendance (OR 5.01-10km vs. 0-1km = 1.71, 95 % CI 1.08, 2.70, p = 0.02; OR >10km vs. 0-1 km = 2.80, 95 % CI 1.26, 6.21, p = 0.01), adjusting for age and district of residence. We found 5 km marked the threshold distance beyond which follow-up attendance significantly dropped. These results demonstrate distance is an important predictor of attending follow-up, and this relationship appears to be modified by facility type.
26424709	4	16	Relationship	T080	C0439849
26424709	25	33	Distance	T081	C0012751
26424709	38	52	Post-operative	T033	C0241311
26424709	53	58	Visit	T053	C0545082
26424709	59	69	Attendance	T052	C2827364
26424709	80	87	Medical	T169	C0205476
26424709	88	105	Male Circumcision	T061	C0008819
26424709	109	124	Nyanza Province	T083	C1514578
26424709	126	131	Kenya	T083	C0022558
26424709	153	161	research	T062	C0035168
26424709	165	174	voluntary	T055	C0439656
26424709	175	182	medical	T169	C0205476
26424709	183	200	male circumcision	T061	C0008819
26424709	202	206	VMMC	T061	C0008819
26424709	208	223	catchment areas	T083	C0007403
26424709	231	243	relationship	T080	C0439849
26424709	252	260	distance	T081	C0012751
26424709	266	270	VMMC	T061	C0008819
26424709	271	279	facility	T073,T093	C0018704
26424709	284	294	attendance	T052	C2827364
26424709	300	314	post-operative	T033	C0241311
26424709	315	330	follow-up visit	T058	C0589121
26424709	335	343	analyzed	T062	C0936012
26424709	344	348	data	T078	C1511726
26424709	356	364	randomly	T080	C0439605
26424709	365	373	selected	T052	C1707391
26424709	374	380	subset	T185	C1515021
26424709	384	389	males	T098	C0025266
26424709	390	415	self-seeking circumcision	T061	C0008819
26424709	429	442	participating	T169	C0679823
26424709	443	453	facilities	T073,T093	C0018704
26424709	457	472	Nyanza Province	T083	C1514578
26424709	474	479	Kenya	T083	C0022558
26424709	514	526	participants	T098	C0679646
26424709	535	543	attended	T169	C1456498
26424709	544	553	follow-up	T058	C1522577
26424709	559	565	median	T082	C2939193
26424709	566	574	distance	T081	C0012751
26424709	580	589	residence	T082	C0237096
26424709	602	610	facility	T073,T093	C0018704
26424709	624	627	IQR	T081	C1711350
26424709	651	663	participants	T098	C0679646
26424709	673	678	lived	T052	C2982691
26424709	698	706	facility	T073,T093	C0018704
26424709	724	731	visited	T053	C0545082
26424709	734	742	facility	T073,T093	C0018704
26424709	764	774	Stratified	T080	C0205363
26424709	775	782	results	T169	C1274040
26424709	823	828	fixed	T169	C0205245
26424709	829	839	facilities	T073,T093	C0018704
26424709	841	848	greater	T081	C1704243
26424709	849	857	distance	T081	C0012751
26424709	862	877	associated with	T080	C0332281
26424709	878	884	higher	T080	C0205250
26424709	885	889	odds	T081	C0028873
26424709	893	902	follow-up	T058	C1522577
26424709	903	917	non-attendance	T052	C2827364
26424709	919	921	OR	T081	C0028873
26424709	955	957	CI	T081	C0009667
26424709	980	982	OR	T081	C0028873
26424709	1013	1015	CI	T081	C0009667
26424709	1053	1056	age	T032	C0001779
26424709	1061	1069	district	UnknownType	C0681784
26424709	1073	1082	residence	T082	C0237096
26424709	1109	1118	threshold	T080	C0449864
26424709	1119	1127	distance	T081	C0012751
26424709	1141	1150	follow-up	T058	C1522577
26424709	1151	1161	attendance	T052	C2827364
26424709	1162	1175	significantly	T078	C0750502
26424709	1176	1183	dropped	T081	C0205216
26424709	1191	1198	results	T169	C1274040
26424709	1211	1219	distance	T081	C0012751
26424709	1236	1245	predictor	T078	C2698872
26424709	1249	1258	attending	T169	C1999232
26424709	1259	1268	follow-up	T058	C1522577
26424709	1279	1291	relationship	T080	C0439849
26424709	1306	1317	modified by	T080	C0205349
26424709	1318	1326	facility	T073,T093	C0018704
26424709	1327	1331	type	T080	C0332307

26476440|t|Promoting lifestyle behaviour change and well-being in hospital patients: a pilot study of an evidence-based psychological intervention
26476440|a|Lifestyle risk behaviours show an inverse social gradient, clustering in vulnerable groups. We designed and piloted an intervention to address barriers to lifestyle behaviour change among hospital patients. We designed our intervention using effective components of behaviour change interventions informed by psychological theory. Delivered by a health psychologist based at the Royal Free London NHS Foundation Trust, the 4-week intervention included detailed baseline assessment, personalized goal setting, psychological skills development, motivation support and referral to community services. Primary outcomes were feasibility and patient acceptability. We also evaluated changes to health and well-being. From 1 July 2013 to 31 September 2014, 686 patients were referred, 338 (49.3%) attended a first appointment and 172 (25.1%) completed follow-up. Furthermore, 72.1% of attenders were female with the median age 55 years and poor self-reported baseline health. After 4 weeks, self-efficacy, health and well-being scores significantly improved: 63% of lifestyle goals and 89% of health management goals were fully achieved; 58% of referrals to community lifestyle behaviour change services and 79% of referrals to other services (e.g. Citizen's Advice Bureau) were accepted; 99% were satisfied / very satisfied with the service. Our hospital-based intervention was feasible, acceptable and showed preliminary health and well-being gains.
26476440	0	9	Promoting	T052	C0033414
26476440	10	36	lifestyle behaviour change	T054	C0870811
26476440	41	51	well-being	T033	C0424578
26476440	55	72	hospital patients	T101	C0021562
26476440	76	87	pilot study	T062	C0031928
26476440	109	122	psychological	T169	C0205486
26476440	123	135	intervention	T061	C0184661
26476440	146	161	risk behaviours	T055	C0086931
26476440	170	177	inverse	T080	C0439850
26476440	178	184	social	T169	C0728831
26476440	185	193	gradient	T081	C0812409
26476440	195	205	clustering	T081	C1704332
26476440	209	226	vulnerable groups	T098	C1257890
26476440	255	267	intervention	T061	C0184661
26476440	291	317	lifestyle behaviour change	T054	C0870811
26476440	324	341	hospital patients	T101	C0021562
26476440	359	371	intervention	T061	C0184661
26476440	402	418	behaviour change	T055	C0542299
26476440	419	432	interventions	T061	C0184661
26476440	445	465	psychological theory	T170	C0033906
26476440	482	501	health psychologist	T097	C1555909
26476440	515	553	Royal Free London NHS Foundation Trust	T093	C0596660
26476440	566	578	intervention	T061	C0184661
26476440	597	616	baseline assessment	T058	C0558020
26476440	618	630	personalized	T080	C1709510
26476440	631	643	goal setting	T061	C0700350
26476440	645	677	psychological skills development	T041	C0678967
26476440	679	697	motivation support	T058	C0600015
26476440	702	713	referral to	T058	C2585021
26476440	714	732	community services	T095	C0009482
26476440	734	750	Primary outcomes	T169	C1274040
26476440	772	779	patient	T101	C0030705
26476440	780	793	acceptability	T080	C0000898
26476440	813	820	changes	T169	C0392747
26476440	824	830	health	T078	C0018684
26476440	835	845	well-being	T033	C0424578
26476440	854	858	July	T080	C3829447
26476440	870	879	September	T079	C3828193
26476440	890	898	patients	T101	C0030705
26476440	904	912	referred	T169	C0205543
26476440	943	954	appointment	T079	C0003629
26476440	981	990	follow-up	T058	C1522577
26476440	1014	1023	attenders	T097	C1555321
26476440	1029	1035	female	T032	C0086287
26476440	1052	1055	age	T032	C0001779
26476440	1059	1064	years	T079	C0439234
26476440	1069	1103	poor self-reported baseline health	T080	C0018759
26476440	1113	1118	weeks	T079	C0439230
26476440	1120	1133	self-efficacy	T041	C0600564
26476440	1135	1141	health	T078	C0018684
26476440	1146	1163	well-being scores	T081	C0449820
26476440	1164	1186	significantly improved	T033	C0184511
26476440	1195	1210	lifestyle goals	T033	C4062319
26476440	1222	1239	health management	T058	C1328735
26476440	1240	1245	goals	T170	C0018017
26476440	1257	1265	achieved	T033	C1272277
26476440	1274	1286	referrals to	T058	C2585021
26476440	1287	1296	community	T095	C0009482
26476440	1297	1323	lifestyle behaviour change	T054	C0870811
26476440	1363	1371	services	T058	C0018747
26476440	1378	1401	Citizen's Advice Bureau	T097	C1522486
26476440	1427	1436	satisfied	T170	C4084799
26476440	1439	1453	very satisfied	T033	C3840671
26476440	1463	1470	service	T058	C0018747
26476440	1476	1503	hospital-based intervention	T061	C0184661
26476440	1518	1528	acceptable	T080	C1879533
26476440	1540	1579	preliminary health and well-being gains	T033	C0243095

26797704|t|The Impact of Deployment on Parental, Family and Child Adjustment in Military Families
26797704|a|Since 9/11, military service in the United States has been characterized by wartime deployments and reintegration challenges that contribute to a context of stress for military families. Research indicates the negative impact of wartime deployment on the well being of service members, military spouses, and children. Yet, few studies have considered how parental deployments may affect adjustment in young children and their families. Using deployment records and parent - reported measures from primary caregiving (N = 680) and military (n = 310) parents, we examined the influence of deployment on adjustment in military families with children ages 0-10 years. Greater deployment exposure was related to impaired family functioning and marital instability. Parental depressive and posttraumatic stress symptoms were associated with impairments in social emotional adjustment in young children, increased anxiety in early childhood, and adjustment problems in school-age children. Conversely, parental sensitivity was associated with improved social and emotional outcomes across childhood. These findings provide guidance to developing preventive approaches for military families with young children.
26797704	14	24	Deployment	T052	C2825812
26797704	28	36	Parental	T099	C0030551
26797704	38	44	Family	T099	C0015576
26797704	49	54	Child	T100	C0008059
26797704	55	65	Adjustment	T055	C0376209
26797704	69	86	Military Families	T099	C3850016
26797704	99	115	military service	T097	C1550414
26797704	123	136	United States	T083	C0041703
26797704	163	170	wartime	T079	C1254367
26797704	171	182	deployments	T052	C2825812
26797704	244	250	stress	T033	C0038435
26797704	255	272	military families	T099	C3850016
26797704	274	282	Research	T062	C0035168
26797704	297	312	negative impact	T033	C1513916
26797704	324	334	deployment	T052	C2825812
26797704	342	352	well being	T078	C0018684
26797704	356	363	service	T097	C1550414
26797704	364	371	members	T098	C0680022
26797704	373	381	military	T097	C3245458
26797704	382	389	spouses	T099	C0162409
26797704	395	403	children	T100	C0008059
26797704	442	450	parental	T099	C0030551
26797704	451	462	deployments	T052	C2825812
26797704	474	484	adjustment	T055	C0376209
26797704	488	502	young children	T100	C0728836
26797704	513	521	families	T099	C3850016
26797704	529	539	deployment	T052	C2825812
26797704	529	547	deployment records	T170	C0034869
26797704	552	558	parent	T099	C0030551
26797704	561	569	reported	T170	C0684224
26797704	592	602	caregiving	T052	C1947933
26797704	617	625	military	T097	C3245458
26797704	636	643	parents	T099	C0030551
26797704	674	684	deployment	T052	C2825812
26797704	688	698	adjustment	T055	C0376209
26797704	702	719	military families	T099	C3850016
26797704	725	733	children	T100	C0008059
26797704	759	769	deployment	T052	C2825812
26797704	794	802	impaired	T169	C0221099
26797704	803	821	family functioning	T054	C0680051
26797704	826	833	marital	T033	C0024841
26797704	834	845	instability	T033	C1444783
26797704	847	855	Parental	T099	C0030551
26797704	856	866	depressive	T048	C0011570
26797704	871	900	posttraumatic stress symptoms	T048	C0038436
26797704	906	921	associated with	T080	C0332281
26797704	922	933	impairments	T169	C0221099
26797704	937	943	social	T054	C0035820
26797704	944	953	emotional	T033	C0849912
26797704	954	964	adjustment	T055	C0376209
26797704	968	982	young children	T100	C0728836
26797704	994	1001	anxiety	T033	C0003467
26797704	1011	1020	childhood	T079	C0231335
26797704	1026	1036	adjustment	T055	C0376209
26797704	1049	1068	school-age children	T100	C2827631
26797704	1082	1090	parental	T099	C0030551
26797704	1091	1102	sensitivity	T041	C0312418
26797704	1107	1122	associated with	T080	C0332281
26797704	1132	1138	social	T054	C0035820
26797704	1143	1161	emotional outcomes	T033	C0849912
26797704	1169	1178	childhood	T079	C0231335
26797704	1186	1194	findings	T033	C0243095
26797704	1226	1236	preventive	T080	C1456501
26797704	1252	1269	military families	T099	C3850016
26797704	1281	1289	children	T100	C0008059

26864880|t|Combining electrostatic powder with an insecticide: effect on stored - product beetles and on the commodity
26864880|a|The opportunity to reduce the amount of pirimiphos-methyl applied to grain by formulating it in an electrostatic powder was investigated. The insecticidal efficacy of pirimiphos-methyl in EC formulation or formulated using electrostatic powder (EP) as an inert carrier was investigated against Sitophilus oryzae (L.), Oryzaephilus surinamensis (L.), Rhyzopertha dominica (F.) and Tribolium confusum Jacquelin du Val. Furthermore, the adhesive properties of EP to rice, corn and wheat, together with the effect on bulk density and bread - and pasta - making properties, were investigated. The results showed that pirimiphos-methyl formulated with EP provided better efficacy against adults when compared with EC formulation for O. surinamensis and T. confusum, but there was no difference for R. dominica. Progeny production was consistently lower in grain treated with the EP formulation than in grain treated with the EC. Tests showed that EP adhered to the kernels for longer on hard wheat than on maize or rice. In most commodities, EP did not alter the bulk density. Finally, the addition of EP did not affect flour - and bread - making properties, nor the pasta -making properties. The results of the present study suggest that an EP could be used to reduce the amount of pirimiphos-methyl applied to grain for effective pest control, with no detrimental effects on grain quality. Â© 2016 Society of Chemical Industry.
26864880	10	30	electrostatic powder	T167	C0439861
26864880	39	50	insecticide	T131	C0021576
26864880	62	68	stored	T169	C1698986
26864880	71	78	product	T071	C1514468
26864880	79	86	beetles	T204	C0009276
26864880	98	107	commodity	T168	C0453860
26864880	148	165	pirimiphos-methyl	T109,T121	C0071138
26864880	177	182	grain	T168	C0007757
26864880	207	227	electrostatic powder	T167	C0439861
26864880	250	262	insecticidal	T131	C0021576
26864880	263	271	efficacy	T080	C1280519
26864880	275	292	pirimiphos-methyl	T109,T121	C0071138
26864880	296	310	EC formulation	T131	C0021576
26864880	331	351	electrostatic powder	T167	C0439861
26864880	353	355	EP	T167	C0439861
26864880	363	376	inert carrier	T167	C0520810
26864880	402	419	Sitophilus oryzae	T204	C0998410
26864880	426	451	Oryzaephilus surinamensis	T204	C0322563
26864880	458	478	Rhyzopertha dominica	T204	C1041701
26864880	488	523	Tribolium confusum Jacquelin du Val	T204	C0598191
26864880	542	550	adhesive	T067	C3714578
26864880	565	567	EP	T167	C0439861
26864880	571	575	rice	T168	C0035567
26864880	577	581	corn	T168	C1138842
26864880	586	591	wheat	T168	C0043137
26864880	626	633	density	T081	C0178587
26864880	638	643	bread	T168	C0006138
26864880	650	655	pasta	T168	C0452694
26864880	658	664	making	T052	C1521827
26864880	665	675	properties	T080	C0871161
26864880	720	737	pirimiphos-methyl	T109,T121	C0071138
26864880	754	756	EP	T167	C0439861
26864880	773	781	efficacy	T080	C1280519
26864880	790	796	adults	T204	C0563200
26864880	816	830	EC formulation	T131	C0021576
26864880	835	850	O. surinamensis	T204	C0322563
26864880	855	866	T. confusum	T204	C0598191
26864880	900	911	R. dominica	T204	C1041701
26864880	913	920	Progeny	T099	C0680063
26864880	958	963	grain	T168	C0007757
26864880	964	976	treated with	T061	C0332293
26864880	981	983	EP	T167	C0439861
26864880	1004	1009	grain	T168	C0007757
26864880	1010	1022	treated with	T061	C0332293
26864880	1027	1029	EC	T131	C0021576
26864880	1049	1051	EP	T167	C0439861
26864880	1052	1059	adhered	T067	C3714578
26864880	1067	1074	kernels	T168	C0016452
26864880	1094	1099	wheat	T168	C0043137
26864880	1108	1113	maize	T168	C1138842
26864880	1117	1121	rice	T168	C0035567
26864880	1131	1142	commodities	T168	C0453860
26864880	1144	1146	EP	T167	C0439861
26864880	1170	1177	density	T081	C0178587
26864880	1204	1206	EP	T167	C0439861
26864880	1222	1227	flour	T168	C0016260
26864880	1234	1239	bread	T168	C0006138
26864880	1242	1248	making	T052	C1521827
26864880	1249	1259	properties	T080	C0871161
26864880	1269	1274	pasta	T168	C0452694
26864880	1283	1293	properties	T080	C0871161
26864880	1344	1346	EP	T167	C0439861
26864880	1385	1402	pirimiphos-methyl	T109,T121	C0071138
26864880	1414	1419	grain	T168	C0007757
26864880	1434	1446	pest control	T057	C0031249
26864880	1453	1475	no detrimental effects	T080	C1301751
26864880	1479	1484	grain	T168	C0007757
26864880	1485	1492	quality	T080	C0332306

26867927|t|Radiofrequency ablation of posteroseptal accessory pathways associated with coronary sinus diverticula
26867927|a|Posteroseptal accessory pathways may be associated with a coronary sinus (CS) diverticulum. Our purpose was to describe the clinical characteristics, mapping and ablation of these pathways. This was a retrospective study of all patients who underwent ablation of posteroseptal accessory pathways in a single centre. Patients with a diverticulum of the CS or one of its tributaries were included in group I, while the other patients formed group II. Clinical presentation, ablation procedure and outcome were compared between the two groups. A total of 51 patients were included, 16 in group I and 35 in group II. There were no significant differences in age or sex distribution. Atrial fibrillation (AF) and previous unsuccessful ablation were more common in group I. A negative delta wave in lead II was the ECG finding with best sensitivity and specificity for the presence of a diverticulum. A pathway potential was common at the successful site in group I, and the interval between local ventricular electrogram and delta wave onset was shorter (19.5 Â± 8 vs 33.1 Â± 7.6 ms, p < 0.001). There was a trend toward lower procedural success rate and higher recurrence rate in group I, although this was not significant. CS diverticula should be suspected in patients with manifest posteroseptal accessory pathways who have a previous failed ablation, documented AF or typical electrocardiographic signs. A discrete potential is frequently seen at the successful site, but the local ventricular electrogram is not as early as in other accessory pathways.
26867927	0	23	Radiofrequency ablation	T061	C0850292
26867927	27	59	posteroseptal accessory pathways	T023	C0447025
26867927	60	75	associated with	T080	C0332281
26867927	76	102	coronary sinus diverticula	T019,T047	C3163894
26867927	103	135	Posteroseptal accessory pathways	T023	C0447025
26867927	143	158	associated with	T080	C0332281
26867927	161	193	coronary sinus (CS) diverticulum	T019,T047	C3163894
26867927	227	251	clinical characteristics	T201	C0683325
26867927	253	260	mapping	T052	C1283195
26867927	265	291	ablation of these pathways	T061	C3275043
26867927	304	323	retrospective study	T062	C0035363
26867927	331	339	patients	T101	C0030705
26867927	354	362	ablation	T061	C0547070
26867927	366	398	posteroseptal accessory pathways	T023	C0447025
26867927	404	417	single centre	T082	C0205099
26867927	419	427	Patients	T101	C0030705
26867927	435	457	diverticulum of the CS	T019,T047	C3163894
26867927	472	483	tributaries	T023	C1180121
26867927	501	508	group I	T078	C0441833
26867927	526	534	patients	T101	C0030705
26867927	542	550	group II	T078	C0441833
26867927	552	573	Clinical presentation	T170	C2708283
26867927	575	593	ablation procedure	T061	C0547070
26867927	636	642	groups	T078	C0441833
26867927	658	666	patients	T101	C0030705
26867927	688	695	group I	T078	C0441833
26867927	706	714	group II	T078	C0441833
26867927	757	760	age	T081	C0001782
26867927	764	780	sex distribution	T081	C0036878
26867927	782	801	Atrial fibrillation	T047	C0004238
26867927	803	805	AF	T047	C0004238
26867927	833	841	ablation	T061	C0547070
26867927	862	869	group I	T078	C0441833
26867927	873	881	negative	T033	C0205160
26867927	882	892	delta wave	T033	C1880434
26867927	896	903	lead II	T078	C0441833
26867927	912	915	ECG	T060	C1623258
26867927	916	923	finding	T033	C0243095
26867927	934	945	sensitivity	T081	C1511883
26867927	950	961	specificity	T081	C1511884
26867927	984	996	diverticulum	T046	C0012817
26867927	1000	1007	pathway	T023	C0447025
26867927	1008	1017	potential	T080	C3245505
26867927	1047	1051	site	T082	C0205145
26867927	1055	1062	group I	T078	C0441833
26867927	1089	1118	local ventricular electrogram	T060	C0849666
26867927	1123	1133	delta wave	T033	C1880434
26867927	1144	1151	shorter	T081	C1806781
26867927	1217	1222	lower	T080	C0205251
26867927	1242	1246	rate	T081	C1521828
26867927	1251	1257	higher	T080	C0205250
26867927	1258	1268	recurrence	T067	C0034897
26867927	1269	1273	rate	T081	C1521828
26867927	1277	1284	group I	T078	C0441833
26867927	1308	1319	significant	T078	C0750502
26867927	1321	1335	CS diverticula	T019,T047	C3163894
26867927	1359	1367	patients	T101	C0030705
26867927	1382	1414	posteroseptal accessory pathways	T023	C0447025
26867927	1442	1450	ablation	T061	C0547070
26867927	1463	1465	AF	T047	C0004238
26867927	1477	1503	electrocardiographic signs	T033	C0438154
26867927	1516	1525	potential	T080	C3245505
26867927	1577	1606	local ventricular electrogram	T060	C0849666
26867927	1635	1653	accessory pathways	T023	C0006383

26868132|t|Association of RBP4 levels with increased arterial stiffness in adolescents with family history of type 2 diabetes
26868132|a|The aim of this study was to explore the impact of family history of type 2 diabetes (FH2D) on arterial stiffness in young people and its relationship to adipocytokines. This case-control study included 52 adolescents (male / female 28/24) with FH2D (FH2D+) and 40 adolescents (male / female 21/19) without FH2D (FH2D-). Anthropometric measurements, including height, weight, waist circumference (WC), and blood pressure, were obtained. Blood samples were collected, fasting plasma glucose (FPG), serum lipids, Retinol Binding Protein 4 (RBP4), C reactive protein (CRP), adiponectin and visfatin were examined. Brachial-ankle pulse wave velocity (baPWV) was used to evaluate arterial stiffness. Visceral fat area (VFA) was measured by computerized tomography. Compared with FH2D- group, FH2D+ group had a significantly higher oral glucose tolerance test (OGTT) 2-hour insulin, RBP4 and baPWV levels, a lower adiponectin and glucose infusing rate (GIR) (P<0.05). BaPWV was positively correlated with age, systolic blood pressure (SBP), diastolic blood pressure (DBP), 2-hour (OGTT) insulin, RBP4, and VFA, and negatively correlated with GIR in FH2D+ group. After multivariate analysis, age, SBP, RBP4 and VFA maintained an independent association with baPWV in FH2D+ group (P<0.05), while only age, SBP, and VFA were independent predictors of baPWV in FH2D- group (P<0.05). These findings led to the conclusion that RBP4 level was associated with increased arterial stiffness in young subjects with family history of type 2 diabetes.
26868132	15	19	RBP4	T116,T123	C1438309
26868132	42	60	arterial stiffness	T039	C0599949
26868132	64	75	adolescents	T100	C0205653
26868132	81	114	family history of type 2 diabetes	T033	C2316287
26868132	131	136	study	T062	C2603343
26868132	166	199	family history of type 2 diabetes	T033	C2316287
26868132	201	205	FH2D	T033	C2316287
26868132	210	228	arterial stiffness	T039	C0599949
26868132	232	237	young	T079	C0332239
26868132	238	244	people	T098	C0027361
26868132	269	283	adipocytokines	T116,T123	C1955907
26868132	290	308	case-control study	T062	C0007328
26868132	321	332	adolescents	T100	C0205653
26868132	334	338	male	T032	C0086582
26868132	341	347	female	T032	C0086287
26868132	360	364	FH2D	T033	C2316287
26868132	366	371	FH2D+	T033	C2316287
26868132	380	391	adolescents	T100	C0205653
26868132	393	397	male	T032	C0086582
26868132	400	406	female	T032	C0086287
26868132	422	426	FH2D	T033	C2316287
26868132	428	433	FH2D-	T033	C1513916
26868132	436	463	Anthropometric measurements	T081	C0815129
26868132	475	481	height	T032	C0005890
26868132	483	489	weight	T032	C0005910
26868132	491	510	waist circumference	T201	C0455829
26868132	512	514	WC	T201	C0455829
26868132	521	535	blood pressure	T040	C0005823
26868132	552	565	Blood samples	T031	C0178913
26868132	582	604	fasting plasma glucose	T059	C0583513
26868132	606	609	FPG	T059	C0583513
26868132	612	624	serum lipids	T059	C0428462
26868132	626	651	Retinol Binding Protein 4	T116,T123	C1438309
26868132	653	657	RBP4	T116,T123	C1438309
26868132	660	678	C reactive protein	T059	C0201657
26868132	680	683	CRP	T059	C0201657
26868132	686	697	adiponectin	T059	C2700366
26868132	702	710	visfatin	T116,T126	C0068707
26868132	726	760	Brachial-ankle pulse wave velocity	T081	C3494431
26868132	762	767	baPWV	T081	C3494431
26868132	790	808	arterial stiffness	T039	C0599949
26868132	810	827	Visceral fat area	T201	C3654464
26868132	829	832	VFA	T201	C3654464
26868132	850	873	computerized tomography	T060	C0040405
26868132	889	894	FH2D-	T033	C1513916
26868132	895	900	group	T098	C1257890
26868132	902	907	FH2D+	T033	C2316287
26868132	908	913	group	T098	C1257890
26868132	941	990	oral glucose tolerance test (OGTT) 2-hour insulin	T059	C2041409
26868132	992	996	RBP4	T116,T123	C1438309
26868132	1001	1006	baPWV	T081	C3494431
26868132	1023	1034	adiponectin	T059	C2700366
26868132	1039	1060	glucose infusing rate	T079	C2964135
26868132	1062	1065	GIR	T079	C2964135
26868132	1077	1082	BaPWV	T081	C3494431
26868132	1114	1117	age	T032	C0001779
26868132	1119	1142	systolic blood pressure	T201	C0871470
26868132	1144	1147	SBP	T201	C0871470
26868132	1150	1174	diastolic blood pressure	T201	C0428883
26868132	1176	1179	DBP	T201	C0428883
26868132	1182	1203	2-hour (OGTT) insulin	T059	C2041409
26868132	1205	1209	RBP4	T116,T123	C1438309
26868132	1215	1218	VFA	T201	C3654464
26868132	1258	1263	FH2D+	T033	C2316287
26868132	1264	1269	group	T098	C1257890
26868132	1277	1298	multivariate analysis	T081	C0026777
26868132	1300	1303	age	T032	C0001779
26868132	1305	1308	SBP	T201	C0871470
26868132	1310	1314	RBP4	T116,T123	C1438309
26868132	1319	1322	VFA	T201	C3654464
26868132	1366	1371	baPWV	T081	C3494431
26868132	1375	1380	FH2D+	T033	C2316287
26868132	1381	1386	group	T098	C1257890
26868132	1408	1411	age	T032	C0001779
26868132	1413	1416	SBP	T201	C0871470
26868132	1422	1425	VFA	T201	C3654464
26868132	1443	1453	predictors	T078	C2698872
26868132	1457	1462	baPWV	T081	C3494431
26868132	1466	1471	FH2D-	T033	C1513916
26868132	1472	1477	group	T098	C1257890
26868132	1494	1502	findings	T033	C0243095
26868132	1530	1534	RBP4	T116,T123	C1438309
26868132	1571	1589	arterial stiffness	T039	C0599949
26868132	1593	1598	young	T079	C0332239
26868132	1599	1607	subjects	T098	C0080105
26868132	1613	1646	family history of type 2 diabetes	T033	C2316287

26876532|t|EZH2 and ZFX oncogenes in malignant behaviour of parathyroid neoplasms
26876532|a|Several studies reported somatic mutations of many genes (MEN1, CTNNB1, CDKIs and others) in parathyroid adenoma, although with different prevalence. Recently, activating mutations of the EZH2 and ZFX oncogenes were identified in benign parathyroid adenoma by whole exome sequencing. The same mutations had been found in blood and ovary malignant tumours. On one hand, this result raised the hypothesis that these oncogenes may play a role in the onset of parathyroid tumour, but it would also suggest they may be involved in malignant, rather benign, parathyroid neoplasm. Our aim was to verify the occurrence of selected mutations of the EZH2 and ZFX genes in an Italian cohort of 23 sporadic parathyroid carcinomas, 12 atypical and 45 typical adenomas. DNA was extracted from paraffin-embedded tissues, PCR amplified and directly sequenced. No mutations were detected in the coding sequence and boundaries of both genes in any of the samples. Two polymorphisms of the EZH2 gene were identified with different prevalence: the rs2072407 variant was present in the 30 % of the samples, in keeping with the overall frequency in larger populations, while the rs78589034 variant, located close to the 5' end of the exon 16, was detected in only one proband with familial isolated hyperparathyroidism; we investigated the possible outcome on the splicing process. EZH2 and ZFX genes do not seem to have an impact on the onset of most parathyroid tumours, both benign and malignant, though further studies on larger cohorts of different ethnicity are needed.
26876532	0	4	EZH2	T028	C1333368
26876532	9	12	ZFX	T028	C1421578
26876532	13	22	oncogenes	T028	C0029016
26876532	26	45	malignant behaviour	T080	C0205282
26876532	49	70	parathyroid neoplasms	T191	C0030521
26876532	79	86	studies	T062	C0008972
26876532	96	113	somatic mutations	T049	C0544886
26876532	122	127	genes	T028	C0017337
26876532	129	133	MEN1	T028	C0694884
26876532	135	141	CTNNB1	T028	C1332803
26876532	143	148	CDKIs	T028	C0919539
26876532	164	183	parathyroid adenoma	T191	C0262587
26876532	199	208	different	T080	C1705242
26876532	209	219	prevalence	T081	C0220900
26876532	231	241	activating	T052	C1879547
26876532	242	251	mutations	T045	C0026882
26876532	259	263	EZH2	T028	C1333368
26876532	268	271	ZFX	T028	C1421578
26876532	272	281	oncogenes	T028	C0029016
26876532	301	307	benign	T080	C0205183
26876532	308	327	parathyroid adenoma	T191	C0262587
26876532	331	353	whole exome sequencing	T063	C3640077
26876532	364	373	mutations	T045	C0026882
26876532	392	397	blood	T031	C0005767
26876532	402	407	ovary	T023	C0029939
26876532	408	425	malignant tumours	T191	C0006826
26876532	463	473	hypothesis	T078	C1512571
26876532	485	494	oncogenes	T028	C0029016
26876532	518	523	onset	T080	C0332162
26876532	527	545	parathyroid tumour	T191	C0030521
26876532	597	606	malignant	T080	C0205282
26876532	615	621	benign	T080	C0205183
26876532	623	643	parathyroid neoplasm	T191	C0030521
26876532	649	652	aim	T078	C1947946
26876532	671	681	occurrence	T079	C2745955
26876532	694	703	mutations	T045	C0026882
26876532	711	715	EZH2	T028	C1333368
26876532	720	729	ZFX genes	T028	C1421578
26876532	736	743	Italian	T098	C0337810
26876532	744	750	cohort	T098	C0599755
26876532	757	765	sporadic	T079	C0205422
26876532	766	788	parathyroid carcinomas	T191	C0687150
26876532	793	801	atypical	T080	C0205182
26876532	809	816	typical	T080	C3538928
26876532	817	825	adenomas	T191	C0001430
26876532	827	830	DNA	T114,T123	C0012854
26876532	835	844	extracted	T061	C0185115
26876532	850	875	paraffin-embedded tissues	T024	C1519524
26876532	877	880	PCR	T063	C0032520
26876532	881	890	amplified	T067	C1521871
26876532	904	913	sequenced	T169	C1561491
26876532	915	917	No	T033	C0205160
26876532	918	927	mutations	T045	C0026882
26876532	933	941	detected	T033	C0442726
26876532	949	964	coding sequence	T114,T123	C0015295
26876532	969	979	boundaries	T114,T123	C1136191
26876532	988	993	genes	T028	C0017337
26876532	1008	1015	samples	T167	C0370003
26876532	1021	1034	polymorphisms	T045	C0678951
26876532	1042	1051	EZH2 gene	T028	C1333368
26876532	1057	1067	identified	T080	C0205396
26876532	1073	1082	different	T080	C1705242
26876532	1083	1093	prevalence	T081	C0033105
26876532	1099	1116	rs2072407 variant	T028	C0678941
26876532	1121	1128	present	T033	C0150312
26876532	1148	1155	samples	T167	C0370003
26876532	1177	1184	overall	T080	C1561607
26876532	1185	1194	frequency	T079	C0439603
26876532	1198	1204	larger	T081	C0549177
26876532	1205	1216	populations	T081	C0032659
26876532	1228	1246	rs78589034 variant	T028	C0678941
26876532	1269	1275	5' end	T114	C1254348
26876532	1283	1290	exon 16	T114,T123	C0015295
26876532	1296	1304	detected	T033	C0442726
26876532	1317	1324	proband	T099	C1948021
26876532	1330	1338	familial	T169	C0241888
26876532	1339	1347	isolated	T169	C0205409
26876532	1348	1367	hyperparathyroidism	T047	C0020502
26876532	1372	1384	investigated	T169	C1292732
26876532	1398	1405	outcome	T169	C1274040
26876532	1413	1429	splicing process	T045	C0035687
26876532	1431	1435	EZH2	T028	C1333368
26876532	1440	1449	ZFX genes	T028	C1421578
26876532	1473	1479	impact	T080	C4049986
26876532	1487	1492	onset	T080	C0332162
26876532	1501	1520	parathyroid tumours	T191	C0030521
26876532	1527	1533	benign	T080	C0205183
26876532	1538	1547	malignant	T080	C0205282
26876532	1575	1581	larger	T081	C0549177
26876532	1582	1589	cohorts	T098	C0599755
26876532	1593	1602	different	T080	C1705242
26876532	1603	1612	ethnicity	T080	C0243103

26883265|t|The effect of total hip arthroplasty on sagittal spinal - pelvic-leg alignment and low back pain in patients with severe hip osteoarthritis
26883265|a|Sagittal spinopelvic malalignment has been reported in spinal disorders such as low back pain (LBP), and restoration of normal alignment is targeted when treating these disorders. Abnormal sagittal spinal - pelvic-leg alignment has been reported in patients with severe hip osteoarthritis (OA), who have a high prevalence of associated LBP. This prospective longitudinal study aimed to investigate changes in sagittal spinal - pelvic-leg alignment after total hip arthroplasty (THA) in patients with severe hip OA, and whether these changes contribute to LBP relief. Patients undergoing primary THA due to severe unilateral hip OA were recruited. Physical examination and X-ray films were taken to rule out any spinal disorder. Sagittal alignment of pelvis, hip, and spine was analyzed on lateral radiographs taken before (baseline) and 1 year after (follow-up) THA. Functional instruments were completed by patients including: visual analog scale (VAS) for LBP, Roland-Morris Disability Questionnaire (RMDQ), and Harris Hip Score (HHS). Comparisons were carried out at baseline and follow-up, and between patients with and without LBP. The recruited 69 patients showed significantly reduced hip flexion and improved global spinal balance at follow-up compared with baseline. LBP was reported by 39 patients (56.5 %) before surgery; at follow-up, 17 reported complete resolution, while 22 reported significant relief. Significant decreases in VAS and RMDQ scores in lumbar spine and increase in hip HHS were observed. THA in patients with severe hip OA could help correct abnormal sagittal spinal - pelvic-leg alignment and relieve comorbid LBP. Improvements in hip flexion and global spinal balance might be involved in the mechanism of LBP relief.
26883265	14	36	total hip arthroplasty	T061	C0040508
26883265	40	48	sagittal	T029	C0935598
26883265	49	55	spinal	T082	C0521329
26883265	58	68	pelvic-leg	T023	C0229962
26883265	69	78	alignment	T033	C1821889
26883265	83	96	low back pain	T184	C0024031
26883265	100	108	patients	T101	C0030705
26883265	114	120	severe	T080	C0205082
26883265	121	139	hip osteoarthritis	T047	C0029410
26883265	140	148	Sagittal	T029	C0935598
26883265	149	160	spinopelvic	T023	C0229962
26883265	161	173	malalignment	T046	C0206231
26883265	195	211	spinal disorders	T047	C0037928
26883265	220	233	low back pain	T184	C0024031
26883265	235	238	LBP	T184	C0024031
26883265	267	276	alignment	T033	C1821889
26883265	294	302	treating	T061	C0087111
26883265	309	318	disorders	T047	C0037928
26883265	320	328	Abnormal	T033	C0205161
26883265	329	337	sagittal	T029	C0935598
26883265	338	344	spinal	T082	C0521329
26883265	347	357	pelvic-leg	T023	C0229962
26883265	358	367	alignment	T033	C1821889
26883265	389	397	patients	T101	C0030705
26883265	403	409	severe	T080	C0205082
26883265	410	428	hip osteoarthritis	T047	C0029410
26883265	430	432	OA	T047	C0029410
26883265	451	461	prevalence	T081	C0220900
26883265	476	479	LBP	T184	C0024031
26883265	486	516	prospective longitudinal study	T062	C0033522
26883265	549	557	sagittal	T029	C0935598
26883265	558	564	spinal	T082	C0521329
26883265	567	577	pelvic-leg	T023	C0229962
26883265	578	587	alignment	T033	C1821889
26883265	594	616	total hip arthroplasty	T061	C0040508
26883265	618	621	THA	T061	C0040508
26883265	626	634	patients	T101	C0030705
26883265	640	646	severe	T080	C0205082
26883265	647	653	hip OA	T047	C0029410
26883265	695	698	LBP	T184	C0024031
26883265	699	705	relief	T033	C0564405
26883265	707	715	Patients	T101	C0030705
26883265	735	738	THA	T061	C0040508
26883265	746	752	severe	T080	C0205082
26883265	764	770	hip OA	T047	C0029410
26883265	787	807	Physical examination	T058	C0031809
26883265	812	823	X-ray films	T074	C0043303
26883265	851	866	spinal disorder	T047	C0037928
26883265	868	876	Sagittal	T029	C0935598
26883265	877	886	alignment	T033	C1821889
26883265	890	896	pelvis	T023	C0030797
26883265	898	901	hip	T023	C0019552
26883265	907	912	spine	T023	C0037949
26883265	929	948	lateral radiographs	T060	C3257974
26883265	963	971	baseline	T081	C1442488
26883265	979	983	year	T079	C0439234
26883265	991	1000	follow-up	T058	C1522577
26883265	1002	1005	THA	T061	C0040508
26883265	1007	1029	Functional instruments	T074	C0348000
26883265	1048	1056	patients	T101	C0030705
26883265	1068	1087	visual analog scale	T060	C3536884
26883265	1089	1092	VAS	T060	C3536884
26883265	1098	1101	LBP	T184	C0024031
26883265	1103	1141	Roland-Morris Disability Questionnaire	T170	C3639717
26883265	1143	1147	RMDQ	T170	C3639717
26883265	1154	1170	Harris Hip Score	T033	C2919875
26883265	1172	1175	HHS	T033	C2919875
26883265	1210	1218	baseline	T081	C1442488
26883265	1223	1232	follow-up	T058	C1522577
26883265	1246	1254	patients	T101	C0030705
26883265	1272	1275	LBP	T184	C0024031
26883265	1294	1302	patients	T101	C0030705
26883265	1310	1331	significantly reduced	T080	C0392756
26883265	1332	1343	hip flexion	T033	C2237371
26883265	1357	1378	global spinal balance	T033	C0243095
26883265	1382	1391	follow-up	T058	C1522577
26883265	1406	1414	baseline	T081	C1442488
26883265	1416	1419	LBP	T184	C0024031
26883265	1439	1447	patients	T101	C0030705
26883265	1464	1471	surgery	T169	C0038895
26883265	1476	1485	follow-up	T058	C1522577
26883265	1508	1518	resolution	T077	C2699488
26883265	1550	1556	relief	T033	C0564405
26883265	1570	1579	decreases	T081	C0547047
26883265	1583	1586	VAS	T201	C2960751
26883265	1591	1595	RMDQ	T170	C3639717
26883265	1596	1602	scores	T081	C0449820
26883265	1606	1618	lumbar spine	T029	C3887615
26883265	1635	1638	hip	T023	C0019552
26883265	1639	1642	HHS	T033	C2919875
26883265	1658	1661	THA	T061	C0040508
26883265	1665	1673	patients	T101	C0030705
26883265	1679	1685	severe	T080	C0205082
26883265	1686	1692	hip OA	T047	C0029410
26883265	1721	1729	sagittal	T029	C0935598
26883265	1730	1736	spinal	T082	C0521329
26883265	1739	1749	pelvic-leg	T023	C0229962
26883265	1750	1759	alignment	T033	C1821889
26883265	1772	1780	comorbid	T033	C1275743
26883265	1781	1784	LBP	T184	C0024031
26883265	1802	1813	hip flexion	T033	C2237371
26883265	1818	1824	global	T080	C2348867
26883265	1825	1831	spinal	T082	C0521329
26883265	1832	1839	balance	T040	C0014653
26883265	1878	1881	LBP	T184	C0024031
26883265	1882	1888	relief	T033	C0564405

26931495|t|Beyond neutral and forbidden links: morphological matches and the assembly of mutualistic hawkmoth - plant networks
26931495|a|A major challenge in evolutionary ecology is to understand how co-evolutionary processes shape patterns of interactions between species at community level. Pollination of flowers with long corolla tubes by long-tongued hawkmoths has been invoked as a showcase model of co-evolution. Recently, optimal foraging models have predicted that there might be a close association between mouthparts' length and the corolla depth of the visited flowers, thus favouring trait convergence and specialization at community level. Here, we assessed whether hawkmoths more frequently pollinate plants with floral tube lengths similar to their proboscis lengths (morphological match hypothesis) against abundance -based processes (neutral hypothesis) and ecological trait mismatches constraints (forbidden links hypothesis), and how these processes structure hawkmoth - plant mutualistic networks from five communities in four biogeographical regions of South America. We found convergence in morphological traits across the five communities and that the distribution of morphological differences between hawkmoths and plants is consistent with expectations under the morphological match hypothesis in three of the five communities. In the two remaining communities, which are ecotones between two distinct biogeographical areas, interactions are better predicted by the neutral hypothesis. Our findings are consistent with the idea that diffuse co-evolution drives the evolution of extremely long proboscises and flower tubes, and highlight the importance of morphological traits, beyond the forbidden links hypothesis, in structuring interactions between mutualistic partners, revealing that the role of niche-based processes can be much more complex than previously known.
26931495	7	14	neutral	T077	C1254372
26931495	19	34	forbidden links	T077	C1254372
26931495	36	49	morphological	T082	C0543482
26931495	50	57	matches	T080	C1708943
26931495	66	74	assembly	T078	C0441833
26931495	78	89	mutualistic	T067	C1254366
26931495	90	98	hawkmoth	T204	C0599456
26931495	101	106	plant	T002	C0032098
26931495	107	115	networks	T169	C1882071
26931495	137	157	evolutionary ecology	T090	C0013546
26931495	179	204	co-evolutionary processes	T067	C1522240
26931495	211	219	patterns	T082	C0449774
26931495	223	235	interactions	T169	C1704675
26931495	244	251	species	T185	C1705920
26931495	255	264	community	T096	C0009462
26931495	265	270	level	T080	C0441889
26931495	272	283	Pollination	T040	C1522786
26931495	287	294	flowers	T002	C0330090
26931495	300	318	long corolla tubes	T002	C2699452
26931495	322	344	long-tongued hawkmoths	T204	C0599456
26931495	376	381	model	T075	C0026336
26931495	385	397	co-evolution	T045	C0015219
26931495	426	432	models	T075	C0026336
26931495	476	487	association	T080	C0439849
26931495	496	514	mouthparts' length	T081	C1444754
26931495	523	530	corolla	T002	C2699452
26931495	531	536	depth	T082	C0205125
26931495	552	559	flowers	T002	C0330090
26931495	576	581	trait	T032	C0599883
26931495	582	593	convergence	T052	C2700387
26931495	598	612	specialization	T090	C0037776
26931495	616	625	community	T096	C0009462
26931495	642	650	assessed	T052	C1516048
26931495	659	668	hawkmoths	T204	C0599456
26931495	685	701	pollinate plants	T002	C0032098
26931495	707	718	floral tube	T185	C2698828
26931495	719	726	lengths	T081	C1444754
26931495	744	753	proboscis	T204	C3463932
26931495	754	761	lengths	T081	C1444754
26931495	763	776	morphological	T082	C0543482
26931495	777	782	match	T080	C1708943
26931495	783	793	hypothesis	T078	C1512571
26931495	803	812	abundance	T080	C2346714
26931495	820	829	processes	T067	C1522240
26931495	831	849	neutral hypothesis	T078	C1512571
26931495	855	871	ecological trait	T032	C0599883
26931495	872	882	mismatches	T080	C1881865
26931495	883	894	constraints	T057	C2986806
26931495	896	911	forbidden links	T077	C1254372
26931495	912	922	hypothesis	T078	C1512571
26931495	939	948	processes	T067	C1522240
26931495	949	958	structure	T082	C0678594
26931495	959	967	hawkmoth	T204	C0599456
26931495	970	975	plant	T002	C0032098
26931495	976	996	mutualistic networks	T169	C1882071
26931495	1007	1018	communities	T096	C0009462
26931495	1027	1050	biogeographical regions	T083	C0017446
26931495	1054	1067	South America	T083	C0037713
26931495	1078	1089	convergence	T052	C2700387
26931495	1093	1106	morphological	T082	C0543482
26931495	1107	1113	traits	T032	C0599883
26931495	1130	1141	communities	T096	C0009462
26931495	1155	1167	distribution	T169	C1704711
26931495	1171	1184	morphological	T082	C0543482
26931495	1205	1214	hawkmoths	T204	C0599456
26931495	1219	1225	plants	T002	C0032098
26931495	1268	1281	morphological	T082	C0543482
26931495	1282	1287	match	T080	C1708943
26931495	1288	1298	hypothesis	T078	C1512571
26931495	1320	1331	communities	T096	C0009462
26931495	1354	1365	communities	T096	C0009462
26931495	1407	1428	biogeographical areas	T083	C0017446
26931495	1430	1442	interactions	T169	C1704675
26931495	1471	1489	neutral hypothesis	T078	C1512571
26931495	1495	1503	findings	T169	C2607943
26931495	1546	1558	co-evolution	T045	C0015219
26931495	1570	1579	evolution	T045	C0015219
26931495	1593	1609	long proboscises	T204	C3463932
26931495	1614	1626	flower tubes	T002	C0330090
26931495	1660	1673	morphological	T082	C0543482
26931495	1674	1680	traits	T032	C0599883
26931495	1693	1708	forbidden links	T077	C1254372
26931495	1709	1719	hypothesis	T078	C1512571
26931495	1736	1748	interactions	T169	C1704675
26931495	1757	1777	mutualistic partners	T078	C0441833
26931495	1798	1802	role	T077	C1705810
26931495	1806	1827	niche-based processes	T067	C1522240

26944725|t|Impact of totally laparoscopic combined management of colorectal cancer with synchronous hepatic metastases on severity of complications: a propensity-score -based analysis
26944725|a|Thanks to widespread diffusion of minimally invasive approach in the setting of both colorectal and hepatic surgeries, the interest in combined resections for colorectal cancer and synchronous liver metastases (SCLM) by totally laparoscopic approach (TLA) has increased. Aim of this study was to compare outcome of combined resections for SCLM performed by TLA or by open approach, in a propensity-score-based study. All 25 patients undergoing combined TLA for SCLM at San Raffaele Hospital in Milano were compared in a case-matched analysis with 25 out of 91 patients undergoing totally open approach (TOA group). Groups were matched with 1:2 ratio using propensity scores based on covariates representing disease severity. Main endpoints were postoperative morbidity and long-term outcome. The Modified Accordion Severity Grading System was used to quantify complications. The groups resulted comparable in terms of patients and disease characteristics. The TLA group, as compared to the TOA group, had lower blood loss (350 vs 600 mL), shorter postoperative stay (9 vs 12 days), lower postoperative morbidity index (0.14 vs 0.20) and severity score for complicated patients (0.60 vs 0.85). Colonic anastomosis leakage had the highest fractional complication burden in both groups. In spite of comparable long-term overall survival, the TLA group had better recurrence-free survival. TLA for combined resections is feasible, and its indications can be widened to encompass a larger population of patients, provided its benefits in terms of reduced overall risk and severity of complications, rapid functional recovery and favorable long-term outcomes.
26944725	18	30	laparoscopic	T060	C0031150
26944725	54	71	colorectal cancer	T191	C1527249
26944725	77	88	synchronous	T079	C0439580
26944725	89	107	hepatic metastases	T191	C0494165
26944725	140	156	propensity-score	T081	C2718044
26944725	164	172	analysis	T062	C0871424
26944725	207	234	minimally invasive approach	T061	C0282624
26944725	258	268	colorectal	T061	C2608114
26944725	273	290	hepatic surgeries	T061	C0193373
26944725	332	349	colorectal cancer	T191	C1527249
26944725	354	365	synchronous	T079	C0439580
26944725	366	382	liver metastases	T191	C0494165
26944725	384	388	SCLM	T191	C0494165
26944725	393	422	totally laparoscopic approach	T060	C0031150
26944725	424	427	TLA	T060	C0031150
26944725	512	516	SCLM	T191	C0494165
26944725	530	533	TLA	T060	C0031150
26944725	560	588	propensity-score-based study	T062	C0871424
26944725	597	605	patients	T101	C0030705
26944725	626	629	TLA	T060	C0031150
26944725	634	638	SCLM	T191	C0494165
26944725	642	663	San Raffaele Hospital	T073,T093	C0019994
26944725	693	714	case-matched analysis	T062	C0024907
26944725	733	741	patients	T101	C0030705
26944725	753	774	totally open approach	T061	C4283938
26944725	776	785	TOA group	T098	C1257890
26944725	788	794	Groups	T098	C1257890
26944725	918	931	postoperative	T079	C0032790
26944725	932	941	morbidity	T081	C0026538
26944725	946	955	long-term	T079	C0443252
26944725	956	963	outcome	T169	C1274040
26944725	969	1011	Modified Accordion Severity Grading System	T058	C1273712
26944725	1091	1099	patients	T101	C0030705
26944725	1104	1127	disease characteristics	T046	C0599878
26944725	1133	1142	TLA group	T098	C1257890
26944725	1163	1172	TOA group	T098	C1257890
26944725	1184	1194	blood loss	T046	C0079027
26944725	1220	1233	postoperative	T079	C0032790
26944725	1261	1290	postoperative morbidity index	T170	C0580966
26944725	1310	1324	severity score	T081	C0457451
26944725	1341	1349	patients	T101	C0030705
26944725	1366	1385	Colonic anastomosis	T061	C0852681
26944725	1386	1393	leakage	T046	C0015376
26944725	1449	1455	groups	T098	C1257890
26944725	1512	1515	TLA	T060	C0031150
26944725	1512	1521	TLA group	T098	C1257890
26944725	1533	1557	recurrence-free survival	T033	C2919733
26944725	1559	1562	TLA	T060	C0031150
26944725	1671	1679	patients	T101	C0030705
26944725	1731	1735	risk	T078	C0035647
26944725	1740	1748	severity	T080	C0439793
26944725	1773	1792	functional recovery	T184	C0599766
26944725	1807	1816	long-term	T079	C0443252
26944725	1817	1825	outcomes	T169	C1274040

27010511|t|Application of an Analytical Solution as a Screening Tool for Sea Water Intrusion
27010511|a|Sea water intrusion into aquifers is problematic in many coastal areas. The physics and chemistry of this issue are complex, and sea water intrusion remains challenging to quantify. Simple assessment tools like analytical models offer advantages of rapid application, but their applicability to field situations is unclear. This study examines the reliability of a popular sharp-interface analytical approach for estimating the extent of sea water in a homogeneous coastal aquifer subjected to pumping and regional flow effects and under steady-state conditions. The analytical model is tested against observations from Canada, the United States, and Australia to assess its utility as an initial approximation of sea water extent for the purposes of rapid groundwater management decision making. The occurrence of sea water intrusion resulting in increased salinity at pumping wells was correctly predicted in approximately 60% of cases. Application of a correction to account for dispersion did not markedly improve the results. Failure of the analytical model to provide correct predictions can be attributed to mismatches between its simplifying assumptions and more complex field settings. The best results occurred where the toe of the salt water wedge is expected to be the closest to the coast under predevelopment conditions. Predictions were the poorest for aquifers where the salt water wedge was expected to extend further inland under predevelopment conditions and was therefore more dispersive prior to pumping. Sharp-interface solutions remain useful tools to screen for the vulnerability of coastal aquifers to sea water intrusion, although the significant sources of uncertainty identified in this study require careful consideration to avoid misinterpreting sharp-interface results.
27010511	0	11	Application	T169	C4048755
27010511	18	28	Analytical	T170	C0178476
27010511	29	37	Solution	T077	C2699488
27010511	43	52	Screening	T058	C0220908
27010511	53	57	Tool	T170	C0025663
27010511	62	71	Sea Water	T167	C0036499
27010511	72	81	Intrusion	T067	C1254366
27010511	82	91	Sea water	T167	C0036499
27010511	92	101	intrusion	T067	C1254366
27010511	107	115	aquifers	T070	C3178977
27010511	119	130	problematic	T033	C0033213
27010511	139	152	coastal areas	T082	C0557760
27010511	158	165	physics	T090	C0031837
27010511	170	179	chemistry	T169	C0079107
27010511	198	205	complex	T080	C0439855
27010511	211	220	sea water	T167	C0036499
27010511	221	230	intrusion	T067	C1254366
27010511	254	262	quantify	T081	C1709793
27010511	271	287	assessment tools	T170	C0282574
27010511	293	310	analytical models	T170	C0026350
27010511	337	348	application	T169	C4048755
27010511	411	416	study	T062	C2603343
27010511	455	490	sharp-interface analytical approach	T170	C0178476
27010511	495	505	estimating	T081	C0750572
27010511	520	529	sea water	T167	C0036499
27010511	535	546	homogeneous	T080	C1881065
27010511	547	554	coastal	T082	C0557760
27010511	555	562	aquifer	T070	C3178977
27010511	576	583	pumping	T169	C0205245
27010511	588	601	regional flow	T067	C1254366
27010511	602	609	effects	T080	C1280500
27010511	620	643	steady-state conditions	T070	C0678587
27010511	649	665	analytical model	T170	C0026350
27010511	669	675	tested	T169	C0039593
27010511	684	696	observations	T078	C1554188
27010511	702	708	Canada	T083	C0006823
27010511	714	727	United States	T083	C0041703
27010511	733	742	Australia	T083	C0004340
27010511	746	752	assess	T058	C0184514
27010511	771	778	initial	T079	C0205265
27010511	779	792	approximation	T061	C1283102
27010511	796	805	sea water	T167	C0036499
27010511	839	850	groundwater	T082	C0596631
27010511	851	861	management	T057	C1273870
27010511	862	877	decision making	T041	C0011109
27010511	883	893	occurrence	T079	C2745955
27010511	897	906	sea water	T167	C0036499
27010511	907	916	intrusion	T067	C1254366
27010511	930	939	increased	T081	C0205217
27010511	940	948	salinity	T034	C1956027
27010511	952	965	pumping wells	T073	C3146287
27010511	993	1006	approximately	T080	C0332232
27010511	1014	1019	cases	T169	C0868928
27010511	1021	1032	Application	T169	C4048755
27010511	1038	1048	correction	T169	C1947976
27010511	1064	1074	dispersion	T082	C0332624
27010511	1092	1099	improve	T033	C0184511
27010511	1104	1111	results	T169	C1274040
27010511	1113	1120	Failure	T169	C0231175
27010511	1128	1144	analytical model	T170	C0026350
27010511	1156	1163	correct	T080	C2349182
27010511	1164	1175	predictions	T078	C0681842
27010511	1197	1207	mismatches	T080	C1881865
27010511	1286	1293	results	T169	C1274040
27010511	1324	1334	salt water	T197	C0337055
27010511	1335	1340	wedge	T082	C0439639
27010511	1378	1383	coast	T083	C0017446
27010511	1390	1415	predevelopment conditions	T080	C0348080
27010511	1417	1428	Predictions	T078	C0681842
27010511	1450	1458	aquifers	T070	C3178977
27010511	1469	1479	salt water	T197	C0337055
27010511	1480	1485	wedge	T082	C0439639
27010511	1517	1523	inland	T083	C0442536
27010511	1530	1555	predevelopment conditions	T080	C0348080
27010511	1599	1606	pumping	T169	C0205245
27010511	1608	1633	Sharp-interface solutions	T077	C2699488
27010511	1648	1653	tools	T170	C0025663
27010511	1657	1663	screen	T058	C0220908
27010511	1672	1685	vulnerability	T033	C1821973
27010511	1689	1696	coastal	T082	C0557760
27010511	1697	1705	aquifers	T070	C3178977
27010511	1709	1718	sea water	T167	C0036499
27010511	1719	1728	intrusion	T067	C1254366
27010511	1797	1802	study	T062	C2603343
27010511	1858	1881	sharp-interface results	T169	C1274040

27059693|t|Patient - Physician Discordance in Global Assessment in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis
27059693|a|The integration of the patient in therapeutic decision-making is important in the management of rheumatoid arthritis (RA), but the patient opinion regarding disease status may differ from the physician's opinion. The aim of this study was to assess in the published literature the frequency and drivers of patient - physician discordance in global assessment in RA. A systematic literature review of all articles published up to January 2015 in Medline or Embase, reporting discordance in RA, was conducted by 2 investigators. Discordance was defined based on the absolute difference of patient global (PGA) and physician global assessments (PhGA) on 0-10-cm scales. The frequency of discordance and its predictors were collected in each study. Frequencies of discordance were pooled by meta-analysis using random effect. In all, 12 studies were selected (i.e., 11,879 patients): weighted mean Â± SD age was 55.1 Â± 13.9 years, weighted mean Â± SD disease duration was 10.4 Â± 9.3 years, and 80.7% were women. The value of the difference | PGA - PhGA | defining discordance varied between â¥0.5 cm (n = 2 studies) to â¥3 cm (n = 5 studies); the weighted mean value was 2.7 cm. The pooled percentage of patients with discordance was 43% (95% confidence interval 36%-51%; range 25%-76%). PGA was usually higher than PhGA. The drivers of PGA were pain and functional incapacity, whereas drivers of PhGA were joint counts and acute-phase reactants. Discordance in global assessment was most frequently defined as a difference of 3 points or more; even with such a stringent definition, up to half the patients were found to be discordant. The long-term consequences of this discordance remain to be determined.
27059693	0	7	Patient	T101	C0030705
27059693	10	19	Physician	T097	C0031831
27059693	20	31	Discordance	T080	C1705242
27059693	35	52	Global Assessment	T062	C0281858
27059693	56	76	Rheumatoid Arthritis	T047	C0003873
27059693	80	90	Systematic	T169	C0220922
27059693	91	108	Literature Review	T170	C0282441
27059693	114	127	Meta-Analysis	T062	C0920317
27059693	151	158	patient	T101	C0030705
27059693	162	173	therapeutic	T169	C0302350
27059693	174	189	decision-making	T041	C0011109
27059693	210	220	management	T058	C0376636
27059693	224	244	rheumatoid arthritis	T047	C0003873
27059693	246	248	RA	T047	C0003873
27059693	259	266	patient	T101	C0030705
27059693	267	274	opinion	T041	C0871010
27059693	285	292	disease	T047	C0012634
27059693	293	299	status	T080	C0449438
27059693	320	331	physician's	T097	C0031831
27059693	332	339	opinion	T041	C0871010
27059693	357	362	study	T062	C2603343
27059693	370	376	assess	T052	C1516048
27059693	384	404	published literature	T170	C0023866
27059693	409	418	frequency	T079	C0376249
27059693	434	441	patient	T101	C0030705
27059693	444	453	physician	T097	C0031831
27059693	454	465	discordance	T080	C1705242
27059693	469	486	global assessment	T062	C0281858
27059693	490	492	RA	T047	C0003873
27059693	496	506	systematic	T169	C0220922
27059693	507	524	literature review	T170	C0282441
27059693	532	540	articles	T170	C1706852
27059693	541	550	published	T057	C0034037
27059693	573	580	Medline	T170	C0025141
27059693	584	590	Embase	T170	C0282574
27059693	602	613	discordance	T080	C1705242
27059693	617	619	RA	T047	C0003873
27059693	640	653	investigators	T097	C0035173
27059693	655	666	Discordance	T080	C1705242
27059693	692	711	absolute difference	T080	C1705242
27059693	715	729	patient global	T170	C4054229
27059693	731	734	PGA	T170	C4054229
27059693	740	768	physician global assessments	T062	C0281858
27059693	770	774	PhGA	T062	C0281858
27059693	799	808	frequency	T079	C0376249
27059693	812	823	discordance	T080	C1705242
27059693	832	842	predictors	T033	C0035648
27059693	866	871	study	T062	C2603343
27059693	873	884	Frequencies	T079	C0376249
27059693	888	899	discordance	T080	C1705242
27059693	905	911	pooled	T169	C2349200
27059693	915	928	meta-analysis	T062	C0920317
27059693	935	941	random	T080	C0439605
27059693	942	948	effect	T080	C1280500
27059693	961	968	studies	T062	C2603343
27059693	997	1005	patients	T101	C0030705
27059693	1008	1021	weighted mean	T081	C0444504
27059693	1027	1030	age	T032	C0001779
27059693	1047	1052	years	T079	C0439234
27059693	1054	1067	weighted mean	T081	C0444504
27059693	1073	1089	disease duration	T079	C0872146
27059693	1105	1110	years	T079	C0439234
27059693	1127	1132	women	T098	C0043210
27059693	1138	1143	value	T081	C1522609
27059693	1151	1161	difference	T081	C1705241
27059693	1164	1167	PGA	T170	C4054229
27059693	1170	1174	PhGA	T062	C0281858
27059693	1186	1197	discordance	T080	C1705242
27059693	1267	1286	weighted mean value	T081	C0444504
27059693	1303	1309	pooled	T169	C2349200
27059693	1310	1320	percentage	T081	C0439165
27059693	1324	1332	patients	T101	C0030705
27059693	1338	1349	discordance	T080	C1705242
27059693	1363	1382	confidence interval	T081	C0009667
27059693	1392	1397	range	T081	C1514721
27059693	1408	1411	PGA	T170	C4054229
27059693	1424	1430	higher	T080	C0205250
27059693	1436	1440	PhGA	T062	C0281858
27059693	1457	1460	PGA	T170	C4054229
27059693	1466	1470	pain	T184	C0030193
27059693	1475	1485	functional	T169	C0205245
27059693	1486	1496	incapacity	T201	C3176592
27059693	1517	1521	PhGA	T062	C0281858
27059693	1527	1539	joint counts	T170	C0282574
27059693	1544	1565	acute-phase reactants	T116,T123	C0001347
27059693	1567	1578	Discordance	T080	C1705242
27059693	1582	1599	global assessment	T062	C0281858
27059693	1609	1619	frequently	T079	C0332183
27059693	1633	1643	difference	T080	C1705242
27059693	1710	1714	half	T081	C2825407
27059693	1719	1727	patients	T101	C0030705
27059693	1745	1755	discordant	T080	C1705242
27059693	1761	1770	long-term	T079	C0443252
27059693	1771	1783	consequences	T169	C0686907
27059693	1792	1803	discordance	T080	C1705242

27061776|t|Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective
27061776|a|Adopting a unique Spanish perspective, this study aims to assess healthcare resource utilization (HCRU) and the costs of treating nosocomial pneumonia (NP) produced by methicillin-resistant Staphylococcus aureus (MRSA) in hospitalized adults using linezolid or vancomycin. An evaluation is also made of the renal failure rate and related economic outcomes between study groups. An economic post hoc evaluation of a randomized, double-blind, multicenter phase 4 study was carried out. Nosocomial pneumonia due to MRSA in hospitalized adults. The modified intent to treat (mITT) population comprised 224 linezolid - and 224 vancomycin - treated patients. Costs and HCRU were evaluated between patients administered either linezolid or vancomycin, and between patients who developed renal failure and those who did not. Analysis of HCRU outcomes and costs. Total costs were similar between the linezolid - (â¬17,782Â±â¬9,615) and vancomycin - treated patients (â¬17,423Â±â¬9,460) (P=.69). The renal failure rate was significantly lower in the linezolid - treated patients (4% vs. 15%; P<.001). The total costs tended to be higher in patients who developed renal failure (â¬19,626Â±â¬10,840 vs. â¬17,388Â±â¬9,369; P=.14). Among the patients who developed renal failure, HCRU (days on mechanical ventilation: 13.2Â±10.7 vs. 7.6Â±3.6 days; P=.21; ICU stay: 14.4Â±10.5 vs. 9.9Â±6.6 days; P=.30; hospital stay: 19.5Â±9.5 vs. 16.1Â±11.0 days; P=.26) and cost (â¬17,219Â±â¬8,792 vs. â¬20,263Â±â¬11,350; P=.51) tended to be lower in the linezolid - vs. vancomycin - treated patients. There were no statistically significant differences in costs per patient - day between cohorts after correcting for mortality (â¬1000 vs. â¬1,010; P=.98). From a Spanish perspective, there were no statistically significant differences in total costs between the linezolid and vancomycin pneumonia cohorts. The drug cost corresponding to linezolid was partially offset by fewer renal failure adverse events.
27061776	0	20	Nosocomial pneumonia	T047	C0949083
27061776	31	74	methicillin-resistant Staphylococcus aureus	T007	C1265292
27061776	75	87	treated with	T061	C0332293
27061776	88	97	linezolid	T109,T121	C0663241
27061776	101	111	vancomycin	T116,T195	C0042313
27061776	125	142	economic analysis	T057	C0680954
27061776	146	158	resource use	T078	C1704738
27061776	166	173	Spanish	T083	C0037747
27061776	174	185	perspective	UnknownType	C0680951
27061776	204	211	Spanish	T083	C0037747
27061776	212	223	perspective	UnknownType	C0680951
27061776	230	235	study	T062	C2603343
27061776	251	282	healthcare resource utilization	T078	C1704738
27061776	284	288	HCRU	T078	C1704738
27061776	298	303	costs	T081	C0085552
27061776	307	315	treating	T169	C1522326
27061776	316	336	nosocomial pneumonia	T047	C0949083
27061776	338	340	NP	T047	C0949083
27061776	354	397	methicillin-resistant Staphylococcus aureus	T007	C1265292
27061776	399	403	MRSA	T007	C1265292
27061776	408	427	hospitalized adults	T033	C0701159
27061776	434	443	linezolid	T109,T121	C0663241
27061776	447	457	vancomycin	T116,T195	C0042313
27061776	493	506	renal failure	T047	C0035078
27061776	507	511	rate	T081	C1521828
27061776	524	541	economic outcomes	T169	C1274040
27061776	550	562	study groups	UnknownType	C0681860
27061776	576	595	post hoc evaluation	T058	C1254363
27061776	601	611	randomized	T062	C2986910
27061776	613	625	double-blind	T062	C0013072
27061776	627	652	multicenter phase 4 study	T062	C0282462
27061776	670	690	Nosocomial pneumonia	T047	C0949083
27061776	698	702	MRSA	T007	C1265292
27061776	706	725	hospitalized adults	T033	C0701159
27061776	731	755	modified intent to treat	T169	C1292734
27061776	757	761	mITT	T169	C1292734
27061776	763	773	population	T098	C1257890
27061776	788	797	linezolid	T109,T121	C0663241
27061776	808	818	vancomycin	T116,T195	C0042313
27061776	821	828	treated	T061	C0332293
27061776	829	837	patients	T101	C0030705
27061776	839	844	Costs	T081	C0085552
27061776	849	853	HCRU	T078	C1704738
27061776	877	885	patients	T101	C0030705
27061776	886	898	administered	T169	C1521801
27061776	906	915	linezolid	T109,T121	C0663241
27061776	919	929	vancomycin	T116,T195	C0042313
27061776	943	951	patients	T101	C0030705
27061776	966	979	renal failure	T047	C0035078
27061776	1015	1019	HCRU	T078	C1704738
27061776	1020	1028	outcomes	T169	C1274040
27061776	1033	1038	costs	T081	C0085552
27061776	1046	1051	costs	T081	C0085552
27061776	1077	1086	linezolid	T109,T121	C0663241
27061776	1110	1120	vancomycin	T116,T195	C0042313
27061776	1123	1130	treated	T061	C0332293
27061776	1131	1139	patients	T101	C0030705
27061776	1170	1183	renal failure	T047	C0035078
27061776	1184	1188	rate	T081	C1521828
27061776	1220	1229	linezolid	T109,T121	C0663241
27061776	1232	1239	treated	T061	C0332293
27061776	1240	1248	patients	T101	C0030705
27061776	1281	1286	costs	T081	C0085552
27061776	1310	1318	patients	T101	C0030705
27061776	1333	1346	renal failure	T047	C0035078
27061776	1402	1410	patients	T101	C0030705
27061776	1425	1438	renal failure	T047	C0035078
27061776	1440	1444	HCRU	T078	C1704738
27061776	1446	1450	days	T079	C0439228
27061776	1454	1476	mechanical ventilation	T061	C0199470
27061776	1500	1504	days	T079	C0439228
27061776	1513	1521	ICU stay	T079	C1254367
27061776	1545	1549	days	T079	C0439228
27061776	1558	1571	hospital stay	T079	C3489408
27061776	1596	1600	days	T079	C0439228
27061776	1613	1617	cost	T081	C0085552
27061776	1688	1697	linezolid	T109,T121	C0663241
27061776	1704	1714	vancomycin	T116,T195	C0042313
27061776	1717	1724	treated	T061	C0332293
27061776	1725	1733	patients	T101	C0030705
27061776	1790	1795	costs	T081	C0085552
27061776	1800	1807	patient	T101	C0030705
27061776	1810	1813	day	T079	C0439228
27061776	1822	1829	cohorts	T098	C0599755
27061776	1851	1860	mortality	T081	C0392762
27061776	1895	1902	Spanish	T083	C0037747
27061776	1903	1914	perspective	UnknownType	C0680951
27061776	1977	1982	costs	T081	C0085552
27061776	1995	2004	linezolid	T109,T121	C0663241
27061776	2009	2019	vancomycin	T116,T195	C0042313
27061776	2020	2029	pneumonia	T047	C0032285
27061776	2030	2037	cohorts	T098	C0599755
27061776	2043	2052	drug cost	T081	C0085123
27061776	2070	2079	linezolid	T109,T121	C0663241
27061776	2094	2100	offset	T081	C1711330
27061776	2110	2123	renal failure	T047	C0035078
27061776	2124	2138	adverse events	T046	C0877248

27086366|t|The Role of TRAF4 and B3GAT1 Gene Expression in the Food Hypersensitivity and Insect Venom Allergy in Mastocytosis
27086366|a|Mastocytosis is an uncommon disease classified as a myeloproliferative neoplasm, however, its symptoms are broad and place patients at crossroads between dermatology, hematology and allergology. Patients with mastocytosis often suffer from symptoms resulting from the activation and release of mediators from the mast cells, such as generalized itching, redness, headache, abdominal cramps, diarrhea, bone pain or arthritis, hypotension and shock. The possible severe, fatal or near fatal reactions caused by food hypersensitivity are reasons for the research focused on marker identification. The aim of the study was to analyse the gene expression differences in mastocytosis patients with and without food and drug hypersensitivity and insect venom allergy (IVA). A total of 57 Caucasian patients with mastocytosis were studied [median age 41.8; range 18-77 years; 15 (26.3 %) males and 42 (73.7 %) females]. Quantitative RT-PCRs of 11 genes plus ribosomal 18S RNA were run. Symptoms of food hypersensitivity were found in 12 patients (21 %), including 3 patients (13 %) with cutaneous mastocytosis (CM), and 9 (28 %) with indolent systemic mastocytosis (ISM). IVA was confirmed in 13 patients (22.8 %) including 6 patients (10.5 %) with CM, and 7 patients (12.3 %) with ISM. Drug hypersensitivity was diagnosed in 10 patients (17.5 %). Significant differences in the gene expression were found for TRAF4 (p = 0.008) in the comparison of the mastocytosis patients with and without concomitant food hypersensitivity. Furthermore significant differences were found in gene expression for B3GAT1 (p = 0.003) in patients with IVA compared to patients without insect sting anaphylaxis in the medical history. The expression of studied genes did not differ according to the presence of drug hypersensitivity. The TRAF4 expression was higher in mastocytosis patients with food hypersensitivity in their medical history, the B3GAT1 expression was lower in mastocytosis patients with IVA in history.
27086366	12	17	TRAF4	T028	C1336665
27086366	22	28	B3GAT1	T028	C1412716
27086366	29	44	Gene Expression	T045	C0017262
27086366	52	73	Food Hypersensitivity	T046	C0016470
27086366	78	98	Insect Venom Allergy	T046	C0020517
27086366	102	114	Mastocytosis	T047	C0024899
27086366	115	127	Mastocytosis	T047	C0024899
27086366	143	150	disease	T047	C0012634
27086366	167	194	myeloproliferative neoplasm	T191	C0027022
27086366	209	217	symptoms	T184	C1457887
27086366	238	246	patients	T101	C0030705
27086366	269	280	dermatology	T091	C0011627
27086366	282	292	hematology	T091	C0018943
27086366	310	318	Patients	T101	C0030705
27086366	324	336	mastocytosis	T047	C0024899
27086366	355	363	symptoms	T184	C1457887
27086366	383	393	activation	T052	C1879547
27086366	428	438	mast cells	T025	C0024880
27086366	460	467	itching	T184	C0033774
27086366	469	476	redness	T047	C0041834
27086366	478	486	headache	T184	C0018681
27086366	488	504	abdominal cramps	T184	C0000729
27086366	506	514	diarrhea	T184	C0011991
27086366	516	525	bone pain	T184	C0151825
27086366	529	538	arthritis	T047	C0003864
27086366	540	551	hypotension	T033	C0020649
27086366	556	561	shock	T046	C0036974
27086366	584	589	fatal	T080	C1302234
27086366	598	603	fatal	T080	C1302234
27086366	624	645	food hypersensitivity	T046	C0016470
27086366	686	692	marker	T201	C0005516
27086366	724	729	study	T062	C2603343
27086366	749	764	gene expression	T045	C0017262
27086366	780	792	mastocytosis	T047	C0024899
27086366	793	801	patients	T101	C0030705
27086366	819	823	food	T046	C0016470
27086366	828	849	drug hypersensitivity	T046	C0013182
27086366	854	874	insect venom allergy	T046	C0020517
27086366	876	879	IVA	T046	C0020517
27086366	896	905	Caucasian	T098	C0043157
27086366	906	914	patients	T101	C0030705
27086366	920	932	mastocytosis	T047	C0024899
27086366	954	957	age	T032	C0001779
27086366	976	981	years	T079	C0439234
27086366	995	1000	males	T032	C0086582
27086366	1017	1024	females	T032	C0086287
27086366	1027	1047	Quantitative RT-PCRs	T063	C3179034
27086366	1054	1059	genes	T028	C0017337
27086366	1065	1082	ribosomal 18S RNA	T114,T123	C0035703
27086366	1093	1101	Symptoms	T184	C1457887
27086366	1105	1126	food hypersensitivity	T046	C0016470
27086366	1144	1152	patients	T101	C0030705
27086366	1173	1181	patients	T101	C0030705
27086366	1194	1216	cutaneous mastocytosis	T191	C1136033
27086366	1218	1220	CM	T191	C1136033
27086366	1241	1271	indolent systemic mastocytosis	T047	C0272203
27086366	1273	1276	ISM	T047	C0272203
27086366	1279	1282	IVA	T046	C0020517
27086366	1303	1311	patients	T101	C0030705
27086366	1333	1341	patients	T101	C0030705
27086366	1356	1358	CM	T191	C1136033
27086366	1366	1374	patients	T101	C0030705
27086366	1389	1392	ISM	T047	C0272203
27086366	1394	1415	Drug hypersensitivity	T046	C0013182
27086366	1420	1429	diagnosed	T033	C0011900
27086366	1436	1444	patients	T101	C0030705
27086366	1486	1501	gene expression	T045	C0017262
27086366	1517	1522	TRAF4	T028	C1336665
27086366	1560	1572	mastocytosis	T047	C0024899
27086366	1573	1581	patients	T101	C0030705
27086366	1611	1632	food hypersensitivity	T046	C0016470
27086366	1684	1699	gene expression	T045	C0017262
27086366	1704	1710	B3GAT1	T028	C1412716
27086366	1726	1734	patients	T101	C0030705
27086366	1740	1743	IVA	T046	C0020517
27086366	1756	1764	patients	T101	C0030705
27086366	1773	1785	insect sting	T037	C0079626
27086366	1786	1797	anaphylaxis	T046	C0002792
27086366	1826	1836	expression	T045	C0017262
27086366	1848	1853	genes	T028	C0017337
27086366	1898	1919	drug hypersensitivity	T046	C0013182
27086366	1925	1930	TRAF4	T028	C1336665
27086366	1931	1941	expression	T045	C0017262
27086366	1956	1968	mastocytosis	T047	C0024899
27086366	1969	1977	patients	T101	C0030705
27086366	1983	2004	food hypersensitivity	T046	C0016470
27086366	2014	2029	medical history	T033	C0262926
27086366	2035	2041	B3GAT1	T028	C1412716
27086366	2042	2052	expression	T045	C0017262
27086366	2066	2078	mastocytosis	T047	C0024899
27086366	2079	2087	patients	T101	C0030705
27086366	2093	2096	IVA	T046	C0020517

27093899|t|Generalized Weakness in a Transplant Patient: A Case Presentation
27093899|a|Generalized weakness in transplant patients is a major complaint in tertiary rehabilitation hospitals. The diagnosis and management of generalized weakness in this population pose challenges for physicians. We present the case of a transplant patient with generalized weakness who was eventually diagnosed with calciphylaxis using a multidisciplinary diagnostic approach of electrodiagnostics, vascular study, and skin biopsy. Calciphylaxis is a rare cutaneous disorder that mimics other collagen vascular diseases in its presentation and fulminant course. Physiatrists should be cognizant of calciphylaxis, as it signals a poor prognosis if not correctly diagnosed and treated in a timely manner, with high incidence of sepsis, wound pain, and disability. V.
27093899	0	20	Generalized Weakness	T184	C3714552
27093899	26	36	Transplant	T033	C3841811
27093899	37	44	Patient	T101	C0030705
27093899	48	65	Case Presentation	T170	C0085973
27093899	66	86	Generalized weakness	T184	C3714552
27093899	90	100	transplant	T033	C3841811
27093899	101	109	patients	T101	C0030705
27093899	143	167	rehabilitation hospitals	T073,T093	C0337962
27093899	173	182	diagnosis	T033	C0011900
27093899	187	197	management	T061	C1536570
27093899	201	221	generalized weakness	T184	C3714552
27093899	230	240	population	T098	C1257890
27093899	261	271	physicians	T097	C0031831
27093899	298	308	transplant	T033	C3841811
27093899	309	316	patient	T101	C0030705
27093899	322	342	generalized weakness	T184	C3714552
27093899	362	371	diagnosed	T033	C0011900
27093899	377	390	calciphylaxis	T047	C0006666
27093899	399	436	multidisciplinary diagnostic approach	T060	C0729737
27093899	440	458	electrodiagnostics	T060	C0013816
27093899	460	468	vascular	T023	C0005847
27093899	469	474	study	T060	C0086143
27093899	480	491	skin biopsy	T060	C0150866
27093899	493	506	Calciphylaxis	T047	C0006666
27093899	517	535	cutaneous disorder	T047	C0037274
27093899	554	580	collagen vascular diseases	T047	C0262428
27093899	623	635	Physiatrists	T097	C0260138
27093899	659	672	calciphylaxis	T047	C0006666
27093899	690	704	poor prognosis	T033	C0278252
27093899	712	731	correctly diagnosed	T080	C0205556
27093899	736	743	treated	T169	C1522326
27093899	749	762	timely manner	T080	C3827828
27093899	774	783	incidence	T081	C0021149
27093899	787	793	sepsis	T047	C0243026
27093899	795	805	wound pain	T184	C0241745
27093899	811	821	disability	T033	C0231170

27113387|t|Use of ecoacoustics to determine biodiversity patterns across ecological gradients
27113387|a|The variety of local animal sounds characterizes a landscape. We used ecoacoustics to noninvasively assess the species richness of various biotopes typical of an ecofriendly forest plantation with diverse ecological gradients and both nonnative and indigenous vegetation. The reference area was an adjacent large World Heritage Site protected area (PA). All sites were in a global biodiversity hotspot. Our results showed how taxa segregated into various biotopes. We identified 65 singing species, including birds, frogs, crickets, and katydids. Large, natural, protected grassland sites in the PA had the highest mean acoustic diversity (14.1 species / site). Areas covered in nonnative timber or grass species were devoid of acoustic species. Sites grazed by native and domestic megaherbivores were fairly rich (5.1) in acoustic species but none were unique to this habitat type, where acoustic diversity was greater than in intensively managed grassland sites (0.04). Natural vegetation patches inside the plantation mosaic supported high mean acoustic diversity (indigenous forests 7.6, grasslands 8.0, wetlands 9.1), which increased as plant heterogeneity and patch size increased. Indigenous forest patches within the plantation mosaic contained a highly characteristic acoustic species assemblage, emphasizing their complementary contribution to local biodiversity. Overall, acoustic signals determined spatial biodiversity patterns and can be a useful tool for guiding conservation.
27113387	7	19	ecoacoustics	T057	C0242479
27113387	33	45	biodiversity	T080	C0282469
27113387	46	54	patterns	T082	C0449774
27113387	62	72	ecological	T082	C0565987
27113387	73	82	gradients	T081	C0812409
27113387	98	103	local	T082	C0205276
27113387	104	110	animal	T008	C0003062
27113387	111	117	sounds	T070	C0037709
27113387	118	131	characterizes	T078	C3875152
27113387	134	143	landscape	T082	C0870781
27113387	153	165	ecoacoustics	T057	C0242479
27113387	183	189	assess	T169	C0205245
27113387	194	201	species	T185	C1705920
27113387	214	221	various	T081	C0439064
27113387	222	230	biotopes	T083	C0017446
27113387	245	274	ecofriendly forest plantation	T070	C0086312
27113387	280	287	diverse	T080	C1880371
27113387	288	298	ecological	T082	C0565987
27113387	299	308	gradients	T081	C0812409
27113387	318	327	nonnative	T033	C2230122
27113387	332	342	indigenous	T102	C1512704
27113387	343	353	vegetation	T002	C0032098
27113387	359	368	reference	T077	C1706462
27113387	369	373	area	T083	C0017446
27113387	381	389	adjacent	T082	C0205117
27113387	396	430	World Heritage Site protected area	T083	C0017446
27113387	432	434	PA	T083	C0017446
27113387	441	446	sites	T082	C0205145
27113387	457	484	global biodiversity hotspot	T083	C0017446
27113387	490	497	results	T169	C1274040
27113387	509	513	taxa	T077	C1515221
27113387	514	524	segregated	T080	C0443299
27113387	530	537	various	T081	C0439064
27113387	538	546	biotopes	T083	C0017446
27113387	551	561	identified	T080	C0205396
27113387	565	572	singing	T055	C0042932
27113387	573	580	species	T185	C1705920
27113387	592	597	birds	T012	C0005595
27113387	599	604	frogs	T011	C0003459
27113387	606	614	crickets	T204	C0018288
27113387	620	628	katydids	T204	C0684063
27113387	630	635	Large	T081	C0549177
27113387	637	644	natural	T169	C0205296
27113387	656	671	grassland sites	T082	C0442534
27113387	679	681	PA	T083	C0017446
27113387	690	697	highest	T080	C1522410
27113387	698	721	mean acoustic diversity	T081	C0392762
27113387	728	735	species	T185	C1705920
27113387	738	742	site	T082	C0205145
27113387	745	750	Areas	T082	C0205146
27113387	762	778	nonnative timber	T002	C0032098
27113387	782	787	grass	T002	C0018210
27113387	788	795	species	T185	C1705920
27113387	811	827	acoustic species	T185	C1705920
27113387	829	834	Sites	T082	C0205145
27113387	845	851	native	T169	C0302891
27113387	856	864	domestic	T080	C1880391
27113387	865	879	megaherbivores	T008	C0562691
27113387	906	922	acoustic species	T185	C1705920
27113387	937	943	unique	T080	C1710548
27113387	952	964	habitat type	T082	C0871648
27113387	972	990	acoustic diversity	T080	C1880371
27113387	1031	1040	grassland	T082	C0442534
27113387	1041	1046	sites	T082	C0205145
27113387	1055	1073	Natural vegetation	T070	C0086312
27113387	1093	1110	plantation mosaic	T082	C1254362
27113387	1126	1149	mean acoustic diversity	T081	C0392762
27113387	1151	1161	indigenous	T102	C1512704
27113387	1162	1169	forests	T070	C0086312
27113387	1175	1185	grasslands	T082	C0442534
27113387	1191	1199	wetlands	T070	C1721088
27113387	1225	1230	plant	T002	C0032098
27113387	1231	1244	heterogeneity	T080	C0019409
27113387	1249	1259	patch size	T082	C0449456
27113387	1260	1269	increased	T081	C0205217
27113387	1271	1281	Indigenous	T102	C1512704
27113387	1282	1296	forest patches	T070	C0086312
27113387	1308	1325	plantation mosaic	T082	C1254362
27113387	1345	1359	characteristic	T080	C1521970
27113387	1360	1376	acoustic species	T185	C1705920
27113387	1377	1387	assemblage	T078	C1254370
27113387	1421	1433	contribution	T052	C1880177
27113387	1437	1442	local	T082	C0205276
27113387	1443	1455	biodiversity	T080	C0282469
27113387	1466	1482	acoustic signals	T067	C0028263
27113387	1502	1514	biodiversity	T080	C0282469
27113387	1515	1523	patterns	T082	C0449774
27113387	1561	1573	conservation	T080	C2347858

27117874|t|A Randomized Controlled Noninferiority Trial of Single Dose of Oral Dexamethasone Versus 5 Days of Oral Prednisone in Acute Adult Asthma
27117874|a|Oral dexamethasone demonstrates bioavailability similar to that of oral prednisone but has a longer half-life. We evaluate whether a single dose of oral dexamethasone plus 4 days of placebo is not inferior to 5 days of oral prednisone in treatment of adults with mild to moderate asthma exacerbations to prevent relapse defined as an unscheduled return visit for additional treatment for persistent or worsening asthma within 14 days. Adult emergency department patients (aged 18 to 55 years) were randomized to receive either a single dose of 12 mg of oral dexamethasone with 4 days of placebo or a 5- day course of oral prednisone 60 mg a day. Outcomes including relapse were assessed by a follow-up telephone interview at 2 weeks. One hundred seventy-three dexamethasone and 203 prednisone subjects completed the study regimen and telephone follow-up. The dexamethasone group by a small margin surpassed the preset 8% difference between groups for noninferiority in relapse rates within 14 days (12.1% versus 9.8%; difference 2.3%; 95% confidence interval -4.1% to 8.6%). Subjects in the 2 groups had similar rates of hospitalization for their relapse visit (dexamethasone 3.4% versus prednisone 2.9%; difference 0.5%; 95% confidence interval -4.1% to 3.1%). Adverse effect rates were generally the same in the 2 groups. A single dose of oral dexamethasone did not demonstrate noninferiority to prednisone for 5 days by a very small margin for treatment of adults with mild to moderate asthma exacerbations. Enhanced compliance and convenience may support the use of dexamethasone regardless.
27117874	2	44	Randomized Controlled Noninferiority Trial	T062	C0206035
27117874	48	59	Single Dose	T081	C0178602
27117874	63	81	Oral Dexamethasone	T200	C0360528
27117874	91	95	Days	T079	C0439228
27117874	99	114	Oral Prednisone	T200	C3216040
27117874	124	129	Adult	T100	C0001675
27117874	130	136	Asthma	T047	C0004096
27117874	137	155	Oral dexamethasone	T200	C0360528
27117874	156	168	demonstrates	T052	C3687625
27117874	169	184	bioavailability	T081	C0005508
27117874	185	192	similar	T080	C2348205
27117874	204	219	oral prednisone	T200	C3216040
27117874	237	246	half-life	T079	C0018517
27117874	270	281	single dose	T081	C0178602
27117874	285	303	oral dexamethasone	T200	C0360528
27117874	304	308	plus	T169	C0332287
27117874	311	315	days	T079	C0439228
27117874	319	326	placebo	T122	C1696465
27117874	334	342	inferior	T082	C0542339
27117874	348	352	days	T079	C0439228
27117874	356	371	oral prednisone	T200	C3216040
27117874	375	384	treatment	T169	C1522326
27117874	388	394	adults	T100	C0001675
27117874	400	404	mild	T033	C0581124
27117874	408	416	moderate	T033	C0581125
27117874	417	437	asthma exacerbations	T033	C0349790
27117874	441	448	prevent	T169	C1292733
27117874	449	456	relapse	T067	C0035020
27117874	471	482	unscheduled	T079	C3854240
27117874	500	520	additional treatment	T033	C1706712
27117874	525	535	persistent	T047	C3266628
27117874	539	548	worsening	T080	C0332271
27117874	549	555	asthma	T047	C0004096
27117874	566	570	days	T079	C0439228
27117874	572	577	Adult	T100	C0001675
27117874	578	598	emergency department	T073,T093	C3840745
27117874	599	607	patients	T101	C0030705
27117874	609	613	aged	T032	C0001779
27117874	623	628	years	T079	C0439234
27117874	635	645	randomized	T062	C0034656
27117874	649	656	receive	T080	C1514756
27117874	666	677	single dose	T081	C0178602
27117874	690	708	oral dexamethasone	T200	C0360528
27117874	716	720	days	T079	C0439228
27117874	724	731	placebo	T122	C1696465
27117874	740	743	day	T079	C0439228
27117874	744	750	course	T079	C0750729
27117874	754	769	oral prednisone	T200	C3216040
27117874	778	781	day	T079	C0439228
27117874	783	791	Outcomes	T169	C1274040
27117874	792	801	including	T169	C0332257
27117874	802	809	relapse	T067	C0035020
27117874	815	823	assessed	T052	C1516048
27117874	829	858	follow-up telephone interview	T058	C0178941
27117874	864	869	weeks	T079	C0439230
27117874	875	896	hundred seventy-three	T081	C0392762
27117874	897	910	dexamethasone	T109,T121	C0011777
27117874	919	929	prednisone	T109,T121,T125	C0032952
27117874	930	938	subjects	T096	C0681850
27117874	939	948	completed	T080	C0205197
27117874	971	990	telephone follow-up	T058	C0178941
27117874	996	1009	dexamethasone	T109,T121	C0011777
27117874	1010	1015	group	UnknownType	C0681860
27117874	1058	1068	difference	T080	C1705242
27117874	1077	1083	groups	UnknownType	C0681860
27117874	1088	1102	noninferiority	T080	C0205556
27117874	1106	1113	relapse	T067	C0035020
27117874	1114	1119	rates	T081	C1521828
27117874	1130	1134	days	T079	C0439228
27117874	1155	1165	difference	T080	C1705242
27117874	1176	1195	confidence interval	T081	C0009667
27117874	1212	1220	Subjects	T096	C0681850
27117874	1230	1236	groups	UnknownType	C0681860
27117874	1249	1254	rates	T081	C1521828
27117874	1258	1273	hospitalization	T058	C0019993
27117874	1284	1291	relapse	T067	C0035020
27117874	1292	1297	visit	T058	C1512346
27117874	1299	1312	dexamethasone	T109,T121	C0011777
27117874	1325	1335	prednisone	T109,T121,T125	C0032952
27117874	1342	1352	difference	T080	C1705242
27117874	1363	1382	confidence interval	T081	C0009667
27117874	1399	1413	Adverse effect	T080	C1280500
27117874	1414	1419	rates	T081	C1521828
27117874	1453	1459	groups	UnknownType	C0681860
27117874	1463	1474	single dose	T081	C0178602
27117874	1478	1496	oral dexamethasone	T200	C0360528
27117874	1505	1516	demonstrate	T052	C3687625
27117874	1517	1531	noninferiority	T080	C0205556
27117874	1535	1545	prednisone	T109,T121,T125	C0032952
27117874	1552	1556	days	T079	C0439228
27117874	1584	1593	treatment	T169	C1522326
27117874	1597	1603	adults	T100	C0001675
27117874	1609	1613	mild	T033	C0581124
27117874	1617	1625	moderate	T033	C0581125
27117874	1626	1646	asthma exacerbations	T033	C0349790
27117874	1648	1656	Enhanced	T052	C2349975
27117874	1657	1667	compliance	T033	C3714738
27117874	1672	1683	convenience	T080	C3831015
27117874	1700	1703	use	T169	C0457083
27117874	1707	1720	dexamethasone	T109,T121	C0011777

27121486|t|Relationship between XspI Site Polymorphisms of LDL-R Gene and Serum IL-2 and IL-10 in Patients with Hypercholesterolemia
27121486|a|Relationship has been identified in sporadic reports between polymorphisms and hypercholesterolemia. However, the relationship between inflammatory cytokines and polymorphism of low-density lipoprotein receptor (LDL-R) gene in hypercholesterolemia is unclear. This study aimed to explore the relationship and significance between polymorphisms of LDL-R gene and serum Interleukin-2 (IL-2), IL-10 in patients with hypercholesterolemia. PCR-RFLP and direct DNA sequencing assay were employed to determine polymorphism of LDL-R gene in 900 patients with hypercholesterolemia and 400 healthy cases. ELISA was applied to assay serum concentration of IL-2 and IL-10. Blood lipid indexes were tested in all cases. Compared with the healthy controls, level of IL-2 increased significantly, while IL-10 decreased significantly (P < 0.05). Correlation analysis showed that IL-2 was positively correlated with total cholesterol (TC), LDL-c, and genotype (r = 0.542, 0.410, 0.598, P < 0.05) and negatively correlated with HDL-c (r = -0.352, P < 0.05). Negative relationship also was found between TC, LDL-c, genotype, and IL-10 (r = -0.452, -0.390, -0.613, P < 0.05), and positive correlation between HDL-c and IL-10 (r = 0.398, P < 0.05). Multiple linear regression showed that genotypes and TC were independent factors affecting the levels of IL-2 and IL-10 (P < 0.05). IL-2 and IL-10 were related to gene polymorphisms of LDL-R, which might be involved in the development and progress of hypercholesterolemia.
27121486	0	12	Relationship	T080	C0439849
27121486	21	25	XspI	T116,T126	C0752931
27121486	26	44	Site Polymorphisms	T049	C1709929
27121486	48	58	LDL-R Gene	T028	C1366529
27121486	63	73	Serum IL-2	T116,T129	C0021756
27121486	78	83	IL-10	T116,T129	C0085295
27121486	87	95	Patients	T101	C0030705
27121486	101	121	Hypercholesterolemia	T047	C0020443
27121486	122	134	Relationship	T080	C0439849
27121486	144	154	identified	T080	C0205396
27121486	158	174	sporadic reports	T033	C0243095
27121486	183	196	polymorphisms	T045	C0678951
27121486	201	221	hypercholesterolemia	T047	C0020443
27121486	236	248	relationship	T080	C0439849
27121486	257	269	inflammatory	T169	C0333348
27121486	270	279	cytokines	T116,T129	C0079189
27121486	284	296	polymorphism	T045	C0678951
27121486	300	345	low-density lipoprotein receptor (LDL-R) gene	T028	C1366529
27121486	349	369	hypercholesterolemia	T047	C0020443
27121486	373	380	unclear	T033	C3845108
27121486	387	392	study	T062	C2603343
27121486	393	398	aimed	T078	C1947946
27121486	414	426	relationship	T080	C0439849
27121486	431	443	significance	T078	C0750502
27121486	452	465	polymorphisms	T045	C0678951
27121486	469	479	LDL-R gene	T028	C1366529
27121486	484	503	serum Interleukin-2	T116,T129	C0021756
27121486	505	509	IL-2	T116,T129	C0021756
27121486	512	517	IL-10	T116,T129	C0085295
27121486	521	529	patients	T101	C0030705
27121486	535	555	hypercholesterolemia	T047	C0020443
27121486	557	565	PCR-RFLP	T059	C0200930
27121486	570	597	direct DNA sequencing assay	T059,T063	C0917792
27121486	603	611	employed	T033	C0557351
27121486	625	637	polymorphism	T045	C0678951
27121486	641	651	LDL-R gene	T028	C1366529
27121486	659	667	patients	T101	C0030705
27121486	673	693	hypercholesterolemia	T047	C0020443
27121486	702	709	healthy	T080	C3898900
27121486	710	715	cases	T169	C0868928
27121486	717	722	ELISA	T059	C0014441
27121486	727	734	applied	T169	C4048755
27121486	738	763	assay serum concentration	T081	C0683149
27121486	767	771	IL-2	T116,T129	C0021756
27121486	776	781	IL-10	T116,T129	C0085295
27121486	783	794	Blood lipid	T109	C0596192
27121486	795	802	indexes	T170	C0600653
27121486	808	814	tested	T169	C0039593
27121486	822	827	cases	T169	C0868928
27121486	829	837	Compared	T052	C1707455
27121486	847	863	healthy controls	T080	C2986479
27121486	865	870	level	T080	C0441889
27121486	874	878	IL-2	T116,T129	C0021756
27121486	879	888	increased	T081	C0205217
27121486	889	902	significantly	T078	C0750502
27121486	910	915	IL-10	T116,T129	C0085295
27121486	916	925	decreased	T081	C0205216
27121486	926	939	significantly	T078	C0750502
27121486	952	972	Correlation analysis	T062,T170	C0010101
27121486	985	989	IL-2	T116,T129	C0021756
27121486	994	1004	positively	T033	C3843166
27121486	1005	1015	correlated	T080	C1707520
27121486	1021	1038	total cholesterol	T109	C0543421
27121486	1040	1042	TC	T109	C0543421
27121486	1045	1050	LDL-c	T109,T123	C0023824
27121486	1056	1064	genotype	T032	C0017431
27121486	1105	1115	negatively	T033	C0243095
27121486	1116	1126	correlated	T080	C1707520
27121486	1132	1137	HDL-c	T109,T123	C0023822
27121486	1162	1170	Negative	T033	C0205160
27121486	1171	1183	relationship	T080	C0439849
27121486	1207	1209	TC	T109	C0543421
27121486	1211	1216	LDL-c	T109,T123	C0023824
27121486	1218	1226	genotype	T032	C0017431
27121486	1232	1237	IL-10	T116,T129	C0085295
27121486	1282	1290	positive	T033	C1446409
27121486	1291	1302	correlation	T080	C1707520
27121486	1311	1316	HDL-c	T109,T123	C0023822
27121486	1321	1326	IL-10	T116,T129	C0085295
27121486	1350	1376	Multiple linear regression	T081	C0023733
27121486	1389	1398	genotypes	T032	C0017431
27121486	1403	1405	TC	T109	C0543421
27121486	1411	1422	independent	T078	C0085862
27121486	1423	1430	factors	T169	C1521761
27121486	1431	1440	affecting	T169	C0392760
27121486	1445	1459	levels of IL-2	T059	C0022885
27121486	1455	1459	IL-2	T116,T129	C0021756
27121486	1464	1469	IL-10	T059	C0022885
27121486	1482	1486	IL-2	T116,T129	C0021756
27121486	1491	1496	IL-10	T116,T129	C0085295
27121486	1502	1509	related	T080	C0439849
27121486	1513	1531	gene polymorphisms	T045	C0678951
27121486	1535	1540	LDL-R	T028	C1366529
27121486	1557	1565	involved	T169	C1314939
27121486	1573	1584	development	T169	C1527148
27121486	1589	1597	progress	T169	C1280477
27121486	1601	1621	hypercholesterolemia	T047	C0020443

27131339|t|HERG1 potassium channel expression in potentially malignant disorders of the oral mucosa and prognostic relevance in oral squamous cell carcinoma
27131339|a|HERG1 potassium channel plays a critical role in the cell proliferation. HERG1 protein expression was analyzed by immunohistochemistry (IHC) in 62 patients with oral leukoplakias and 100 patients with oral squamous cell carcinomas (OSCC). HERG1 mRNA levels were assessed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) in 22 patients with primary head and neck squamous cell carcinoma (HNSCC). Statistically significant associations were found between HERG1 expression and tobacco consumption, disease stage, tumor differentiation, tumor recurrence, and reduced survival. There was no association between HERG1 expression and the risk of progression from oral leukoplakia to OSCC. In addition, a high proportion of tumors (80%) showed increased HERG1 mRNA levels compared to normal mucosa from nononcologic patients. Aberrant HERG1 expression increases as oral tumorigenesis progresses from oral hyperplasia to OSCC. Increased HERG1 mRNA levels were also frequently detected in OSCC and other HNSCC subsites. HERG1 expression emerges as a clinically relevant feature during tumor progression and a potential poor prognostic biomarker for OSCC. Â© 2016 Wiley Periodicals, Inc. Head Neck 38: 1708-1716, 2016.
27131339	0	5	HERG1	T116,T123	C1566128
27131339	6	23	potassium channel	T116,T123	C0032824
27131339	24	34	expression	T045	C1171362
27131339	38	49	potentially	T080	C3245505
27131339	50	69	malignant disorders	T191	C0006826
27131339	77	88	oral mucosa	T023	C0026639
27131339	93	103	prognostic	T170	C0220901
27131339	104	113	relevance	T080	C2347946
27131339	117	145	oral squamous cell carcinoma	T191	C0585362
27131339	146	151	HERG1	T116,T123	C1566128
27131339	152	169	potassium channel	T116,T123	C0032824
27131339	178	186	critical	T080	C1511545
27131339	187	191	role	T077	C1705810
27131339	199	217	cell proliferation	T043	C0596290
27131339	219	232	HERG1 protein	T116,T123	C1566128
27131339	233	243	expression	T045	C1171362
27131339	248	256	analyzed	T062	C0936012
27131339	260	280	immunohistochemistry	T060	C0021044
27131339	282	285	IHC	T060	C0021044
27131339	293	301	patients	T101	C0030705
27131339	307	324	oral leukoplakias	T191	C0023532
27131339	333	341	patients	T101	C0030705
27131339	347	376	oral squamous cell carcinomas	T191	C0585362
27131339	378	382	OSCC	T191	C0585362
27131339	385	390	HERG1	T028	C1416571
27131339	391	395	mRNA	T114,T123	C0035696
27131339	396	402	levels	T080	C0441889
27131339	408	416	assessed	T052	C1516048
27131339	420	477	real-time reverse transcriptase-polymerase chain reaction	T063	C0599161
27131339	479	485	RT-PCR	T063	C0599161
27131339	493	501	patients	T101	C0030705
27131339	507	514	primary	T080	C0205225
27131339	515	552	head and neck squamous cell carcinoma	T191	C1168401
27131339	554	559	HNSCC	T191	C1168401
27131339	562	587	Statistically significant	T081	C0237881
27131339	588	600	associations	T080	C0439849
27131339	620	625	HERG1	T116,T123	C1566128
27131339	626	636	expression	T045	C1171362
27131339	641	660	tobacco consumption	T055	C0543414
27131339	662	675	disease stage	T060	C0699749
27131339	677	682	tumor	T191	C0027651
27131339	683	698	differentiation	T043	C0007589
27131339	700	716	tumor recurrence	T191	C0521158
27131339	722	729	reduced	T080	C0392756
27131339	730	738	survival	T052	C0038952
27131339	750	752	no	T169	C1518422
27131339	753	764	association	T080	C0439849
27131339	773	778	HERG1	T116,T123	C1566128
27131339	779	789	expression	T045	C1171362
27131339	798	802	risk	T078	C0035647
27131339	806	817	progression	T191	C0178874
27131339	823	839	oral leukoplakia	T191	C0023532
27131339	843	847	OSCC	T191	C0585362
27131339	864	868	high	T080	C0205250
27131339	869	879	proportion	T081	C1709707
27131339	883	889	tumors	T191	C0027651
27131339	903	912	increased	T081	C0205217
27131339	913	918	HERG1	T028	C1416571
27131339	919	923	mRNA	T114,T123	C0035696
27131339	924	930	levels	T080	C0441889
27131339	931	939	compared	T052	C1707455
27131339	943	956	normal mucosa	T024	C0026724
27131339	962	983	nononcologic patients	T101	C0030705
27131339	985	993	Aberrant	T080	C0443127
27131339	994	999	HERG1	T116,T123	C1566128
27131339	1000	1010	expression	T045	C1171362
27131339	1011	1020	increases	T169	C0442805
27131339	1029	1053	tumorigenesis progresses	T191	C0178874
27131339	1059	1075	oral hyperplasia	T046	C1400010
27131339	1079	1083	OSCC	T191	C0585362
27131339	1085	1094	Increased	T081	C0205217
27131339	1095	1100	HERG1	T028	C1416571
27131339	1101	1105	mRNA	T114,T123	C0035696
27131339	1106	1112	levels	T080	C0441889
27131339	1134	1142	detected	T033	C0442726
27131339	1146	1150	OSCC	T191	C0585362
27131339	1161	1166	HNSCC	T191	C1168401
27131339	1167	1175	subsites	T082	C1710234
27131339	1177	1182	HERG1	T116,T123	C1566128
27131339	1183	1193	expression	T045	C1171362
27131339	1207	1217	clinically	T080	C0205210
27131339	1218	1226	relevant	T080	C2347946
27131339	1227	1234	feature	T080	C2348519
27131339	1242	1259	tumor progression	T191	C0178874
27131339	1266	1275	potential	T080	C3245505
27131339	1276	1280	poor	T080	C2700379
27131339	1281	1291	prognostic	T170	C0220901
27131339	1292	1301	biomarker	T201	C0005516
27131339	1306	1310	OSCC	T191	C0585362

27172917|t|Malignancy is associated with microcalcification and higher AP/T ratio in ultrasonography, but not with Hashimoto's thyroiditis in histopathology in patients with thyroid nodules evaluated as Bethesda Category III (AUS / FLUS) in cytology
27172917|a|The predictors of malignancy are important for the decision of appropriate management in nodules with atypia of undetermined significance / follicular lesion of undetermined significance (AUS / FLUS). Our aim was to determine the ultrasonographical, clinical, and biochemical predictors of malignancy in these patients. A total of 427 patients with cytologically Bethesda Category III (AUS / FLUS) thyroid nodules were included in this retrospective study. We divided the nodules into two subgroups according to the histopathology as benign and malignant, and compared the preoperative ultrasonographical, clinical, and biochemical findings. In overall, 427 patients with 449 AUS / FLUS nodules who had undergone surgery, the rate of malignancy was 23.4 % (105/449). When evaluated separately, the rate of malignancy was 25.8 % in nodules with AUS (82/318) and 17.6 % in nodules with FLUS (23/131) (p = 0.061). The vast majority of malignant specimens in histopathology consisted of papillary thyroid carcinoma (PTC) (n = 91, 86.7 %). Preoperative ultrasonographic features of 105 malignant nodules in histopathology were compared with the 344 benign nodules in histopathology. Anteroposterior/Transverse (AP/T) ratio was significantly higher in malignant group compared to benign group (p = 0.013). In multiple logistic analysis, we found that higher AP/T ratio and microcalcification were independently associated with malignancy (p < 0.05). The malignancy -associated cut-off value of AP/T ratio at maximum sensitivity and specificity was â¥0.81. We did not find any correlation between malignancy and Hashimoto's thyroiditis in histopathology in multivariate analysis (p > 0.05). In Bethesda Category III nodules with higher AP/T ratio and microcalcification, surgery might be considered as a first therapeutic option instead of repeat fine-needle aspiration biopsy or observation.
27172917	0	10	Malignancy	T191	C4282132
27172917	14	29	associated with	T080	C0332281
27172917	30	48	microcalcification	T046	C0521174
27172917	53	70	higher AP/T ratio	T081	C0456603
27172917	74	89	ultrasonography	T060	C0041618
27172917	104	127	Hashimoto's thyroiditis	T047	C0677607
27172917	131	145	histopathology	T059	C0430445
27172917	149	157	patients	T101	C0030705
27172917	163	178	thyroid nodules	T191	C0040137
27172917	192	213	Bethesda Category III	T191	C0040137
27172917	215	218	AUS	T049	C0522580
27172917	221	225	FLUS	T033	C1272585
27172917	230	238	cytology	T059	C1305671
27172917	243	253	predictors	T170	C0683956
27172917	257	267	malignancy	T191	C4282132
27172917	314	324	management	T058	C0376636
27172917	328	335	nodules	T191	C0040137
27172917	341	376	atypia of undetermined significance	T049	C0522580
27172917	379	425	follicular lesion of undetermined significance	T033	C1272585
27172917	427	430	AUS	T049	C0522580
27172917	433	437	FLUS	T033	C1272585
27172917	469	487	ultrasonographical	T170	C0683956
27172917	489	497	clinical	T170	C0683956
27172917	503	525	biochemical predictors	T170	C0683956
27172917	529	539	malignancy	T191	C4282132
27172917	549	557	patients	T101	C0030705
27172917	574	582	patients	T101	C0030705
27172917	588	623	cytologically Bethesda Category III	T191	C0040137
27172917	625	628	AUS	T049	C0522580
27172917	631	635	FLUS	T033	C1272585
27172917	637	652	thyroid nodules	T191	C0040137
27172917	675	694	retrospective study	T062	C0035363
27172917	711	718	nodules	T191	C0040137
27172917	728	737	subgroups	T098	C1257890
27172917	755	769	histopathology	T059	C0430445
27172917	773	779	benign	T080	C0205183
27172917	784	793	malignant	T080	C0205282
27172917	812	824	preoperative	T079	C0445204
27172917	825	843	ultrasonographical	T201	C1720195
27172917	845	853	clinical	T201	C3854293
27172917	859	879	biochemical findings	T033	C0243095
27172917	897	905	patients	T101	C0030705
27172917	915	918	AUS	T049	C0522580
27172917	921	925	FLUS	T033	C1272585
27172917	926	933	nodules	T191	C0040137
27172917	952	959	surgery	T061	C0543467
27172917	973	983	malignancy	T191	C4282132
27172917	1045	1055	malignancy	T191	C4282132
27172917	1070	1077	nodules	T191	C0040137
27172917	1083	1086	AUS	T049	C0522580
27172917	1110	1117	nodules	T191	C0040137
27172917	1123	1127	FLUS	T033	C1272585
27172917	1171	1190	malignant specimens	T077	C2347026
27172917	1194	1208	histopathology	T059	C0430445
27172917	1222	1249	papillary thyroid carcinoma	T191	C0238463
27172917	1251	1254	PTC	T191	C0238463
27172917	1274	1286	Preoperative	T079	C0445204
27172917	1287	1312	ultrasonographic features	T201	C1720195
27172917	1320	1337	malignant nodules	T191	C0040137
27172917	1341	1355	histopathology	T059	C0430445
27172917	1383	1397	benign nodules	T191	C0749467
27172917	1401	1415	histopathology	T059	C0430445
27172917	1417	1456	Anteroposterior/Transverse (AP/T) ratio	T081	C0456603
27172917	1485	1500	malignant group	T098	C1257890
27172917	1513	1525	benign group	T098	C1257890
27172917	1542	1568	multiple logistic analysis	T062	C0936012
27172917	1584	1601	higher AP/T ratio	T081	C0456603
27172917	1606	1624	microcalcification	T046	C0521174
27172917	1644	1659	associated with	T080	C0332281
27172917	1660	1670	malignancy	T191	C4282132
27172917	1687	1697	malignancy	T191	C4282132
27172917	1727	1737	AP/T ratio	T081	C0456603
27172917	1749	1776	sensitivity and specificity	T081	C0036668
27172917	1808	1819	correlation	T080	C1707520
27172917	1828	1838	malignancy	T191	C4282132
27172917	1843	1866	Hashimoto's thyroiditis	T047	C0677607
27172917	1870	1884	histopathology	T059	C0430445
27172917	1888	1909	multivariate analysis	T081	C0026777
27172917	1925	1954	Bethesda Category III nodules	T191	C0040137
27172917	1960	1977	higher AP/T ratio	T081	C0456603
27172917	1982	2000	microcalcification	T046	C0521174
27172917	2002	2009	surgery	T061	C0543467
27172917	2078	2107	fine-needle aspiration biopsy	T060	C1510483
27172917	2111	2122	observation	T062	C0302523

27196563|t|Low serum vitamin D is associated with higher cortical porosity in elderly men
27196563|a|Bone loss at peripheral sites in the elderly is mainly cortical and involves increased cortical porosity. However, an association between bone loss at these sites and 25-hydroxyvitamin D has not been reported. To investigate the association between serum levels of 25-hydroxyvitamin D, bone microstructure and areal bone mineral density (BMD) in elderly men. A population -based cohort of 444 elderly men (mean Â± SD age 80.2 Â± 3.5 years) was investigated. Bone microstructure was measured by high-resolution peripheral quantitative computed tomography, areal BMD by dual-energy X-ray absorptiometry and serum 25-hydroxyvitamin D and parathyroid hormone levels by immunoassay. Mean cortical porosity at the distal tibia was 14.7% higher (12.5 Â± 4.3% vs. 10.9 Â± 4.1%, P < 0.05) whilst cortical volumetric BMD, area, trabecular bone volume fraction and femoral neck areal BMD were lower in men in the lowest quartile of vitamin D levels compared to the highest. In men with vitamin D deficiency (<25 nmol L(-1)) or insufficiency [25-49 nmol L(-1), in combination with an elevated serum level of parathyroid hormone (>6.8 pmol L(-1))], cortical porosity was 17.2% higher than in vitamin D - sufficient men (P < 0.01). A linear regression model including age, weight, height, daily calcium intake, physical activity, smoking vitamin D supplementation and parathyroid hormone showed that 25-hydroxyvitamin D independently predicted cortical porosity (standardized Î² = -0.110, R(2) = 1.1%, P = 0.024), area (Î² = 0.123, R(2) = 1.4%, P = 0.007) and cortical volumetric BMD (Î² = 0.125, R(2) = 1.4%, P = 0.007) of the tibia as well as areal BMD of the femoral neck (Î² = 0.102, R(2) = 0.9%, P = 0.04). Serum vitamin D is associated with cortical porosity, area and density, indicating that bone fragility as a result of low vitamin D could be due to changes in cortical bone microstructure and geometry.
27196563	0	3	Low	T080	C0205251
27196563	4	9	serum	T031	C0229671
27196563	10	19	vitamin D	T109,T121,T127	C0042866
27196563	23	38	associated with	T080	C0332281
27196563	46	54	cortical	T023	C0222652
27196563	55	63	porosity	T080	C0080037
27196563	67	74	elderly	T098	C0001792
27196563	75	78	men	T098	C0025266
27196563	79	88	Bone loss	T047	C0029453
27196563	92	102	peripheral	T082	C0205100
27196563	103	108	sites	T029	C1515974
27196563	116	123	elderly	T098	C0001792
27196563	134	142	cortical	T023	C0222652
27196563	156	165	increased	T081	C0205217
27196563	166	174	cortical	T023	C0222652
27196563	175	183	porosity	T080	C0080037
27196563	197	208	association	T080	C0439849
27196563	217	226	bone loss	T047	C0029453
27196563	236	241	sites	T029	C1515974
27196563	246	265	25-hydroxyvitamin D	T109,T127	C0535968
27196563	292	303	investigate	T169	C1292732
27196563	308	319	association	T080	C0439849
27196563	328	333	serum	T031	C0229671
27196563	334	363	levels of 25-hydroxyvitamin D	T059	C2984945
27196563	365	384	bone microstructure	T023	C0262950
27196563	389	415	areal bone mineral density	T201	C0005938
27196563	417	420	BMD	T201	C0005938
27196563	425	432	elderly	T098	C0001792
27196563	433	436	men	T098	C0025266
27196563	440	450	population	T098	C1257890
27196563	458	464	cohort	T098	C0599755
27196563	472	479	elderly	T098	C0001792
27196563	480	483	men	T098	C0025266
27196563	495	498	age	T032	C0001779
27196563	510	515	years	T079	C1510829
27196563	521	533	investigated	T169	C1292732
27196563	535	554	Bone microstructure	T023	C0262950
27196563	571	630	high-resolution peripheral quantitative computed tomography	T060	C0040405
27196563	632	641	areal BMD	T201	C0005938
27196563	645	677	dual-energy X-ray absorptiometry	T060	C1510486
27196563	682	687	serum	T031	C0229671
27196563	688	707	25-hydroxyvitamin D	T059	C2984945
27196563	712	738	parathyroid hormone levels	T059	C0202159
27196563	742	753	immunoassay	T059	C0020980
27196563	755	759	Mean	T081	C0444504
27196563	760	768	cortical	T023	C0222652
27196563	769	777	porosity	T080	C0080037
27196563	785	797	distal tibia	T023	C0588200
27196563	862	870	cortical	T023	C0222652
27196563	871	885	volumetric BMD	T201	C0005938
27196563	887	891	area	T082	C0205146
27196563	893	908	trabecular bone	T024	C0222660
27196563	909	924	volume fraction	T081	C0560268
27196563	929	941	femoral neck	T023	C0015815
27196563	942	951	areal BMD	T201	C0005938
27196563	966	969	men	T098	C0025266
27196563	984	992	quartile	T080	C2828255
27196563	996	1012	vitamin D levels	T059	C0919758
27196563	1041	1044	men	T098	C0025266
27196563	1050	1070	vitamin D deficiency	T047	C0042870
27196563	1091	1104	insufficiency	T169	C0231179
27196563	1147	1155	elevated	T080	C3163633
27196563	1156	1161	serum	T031	C0229671
27196563	1162	1190	level of parathyroid hormone	T059	C0202159
27196563	1211	1219	cortical	T023	C0222652
27196563	1220	1228	porosity	T080	C0080037
27196563	1254	1263	vitamin D	T109,T121,T127	C0042866
27196563	1266	1276	sufficient	T080	C0205410
27196563	1277	1280	men	T098	C0025266
27196563	1295	1312	linear regression	T081	C0023733
27196563	1313	1318	model	T170	C3161035
27196563	1329	1332	age	T032	C0001779
27196563	1334	1340	weight	T032	C0005910
27196563	1342	1348	height	T032	C0005890
27196563	1350	1370	daily calcium intake	T061	C2183363
27196563	1372	1389	physical activity	T056	C0026606
27196563	1391	1398	smoking	T055	C0037369
27196563	1399	1408	vitamin D	T109,T121,T127	C0042866
27196563	1409	1424	supplementation	T121	C0302837
27196563	1429	1448	parathyroid hormone	T116,T121,T125	C0030520
27196563	1461	1480	25-hydroxyvitamin D	T109,T127	C0535968
27196563	1505	1513	cortical	T023	C0222652
27196563	1514	1522	porosity	T080	C0080037
27196563	1574	1578	area	T082	C0205146
27196563	1619	1627	cortical	T023	C0222652
27196563	1628	1642	volumetric BMD	T201	C0005938
27196563	1686	1691	tibia	T023	C0040184
27196563	1703	1712	areal BMD	T201	C0005938
27196563	1720	1732	femoral neck	T023	C0015815
27196563	1769	1774	Serum	T031	C0229671
27196563	1775	1784	vitamin D	T109,T121,T127	C0042866
27196563	1788	1803	associated with	T080	C0332281
27196563	1804	1812	cortical	T023	C0222652
27196563	1813	1821	porosity	T080	C0080037
27196563	1823	1827	area	T082	C0205146
27196563	1832	1839	density	T201	C0005938
27196563	1857	1861	bone	T023	C0262950
27196563	1862	1871	fragility	T049	C0302113
27196563	1887	1890	low	T080	C0205251
27196563	1891	1900	vitamin D	T109,T121,T127	C0042866
27196563	1917	1924	changes	T169	C0392747
27196563	1928	1936	cortical	T023	C0222652
27196563	1937	1956	bone microstructure	T023	C0262950
27196563	1961	1969	geometry	T082	C0678594

27213687|t|Nationwide reduction in the number of corneal transplantations for keratoconus following the implementation of cross-linking
27213687|a|Keratoconus is characterized by corneal ectasia and irregular astigmatism, which can lead to diminished vision and corneal scarring. Approximately 10-20% of patients with keratoconus eventually require a corneal transplant. Corneal cross-linking (CXL) is a relatively new treatment that may help prevent the need for corneal transplantation. Here, we investigated whether the introduction of CXL has reduced the number of corneal transplants performed annually. Data regarding the transplantation procedures performed in patients under the age of 50 years were extracted from the Dutch National Organ Transplant Registry. The number of corneal transplants performed prior to (i.e. in 2005 through 2007) and following the introduction of CXL (i.e. in 2012 through 2014) were compared. Furthermore, a trend analysis on annual keratoplasties over time was performed. Approximately 25% fewer corneal transplants were performed in the 3- year period following the introduction of CXL compared to the 3- year period prior to the introduction of CXL (201 versus 269 transplants, respectively; p = 0.005). Age, gender and visual acuity were similar between the patient groups in the two time periods. Trend analysis also demonstrated a significant decrease in the amount of corneal transplants (p = 0.001). Significantly fewer corneal transplants were performed for treating keratoconus following the nationwide introduction of CXL. This reduction suggests that corneal cross-linking can significantly reduce the need for corneal transplantation.
27213687	0	10	Nationwide	T082	C1254362
27213687	11	20	reduction	T081	C0547047
27213687	38	62	corneal transplantations	T061	C0010042
27213687	67	78	keratoconus	T047	C0022578
27213687	93	107	implementation	T052	C1708476
27213687	111	124	cross-linking	T061	C4065848
27213687	125	136	Keratoconus	T047	C0022578
27213687	157	172	corneal ectasia	T047	C0155135
27213687	177	198	irregular astigmatism	T047	C0152194
27213687	218	235	diminished vision	T047	C0042798
27213687	240	256	corneal scarring	T033	C0349702
27213687	282	290	patients	T101	C0030705
27213687	296	307	keratoconus	T047	C0022578
27213687	329	347	corneal transplant	T061	C0010042
27213687	349	370	Corneal cross-linking	T061	C4065848
27213687	372	375	CXL	T061	C4065848
27213687	397	406	treatment	T061	C0087111
27213687	442	465	corneal transplantation	T061	C0010042
27213687	476	488	investigated	T169	C1292732
27213687	501	513	introduction	T169	C0579004
27213687	517	520	CXL	T061	C4065848
27213687	547	566	corneal transplants	T061	C0010042
27213687	567	576	performed	T169	C0884358
27213687	577	585	annually	T079	C0332181
27213687	587	591	Data	T078	C1511726
27213687	606	632	transplantation procedures	T061	C0040732
27213687	633	642	performed	T169	C0884358
27213687	646	654	patients	T101	C0030705
27213687	665	668	age	T032	C0001779
27213687	675	680	years	T079	C0439234
27213687	705	745	Dutch National Organ Transplant Registry	T170	C0034975
27213687	761	780	corneal transplants	T061	C0010042
27213687	781	790	performed	T169	C0884358
27213687	846	858	introduction	T169	C0579004
27213687	862	865	CXL	T061	C4065848
27213687	899	907	compared	T052	C1707455
27213687	924	938	trend analysis	UnknownType	C0681702
27213687	942	948	annual	T079	C0332181
27213687	949	963	keratoplasties	T061	C0010042
27213687	978	987	performed	T169	C0884358
27213687	1013	1032	corneal transplants	T061	C0010042
27213687	1038	1047	performed	T169	C0884358
27213687	1058	1062	year	T079	C0439234
27213687	1084	1096	introduction	T169	C0579004
27213687	1100	1103	CXL	T061	C4065848
27213687	1104	1112	compared	T052	C1707455
27213687	1123	1127	year	T079	C0439234
27213687	1148	1160	introduction	T169	C0579004
27213687	1164	1167	CXL	T061	C4065848
27213687	1184	1195	transplants	T061	C0010042
27213687	1223	1226	Age	T032	C0001779
27213687	1228	1234	gender	T032	C0079399
27213687	1239	1252	visual acuity	T201	C0042812
27213687	1278	1285	patient	T101	C0030705
27213687	1304	1316	time periods	T079	C1948053
27213687	1318	1332	Trend analysis	UnknownType	C0681702
27213687	1365	1373	decrease	T081	C0547047
27213687	1391	1410	corneal transplants	T061	C0010042
27213687	1444	1463	corneal transplants	T061	C0010042
27213687	1492	1503	keratoconus	T047	C0022578
27213687	1518	1528	nationwide	T082	C1254362
27213687	1529	1541	introduction	T169	C0579004
27213687	1545	1548	CXL	T061	C4065848
27213687	1555	1564	reduction	T081	C0547047
27213687	1579	1600	corneal cross-linking	T061	C4065848
27213687	1619	1625	reduce	T080	C0392756
27213687	1639	1662	corneal transplantation	T061	C0010042

27216824|t|Rapid Fabrication of a Cell - Seeded Collagen Gel -Based Tubular Construct that Withstands Arterial Pressure: Rapid Fabrication of a Gel -Based Media Equivalent
27216824|a|Based on plastically compressed cell - seeded collagen gels, we fabricated a small-diameter tubular construct that withstands arterial pressure without prolonged culture in vitro. Specifically, to mimic the microstructure of vascular media, the cell - seeded collagen gel was uniaxially stretched prior to plastic compression to align collagen fibers and hence cells in the gel. The resulting gel sheet was then wrapped around a custom-made multi-layered braided tube to form aligned tubular constructs whereas the gel sheet prepared similarly but without uniaxial stretching formed control constructs. With the braided tube, fluid in the gel construct was further removed by vacuum suction aiming to consolidate the concentric layers of the construct. The construct was finally treated with transglutaminase. Both SEM and histology confirmed the absence of gaps in the wall of the construct. Particularly, cells in the wall of the aligned tubular construct were circumferentially aligned. The enzyme -mediated crosslinking increased burst pressure of both the constructs significantly; the extent of the increase of burst pressure for the aligned tubular construct was greater than that for the control counterpart. Increasing crosslinking left the compliance of the aligned tubular construct unchanged but reduced that of the control construct. Cells remained viable in transglutaminase -treated plastically compressed gels after 6 days in culture. This study demonstrated that by combining stretch-induced fiber alignment, plastic compression, and enzyme -mediated crosslinking, a cell - seeded collagen gel -based tubular construct with potential to be used as vascular media can be made within 3 days.
27216824	6	17	Fabrication	T052	C0441655
27216824	23	27	Cell	T025	C0007634
27216824	30	36	Seeded	T059	C3828225
27216824	37	45	Collagen	T116	C0009325
27216824	46	49	Gel	T122	C0017243
27216824	57	74	Tubular Construct	T074	C0175730
27216824	91	108	Arterial Pressure	T042	C0232108
27216824	116	127	Fabrication	T052	C0441655
27216824	133	136	Gel	T122	C0017243
27216824	144	149	Media	T167	C1705217
27216824	170	192	plastically compressed	T070	C0728907
27216824	193	197	cell	T025	C0007634
27216824	200	206	seeded	T059	C3828225
27216824	207	215	collagen	T116	C0009325
27216824	216	220	gels	T122	C0017243
27216824	225	235	fabricated	T052	C0441655
27216824	253	270	tubular construct	T074	C0175730
27216824	287	304	arterial pressure	T042	C0232108
27216824	323	330	culture	T059	C0430400
27216824	331	339	in vitro	T080	C1533691
27216824	368	382	microstructure	T082	C0678594
27216824	386	400	vascular media	T024	C0162867
27216824	406	410	cell	T025	C0007634
27216824	413	419	seeded	T059	C3828225
27216824	420	428	collagen	T116	C0009325
27216824	429	432	gel	T122	C0017243
27216824	467	474	plastic	T167	C0032167
27216824	475	486	compression	T070	C0728907
27216824	496	511	collagen fibers	T024	C0225325
27216824	522	527	cells	T025	C0007634
27216824	535	538	gel	T122	C0017243
27216824	554	557	gel	T122	C0017243
27216824	558	563	sheet	T122	C0005479
27216824	602	628	multi-layered braided tube	T074	C0184166
27216824	645	663	tubular constructs	T074	C0175730
27216824	676	679	gel	T122	C0017243
27216824	680	685	sheet	T122	C0005479
27216824	752	762	constructs	T074	C0175730
27216824	773	785	braided tube	T074	C0184166
27216824	787	792	fluid	T167	C1704353
27216824	800	803	gel	T122	C0017243
27216824	804	813	construct	T074	C0175730
27216824	837	851	vacuum suction	T074	C0182957
27216824	903	912	construct	T074	C0175730
27216824	918	927	construct	T074	C0175730
27216824	953	969	transglutaminase	T116,T126	C0033679
27216824	976	979	SEM	T059	C0026020
27216824	984	993	histology	T059	C0344441
27216824	1043	1052	construct	T074	C0175730
27216824	1068	1073	cells	T025	C0007634
27216824	1101	1118	tubular construct	T074	C0175730
27216824	1155	1161	enzyme	T116,T126	C0014442
27216824	1172	1184	crosslinking	T070	C0178576
27216824	1195	1209	burst pressure	T067	C0033095
27216824	1222	1232	constructs	T074	C0175730
27216824	1278	1292	burst pressure	T067	C0033095
27216824	1309	1326	tubular construct	T074	C0175730
27216824	1389	1401	crosslinking	T070	C0178576
27216824	1437	1454	tubular construct	T074	C0175730
27216824	1497	1506	construct	T074	C0175730
27216824	1508	1513	Cells	T025	C0007634
27216824	1533	1549	transglutaminase	T116,T126	C0033679
27216824	1559	1581	plastically compressed	T070	C0728907
27216824	1582	1586	gels	T122	C0017243
27216824	1595	1599	days	T079	C0439228
27216824	1617	1622	study	T062	C2603343
27216824	1670	1675	fiber	T024	C0225325
27216824	1676	1685	alignment	T081	C1706765
27216824	1687	1694	plastic	T167	C0032167
27216824	1695	1706	compression	T070	C0728907
27216824	1712	1718	enzyme	T116,T126	C0014442
27216824	1729	1741	crosslinking	T070	C0178576
27216824	1745	1749	cell	T025	C0007634
27216824	1752	1758	seeded	T059	C3828225
27216824	1759	1767	collagen	T116	C0009325
27216824	1768	1771	gel	T122	C0017243
27216824	1779	1796	tubular construct	T074	C0175730
27216824	1826	1840	vascular media	T024	C0162867
27216824	1862	1866	days	T079	C0439228

27233131|t|Impact of cofactor - binding loop mutations on thermotolerance and activity of E. coli transketolase
27233131|a|Improvement of thermostability in engineered enzymes can allow biocatalysis on substrates with poor aqueous solubility. Denaturation of the cofactor - binding loops of Escherichia coli transketolase (TK) was previously linked to the loss of enzyme activity under conditions of high pH or urea. Incubation at temperatures just below the thermal melting transition, above which the protein aggregates, was also found to anneal the enzyme to give an increased specific activity. The potential role of cofactor - binding loop instability in this process remained unclear. In this work, the two cofactor - binding loops (residues 185-192 and 382-392) were progressively mutated towards the equivalent sequence from the thermostable Thermus thermophilus TK and variants assessed for their impact on both thermostability and activity. Cofactor-binding loop 2 variants had detrimental effects on specific activity at elevated temperatures, whereas the H192P mutation in cofactor-binding loop 1 resulted in a two-fold improved stability to inactivation at elevated temperatures, and increased the critical onset temperature for aggregation. The specific activity of H192P was 3-fold and 19-fold higher than that for wild-type at 60Â°C and 65Â°C respectively, and also remained 2.7-4 fold higher after re-cooling from pre-incubations at either 55Â°C or 60Â°C for 1h. Interestingly, H192P was also 2-times more active than wild-type TK at 25Â°C. Optimal activity was achieved at 60Â°C for H192P compared to 55Â°C for wild type. These results show that cofactor-binding loop 1, plays a pivotal role in partial denaturation and aggregation at elevated temperatures. Furthermore, a single rigidifying mutation within this loop can significantly improve the enzyme specific activity, as well as the stability to thermal denaturation and aggregation, to give an increased temperature optimum for activity.
27233131	0	6	Impact	T080	C4049986
27233131	10	18	cofactor	T123	C0178555
27233131	21	33	binding loop	T087	C0682969
27233131	34	43	mutations	T045	C0026882
27233131	47	62	thermotolerance	T039	C3544386
27233131	67	75	activity	T044	C0243102
27233131	79	86	E. coli	T007	C0014834
27233131	87	100	transketolase	T116,T126	C0040709
27233131	101	112	Improvement	T077	C2986411
27233131	116	131	thermostability	T070	C0597571
27233131	135	153	engineered enzymes	T116,T126	C0014442
27233131	164	176	biocatalysis	T070	C2350294
27233131	180	190	substrates	T167	C3891814
27233131	201	208	aqueous	T080	C0599956
27233131	209	219	solubility	T080	C0037628
27233131	221	233	Denaturation	T044	C0033627
27233131	241	249	cofactor	T123	C0178555
27233131	252	265	binding loops	T087	C0682969
27233131	269	285	Escherichia coli	T007	C0014834
27233131	286	299	transketolase	T116,T126	C0040709
27233131	301	303	TK	T116,T126	C0040709
27233131	334	338	loss	T081	C1517945
27233131	342	357	enzyme activity	T044	C0243102
27233131	364	374	conditions	T080	C0348080
27233131	378	382	high	T080	C0205250
27233131	383	385	pH	T081	C0020283
27233131	389	393	urea	T109,T121,T123	C0041942
27233131	395	405	Incubation	T059	C0022885
27233131	409	421	temperatures	T081	C0039476
27233131	437	463	thermal melting transition	T070	C1254365
27233131	481	488	protein	T116,T123	C0033684
27233131	489	499	aggregates	T169	C0332621
27233131	519	525	anneal	T169	C0205245
27233131	530	536	enzyme	T116,T126	C0014442
27233131	548	557	increased	T081	C0205217
27233131	567	575	activity	T044	C0243102
27233131	591	595	role	T077	C1705810
27233131	599	607	cofactor	T123	C0178555
27233131	610	622	binding loop	T087	C0682969
27233131	623	634	instability	T033	C1444783
27233131	691	699	cofactor	T123	C0178555
27233131	702	715	binding loops	T087	C0682969
27233131	717	733	residues 185-192	T087	C0002518
27233131	738	745	382-392	T087	C0002518
27233131	797	805	sequence	T086	C0004793
27233131	815	827	thermostable	T080	C0205556
27233131	828	848	Thermus thermophilus	T007	C0085475
27233131	849	851	TK	T116,T126	C0040709
27233131	856	864	variants	T028	C0678941
27233131	865	873	assessed	T052	C1516048
27233131	884	890	impact	T080	C4049986
27233131	899	914	thermostability	T070	C0597571
27233131	919	927	activity	T052	C0441655
27233131	929	952	Cofactor-binding loop 2	T086	C0004793
27233131	953	961	variants	T028	C0678941
27233131	966	985	detrimental effects	T080	C1280500
27233131	998	1006	activity	T052	C0441655
27233131	1010	1018	elevated	T080	C3163633
27233131	1019	1031	temperatures	T081	C0039476
27233131	1045	1059	H192P mutation	T045	C0026882
27233131	1063	1086	cofactor-binding loop 1	T086	C0004793
27233131	1119	1128	stability	T070	C0597571
27233131	1132	1144	inactivation	T169	C0544461
27233131	1148	1156	elevated	T080	C3163633
27233131	1157	1169	temperatures	T081	C0039476
27233131	1175	1184	increased	T081	C0205217
27233131	1189	1215	critical onset temperature	T081	C0039476
27233131	1220	1231	aggregation	T169	C0332621
27233131	1246	1254	activity	T052	C0441655
27233131	1258	1263	H192P	T045	C0026882
27233131	1287	1293	higher	T080	C0205250
27233131	1308	1317	wild-type	T028	C1883559
27233131	1378	1384	higher	T080	C0205250
27233131	1391	1401	re-cooling	T070	C0678568
27233131	1407	1422	pre-incubations	T059	C0022885
27233131	1469	1474	H192P	T045	C0026882
27233131	1497	1503	active	T169	C0205177
27233131	1509	1518	wild-type	T028	C1883559
27233131	1519	1521	TK	T116,T126	C0040709
27233131	1531	1538	Optimal	T080	C2698651
27233131	1539	1547	activity	T052	C0441655
27233131	1573	1578	H192P	T045	C0026882
27233131	1600	1609	wild type	T028	C1883559
27233131	1635	1658	cofactor-binding loop 1	T086	C0004793
27233131	1676	1680	role	T077	C1705810
27233131	1684	1691	partial	T081	C0728938
27233131	1692	1704	denaturation	T044	C0033627
27233131	1709	1720	aggregation	T169	C0332621
27233131	1724	1732	elevated	T080	C3163633
27233131	1733	1745	temperatures	T081	C0039476
27233131	1762	1789	single rigidifying mutation	T045	C0026882
27233131	1802	1806	loop	T086	C0004793
27233131	1837	1861	enzyme specific activity	T044	C0243102
27233131	1878	1887	stability	T070	C0597571
27233131	1891	1898	thermal	T070	C0018837
27233131	1899	1911	denaturation	T044	C0033627
27233131	1916	1927	aggregation	T169	C0332621
27233131	1940	1949	increased	T081	C0205217
27233131	1950	1961	temperature	T081	C0039476
27233131	1962	1969	optimum	T080	C2698651
27233131	1974	1982	activity	T044	C0243102

27233260|t|Expression and Purification of E2 Glycoprotein from Insect Cells (Sf9) for Use in Serology
27233260|a|Chikungunya virus (CHIKV) is a mosquito - borne arbovirus which poses a major threat to global public health. Definitive CHIKV diagnosis is crucial, especially in distinguishing the disease from dengue virus, which co-circulates in endemic areas and shares the same mosquito vectors. Laboratory diagnosis is mainly based on serological or molecular approaches. The E2 glycoprotein is a good candidate for serological diagnosis since it is the immunodominant antigen during the course of infection, and reacts with seropositive CHIKV sera. In this chapter, we describe the generation of stable clone Sf9 (Spodoptera frugiperda) cells expressing secreted, soluble, and native recombinant CHIKV E2 glycoprotein. We use direct plasmid expression in insect cells, rather than the traditional technique of generating recombinant baculovirus. This recombinant protein is useful for serological diagnosis of CHIKV infection.
27233260	0	10	Expression	T045	C1171362
27233260	15	27	Purification	T059	C0597301
27233260	31	46	E2 Glycoprotein	T116,T123	C0017968
27233260	52	58	Insect	T204	C0021585
27233260	59	64	Cells	T025	C0007634
27233260	66	69	Sf9	T025	C3494245
27233260	82	90	Serology	T059	C0036743
27233260	91	108	Chikungunya virus	T005	C0008056
27233260	110	115	CHIKV	T005	C0008056
27233260	122	130	mosquito	T204	C0026584
27233260	133	138	borne	T033	C0699809
27233260	139	148	arbovirus	T005	C0003725
27233260	169	175	threat	T078	C0749385
27233260	179	185	global	T080	C2348867
27233260	186	199	public health	T058	C0699943
27233260	201	211	Definitive	T079	C0443196
27233260	212	217	CHIKV	T005	C0008056
27233260	218	227	diagnosis	T033	C0011900
27233260	273	280	disease	T047	C0012634
27233260	286	298	dengue virus	T005	C0011315
27233260	306	319	co-circulates	T169	C0175630
27233260	323	330	endemic	T082	C1254362
27233260	331	336	areas	T082	C0205146
27233260	357	373	mosquito vectors	T204	C4277713
27233260	375	395	Laboratory diagnosis	T060	C0011911
27233260	406	411	based	T169	C1527178
27233260	415	426	serological	T169	C0220911
27233260	430	439	molecular	T080	C1521991
27233260	456	471	E2 glycoprotein	T116,T123	C0017968
27233260	496	517	serological diagnosis	T059	C0036743
27233260	534	556	immunodominant antigen	T129	C0078968
27233260	557	563	during	T079	C0347984
27233260	568	574	course	T079	C0750729
27233260	578	587	infection	T046	C3714514
27233260	593	599	reacts	T169	C0443286
27233260	605	617	seropositive	T080	C0521143
27233260	618	623	CHIKV	T005	C0008056
27233260	624	628	sera	T031	C0229671
27233260	638	645	chapter	T078	C1552857
27233260	650	658	describe	T078	C1552738
27233260	663	673	generation	T052	C3146294
27233260	677	683	stable	T080	C0205360
27233260	684	689	clone	T025	C0009013
27233260	690	693	Sf9	T025	C3494245
27233260	695	716	Spodoptera frugiperda	T204	C0242626
27233260	718	723	cells	T025	C0009013
27233260	724	734	expressing	T045	C1171362
27233260	735	743	secreted	T043	C1327616
27233260	745	752	soluble	T026	C1749467
27233260	758	764	native	T169	C0302891
27233260	765	776	recombinant	T001	C1514798
27233260	777	782	CHIKV	T005	C0008056
27233260	783	798	E2 glycoprotein	T116,T123	C0017968
27233260	814	821	plasmid	T114,T123	C0032136
27233260	822	832	expression	T061	C0185117
27233260	836	842	insect	T204	C0021585
27233260	843	848	cells	T025	C0007634
27233260	866	877	traditional	T169	C0443324
27233260	878	887	technique	T169	C0449851
27233260	891	901	generating	T052	C3146294
27233260	902	925	recombinant baculovirus	T005	C0597363
27233260	932	951	recombinant protein	T116	C0034861
27233260	966	987	serological diagnosis	T059	C0036743
27233260	991	996	CHIKV	T005	C0008056
27233260	997	1006	infection	T046	C3714514

27233466|t|Acute risk factors for suicide attempts and death: prospective findings from the STEP - BD study
27233466|a|Suicide is unfortunately common in psychiatric practice, but difficult to predict. The present study sought to assess which clinical symptoms increase in the months before suicidal behavior in a sample of psychiatric outpatients with bipolar disorder. Data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP - BD) trial were used. A total of 103 participants who attempted suicide or died by suicide during the trial were included; a 15% random sample of the remaining participants (n = 427) was used as a comparison sample. Linear mixed models in the six months before suicidal behavior were conducted for each of five proposed acute risk factors for suicidal behavior. Participants were assessed using the Clinical Monitoring Form (CMF) at each visit for the following potential acute risk factors for suicidal behavior: suicidal ideation, loss of interest, anxiety, psychomotor agitation, and high-risk behavior. Each of the five symptoms was elevated overall in individuals who engaged in suicidal behavior (p < 0.05). The severity of both suicidal ideation and loss of interest significantly increased in the months before suicidal behavior (p < 0.001). Anxiety demonstrated comparable effect sizes across multiple models. Psychomotor agitation and high-risk behavior were not significantly elevated before suicidal behavior. Suicidal ideation, loss of interest and, to a lesser extent, anxiety may represent acute suicide risk factors up to four months before suicidal behavior in outpatients with bipolar disorder. Further investigation of these potential acute risk factors in prospective analyses is warranted.
27233466	0	5	Acute	T079	C0205178
27233466	6	18	risk factors	T033	C0035648
27233466	23	39	suicide attempts	T033	C0038663
27233466	44	49	death	T033	C1306577
27233466	51	71	prospective findings	T062	C0033522
27233466	81	85	STEP	T058	C1254363
27233466	88	90	BD	T048	C0005586
27233466	91	96	study	T062	C2603343
27233466	97	104	Suicide	T033	C0038661
27233466	132	143	psychiatric	T091	C0033873
27233466	144	152	practice	T041	C0237607
27233466	171	178	predict	T078	C0681842
27233466	192	197	study	T062	C2603343
27233466	208	214	assess	T058	C0184514
27233466	221	229	clinical	T080	C0205210
27233466	230	238	symptoms	T184	C1457887
27233466	239	247	increase	T169	C0442805
27233466	255	261	months	T079	C0439231
27233466	269	286	suicidal behavior	T033	C1760428
27233466	292	298	sample	T167	C0370003
27233466	302	313	psychiatric	T091	C0033873
27233466	314	325	outpatients	T101	C0029921
27233466	331	347	bipolar disorder	T048	C0005586
27233466	349	353	Data	T078	C1511726
27233466	363	403	Systematic Treatment Enhancement Program	T058	C1254363
27233466	408	424	Bipolar Disorder	T048	C0005586
27233466	426	430	STEP	T058	C1254363
27233466	433	435	BD	T048	C0005586
27233466	437	442	trial	T062	C0008976
27233466	469	481	participants	T098	C0679646
27233466	486	503	attempted suicide	T033	C0038663
27233466	507	511	died	T033	C4264514
27233466	515	522	suicide	T033	C0038661
27233466	534	539	trial	T062	C0008976
27233466	561	567	random	T080	C0439605
27233466	568	574	sample	T167	C0370003
27233466	592	604	participants	T098	C0679646
27233466	629	639	comparison	T052	C1707455
27233466	640	646	sample	T167	C0370003
27233466	648	667	Linear mixed models	T081	C0023732
27233466	679	685	months	T079	C0439231
27233466	693	710	suicidal behavior	T033	C1760428
27233466	752	757	acute	T079	C0205178
27233466	758	770	risk factors	T033	C0035648
27233466	775	792	suicidal behavior	T033	C1760428
27233466	794	806	Participants	T098	C0679646
27233466	812	820	assessed	T052	C1516048
27233466	831	855	Clinical Monitoring Form	T062	C1516647
27233466	857	860	CMF	T062	C1516647
27233466	870	875	visit	T058	C1512346
27233466	904	909	acute	T079	C0205178
27233466	910	922	risk factors	T033	C0035648
27233466	927	944	suicidal behavior	T033	C1760428
27233466	946	963	suicidal ideation	T033	C0424000
27233466	965	981	loss of interest	T033	C0424091
27233466	983	990	anxiety	T033	C0003467
27233466	992	1013	psychomotor agitation	T033	C3887612
27233466	1019	1037	high-risk behavior	T055	C1171309
27233466	1056	1064	symptoms	T184	C1457887
27233466	1069	1077	elevated	T080	C3163633
27233466	1089	1100	individuals	T098	C0237401
27233466	1116	1133	suicidal behavior	T033	C1760428
27233466	1150	1158	severity	T080	C0439793
27233466	1167	1184	suicidal ideation	T033	C0424000
27233466	1189	1205	loss of interest	T033	C0424091
27233466	1220	1229	increased	T081	C0205217
27233466	1237	1243	months	T079	C0439231
27233466	1251	1268	suicidal behavior	T033	C1760428
27233466	1282	1289	Anxiety	T033	C0003467
27233466	1314	1320	effect	T080	C1280500
27233466	1321	1326	sizes	T082	C0456389
27233466	1334	1349	multiple models	T170	C3161035
27233466	1351	1372	Psychomotor agitation	T033	C3887612
27233466	1377	1395	high-risk behavior	T055	C1171309
27233466	1419	1427	elevated	T080	C3163633
27233466	1435	1452	suicidal behavior	T033	C1760428
27233466	1454	1471	Suicidal ideation	T033	C0424000
27233466	1473	1489	loss of interest	T033	C0424091
27233466	1500	1506	lesser	T080	C0547044
27233466	1507	1513	extent	T082	C0439792
27233466	1515	1522	anxiety	T033	C0003467
27233466	1537	1542	acute	T079	C0205178
27233466	1543	1550	suicide	T033	C0038661
27233466	1551	1563	risk factors	T033	C0035648
27233466	1575	1581	months	T079	C0439231
27233466	1589	1606	suicidal behavior	T033	C1760428
27233466	1610	1621	outpatients	T101	C0029921
27233466	1627	1643	bipolar disorder	T048	C0005586
27233466	1653	1666	investigation	T058	C0220825
27233466	1686	1691	acute	T079	C0205178
27233466	1692	1704	risk factors	T033	C0035648
27233466	1708	1728	prospective analyses	T062	C0033522

27233592|t|Measurement of Outcomes of Upper Limb Reconstructive Surgery for Tetraplegia
27233592|a|Reconstructive arm/hand surgery for tetraplegia is performed to improve arm/hand function and therefore personal well-being for individuals who accept such elective surgeries. However, changes at an impairment level do not always translate into functional or quality of life changes. Therefore, multiple outcome tools should be used that incorporate sufficient responsiveness to detect changes in arm/hand function, activity and participation, and quality of life of the individuals involved. This narrative review aims to assist clinicians to choose the most appropriate tools to assess the need for reconstructive surgery and to evaluate its outcomes. Our specific objectives are (1) to describe aspects to consider when choosing a measure and (2) to describe the measures advised by an international therapist consensus group established in 2007. All advised measures are appraised in terms of the underlying construct, administration, and clinical relevance to arm/hand reconstructions. Essentially there are currently no criterion standard measures to evaluate the consequences of reconstructive arm/hand surgery. However, with judicious use of available measures it is possible to ensure the questions asked or tasks completed are relevant to the surgical reconstruction (s) undertaken. Further work in this field is required. This would be best met by immediate collaboration between 2 outcome's tool developers and by analysis of pre - and postoperative data already held in various international sites, which would allow further evaluation of the measures already in use, or components thereof.
27233592	0	11	Measurement	T169	C0242485
27233592	15	23	Outcomes	T080	C0085415
27233592	27	60	Upper Limb Reconstructive Surgery	T033	C1408821
27233592	65	76	Tetraplegia	T047	C0034372
27233592	77	108	Reconstructive arm/hand surgery	T033	C1408821
27233592	113	124	tetraplegia	T047	C0034372
27233592	128	137	performed	T169	C0884358
27233592	141	148	improve	T033	C0184511
27233592	149	166	arm/hand function	T040	C0562230
27233592	181	200	personal well-being	T033	C1821407
27233592	205	216	individuals	T098	C0237401
27233592	221	227	accept	T080	C1272684
27233592	233	251	elective surgeries	T061	C0206058
27233592	262	269	changes	T169	C0392747
27233592	276	286	impairment	T169	C0221099
27233592	322	332	functional	T169	C0205245
27233592	336	351	quality of life	T078	C0034380
27233592	352	359	changes	T169	C0392747
27233592	372	394	multiple outcome tools	T073	C0336791
27233592	415	426	incorporate	T169	C0243126
27233592	427	452	sufficient responsiveness	T033	C3261286
27233592	456	462	detect	T033	C0442726
27233592	463	470	changes	T169	C0392747
27233592	474	491	arm/hand function	T040	C0562230
27233592	493	501	activity	T052	C0441655
27233592	506	519	participation	T169	C0679823
27233592	525	540	quality of life	T078	C0034380
27233592	548	559	individuals	T098	C0237401
27233592	575	591	narrative review	UnknownType	C0815257
27233592	592	596	aims	T078	C1947946
27233592	600	606	assist	T058	C0557034
27233592	607	617	clinicians	T097	C0871685
27233592	637	648	appropriate	T080	C1548787
27233592	649	654	tools	T073	C0336791
27233592	658	664	assess	T052	C1516048
27233592	678	700	reconstructive surgery	T033	C1408821
27233592	708	716	evaluate	T058	C0220825
27233592	721	729	outcomes	T080	C0085415
27233592	744	754	objectives	T170	C0018017
27233592	766	774	describe	T078	C1552738
27233592	775	782	aspects	T081	C1547011
27233592	811	818	measure	T169	C0242485
27233592	830	838	describe	T078	C1552738
27233592	843	851	measures	T169	C0242485
27233592	866	879	international	T078	C1512888
27233592	880	889	therapist	T097	C0871525
27233592	900	905	group	T078	C0441833
27233592	906	917	established	T080	C0443211
27233592	939	947	measures	T169	C0242485
27233592	989	998	construct	T185	C2827421
27233592	1000	1014	administration	T061	C1533734
27233592	1020	1028	clinical	T080	C0205210
27233592	1029	1038	relevance	T080	C2347946
27233592	1042	1066	arm/hand reconstructions	T061	C0841296
27233592	1068	1079	Essentially	T080	C0205224
27233592	1103	1112	criterion	T078	C0243161
27233592	1113	1121	standard	T081	C0034925
27233592	1122	1130	measures	T169	C0242485
27233592	1134	1142	evaluate	T058	C0220825
27233592	1147	1162	consequences of	T169	C0686907
27233592	1163	1194	reconstructive arm/hand surgery	T033	C1408821
27233592	1220	1223	use	T169	C0042153
27233592	1237	1245	measures	T169	C0242485
27233592	1275	1290	questions asked	T033	C0566217
27233592	1294	1299	tasks	T057	C3540678
27233592	1300	1309	completed	T080	C0205197
27233592	1314	1322	relevant	T080	C2347946
27233592	1330	1353	surgical reconstruction	T061	C0524865
27233592	1378	1382	work	T057	C0043227
27233592	1391	1396	field	T077	C1521738
27233592	1400	1408	required	T169	C1514873
27233592	1436	1445	immediate	T079	C0205253
27233592	1446	1459	collaboration	T054	C0282116
27233592	1470	1495	outcome's tool developers	T057	C0085565
27233592	1503	1511	analysis	T057	C0010992
27233592	1515	1518	pre	T079	C0445204
27233592	1525	1538	postoperative	T079	C0032790
27233592	1539	1543	data	T078	C1511726
27233592	1568	1581	international	T078	C1512888
27233592	1615	1625	evaluation	T058	C0220825
27233592	1633	1641	measures	T169	C0242485
27233592	1653	1656	use	T169	C0042153
27233592	1661	1671	components	T073	C0449432

27233918|t|Basal and maximal metabolic rates differ in their response to rapid temperature change among avian species
27233918|a|In birds, acclimation and acclimatization to temperature are associated with changes in basal (BMR), summit (Msum) and maximal (MMR) metabolic rates but little is known about the rate at which species adjust their phenotype to short-term temperature variations. Our aims were (1) to determine the pattern of metabolic adjustments following a rapid temperature change, (2) to determine whether performance varies at similar rates during exposure to warm or cold environments, and (3) to determine if BMR, Msum and MMR change at comparable rates during thermal acclimation. We measured these parameters in white-throated sparrows (Zonotrichia albicollis), black-capped chickadees (Poecile atricapillus), and snow buntings (Plectrophenax nivalis) after acclimation to 10 Â°C (day 0) and on the 4th and 8th days of acclimation to either -5 or 28 Â°C. Birds changed their metabolic phenotype within 8 days with patterns differing among species. Sparrows expressed the expected metabolic increases in the cold and decreases at thermoneutrality while performance in chickadees and buntings was not influenced by temperature but changed over time with inverse patterns. Our results suggest that BMR varies at comparable rates in warm and cold environments but changes faster than Msum and MMR, likely due to limitations in the rate of change in organ size and function. They also suggest that maximal metabolic capacity is lost faster in a warm environment than it is gained in a cold environment. With the expected increase in temperature stochasticity at northern latitudes, a loss of thermogenic capacity during warm winter days could, therefore, be detrimental if birds are slow to readjust their phenotype with the return of cold days.
27233918	0	5	Basal	T040	C0678121
27233918	10	17	maximal	T080	C0205289
27233918	18	33	metabolic rates	T039	C0870882
27233918	50	58	response	T032	C0871261
27233918	68	86	temperature change	T080	C0450031
27233918	93	98	avian	T012	C0005595
27233918	99	106	species	T185	C1705920
27233918	110	115	birds	T012	C0005595
27233918	117	128	acclimation	T040	C0000934
27233918	133	148	acclimatization	T040	C0000934
27233918	152	163	temperature	T081	C0039476
27233918	195	200	basal	T040	C0678121
27233918	202	205	BMR	T040	C0678121
27233918	208	214	summit	T039	C0870882
27233918	216	220	Msum	T039	C0870882
27233918	226	233	maximal	T080	C0205289
27233918	235	238	MMR	T039	C0870882
27233918	240	255	metabolic rates	T039	C0870882
27233918	286	290	rate	T039	C0870882
27233918	300	307	species	T185	C1705920
27233918	321	330	phenotype	T032	C0031437
27233918	334	344	short-term	T079	C0443303
27233918	345	356	temperature	T081	C0039476
27233918	357	367	variations	T080	C0205419
27233918	373	377	aims	T078	C1947946
27233918	404	411	pattern	T082	C0449774
27233918	415	424	metabolic	T169	C0311400
27233918	455	473	temperature change	T080	C0450031
27233918	530	535	rates	T039	C0870882
27233918	543	554	exposure to	T080	C0332157
27233918	555	559	warm	T067	C0563030
27233918	563	580	cold environments	T067	C0241842
27233918	606	609	BMR	T040	C0678121
27233918	611	615	Msum	T039	C0870882
27233918	620	623	MMR	T039	C0870882
27233918	645	650	rates	T039	C0870882
27233918	658	665	thermal	T070	C0018837
27233918	666	677	acclimation	T040	C0000934
27233918	711	734	white-throated sparrows	T012	C1093387
27233918	736	758	Zonotrichia albicollis	T012	C1093387
27233918	761	784	black-capped chickadees	T012	C0326488
27233918	786	806	Poecile atricapillus	T012	C0326488
27233918	813	826	snow buntings	T012	C0326923
27233918	828	849	Plectrophenax nivalis	T012	C0326923
27233918	857	868	acclimation	T040	C0000934
27233918	879	882	day	T079	C0439228
27233918	909	913	days	T079	C0439228
27233918	917	928	acclimation	T040	C0000934
27233918	952	957	Birds	T012	C0005595
27233918	972	981	metabolic	T169	C0311400
27233918	982	991	phenotype	T032	C0031437
27233918	1001	1005	days	T079	C0439228
27233918	1011	1019	patterns	T082	C0449774
27233918	1036	1043	species	T185	C1705920
27233918	1045	1053	Sparrows	T012	C1093387
27233918	1077	1086	metabolic	T169	C0311400
27233918	1087	1096	increases	T169	C0442805
27233918	1104	1108	cold	T067	C0241842
27233918	1126	1142	thermoneutrality	T078	C0680444
27233918	1164	1174	chickadees	T012	C0326488
27233918	1179	1187	buntings	T012	C0326923
27233918	1196	1206	influenced	T077	C4054723
27233918	1210	1221	temperature	T081	C0039476
27233918	1257	1265	patterns	T082	C0449774
27233918	1271	1278	results	T033	C0683954
27233918	1292	1295	BMR	T040	C0678121
27233918	1317	1322	rates	T039	C0870882
27233918	1326	1330	warm	T067	C0563030
27233918	1335	1352	cold environments	T067	C0241842
27233918	1377	1381	Msum	T039	C0870882
27233918	1386	1389	MMR	T039	C0870882
27233918	1405	1416	limitations	T169	C0449295
27233918	1424	1428	rate	T039	C0870882
27233918	1442	1452	organ size	T032	C1450569
27233918	1457	1465	function	T169	C0542341
27233918	1490	1497	maximal	T080	C0205289
27233918	1498	1507	metabolic	T169	C0311400
27233918	1508	1516	capacity	T081	C1516240
27233918	1520	1524	lost	T169	C0745777
27233918	1537	1553	warm environment	T067	C0563030
27233918	1565	1571	gained	T081	C1517378
27233918	1577	1593	cold environment	T067	C0241842
27233918	1625	1636	temperature	T081	C0039476
27233918	1637	1650	stochasticity	T081	C0038347
27233918	1654	1672	northern latitudes	T083	C0017446
27233918	1676	1680	loss	T081	C1517945
27233918	1684	1695	thermogenic	T070	C0018837
27233918	1696	1704	capacity	T081	C1516240
27233918	1712	1716	warm	T067	C0563030
27233918	1717	1723	winter	T079	C0241737
27233918	1724	1728	days	T079	C0439228
27233918	1765	1770	birds	T012	C0005595
27233918	1798	1807	phenotype	T032	C0031437
27233918	1827	1831	cold	T067	C0241842
27233918	1832	1836	days	T079	C0439228

27234004|t|Factors preventing kneeling in a group of pre-educated patients post total knee arthroplasty
27234004|a|Difficulties in kneeling, one of the poorest scoring functional outcomes post total knee arthroplasty (TKA),have been attributed to a lack of patient education. This is the first study to investigate specific factors affecting a patient's perceived ability to kneel post TKA, following exposure to a preoperative kneeling education session. A cross-sectional study was conducted following TKA with patients who had been educated about kneeling prior to the operation. Patients completed kneeling questionnaires at 6 (n = 115) and 12 (n = 82) months post TKA. In addition to the 12-month kneeling questionnaire, patients also completed the Oxford knee score (OKS) survey. Seventy-two percent of patients perceived they could kneel at 12 months post TKA. Overall, pain and discomfort were the most common factors deterring patients from kneeling. Perceived kneeling ability was the poorest scored outcome on the OKS with patients reporting mild to moderate difficulty with this task. Kneeling scores were strongly correlated with overall knee function scores (R = 0.70), strongly correlated with pain scores (R = 0.45) and weakly correlated with knee stability scores (R = 0.29). When asked about other factors preventing kneeling other than pain or discomfor t, 75 % had reasons unrelated to the knee or TKA. The most common reason was 'problems with the other knee ' (n = 19). Patients in this study were provided with education regarding their kneeling ability post TKA, yet still experienced limitations in perceived kneeling ability post operatively. Contrary to previous research, our study suggests that factors other than patient education affect a patient's perceived kneeling ability post TKA.
27234004	0	7	Factors	T169	C1521761
27234004	8	18	preventing	T169	C1292733
27234004	19	27	kneeling	T039	C2584307
27234004	33	38	group	T078	C0441833
27234004	42	54	pre-educated	T065	C2106353
27234004	55	63	patients	T101	C0030705
27234004	64	68	post	T079	C0687676
27234004	69	92	total knee arthroplasty	T061	C0086511
27234004	93	117	Difficulties in kneeling	T033	C0555092
27234004	130	165	poorest scoring functional outcomes	T033	C0243095
27234004	166	170	post	T079	C0687676
27234004	171	194	total knee arthroplasty	T061	C0086511
27234004	196	199	TKA	T061	C0086511
27234004	211	221	attributed	T078	C0449234
27234004	227	231	lack	T080	C0332268
27234004	235	242	patient	T101	C0030705
27234004	243	252	education	T065	C2106353
27234004	281	292	investigate	T169	C1292732
27234004	293	301	specific	T080	C0205369
27234004	302	309	factors	T169	C1521761
27234004	310	319	affecting	T169	C0392760
27234004	322	331	patient's	T101	C0030705
27234004	332	341	perceived	T041	C0030971
27234004	342	358	ability to kneel	T032	C0560891
27234004	359	363	post	T079	C0687676
27234004	364	367	TKA	T061	C0086511
27234004	379	390	exposure to	T080	C0332157
27234004	393	405	preoperative	T079	C0445204
27234004	406	414	kneeling	T039	C2584307
27234004	415	432	education session	T065	C2106353
27234004	436	457	cross-sectional study	T062	C0010362
27234004	482	485	TKA	T061	C0086511
27234004	491	499	patients	T101	C0030705
27234004	513	521	educated	T065	C2106353
27234004	528	536	kneeling	T039	C2584307
27234004	537	542	prior	T079	C0332152
27234004	550	559	operation	T061	C0543467
27234004	561	569	Patients	T101	C0030705
27234004	580	588	kneeling	T039	C2584307
27234004	589	603	questionnaires	T170	C0034394
27234004	635	641	months	T079	C0439231
27234004	642	646	post	T079	C0687676
27234004	647	650	TKA	T061	C0086511
27234004	671	679	12-month	T079	C0439231
27234004	680	688	kneeling	T039	C2584307
27234004	689	702	questionnaire	T170	C0034394
27234004	704	712	patients	T101	C0030705
27234004	732	749	Oxford knee score	T201	C1997265
27234004	751	754	OKS	T201	C1997265
27234004	776	783	percent	T081	C0439165
27234004	787	795	patients	T101	C0030705
27234004	796	805	perceived	T041	C0030971
27234004	817	822	kneel	T039	C2584307
27234004	829	835	months	T079	C0439231
27234004	836	840	post	T079	C0687676
27234004	841	844	TKA	T061	C0086511
27234004	855	859	pain	T184	C0030193
27234004	864	874	discomfort	T184	C2364135
27234004	896	903	factors	T169	C1521761
27234004	914	922	patients	T101	C0030705
27234004	928	936	kneeling	T039	C2584307
27234004	938	947	Perceived	T041	C0030971
27234004	948	956	kneeling	T039	C2584307
27234004	957	964	ability	T032	C0085732
27234004	988	995	outcome	T169	C1274040
27234004	1003	1006	OKS	T201	C1997265
27234004	1012	1020	patients	T101	C0030705
27234004	1031	1047	mild to moderate	T080	C1299392
27234004	1048	1058	difficulty	T033	C0555092
27234004	1075	1083	Kneeling	T039	C2584307
27234004	1105	1115	correlated	T080	C1707520
27234004	1129	1149	knee function scores	T033	C0243095
27234004	1171	1181	correlated	T080	C1707520
27234004	1187	1198	pain scores	T033	C0582148
27234004	1221	1231	correlated	T080	C1707520
27234004	1237	1258	knee stability scores	T033	C0243095
27234004	1294	1301	factors	T169	C1521761
27234004	1302	1312	preventing	T169	C1292733
27234004	1313	1321	kneeling	T039	C2584307
27234004	1333	1337	pain	T184	C0030193
27234004	1341	1350	discomfor	T184	C2364135
27234004	1371	1380	unrelated	T033	C0445356
27234004	1388	1392	knee	T023	C0022742
27234004	1396	1399	TKA	T061	C0086511
27234004	1453	1457	knee	T023	C0022742
27234004	1470	1478	Patients	T101	C0030705
27234004	1512	1521	education	T065	C2106353
27234004	1538	1546	kneeling	T039	C2584307
27234004	1547	1554	ability	T032	C0085732
27234004	1555	1559	post	T079	C0687676
27234004	1560	1563	TKA	T061	C0086511
27234004	1602	1611	perceived	T041	C0030971
27234004	1612	1620	kneeling	T039	C2584307
27234004	1629	1633	post	T079	C0687676
27234004	1702	1709	factors	T169	C1521761
27234004	1721	1728	patient	T101	C0030705
27234004	1729	1738	education	T065	C2106353
27234004	1739	1745	affect	T058	C2237113
27234004	1748	1757	patient's	T101	C0030705
27234004	1758	1767	perceived	T041	C0030971
27234004	1768	1776	kneeling	T039	C2584307
27234004	1777	1784	ability	T032	C0085732
27234004	1785	1789	post	T079	C0687676
27234004	1790	1793	TKA	T061	C0086511

27234031|t|Improved diagnostic yield of neuromuscular disorders applying clinical exome sequencing in patients arising from a consanguineous population
27234031|a|Neuromuscular diseases (NMDs) include a broad range of disorders affecting muscles, nerves and neuromuscular junctions. Their overlapping phenotypes and heterogeneous genetic nature have created challenges in diagnosis which calls for the implementation of massive parallel sequencing as a candidate strategy to increase the diagnostic yield. In this study, total of 45 patients, mostly offspring of consanguineous marriages were examined using whole exome sequencing. Data analysis was performed to identify the most probable pathogenic rare variants in known NMD genes which led to identification of causal variants for 33 out of 45 patients (73.3%) in the following known genes: CAPN3, Col6A1, Col6A3, DMD, DYSF, FHL1, GJB1, ISPD, LAMA2, LMNA, PLEC1, RYR1, SGCA, SGCB, SYNE1, TNNT1 and 22 novel pathogenic variants were detected. Today, the advantage of whole exome sequencing in clinical diagnostic strategies of heterogeneous disorders is clear. In this cohort, a diagnostic yield of 73.3% was achieved which is quite high compared to the overall reported diagnostic yield of 25% to 50%. This could be explained by the consanguineous background of these patients and is another strong advantage of offering clinical exome sequencing in diagnostic laboratories, especially in populations with high rate of consanguinity.
27234031	0	8	Improved	T033	C0184511
27234031	9	25	diagnostic yield	T080	C0205556
27234031	29	52	neuromuscular disorders	T047	C0027868
27234031	62	70	clinical	T080	C0205210
27234031	71	87	exome sequencing	T063	C3640077
27234031	91	99	patients	T101	C0030705
27234031	115	129	consanguineous	UnknownType	C0680040
27234031	130	140	population	T098	C1257890
27234031	141	163	Neuromuscular diseases	T047	C0027868
27234031	165	169	NMDs	T047	C0027868
27234031	196	205	disorders	T047	C0012634
27234031	216	223	muscles	T024	C0026845
27234031	225	231	nerves	T024	C0027740
27234031	236	259	neuromuscular junctions	T026	C0027869
27234031	279	289	phenotypes	T032	C0031437
27234031	294	322	heterogeneous genetic nature	T032	C0242960
27234031	350	359	diagnosis	T033	C0011900
27234031	380	394	implementation	T052	C1708476
27234031	398	425	massive parallel sequencing	T063	C2936622
27234031	466	482	diagnostic yield	T080	C0205556
27234031	492	497	study	T062	C2603343
27234031	511	519	patients	T101	C0030705
27234031	528	537	offspring	T099	C0680063
27234031	541	565	consanguineous marriages	T054	C0870340
27234031	586	608	whole exome sequencing	T063	C3640077
27234031	610	623	Data analysis	T057	C0010992
27234031	668	678	pathogenic	T033	C3816499
27234031	679	692	rare variants	T028	C0678941
27234031	702	705	NMD	T047	C0027868
27234031	706	711	genes	T028	C0017337
27234031	743	758	causal variants	T080	C0205419
27234031	776	784	patients	T101	C0030705
27234031	816	821	genes	T028	C0017337
27234031	823	828	CAPN3	T028	C1413113
27234031	830	836	Col6A1	T028	C1413589
27234031	838	844	Col6A3	T028	C1413591
27234031	846	849	DMD	T028	C1414083
27234031	851	855	DYSF	T028	C1414209
27234031	857	861	FHL1	T028	C1414612
27234031	863	867	GJB1	T028	C1415076
27234031	869	873	ISPD	T028	C2829592
27234031	875	880	LAMA2	T028	C1416776
27234031	882	886	LMNA	T028	C1416877
27234031	888	893	PLEC1	T028	C1418643
27234031	895	899	RYR1	T028	C1419778
27234031	901	905	SGCA	T028	C1420005
27234031	907	911	SGCB	T028	C1420006
27234031	913	918	SYNE1	T028	C1424736
27234031	920	925	TNNT1	T028	C1420827
27234031	939	949	pathogenic	T033	C3816499
27234031	950	958	variants	T028	C0678941
27234031	964	972	detected	T033	C0442726
27234031	998	1020	whole exome sequencing	T063	C3640077
27234031	1024	1043	clinical diagnostic	T060	C0332140
27234031	1058	1081	heterogeneous disorders	T033	C1858576
27234031	1100	1106	cohort	T098	C0599755
27234031	1110	1126	diagnostic yield	T080	C0205556
27234031	1169	1177	compared	T052	C1707455
27234031	1185	1192	overall	T080	C1561607
27234031	1202	1218	diagnostic yield	T080	C0205556
27234031	1265	1279	consanguineous	UnknownType	C0680040
27234031	1300	1308	patients	T101	C0030705
27234031	1353	1361	clinical	T080	C0205210
27234031	1362	1378	exome sequencing	T063	C3640077
27234031	1382	1392	diagnostic	T169	C0348026
27234031	1393	1405	laboratories	T073,T093	C0022877
27234031	1421	1432	populations	T098	C1257890
27234031	1451	1464	consanguinity	T033	C0009789

27234220|t|Safety of transradial diagnostic cardiac catheterization in patients under oral anticoagulant therapy
27234220|a|Cardiac catheterization in anticoagulated patients is usually performed after the anticoagulation has been withdrawn, at least in the previous 48h, and sometimes bridging therapy with heparin is used. A prospective observational study including 489 patients undergoing transradial catheterization was conducted. A total of 140 patients were under acenocoumarol (group A) and they were compared with the remainder (group B) for complications after the procedure (bleeding and vascular access complications). Patients in group A were older (74Â±12 years vs. 68Â±17 years, p<0.01) and the main indication for anticoagulation was atrial fibrillation (58.6%). No complications occurred during the procedures. There were no acute bleedings just after the bandage removal. During the first 24h, only 3 (2.1%) radial occlusions in group A and 2 (0.6%) in group B (p=0.14) were recorded. Hematomas between 5 and 10cm appeared in 5% of the group A vs. 4.6% in group B. During the 1-month follow-up period, one more radial occlusion in each group was recorded and there were 4 (1.1%) additional mild hematomas in group B and none in group A (p=0.48). Performing a transradial diagnostic cardiac catheterization without removal of the oral chronic anticoagulation appears safe in patients under acenocumarol therapy.
27234220	0	6	Safety	T062	C1705187
27234220	10	56	transradial diagnostic cardiac catheterization	T060	C2041518
27234220	60	68	patients	T101	C0030705
27234220	75	79	oral	T082	C0442027
27234220	80	101	anticoagulant therapy	T061	C0150457
27234220	102	125	Cardiac catheterization	T058	C0018795
27234220	129	143	anticoagulated	UnknownType	C0741134
27234220	144	152	patients	T101	C0030705
27234220	164	173	performed	T169	C0884358
27234220	184	199	anticoagulation	T061	C0003281
27234220	209	218	withdrawn	T061	C1707825
27234220	264	293	bridging therapy with heparin	T061	C3873426
27234220	317	336	observational study	T062	C1518527
27234220	351	359	patients	T101	C0030705
27234220	371	398	transradial catheterization	T058	C0018795
27234220	429	437	patients	T101	C0030705
27234220	449	462	acenocoumarol	T109,T121	C0000956
27234220	464	471	group A	T185	C0441835
27234220	487	495	compared	T052	C1707455
27234220	505	514	remainder	T080	C1527428
27234220	516	523	group B	T185	C0441836
27234220	529	542	complications	T046	C0009566
27234220	553	562	procedure	T058	C0018795
27234220	564	572	bleeding	T046	C0019080
27234220	577	606	vascular access complications	T046	C0920165
27234220	609	617	Patients	T101	C0030705
27234220	621	628	group A	T185	C0441835
27234220	634	639	older	T098	C1518563
27234220	691	701	indication	T078	C3146298
27234220	706	721	anticoagulation	T061	C0003281
27234220	726	745	atrial fibrillation	T047	C0004238
27234220	755	757	No	T033	C1513916
27234220	758	771	complications	T046	C0009566
27234220	792	802	procedures	T058	C0018795
27234220	815	817	no	T033	C1513916
27234220	818	833	acute bleedings	T046	C0333276
27234220	839	844	after	T079	C0687676
27234220	849	856	bandage	T074	C0004726
27234220	857	864	removal	T052	C1883720
27234220	902	919	radial occlusions	T046	C1110554
27234220	923	930	group A	T185	C0441835
27234220	947	954	group B	T185	C0441836
27234220	969	977	recorded	T080	C2355580
27234220	979	988	Hematomas	T046	C0018944
27234220	1030	1037	group A	T185	C0441835
27234220	1050	1057	group B	T185	C0441836
27234220	1070	1077	1-month	T079	C1442451
27234220	1078	1087	follow-up	T058	C1522577
27234220	1088	1094	period	T079	C1948053
27234220	1105	1121	radial occlusion	T046	C1110554
27234220	1130	1135	group	T078	C0441833
27234220	1140	1148	recorded	T080	C2355580
27234220	1184	1188	mild	T080	C2945599
27234220	1189	1198	hematomas	T046	C0018944
27234220	1202	1209	group B	T185	C0441836
27234220	1222	1229	group A	T185	C0441835
27234220	1240	1250	Performing	T169	C0884358
27234220	1253	1299	transradial diagnostic cardiac catheterization	T060	C2041518
27234220	1300	1307	without	T080	C0332288
27234220	1308	1315	removal	T052	C1883720
27234220	1323	1327	oral	T082	C0442027
27234220	1328	1351	chronic anticoagulation	UnknownType	C0694554
27234220	1360	1364	safe	T033	C3266157
27234220	1368	1376	patients	T101	C0030705
27234220	1383	1395	acenocumarol	T109,T121	C0000956
27234220	1396	1403	therapy	T061	C0087111

27235559|t|Does infrared visualization improve selection of venipuncture sites for indwelling needle at the forearm in second-year nursing students?
27235559|a|To evaluate the effectiveness of a vein visualization display system using near-infrared light (" Vein Display ") for the safe and proper selection of venipuncture sites for indwelling needle placement in the forearm. Ten second year nursing students were recruited to apply an indwelling needle line with and without Vein Display. Another ten participants were recruited from various faculty to serve as patients. The quality of the venipuncture procedure at various selected sites was evaluated according to a scale developed by the authors. Time, scores and patterns of puncture - site selection were compared with respect to three different methods: [1] attempt 1 (tourniquet only), [2] attempt 2 (Vein Display only) and [3] attempt 3 (both). To validate the effectiveness of Vein Display, 52 trials were conducted in total. We found that venipuncture site selection time was significantly improved with the Vein Display, particularly in the case of difficult to administer venipuncture sites. Overall, we found no significant difference with respect to venipuncture quality, as determined by our scale. These results suggest that equipment such as the Vein Display can contribute immensely to the improvement of practical skills, such as venipuncture, especially in the context of elderly patients.
27235559	5	13	infrared	T074	C0181645
27235559	14	27	visualization	T169	C0234621
27235559	36	45	selection	T052	C1707391
27235559	49	61	venipuncture	T060	C0600406
27235559	62	67	sites	T082	C0205145
27235559	72	82	indwelling	T169	C0439848
27235559	83	89	needle	T074	C0027551
27235559	97	104	forearm	T023	C0016536
27235559	120	136	nursing students	T097	C0038496
27235559	154	167	effectiveness	T080	C1280519
27235559	173	206	vein visualization display system	T074	C0025080
27235559	213	232	near-infrared light	T070	C1289901
27235559	236	248	Vein Display	T074	C0025080
27235559	276	285	selection	T052	C1707391
27235559	289	301	venipuncture	T060	C0600406
27235559	302	307	sites	T082	C0205145
27235559	312	322	indwelling	T169	C0439848
27235559	323	329	needle	T074	C0027551
27235559	347	354	forearm	T023	C0016536
27235559	372	388	nursing students	T097	C0038496
27235559	416	426	indwelling	T169	C0439848
27235559	427	433	needle	T074	C0027551
27235559	456	460	Vein	T023	C0042449
27235559	461	468	Display	T169	C0870432
27235559	482	494	participants	T098	C0679646
27235559	523	530	faculty	T097	C0015535
27235559	543	551	patients	T101	C0030705
27235559	572	594	venipuncture procedure	T060	C0600406
27235559	615	620	sites	T082	C0205145
27235559	650	655	scale	T170	C0349674
27235559	673	680	authors	T097	C3812881
27235559	682	686	Time	T079	C0040223
27235559	688	694	scores	T081	C0449820
27235559	699	707	patterns	T080	C0332307
27235559	711	719	puncture	T060	C0600406
27235559	722	726	site	T082	C0205145
27235559	727	736	selection	T052	C1707391
27235559	807	817	tourniquet	T074	C0040519
27235559	840	852	Vein Display	T074	C0025080
27235559	901	914	effectiveness	T080	C1280519
27235559	918	922	Vein	T023	C0042449
27235559	923	930	Display	T169	C0870432
27235559	981	993	venipuncture	T060	C0600406
27235559	994	998	site	T082	C0205145
27235559	999	1008	selection	T052	C1707391
27235559	1050	1062	Vein Display	T074	C0025080
27235559	1105	1115	administer	T169	C1621583
27235559	1116	1128	venipuncture	T060	C0600406
27235559	1129	1134	sites	T082	C0205145
27235559	1196	1208	venipuncture	T060	C0600406
27235559	1209	1216	quality	T080	C0332306
27235559	1239	1244	scale	T170	C0349674
27235559	1295	1307	Vein Display	T074	C0025080
27235559	1355	1371	practical skills	T080	C0008973
27235559	1381	1393	venipuncture	T060	C0600406
27235559	1424	1431	elderly	T098	C0001792
27235559	1432	1440	patients	T101	C0030705

27235789|t|Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma
27235789|a|There is no consensus regarding a protective effect on mortality due to a cause other than cancer in patients treated with elective nephron sparing surgery relative to their radical nephrectomy counterparts. We test whether the protective effect of nephron sparing surgery relative to radical nephrectomy is universal or present in specific subgroups of patients. A collaborative database of 5 institutions was queried to evaluate 1,783 patients without chronic kidney disease diagnosed with a clinical T1 renal mass that was treated with nephron sparing surgery or radical nephrectomy. Multivariable Cox regression analysis was done to assess the impact of surgery type (nephron sparing surgery vs radical nephrectomy) on other cause mortality after adjustment for patient and cancer characteristics. Interaction terms were used to test the hypothesis that the impact of surgery type varies according to specific subcohorts of patients. Ten-year other cause mortality -free survival rates were 90% and 88% after nephron sparing surgery and radical nephrectomy, respectively. In the overall population radical nephrectomy was not associated with an increased risk of other cause mortality on multivariable analysis compared to nephron sparing surgery (HR 0.91, 95% CI 0.6-1.38, p = 0.6). However, radical nephrectomy increased the risk of other cause mortality according to the increasing baseline Charlson comorbidity index (interaction test p = 0.0008). For example, in a patient with a Charlson comorbidity index of 4 the probability of 10-year other cause mortality -free survival was 86% after nephron sparing surgery and 60% after radical nephrectomy. Elective nephron sparing surgery does not improve other cause survival relative to radical nephrectomy consistently in all patients with kidney cancer. Patients who are more ill with relevant comorbidities are those who benefit the most from nephron sparing surgery in terms of other cause mortality.
27235789	0	8	Elective	T061	C0206058
27235789	9	32	Nephron Sparing Surgery	T061	C0194086
27235789	33	42	Decreases	T081	C0205216
27235789	43	64	Other Cause Mortality	T033	C0476465
27235789	65	73	Relative	T080	C0205345
27235789	77	96	Radical Nephrectomy	T061	C0401181
27235789	105	113	Specific	T080	C0205369
27235789	114	123	Subgroups	T185	C1515021
27235789	127	135	Patients	T101	C0030705
27235789	141	161	Renal Cell Carcinoma	T191	C0007134
27235789	174	183	consensus	T054	C0376298
27235789	196	213	protective effect	T033	C1545588
27235789	217	226	mortality	T081	C0205848
27235789	253	259	cancer	T191	C0006826
27235789	263	271	patients	T101	C0030705
27235789	272	284	treated with	T061	C0332293
27235789	285	293	elective	T061	C0206058
27235789	294	317	nephron sparing surgery	T061	C0194086
27235789	318	326	relative	T080	C0205345
27235789	336	355	radical nephrectomy	T061	C0401181
27235789	373	377	test	T169	C0039593
27235789	390	407	protective effect	T033	C1545588
27235789	411	434	nephron sparing surgery	T061	C0194086
27235789	435	443	relative	T080	C0205345
27235789	447	466	radical nephrectomy	T061	C0401181
27235789	470	479	universal	T080	C0175671
27235789	494	502	specific	T080	C0205369
27235789	503	512	subgroups	T185	C1515021
27235789	516	524	patients	T101	C0030705
27235789	528	541	collaborative	T081	C0392762
27235789	542	550	database	T170	C0242356
27235789	556	568	institutions	T078	C1272753
27235789	573	580	queried	T170	C1522634
27235789	584	592	evaluate	T058	C0220825
27235789	599	607	patients	T101	C0030705
27235789	616	638	chronic kidney disease	T047	C1561643
27235789	639	648	diagnosed	T033	C0011900
27235789	656	664	clinical	T080	C0205210
27235789	665	678	T1 renal mass	T191	C2217020
27235789	688	700	treated with	T061	C0332293
27235789	701	724	nephron sparing surgery	T061	C0194086
27235789	728	747	radical nephrectomy	T061	C0401181
27235789	749	786	Multivariable Cox regression analysis	T170	C0034980
27235789	799	805	assess	T058	C0184514
27235789	810	816	impact	T080	C4049986
27235789	820	827	surgery	T061	C0543467
27235789	834	857	nephron sparing surgery	T061	C0194086
27235789	861	880	radical nephrectomy	T061	C0401181
27235789	885	906	other cause mortality	T033	C0476465
27235789	928	935	patient	T101	C0030705
27235789	940	946	cancer	T191	C0006826
27235789	947	962	characteristics	T080	C1521970
27235789	964	975	Interaction	T169	C1704675
27235789	995	999	test	T169	C0039593
27235789	1024	1030	impact	T080	C4049986
27235789	1034	1041	surgery	T061	C0543467
27235789	1067	1075	specific	T080	C0205369
27235789	1076	1086	subcohorts	T098	C0599755
27235789	1090	1098	patients	T101	C0030705
27235789	1100	1108	Ten-year	T079	C1254367
27235789	1109	1130	other cause mortality	T033	C0476465
27235789	1137	1151	survival rates	T081	C0038954
27235789	1175	1198	nephron sparing surgery	T061	C0194086
27235789	1203	1222	radical nephrectomy	T061	C0401181
27235789	1245	1252	overall	T080	C1561607
27235789	1253	1263	population	T098	C1257890
27235789	1264	1283	radical nephrectomy	T061	C0401181
27235789	1292	1307	associated with	T080	C0332281
27235789	1311	1320	increased	T081	C0205217
27235789	1321	1325	risk	T078	C0035647
27235789	1329	1350	other cause mortality	T033	C0476465
27235789	1354	1376	multivariable analysis	T081	C0026777
27235789	1389	1412	nephron sparing surgery	T061	C0194086
27235789	1414	1416	HR	T081	C2985465
27235789	1427	1429	CI	T081	C0009667
27235789	1459	1478	radical nephrectomy	T061	C0401181
27235789	1479	1488	increased	T081	C0205217
27235789	1493	1497	risk	T078	C0035647
27235789	1501	1522	other cause mortality	T033	C0476465
27235789	1540	1550	increasing	T081	C0205217
27235789	1551	1559	baseline	T081	C1442488
27235789	1560	1586	Charlson comorbidity index	T170	C3714916
27235789	1588	1599	interaction	T169	C1704675
27235789	1600	1604	test	T169	C0039593
27235789	1636	1643	patient	T101	C0030705
27235789	1651	1677	Charlson comorbidity index	T170	C3714916
27235789	1687	1698	probability	T081	C0033204
27235789	1702	1709	10-year	T079	C1254367
27235789	1710	1731	other cause mortality	T033	C0476465
27235789	1738	1746	survival	T052	C0038952
27235789	1761	1784	nephron sparing surgery	T061	C0194086
27235789	1799	1818	radical nephrectomy	T061	C0401181
27235789	1820	1828	Elective	T061	C0206058
27235789	1829	1852	nephron sparing surgery	T061	C0194086
27235789	1862	1869	improve	T033	C0184511
27235789	1882	1890	survival	T052	C0038952
27235789	1891	1899	relative	T080	C0205345
27235789	1903	1922	radical nephrectomy	T061	C0401181
27235789	1943	1951	patients	T101	C0030705
27235789	1957	1970	kidney cancer	T191	C0740457
27235789	1972	1980	Patients	T101	C0030705
27235789	1994	1997	ill	T184	C0221423
27235789	2003	2011	relevant	T080	C2347946
27235789	2012	2025	comorbidities	T078	C0009488
27235789	2040	2047	benefit	T081	C0814225
27235789	2062	2085	nephron sparing surgery	T061	C0194086
27235789	2098	2119	other cause mortality	T033	C0476465

27235824|t|A prime a day keeps calories away: The effects of supraliminal priming on food consumption and the moderating role of gender and eating restraint
27235824|a|The link between intentions and action in weight control is weaker than previously thought, so recent research has called for further investigation of ways to improve weight control that bypass conscious intentions. Priming has been shown to have effects on individual behavior in a variety of contexts by influencing subconscious cognition. This paper investigates the effects of semantic priming using healthy body image, goal-oriented words on food consumption. The moderating role of both restrained eating and gender is investigated. 161 participants were involved in an experiment using a novel version of a scrambled sentence priming game. The outcome measure was the number of kilocalories consumed, examined using a between subjects ANCOVA with priming, gender, restrained eating index, self-reported BMI, and two interaction terms (priming x gender, and priming x restrained eating index). There was no main effect of priming but there was an interaction of priming with gender. Females consumed significantly fewer kilocalories after being exposed to priming words related to a healthy body image (i.e. "slim", "fit,") compared to females receiving the neutral prime, with a medium effect size (d = 0.58). The body image prime did not significantly affect food intake for males, nor did it have a differential effect on restrained eaters. This study shows that priming can be an effective method for influencing females to reduce food intake, regardless of whether they are restrained or unrestrained eaters. Future studies could investigate whether different priming words related to a male's healthy body image goal (i.e. "buff," " muscles ," etc.) would similarly reduce food intake for males.
27235824	2	7	prime	T041	C3825344
27235824	20	28	calories	T081	C1556156
27235824	39	49	effects of	T080	C1704420
27235824	50	70	supraliminal priming	T041	C3825344
27235824	74	90	food consumption	T052	C2983605
27235824	99	114	moderating role	T170	C1704326
27235824	118	124	gender	T032	C0079399
27235824	129	145	eating restraint	T170	C0451424
27235824	163	173	intentions	T041	C0162425
27235824	178	184	action	T052	C3266814
27235824	188	202	weight control	T061	C0920298
27235824	248	256	research	T062	C0035168
27235824	313	327	weight control	T061	C0920298
27235824	340	349	conscious	T041	C0234421
27235824	350	360	intentions	T041	C0162425
27235824	362	369	Priming	T041	C3825344
27235824	464	476	subconscious	T041	C0038535
27235824	477	486	cognition	T041	C0009240
27235824	516	526	effects of	T080	C1704420
27235824	527	543	semantic priming	T169	C0871332
27235824	550	557	healthy	T080	C3898900
27235824	558	568	body image	T041	C0005891
27235824	570	589	goal-oriented words	T170	C0042926
27235824	593	609	food consumption	T052	C2983605
27235824	615	630	moderating role	T170	C1704326
27235824	639	656	restrained eating	T170	C0451424
27235824	661	667	gender	T032	C0079399
27235824	689	701	participants	T098	C0679646
27235824	722	732	experiment	T062	C0681814
27235824	770	778	sentence	T170	C0876929
27235824	779	786	priming	T041	C3825344
27235824	787	791	game	T056	C0150593
27235824	831	843	kilocalories	T081	C0439259
27235824	844	852	consumed	T061	C0513065
27235824	888	894	ANCOVA	T081	C0814908
27235824	900	907	priming	T041	C3825344
27235824	909	915	gender	T032	C0079399
27235824	917	940	restrained eating index	T170	C0451424
27235824	942	955	self-reported	T062	C2700446
27235824	956	959	BMI	T201	C1305855
27235824	969	980	interaction	T169	C1704675
27235824	988	995	priming	T041	C3825344
27235824	998	1004	gender	T032	C0079399
27235824	1010	1017	priming	T041	C3825344
27235824	1020	1043	restrained eating index	T170	C0451424
27235824	1064	1073	effect of	T080	C1704420
27235824	1074	1081	priming	T041	C3825344
27235824	1099	1110	interaction	T169	C1704675
27235824	1114	1121	priming	T041	C3825344
27235824	1127	1133	gender	T032	C0079399
27235824	1135	1142	Females	T032	C0086287
27235824	1172	1184	kilocalories	T081	C0439259
27235824	1208	1215	priming	T041	C3825344
27235824	1216	1221	words	T170	C0042926
27235824	1235	1242	healthy	T080	C3898900
27235824	1243	1253	body image	T041	C0005891
27235824	1288	1295	females	T032	C0086287
27235824	1318	1323	prime	T041	C3825344
27235824	1367	1377	body image	T041	C0005891
27235824	1378	1383	prime	T041	C3825344
27235824	1413	1424	food intake	T040	C0013470
27235824	1429	1434	males	T032	C0086582
27235824	1477	1494	restrained eaters	T098	C0679646
27235824	1518	1525	priming	T041	C3825344
27235824	1569	1576	females	T032	C0086287
27235824	1587	1598	food intake	T040	C0013470
27235824	1631	1641	restrained	T098	C0679646
27235824	1645	1664	unrestrained eaters	T098	C0679646
27235824	1717	1724	priming	T041	C3825344
27235824	1725	1730	words	T170	C0042926
27235824	1744	1750	male's	T032	C0086582
27235824	1751	1758	healthy	T080	C3898900
27235824	1759	1769	body image	T041	C0005891
27235824	1791	1798	muscles	T024	C0026845
27235824	1831	1842	food intake	T040	C0013470
27235824	1847	1852	males	T032	C0086582

27235870|t|Neurotrophins and specific receptors in the oviduct tracts of Japanese quail (Coturnix coturnix japonica)
27235870|a|Neurotrophins (NGF, BDNF and NT-3) and their specific receptors (TrkA, TrkB and TrkC) were studied in the oviduct of egg laying quails. Neurotrophins (NTs) are mainly involved in the development and maintenance of neuronal populations in the central and peripheral nervous system, but also in reproductive system. In this survey, we first studied the morphological organization of the quail oviduct, distinguished in infundibulum, magnum, isthmus, uterus and vagina, and then we analyzed the expression and localization of NTs and Trks receptors in the whole tracts. By western blotting we detected that the investigated NTs and Trks receptors are expressed in all oviductal tracts. By immunohistochemistry we were able to define the distribution of NTs and Trks. Specifically, NGF, BDNF and NT3 were localized in lining and ductal epithelial cells, and NGF was also detected in secretory cells of tubular glands and in nervous fibers of vessel wall. TrkA and TrkB were present in the lining and ductal epithelium; TrkA and TrkC were present in nervous fibers of vessel wall in all oviductal tracts. Furthermore, we also observed NGF and BDNF co-localized with TrkA and TrkB in cells of the lining and ductal epithelium, suggesting an autocrine mechanism of action.
27235870	0	13	Neurotrophins	T116,T123	C0027754
27235870	18	36	specific receptors	T116,T192	C0254837
27235870	44	58	oviduct tracts	T023	C0029954
27235870	62	76	Japanese quail	T012	C0022345
27235870	78	104	Coturnix coturnix japonica	T012	C0022345
27235870	106	119	Neurotrophins	T116,T123	C0027754
27235870	121	124	NGF	T116,T123	C0027752
27235870	126	130	BDNF	T116,T123	C0107103
27235870	135	139	NT-3	T116,T123	C0083735
27235870	151	169	specific receptors	T116,T192	C0254837
27235870	171	175	TrkA	T116,T126,T192	C0072482
27235870	177	181	TrkB	T116,T126,T192	C0084873
27235870	186	190	TrkC	T116,T126,T192	C0132300
27235870	197	204	studied	T062	C2603343
27235870	212	219	oviduct	T023	C0029954
27235870	223	233	egg laying	T040	C1622979
27235870	234	240	quails	T012	C0022345
27235870	242	255	Neurotrophins	T116,T123	C0027754
27235870	257	260	NTs	T116,T123	C0027754
27235870	289	300	development	T169	C1527148
27235870	305	316	maintenance	T169	C0587894
27235870	320	340	neuronal populations	T025	C0027882
27235870	348	355	central	T022	C3714787
27235870	360	385	peripheral nervous system	T022	C0206417
27235870	399	418	reproductive system	T022	C1261210
27235870	445	452	studied	T062	C2603343
27235870	457	470	morphological	T080	C0332437
27235870	471	483	organization	T039	C0029237
27235870	491	496	quail	T012	C0022345
27235870	497	504	oviduct	T023	C0029954
27235870	523	535	infundibulum	T023	C0227911
27235870	537	543	magnum	T023	C0229962
27235870	545	552	isthmus	T023	C0227909
27235870	554	560	uterus	T023	C0042149
27235870	565	571	vagina	T023	C0042232
27235870	585	593	analyzed	T062	C0936012
27235870	598	608	expression	T045	C1171362
27235870	613	625	localization	T043	C0007613
27235870	629	632	NTs	T116,T123	C0027754
27235870	637	651	Trks receptors	T116,T192	C0254837
27235870	665	671	tracts	T023	C0029954
27235870	676	692	western blotting	T059,T063	C0005863
27235870	714	726	investigated	T169	C1292732
27235870	727	730	NTs	T116,T123	C0027754
27235870	735	749	Trks receptors	T116,T192	C0254837
27235870	754	763	expressed	T045	C1171362
27235870	771	787	oviductal tracts	T023	C0029954
27235870	792	812	immunohistochemistry	T060	C0021044
27235870	840	852	distribution	T043	C0872250
27235870	856	859	NTs	T116,T123	C0027754
27235870	864	868	Trks	T116,T192	C0254837
27235870	884	887	NGF	T116,T123	C0027752
27235870	889	893	BDNF	T116,T123	C0107103
27235870	898	901	NT3	T116,T123	C0083735
27235870	920	926	lining	T082	C1254362
27235870	931	954	ductal epithelial cells	T025	C1512085
27235870	960	963	NGF	T116,T123	C0027752
27235870	985	1000	secretory cells	T025	C1519221
27235870	1004	1018	tubular glands	T023	C1179446
27235870	1026	1040	nervous fibers	T026	C0027749
27235870	1044	1055	vessel wall	T023	C0507777
27235870	1057	1061	TrkA	T116,T126,T192	C0072482
27235870	1066	1070	TrkB	T116,T126,T192	C0084873
27235870	1091	1097	lining	T082	C1254362
27235870	1102	1119	ductal epithelium	T024	C1512086
27235870	1121	1125	TrkA	T116,T126,T192	C0072482
27235870	1130	1134	TrkC	T116,T126,T192	C0132300
27235870	1151	1165	nervous fibers	T026	C0027749
27235870	1169	1180	vessel wall	T023	C0507777
27235870	1188	1204	oviductal tracts	T023	C0029954
27235870	1236	1239	NGF	T116,T123	C0027752
27235870	1244	1248	BDNF	T116,T123	C0107103
27235870	1267	1271	TrkA	T116,T126,T192	C0072482
27235870	1276	1280	TrkB	T116,T126,T192	C0084873
27235870	1284	1289	cells	T025	C0007634
27235870	1297	1303	lining	T082	C1254362
27235870	1308	1325	ductal epithelium	T024	C1512086
27235870	1341	1360	autocrine mechanism	T043	C3825249
27235870	1364	1370	action	T052	C3266814

27235977|t|Laser -facilitated epicutaneous immunotherapy to IgE-mediated allergy
27235977|a|Allergen specific immunotherapy has been shown to be the only effective treatment for long-lasting clinical benefit to IgE-mediated allergic diseases, but a fewer than 5% of patients choose the treatment because of inconvenience and a high risk of anaphylaxis. Recently, epicutaneous allergen-specific immunotherapy (EPIT) has proven effective, yet with limitations owing to strong skin reactions. We demonstrate here safer and faster EPIT, named Î¼EPIT, by delivering powdered allergen and adjuvants into many micropores in the epidermis. We fabricated a microarray patch fractionally coated with a powder mixture of ovalbumin (OVA) model allergen, CpG, and 1,25-dihydroxyvitamin D3 (VD3). Topical application of the patch onto laser-microperforated skin resulted in a high level of epidermal delivery while greatly minimizing allergen leakage into circulation system as compared to current subcutaneous immunotherapy (SCIT). Moreover, only three times of Î¼EPIT over two weeks could sufficiently inhibit allergen-specific IgE responses in mice suffering OVA -induced airway hyperresponsivness (AHR), which was unattainable by eight times of SCIT over three weeks. Mechanistically, Î¼EPIT preferably enhanced IgG2a production suggesting TH1-biased immune responses and induced a high level of T-regulatory (Treg) cells against repeated allergen sensitization. The immune tolerance was confirmed by marked reduction in airway wall thickness as well as eosinophil and neutrophil infiltration into the respiratory airway. The Î¼EPIT represents a novel and painless technology to treat IgE-mediated allergic diseases with little local skin reaction and a minimal risk of anaphylaxis.
27235977	0	5	Laser	T073	C0023089
27235977	19	31	epicutaneous	T061	C0001558
27235977	32	45	immunotherapy	T061	C0021083
27235977	49	69	IgE-mediated allergy	T047	C1706410
27235977	70	101	Allergen specific immunotherapy	T061	C0162352
27235977	132	141	effective	T080	C1704419
27235977	142	151	treatment	T061	C0087111
27235977	156	168	long-lasting	T079	C0443252
27235977	169	177	clinical	T080	C0205210
27235977	178	185	benefit	T081	C0814225
27235977	189	219	IgE-mediated allergic diseases	T047	C1706410
27235977	244	252	patients	T101	C0030705
27235977	264	273	treatment	T061	C0087111
27235977	305	317	high risk of	T033	C0332167
27235977	318	329	anaphylaxis	T046	C0002792
27235977	341	385	epicutaneous allergen-specific immunotherapy	T061	C0162352
27235977	387	391	EPIT	T061	C0162352
27235977	404	413	effective	T080	C1704419
27235977	424	435	limitations	T169	C0449295
27235977	445	466	strong skin reactions	T201	C0221743
27235977	505	509	EPIT	T061	C0162352
27235977	517	522	Î¼EPIT	T061	C0162352
27235977	527	537	delivering	T169	C1705822
27235977	538	555	powdered allergen	T129	C0002092
27235977	560	569	adjuvants	T121,T129	C0001551
27235977	580	590	micropores	T026	C1325742
27235977	598	607	epidermis	T024	C0014520
27235977	625	635	microarray	T073	C1709016
27235977	636	641	patch	T074	C0991556
27235977	655	661	coated	T080	C1522408
27235977	669	696	powder mixture of ovalbumin	T116,T123	C0029923
27235977	698	701	OVA	T116,T123	C0029923
27235977	709	717	allergen	T129	C0002092
27235977	719	722	CpG	T114,T123	C0056912
27235977	728	752	1,25-dihydroxyvitamin D3	T109,T121,T127	C0006674
27235977	754	757	VD3	T109,T121,T127	C0006674
27235977	760	779	Topical application	T061	C0683174
27235977	787	792	patch	T074	C0991556
27235977	798	819	laser-microperforated	T033	C1709025
27235977	820	824	skin	T022	C1123023
27235977	825	836	resulted in	T169	C0332294
27235977	844	849	level	T080	C0441889
27235977	853	862	epidermal	T024	C0014520
27235977	863	871	delivery	T169	C1705822
27235977	897	905	allergen	T129	C0002092
27235977	906	913	leakage	T033	C4281748
27235977	919	937	circulation system	T022	C0007226
27235977	941	949	compared	T052	C1707455
27235977	961	987	subcutaneous immunotherapy	T061	C0413381
27235977	989	993	SCIT	T061	C0413381
27235977	1026	1031	Î¼EPIT	T061	C0162352
27235977	1066	1073	inhibit	T052	C3463820
27235977	1074	1095	allergen-specific IgE	T116,T129	C0443736
27235977	1096	1105	responses	T032	C0871261
27235977	1109	1113	mice	T015	C0025929
27235977	1124	1127	OVA	T116,T123	C0029923
27235977	1137	1162	airway hyperresponsivness	T046	C0035228
27235977	1164	1167	AHR	T046	C0035228
27235977	1211	1215	SCIT	T061	C0413381
27235977	1251	1256	Î¼EPIT	T061	C0162352
27235977	1268	1276	enhanced	T052	C2349975
27235977	1277	1282	IgG2a	T116,T129	C0020857
27235977	1283	1293	production	T038	C0003261
27235977	1305	1315	TH1-biased	T025	C0242632
27235977	1316	1332	immune responses	T042	C0301872
27235977	1337	1344	induced	T169	C0205263
27235977	1352	1357	level	T080	C0441889
27235977	1361	1373	T-regulatory	T025	C0039198
27235977	1375	1379	Treg	T025	C0039198
27235977	1381	1386	cells	T025	C0007634
27235977	1404	1426	allergen sensitization	T047	C2938930
27235977	1432	1448	immune tolerance	T046	C0020963
27235977	1453	1465	confirmed by	T080	C0521093
27235977	1473	1482	reduction	T061	C0441610
27235977	1486	1497	airway wall	T023	C0458827
27235977	1498	1507	thickness	T033	C0205400
27235977	1519	1529	eosinophil	T025	C0014467
27235977	1534	1557	neutrophil infiltration	T039	C0751982
27235977	1567	1585	respiratory airway	T023	C0282335
27235977	1591	1596	Î¼EPIT	T061	C0162352
27235977	1597	1607	represents	T052	C1882932
27235977	1610	1615	novel	T080	C0205314
27235977	1620	1628	painless	T169	C0234226
27235977	1629	1639	technology	T090	C0039421
27235977	1643	1648	treat	T061	C0087111
27235977	1649	1679	IgE-mediated allergic diseases	T047	C1706410
27235977	1692	1711	local skin reaction	T201	C0221743
27235977	1734	1745	anaphylaxis	T046	C0002792

27235985|t|Predicting real - world functional milestones in schizophrenia
27235985|a|Schizophrenia is a severe disorder that often causes impairments in major areas of functioning, and most patients do not achieve expected real - world functional milestones. The aim of this study was to identify which variables of demography, illness activity, and functional capacity predict patients ' ability to attain real - world functional milestones. Participants were 235 outpatients, 149 men and 86 women, diagnosed with schizophrenia spectrum disorder. Our results showed that younger patients managed to achieve a higher level of functioning in educational level, marital status, and social contacts. Patients ' functional capacity was primarily associated with educational level and housing situation. We also found that women needed less support regarding housing and obtained a higher level of marital status as compared with men. Our findings demonstrate the importance of considering current symptoms, especially negative symptoms, and remission stability over time, together with age, duration of illness, gender, educational level, and current functional capacity, when predicting patients ' future real - world functioning. We also conclude that there is an advantage in exploring symptoms divided into positive, negative, and general domains considering their probable impact on functional achievements.
27235985	0	10	Predicting	T078	C0681842
27235985	11	15	real	T080	C0237400
27235985	18	23	world	T098	C2700280
27235985	24	34	functional	T169	C0205245
27235985	35	45	milestones	T077	C2347129
27235985	49	62	schizophrenia	T048	C0036341
27235985	63	76	Schizophrenia	T048	C0036341
27235985	82	97	severe disorder	T033	C1836348
27235985	116	127	impairments	T169	C0221099
27235985	146	157	functioning	T169	C0542341
27235985	168	176	patients	T101	C0030705
27235985	201	205	real	T080	C0237400
27235985	208	213	world	T098	C2700280
27235985	214	224	functional	T169	C0205245
27235985	225	235	milestones	T077	C2347129
27235985	253	258	study	T062	C2603343
27235985	281	290	variables	T080	C0439828
27235985	294	304	demography	T090	C0011298
27235985	306	313	illness	T184	C0221423
27235985	314	322	activity	T052	C0441655
27235985	328	347	functional capacity	T033	C1998319
27235985	356	364	patients	T101	C0030705
27235985	385	389	real	T080	C0237400
27235985	392	397	world	T098	C2700280
27235985	398	408	functional	T169	C0205245
27235985	409	419	milestones	T077	C2347129
27235985	421	433	Participants	T098	C0679646
27235985	443	454	outpatients	T101	C0029921
27235985	460	463	men	T098	C0025266
27235985	471	476	women	T098	C0043210
27235985	478	487	diagnosed	T033	C0011900
27235985	493	506	schizophrenia	T048	C0036341
27235985	507	524	spectrum disorder	T048	C0004936
27235985	550	557	younger	T079	C0332239
27235985	558	566	patients	T101	C0030705
27235985	588	594	higher	T080	C0205250
27235985	595	600	level	T080	C0441889
27235985	604	615	functioning	T169	C0542341
27235985	619	636	educational level	T033	C0013658
27235985	638	652	marital status	T102	C0024819
27235985	658	673	social contacts	T033	C0243095
27235985	675	683	Patients	T101	C0030705
27235985	686	705	functional capacity	T033	C1998319
27235985	736	753	educational level	T033	C0013658
27235985	758	765	housing	T073	C0020056
27235985	796	801	women	T098	C0043210
27235985	832	839	housing	T073	C0020056
27235985	855	861	higher	T080	C0205250
27235985	862	867	level	T080	C0441889
27235985	871	885	marital status	T102	C0024819
27235985	903	906	men	T098	C0025266
27235985	912	920	findings	T033	C0243095
27235985	963	970	current	T079	C0521116
27235985	971	979	symptoms	T184	C1457887
27235985	992	1000	negative	T033	C0205160
27235985	1001	1009	symptoms	T184	C1457887
27235985	1015	1024	remission	T033	C0544452
27235985	1025	1034	stability	T080	C0205360
27235985	1040	1044	time	T079	C0040223
27235985	1060	1063	age	T032	C0001779
27235985	1065	1084	duration of illness	T079	C3176590
27235985	1086	1092	gender	T032	C0079399
27235985	1094	1111	educational level	T033	C0013658
27235985	1117	1124	current	T079	C0521116
27235985	1125	1144	functional capacity	T033	C1998319
27235985	1162	1170	patients	T101	C0030705
27235985	1180	1184	real	T080	C0237400
27235985	1187	1192	world	T098	C2700280
27235985	1193	1204	functioning	T169	C0542341
27235985	1263	1271	symptoms	T184	C1457887
27235985	1285	1293	positive	T033	C1446409
27235985	1295	1303	negative	T033	C0205160
27235985	1352	1358	impact	T080	C4049986
27235985	1362	1372	functional	T169	C0205245
27235985	1373	1385	achievements	T053	C0001072

27236033|t|LDLR, ApoB and ApoE genes polymorphisms and classical risk factors in premature coronary artery disease
27236033|a|Lipoproteins play a central role in the development of atherosclerotic disease. So, with their ability to affect lipid levels, the LDLR, ApoB and ApoE polymorphisms could be one of the factors influencing development of atherosclerosis. This hypothesis has been tested in different populations with conflicting results. The purpose of the present study was to investigate the association between the LDLR, ApoB and ApoE genes polymorphisms with premature CAD (PCAD) in Egyptians. One hundred thirty-five patients of PCAD and one hundred thirty-two ages and sex matched control subjects were included in the study. LDLR and ApoB genes polymorphisms were analyzed by polymerase chain reaction (PCR). The ApoE genotypes were identified by multiplex amplification refractory mutation system (multi-AMRS). We found that LDLR A(+)A(+) genotype, ApoB X(+) allele and ApoE E4 allele increased the risk of PCAD by 1.8, 2.1 and 12.1 respectively. The present study proved that smoking, metabolic syndrome, ApoB X(+)X(+) genotype and ApoE E4 allele were independent risk factors for the development of PCAD. This is the first study investigate the association between low density lipoprotein receptor, apolipoprotein B and apolipoprotein E genes polymorphisms with PCAD and lipid levels in Egyptians and we concluded that the LDLR A(+)A(+) genotype, ApoB X(+) allele and ApoE E4 allele may be associated with an increased risk for development of PCAD by elevated levels of total cholesterol (TC) and low density lipoprotein (LDLc). The coexistence of CAD risk factors with LDLR A(+)A(+) genotype, ApoB X(+) allele and ApoE E4 allele may increase the risk of the development of PCAD in Egyptian patients.
27236033	0	4	LDLR	T028	C1366529
27236033	6	10	ApoB	T028	C1412471
27236033	15	25	ApoE genes	T028	C1412481
27236033	26	39	polymorphisms	T045	C0678951
27236033	54	66	risk factors	T033	C0035648
27236033	70	103	premature coronary artery disease	T047	C1867743
27236033	104	116	Lipoproteins	T116,T123	C0023820
27236033	144	155	development	T169	C1527148
27236033	159	182	atherosclerotic disease	T047	C0004153
27236033	217	229	lipid levels	T034	C0428460
27236033	235	239	LDLR	T028	C1366529
27236033	241	245	ApoB	T028	C1412471
27236033	250	254	ApoE	T028	C1412481
27236033	255	268	polymorphisms	T045	C0678951
27236033	309	320	development	T169	C1527148
27236033	324	339	atherosclerosis	T047	C0004153
27236033	346	356	hypothesis	T078	C1512571
27236033	366	372	tested	T170	C0392366
27236033	386	397	populations	T081	C0032659
27236033	464	475	investigate	T169	C1292732
27236033	504	508	LDLR	T028	C1366529
27236033	510	514	ApoB	T028	C1412471
27236033	519	529	ApoE genes	T028	C1412481
27236033	530	543	polymorphisms	T045	C0678951
27236033	549	562	premature CAD	T047	C1867743
27236033	564	568	PCAD	T047	C1867743
27236033	573	582	Egyptians	T098	C0337801
27236033	608	616	patients	T101	C0030705
27236033	620	624	PCAD	T047	C1867743
27236033	652	656	ages	T032	C0001779
27236033	661	664	sex	T032	C1522384
27236033	718	722	LDLR	T028	C1366529
27236033	727	737	ApoB genes	T028	C1412471
27236033	738	751	polymorphisms	T045	C0678951
27236033	757	765	analyzed	T062	C0936012
27236033	769	794	polymerase chain reaction	T063	C0032520
27236033	796	799	PCR	T063	C0032520
27236033	806	810	ApoE	T028	C1412481
27236033	811	820	genotypes	T032	C0017431
27236033	840	890	multiplex amplification refractory mutation system	T059	C2732542
27236033	892	902	multi-AMRS	T059	C2732542
27236033	919	932	LDLR A(+)A(+)	T028	C1366529
27236033	933	941	genotype	T032	C0017431
27236033	943	952	ApoB X(+)	T028	C1412471
27236033	953	959	allele	T028	C0002085
27236033	964	971	ApoE E4	T028	C1412481
27236033	972	978	allele	T028	C0002085
27236033	1001	1005	PCAD	T047	C1867743
27236033	1071	1078	smoking	T055	C0037369
27236033	1080	1098	metabolic syndrome	T047	C0524620
27236033	1100	1113	ApoB X(+)X(+)	T028	C1412471
27236033	1114	1122	genotype	T032	C0017431
27236033	1127	1134	ApoE E4	T028	C1412481
27236033	1135	1141	allele	T028	C0002085
27236033	1159	1171	risk factors	T033	C0035648
27236033	1180	1191	development	T169	C1527148
27236033	1195	1199	PCAD	T047	C1867743
27236033	1225	1236	investigate	T169	C1292732
27236033	1261	1293	low density lipoprotein receptor	T028	C1366529
27236033	1295	1311	apolipoprotein B	T028	C1412471
27236033	1316	1338	apolipoprotein E genes	T028	C1412481
27236033	1339	1352	polymorphisms	T045	C0678951
27236033	1358	1362	PCAD	T047	C1867743
27236033	1367	1379	lipid levels	T034	C0428460
27236033	1383	1392	Egyptians	T098	C0337801
27236033	1419	1432	LDLR A(+)A(+)	T028	C1366529
27236033	1433	1441	genotype	T032	C0017431
27236033	1443	1452	ApoB X(+)	T028	C1412471
27236033	1453	1459	allele	T028	C0002085
27236033	1464	1471	ApoE E4	T028	C1412481
27236033	1472	1478	allele	T028	C0002085
27236033	1486	1501	associated with	T080	C0332281
27236033	1524	1535	development	T169	C1527148
27236033	1539	1543	PCAD	T047	C1867743
27236033	1556	1588	levels of total cholesterol (TC)	T059	C0201950
27236033	1593	1616	low density lipoprotein	T059	C0202116
27236033	1618	1622	LDLc	T059	C0202116
27236033	1644	1647	CAD	T047	C1867743
27236033	1648	1660	risk factors	T033	C0035648
27236033	1666	1679	LDLR A(+)A(+)	T028	C1366529
27236033	1680	1688	genotype	T032	C0017431
27236033	1690	1699	ApoB X(+)	T028	C1412471
27236033	1700	1706	allele	T028	C0002085
27236033	1711	1718	ApoE E4	T028	C1412481
27236033	1719	1725	allele	T028	C0002085
27236033	1755	1766	development	T169	C1527148
27236033	1770	1774	PCAD	T047	C1867743
27236033	1778	1786	Egyptian	T098	C0337801
27236033	1787	1795	patients	T101	C0030705

27236097|t|The influence of liposomal formulation on the incorporation and retention of PNA oligomers
27236097|a|Liposomal formulations composed of phospholipids with different unsaturation degrees, head groups and at different cholesterol content have been tested for the encapsulation of Peptide Nucleic Acid (PNA) oligomers. The best loading capability (177Î¼g, ER %=87.2) was obtained for pure liposomes of phosphatidylglycerol (DOPG) with negatively charged head group. The insertion of a 10-20% of cholesterol in DOPG based liposomes provides a slight decrease (â¼160Î¼g) of the PNA loading. On the other hand, the cholesterol addition (20-30%) slows down the PNA's release (â¼27%) in fetal bovine serum from the liposomal formulation. Based on the encapsulation and the release properties, PEGylated DOPG liposomes with a percentage of cholesterol of 10-20% are the optimal formulation for the loading of PNA-a210.
27236097	17	26	liposomal	T109	C0023828
27236097	27	38	formulation	T077	C1705957
27236097	46	59	incorporation	T169	C0243126
27236097	64	73	retention	T169	C0333117
27236097	77	90	PNA oligomers	T114	C0600500
27236097	91	100	Liposomal	T109	C0023828
27236097	101	113	formulations	T077	C1705957
27236097	126	139	phospholipids	T109,T123	C0031676
27236097	155	175	unsaturation degrees	T080	C0522535
27236097	177	188	head groups	T169	C0205245
27236097	206	242	cholesterol content have been tested	T059	C0201950
27236097	251	264	encapsulation	T067	C2348438
27236097	268	304	Peptide Nucleic Acid (PNA) oligomers	T114	C0600500
27236097	310	333	best loading capability	T081	C3714444
27236097	342	344	ER	T081	C0456603
27236097	375	384	liposomes	T109	C0023828
27236097	388	408	phosphatidylglycerol	T109	C0043840
27236097	410	414	DOPG	T109	C0043840
27236097	421	439	negatively charged	T196	C0003075
27236097	440	450	head group	T169	C0205245
27236097	456	465	insertion	T058	C0441587
27236097	481	492	cholesterol	T109,T123	C0008377
27236097	496	500	DOPG	T109	C0043840
27236097	507	516	liposomes	T109	C0023828
27236097	535	543	decrease	T081	C0547047
27236097	560	563	PNA	T114	C0600500
27236097	564	571	loading	T052	C1708715
27236097	596	607	cholesterol	T109,T123	C0008377
27236097	608	616	addition	T169	C1524062
27236097	641	646	PNA's	T114	C0600500
27236097	647	654	release	T070	C3850077
27236097	665	683	fetal bovine serum	T130	C3812213
27236097	693	702	liposomal	T109	C0023828
27236097	703	714	formulation	T077	C1705957
27236097	729	742	encapsulation	T067	C2348438
27236097	751	769	release properties	T070	C3850077
27236097	771	780	PEGylated	T109,T121,T122	C0032483
27236097	781	785	DOPG	T109	C0043840
27236097	786	795	liposomes	T109	C0023828
27236097	817	828	cholesterol	T109,T123	C0008377
27236097	847	866	optimal formulation	T062	C0524527
27236097	875	882	loading	T052	C1708715
27236097	886	894	PNA-a210	T114	C0600500

27236596|t|Mandibular kinesiographic pattern of women with chronic TMD after management with educational and self-care therapies: A double-blind, randomized clinical trial
27236596|a|Limited mandibular movements are one of the most important signs of temporomandibular disorders (TMDs) and may cause functional difficulties. The purpose of this double-blind, randomized clinical trial was to evaluate the effect of treatment with only educational or education associated with self-care therapies on the pattern of mandibular movements of women with chronic painful TMDs. Forty-two women were selected and randomly divided into 3 groups, control group (CG, n=13), education group (EG, n=16), and education and self-care group (ESG, n=13), according to the sequence of treatment they received. A kinesiograph device recorded mandibular movements during maximum mouth opening and mastication at baseline (T0) and at 30-day (T1) and 60-day (T2) follow-up. Kinesiographic data were statistically analyzed using 1-way ANOVA, followed by the Bonferroni test for multiple comparisons of means (Î±=.05). The ESG group demonstrated an improvement in the maximum vertical opening (MVO = 5.1 Â±3.4 mm; P=.012) and anteroposterior mandibular movement (MAM) during maximum opening (7.4 Â±9.5; P=.019), significantly higher than that of the EG (MVO =1.8 Â±3.5 mm; MAM =0.8 Â±5.0 mm) and the CG (MVO =0.9 Â±3.8 mm; MAM =0.8 Â±4.4 mm) after 30 days of follow-up. Moreover, at T1, vertical mandibular movement during mastication was significantly higher in the ESG group (17.4 Â±1.7 mm) than in the EG group (15.0 Â±2.8, P=.027). No significant differences were found between the women who received treatment with educational and self-care therapies for 60 days and the women who received this treatment for 30 days. In the short-term, education and self-care treatment positively influenced the mandibular movement pattern of women with chronic painful TMDs.
27236596	0	10	Mandibular	T023	C0024687
27236596	11	33	kinesiographic pattern	T170	C0282574
27236596	37	42	women	T098	C0043210
27236596	48	55	chronic	T079	C0205191
27236596	56	59	TMD	T047	C0039494
27236596	66	76	management	T058	C0376636
27236596	82	93	educational	T185	C0013622
27236596	98	117	self-care therapies	T061	C0567459
27236596	121	133	double-blind	T062	C0013072
27236596	135	160	randomized clinical trial	T062,T170	C0206034
27236596	161	189	Limited mandibular movements	T033	C4228933
27236596	210	219	important	T080	C3898777
27236596	220	225	signs	T184	C0037088
27236596	229	256	temporomandibular disorders	T047	C0039494
27236596	258	262	TMDs	T047	C0039494
27236596	272	277	cause	T169	C0015127
27236596	278	288	functional	T169	C0205245
27236596	289	301	difficulties	T080	C0332218
27236596	323	335	double-blind	T062	C0013072
27236596	337	362	randomized clinical trial	T062,T170	C0206034
27236596	370	378	evaluate	T058	C0220825
27236596	383	389	effect	T080	C1280500
27236596	393	402	treatment	T061	C0087111
27236596	413	424	educational	T185	C0013622
27236596	428	437	education	T185	C0013622
27236596	438	453	associated with	T080	C0332281
27236596	454	473	self-care therapies	T061	C0567459
27236596	481	488	pattern	T170	C0282574
27236596	492	502	mandibular	T023	C0024687
27236596	503	512	movements	T040	C0026649
27236596	516	521	women	T098	C0043210
27236596	527	542	chronic painful	T184	C0150055
27236596	543	547	TMDs	T047	C0039494
27236596	549	558	Forty-two	T081	C0392762
27236596	559	564	women	T098	C0043210
27236596	570	578	selected	T052	C1707391
27236596	583	591	randomly	T080	C0439605
27236596	592	599	divided	T169	C0332849
27236596	607	613	groups	UnknownType	C0681860
27236596	615	628	control group	T096	C0009932
27236596	630	632	CG	T096	C0009932
27236596	641	656	education group	UnknownType	C0681860
27236596	658	660	EG	UnknownType	C0681860
27236596	673	702	education and self-care group	UnknownType	C0681860
27236596	704	707	ESG	UnknownType	C0681860
27236596	733	741	sequence	T169	C1519249
27236596	745	754	treatment	T061	C0087111
27236596	760	768	received	T080	C1514756
27236596	772	791	kinesiograph device	T074	C0025080
27236596	792	800	recorded	T080	C2355580
27236596	801	811	mandibular	T023	C0024687
27236596	812	821	movements	T040	C0026649
27236596	822	828	during	T079	C0347984
27236596	829	836	maximum	T081	C0806909
27236596	837	842	mouth	T030	C0226896
27236596	843	850	opening	T040	C0026649
27236596	855	866	mastication	T042	C0024888
27236596	870	878	baseline	T081	C1442488
27236596	880	882	T0	T079	C1254367
27236596	891	897	30-day	T079	C0439228
27236596	899	901	T1	T079	C1254367
27236596	907	913	60-day	T079	C0439228
27236596	915	917	T2	T079	C1254367
27236596	919	928	follow-up	T058	C1522577
27236596	930	949	Kinesiographic data	T170	C1516606
27236596	955	977	statistically analyzed	T062	C0871424
27236596	978	983	using	T169	C1524063
27236596	984	995	1-way ANOVA	T081	C1709320
27236596	997	1008	followed by	T079	C0332283
27236596	1013	1028	Bonferroni test	T081	C1879894
27236596	1033	1041	multiple	T081	C0439064
27236596	1042	1053	comparisons	T052	C1707455
27236596	1057	1062	means	T077	C1704970
27236596	1076	1085	ESG group	UnknownType	C0681860
27236596	1102	1113	improvement	T077	C2986411
27236596	1121	1145	maximum vertical opening	T040	C0026649
27236596	1147	1150	MVO	T040	C0026649
27236596	1178	1213	anteroposterior mandibular movement	T040	C0026649
27236596	1215	1218	MAM	T040	C0026649
27236596	1220	1226	during	T079	C0347984
27236596	1227	1234	maximum	T081	C0806909
27236596	1235	1242	opening	T040	C0026649
27236596	1263	1283	significantly higher	T081	C4055637
27236596	1301	1303	EG	UnknownType	C0681860
27236596	1305	1308	MVO	T040	C0026649
27236596	1323	1326	MAM	T040	C0026649
27236596	1349	1351	CG	T096	C0009932
27236596	1353	1356	MVO	T040	C0026649
27236596	1371	1374	MAM	T040	C0026649
27236596	1395	1402	30 days	T079	C0439228
27236596	1406	1415	follow-up	T058	C1522577
27236596	1430	1432	T1	T079	C1254367
27236596	1434	1442	vertical	T082	C0205128
27236596	1443	1453	mandibular	T023	C0024687
27236596	1454	1462	movement	T040	C0026649
27236596	1463	1469	during	T079	C0347984
27236596	1470	1481	mastication	T042	C0024888
27236596	1486	1506	significantly higher	T081	C4055637
27236596	1514	1523	ESG group	UnknownType	C0681860
27236596	1551	1559	EG group	UnknownType	C0681860
27236596	1581	1595	No significant	T033	C1273937
27236596	1596	1607	differences	T080	C1705242
27236596	1613	1618	found	T033	C0150312
27236596	1631	1636	women	T098	C0043210
27236596	1641	1649	received	T080	C1514756
27236596	1650	1659	treatment	T061	C0087111
27236596	1665	1676	educational	T185	C0013622
27236596	1681	1700	self-care therapies	T061	C0567459
27236596	1705	1712	60 days	T079	C0439228
27236596	1721	1726	women	T098	C0043210
27236596	1731	1739	received	T080	C1514756
27236596	1745	1754	treatment	T061	C0087111
27236596	1759	1766	30 days	T079	C0439228
27236596	1775	1785	short-term	T079	C0443303
27236596	1787	1796	education	T185	C0013622
27236596	1801	1820	self-care treatment	T061	C0567459
27236596	1821	1831	positively	T033	C1446409
27236596	1832	1842	influenced	T077	C4054723
27236596	1847	1857	mandibular	T023	C0024687
27236596	1858	1866	movement	T040	C0026649
27236596	1867	1874	pattern	T170	C0282574
27236596	1878	1883	women	T098	C0043210
27236596	1889	1904	chronic painful	T184	C0150055
27236596	1905	1909	TMDs	T047	C0039494

27236780|t|Histopathology of the filum terminale in children with and without tethered cord syndrome with attention to the elastic tissue within the filum
27236780|a|To compare histologically transected fila from pediatric patients with tethered cord syndrome (TCS), with and without a low conus, with controls, focusing on collagenous and elastic tissue. Thirty fila from patients with TCS, including 5 where minimal cautery was used prior to filum section, were compared with fila from 27 pediatric cadavers without TCS (controls). Sections of fila were stained with H&E, Masson trichrome and Verhoeff von Gieson elastic stains, and 7 with Gordon and Sweet's reticulin stain. Fila from controls showed loose fibrous connective tissue (FCT) with thin and evenly dispersed elastic fibers (EFs). Reticulin fibers (RFs) were seen in blood vessel walls and nerve twigs. Fat was identified microscopically in 2 fila. All fila from patients with TCS had dense FCT. The EFs were in normal numbers in 17, and focally or diffusely decreased in 13. All 25 patients where the fila were cauterized during resection had thick and coiled EFs. Coiling was not seen when minimal cautery was applied. RFs were seen in blood vessel walls and nerve twigs. Fat was identified in 19 patients. Findings were similar, whether the conus termination was normal or low. The fila of all patients with TCS, whether or not the conus was low, showed abnormal FCT. EFs were decreased in 48 % of patients; however, there were thick and coiled EFs in all patients. Coiling of EFs, initially thought to be an abnormality in patients, is considered most likely to be a result of cautery (i.e., artifactual / iatrogenic coiling).
27236780	0	14	Histopathology	T091	C0677043
27236780	22	37	filum terminale	T023	C0016109
27236780	41	49	children	T100	C0008059
27236780	59	66	without	T080	C0332288
27236780	67	89	tethered cord syndrome	T047	C0080218
27236780	112	126	elastic tissue	T024	C0013762
27236780	138	143	filum	T023	C0016109
27236780	147	154	compare	T052	C1707455
27236780	155	169	histologically	T169	C0205462
27236780	170	180	transected	T169	C0332847
27236780	181	185	fila	T023	C0016109
27236780	191	200	pediatric	T080	C1521725
27236780	201	209	patients	T101	C0030705
27236780	215	237	tethered cord syndrome	T047	C0080218
27236780	239	242	TCS	T047	C0080218
27236780	254	261	without	T080	C0332288
27236780	264	267	low	T029	C1548802
27236780	268	273	conus	T023	C0149601
27236780	302	313	collagenous	T024	C0225333
27236780	318	332	elastic tissue	T024	C0013762
27236780	341	345	fila	T023	C0016109
27236780	351	359	patients	T101	C0030705
27236780	365	368	TCS	T047	C0080218
27236780	388	395	minimal	T080	C0547040
27236780	396	403	cautery	T061	C0007471
27236780	422	427	filum	T023	C0016109
27236780	428	435	section	T059	C0700320
27236780	442	450	compared	T052	C1707455
27236780	456	460	fila	T023	C0016109
27236780	469	478	pediatric	T080	C1521725
27236780	479	487	cadavers	T017	C0006629
27236780	488	495	without	T080	C0332288
27236780	496	499	TCS	T047	C0080218
27236780	501	509	controls	T096	C0009932
27236780	512	520	Sections	T167	C1522472
27236780	524	528	fila	T023	C0016109
27236780	534	541	stained	T059	C0487602
27236780	547	550	H&E	T059	C0523207
27236780	552	568	Masson trichrome	T059	C1294297
27236780	573	607	Verhoeff von Gieson elastic stains	T059	C1294321
27236780	620	654	Gordon and Sweet's reticulin stain	T059	C1293950
27236780	656	660	Fila	T023	C0016109
27236780	666	674	controls	T096	C0009932
27236780	682	687	loose	T080	C0205407
27236780	688	713	fibrous connective tissue	T024	C1184823
27236780	715	718	FCT	T024	C1184823
27236780	725	729	thin	T080	C0205168
27236780	734	750	evenly dispersed	T169	C1704711
27236780	751	765	elastic fibers	T024	C0230899
27236780	767	770	EFs	T024	C0230899
27236780	773	789	Reticulin fibers	T116,T123	C0035285
27236780	791	794	RFs	T116,T123	C0035285
27236780	809	827	blood vessel walls	T023	C1180033
27236780	832	837	nerve	T024	C0027740
27236780	845	848	Fat	T109,T121	C0015677
27236780	853	863	identified	T080	C0205396
27236780	864	879	microscopically	T080	C0205288
27236780	885	889	fila	T023	C0016109
27236780	895	899	fila	T023	C0016109
27236780	905	913	patients	T101	C0030705
27236780	919	922	TCS	T047	C0080218
27236780	927	936	dense FCT	T024	C0225333
27236780	942	945	EFs	T024	C0230899
27236780	954	960	normal	T080	C0205307
27236780	980	987	focally	T082	C0205234
27236780	991	1000	diffusely	T080	C0332261
27236780	1001	1010	decreased	T081	C0205216
27236780	1025	1033	patients	T101	C0030705
27236780	1044	1048	fila	T023	C0016109
27236780	1054	1064	cauterized	T061	C0007471
27236780	1072	1081	resection	T061	C0728940
27236780	1086	1091	thick	T080	C1280412
27236780	1096	1102	coiled	T082	C1880179
27236780	1103	1106	EFs	T024	C0230899
27236780	1108	1115	Coiling	T082	C0444764
27236780	1134	1141	minimal	T080	C0547040
27236780	1142	1149	cautery	T061	C0007471
27236780	1163	1166	RFs	T116,T123	C0035285
27236780	1180	1198	blood vessel walls	T023	C1180033
27236780	1216	1219	Fat	T109,T121	C0015677
27236780	1224	1234	identified	T080	C0205396
27236780	1241	1249	patients	T101	C0030705
27236780	1251	1259	Findings	T033	C0243095
27236780	1265	1272	similar	T080	C2348205
27236780	1286	1291	conus	T023	C0149601
27236780	1308	1314	normal	T080	C0205307
27236780	1318	1321	low	T082	C0441994
27236780	1327	1331	fila	T023	C0016109
27236780	1339	1347	patients	T101	C0030705
27236780	1353	1356	TCS	T047	C0080218
27236780	1377	1382	conus	T023	C0149601
27236780	1387	1390	low	T082	C0441994
27236780	1399	1407	abnormal	T033	C0205161
27236780	1408	1411	FCT	T024	C1184823
27236780	1413	1416	EFs	T024	C0230899
27236780	1422	1431	decreased	T081	C0205216
27236780	1443	1451	patients	T101	C0030705
27236780	1473	1478	thick	T080	C1280412
27236780	1483	1489	coiled	T082	C1880179
27236780	1490	1493	EFs	T024	C0230899
27236780	1501	1509	patients	T101	C0030705
27236780	1511	1518	Coiling	T082	C0444764
27236780	1522	1525	EFs	T024	C0230899
27236780	1554	1565	abnormality	T033	C1704258
27236780	1569	1577	patients	T101	C0030705
27236780	1613	1619	result	T033	C0808233
27236780	1623	1630	cautery	T061	C0007471
27236780	1638	1649	artifactual	T068	C0085089
27236780	1652	1662	iatrogenic	T080	C0439669
27236780	1663	1670	coiling	T082	C0444764

27237301|t|Clinical value of pathologic examination of non-neoplastic kidney in patients with upper urinary tract malignancies
27237301|a|While surgical resection remains the standard of care in the treatment of upper urinary tract malignancies, nephrectomy is a risk factor for the development of chronic kidney disease (CKD). The aim of this study was to determine whether histologic evaluation of non-neoplastic kidney could enable early identification of unrecognized kidney disease and could be of prognostic value in predicting postoperative renal outcomes. We retrospectively analyzed 51 patients with upper urinary tract malignancies who received uninephrectomy or uninephroureterectomy. A thorough pathologic evaluation of non-neoplastic kidney including special stains, immunofluorescence, and electron microscopic studies was performed. The degree of parenchymal changes was graded from 0 to 15. Of 51 patients, only 13 showed normal kidney pathology. Fifteen patients showed glomerular abnormalities, 14 showed diabetic nephropathy, and 11 showed vascular nephropathy. There was one case each of reflux nephropathy and chronic pyelonephritis. The median histologic score was 5 points. Only 25.4% of patients had â¤ 3 points. Score more than 5 was observed in 47.1% of patients. Postoperative estimated glomerular filtration rate (eGFR) at 3 to 36 months were obtained from 90.2% of patients, and of those, 34.8% had de novo CKD. Since no one had CKD in partial nephrectomized patients, we determined risk factors for CKD in radical nephrectomized patients. Cox regression analysis revealed that postoperative AKI, preoperative eGFR, and histologic score of non-neoplastic kidney were the independent predictors for CKD. We conclude that routine pathologic evaluation of non-neoplastic kidney provides valuable diagnostic and prognostic information.
27237301	0	14	Clinical value	T033	C2826293
27237301	18	40	pathologic examination	T060	C4086729
27237301	44	65	non-neoplastic kidney	T023	C0022646
27237301	69	77	patients	T101	C0030705
27237301	83	102	upper urinary tract	T022	C1278977
27237301	103	115	malignancies	T191	C4282132
27237301	122	140	surgical resection	T061	C0728940
27237301	165	169	care	T052	C1947933
27237301	177	186	treatment	T061	C0087111
27237301	190	209	upper urinary tract	T022	C1278977
27237301	210	222	malignancies	T191	C4282132
27237301	224	235	nephrectomy	T061	C0027695
27237301	241	252	risk factor	T033	C0035648
27237301	261	272	development	T169	C1527148
27237301	276	298	chronic kidney disease	T047	C1561643
27237301	300	303	CKD	T047	C1561643
27237301	322	327	study	T062	C2603343
27237301	353	363	histologic	T169	C0205462
27237301	364	374	evaluation	T058	C0220825
27237301	378	399	non-neoplastic kidney	T023	C0022646
27237301	413	433	early identification	T061	C0814435
27237301	450	464	kidney disease	T047	C0022658
27237301	481	491	prognostic	T170	C0220901
27237301	512	525	postoperative	T079	C0032790
27237301	526	531	renal	T023	C0022646
27237301	532	540	outcomes	T080	C0085415
27237301	545	569	retrospectively analyzed	T062	C0035363
27237301	573	581	patients	T101	C0030705
27237301	587	606	upper urinary tract	T022	C1278977
27237301	607	619	malignancies	T191	C4282132
27237301	633	647	uninephrectomy	T061	C0027695
27237301	651	672	uninephroureterectomy	T061	C0027732
27237301	685	695	pathologic	T169	C1521733
27237301	696	706	evaluation	T058	C0220825
27237301	710	731	non-neoplastic kidney	T023	C0022646
27237301	742	756	special stains	T061	C2038188
27237301	758	776	immunofluorescence	T059	C0079603
27237301	782	810	electron microscopic studies	T059	C0026019
27237301	830	836	degree	T081	C0449286
27237301	840	851	parenchymal	T023	C0933845
27237301	852	859	changes	T169	C0392747
27237301	891	899	patients	T101	C0030705
27237301	923	929	kidney	T023	C0022646
27237301	930	939	pathology	T091	C0030664
27237301	949	957	patients	T101	C0030705
27237301	965	989	glomerular abnormalities	T047	C1398788
27237301	1001	1021	diabetic nephropathy	T047	C0011881
27237301	1037	1045	vascular	T023	C0005847
27237301	1046	1057	nephropathy	T061	C0027695
27237301	1086	1104	reflux nephropathy	T047	C3495566
27237301	1109	1131	chronic pyelonephritis	T047	C0085697
27237301	1144	1160	histologic score	T081	C0449820
27237301	1189	1197	patients	T101	C0030705
27237301	1214	1219	Score	T081	C0449820
27237301	1257	1265	patients	T101	C0030705
27237301	1267	1280	Postoperative	T079	C0032790
27237301	1281	1317	estimated glomerular filtration rate	T059	C3811844
27237301	1319	1323	eGFR	T059	C3811844
27237301	1336	1342	months	T079	C0439231
27237301	1371	1379	patients	T101	C0030705
27237301	1413	1416	CKD	T047	C1561643
27237301	1435	1438	CKD	T047	C1561643
27237301	1450	1473	nephrectomized patients	T101	C0030705
27237301	1489	1501	risk factors	T033	C0035648
27237301	1506	1509	CKD	T047	C1561643
27237301	1521	1544	nephrectomized patients	T101	C0030705
27237301	1546	1569	Cox regression analysis	T170	C0034980
27237301	1584	1597	postoperative	T079	C0032790
27237301	1598	1601	AKI	T037	C2609414
27237301	1603	1615	preoperative	T079	C0445204
27237301	1616	1620	eGFR	T059	C3811844
27237301	1626	1636	histologic	T169	C0205462
27237301	1646	1667	non-neoplastic kidney	T023	C0022646
27237301	1689	1699	predictors	T078	C2698872
27237301	1704	1707	CKD	T047	C1561643
27237301	1734	1744	pathologic	T169	C1521733
27237301	1745	1755	evaluation	T058	C0220825
27237301	1759	1780	non-neoplastic kidney	T023	C0022646
27237301	1799	1809	diagnostic	T169	C0348026
27237301	1814	1824	prognostic	T170	C0220901

27237609|t|Prospective study of dietary Non Enzymatic Antioxidant Capacity on the risk of hip fracture in the elderly
27237609|a|Dietary antioxidants may play an important role in the prevention of bone loss and associated fractures by reducing levels of oxidative stress. We prospectively investigated the association between dietary Non Enzymatic Antioxidant Capacity (NEAC) and the risk of hip fracture and whether this effect was modified by smoking. In the Swedish National March Cohort 13,409 men and women over the age of 55 who had not experienced cancer, cardiovascular disease or hip fracture, were followed through record-linkages from 1997 through 2010. NEAC was assessed by a validated food frequency questionnaire collected at baseline. We categorized the distribution of NEAC into sex - specific quartiles and used multivariable adjusted Cox proportional hazards regression models to estimate hazard ratios (HRs) with 95% confidence intervals (95% CI). During a mean follow-up time of 12.4years, we identified 491 incident cases of first hip fracture. Subjects in the highest quartile of dietary NEAC had a 39% lower risk of incident hip fracture compared to those in the lowest quartile (HR: 0.61; 95% CI: 0.44-0.85). The association was non-linear (p for non-linearity: 0.004) with a potential threshold between the first and the second quartile and no further risk reduction at higher levels of dietary NEAC. Due to a low smoking prevalence in our study population, we had limited power to detect effect modification between dietary NEAC and smoking on a multiplicative or additive scale. Higher dietary NEAC intake is associated with lower risk of hip fracture in the elderly.
27237609	21	28	dietary	T168	C0012155
27237609	29	63	Non Enzymatic Antioxidant Capacity	T059	C4049177
27237609	71	75	risk	T078	C0035647
27237609	79	91	hip fracture	T037	C0019557
27237609	99	106	elderly	T098	C0001792
27237609	107	127	Dietary antioxidants	T168	C0729311
27237609	176	185	bone loss	T047	C0029453
27237609	201	210	fractures	T037	C0016658
27237609	233	249	oxidative stress	T049	C0242606
27237609	305	312	dietary	T168	C0012155
27237609	313	347	Non Enzymatic Antioxidant Capacity	T059	C4049177
27237609	349	353	NEAC	T059	C4049177
27237609	363	367	risk	T078	C0035647
27237609	371	383	hip fracture	T037	C0019557
27237609	424	431	smoking	T055	C0037369
27237609	440	469	Swedish National March Cohort	T098	C0599755
27237609	477	480	men	T098	C0025266
27237609	485	490	women	T098	C0043210
27237609	534	540	cancer	T191	C0006826
27237609	542	564	cardiovascular disease	T047	C0007222
27237609	568	580	hip fracture	T037	C0019557
27237609	604	619	record-linkages	T062,T078	C0025101
27237609	644	648	NEAC	T059	C4049177
27237609	677	705	food frequency questionnaire	T170	C2986698
27237609	719	727	baseline	T081	C1442488
27237609	764	768	NEAC	T059	C4049177
27237609	774	777	sex	T032	C0079399
27237609	780	788	specific	T080	C0205369
27237609	789	798	quartiles	T080	C2828255
27237609	808	873	multivariable adjusted Cox proportional hazards regression models	T081,T170	C0033489
27237609	886	899	hazard ratios	T081	C2985465
27237609	901	904	HRs	T081	C2985465
27237609	915	935	confidence intervals	T081	C0009667
27237609	941	943	CI	T081	C0009667
27237609	960	969	follow-up	T058	C1522577
27237609	970	974	time	T079	C0040223
27237609	1031	1043	hip fracture	T037	C0019557
27237609	1069	1077	quartile	T080	C2828255
27237609	1081	1088	dietary	T168	C0012155
27237609	1089	1093	NEAC	T059	C4049177
27237609	1104	1114	lower risk	T033	C3843763
27237609	1127	1139	hip fracture	T037	C0019557
27237609	1172	1180	quartile	T080	C2828255
27237609	1182	1184	HR	T081	C2985465
27237609	1196	1198	CI	T081	C0009667
27237609	1332	1340	quartile	T080	C2828255
27237609	1356	1370	risk reduction	T055	C1137094
27237609	1391	1398	dietary	T168	C0012155
27237609	1399	1403	NEAC	T059	C4049177
27237609	1521	1528	dietary	T168	C0012155
27237609	1529	1533	NEAC	T059	C4049177
27237609	1538	1545	smoking	T055	C0037369
27237609	1551	1565	multiplicative	T081	C2911648
27237609	1569	1583	additive scale	T081	C0392762
27237609	1600	1604	NEAC	T059	C4049177
27237609	1637	1641	risk	T078	C0035647
27237609	1645	1657	hip fracture	T037	C0019557

27237979|t|MiR-211 is epigenetically regulated by DNMT1 mediated methylation and inhibits EMT of melanoma cells by targeting RAB22A
27237979|a|MiR-211 has strong inhibitive effects on melanoma cell growth, invasion and metastasis. However, how it is downregulated and whether other genes are involved its downstream regulation in melanoma are not clear. In this study, we firstly verified the expression of miR-211 in melanoma cell lines and observed that its downregulation is associated with increased DNMT1 expression. By performing qRT-PCR and MSP analysis, we confirmed that DNMT1 is negatively correlated with miR-211 expression and can modulate DNA methylation in the promoter region of miR-211. By performing bioinformatics analysis, we found that RAB22A is a possible target of miR-211, which has two broadly conversed binding sites with miR-211 in the 3'UTR. Following dual luciferase assay, qRT-PCR and western blot analysis confirmed the direct binding between miR-211 and RAB22A and the suppressive effect of miR-211 on RAB22A expression. Knockdown of RAB22A increased epithelial properties and impaired mesenchymal properties of the melanoma cells, suggesting that miR-211 modulates epithelial mesenchymal transition (EMT) of melanoma cells via downregulating RAB22A. In summary, the present study firstly demonstrated that DNMT1 mediated promoter methylation is a mechanism of miRNA suppression in melanoma and revealed a new tumor suppressor role of the miR-211 by targeting RAB22A in melanoma. The DNMT1 / miR-211 / RAB22A axis provides a novel insight into the pathogenesis of melanoma, particularly in the EMT process.
27237979	0	7	MiR-211	T028	C1537847
27237979	11	35	epigenetically regulated	T043	C1160454
27237979	39	44	DNMT1	T028	C1414121
27237979	54	65	methylation	T044	C0025723
27237979	70	78	inhibits	T052	C3463820
27237979	79	82	EMT	T043	C1523298
27237979	86	100	melanoma cells	T025	C1513095
27237979	104	113	targeting	T063	C0242613
27237979	114	120	RAB22A	T028	C1419193
27237979	121	128	MiR-211	T028	C1537847
27237979	140	150	inhibitive	T052	C3463820
27237979	162	170	melanoma	T191	C0025202
27237979	171	182	cell growth	T043	C0007595
27237979	184	192	invasion	T046	C2699153
27237979	197	207	metastasis	T046	C4255448
27237979	228	241	downregulated	T044	C0013081
27237979	260	265	genes	T028	C0017337
27237979	283	293	downstream	T082	C0522506
27237979	294	304	regulation	T044	C0013081
27237979	308	316	melanoma	T191	C0025202
27237979	371	381	expression	T045	C0017262
27237979	385	392	miR-211	T028	C1537847
27237979	396	415	melanoma cell lines	T025	C1513095
27237979	438	452	downregulation	T044	C0013081
27237979	456	471	associated with	T080	C0332281
27237979	482	487	DNMT1	T028	C1414121
27237979	488	498	expression	T045	C0017262
27237979	514	521	qRT-PCR	T063	C1514628
27237979	526	538	MSP analysis	T062	C0026031
27237979	558	563	DNMT1	T028	C1414121
27237979	567	577	negatively	T033	C1513916
27237979	578	588	correlated	T080	C1707520
27237979	594	601	miR-211	T028	C1537847
27237979	602	612	expression	T045	C0017262
27237979	621	629	modulate	T082	C0443264
27237979	630	645	DNA methylation	T044	C0376452
27237979	653	668	promoter region	T114,T123	C0033413
27237979	672	679	miR-211	T028	C1537847
27237979	695	718	bioinformatics analysis	T091	C1140694
27237979	734	740	RAB22A	T028	C1419193
27237979	755	761	target	T169	C1521840
27237979	765	772	miR-211	T028	C1537847
27237979	796	805	conversed	T086	C0009802
27237979	806	819	binding sites	T192	C0005456
27237979	825	832	miR-211	T028	C1537847
27237979	840	845	3'UTR	T086,T123	C0600600
27237979	862	872	luciferase	T116,T126,T130	C0024075
27237979	873	878	assay	T059	C0005507
27237979	880	887	qRT-PCR	T063	C1514628
27237979	892	913	western blot analysis	T059	C0949466
27237979	935	942	binding	T044	C1167622
27237979	951	958	miR-211	T028	C1537847
27237979	963	969	RAB22A	T028	C1419193
27237979	978	996	suppressive effect	T045	C0038855
27237979	1000	1007	miR-211	T028	C1537847
27237979	1011	1017	RAB22A	T028	C1419193
27237979	1018	1028	expression	T045	C0017262
27237979	1030	1039	Knockdown	T063	C2350567
27237979	1043	1049	RAB22A	T028	C1419193
27237979	1060	1070	epithelial	T080	C0221908
27237979	1086	1094	impaired	T169	C0221099
27237979	1095	1106	mesenchymal	T080	C1513143
27237979	1125	1139	melanoma cells	T025	C1513095
27237979	1157	1164	miR-211	T028	C1537847
27237979	1165	1174	modulates	T082	C0443264
27237979	1175	1208	epithelial mesenchymal transition	T043	C1523298
27237979	1210	1213	EMT	T043	C1523298
27237979	1218	1232	melanoma cells	T025	C1513095
27237979	1237	1251	downregulating	T044	C0013081
27237979	1252	1258	RAB22A	T028	C1419193
27237979	1316	1321	DNMT1	T028	C1414121
27237979	1331	1339	promoter	T114,T123	C0033413
27237979	1340	1351	methylation	T044	C0025723
27237979	1357	1366	mechanism	T169	C0441712
27237979	1370	1375	miRNA	T114,T123	C1101610
27237979	1376	1387	suppression	T045	C0038855
27237979	1391	1399	melanoma	T191	C0025202
27237979	1419	1435	tumor suppressor	T028	C0079427
27237979	1448	1455	miR-211	T028	C1537847
27237979	1459	1468	targeting	T063	C0242613
27237979	1469	1475	RAB22A	T028	C1419193
27237979	1479	1487	melanoma	T191	C0025202
27237979	1493	1498	DNMT1	T028	C1414121
27237979	1501	1508	miR-211	T028	C1537847
27237979	1511	1517	RAB22A	T028	C1419193
27237979	1557	1569	pathogenesis	T046	C0699748
27237979	1573	1581	melanoma	T191	C0025202
27237979	1603	1614	EMT process	T043	C1523298

27239027|t|Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient -Specific Myoblasts Derived using a Human iPSC -Based Model
27239027|a|Duchenne muscular dystrophy (DMD) remains an intractable genetic disease. Althogh there are several animal models of DMD, there is no human cell model that carries patient -specific DYSTROPHIN mutations. Here, we present a human DMD model using human induced pluripotent stem cells (hiPSCs). Our model reveals concordant disease - related phenotypes with patient - dependent variation, which are partially reversed by genetic and pharmacological approaches. Our " chemical-compound -based" strategy successfully directs hiPSCs into expandable myoblasts, which exhibit a myogenic transcriptional program, forming striated contractile myofibers and participating in muscle regeneration in vivo. DMD - hiPSC -derived myoblasts show disease - related phenotypes with patient -to- patient variability, including aberrant expression of inflammation or immune-response genes and collagens, increased BMP / TGFÎ² signaling, and reduced fusion competence. Furthermore, by genetic correction and pharmacological "dual- SMAD " inhibition, the DMD - hiPSC -derived myoblasts and genetically corrected isogenic myoblasts form "rescued" multi - nucleated myotubes. In conclusion, our findings demonstrate the feasibility of establishing a human " DMD -in-a-dish" model using hiPSC -based disease modeling.
27239027	22	32	Phenotypes	T032	C0031437
27239027	39	66	Duchenne Muscular Dystrophy	T047	C0013264
27239027	67	74	Patient	T101	C0030705
27239027	85	94	Myoblasts	T025	C0596995
27239027	111	116	Human	T016	C0086418
27239027	117	121	iPSC	T025	C2717959
27239027	129	134	Model	T050	C0684309
27239027	135	162	Duchenne muscular dystrophy	T047	C0013264
27239027	164	167	DMD	T047	C0013264
27239027	192	207	genetic disease	T047	C0019247
27239027	235	248	animal models	T050	C0012644
27239027	252	255	DMD	T047	C0013264
27239027	269	279	human cell	T025	C0682523
27239027	299	306	patient	T101	C0030705
27239027	317	327	DYSTROPHIN	T028	C1414083
27239027	328	337	mutations	T045	C0596611
27239027	358	363	human	T016	C0086418
27239027	364	367	DMD	T047	C0013264
27239027	368	373	model	T050	C0684309
27239027	380	416	human induced pluripotent stem cells	T025	C3658289
27239027	418	424	hiPSCs	T025	C3658289
27239027	456	463	disease	T047	C0012634
27239027	466	473	related	T169	C1552599
27239027	474	484	phenotypes	T032	C0031437
27239027	490	497	patient	T101	C0030705
27239027	500	509	dependent	T080	C0851827
27239027	510	519	variation	T080	C0205419
27239027	553	560	genetic	T169	C0314603
27239027	565	580	pharmacological	T169	C0205464
27239027	599	616	chemical-compound	T103	C0220806
27239027	625	633	strategy	T062	C0035171
27239027	655	661	hiPSCs	T025	C3658289
27239027	678	687	myoblasts	T025	C0596995
27239027	705	729	myogenic transcriptional	T045	C0040649
27239027	730	737	program	T169	C3484370
27239027	747	755	striated	T080	C0205364
27239027	756	767	contractile	T026	C1752744
27239027	768	777	myofibers	T026	C3179197
27239027	799	818	muscle regeneration	T033	C1850849
27239027	819	826	in vivo	T082	C1515655
27239027	828	831	DMD	T047	C0013264
27239027	834	839	hiPSC	T025	C3658289
27239027	849	858	myoblasts	T025	C0596995
27239027	864	871	disease	T047	C0012634
27239027	874	881	related	T169	C1552599
27239027	882	892	phenotypes	T032	C0031437
27239027	898	905	patient	T101	C0030705
27239027	911	918	patient	T101	C0030705
27239027	919	930	variability	T077	C2827666
27239027	942	950	aberrant	T080	C0443127
27239027	965	977	inflammation	T046	C0021368
27239027	981	1002	immune-response genes	T028	C0086344
27239027	1007	1016	collagens	T116	C0009325
27239027	1028	1031	BMP	T044	C1155364
27239027	1034	1048	TGFÎ² signaling	T044	C1155363
27239027	1097	1104	genetic	T169	C0314603
27239027	1105	1115	correction	T169	C1947976
27239027	1120	1135	pharmacological	T169	C0205464
27239027	1143	1147	SMAD	T116,T123	C1571580
27239027	1150	1160	inhibition	T043	C1519312
27239027	1166	1169	DMD	T047	C0013264
27239027	1172	1177	hiPSC	T025	C3658289
27239027	1187	1196	myoblasts	T025	C0596995
27239027	1201	1212	genetically	T169	C0314603
27239027	1223	1231	isogenic	T080	C2348628
27239027	1232	1241	myoblasts	T025	C0596995
27239027	1257	1262	multi	T081	C0439064
27239027	1265	1274	nucleated	T080	C1979936
27239027	1275	1283	myotubes	T025	C0242697
27239027	1359	1364	human	T016	C0086418
27239027	1367	1370	DMD	T047	C0013264
27239027	1383	1388	model	T050	C0684309
27239027	1395	1400	hiPSC	T025	C3658289
27239027	1408	1424	disease modeling	T050	C0684309

27239445|t|SNAI1 promotes the development of HCC through the enhancement of proliferation and inhibition of apoptosis
27239445|a|SNAI1, a zinc-finger transcription factor, plays an important role in the induction of epithelial-mesenchymal transition (EMT) in various cancers. However, the possible functions of SNAI1 in the proliferation and apoptosis of hepatocellular carcinoma have not been clearly identified. In this study, we investigated the effects and mechanisms of SNAI1 in the proliferation and apoptosis of hepatocellular carcinoma using clinical samples and cell lines. We found that SNAI1 is highly expressed in the tissues of liver cancer compared with adjacent nontumor tissues. SNAI1 is also highly expressed in the hepatoma cell lines HepG2, SMMC-7721, and BEL-7402 compared with the human normal liver cell line L02. We also observed that SNAI1 expression was correlated with distal metastasis, incomplete tumor capsule formation, and histological differentiation in hepatocellular carcinoma (HCC). Moreover, we demonstrated that knockdown of SNAI1 via lentiviral vectors of RNAi against SNAI inhibited cell proliferation by inducing G1 arrest, which was accompanied by the downregulation of cyclin D1 but not that of cyclin A. In addition, knockdown of SNAI1 promoted apoptosis by decreasing the expression of Bcl-2. In conclusion, our findings revealed that SNAI1 is involved in the development of hepatocellular carcinoma via regulating the growth and apoptosis of tumor cells.
27239445	0	5	SNAI1	T116,T123	C4308198
27239445	6	14	promotes	T052	C0033414
27239445	19	30	development	T169	C1527148
27239445	34	37	HCC	T191	C2239176
27239445	50	61	enhancement	T052	C2349975
27239445	65	78	proliferation	T169	C1514485
27239445	83	106	inhibition of apoptosis	T043	C1512772
27239445	107	112	SNAI1	T116,T123	C4308198
27239445	116	148	zinc-finger transcription factor	T116,T123	C0040648
27239445	181	190	induction	T169	C0205263
27239445	194	227	epithelial-mesenchymal transition	T043	C1523298
27239445	229	232	EMT	T043	C1523298
27239445	245	252	cancers	T191	C0006826
27239445	289	294	SNAI1	T116,T123	C4308198
27239445	302	315	proliferation	T169	C1514485
27239445	320	329	apoptosis	T043	C0162638
27239445	333	357	hepatocellular carcinoma	T191	C2239176
27239445	400	405	study	T062	C2603343
27239445	427	434	effects	T080	C1280500
27239445	439	449	mechanisms	T169	C0441712
27239445	453	458	SNAI1	T116,T123	C4308198
27239445	466	479	proliferation	T169	C1514485
27239445	484	493	apoptosis	T043	C0162638
27239445	497	521	hepatocellular carcinoma	T191	C2239176
27239445	528	536	clinical	T080	C0205210
27239445	537	544	samples	T167	C0370003
27239445	549	559	cell lines	T025	C0085983
27239445	575	580	SNAI1	T116,T123	C4308198
27239445	591	600	expressed	T045	C1171362
27239445	608	615	tissues	T024	C0040300
27239445	619	631	liver cancer	T191	C2239176
27239445	655	671	nontumor tissues	T024	C0040300
27239445	673	678	SNAI1	T116,T123	C4308198
27239445	694	703	expressed	T045	C1171362
27239445	711	736	hepatoma cell lines HepG2	T025	C2717940
27239445	738	747	SMMC-7721	T025	C0085983
27239445	753	761	BEL-7402	T025	C0085983
27239445	780	812	human normal liver cell line L02	T025	C0682523
27239445	836	841	SNAI1	T116,T123	C4308198
27239445	842	852	expression	T045	C1171362
27239445	873	890	distal metastasis	T046	C4255448
27239445	903	926	tumor capsule formation	T191	C0027671
27239445	932	960	histological differentiation	T201	C1511938
27239445	964	988	hepatocellular carcinoma	T191	C2239176
27239445	990	993	HCC	T191	C2239176
27239445	1027	1036	knockdown	T063	C2350567
27239445	1040	1045	SNAI1	T028	C1420267
27239445	1050	1060	lentiviral	T005	C0079679
27239445	1061	1068	vectors	T121	C1520007
27239445	1072	1076	RNAi	T045	C1136031
27239445	1085	1089	SNAI	T116,T123	C4308198
27239445	1100	1118	cell proliferation	T169	C1514485
27239445	1131	1140	G1 arrest	T043	C3178834
27239445	1171	1185	downregulation	T044	C0013081
27239445	1189	1198	cyclin D1	T116,T123	C0174680
27239445	1215	1223	cyclin A	T116,T123	C0079184
27239445	1238	1247	knockdown	T063	C2350567
27239445	1251	1256	SNAI1	T028	C1420267
27239445	1257	1265	promoted	T052	C0033414
27239445	1266	1275	apoptosis	T043	C0162638
27239445	1294	1304	expression	T045	C1171362
27239445	1308	1313	Bcl-2	T116	C4042483
27239445	1357	1362	SNAI1	T116,T123	C4308198
27239445	1382	1393	development	T169	C1527148
27239445	1397	1421	hepatocellular carcinoma	T191	C2239176
27239445	1426	1447	regulating the growth	T040	C1160191
27239445	1452	1461	apoptosis	T043	C0162638
27239445	1465	1476	tumor cells	T025	C0597032

27239541|t|Function and clinical meaningfulness of treatments for mild Alzheimer's disease
27239541|a|Effectiveness of Alzheimer's disease (AD) treatments is commonly evaluated with coprimary outcomes; cognition with function to ensure clinical meaningfulness of a cognitive effect. We reviewed the literature for functional outcomes in mild AD or mild cognitive impairment (MCI) patients (distinct from combined mild-moderate / severe AD) treated with approved AD drugs. Cognitive and functional treatment differences in mild AD patients in solanezumab EXPEDITION / EXPEDITION2 studies were compared across time. Seven publications provided MCI / mild AD functional outcomes, one of which reported a significant functional treatment effect. Secondary analyses of EXPEDITION studies suggested a smaller functional effect of solanezumab relative to cognition. An increasing effect of solanezumab over 18 months was shown for cognition and function. Function as the sole measure to demonstrate clinical meaningfulness of cognitive effects in mild AD may have limitations. For disease - modifying treatments, point differences on cognitive and functional scales should be qualified with duration of treatment.
27239541	0	8	Function	T041	C0563143
27239541	13	21	clinical	T080	C0205210
27239541	22	36	meaningfulness	T080	C1280519
27239541	40	50	treatments	T061	C0087111
27239541	55	59	mild	T080	C2945599
27239541	60	79	Alzheimer's disease	T047	C0002395
27239541	80	93	Effectiveness	T080	C1280519
27239541	97	116	Alzheimer's disease	T047	C0002395
27239541	118	120	AD	T047	C0002395
27239541	122	132	treatments	T061	C0087111
27239541	160	178	coprimary outcomes	T169	C1274040
27239541	180	189	cognition	T041	C0009240
27239541	195	203	function	T041	C0563143
27239541	214	222	clinical	T080	C0205210
27239541	223	237	meaningfulness	T080	C1280519
27239541	243	252	cognitive	T041	C0009240
27239541	253	259	effect	T080	C1280500
27239541	264	272	reviewed	T080	C1709940
27239541	277	287	literature	T170	C0023866
27239541	292	302	functional	T041	C0563143
27239541	303	311	outcomes	T169	C1274040
27239541	315	319	mild	T080	C2945599
27239541	320	322	AD	T047	C0002395
27239541	326	351	mild cognitive impairment	T048	C1270972
27239541	353	356	MCI	T048	C1270972
27239541	358	366	patients	T101	C0030705
27239541	391	404	mild-moderate	T080	C1299392
27239541	407	413	severe	T080	C0205082
27239541	414	416	AD	T047	C0002395
27239541	418	430	treated with	T061	C0332293
27239541	440	442	AD	T047	C0002395
27239541	443	448	drugs	T121	C0013227
27239541	450	459	Cognitive	T061	C0009244
27239541	464	474	functional	T041	C0563143
27239541	475	484	treatment	T061	C0087111
27239541	500	504	mild	T080	C2945599
27239541	505	507	AD	T047	C0002395
27239541	508	516	patients	T101	C0030705
27239541	520	531	solanezumab	T116,T121,T129	C2935150
27239541	532	542	EXPEDITION	T052	C0015315
27239541	545	556	EXPEDITION2	T052	C0015315
27239541	557	564	studies	T062	C2603343
27239541	570	578	compared	T052	C1707455
27239541	586	590	time	T079	C0040223
27239541	598	610	publications	T073,T170	C0034036
27239541	620	623	MCI	T048	C1270972
27239541	626	630	mild	T080	C2945599
27239541	631	633	AD	T047	C0002395
27239541	634	644	functional	T041	C0563143
27239541	645	653	outcomes	T169	C1274040
27239541	691	701	functional	T041	C0563143
27239541	702	718	treatment effect	T033	C1518681
27239541	720	738	Secondary analyses	UnknownType	C0683944
27239541	742	752	EXPEDITION	T052	C0015315
27239541	753	760	studies	T062	C2603343
27239541	781	791	functional	T041	C0563143
27239541	792	798	effect	T080	C1280500
27239541	802	813	solanezumab	T116,T121,T129	C2935150
27239541	826	835	cognition	T041	C0009240
27239541	840	850	increasing	T169	C0442808
27239541	851	857	effect	T080	C1280500
27239541	861	872	solanezumab	T116,T121,T129	C2935150
27239541	881	887	months	T079	C0439231
27239541	902	911	cognition	T041	C0009240
27239541	916	924	function	T041	C0563143
27239541	926	934	Function	T041	C0563143
27239541	947	954	measure	T081	C0079809
27239541	970	978	clinical	T080	C0205210
27239541	979	993	meaningfulness	T080	C1280519
27239541	997	1006	cognitive	T041	C0009240
27239541	1007	1014	effects	T080	C1280500
27239541	1018	1022	mild	T080	C2945599
27239541	1023	1025	AD	T047	C0002395
27239541	1035	1046	limitations	T169	C0449295
27239541	1052	1059	disease	T047	C0012634
27239541	1062	1071	modifying	T169	C0392747
27239541	1072	1082	treatments	T061	C0087111
27239541	1105	1114	cognitive	T041	C0009240
27239541	1119	1129	functional	T041	C0563143
27239541	1130	1136	scales	T170	C0349674
27239541	1162	1183	duration of treatment	T079	C0444921

27239953|t|Body mass index and suicide methods
27239953|a|Overweight and obesity is associated with lower rates of suicide. However, little is known about the association with different suicide methods. We studied the association between groups of body mass index and suicide methods. We identified all medicolegal autopsy cases with a cause of death due to external causes in Sweden during 1999-2013 (N = 39,368) and included 11,715 suicides and 13,316 accidents or homicides as controls. We applied multinomial regression models adjusted for age, sex, year and season of death. Obesity was associated with suicidal intoxication, OR 1.15 [95% confidence interval (CI) 1.02, 1.30] and negatively associated with all other suicide methods studied. Underweight showed a negative association with suicidal drowning and there was an indication towards a negative association with hanging in men OR 0.81 (95% CI 0.65, 1.01). We conclude that body mass index (BMI) is associated with the choice of suicide method. This may be of importance in a public health perspective, e.g. potential for prevention of intoxications. In the practice of forensic medicine, the physician's level of suspicion may rise if the apparent suicidal method is less common for the individual characteristics of the deceased, such as BMI.
27239953	0	15	Body mass index	T201	C1305855
27239953	20	27	suicide	T033	C0038661
27239953	28	35	methods	T169	C0449851
27239953	36	46	Overweight	T184	C0497406
27239953	51	58	obesity	T047	C0028754
27239953	62	77	associated with	T080	C0332281
27239953	78	89	lower rates	T081	C1521828
27239953	93	100	suicide	T033	C0038661
27239953	137	148	association	T080	C0439849
27239953	164	171	suicide	T033	C0038661
27239953	172	179	methods	T169	C0449851
27239953	196	207	association	T080	C0439849
27239953	226	241	body mass index	T201	C1305855
27239953	246	253	suicide	T033	C0038661
27239953	254	261	methods	T169	C0449851
27239953	281	292	medicolegal	T089	C0243119
27239953	293	300	autopsy	T060	C0004398
27239953	301	306	cases	T169	C0868928
27239953	314	328	cause of death	T033	C0007465
27239953	336	351	external causes	T033	C1407879
27239953	355	361	Sweden	T083	C0038995
27239953	396	404	included	T169	C0332257
27239953	412	420	suicides	T033	C0038661
27239953	432	441	accidents	T067	C0000924
27239953	445	454	homicides	T055	C0019872
27239953	458	466	controls	T096	C0009932
27239953	479	490	multinomial	T081	C1709090
27239953	491	508	regression models	T170	C0034980
27239953	522	525	age	T032	C0001779
27239953	527	530	sex	T032	C0079399
27239953	532	536	year	T079	C0439234
27239953	541	547	season	T079	C0036497
27239953	551	556	death	T033	C1306577
27239953	558	565	Obesity	T047	C0028754
27239953	570	585	associated with	T080	C0332281
27239953	586	594	suicidal	T033	C0438696
27239953	595	607	intoxication	T033	C0728899
27239953	609	611	OR	T081	C0028873
27239953	622	641	confidence interval	T081	C0009667
27239953	643	645	CI	T081	C0009667
27239953	663	673	negatively	T033	C0205160
27239953	674	689	associated with	T080	C0332281
27239953	700	707	suicide	T033	C0038661
27239953	708	715	methods	T169	C0449851
27239953	725	736	Underweight	T033	C0041667
27239953	746	754	negative	T033	C0205160
27239953	755	766	association	T080	C0439849
27239953	772	780	suicidal	T033	C0438696
27239953	781	789	drowning	T037	C0013142
27239953	807	817	indication	T078	C3146298
27239953	828	836	negative	T033	C0205160
27239953	837	848	association	T080	C0439849
27239953	854	861	hanging	T037	C0544691
27239953	865	868	men	T098	C0025266
27239953	869	871	OR	T081	C0028873
27239953	882	884	CI	T081	C0009667
27239953	901	909	conclude	T078	C1707478
27239953	915	930	body mass index	T201	C1305855
27239953	932	935	BMI	T201	C1305855
27239953	940	955	associated with	T080	C0332281
27239953	970	977	suicide	T033	C0038661
27239953	978	984	method	T169	C0449851
27239953	1017	1042	public health perspective	T058	C0699943
27239953	1049	1058	potential	T080	C3245505
27239953	1063	1073	prevention	T061	C0204732
27239953	1077	1090	intoxications	T033	C0728899
27239953	1111	1128	forensic medicine	T091	C0016557
27239953	1134	1145	physician's	T097	C0031831
27239953	1155	1164	suspicion	T041	C0242114
27239953	1181	1189	apparent	T078	C0750489
27239953	1190	1198	suicidal	T033	C0438696
27239953	1209	1220	less common	T081	C0205214
27239953	1229	1255	individual characteristics	T080	C1521970
27239953	1263	1271	deceased	T040	C0011065
27239953	1281	1284	BMI	T201	C1305855

27240257|t|Quantitative assessment of fluorescent proteins
27240257|a|The advent of fluorescent proteins (FPs) for genetic labeling of molecules and cells has revolutionized fluorescence microscopy. Genetic manipulations have created a vast array of bright and stable FPs spanning blue to red spectral regions. Common to autofluorescent FPs is their tight Î²-barrel structure, which provides the rigidity and chemical environment needed for effectual fluorescence. Despite the common structure, each FP has unique properties. Thus, there is no single 'best' FP for every circumstance, and each FP has advantages and disadvantages. To guide decisions about which FP is right for a given application, we have quantitatively characterized the brightness, photostability, pH stability and monomeric properties of more than 40 FPs to enable straightforward and direct comparison between them. We focus on popular and/or top-performing FPs in each spectral region.
27240257	0	23	Quantitative assessment	T081	C0034384
27240257	27	47	fluorescent proteins	T116,T123	C0033684
27240257	62	82	fluorescent proteins	T116,T123	C0033684
27240257	84	87	FPs	T116,T123	C0033684
27240257	93	109	genetic labeling	T063	C1513384
27240257	113	122	molecules	T167	C0567416
27240257	127	132	cells	T025	C0007634
27240257	152	175	fluorescence microscopy	T059	C0026022
27240257	177	198	Genetic manipulations	T063	C0178659
27240257	246	249	FPs	T116,T123	C0033684
27240257	259	287	blue to red spectral regions	T082	C1254362
27240257	299	314	autofluorescent	T059	C0544711
27240257	315	318	FPs	T116,T123	C0033684
27240257	334	352	Î²-barrel structure	T087	C0599216
27240257	373	381	rigidity	T080	C0205556
27240257	386	394	chemical	T103	C0220806
27240257	395	406	environment	T082	C0014406
27240257	428	440	fluorescence	T070	C0016315
27240257	461	470	structure	T085	C0026383
27240257	477	479	FP	T116,T123	C0033684
27240257	491	501	properties	T080	C0871161
27240257	535	537	FP	T116,T123	C0033684
27240257	571	573	FP	T116,T123	C0033684
27240257	639	641	FP	T116,T123	C0033684
27240257	684	698	quantitatively	T081	C0392762
27240257	717	727	brightness	T070	C0678578
27240257	729	743	photostability	T033	C0243095
27240257	745	747	pH	T081	C0020283
27240257	748	757	stability	T080	C0205360
27240257	762	771	monomeric	T104	C0596973
27240257	772	782	properties	T080	C0871161
27240257	799	802	FPs	T116,T123	C0033684
27240257	813	828	straightforward	T080	C1272701
27240257	840	850	comparison	T052	C1707455
27240257	907	910	FPs	T116,T123	C0033684
27240257	919	934	spectral region	T082	C1254362

27240437|t|Cognitive impairment in HIV and HCV co-infected patients: a systematic review and meta-analysis
27240437|a|Cognitive impairment has been well documented in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) mono-infections. However, in the context of HIV / HCV co-infection the research is more limited. The aim of this systematic review was to describe the characteristics of cognitive impairment in HIV / HCV co-infection and to examine the differences in cognitive performance between HIV / HCV and HIV and HCV mono-infected patients. Of the 437 records initially screened, 24 papers met the inclusion criteria and were included in the systematic review. Four studies were included in the meta-analysis. Most studies indicated that HIV / HCV co-infected patients had a higher level of cognitive impairment than HIV mono-infected patients. Meta-analysis also indicated that HIV mono-infected patients had a significantly lower global deficit score than co-infected patients. The results also indicated that co-infected patients were more likely to be impaired in information processing speed than HIV mono-infected patients. These findings can be challenged by biasing factors such as the small number of included studies, heterogeneity of the samples and a large diversity of methodological procedures. Future research with consistent and comprehensive neuropsychological batteries and covering a greater diversity of risk factors is needed, in order to clarify the effects of both viruses on cognitive function and the mechanisms that underlie these effects. Because cognitive impairments may pose significant challenges to medication adherence, quality of life and overall functioning, such knowledge may have important implications to the planning and implementation of effective interventions aimed at optimising the clinical management of these infections.
27240437	0	20	Cognitive impairment	T048	C0338656
27240437	24	27	HIV	T005	C0019682
27240437	32	35	HCV	T005	C0220847
27240437	36	47	co-infected	T047	C0275524
27240437	48	56	patients	T101	C0030705
27240437	71	77	review	T170	C0282443
27240437	82	95	meta-analysis	T062	C0920317
27240437	96	116	Cognitive impairment	T048	C0338656
27240437	145	173	human immunodeficiency virus	T005	C0019682
27240437	175	178	HIV	T005	C0019682
27240437	184	201	hepatitis C virus	T005	C0220847
27240437	203	206	HCV	T005	C0220847
27240437	208	223	mono-infections	T046	C3714514
27240437	252	255	HIV	T005	C0019682
27240437	258	261	HCV	T005	C0220847
27240437	262	274	co-infection	T047	C0275524
27240437	332	338	review	T170	C0282443
27240437	378	398	cognitive impairment	T048	C0338656
27240437	402	405	HIV	T005	C0019682
27240437	408	411	HCV	T005	C0220847
27240437	412	424	co-infection	T047	C0275524
27240437	432	439	examine	T033	C0332128
27240437	459	480	cognitive performance	T041	C0392335
27240437	489	492	HIV	T005	C0019682
27240437	495	498	HCV	T005	C0220847
27240437	503	506	HIV	T005	C0019682
27240437	511	514	HCV	T005	C0220847
27240437	515	528	mono-infected	T046	C3714514
27240437	529	537	patients	T101	C0030705
27240437	568	576	screened	T058	C0220908
27240437	651	657	review	T170	C0282443
27240437	664	671	studies	T062	C2603343
27240437	693	706	meta-analysis	T062	C0920317
27240437	713	720	studies	T062	C2603343
27240437	736	739	HIV	T005	C0019682
27240437	742	745	HCV	T005	C0220847
27240437	746	757	co-infected	T047	C0275524
27240437	758	766	patients	T101	C0030705
27240437	789	809	cognitive impairment	T048	C0338656
27240437	815	818	HIV	T005	C0019682
27240437	819	832	mono-infected	T046	C3714514
27240437	833	841	patients	T101	C0030705
27240437	843	856	Meta-analysis	T062	C0920317
27240437	877	880	HIV	T005	C0019682
27240437	881	894	mono-infected	T046	C3714514
27240437	895	903	patients	T101	C0030705
27240437	930	950	global deficit score	T081	C0449820
27240437	956	967	co-infected	T047	C0275524
27240437	968	976	patients	T101	C0030705
27240437	1010	1021	co-infected	T047	C0275524
27240437	1022	1030	patients	T101	C0030705
27240437	1054	1062	impaired	T048	C0338656
27240437	1066	1094	information processing speed	T041	C0870707
27240437	1100	1103	HIV	T005	C0019682
27240437	1104	1117	mono-infected	T046	C3714514
27240437	1118	1126	patients	T101	C0030705
27240437	1134	1142	findings	T033	C0243095
27240437	1217	1224	studies	T062	C2603343
27240437	1226	1239	heterogeneity	T102	C0086833
27240437	1247	1254	samples	T081	C0871429
27240437	1267	1276	diversity	T080	C1880371
27240437	1357	1385	neuropsychological batteries	T170	C0451331
27240437	1409	1418	diversity	T080	C1880371
27240437	1422	1434	risk factors	T033	C0035648
27240437	1486	1493	viruses	T005	C0042776
27240437	1497	1515	cognitive function	T041	C0392335
27240437	1572	1593	cognitive impairments	T048	C0338656
27240437	1615	1625	challenges	T058	C0805586
27240437	1629	1649	medication adherence	T033	C2364172
27240437	1651	1666	quality of life	T078	C0034380
27240437	1671	1690	overall functioning	T169	C0542341
27240437	1746	1754	planning	T058	C0018727
27240437	1759	1773	implementation	T058	C0018726
27240437	1825	1844	clinical management	T058	C1516615
27240437	1854	1864	infections	T046	C3714514

27240560|t|Consumption of fruits and vegetables associated with other risk behaviors among adolescents in Northeast Brazil
27240560|a|To determine the prevalence of consumption of fruits and vegetables and identify the association with low level of physical activity, exposure to sedentary behavior, consumption of soft drinks and overweight / obesity in adolescents. This is a cross-sectional school-based study with a representative sample of 3992 students aged 14-19 years from the state of Sergipe, Brazil. The outcome was low consumption of fruits and vegetables (<5 servings/day). Independent variables were: level of physical activity, sedentary behavior, consumption of soft drinks, and overweight / obesity. Global Student Health Survey questionnaire and body mass and height measurements were used, as well as chi-square test and crude and adjusted binary logistic regression. The significance level adopted was 5%. The prevalence of inadequate consumption of fruits and vegetables was high - 88.6% (95% CI =87.6-89.5). Higher likelihood of low consumption of fruits and vegetables was verified among boys who were exposed to sedentary behavior (OR =1.63; 95% CI =1.18-2.24), who consumed soft drinks (OR =3.04; 95% CI =2.10-4.40), with insufficiently physical activity (OR =1.98; 95% CI =1.43-2.73) and girls who consumed soft drinks (OR =1.88; 95% CI =1.43-2.47) and those with overweight / obesity (OR =1.63; 95% CI =1.19-2.23). There is a need of public policies aimed at encouraging the consumption of healthy foods among adolescents.
27240560	0	36	Consumption of fruits and vegetables	T040	C1271941
27240560	37	52	associated with	T080	C0332281
27240560	59	73	risk behaviors	T055	C0086931
27240560	80	91	adolescents	T100	C0205653
27240560	95	111	Northeast Brazil	T083	C0006137
27240560	129	139	prevalence	T081	C0220900
27240560	143	179	consumption of fruits and vegetables	T040	C1271941
27240560	197	213	association with	T080	C0332281
27240560	214	217	low	T080	C0205251
27240560	218	223	level	T080	C0441889
27240560	227	244	physical activity	T056	C0026606
27240560	246	257	exposure to	T080	C0332157
27240560	258	276	sedentary behavior	T033	C3824706
27240560	278	289	consumption	T052	C2983605
27240560	293	304	soft drinks	T168	C3489624
27240560	309	319	overweight	T184	C0497406
27240560	322	329	obesity	T047	C0028754
27240560	333	344	adolescents	T100	C0205653
27240560	356	390	cross-sectional school-based study	T062	C0010362
27240560	413	419	sample	T167	C0370003
27240560	428	436	students	T098	C0038492
27240560	448	453	years	T079	C1510829
27240560	463	479	state of Sergipe	T083	C1301808
27240560	481	487	Brazil	T083	C0006137
27240560	493	500	outcome	T169	C1274040
27240560	505	508	low	T080	C0205251
27240560	509	545	consumption of fruits and vegetables	T040	C1271941
27240560	550	562	servings/day	T079	C0439505
27240560	565	586	Independent variables	T169	C0870693
27240560	593	598	level	T080	C0441889
27240560	602	619	physical activity	T056	C0026606
27240560	621	639	sedentary behavior	T033	C3824706
27240560	641	652	consumption	T052	C2983605
27240560	656	667	soft drinks	T168	C3489624
27240560	673	683	overweight	T184	C0497406
27240560	686	693	obesity	T047	C0028754
27240560	695	737	Global Student Health Survey questionnaire	T170	C0034394
27240560	742	751	body mass	T058	C3698309
27240560	756	762	height	T032	C0005890
27240560	763	775	measurements	T058	C0947289
27240560	798	813	chi-square test	T170	C0008041
27240560	818	863	crude and adjusted binary logistic regression	T062	C0206031
27240560	869	887	significance level	T062	C0814896
27240560	908	918	prevalence	T081	C0220900
27240560	922	932	inadequate	T080	C0205412
27240560	933	969	consumption of fruits and vegetables	T040	C1271941
27240560	974	978	high	T080	C0205250
27240560	992	994	CI	T081	C0009667
27240560	1008	1014	Higher	T080	C0205250
27240560	1029	1032	low	T080	C0205251
27240560	1033	1069	consumption of fruits and vegetables	T040	C1271941
27240560	1089	1093	boys	T100	C0870221
27240560	1103	1113	exposed to	T080	C0332157
27240560	1114	1132	sedentary behavior	T033	C3824706
27240560	1134	1136	OR	T081	C0028873
27240560	1148	1150	CI	T081	C0009667
27240560	1168	1176	consumed	T052	C2983605
27240560	1177	1188	soft drinks	T168	C3489624
27240560	1190	1192	OR	T081	C0028873
27240560	1204	1206	CI	T081	C0009667
27240560	1225	1239	insufficiently	T080	C0231180
27240560	1240	1257	physical activity	T056	C0026606
27240560	1259	1261	OR	T081	C0028873
27240560	1273	1275	CI	T081	C0009667
27240560	1292	1297	girls	T100	C0870604
27240560	1302	1310	consumed	T052	C2983605
27240560	1311	1322	soft drinks	T168	C3489624
27240560	1324	1326	OR	T081	C0028873
27240560	1338	1340	CI	T081	C0009667
27240560	1368	1378	overweight	T184	C0497406
27240560	1381	1388	obesity	T047	C0028754
27240560	1390	1392	OR	T081	C0028873
27240560	1404	1406	CI	T081	C0009667
27240560	1439	1454	public policies	T064	C0034033
27240560	1480	1508	consumption of healthy foods	T052	C2983605
27240560	1515	1526	adolescents	T100	C0205653

27241087|t|Usefulness of Embolization for Iatrogenic Dural Arteriovenous Fistula Associated with Recurrent Chronic Subdural Hematoma: A Case Report and Literature Review
27241087|a|Refractory chronic subdural hematomas due to iatrogenic dural arteriovenous fistulas (dAVFs) are difficult to treat. We report our experience and propose a guideline on basis of a literature review for the usefulness of embolization of middle meningeal artery (MMA) for the treatment of the same. We report a case with right hemiparesis and aphasia 1 month after a fall from a bicycle. Computed tomography scan of the head showed left chronic subdural hematoma, which was evacuated by burr-hole drainage. The postoperative course was complicated by reaccumulation within short period of time. On superselective digital subtraction angiography of MMA, iatrogenic dAVF was found on left side. We embolized successfully it using n-butyl cyanoacrylate after a third irrigation. No reaccumulation found in the postoperative period or at last follow-up. We propose treatment protocol based on our experience and literature review. Refractory chronic subdural hematoma with reaccumulation within a short interval should be subjected to digital subtraction angiography of the MMA. Embolization of ipsilateral MMA is safe, effective, and a useful option for the treatment of iatrogenic dAVF and resolution of hematoma.
27241087	0	10	Usefulness	T080	C3827682
27241087	14	26	Embolization	T061	C0013931
27241087	31	41	Iatrogenic	T047	C1512608
27241087	42	69	Dural Arteriovenous Fistula	T190	C0752156
27241087	70	85	Associated with	T080	C0332281
27241087	86	95	Recurrent	T079	C2945760
27241087	96	121	Chronic Subdural Hematoma	T046	C0749095
27241087	125	136	Case Report	T170	C0085973
27241087	141	158	Literature Review	T170	C0282441
27241087	159	169	Refractory	T169	C0205269
27241087	170	196	chronic subdural hematomas	T046	C0749095
27241087	204	214	iatrogenic	T047	C1512608
27241087	215	243	dural arteriovenous fistulas	T190	C0752156
27241087	245	250	dAVFs	T190	C0752156
27241087	256	265	difficult	T080	C0332218
27241087	269	274	treat	T169	C1522326
27241087	315	324	guideline	T061	C0935576
27241087	339	356	literature review	T170	C0282441
27241087	365	375	usefulness	T080	C3827682
27241087	379	391	embolization	T061	C0013931
27241087	395	418	middle meningeal artery	T023	C0226147
27241087	420	423	MMA	T023	C0226147
27241087	433	442	treatment	T061	C0087111
27241087	468	472	case	T169	C0868928
27241087	478	495	right hemiparesis	T033	C0457435
27241087	500	507	aphasia	T048	C0003537
27241087	510	515	month	T079	C0439231
27241087	524	528	fall	T033	C0085639
27241087	536	543	bicycle	T073	C0005375
27241087	545	569	Computed tomography scan	T060	C0040405
27241087	577	581	head	T029	C0018670
27241087	589	593	left	T082	C0443246
27241087	594	619	chronic subdural hematoma	T046	C0749095
27241087	631	662	evacuated by burr-hole drainage	T061	C2005662
27241087	668	688	postoperative course	T079	C0032790
27241087	693	704	complicated	T169	C0231242
27241087	708	722	reaccumulation	T033	C4055506
27241087	736	742	period	T079	C1948053
27241087	746	750	time	T079	C0040223
27241087	755	801	superselective digital subtraction angiography	T060	C0002979
27241087	805	808	MMA	T023	C0226147
27241087	810	820	iatrogenic	T047	C1512608
27241087	821	825	dAVF	T190	C0752156
27241087	839	848	left side	T082	C0205091
27241087	853	862	embolized	T061	C0013931
27241087	863	875	successfully	T080	C1272703
27241087	885	906	n-butyl cyanoacrylate	T109,T122	C0014035
27241087	921	931	irrigation	T061	C2936738
27241087	936	950	reaccumulation	T033	C4055506
27241087	964	984	postoperative period	T079	C0032790
27241087	996	1005	follow-up	T058	C1522577
27241087	1018	1036	treatment protocol	T061	C0040808
27241087	1050	1060	experience	T080	C0871521
27241087	1065	1082	literature review	T170	C0282441
27241087	1084	1094	Refractory	T169	C0205269
27241087	1095	1120	chronic subdural hematoma	T046	C0749095
27241087	1126	1140	reaccumulation	T033	C4055506
27241087	1150	1164	short interval	T079	C1272706
27241087	1188	1219	digital subtraction angiography	T060	C0002979
27241087	1227	1230	MMA	T023	C0226147
27241087	1232	1244	Embolization	T061	C0013931
27241087	1248	1259	ipsilateral	T082	C0441989
27241087	1260	1263	MMA	T023	C0226147
27241087	1273	1282	effective	T080	C1704419
27241087	1312	1321	treatment	T061	C0087111
27241087	1325	1335	iatrogenic	T047	C1512608
27241087	1336	1340	dAVF	T190	C0752156
27241087	1345	1355	resolution	T077	C2699488
27241087	1359	1367	hematoma	T046	C0018946

27241291|t|In Search of the E. coli Compounds that Change the Antibiotic Production Pattern of Streptomyces coelicolor During Inter-species Interaction
27241291|a|The aim of this work was to investigate the interaction between E.coli and Streptomyces coelicolor A3 (2) for the increased production of undecylprodigiosin and identify the E. coli actives mediating this inter-species interaction. The antibiotics of interest were the red-pigmented undecylprodigiosin and blue-pigmented actinorhodin. Pure cultures of S. coelicolor in a defined medium produced higher concentrations of actinorhodin compared to those of undecylprodigiosin. The latter however, is more important due to its immunosuppressive and antitumor properties. As a strategy to increase undecylprodigiosin production, we added separately, live cells and heat-killed cells of E. coli C600, and the cell-free supernatant of E. coli culture to S. coelicolor cultures in shake flasks. The interaction with live cells of E. coli altered the antibiotic production pattern and undecylprodigiosin production was enhanced by 3.5-fold compared to the pure cultures of S. coelicolor and actinorhodin decreased by 15-fold. The heat-killed cells of E. coli however, had no effect on antibiotic production. In all cases, growth and glucose consumption of S. coelicolor remained almost the same as those observed in the pure culture indicating that the changes in antibiotic production were not due to nutritional stress. Results with cell-free supernatant of E. coli culture indicated that the interaction between S. coelicolor and E. coli was mediated via diffusible molecule(s). Using a set of extraction procedures and agar-well diffusion bioassays, we isolated and preliminarily identified a class of compounds. For the preliminary verification, we added the compound which was the common chemical structural moiety in this class of compounds to the pure S. coelicolor cultures. We observed similar effects on antibiotic production as with the live E. coli cells and their supernatant indicating that this class of compounds secreted by E. coli indeed could act as actives during interspecies interaction and increase the production of undecylprodigiosin.
27241291	17	24	E. coli	T007	C0014834
27241291	25	34	Compounds	T123	C0574031
27241291	51	61	Antibiotic	T195	C0003232
27241291	62	72	Production	T169	C0205245
27241291	84	107	Streptomyces coelicolor	T007	C0995741
27241291	115	140	Inter-species Interaction	T054	C0870742
27241291	169	180	investigate	T169	C1292732
27241291	185	196	interaction	T169	C1704675
27241291	205	211	E.coli	T007	C0014834
27241291	216	246	Streptomyces coelicolor A3 (2)	T007	C1449847
27241291	255	264	increased	T081	C0205217
27241291	265	275	production	T169	C0205245
27241291	279	297	undecylprodigiosin	T109,T121	C0077826
27241291	315	322	E. coli	T007	C0014834
27241291	323	330	actives	T169	C0205177
27241291	331	340	mediating	T054	C0086597
27241291	346	371	inter-species interaction	T054	C0870742
27241291	377	388	antibiotics	T195	C0003232
27241291	410	442	red-pigmented undecylprodigiosin	T109,T121	C0526040
27241291	447	461	blue-pigmented	T080	C0333610
27241291	462	474	actinorhodin	T109,T195	C0050663
27241291	481	489	cultures	T059	C0430402
27241291	493	506	S. coelicolor	T007	C0995741
27241291	520	526	medium	T130	C0010454
27241291	543	557	concentrations	T081	C1264643
27241291	561	573	actinorhodin	T109,T195	C0050663
27241291	574	582	compared	T052	C1707455
27241291	595	613	undecylprodigiosin	T109,T121	C0077826
27241291	664	681	immunosuppressive	T040	C0021080
27241291	686	706	antitumor properties	T042	C1516031
27241291	725	733	increase	T169	C0442805
27241291	734	752	undecylprodigiosin	T109,T121	C0077826
27241291	753	763	production	T169	C0205245
27241291	786	796	live cells	T025	C1441322
27241291	801	812	heat-killed	T067	C1522240
27241291	813	818	cells	T025	C0007634
27241291	822	834	E. coli C600	T007	C0014834
27241291	844	865	cell-free supernatant	T031	C1550101
27241291	869	876	E. coli	T007	C0014834
27241291	877	884	culture	T059	C0430402
27241291	888	901	S. coelicolor	T007	C0995741
27241291	902	926	cultures in shake flasks	T059	C3179108
27241291	932	943	interaction	T169	C1704675
27241291	949	959	live cells	T025	C1441322
27241291	963	970	E. coli	T007	C0014834
27241291	983	993	antibiotic	T195	C0003232
27241291	994	1004	production	T169	C0205245
27241291	1017	1035	undecylprodigiosin	T109,T121	C0077826
27241291	1036	1046	production	T169	C0205245
27241291	1051	1059	enhanced	T052	C2349975
27241291	1088	1101	pure cultures	T059	C0430402
27241291	1105	1118	S. coelicolor	T007	C0995741
27241291	1123	1135	actinorhodin	T109,T195	C0050663
27241291	1136	1145	decreased	T081	C0205216
27241291	1162	1173	heat-killed	T067	C1522240
27241291	1174	1179	cells	T025	C0007634
27241291	1183	1190	E. coli	T007	C0014834
27241291	1204	1213	no effect	T080	C1301751
27241291	1217	1227	antibiotic	T195	C0003232
27241291	1228	1238	production	T169	C0205245
27241291	1254	1260	growth	T040	C0178747
27241291	1265	1284	glucose consumption	T033	C0556133
27241291	1288	1301	S. coelicolor	T007	C0995741
27241291	1322	1326	same	T080	C0445247
27241291	1336	1344	observed	T169	C1441672
27241291	1352	1364	pure culture	T059	C0430402
27241291	1385	1392	changes	T169	C0392747
27241291	1396	1406	antibiotic	T195	C0003232
27241291	1407	1417	production	T169	C0205245
27241291	1434	1445	nutritional	T040	C1442959
27241291	1446	1452	stress	T033	C0038435
27241291	1454	1461	Results	T169	C1274040
27241291	1467	1488	cell-free supernatant	T031	C1550101
27241291	1492	1499	E. coli	T007	C0014834
27241291	1500	1507	culture	T059	C0430402
27241291	1527	1538	interaction	T169	C1704675
27241291	1547	1560	S. coelicolor	T007	C0995741
27241291	1565	1572	E. coli	T007	C0014834
27241291	1577	1585	mediated	T054	C0086597
27241291	1590	1612	diffusible molecule(s)	T123	C0574031
27241291	1629	1650	extraction procedures	T059	C0684295
27241291	1655	1684	agar-well diffusion bioassays	T059	C0005507
27241291	1689	1697	isolated	T169	C0205409
27241291	1716	1726	identified	T080	C0205396
27241291	1729	1747	class of compounds	T123	C0574031
27241291	1769	1781	verification	T169	C1711411
27241291	1796	1804	compound	T123	C0574031
27241291	1826	1852	chemical structural moiety	T104	C1254350
27241291	1861	1879	class of compounds	T123	C0574031
27241291	1892	1905	S. coelicolor	T007	C0995741
27241291	1906	1914	cultures	T059	C1331092
27241291	1936	1943	effects	T080	C1280500
27241291	1947	1957	antibiotic	T195	C0003232
27241291	1958	1968	production	T169	C0205245
27241291	1986	1993	E. coli	T007	C0014834
27241291	1994	1999	cells	T025	C0007634
27241291	2010	2021	supernatant	T031	C1550101
27241291	2043	2061	class of compounds	T123	C0574031
27241291	2062	2070	secreted	T043	C1327616
27241291	2074	2081	E. coli	T007	C0014834
27241291	2102	2109	actives	T169	C0205177
27241291	2117	2141	interspecies interaction	T054	C0870742
27241291	2146	2154	increase	T169	C0442805
27241291	2159	2169	production	T169	C0205245
27241291	2173	2191	undecylprodigiosin	T109,T121	C0077826

27241818|t|Group III/IV muscle afferents limit the intramuscular metabolic perturbation during whole body exercise in humans
27241818|a|The purpose of this study was to determine the role of group III/IV muscle afferents in limiting the endurance exercise - induced metabolic perturbation assayed in muscle biopsy samples taken from locomotor muscle. Lumbar intrathecal fentanyl was used to attenuate the central projection of Î¼-opioid receptor - sensitive locomotor muscle afferents during a 5 km cycling time trial. The findings suggest that the central projection of group III/IV muscle afferent feedback constrains voluntary neural ' drive ' to working locomotor muscle and limits the exercise - induced intramuscular metabolic perturbation. Therefore, the CNS might regulate the degree of metabolic perturbation within locomotor muscle and thereby limit peripheral fatigue. It appears that the group III/IV muscle afferents are an important neural link in this regulatory mechanism, which probably serves to protect locomotor muscle from the potentially severe functional impairment as a consequence of severe intramuscular metabolic disturbance. To investigate the role of metabo - and mechanosensitive group III/IV muscle afferents in limiting the intramuscular metabolic perturbation during whole body endurance exercise, eight subjects performed 5 km cycling time trials under control conditions (CTRL) and with lumbar intrathecal fentanyl impairing lower limb muscle afferent feedback (FENT). Vastus lateralis muscle biopsies were obtained before and immediately after exercise. Motoneuronal output was estimated through vastus lateralis surface electromyography (EMG). Exercise - induced changes in intramuscular metabolites were determine d using liquid and gas chromatography-mass spectrometry. Quadriceps fatigue was quantified by pre - to post - exercise changes in potentiated quadriceps twitch torque (ÎQTsingle) evoked by electrical femoral nerve stimulation. Although motoneuronal output was 21 Â± 12% higher during FENT compared to CTRL (P < 0.05), time to complete the time trial was similar (â¼8.8 min). Compared to CTRL, power output during FENT was 10 Â± 4% higher in the first half of the time trial, but 11 Â± 5% lower in the second half (both P < 0.01). The exercise - induced increase in intramuscular inorganic phosphate, H(+), adenosine diphosphate, lactate and phosphocreatine depletion was 55 Â± 30, 62 Â± 18, 129 Â± 63, 47 Â± 14 (P < 0.001) and 27 Â± 14% (P < 0.01) greater in FENT than CTRL. ÎQTsingle was greater following FENT than CTRL (-52 Â± 2 vs -31 Â± 1%, P < 0.001) and this difference was positively correlated with the difference in inorganic phosphate (r(2) = 0.79; P < 0.01) and H(+) (r(2) = 0.92; P < 0.01). In conclusion, during whole body exercise, group III/IV muscle afferents provide feedback to the CNS which, in turn, constrains motoneuronal output to the active skeletal muscle. This regulatory mechanism limits the exercise - induced intramuscular metabolic perturbation, preventing an abnormal homeostatic challenge and excessive peripheral fatigue.
27241818	0	19	Group III/IV muscle	T024	C0026845
27241818	20	29	afferents	T025	C0027883
27241818	30	35	limit	T169	C0439801
27241818	40	53	intramuscular	T082	C0442117
27241818	54	63	metabolic	T169	C0311400
27241818	64	76	perturbation	T169	C0332453
27241818	84	94	whole body	T017	C0444584
27241818	95	103	exercise	T056	C0015259
27241818	107	113	humans	T016	C0086418
27241818	118	125	purpose	T169	C1285529
27241818	134	139	study	T062	C2603343
27241818	147	156	determine	T059	C1148554
27241818	161	165	role	T077	C1705810
27241818	169	188	group III/IV muscle	T024	C0026845
27241818	189	198	afferents	T025	C0027883
27241818	202	210	limiting	T169	C0439801
27241818	215	224	endurance	T033	C0518031
27241818	225	233	exercise	T056	C0015259
27241818	236	243	induced	T169	C0205263
27241818	244	253	metabolic	T169	C0311400
27241818	254	266	perturbation	T169	C0332453
27241818	267	274	assayed	T059	C1510438
27241818	278	284	muscle	T024	C0026845
27241818	285	299	biopsy samples	T024	C0677862
27241818	311	320	locomotor	T040	C0023946
27241818	321	327	muscle	T024	C0026845
27241818	329	335	Lumbar	T029	C0024090
27241818	336	347	intrathecal	T030	C1370196
27241818	348	356	fentanyl	T109,T121	C0015846
27241818	369	378	attenuate	T052	C0599946
27241818	383	390	central	T082	C0205099
27241818	391	401	projection	T082	C0348018
27241818	405	422	Î¼-opioid receptor	T116,T192	C0066908
27241818	425	434	sensitive	T169	C0332324
27241818	435	444	locomotor	T040	C0023946
27241818	445	451	muscle	T024	C0026845
27241818	452	461	afferents	T025	C0027883
27241818	476	483	cycling	T079	C1511572
27241818	484	488	time	T079	C0040223
27241818	489	494	trial	T062	C0008976
27241818	500	508	findings	T033	C0243095
27241818	526	533	central	T082	C0205099
27241818	534	544	projection	T082	C0348018
27241818	548	567	group III/IV muscle	T024	C0026845
27241818	568	576	afferent	T025	C0027883
27241818	577	585	feedback	T039	C0678663
27241818	586	596	constrains	T077	C1707494
27241818	597	606	voluntary	T055	C0439656
27241818	607	613	neural	T169	C3714606
27241818	616	621	drive	T041	C0013126
27241818	627	634	working	T169	C0205177
27241818	635	644	locomotor	T040	C0023946
27241818	645	651	muscle	T024	C0026845
27241818	656	662	limits	T169	C0439801
27241818	667	675	exercise	T056	C0015259
27241818	678	685	induced	T169	C0205263
27241818	686	699	intramuscular	T082	C0442117
27241818	700	709	metabolic	T169	C0311400
27241818	710	722	perturbation	T169	C0332453
27241818	739	742	CNS	T022	C3714787
27241818	749	757	regulate	T038	C1327622
27241818	762	768	degree	T081	C0449286
27241818	772	781	metabolic	T169	C0311400
27241818	782	794	perturbation	T169	C0332453
27241818	802	811	locomotor	T040	C0023946
27241818	812	818	muscle	T024	C0026845
27241818	831	836	limit	T169	C0439801
27241818	837	847	peripheral	T082	C0205100
27241818	848	855	fatigue	T184	C0015672
27241818	860	867	appears	T080	C0700364
27241818	877	896	group III/IV muscle	T024	C0026845
27241818	897	906	afferents	T025	C0027883
27241818	914	923	important	T080	C3898777
27241818	924	930	neural	T169	C3714606
27241818	931	935	link	T030	C0178718
27241818	944	954	regulatory	T038	C1327622
27241818	955	964	mechanism	T169	C0441712
27241818	972	980	probably	T078	C0750492
27241818	991	998	protect	T033	C1545588
27241818	999	1008	locomotor	T040	C0023946
27241818	1009	1015	muscle	T024	C0026845
27241818	1025	1036	potentially	T080	C3245505
27241818	1037	1043	severe	T080	C0205082
27241818	1044	1065	functional impairment	T033	C4062321
27241818	1071	1082	consequence	T169	C0686907
27241818	1086	1092	severe	T080	C0205082
27241818	1093	1106	intramuscular	T082	C0442117
27241818	1107	1116	metabolic	T169	C0311400
27241818	1117	1128	disturbance	T080	C2699787
27241818	1133	1144	investigate	T169	C1292732
27241818	1149	1153	role	T077	C1705810
27241818	1157	1163	metabo	T040	C0025519
27241818	1170	1186	mechanosensitive	T080	C1522640
27241818	1187	1206	group III/IV muscle	T024	C0026845
27241818	1207	1216	afferents	T025	C0027883
27241818	1220	1228	limiting	T169	C0439801
27241818	1233	1246	intramuscular	T082	C0442117
27241818	1247	1256	metabolic	T169	C0311400
27241818	1257	1269	perturbation	T169	C0332453
27241818	1277	1287	whole body	T017	C0444584
27241818	1288	1297	endurance	T033	C0518031
27241818	1298	1306	exercise	T056	C0015259
27241818	1314	1322	subjects	T096	C0681850
27241818	1323	1332	performed	T169	C0884358
27241818	1338	1345	cycling	T079	C1511572
27241818	1346	1350	time	T079	C0040223
27241818	1351	1357	trials	T062	C0008976
27241818	1358	1382	under control conditions	T033	C2911690
27241818	1384	1388	CTRL	T033	C2911690
27241818	1399	1405	lumbar	T029	C0024090
27241818	1406	1417	intrathecal	T030	C1370196
27241818	1418	1426	fentanyl	T109,T121	C0015846
27241818	1427	1436	impairing	T169	C0221099
27241818	1437	1447	lower limb	T023	C0023216
27241818	1448	1454	muscle	T024	C0026845
27241818	1455	1463	afferent	T025	C0027883
27241818	1464	1472	feedback	T039	C0678663
27241818	1474	1478	FENT	T039	C0678663
27241818	1481	1497	Vastus lateralis	T023	C0224444
27241818	1498	1504	muscle	T024	C0026845
27241818	1505	1513	biopsies	T024	C0677862
27241818	1519	1527	obtained	T169	C1301820
27241818	1528	1534	before	T079	C0332152
27241818	1539	1550	immediately	T079	C0205253
27241818	1551	1556	after	T079	C0687676
27241818	1557	1565	exercise	T056	C0015259
27241818	1567	1579	Motoneuronal	T025	C0026609
27241818	1580	1600	output was estimated	T060	C0204709
27241818	1609	1633	vastus lateralis surface	T023	C0224444
27241818	1634	1650	electromyography	T060	C0013839
27241818	1652	1655	EMG	T060	C0013839
27241818	1658	1666	Exercise	T056	C0015259
27241818	1669	1676	induced	T169	C0205263
27241818	1677	1684	changes	T169	C0392747
27241818	1688	1701	intramuscular	T082	C0442117
27241818	1702	1713	metabolites	T123	C0870883
27241818	1719	1728	determine	T059	C1148554
27241818	1737	1743	liquid	T167	C0302908
27241818	1748	1784	gas chromatography-mass spectrometry	T059	C1720784
27241818	1786	1796	Quadriceps	T023	C0224440
27241818	1797	1804	fatigue	T184	C0015672
27241818	1809	1819	quantified	T081	C1709793
27241818	1823	1826	pre	T079	C0332152
27241818	1832	1836	post	T079	C0687676
27241818	1839	1847	exercise	T056	C0015259
27241818	1848	1855	changes	T169	C0392747
27241818	1859	1895	potentiated quadriceps twitch torque	T067	C0376590
27241818	1897	1906	ÎQTsingle	T067	C0376590
27241818	1908	1914	evoked	T080	C1444748
27241818	1918	1928	electrical	T169	C0442828
27241818	1929	1942	femoral nerve	T023	C0015808
27241818	1943	1954	stimulation	T061	C1292856
27241818	1965	1977	motoneuronal	T025	C0026609
27241818	1978	1984	output	T052	C0441655
27241818	1998	2004	higher	T080	C0205250
27241818	2012	2016	FENT	T039	C0678663
27241818	2017	2025	compared	T052	C1707455
27241818	2029	2033	CTRL	T033	C2911690
27241818	2046	2050	time	T079	C0040223
27241818	2054	2062	complete	T080	C0205197
27241818	2067	2071	time	T079	C0040223
27241818	2072	2077	trial	T062	C0008976
27241818	2082	2089	similar	T080	C2348205
27241818	2102	2110	Compared	T052	C1707455
27241818	2114	2118	CTRL	T033	C2911690
27241818	2120	2132	power output	T070	C0445194
27241818	2140	2144	FENT	T039	C0678663
27241818	2157	2163	higher	T080	C0205250
27241818	2171	2181	first half	T033	C3843058
27241818	2189	2193	time	T079	C0040223
27241818	2194	2199	trial	T062	C0008976
27241818	2213	2218	lower	T080	C0205251
27241818	2226	2237	second half	T033	C3843057
27241818	2259	2267	exercise	T056	C0015259
27241818	2270	2277	induced	T169	C0205263
27241818	2278	2286	increase	T169	C0442805
27241818	2290	2303	intramuscular	T082	C0442117
27241818	2304	2323	inorganic phosphate	T121,T197	C0031603
27241818	2325	2329	H(+)	T196	C0033727
27241818	2331	2352	adenosine diphosphate	T114,T123	C0001459
27241818	2354	2361	lactate	T109	C0022924
27241818	2366	2381	phosphocreatine	T116,T121,T123	C0031634
27241818	2382	2391	depletion	T169	C0333668
27241818	2468	2475	greater	T081	C1704243
27241818	2479	2483	FENT	T039	C0678663
27241818	2489	2493	CTRL	T033	C2911690
27241818	2495	2504	ÎQTsingle	T067	C0376590
27241818	2509	2516	greater	T081	C1704243
27241818	2527	2531	FENT	T039	C0678663
27241818	2537	2541	CTRL	T033	C2911690
27241818	2584	2594	difference	T081	C1705241
27241818	2599	2609	positively	T033	C1446409
27241818	2610	2620	correlated	T080	C1707520
27241818	2630	2640	difference	T081	C1705241
27241818	2644	2663	inorganic phosphate	T121,T197	C0031603
27241818	2725	2735	conclusion	T078	C1707478
27241818	2744	2754	whole body	T017	C0444584
27241818	2755	2763	exercise	T056	C0015259
27241818	2765	2784	group III/IV muscle	T024	C0026845
27241818	2785	2794	afferents	T025	C0027883
27241818	2795	2802	provide	T052	C1999230
27241818	2803	2811	feedback	T039	C0678663
27241818	2819	2822	CNS	T022	C3714787
27241818	2839	2849	constrains	T077	C1707494
27241818	2850	2862	motoneuronal	T025	C0026609
27241818	2863	2869	output	T052	C0441655
27241818	2877	2883	active	T169	C0205177
27241818	2884	2899	skeletal muscle	T024	C0242692
27241818	2906	2916	regulatory	T038	C1327622
27241818	2917	2926	mechanism	T169	C0441712
27241818	2927	2933	limits	T169	C0439801
27241818	2938	2946	exercise	T056	C0015259
27241818	2949	2956	induced	T169	C0205263
27241818	2957	2970	intramuscular	T082	C0442117
27241818	2971	2980	metabolic	T169	C0311400
27241818	2981	2993	perturbation	T169	C0332453
27241818	3009	3029	abnormal homeostatic	T033	C4022950
27241818	3030	3039	challenge	T058	C0805586
27241818	3044	3053	excessive	T080	C0442802
27241818	3054	3064	peripheral	T082	C0205100
27241818	3065	3072	fatigue	T184	C0015672

27242101|t|Incidence of crown fracture and risk factors in the primary dentition: a prospective longitudinal study
27242101|a|Few studies have assessed the incidence and risk factors to crown fractures in preschool children. The aim of this study was to estimate the incidence of crown fracture in the primary dentition over a 1-year follow-up period, identify risk factors, and test the hypothesis that children with previous crown fracture are more prone to experience further cases of crown fracture independently of other risk factors. This study was developed in two phases: cross-sectional and prospective longitudinal study. The cross-sectional study was carried out 261 preschool children. The prospective longitudinal study was carried out 194 children allocated to two groups: exposed group (children with prior exposure to crown fracture) and non - exposed group (children without prior exposure). On both occasions, children were examined for the diagnosis of crown fracture and evaluation of lip coverage and overjet. The parents were interviewed with regard to the socioeconomic indicators. New cases of crown fracture were identified based on the comparison of the two examinations. Data analysis involved Pearson's chi-square test, McNemar's test, and Poisson regression with robust variance. Among the 261 children who participated in the cross-sectional study, 194 were re-examined (65 in the exposed group and 129 in the non - exposed group). The overall incidence of crown fracture was 55.7% (n = 108). The difference in percentage of increased risk of crown fracture in exposed and non - exposed groups was 13.4%. A greater incidence of crown fracture was found in the exposed group (64.6%; P < 0,001). The children exposed (RR: 1.30; 95% CI: 1.01-1.67) had a greater risk of developing new cases of crown fracture in comparison with the non - exposed group. The incidence of crown fracture was high and children with previous crown fracture had a greater risk of suffering new cases of crown fracture during the 1-year follow-up period.
27242101	0	9	Incidence	T081	C0021149
27242101	13	27	crown fracture	T037	C0458012
27242101	32	44	risk factors	T033	C0035648
27242101	52	69	primary dentition	T023	C3266841
27242101	73	103	prospective longitudinal study	T062	C0023981
27242101	134	143	incidence	T081	C0021149
27242101	148	160	risk factors	T033	C0035648
27242101	164	179	crown fractures	T037	C0458012
27242101	183	201	preschool children	T100	C0008100
27242101	245	254	incidence	T081	C0021149
27242101	258	272	crown fracture	T037	C0458012
27242101	280	297	primary dentition	T023	C3266841
27242101	312	321	follow-up	T058	C1522577
27242101	322	328	period	T079	C1948053
27242101	339	351	risk factors	T033	C0035648
27242101	366	376	hypothesis	T078	C1512571
27242101	382	390	children	T100	C0008059
27242101	396	404	previous	T079	C0205156
27242101	405	419	crown fracture	T037	C0458012
27242101	466	480	crown fracture	T037	C0458012
27242101	504	516	risk factors	T033	C0035648
27242101	558	573	cross-sectional	T062	C0010362
27242101	578	608	prospective longitudinal study	T062	C0023981
27242101	614	635	cross-sectional study	T062	C0010362
27242101	656	674	preschool children	T100	C0008100
27242101	680	710	prospective longitudinal study	T062	C0023981
27242101	731	739	children	T100	C0008059
27242101	765	778	exposed group	T098	C2348484
27242101	780	788	children	T100	C0008059
27242101	800	811	exposure to	T080	C0332157
27242101	812	826	crown fracture	T037	C0458012
27242101	832	835	non	T033	C1513916
27242101	838	851	exposed group	T098	C2348484
27242101	853	861	children	T100	C0008059
27242101	876	884	exposure	T080	C0332157
27242101	906	914	children	T100	C0008059
27242101	937	946	diagnosis	T033	C0011900
27242101	950	964	crown fracture	T037	C0458012
27242101	983	986	lip	T023	C0023759
27242101	1000	1007	overjet	T190	C0596028
27242101	1057	1081	socioeconomic indicators	T078	C1711331
27242101	1096	1110	crown fracture	T037	C0458012
27242101	1176	1189	Data analysis	T057	C0010992
27242101	1199	1224	Pearson's chi-square test	T170	C0237913
27242101	1226	1240	McNemar's test	T170	C0237913
27242101	1246	1264	Poisson regression	T170	C0034980
27242101	1270	1276	robust	T080	C2986815
27242101	1277	1285	variance	T080	C1711260
27242101	1301	1309	children	T100	C0008059
27242101	1334	1355	cross-sectional study	T062	C0010362
27242101	1389	1402	exposed group	T098	C2348484
27242101	1418	1421	non	T033	C1513916
27242101	1424	1437	exposed group	T098	C2348484
27242101	1452	1461	incidence	T081	C0021149
27242101	1465	1479	crown fracture	T037	C0458012
27242101	1533	1550	increased risk of	T033	C0332167
27242101	1551	1565	crown fracture	T037	C0458012
27242101	1581	1584	non	T033	C1513916
27242101	1587	1601	exposed groups	T098	C2348484
27242101	1623	1632	incidence	T081	C0021149
27242101	1636	1650	crown fracture	T037	C0458012
27242101	1706	1714	children	T100	C0008059
27242101	1759	1774	greater risk of	T033	C0332167
27242101	1799	1813	crown fracture	T037	C0458012
27242101	1837	1840	non	T033	C1513916
27242101	1843	1856	exposed group	T098	C2348484
27242101	1862	1871	incidence	T081	C0021149
27242101	1875	1889	crown fracture	T037	C0458012
27242101	1903	1911	children	T100	C0008059
27242101	1917	1925	previous	T079	C0205156
27242101	1926	1940	crown fracture	T037	C0458012
27242101	1947	1962	greater risk of	T033	C0332167
27242101	1986	2000	crown fracture	T037	C0458012
27242101	2019	2028	follow-up	T058	C1522577
27242101	2029	2035	period	T079	C1948053

27242395|t|An Efficient and Reliable Statistical Method for Estimating Functional Connectivity in Large Scale Brain Networks Using Partial Correlation
27242395|a|Currently, network-oriented analysis of fMRI data has become an important tool for understanding brain organization and brain networks. Among the range of network modeling methods, partial correlation has shown great promises in accurately detecting true brain network connections. However, the application of partial correlation in investigating brain connectivity, especially in large-scale brain networks, has been limited so far due to the technical challenges in its estimation. In this paper, we propose an efficient and reliable statistical method for estimating partial correlation in large-scale brain network modeling. Our method derives partial correlation based on the precision matrix estimated via Constrained L1-minimization Approach (CLIME), which is a recently developed statistical method that is more efficient and demonstrates better performance than the existing methods. To help select an appropriate tuning parameter for sparsity control in the network estimation, we propose a new Dens-based selection method that provides a more informative and flexible tool to allow the users to select the tuning parameter based on the desired sparsity level. Another appealing feature of the Dens-based method is that it is much faster than the existing methods, which provides an important advantage in neuroimaging applications. Simulation studies show that the Dens-based method demonstrates comparable or better performance with respect to the existing methods in network estimation. We applied the proposed partial correlation method to investigate resting state functional connectivity using rs-fMRI data from the Philadelphia Neurodevelopmental Cohort (PNC) study. Our results show that partial correlation analysis removed considerable between-module marginal connections identified by full correlation analysis, suggesting these connections were likely caused by global effects or common connection to other nodes. Based on partial correlation, we find that the most significant direct connections are between homologous brain locations in the left and right hemisphere. When comparing partial correlation derived under different sparse tuning parameters, an important finding is that the sparse regularization has more shrinkage effects on negative functional connections than on positive connections, which supports previous findings that many of the negative brain connections are due to non-neurophysiological effects. An R package "DensParcorr" can be downloaded from CRAN for implementing the proposed statistical methods.
27242395	3	12	Efficient	T080	C0442799
27242395	17	25	Reliable	T080	C0205556
27242395	26	44	Statistical Method	T062	C1710191
27242395	49	59	Estimating	T081	C0750572
27242395	60	70	Functional	T169	C0205245
27242395	71	83	Connectivity	T082	C0449379
27242395	99	104	Brain	T023	C0006104
27242395	105	113	Networks	T040	C0598941
27242395	120	127	Partial	T081	C0728938
27242395	128	139	Correlation	T080	C1707520
27242395	151	167	network-oriented	T040	C0598941
27242395	168	176	analysis	T062	C0936012
27242395	180	184	fMRI	T060	C0376335
27242395	185	189	data	T078	C1511726
27242395	204	218	important tool	T073	C2827396
27242395	237	242	brain	T023	C0006104
27242395	243	255	organization	T039	C0029237
27242395	260	265	brain	T023	C0006104
27242395	266	274	networks	T040	C0598941
27242395	295	302	network	T040	C0598941
27242395	303	319	modeling methods	T170	C1554090
27242395	321	328	partial	T081	C0728938
27242395	329	340	correlation	T080	C1707520
27242395	380	389	detecting	T033	C0442726
27242395	395	400	brain	T023	C0006104
27242395	401	408	network	T040	C0598941
27242395	409	420	connections	T082	C0449379
27242395	450	457	partial	T081	C0728938
27242395	458	469	correlation	T080	C1707520
27242395	473	486	investigating	T169	C1292732
27242395	487	492	brain	T023	C0006104
27242395	493	505	connectivity	T082	C0449379
27242395	533	538	brain	T023	C0006104
27242395	539	547	networks	T040	C0598941
27242395	584	604	technical challenges	T067	C1710348
27242395	612	622	estimation	T081	C0750572
27242395	653	662	efficient	T080	C0442799
27242395	667	675	reliable	T080	C0205556
27242395	676	694	statistical method	T062	C1710191
27242395	699	709	estimating	T081	C0750572
27242395	710	717	partial	T081	C0728938
27242395	718	729	correlation	T080	C1707520
27242395	745	750	brain	T023	C0006104
27242395	751	758	network	T040	C0598941
27242395	759	767	modeling	T062	C0870071
27242395	773	779	method	T170	C0025663
27242395	788	795	partial	T081	C0728938
27242395	796	807	correlation	T080	C1707520
27242395	821	847	precision matrix estimated	T081	C0750572
27242395	852	888	Constrained L1-minimization Approach	T062	C1710191
27242395	890	895	CLIME	T062	C1710191
27242395	928	946	statistical method	T062	C1710191
27242395	960	969	efficient	T080	C0442799
27242395	994	1005	performance	T052	C1882330
27242395	1024	1031	methods	T170	C0025663
27242395	1063	1079	tuning parameter	T077	C0549193
27242395	1093	1100	control	T080	C0243148
27242395	1108	1115	network	T040	C0598941
27242395	1116	1126	estimation	T081	C0750572
27242395	1145	1172	Dens-based selection method	T062	C1710191
27242395	1194	1205	informative	T080	C2986490
27242395	1210	1218	flexible	T080	C0443220
27242395	1219	1223	tool	T170	C0037589
27242395	1257	1273	tuning parameter	T077	C0549193
27242395	1295	1303	sparsity	T082	C1254362
27242395	1304	1309	level	T080	C0441889
27242395	1344	1361	Dens-based method	T062	C1710191
27242395	1406	1413	methods	T170	C0025663
27242395	1456	1481	neuroimaging applications	T060	C0679575
27242395	1483	1501	Simulation studies	T062	C0679083
27242395	1516	1533	Dens-based method	T062	C1710191
27242395	1568	1579	performance	T052	C1882330
27242395	1609	1616	methods	T170	C0025663
27242395	1620	1627	network	T040	C0598941
27242395	1628	1638	estimation	T081	C0750572
27242395	1664	1671	partial	T081	C0728938
27242395	1672	1683	correlation	T080	C1707520
27242395	1684	1690	method	T170	C0025663
27242395	1694	1705	investigate	T169	C1292732
27242395	1706	1762	resting state functional connectivity using rs-fMRI data	T060	C4288291
27242395	1772	1822	Philadelphia Neurodevelopmental Cohort (PNC) study	T081	C0009247
27242395	1828	1835	results	T169	C1274040
27242395	1846	1853	partial	T081	C0728938
27242395	1854	1865	correlation	T080	C1707520
27242395	1866	1874	analysis	T062	C0936012
27242395	1911	1931	marginal connections	T082	C0449379
27242395	1951	1971	correlation analysis	T062,T170	C0010101
27242395	1990	2001	connections	T082	C0449379
27242395	2049	2059	connection	T082	C0449379
27242395	2069	2074	nodes	T023	C0746922
27242395	2085	2092	partial	T081	C0728938
27242395	2093	2104	correlation	T080	C1707520
27242395	2147	2158	connections	T082	C0449379
27242395	2182	2187	brain	T023	C0006104
27242395	2188	2197	locations	T029	C1515974
27242395	2205	2209	left	T023	C0228176
27242395	2214	2230	right hemisphere	T023	C0228175
27242395	2247	2254	partial	T081	C0728938
27242395	2255	2266	correlation	T080	C1707520
27242395	2291	2297	sparse	T082	C1254362
27242395	2298	2315	tuning parameters	T077	C0549193
27242395	2381	2398	shrinkage effects	T169	C0332513
27242395	2402	2410	negative	T033	C0205160
27242395	2411	2421	functional	T169	C0205245
27242395	2422	2433	connections	T082	C0449379
27242395	2442	2450	positive	T033	C1446409
27242395	2451	2462	connections	T082	C0449379
27242395	2514	2522	negative	T033	C0205160
27242395	2523	2528	brain	T023	C0006104
27242395	2529	2540	connections	T082	C0449379
27242395	2552	2582	non-neurophysiological effects	T039	C1372849
27242395	2587	2610	R package "DensParcorr"	T170	C0037589
27242395	2634	2638	CRAN	T170	C0282574
27242395	2669	2688	statistical methods	T062	C1710191

27242550|t|Mitochondrial Ultrastructure and Glucose Signaling Pathways Attributed to the Kv1.3 Ion Channel
27242550|a|Gene-targeted deletion of the potassium channel Kv1.3 (Kv1.3(-â-)) results i n "S uper-smeller" mice with a se nsory p h enotype t hat includes an increased olfactory ability linked to changes in olfactory circuitry, increased abundance of olfactory cilia, and increased expression of odorant receptors and the G-protein, Golf. Kv1.3(-â-) mice a lso have a metabolic p h enotype i ncluding lo wer b o dy weight a nd de creased a d iposity, in creased total energy expenditure (TEE), increased locomotor activity, and resistance to both diet - and genetic-induced obesity. We explored two cellular aspects to elucidate the mechanism by which loss of Kv1.3 channel in the olfactory bulb (OB) may enhance glucose utilization and metabolic rate. First, using in situ hybridization we find that Kv1.3 and the insulin - dependent glucose transporter type 4 (GLUT4) are co-localized to the mitral cell layer of the OB. Disruption of Kv1.3 conduction via construction of a pore mutation (W386F Kv1.3) was sufficient to independently translocate GLUT4 to the plasma membrane in HEK 293 cells. Because olfactory sensory perception and the maintenance of action potential (AP) firing frequency by mitral cells of the OB is highly energy demanding and Kv1.3 is also expressed in mitochondria, we next explored the structure of this organelle in mitral cells. We challenged wildtype (WT) and Kv1.3(-â-) male mice with a m oderately high-fat diet (M HF, 31.8 % kcal fat) for 4 months and then examined OB ultrastructure using transmission electron microscopy. In WT mice, mitochondria were significantly enlarged following diet-induced obesity (DIO) and there were fewer mitochondria, likely due to mitophagy. Interestingly, mitochondria were significantly smaller in Kv1.3(-â-) mice c ompared with that of W T mice. Similar to their m etabolic r esistance to D IO, the K v1.3(-â-) mice ha d unchanged mit ochondria in terms of cros s sectional area and abundance following a challenge with modified diet. We are very interested to understand how targeted disruption of the Kv1.3 channel in the OB can modify TEE. Our study demonstrates that Kv1.3 regulates mitochondrial structure and alters glucose utilization; two important metabolic changes that could drive whole system changes in metabolism initiated at the OB.
27242550	0	13	Mitochondrial	T026	C0026237
27242550	14	28	Ultrastructure	T025	C3825563
27242550	33	59	Glucose Signaling Pathways	T044	C1622453
27242550	78	95	Kv1.3 Ion Channel	T116,T123	C0290730
27242550	96	109	Gene-targeted	T063	C0242613
27242550	110	118	deletion	T045	C0017260
27242550	126	149	potassium channel Kv1.3	T116,T123	C0290730
27242550	151	172	Kv1.3(-â-)) results i	T034	C0456984
27242550	178	196	uper-smeller" mice	T015	C0025929
27242550	207	214	nsory p	T080	C0445254
27242550	217	226	enotype t	T032	C0031437
27242550	243	252	increased	T081	C0205217
27242550	253	262	olfactory	T040	C0439826
27242550	263	270	ability	T032	C0085732
27242550	292	301	olfactory	T040	C0439826
27242550	302	311	circuitry	UnknownType	C0260041
27242550	313	322	increased	T081	C0205217
27242550	323	332	abundance	T080	C2346714
27242550	336	351	olfactory cilia	T026	C0230758
27242550	357	366	increased	T081	C0205217
27242550	367	377	expression	T045	C0597360
27242550	381	398	odorant receptors	T116,T192	C0164313
27242550	407	422	G-protein, Golf	T116,T123	C0033684
27242550	424	441	Kv1.3(-â-) mice a	T015	C0025929
27242550	453	464	metabolic p	T169	C0311400
27242550	467	476	enotype i	T032	C0031437
27242550	489	494	wer b	T081	C1611820
27242550	497	508	dy weight a	T032	C0005910
27242550	515	524	creased a	T081	C0205216
27242550	527	535	iposity,	T032	C1563743
27242550	539	571	creased total energy expenditure	T033	C0429629
27242550	573	576	TEE	T033	C0429629
27242550	579	588	increased	T081	C0205217
27242550	589	607	locomotor activity	T040	C0023946
27242550	613	623	resistance	T041	C0237834
27242550	632	636	diet	T168	C0012155
27242550	643	658	genetic-induced	T045	C0017391
27242550	659	666	obesity	T047	C0028754
27242550	684	700	cellular aspects	T080	C0935919
27242550	718	727	mechanism	T169	C0441712
27242550	737	741	loss	T081	C1517945
27242550	745	758	Kv1.3 channel	T116,T123	C0290730
27242550	766	780	olfactory bulb	T023	C0028936
27242550	782	784	OB	T023	C0028936
27242550	798	817	glucose utilization	T044	C1148560
27242550	822	836	metabolic rate	T039	C0870882
27242550	851	872	in situ hybridization	T063	C0162788
27242550	886	891	Kv1.3	T116,T123	C0290730
27242550	900	907	insulin	T116,T121,T125	C0021641
27242550	910	919	dependent	T080	C1701901
27242550	920	946	glucose transporter type 4	T116,T123	C0166441
27242550	948	953	GLUT4	T116,T123	C0166441
27242550	979	985	mitral	T023	C0026264
27242550	986	996	cell layer	T025	C0007634
27242550	1004	1006	OB	T023	C0028936
27242550	1008	1018	Disruption	T169	C0332453
27242550	1022	1027	Kv1.3	T116,T123	C0290730
27242550	1028	1038	conduction	T070	C0457405
27242550	1061	1074	pore mutation	T045	C0026882
27242550	1076	1087	W386F Kv1.3	T045	C0026882
27242550	1121	1132	translocate	T043	C0599893
27242550	1133	1138	GLUT4	T116,T123	C0166441
27242550	1146	1161	plasma membrane	T026	C0007603
27242550	1165	1178	HEK 293 cells	T025	C2936239
27242550	1188	1216	olfactory sensory perception	T040	C0037361
27242550	1225	1236	maintenance	T052	C0024501
27242550	1240	1261	action potential (AP)	T043	C0001272
27242550	1282	1288	mitral	T023	C0026264
27242550	1289	1294	cells	T025	C0007634
27242550	1302	1304	OB	T023	C0028936
27242550	1336	1341	Kv1.3	T116,T123	C0290730
27242550	1363	1375	mitochondria	T026	C0026237
27242550	1416	1425	organelle	T026	C0029219
27242550	1429	1435	mitral	T023	C0026264
27242550	1436	1441	cells	T025	C0007634
27242550	1457	1465	wildtype	T015	C1520150
27242550	1467	1469	WT	T015	C1520150
27242550	1475	1495	Kv1.3(-â-) male mice	T015	C0025929
27242550	1505	1530	oderately high-fat diet (	T061	C0521974
27242550	1532	1535	HF,	T061	C0521974
27242550	1559	1565	months	T079	C0439231
27242550	1584	1586	OB	T023	C0028936
27242550	1587	1601	ultrastructure	T025	C3825563
27242550	1608	1640	transmission electron microscopy	T059	C0678118
27242550	1645	1652	WT mice	T015	C1520150
27242550	1654	1666	mitochondria	T026	C0026237
27242550	1686	1694	enlarged	T080	C0442800
27242550	1705	1725	diet-induced obesity	T047	C0028754
27242550	1727	1730	DIO	T047	C0028754
27242550	1753	1765	mitochondria	T026	C0026237
27242550	1781	1790	mitophagy	T043	C1820119
27242550	1807	1819	mitochondria	T026	C0026237
27242550	1839	1846	smaller	T080	C0547044
27242550	1850	1867	Kv1.3(-â-) mice c	T015	C0025929
27242550	1891	1898	T mice.	T015	C1520150
27242550	1918	1928	etabolic r	T169	C0311400
27242550	1944	1947	IO,	T047	C0028754
27242550	1954	1971	v1.3(-â-) mice ha	T015	C0025929
27242550	1988	2000	ochondria in	T026	C0026237
27242550	2015	2026	s sectional	T082	C0552389
27242550	2027	2031	area	T082	C0205146
27242550	2036	2045	abundance	T080	C2346714
27242550	2073	2086	modified diet	T061	C0521974
27242550	2138	2148	disruption	T169	C0332453
27242550	2156	2169	Kv1.3 channel	T116,T123	C0290730
27242550	2177	2179	OB	T023	C0028936
27242550	2191	2194	TEE	T033	C0429629
27242550	2224	2229	Kv1.3	T116,T123	C0290730
27242550	2240	2263	mitochondrial structure	T026	C0026237
27242550	2275	2294	glucose utilization	T044	C1148560
27242550	2310	2319	metabolic	T169	C0311400
27242550	2369	2379	metabolism	T040	C0025519
27242550	2397	2399	OB	T023	C0028936

27242761|t|Cobalamin Protection against Oxidative Stress in the Acidophilic Iron-oxidizing Bacterium Leptospirillum Group II CF-1
27242761|a|Members of the genus Leptospirillum are aerobic iron-oxidizing bacteria belonging to the phylum Nitrospira. They are important members of microbial communities that catalyze the biomining of sulfidic ores, thereby solubilizing metal ions. These microorganisms live under extremely acidic and metal -loaded environments and thus must tolerate high concentrations of reactive oxygen species (ROS). Cobalamin (vitamin B12) is a cobalt -containing tetrapyrrole cofactor involved in intramolecular rearrangement reactions and has recently been suggested to be an intracellular antioxidant. In this work, we investigated the effect of the exogenous addition of cobalamin on oxidative stress parameters in Leptospirillum group II strain CF-1. Our results revealed that the external supplementation of cobalamin reduces the levels of intracellular ROSs and the damage to biomolecules, and also stimulates the growth and survival of cells exposed to oxidative stress exerted by ferric ion, hydrogen peroxide, chromate and diamide. Furthermore, exposure of strain CF-1 to oxidative stress elicitors resulted in the transcriptional activation of the cbiA gene encoding CbiA of the cobalamin biosynthetic pathway. Altogether, these data suggest that cobalamin plays an important role in redox protection of Leptospirillum strain CF-1, supporting survival of this microorganism under extremely oxidative environmental conditions. Understanding the mechanisms underlying the protective effect of cobalamin against oxidative stress may help to develop strategies to make biomining processes more effective.
27242761	0	9	Cobalamin	T114,T127	C0086024
27242761	10	20	Protection	T033	C1545588
27242761	29	45	Oxidative Stress	T049	C0242606
27242761	53	64	Acidophilic	T169	C0333931
27242761	65	89	Iron-oxidizing Bacterium	T007	C0004611
27242761	90	118	Leptospirillum Group II CF-1	T007	C2758310
27242761	140	154	Leptospirillum	T007	C0995279
27242761	159	166	aerobic	T080	C1510824
27242761	167	190	iron-oxidizing bacteria	T007	C0004611
27242761	208	225	phylum Nitrospira	T007	C0995591
27242761	257	266	microbial	T001	C0599840
27242761	267	278	communities	T070	C1253910
27242761	284	292	catalyze	T070	C2350294
27242761	297	306	biomining	T057	C0026175
27242761	310	323	sulfidic ores	T104	C0567321
27242761	346	356	metal ions	T196	C0022023
27242761	364	378	microorganisms	T001	C0445623
27242761	411	416	metal	T197	C0025552
27242761	425	437	environments	T082	C0014406
27242761	466	480	concentrations	T081	C1446561
27242761	484	507	reactive oxygen species	T123,T196	C0162772
27242761	509	512	ROS	T123,T196	C0162772
27242761	515	524	Cobalamin	T114,T127	C0086024
27242761	526	537	vitamin B12	T109,T121,T127	C0042845
27242761	544	550	cobalt	T123,T196	C0009148
27242761	563	575	tetrapyrrole	T109,T123	C0076335
27242761	576	584	cofactor	T123	C0178555
27242761	597	635	intramolecular rearrangement reactions	T067	C0596965
27242761	677	690	intracellular	T082	C0178719
27242761	691	702	antioxidant	T121	C0003402
27242761	721	733	investigated	T169	C1292732
27242761	738	744	effect	T080	C1280500
27242761	752	761	exogenous	T169	C0205228
27242761	774	783	cobalamin	T114,T127	C0086024
27242761	787	803	oxidative stress	T049	C0242606
27242761	804	814	parameters	T077	C0549193
27242761	818	853	Leptospirillum group II strain CF-1	T007	C2758310
27242761	867	875	revealed	T080	C0443289
27242761	885	909	external supplementation	T168	C0681579
27242761	913	922	cobalamin	T114,T127	C0086024
27242761	945	958	intracellular	T082	C0178719
27242761	959	963	ROSs	T123,T196	C0162772
27242761	972	978	damage	T169	C1883709
27242761	982	994	biomolecules	T123	C0574031
27242761	1005	1015	stimulates	T070	C1948023
27242761	1020	1026	growth	T040	C0018270
27242761	1031	1048	survival of cells	T043	C0007620
27242761	1060	1076	oxidative stress	T049	C0242606
27242761	1088	1098	ferric ion	T196	C2346593
27242761	1100	1117	hydrogen peroxide	T121,T130,T197	C0020281
27242761	1119	1127	chromate	T197	C0008543
27242761	1132	1139	diamide	T109,T121,T130	C0011953
27242761	1166	1177	strain CF-1	T007	C0995279
27242761	1181	1197	oxidative stress	T049	C0242606
27242761	1224	1250	transcriptional activation	T045	C0162493
27242761	1258	1267	cbiA gene	T028	C0017337
27242761	1277	1281	CbiA	T116,T123	C0033684
27242761	1289	1298	cobalamin	T114,T127	C0086024
27242761	1299	1319	biosynthetic pathway	T044	C1721101
27242761	1339	1343	data	T078	C1511726
27242761	1357	1366	cobalamin	T114,T127	C0086024
27242761	1394	1399	redox	T044	C0030012
27242761	1400	1410	protection	T033	C1545588
27242761	1414	1440	Leptospirillum strain CF-1	T007	C0995279
27242761	1470	1483	microorganism	T001	C0445623
27242761	1500	1509	oxidative	T169	C0311404
27242761	1510	1534	environmental conditions	T080	C0348080
27242761	1554	1564	mechanisms	T169	C0441712
27242761	1580	1590	protective	T033	C1545588
27242761	1591	1597	effect	T080	C1280500
27242761	1601	1610	cobalamin	T114,T127	C0086024
27242761	1619	1635	oxidative stress	T049	C0242606
27242761	1675	1684	biomining	T057	C0026175
27242761	1685	1694	processes	T067	C1522240
27242761	1700	1709	effective	T080	C1704419

27242865|t|Metabolite Profiling of Italian Tomato Landraces with Different Fruit Types
27242865|a|Increased interest toward traditional tomato varieties is fueled by the need to rescue desirable organoleptic traits and to improve the quality of fresh and processed tomatoes in the market. In addition, the phenotypic and genetic variation preserved in tomato landraces represents a means to understand the genetic basis of traits related to health and organoleptic aspects and improve them in modern varieties. To establish a framework for this approach, we studied the content of several metabolites in a panel of Italian tomato landraces categorized into three broad fruit type classes (flattened / ribbed, pear / oxheart, round / elongate). Three modern hybrids, corresponding to the three fruit shape typologies, were included as reference. Red ripe fruits were morphologically characterized and biochemically analyzed for their content in glycoalkaloids, phenols, amino acids, and Amadori products. The round / elongate types showed a higher content in glycoalkaloids, whereas flattened types had higher levels of phenolic compounds. Flattened tomatoes were also rich in total amino acids and in particular in glutamic acid. Multivariate analysis of amino acid content clearly separated the three classes of fruit types. Making allowance of the very low number of genotypes, phenotype-marker relationships were analyzed after retrieving single nucleotide polymorphisms (SNPs) among the landraces available in the literature. Sixty-six markers were significantly associated with the studied traits. The positions of several of these SNPs showed correspondence with already described genomic regions and QTLs supporting the reliability of the association. Overall the data indicated that significant changes in quality -related metabolites occur depending on the genetic background in traditional tomato germplasm, frequently according to specific fruit shape categories. Such a variability is suitable to harness association mapping for metabolic quality traits using this germplasm as an experimental population, paving the way for investigating their genetic / molecular basis, and facilitating breeding for quality-related compounds in tomato fruits.
27242865	0	10	Metabolite	T123	C0870883
27242865	11	20	Profiling	T169	C2003903
27242865	24	31	Italian	T083	C0022277
27242865	32	38	Tomato	T168	C0242772
27242865	39	48	Landraces	T077	C1883525
27242865	64	69	Fruit	T168	C0016767
27242865	70	75	Types	T080	C0332307
27242865	102	113	traditional	T169	C0443324
27242865	114	120	tomato	T168	C0242772
27242865	121	130	varieties	T077	C1883525
27242865	173	192	organoleptic traits	T080	C0205556
27242865	200	207	improve	T033	C0184511
27242865	212	219	quality	T080	C0332306
27242865	223	228	fresh	T080	C0443224
27242865	243	251	tomatoes	T168	C0242772
27242865	259	265	market	T083	C1318228
27242865	284	294	phenotypic	T032	C0031437
27242865	299	316	genetic variation	T070	C0042333
27242865	330	336	tomato	T168	C0242772
27242865	337	346	landraces	T077	C1883525
27242865	384	397	genetic basis	T169	C0314603
27242865	401	407	traits	T032	C0599883
27242865	419	425	health	T078	C0018684
27242865	430	450	organoleptic aspects	T080	C0205556
27242865	471	487	modern varieties	T077	C1883525
27242865	536	543	studied	T062	C2603343
27242865	567	578	metabolites	T123	C0870883
27242865	593	600	Italian	T083	C0022277
27242865	601	607	tomato	T168	C0242772
27242865	608	617	landraces	T077	C1883525
27242865	647	652	fruit	T168	C0016767
27242865	667	676	flattened	T169	C0016203
27242865	679	685	ribbed	T169	C0205245
27242865	687	691	pear	T168	C1138601
27242865	694	701	oxheart	T168	C0016767
27242865	703	708	round	T082	C0332490
27242865	711	719	elongate	T080	C0205166
27242865	728	742	modern hybrids	T001	C0020205
27242865	771	776	fruit	T168	C0016767
27242865	777	782	shape	T082	C0332479
27242865	783	793	typologies	T170	C0237936
27242865	812	821	reference	T077	C1706462
27242865	823	838	Red ripe fruits	T168	C0016767
27242865	844	859	morphologically	T082	C0543482
27242865	860	873	characterized	T052	C1880022
27242865	878	900	biochemically analyzed	T059	C0850997
27242865	922	936	glycoalkaloids	T109,T121	C0002062
27242865	938	945	phenols	T109,T121	C0031428
27242865	947	958	amino acids	T116,T121,T123	C0002520
27242865	964	980	Amadori products	T109	C0029224
27242865	986	991	round	T082	C0332490
27242865	994	1002	elongate	T080	C0205166
27242865	1036	1050	glycoalkaloids	T109,T121	C0002062
27242865	1060	1069	flattened	T169	C0016203
27242865	1097	1115	phenolic compounds	T109,T121	C0031428
27242865	1117	1126	Flattened	T169	C0016203
27242865	1127	1135	tomatoes	T168	C0242772
27242865	1146	1150	rich	T080	C0699759
27242865	1160	1171	amino acids	T116,T121,T123	C0002520
27242865	1193	1206	glutamic acid	T116,T121,T123	C0061472
27242865	1208	1229	Multivariate analysis	T081	C0026777
27242865	1233	1251	amino acid content	T059	C1328436
27242865	1291	1296	fruit	T168	C0016767
27242865	1347	1356	genotypes	T032	C0017431
27242865	1358	1374	phenotype-marker	T032	C0031437
27242865	1375	1388	relationships	T080	C0439849
27242865	1394	1402	analyzed	T062	C0936012
27242865	1420	1451	single nucleotide polymorphisms	T086	C0752046
27242865	1453	1457	SNPs	T086	C0752046
27242865	1469	1478	landraces	T077	C1883525
27242865	1496	1506	literature	T170	C0023866
27242865	1518	1525	markers	T086	C0012872
27242865	1531	1560	significantly associated with	T080	C0332281
27242865	1565	1572	studied	T062	C2603343
27242865	1573	1579	traits	T032	C0599883
27242865	1615	1619	SNPs	T086	C0752046
27242865	1665	1680	genomic regions	T077	C1517520
27242865	1685	1689	QTLs	T028	C0597336
27242865	1749	1753	data	T078	C1511726
27242865	1792	1799	quality	T080	C0332306
27242865	1809	1820	metabolites	T123	C0870883
27242865	1844	1862	genetic background	T032	C4042916
27242865	1866	1877	traditional	T169	C0443324
27242865	1878	1884	tomato	T168	C0242772
27242865	1885	1894	germplasm	T026	C1820078
27242865	1929	1934	fruit	T168	C0016767
27242865	1935	1940	shape	T082	C0332479
27242865	1995	2014	association mapping	T052	C1283195
27242865	2019	2028	metabolic	T169	C0311400
27242865	2029	2036	quality	T080	C0332306
27242865	2037	2043	traits	T032	C0599883
27242865	2055	2064	germplasm	T026	C1820078
27242865	2071	2083	experimental	T080	C1517586
27242865	2084	2094	population	T081	C0032659
27242865	2115	2128	investigating	T169	C1292732
27242865	2135	2142	genetic	T169	C0314603
27242865	2145	2160	molecular basis	T078	C1853126
27242865	2179	2187	breeding	T040	C0006159
27242865	2192	2207	quality-related	T080	C0332306
27242865	2208	2217	compounds	T103	C1706082
27242865	2221	2227	tomato	T168	C0242772
27242865	2228	2234	fruits	T168	C0016767

27243664|t|Cross-reactivity features of deoxynivalenol (DON)-targeted immunoaffinity columns aiming to achieve simultaneous analysis of DON and major conjugates in cereal samples
27243664|a|Immunoafï¬nity columns (IACs) are a well-established tool in the determination of regulated mycotoxins in food and feed commodities. However, they also have the potential to become attractive pre-concentration and clean-up materials for the determination of masked (also called modified) mycotoxins, which have been recognised as important contributors to the toxicological hazard deriving from fungal spoilage of goods. However, the information available in the literature concerning the cross-reactivity of DON - IACs against the major conjugates (DON-3-G, 15-AcDON and 3-AcDON) is incomplete and often contradictory. We have carried out a detailed characterisation of the cross-reactivity of the four main IACs brands against DON and its conjugates as well as an assessment of the competition among the analytes. Only one IAC enabled the simultaneous analysis of all relevant DON forms while two missed 15-AcDON and the fourth one missed DON-3-G and 3-AcDON. In the case of the multivalent IAC, the analytes modified at the C-3 position compete for the antibody binding with preference for 3-AcDON (less spatially hindered) while DON-3-G has the more-hindered access to the active sites. Taking into consideration the levels of DON conjugates existing in real samples, the cross-reactivity of one DON - IAC allows a quantitative analysis of all of these analytes. Important but rather neglected aspects such as the continuous supply of IACs with identical characteristics, and of columns which are strictly blank, are also addressed in this paper.
27243664	0	16	Cross-reactivity	T044	C0010357
27243664	29	43	deoxynivalenol	T109,T131	C0057445
27243664	45	48	DON	T109,T131	C0057445
27243664	59	73	immunoaffinity	T059	C0596751
27243664	74	81	columns	T074	C0179909
27243664	100	112	simultaneous	T079	C0521115
27243664	113	121	analysis	T059	C0002778
27243664	125	128	DON	T109,T131	C0057445
27243664	139	149	conjugates	T104	C0243072
27243664	153	159	cereal	T168	C0007757
27243664	160	167	samples	T167	C0444315
27243664	168	181	Immunoafï¬nity	T059	C0596751
27243664	182	189	columns	T074	C0179909
27243664	191	195	IACs	T074	C0179909
27243664	259	269	mycotoxins	T109,T131	C0026955
27243664	273	277	food	T168	C0016452
27243664	282	298	feed commodities	T168	C0016452
27243664	359	376	pre-concentration	T052	C2003864
27243664	381	399	clean-up materials	T073	C0589473
27243664	455	465	mycotoxins	T109,T131	C0026955
27243664	527	540	toxicological	T038	C4042799
27243664	541	547	hazard	T080	C0598697
27243664	562	568	fungal	T169	C0521033
27243664	569	577	spoilage	T067	C0868945
27243664	581	586	goods	T168	C0016452
27243664	656	672	cross-reactivity	T044	C0010357
27243664	676	679	DON	T109,T131	C0057445
27243664	682	686	IACs	T074	C0179909
27243664	705	715	conjugates	T104	C0243072
27243664	717	724	DON-3-G	T109	C2717096
27243664	726	734	15-AcDON	T109,T131	C0057445
27243664	739	746	3-AcDON	T109,T131	C0057445
27243664	842	858	cross-reactivity	T044	C0010357
27243664	876	880	IACs	T074	C0179909
27243664	896	899	DON	T109,T131	C0057445
27243664	908	918	conjugates	T104	C0243072
27243664	973	981	analytes	T109,T131	C0057445
27243664	992	995	IAC	T074	C0179909
27243664	1008	1020	simultaneous	T079	C0521115
27243664	1021	1029	analysis	T059	C0002778
27243664	1046	1049	DON	T109,T131	C0057445
27243664	1073	1081	15-AcDON	T109,T131	C0057445
27243664	1108	1115	DON-3-G	T109	C2717096
27243664	1120	1127	3-AcDON	T109,T131	C0057445
27243664	1160	1163	IAC	T074	C0179909
27243664	1169	1177	analytes	T109,T131	C0057445
27243664	1223	1239	antibody binding	T129,T192	C0005457
27243664	1260	1267	3-AcDON	T109,T131	C0057445
27243664	1300	1307	DON-3-G	T109	C2717096
27243664	1344	1356	active sites	T129,T192	C0005457
27243664	1398	1401	DON	T109,T131	C0057445
27243664	1402	1412	conjugates	T104	C0243072
27243664	1425	1437	real samples	T167	C0444315
27243664	1443	1459	cross-reactivity	T044	C0010357
27243664	1467	1470	DON	T109,T131	C0057445
27243664	1473	1476	IAC	T074	C0179909
27243664	1486	1507	quantitative analysis	T081	C0034384
27243664	1524	1532	analytes	T109,T131	C0057445
27243664	1606	1610	IACs	T074	C0179909
27243664	1650	1657	columns	T074	C0179909

27244222|t|A longitudinal study assessing childcare services' adoption of obesity prevention policies and practices
27244222|a|Despite ongoing investments to improve the obesogenic environments of childcare settings, little is known regarding how these services have changed their physical activity and nutrition-promoting practices. This study aims to describe changes in the proportion of Australian childcare services that have adopted best-practice healthy eating and physical activity practices between 2006 and 2013 and to assess whether adoption varied by socio-economic status and locality. A randomly selected sample of nominated supervisors (n = 358) from childcare services located in New South Wales, Australia, participated in a telephone survey in 2006, 2009, 2010 and 2013. Supervisors reported on their service's adoption of six practices: (i) having written nutrition and physical activity policies; (ii) staff trained in physical activity and nutrition in the past year; (iii) scheduled time for fundamental movement skills and (iv) outdoor play; (v) weekly or less screen time opportunitie s; and (vi) serving only non-sweetened beverages. A significant increase in the prevalence of services adopting all but one practice, between 2006 and 2013 was identified. Ninety one percent of services adopted four or more practices, a significant increase from 38% in 2006. There were no differences in the proportion of services adopting each practice by locality and socio-economic status. Government investment in obesity prevention programmes can equitably improve childcare service's adoption of healthy eating and physical activity promoting practices on a jurisdiction -wide basis. The establishment of a routine system to monitor adoption of a broader range of practices by childcare services is warranted.
27244222	2	20	longitudinal study	T062	C0023981
27244222	31	40	childcare	T057	C0683807
27244222	41	50	services'	T057	C0557854
27244222	63	70	obesity	T047	C0028754
27244222	71	104	prevention policies and practices	T058	C1254363
27244222	148	158	obesogenic	T047	C0028754
27244222	159	171	environments	T082	C0014406
27244222	175	184	childcare	T057	C0683807
27244222	231	239	services	T057	C0557854
27244222	259	276	physical activity	T056	C0026606
27244222	281	310	nutrition-promoting practices	T062	C1521729
27244222	369	379	Australian	T098	C0238711
27244222	380	389	childcare	T057	C0683807
27244222	390	398	services	T057	C0557854
27244222	417	430	best-practice	T058	C1254363
27244222	431	445	healthy eating	T061	C0452415
27244222	450	467	physical activity	T056	C0026606
27244222	468	477	practices	T058	C1254363
27244222	541	562	socio-economic status	T080	C0086996
27244222	567	575	locality	T082	C1254362
27244222	579	603	randomly selected sample	T062	C0150105
27244222	617	628	supervisors	T097	C0403172
27244222	644	653	childcare	T057	C0683807
27244222	654	662	services	T057	C0557854
27244222	674	689	New South Wales	T083	C0027975
27244222	691	700	Australia	T083	C0004340
27244222	720	736	telephone survey	T062	C0681820
27244222	767	778	Supervisors	T097	C0403172
27244222	797	806	service's	T057	C0557854
27244222	823	832	practices	T058	C1254363
27244222	853	862	nutrition	T062	C1521729
27244222	867	884	physical activity	T056	C0026606
27244222	885	893	policies	T170	C0242456
27244222	900	905	staff	T097	C0851286
27244222	917	934	physical activity	T056	C0026606
27244222	939	948	nutrition	T062	C1521729
27244222	983	987	time	T079	C0040223
27244222	1004	1012	movement	T040	C0026649
27244222	1013	1019	skills	T055	C0678856
27244222	1029	1041	outdoor play	T056	C0032214
27244222	1047	1053	weekly	T079	C0332174
27244222	1062	1086	screen time opportunitie	T033	C4038978
27244222	1112	1135	non-sweetened beverages	T168	C0005329
27244222	1167	1177	prevalence	T081	C0220900
27244222	1181	1189	services	T057	C0557854
27244222	1211	1219	practice	T058	C1254363
27244222	1281	1289	services	T057	C0557854
27244222	1311	1320	practices	T058	C1254363
27244222	1410	1418	services	T057	C0557854
27244222	1433	1441	practice	T058	C1254363
27244222	1445	1453	locality	T082	C1254362
27244222	1458	1479	socio-economic status	T080	C0086996
27244222	1481	1491	Government	T092	C0018104
27244222	1492	1502	investment	T081	C3242637
27244222	1506	1513	obesity	T047	C0028754
27244222	1514	1535	prevention programmes	T058	C1254363
27244222	1558	1567	childcare	T057	C0683807
27244222	1590	1604	healthy eating	T061	C0452415
27244222	1609	1626	physical activity	T056	C0026606
27244222	1637	1646	practices	T058	C1254363
27244222	1652	1664	jurisdiction	T170	C0680647
27244222	1758	1767	practices	T058	C1254363
27244222	1771	1780	childcare	T057	C0683807
27244222	1781	1789	services	T057	C0557854

27244841|t|Improving Early Identification and Ongoing Care of Children With Autism Spectrum Disorder
27244841|a|Poor adherence to recommended screening for autism spectrum disorder (ASD) and pediatricians ' lack of confidence in providing care for children with ASD reflect quality gaps in primary care. This study aimed to increase the proportion of toddlers screened for ASD and improve physicians ' self-efficacy in providing care to children with ASD. Twenty-six Utah primary care practices participated in a 3 to 6 month learning collaborative (LC) to improve identification and ongoing care of children with ASD. Monthly chart audits assessed whether an ASD screening tool was administered at 18- and 24- month visits. Physicians completed pre-LC and post-LC surveys to assess changes in self-efficacy in providing care and changes in perceived barriers to implementation of screening and caring for children with ASD. Before the LC, 15% of 18- and 24- month visits had documented ASD screening, compared with 91% during the last month of the LC (P < .001). This rate of ASD screening was sustained 4 years after the LC by most practices. Compared with survey responses before the LC, physicians reported significant improvement in their ability to care for children with ASD and decreases in their perceived barriers to screening and caring for children with ASD. The LC was effective in increasing and sustaining recommended ASD screening of toddlers and improving physicians ' perceived self-efficacy in caring for children with ASD. Improving primary care screening, skills, and knowledge may improve the timing of diagnosis, initiation of treatment, quality of care, and outcomes for children with ASD.
27244841	0	9	Improving	T080	C1272745
27244841	10	30	Early Identification	T061	C0814435
27244841	43	47	Care	T052	C1947933
27244841	51	59	Children	T100	C0008059
27244841	65	89	Autism Spectrum Disorder	T033	C4315362
27244841	120	129	screening	T058	C1710032
27244841	134	158	autism spectrum disorder	T033	C4315362
27244841	160	163	ASD	T033	C4315362
27244841	169	182	pediatricians	T097	C0237433
27244841	185	203	lack of confidence	T033	C0558092
27244841	217	221	care	T052	C1947933
27244841	226	234	children	T100	C0008059
27244841	240	243	ASD	T033	C4315362
27244841	268	280	primary care	T058	C0033137
27244841	287	292	study	T062	C2603343
27244841	329	337	toddlers	T100	C0682053
27244841	351	354	ASD	T033	C4315362
27244841	359	366	improve	T033	C0184511
27244841	367	377	physicians	T097	C0031831
27244841	380	393	self-efficacy	T041	C0600564
27244841	407	411	care	T052	C1947933
27244841	415	423	children	T100	C0008059
27244841	429	432	ASD	T033	C4315362
27244841	450	472	primary care practices	T058	C0033137
27244841	498	503	month	T079	C0439231
27244841	504	526	learning collaborative	T092	C1561598
27244841	528	530	LC	T092	C1561598
27244841	535	542	improve	T033	C0184511
27244841	543	557	identification	T041	C0020792
27244841	570	574	care	T052	C1947933
27244841	578	586	children	T100	C0008059
27244841	592	595	ASD	T033	C4315362
27244841	597	604	Monthly	T079	C0332177
27244841	605	617	chart audits	UnknownType	C0184805
27244841	638	641	ASD	T033	C4315362
27244841	642	656	screening tool	T058	C1710032
27244841	689	694	month	T079	C0439231
27244841	695	701	visits	T058	C1512346
27244841	703	713	Physicians	T097	C0031831
27244841	724	730	pre-LC	T079	C1254367
27244841	735	742	post-LC	T079	C1254367
27244841	743	750	surveys	T170	C0038951
27244841	761	768	changes	T169	C0392747
27244841	772	785	self-efficacy	T041	C0600564
27244841	799	803	care	T052	C1947933
27244841	819	828	perceived	T041	C0030971
27244841	829	837	barriers	T080	C0679881
27244841	841	855	implementation	T052	C1708476
27244841	859	868	screening	T058	C1710032
27244841	873	879	caring	T052	C1947933
27244841	884	892	children	T100	C0008059
27244841	898	901	ASD	T033	C4315362
27244841	914	916	LC	T092	C1561598
27244841	937	942	month	T079	C0439231
27244841	943	949	visits	T058	C1512346
27244841	954	964	documented	T058	C1301725
27244841	965	968	ASD	T033	C4315362
27244841	969	978	screening	T058	C1710032
27244841	1014	1019	month	T079	C0439231
27244841	1027	1029	LC	T092	C1561598
27244841	1055	1058	ASD	T033	C4315362
27244841	1059	1068	screening	T058	C1710032
27244841	1085	1090	years	T079	C0439234
27244841	1101	1103	LC	T092	C1561598
27244841	1137	1143	survey	T062	C0018762
27244841	1165	1167	LC	T092	C1561598
27244841	1169	1179	physicians	T097	C0031831
27244841	1201	1212	improvement	T077	C2986411
27244841	1233	1237	care	T052	C1947933
27244841	1242	1250	children	T100	C0008059
27244841	1256	1259	ASD	T033	C4315362
27244841	1283	1292	perceived	T041	C0030971
27244841	1293	1301	barriers	T080	C0679881
27244841	1305	1314	screening	T058	C1710032
27244841	1319	1325	caring	T052	C1947933
27244841	1330	1338	children	T100	C0008059
27244841	1344	1347	ASD	T033	C4315362
27244841	1353	1355	LC	T092	C1561598
27244841	1411	1414	ASD	T033	C4315362
27244841	1415	1424	screening	T058	C1710032
27244841	1428	1436	toddlers	T100	C0682053
27244841	1451	1461	physicians	T097	C0031831
27244841	1474	1487	self-efficacy	T041	C0600564
27244841	1491	1497	caring	T055	C0150499
27244841	1502	1510	children	T100	C0008059
27244841	1516	1519	ASD	T033	C4315362
27244841	1531	1543	primary care	T058	C0033137
27244841	1544	1553	screening	T058	C1710032
27244841	1555	1561	skills	T080	C0008973
27244841	1567	1576	knowledge	T033	C0518904
27244841	1581	1588	improve	T033	C0184511
27244841	1593	1599	timing	T079	C0449243
27244841	1603	1612	diagnosis	T062	C1704656
27244841	1614	1624	initiation	T169	C1704686
27244841	1628	1637	treatment	T061	C0087111
27244841	1639	1654	quality of care	T058	C0034379
27244841	1660	1668	outcomes	T169	C1274040
27244841	1673	1681	children	T100	C0008059
27244841	1687	1690	ASD	T033	C4315362

27245100|t|Describing Self-Care Self-Efficacy: Definition, Measurement, Outcomes, and Implications
27245100|a|The pragmatic utility method of concept analysis was used to explore the usefulness of the concept self-care self-efficacy. Empirical studies across disciplines published between 1996 and 2015 were used as data. A data matrix was developed. Analytical questions and responses were derived from the data to understand patterns, develop new knowledge and achieve synthesis. Usefulness of the concept is contingent on how it is defined and measured. Self-care self-efficacy is associated with performance of self-care activities and positive health outcomes in diverse populations. Research can guide development of targeted interventions to increase patients ' self-care self-efficacy, thus reducing costs, and assisting people to achieve optimal health.
27245100	11	20	Self-Care	T056	C0036592
27245100	21	34	Self-Efficacy	T041	C0600564
27245100	36	46	Definition	T170	C1704788
27245100	48	59	Measurement	T169	C0242485
27245100	61	69	Outcomes	T169	C1274040
27245100	75	87	Implications	T078	C1707478
27245100	92	116	pragmatic utility method	T062	C3658312
27245100	120	127	concept	T078	C0178566
27245100	128	136	analysis	T062	C0936012
27245100	161	171	usefulness	T080	C3827682
27245100	179	186	concept	T078	C0178566
27245100	187	196	self-care	T056	C0036592
27245100	197	210	self-efficacy	T041	C0600564
27245100	212	229	Empirical studies	T062	C0681812
27245100	237	248	disciplines	T090	C0005526
27245100	294	298	data	T078	C1511726
27245100	302	313	data matrix	T078	C1511726
27245100	340	349	questions	T078	C0681799
27245100	354	363	responses	T170	C1706817
27245100	386	390	data	T078	C1511726
27245100	427	436	knowledge	T170	C0376554
27245100	460	470	Usefulness	T080	C3827682
27245100	478	485	concept	T078	C0178566
27245100	535	544	Self-care	T056	C0036592
27245100	545	558	self-efficacy	T041	C0600564
27245100	562	577	associated with	T080	C0332281
27245100	578	589	performance	T052	C1882330
27245100	593	613	self-care activities	T056	C0563471
27245100	618	626	positive	T033	C1446409
27245100	627	642	health outcomes	T057	C3858647
27245100	646	653	diverse	T080	C1880371
27245100	654	665	populations	T098	C1257890
27245100	667	675	Research	T062	C0035168
27245100	686	697	development	T169	C1527148
27245100	710	723	interventions	T058	C0886296
27245100	736	744	patients	T101	C0030705
27245100	747	756	self-care	T056	C0036592
27245100	757	770	self-efficacy	T041	C0600564
27245100	777	785	reducing	T080	C0392756
27245100	786	791	costs	T081	C0010186
27245100	797	806	assisting	T058	C1280910
27245100	807	813	people	T098	C0027361
27245100	825	832	optimal	T080	C2698651
27245100	833	839	health	T078	C0018684

27245303|t|Dynamics of intestinal metabolites and morphology in response to necrotic enteritis challenge in broiler chickens
27245303|a|Despite the relatively small contribution to metabolizable energy that volatile fatty acids (VFAs) provide in chickens, these organic acids have been reported to play beneficial roles in the gastrointestinal tract (GIT) of birds, for example, inhibition of the growth of some pathogenic bacteria. However, information regarding the dynamics of these metabolites in the GIT of chickens is still scarce, especially under disease conditions such as necrotic enteritis (NE). Here, we investigated the dynamics of VFAs and lactic acid, and intestinal morphology in response to NE predisposing factors, that is, excessive dietary fishmeal and Eimeria inoculation, and causative agent Clostridium perfringens producing NetB toxin. The experiment was designed in a 2 Ã 2 Ã 2 factorial arrangement of treatments with or without: fishmeal feeding, Eimeria inoculation and C. perfringens challenge. The results showed that these factors significantly influenced composition and concentration of VFAs and lactic acids, pH and histomorphometry in one way or another. These changes may be important for the onset of NE or only the synergetic responses to micro environmental stress. Eimeria appeared to be more important than fishmeal in predisposing birds to NE, thus the application of Eimeria in NE challenge provides more consistent success in inducing the disease. The metabolic responses to various adverse factors such as excessive dietary fishmeal and Eimeria infection are complex. Thus, intensive efforts are required to better understand NE so as to achieve the control of the disease in the absence of antibiotics.
27245303	0	8	Dynamics	T070	C3826426
27245303	12	22	intestinal	T023	C0021853
27245303	23	34	metabolites	T123	C0870883
27245303	39	49	morphology	T080	C0332437
27245303	53	61	response	T032	C0871261
27245303	65	83	necrotic enteritis	T047	C0267454
27245303	84	93	challenge	T058	C0805586
27245303	97	113	broiler chickens	T012	C2698565
27245303	126	136	relatively	T080	C0205345
27245303	137	142	small	T081	C0700321
27245303	143	155	contribution	T052	C1880177
27245303	159	172	metabolizable	T169	C0311400
27245303	173	179	energy	T081	C1442080
27245303	185	205	volatile fatty acids	T109,T123	C0015691
27245303	207	211	VFAs	T109,T123	C0015691
27245303	213	220	provide	T052	C1999230
27245303	224	232	chickens	T012	C2698565
27245303	240	253	organic acids	T109	C0369760
27245303	264	272	reported	T058	C0700287
27245303	281	291	beneficial	T081	C0086387
27245303	292	297	roles	T077	C1705810
27245303	305	327	gastrointestinal tract	T022	C0017189
27245303	329	332	GIT	T022	C0017189
27245303	337	342	birds	T012	C0005595
27245303	357	381	inhibition of the growth	T040	C2249823
27245303	390	400	pathogenic	T001	C0450254
27245303	401	409	bacteria	T007	C0004611
27245303	420	431	information	T078	C1533716
27245303	446	454	dynamics	T070	C3826426
27245303	464	475	metabolites	T123	C0870883
27245303	483	486	GIT	T022	C0017189
27245303	490	498	chickens	T012	C2698565
27245303	508	514	scarce	T080	C0231180
27245303	516	526	especially	T080	C0205555
27245303	533	551	disease conditions	T033	C1299555
27245303	560	578	necrotic enteritis	T047	C0267454
27245303	580	582	NE	T047	C0267454
27245303	594	606	investigated	T169	C1292732
27245303	611	619	dynamics	T070	C3826426
27245303	623	627	VFAs	T109,T123	C0015691
27245303	632	643	lactic acid	T109,T121,T123	C0064582
27245303	649	659	intestinal	T023	C0021853
27245303	660	670	morphology	T080	C0332437
27245303	674	682	response	T032	C0871261
27245303	686	688	NE	T047	C0267454
27245303	689	709	predisposing factors	T079	C0032946
27245303	720	729	excessive	T080	C0442802
27245303	730	737	dietary	T168	C0012155
27245303	738	746	fishmeal	T167	C3687772
27245303	751	758	Eimeria	T204	C0013739
27245303	759	770	inoculation	T061	C2987620
27245303	776	791	causative agent	T033	C0449411
27245303	792	815	Clostridium perfringens	T007	C0009063
27245303	826	836	NetB toxin	T116,T123,T131	C3492213
27245303	842	852	experiment	T062	C0205664
27245303	857	865	designed	T062	C0015320
27245303	881	890	factorial	UnknownType	C0681865
27245303	891	902	arrangement	T058	C0586001
27245303	906	916	treatments	T061	C0087111
27245303	934	942	fishmeal	T167	C3687772
27245303	943	950	feeding	T052	C2987508
27245303	952	959	Eimeria	T204	C0013739
27245303	960	971	inoculation	T061	C2987620
27245303	976	990	C. perfringens	T007	C0009063
27245303	991	1000	challenge	T058	C0805586
27245303	1006	1013	results	T033	C0683954
27245303	1032	1039	factors	T169	C1521761
27245303	1040	1053	significantly	T078	C0750502
27245303	1054	1064	influenced	T077	C4054723
27245303	1065	1076	composition	T201	C0486616
27245303	1081	1094	concentration	T081	C1446561
27245303	1098	1102	VFAs	T109,T123	C0015691
27245303	1107	1119	lactic acids	T109,T121,T123	C0064582
27245303	1121	1123	pH	T081	C0020283
27245303	1128	1144	histomorphometry	UnknownType	C0679557
27245303	1174	1181	changes	T169	C0392747
27245303	1189	1198	important	T080	C3898777
27245303	1207	1215	onset of	T080	C0332162
27245303	1216	1218	NE	T047	C0267454
27245303	1231	1251	synergetic responses	T032	C0871261
27245303	1255	1274	micro environmental	T082	C4072789
27245303	1275	1281	stress	T033	C0038435
27245303	1283	1290	Eimeria	T204	C0013739
27245303	1306	1310	more	T081	C0205172
27245303	1311	1320	important	T080	C3898777
27245303	1326	1334	fishmeal	T167	C3687772
27245303	1338	1350	predisposing	T169	C0231203
27245303	1351	1356	birds	T012	C0005595
27245303	1360	1362	NE	T047	C0267454
27245303	1373	1384	application	T169	C0542341
27245303	1388	1395	Eimeria	T204	C0013739
27245303	1399	1401	NE	T047	C0267454
27245303	1402	1411	challenge	T058	C0805586
27245303	1412	1420	provides	T052	C1999230
27245303	1426	1436	consistent	T078	C0332290
27245303	1437	1444	success	T080	C0679864
27245303	1448	1456	inducing	T169	C0205263
27245303	1461	1468	disease	T047	C0012634
27245303	1474	1483	metabolic	T169	C0311400
27245303	1484	1493	responses	T032	C0871261
27245303	1505	1512	adverse	T046	C0879626
27245303	1513	1520	factors	T169	C1521761
27245303	1529	1538	excessive	T080	C0442802
27245303	1539	1546	dietary	T168	C0012155
27245303	1547	1555	fishmeal	T167	C3687772
27245303	1560	1567	Eimeria	T204	C0013739
27245303	1568	1577	infection	T046	C3714514
27245303	1582	1589	complex	T080	C0439855
27245303	1597	1606	intensive	T080	C0522510
27245303	1607	1614	efforts	T040	C0015264
27245303	1619	1627	required	T169	C1514873
27245303	1631	1637	better	T080	C0332272
27245303	1638	1648	understand	T041	C0162340
27245303	1649	1651	NE	T047	C0267454
27245303	1673	1695	control of the disease	T058	C0085557
27245303	1703	1710	absence	T169	C0332197
27245303	1714	1725	antibiotics	T195	C0003232

27245335|t|The effects of paternal high-fat diet exposure on offspring metabolism with epigenetic changes in the mouse adiponectin and leptin gene promoters
27245335|a|Recent studies have demonstrated that epigenetic changes resulting from malnutrition might play important roles in transgenerational links with metabolic diseases. Previously, we observed that exposure to a high-fat diet (HFD) in utero caused a metabolic syndrome -like phenomenon through epigenetic modifications of the adiponectin and leptin genes that persisted for multiple generations. Recent etiological studies indicated that paternal BMI had effects on offspring BMI that were independent of but additive to maternal BMI effects. Thus, we examined whether paternal HFD - induced obesity affected the metabolic status of offspring through epigenetic changes in the adiponectin and leptin genes. Additionally, we investigated whether a normal diet during subsequent generations abolished the epigenetic changes associated with paternal HFD exposure before conception. We observed the effects of paternal HFD exposure before conception over multiple generations on offspring metabolic traits, including weight and fat gain, glucose intolerance, hypertriglyceridemia, abnormal adipocytokine levels, hypertension, and adiponectin and leptin gene expression and epigenetic changes. Normal diet consumption by male offspring during the subsequent generation following paternal HFD exposure diminished whereas consumption for two generations completely abolished the effect of paternal HFD exposure on metabolic traits and adipocytokine promoter epigenetic changes in the offspring. The effects of paternal HFD exposure on offspring were relatively weaker than those following HFD exposure in utero. However, paternal HFD exposure had an additive metabolic effect for two generations, suggesting that both paternal and maternal nutrition might affect offspring metabolism through epigenetic modifications of adipocytokine genes for multiple generations.
27245335	4	14	effects of	T080	C1704420
27245335	15	23	paternal	T080	C0337493
27245335	24	37	high-fat diet	T168	C0012155
27245335	38	46	exposure	T080	C0332157
27245335	50	59	offspring	T099	C0680063
27245335	60	70	metabolism	T040	C0025519
27245335	76	94	epigenetic changes	T045	C1516924
27245335	108	119	adiponectin	T028	C1540187
27245335	124	130	leptin	T028	C1416825
27245335	131	145	gene promoters	T028	C0314621
27245335	153	160	studies	T062	C2603343
27245335	184	202	epigenetic changes	T045	C1516924
27245335	218	230	malnutrition	T047	C0162429
27245335	252	257	roles	T077	C1705810
27245335	261	284	transgenerational links	T102	C0871541
27245335	290	308	metabolic diseases	T047	C0025517
27245335	325	333	observed	T169	C1441672
27245335	339	347	exposure	T080	C0332157
27245335	353	366	high-fat diet	T168	C0012155
27245335	368	371	HFD	T168	C0012155
27245335	373	381	in utero	T100	C1708480
27245335	382	388	caused	T169	C0015127
27245335	391	400	metabolic	T169	C0311400
27245335	401	409	syndrome	T047	C0039082
27245335	416	426	phenomenon	T067	C1882365
27245335	427	434	through	T169	C0332273
27245335	435	459	epigenetic modifications	T045	C1516924
27245335	467	478	adiponectin	T028	C1540187
27245335	483	495	leptin genes	T028	C1416825
27245335	515	523	multiple	T081	C0439064
27245335	524	535	generations	T079	C0079411
27245335	544	555	etiological	T169	C0015127
27245335	556	563	studies	T062	C2603343
27245335	564	573	indicated	T033	C1444656
27245335	579	587	paternal	T080	C0337493
27245335	588	591	BMI	T201	C1305855
27245335	596	603	effects	T080	C1280500
27245335	607	616	offspring	T099	C0680063
27245335	617	620	BMI	T201	C1305855
27245335	631	645	independent of	T169	C0332291
27245335	650	658	additive	T080	C0442796
27245335	662	670	maternal	T033	C1858460
27245335	671	674	BMI	T201	C1305855
27245335	675	682	effects	T080	C1280500
27245335	710	718	paternal	T080	C0337493
27245335	719	722	HFD	T168	C0012155
27245335	725	732	induced	T169	C0205263
27245335	733	740	obesity	T047	C0028754
27245335	741	749	affected	T080	C1280500
27245335	754	763	metabolic	T169	C0311400
27245335	764	770	status	T080	C0449438
27245335	774	783	offspring	T099	C0680063
27245335	784	791	through	T169	C0332273
27245335	792	810	epigenetic changes	T045	C1516924
27245335	818	829	adiponectin	T028	C1540187
27245335	834	846	leptin genes	T028	C1416825
27245335	865	877	investigated	T169	C1292732
27245335	888	899	normal diet	T056	C0184625
27245335	900	906	during	T079	C0347984
27245335	907	929	subsequent generations	T078	C1136186
27245335	930	939	abolished	T052	C1947925
27245335	944	962	epigenetic changes	T045	C1516924
27245335	963	978	associated with	T080	C0332281
27245335	979	987	paternal	T080	C0337493
27245335	988	991	HFD	T168	C0012155
27245335	992	1000	exposure	T080	C0332157
27245335	1001	1007	before	T079	C0332152
27245335	1008	1018	conception	T040	C0009637
27245335	1023	1031	observed	T169	C1441672
27245335	1036	1046	effects of	T080	C1704420
27245335	1047	1055	paternal	T080	C0337493
27245335	1056	1059	HFD	T168	C0012155
27245335	1060	1068	exposure	T080	C0332157
27245335	1069	1075	before	T079	C0332152
27245335	1076	1086	conception	T040	C0009637
27245335	1092	1100	multiple	T081	C0439064
27245335	1101	1112	generations	T079	C0079411
27245335	1116	1125	offspring	T099	C0680063
27245335	1126	1135	metabolic	T169	C0311400
27245335	1136	1142	traits	T032	C0599883
27245335	1144	1153	including	T169	C0332257
27245335	1154	1160	weight	T033	C0043094
27245335	1165	1168	fat	T109,T121	C0015677
27245335	1169	1173	gain	T081	C1517378
27245335	1175	1194	glucose intolerance	T047	C0271650
27245335	1196	1216	hypertriglyceridemia	T047	C0020557
27245335	1218	1240	abnormal adipocytokine	T116,T123	C1955907
27245335	1241	1247	levels	T080	C0441889
27245335	1249	1261	hypertension	T047	C0020538
27245335	1267	1278	adiponectin	T028	C1540187
27245335	1283	1294	leptin gene	T028	C1416825
27245335	1295	1305	expression	T045	C0017262
27245335	1310	1328	epigenetic changes	T045	C1516924
27245335	1330	1341	Normal diet	T056	C0184625
27245335	1362	1371	offspring	T099	C0680063
27245335	1415	1423	paternal	T080	C0337493
27245335	1424	1427	HFD	T168	C0012155
27245335	1428	1436	exposure	T080	C0332157
27245335	1437	1447	diminished	T081	C0205216
27245335	1456	1467	consumption	T052	C2983605
27245335	1476	1487	generations	T079	C0079411
27245335	1499	1508	abolished	T052	C1947925
27245335	1513	1519	effect	T080	C1280500
27245335	1523	1531	paternal	T080	C0337493
27245335	1532	1535	HFD	T168	C0012155
27245335	1536	1544	exposure	T080	C0332157
27245335	1548	1557	metabolic	T169	C0311400
27245335	1558	1564	traits	T032	C0599883
27245335	1569	1582	adipocytokine	T116,T123	C1955907
27245335	1592	1610	epigenetic changes	T045	C1516924
27245335	1618	1627	offspring	T099	C0680063
27245335	1633	1643	effects of	T080	C1704420
27245335	1644	1652	paternal	T080	C0337493
27245335	1653	1656	HFD	T168	C0012155
27245335	1657	1665	exposure	T080	C0332157
27245335	1669	1678	offspring	T099	C0680063
27245335	1695	1701	weaker	T080	C1762617
27245335	1713	1722	following	T079	C0332282
27245335	1723	1726	HFD	T168	C0012155
27245335	1727	1735	exposure	T080	C0332157
27245335	1736	1744	in utero	T100	C1708480
27245335	1755	1763	paternal	T080	C0337493
27245335	1764	1767	HFD	T168	C0012155
27245335	1768	1776	exposure	T080	C0332157
27245335	1784	1792	additive	T080	C0442796
27245335	1793	1802	metabolic	T169	C0311400
27245335	1803	1809	effect	T080	C1280500
27245335	1818	1829	generations	T079	C0079411
27245335	1852	1860	paternal	T080	C0337493
27245335	1865	1873	maternal	T033	C1858460
27245335	1874	1883	nutrition	T040	C1442959
27245335	1890	1896	affect	T080	C1280500
27245335	1897	1906	offspring	T099	C0680063
27245335	1907	1917	metabolism	T040	C0025519
27245335	1918	1925	through	T169	C0332273
27245335	1926	1950	epigenetic modifications	T045	C1516924
27245335	1954	1973	adipocytokine genes	T028	C0017337
27245335	1978	1986	multiple	T081	C0439064
27245335	1987	1998	generations	T079	C0079411

27245524|t|Ehlers-Danlos syndrome
27245524|a|The Ehlers-Danlos syndromes (EDSs) were originally described by Ehlers in Denmark and Danlos in Paris in 1898 and 1908, respectively. They had both published individual case studies in which the common factor was laxity of ligaments leading to joint hypermobility and hyperextensibility of the skin. The choice of the name of this eponymous disease had been made by Dr Parkes Weber, an eminent London physician in the 1930s, who had a penchant for eponymous diseases, having had no less than seven attributed to himself, at least in part. Unfortunately, this was before the age of a computerised literature search, and Parkes Weber had inadvertently overlooked the very first description of EDS which had been made by Tchernabogov, a Russian dermatologist, whose description was published in 1891 and remains one of the best descriptions of EDS in the literature.
27245524	0	22	Ehlers-Danlos syndrome	T047	C0013720
27245524	27	50	Ehlers-Danlos syndromes	T047	C0013720
27245524	52	56	EDSs	T047	C0013720
27245524	74	83	described	T170	C0678257
27245524	87	93	Ehlers	T016	C0086418
27245524	97	104	Denmark	T083	C0011318
27245524	109	115	Danlos	T016	C0086418
27245524	119	124	Paris	T083	C0030561
27245524	171	180	published	T057	C0034037
27245524	192	204	case studies	T170	C0085973
27245524	236	255	laxity of ligaments	T046	C0158359
27245524	267	286	joint hypermobility	T184	C0086437
27245524	291	321	hyperextensibility of the skin	T033	C0241074
27245524	341	345	name	T170	C0027365
27245524	354	371	eponymous disease	T170	C0282574
27245524	389	404	Dr Parkes Weber	T016	C0086418
27245524	417	423	London	T083	C0023973
27245524	424	433	physician	T097	C0031831
27245524	458	466	penchant	T055	C3826173
27245524	471	489	eponymous diseases	T170	C0282574
27245524	606	629	computerised literature	T170	C0023866
27245524	630	636	search	T052	C1706202
27245524	642	654	Parkes Weber	T016	C0086418
27245524	699	710	description	T170	C0678257
27245524	714	717	EDS	T047	C0013720
27245524	741	753	Tchernabogov	T016	C0086418
27245524	757	764	Russian	T098	C0337816
27245524	765	778	dermatologist	T097	C0259831
27245524	786	797	description	T170	C0678257
27245524	802	811	published	T057	C0034037
27245524	848	860	descriptions	T170	C0678257
27245524	864	867	EDS	T047	C0013720
27245524	875	885	literature	T170	C0023866

27246120|t|Assessment of laparoscopic stomach preserving surgery with sentinel basin dissection versus standard gastrectomy with lymphadenectomy in early gastric cancer -A multicenter randomized phase III clinical trial (SENORITA trial) protocol
27246120|a|Along with the marked increase in early gastric cancer (EGC) in the Eastern countries, there has been an effort to adopt the sentinel node concept in EGC to preserve gastric function and reduce the occurrence of postoperative complications. Based on promising results from a previous quality control study, this prospective multicenter randomized controlled phase III clinical trial aims to elucidate the oncologic safety of laparoscopic stomach-preserving surgery with sentinel basin dissection (SBD) compared to a standard laparoscopic gastrectomy. This trial is an investigator-initiated, open-label, multicenter randomized controlled phase III trial with a non-inferiority design. Patients diagnosed with a single lesion of clinical stage T1N0M0 gastric adenocarcinoma, with a diameter of 3 cm or less are eligible for the present study. A total of 580 patients (290 per group) will be randomized to either laparoscopic stomach-preserving surgery with SBD or standard surgery. The primary end-point is 3-year disease-free survival (DFS) and the secondary endpoints include postoperative morbidity and mortality, quality of life, 5-year DFS, and overall survival. Qualified investigators who completed the prior quality control study are exclusively allowed to participate in this phase III clinical trial. The proposed trial is expected to verify whether laparoscopic stomach-preserving surgery with SBD achieves similar oncologic outcomes and improved quality of life compared to a standard gastrectomy in EGC patients. This study was registered at the NIH ClinicalTrial.gov database (NCT01804998) on March 4th, 2013.
27246120	0	10	Assessment	T058	C0220825
27246120	14	53	laparoscopic stomach preserving surgery	T061	C0812574
27246120	59	84	sentinel basin dissection	T061	C0242382
27246120	101	112	gastrectomy	T061	C0017118
27246120	118	133	lymphadenectomy	T061	C0024203
27246120	137	157	early gastric cancer	T191	C0349530
27246120	161	234	multicenter randomized phase III clinical trial (SENORITA trial) protocol	T062	C0282461
27246120	269	289	early gastric cancer	T191	C0349530
27246120	291	294	EGC	T191	C0349530
27246120	303	320	Eastern countries	T083	C0017446
27246120	360	373	sentinel node	T023	C1522495
27246120	385	388	EGC	T191	C0349530
27246120	401	417	gastric function	T042	C0232538
27246120	447	474	postoperative complications	T046	C0032787
27246120	510	540	previous quality control study	T062	C3850080
27246120	547	617	prospective multicenter randomized controlled phase III clinical trial	T062	C0282461
27246120	640	649	oncologic	T091	C0205478
27246120	650	656	safety	T062	C1705187
27246120	660	699	laparoscopic stomach-preserving surgery	T061	C0812574
27246120	705	730	sentinel basin dissection	T061	C0242382
27246120	732	735	SBD	T061	C0242382
27246120	760	772	laparoscopic	T082	C0393360
27246120	773	784	gastrectomy	T061	C0017118
27246120	839	888	multicenter randomized controlled phase III trial	T062	C0282461
27246120	896	918	non-inferiority design	T062	C0015320
27246120	920	938	Patients diagnosed	UnknownType	C0679829
27246120	946	959	single lesion	T033	C0577304
27246120	963	984	clinical stage T1N0M0	T079	C0205563
27246120	985	1007	gastric adenocarcinoma	T191	C0278701
27246120	1092	1100	patients	T101	C0030705
27246120	1125	1135	randomized	T033	C3815594
27246120	1146	1185	laparoscopic stomach-preserving surgery	T061	C0812574
27246120	1191	1194	SBD	T061	C0242382
27246120	1198	1214	standard surgery	T061	C0017118
27246120	1248	1269	disease-free survival	T081	C0242793
27246120	1271	1274	DFS	T081	C0242793
27246120	1312	1335	postoperative morbidity	T033	C1822479
27246120	1340	1349	mortality	T081	C0205848
27246120	1351	1366	quality of life	T078	C0034380
27246120	1375	1378	DFS	T081	C0242793
27246120	1384	1400	overall survival	T081	C4086681
27246120	1402	1425	Qualified investigators	T097	C0008961
27246120	1450	1471	quality control study	T169	C0034378
27246120	1519	1543	phase III clinical trial	T062	C0282461
27246120	1594	1633	laparoscopic stomach-preserving surgery	T061	C0812574
27246120	1639	1642	SBD	T061	C0242382
27246120	1660	1678	oncologic outcomes	T033	C0679250
27246120	1692	1707	quality of life	T078	C0034380
27246120	1722	1742	standard gastrectomy	T061	C0017118
27246120	1746	1749	EGC	T191	C0349530
27246120	1750	1758	patients	T101	C0030705

27247892|t|Isolation and characterization of Burkholderia sp. strain CCA53 exhibiting ligninolytic potential
27247892|a|Microbial degradation of lignin releases fermentable sugars, effective utilization of which could support biofuel production from lignocellulosic biomass. In the present study, a lignin-degrading bacterium was isolated from leaf soil and identified as Burkholderia sp. based on 16S rRNA gene sequencing. This strain was named CCA53, and its lignin-degrading capability was assessed by observing its growth on medium containing alkali lignin or lignin -associated aromatic monomers as the sole carbon source. Alkali lignin and at least eight lignin -associated aromatic monomers supported growth of this strain, and the most effective utilization was observed for p-hydroxybenzene monomers. These findings indicate that Burkholderia sp. strain CCA53 has fragmentary activity for lignin degradation.
27247892	0	9	Isolation	T169	C0205409
27247892	14	30	characterization	T052	C1880022
27247892	34	63	Burkholderia sp. strain CCA53	T007	C4130454
27247892	75	87	ligninolytic	T044	C1156998
27247892	88	97	potential	T080	C3245505
27247892	98	107	Microbial	T001	C0599840
27247892	108	119	degradation	T040	C0699900
27247892	123	129	lignin	T109,T123	C0023705
27247892	139	157	fermentable sugars	T109,T121	C0242209
27247892	159	168	effective	T080	C1704419
27247892	169	180	utilization	T169	C0457083
27247892	204	211	biofuel	T109	C2717891
27247892	212	222	production	T057	C0033268
27247892	228	243	lignocellulosic	T109	C0064974
27247892	244	251	biomass	T081	C0005535
27247892	268	273	study	T062	C2603343
27247892	277	293	lignin-degrading	T044	C1156998
27247892	294	303	bacterium	T007	C0004611
27247892	308	316	isolated	T169	C0205409
27247892	322	326	leaf	T002	C0242724
27247892	327	331	soil	T167	C0037592
27247892	350	366	Burkholderia sp.	T007	C1264855
27247892	376	384	16S rRNA	T114	C3537372
27247892	385	400	gene sequencing	T059	C1294197
27247892	407	413	strain	T080	C0456178
27247892	424	429	CCA53	T007	C4130454
27247892	439	455	lignin-degrading	T044	C1156998
27247892	456	466	capability	T080	C2698977
27247892	471	479	assessed	T052	C1516048
27247892	497	503	growth	T040	C0018270
27247892	507	513	medium	T130	C0010454
27247892	525	538	alkali lignin	T109,T123	C0023705
27247892	542	548	lignin	T109,T123	C0023705
27247892	561	578	aromatic monomers	T104	C0596973
27247892	591	597	carbon	T196	C0007009
27247892	598	604	source	T033	C0449416
27247892	606	619	Alkali lignin	T109,T123	C0023705
27247892	639	645	lignin	T109,T123	C0023705
27247892	658	675	aromatic monomers	T104	C0596973
27247892	686	692	growth	T040	C0018270
27247892	701	707	strain	T080	C0456178
27247892	722	731	effective	T080	C1704419
27247892	732	743	utilization	T169	C0457083
27247892	761	786	p-hydroxybenzene monomers	T104	C0596973
27247892	794	802	findings	T033	C0243095
27247892	817	846	Burkholderia sp. strain CCA53	T007	C4130454
27247892	851	871	fragmentary activity	T052	C0441655
27247892	876	894	lignin degradation	T044	C1156998

27249024|t|Association of Metabolites with Obesity and Type 2 Diabetes Based on FTO Genotype
27249024|a|The single nucleotide polymorphism rs9939609 of the gene FTO, which encodes fat mass and obesity -associated protein, is strongly associated with obesity and type 2 diabetes (T2D) in multiple populations; however, the underlying mechanism of this association is unclear. The present study aimed to investigate FTO genotype -dependent metabolic changes in obesity and T2D. To elucidate metabolic dysregulation associated with disease risk genotype, genomic and metabolomic datasets were recruited from 2,577 participants of the Korean Association REsource (KARE) cohort, including 40 homozygous carriers of the FTO risk allele (AA), 570 heterozygous carriers (AT), and 1,967 participants carrying no risk allele (TT). A total of 134 serum metabolites were quantified using a targeted metabolomics approach. Through comparison of various statistical methods, seven metabolites were identified that are significantly altered in obesity and T2D based on the FTO risk allele (adjusted p < 0.05). These identified metabolites are relevant to phosphatidylcholine metabolic pathway, and previously reported to be metabolic markers of obesity and T2D. In conclusion, using metabolomics with the information from genome-wide association studies revealed significantly altered metabolites depending on the FTO genotype in complex disorders. This study may contribute to a better understanding of the biological mechanisms linking obesity and T2D.
27249024	15	26	Metabolites	T123	C0870883
27249024	32	39	Obesity	T047	C0028754
27249024	44	59	Type 2 Diabetes	T047	C0011860
27249024	69	72	FTO	T028	C1970415
27249024	73	81	Genotype	T032	C0017431
27249024	86	116	single nucleotide polymorphism	T086	C0752046
27249024	117	142	rs9939609 of the gene FTO	T028	C1970415
27249024	158	166	fat mass	T032	C3656665
27249024	171	178	obesity	T047	C0028754
27249024	191	198	protein	T116,T123	C0033684
27249024	228	235	obesity	T047	C0028754
27249024	240	255	type 2 diabetes	T047	C0011860
27249024	257	260	T2D	T047	C0011860
27249024	274	285	populations	T098	C1257890
27249024	365	370	study	T062	C2603343
27249024	392	395	FTO	T028	C1970415
27249024	396	404	genotype	T032	C0017431
27249024	416	425	metabolic	T040	C0025519
27249024	426	433	changes	T169	C0392747
27249024	437	444	obesity	T047	C0028754
27249024	449	452	T2D	T047	C0011860
27249024	467	490	metabolic dysregulation	T046	C2362507
27249024	507	519	disease risk	T201	C0012655
27249024	520	528	genotype	T032	C0017431
27249024	530	537	genomic	T170	C0150098
27249024	542	562	metabolomic datasets	T170	C0150098
27249024	589	601	participants	T098	C0679646
27249024	609	650	Korean Association REsource (KARE) cohort	T098	C0599755
27249024	665	675	homozygous	T032	C0019904
27249024	676	684	carriers	T033	C0007294
27249024	692	695	FTO	T028	C1970415
27249024	701	712	allele (AA)	T028	C0002085
27249024	718	730	heterozygous	T032	C0019425
27249024	731	739	carriers	T033	C0007294
27249024	756	768	participants	T098	C0679646
27249024	786	797	allele (TT)	T028	C0002085
27249024	814	819	serum	T031	C0229671
27249024	820	831	metabolites	T123	C0870883
27249024	865	877	metabolomics	T091	C1328813
27249024	918	937	statistical methods	T062	C1710191
27249024	945	956	metabolites	T123	C0870883
27249024	1007	1014	obesity	T047	C0028754
27249024	1019	1022	T2D	T047	C0011860
27249024	1036	1039	FTO	T028	C1970415
27249024	1045	1051	allele	T028	C0002085
27249024	1090	1101	metabolites	T123	C0870883
27249024	1118	1137	phosphatidylcholine	T109,T121,T123	C1959616
27249024	1138	1155	metabolic pathway	T169	C1291081
27249024	1187	1204	metabolic markers	T123	C1513159
27249024	1208	1215	obesity	T047	C0028754
27249024	1220	1223	T2D	T047	C0011860
27249024	1246	1258	metabolomics	T091	C1328813
27249024	1285	1316	genome-wide association studies	T063	C2350277
27249024	1348	1359	metabolites	T123	C0870883
27249024	1377	1380	FTO	T028	C1970415
27249024	1381	1389	genotype	T032	C0017431
27249024	1417	1422	study	T062	C2603343
27249024	1501	1508	obesity	T047	C0028754
27249024	1513	1516	T2D	T047	C0011860

27249236|t|Anthology of Venezuelan psychiatry
27249236|a|Reception of Psychiatry in Venezuela since the 19th Century to the late 20th Century merits a historical approach. The following work proposes to research some of the very origins of Venezuelan psychiatry and its possible influence on contemporary mental health practice. Through documental research, the early works of local authors from the 19th Century through 20th Century finals: Carlos Arvelo, Lisandro Alvarado, Francisco Herrera Luque, Jose Luis Vethencourt and Jose Solanes, are subjected to study. This journey illustrates a descriptive panoramic view which allows to better comprenhend the current state of our psychiatry. In a brief introduction the most important events are described, since the arrival of Pinel's ideas, followed by the early research paperworks published and the beginnings of the academic teachings of this specialty in Venezuela and displaying the main contemporary research groups thorough the country.
27249236	0	9	Anthology	T170	C0600644
27249236	13	23	Venezuelan	T098	C0241664
27249236	24	34	psychiatry	T091	C0033873
27249236	35	44	Reception	T080	C0205556
27249236	48	58	Psychiatry	T091	C0033873
27249236	62	71	Venezuela	T083	C0042469
27249236	181	189	research	T062	C0035168
27249236	218	228	Venezuelan	T098	C0241664
27249236	229	239	psychiatry	T091	C0033873
27249236	257	266	influence	T077	C4054723
27249236	283	305	mental health practice	T058	C0086388
27249236	340	351	early works	T057	C0043227
27249236	355	368	local authors	T097	C3812881
27249236	420	433	Carlos Arvelo	T016	C0086418
27249236	435	452	Lisandro Alvarado	T016	C0086418
27249236	454	477	Francisco Herrera Luque	T016	C0086418
27249236	479	500	Jose Luis Vethencourt	T016	C0086418
27249236	505	517	Jose Solanes	T016	C0086418
27249236	657	667	psychiatry	T091	C0033873
27249236	674	692	brief introduction	T169	C0579004
27249236	712	718	events	T051	C0441471
27249236	744	751	arrival	T052	C1706079
27249236	755	762	Pinel's	T016	C0086418
27249236	763	768	ideas	T078	C1254370
27249236	812	821	published	T057	C0034037
27249236	848	866	academic teachings	UnknownType	C0681341
27249236	888	897	Venezuela	T083	C0042469
27249236	902	912	displaying	T169	C0870432
27249236	922	950	contemporary research groups	UnknownType	C0681822
27249236	951	971	thorough the country	T083	C0042469

27249559|t|Study of the Microfocus X-Ray Tube Based on a Point-Like Target Used for Micro-Computed Tomography
27249559|a|For a micro-Computed Tomography (Micro-CT) system, the microfocus X-ray tube is an essential component because the spatial resolution of CT images, in theory, is mainly determined by the size and stability of the X-ray focal spot of the microfocus X-ray tube. However, many factors, including voltage fluctuations, mechanical vibrations, and temperature changes, can cause the size and the stability of the X-ray focal spot to degrade. A new microfocus X-ray tube based on a point-like micro-target in which the X-ray target is irradiated with an unfocused electron beam was investigated. EGS4 Monte Carlo simulation code was employed for the calculation of the X-ray intensity produced from the point-like micro-target and the substrate. The effects of several arrangements of the target material, target and beam size were studied. The simulation results demonstrated that if the intensity of X-rays generated at the point-like target is greater than half of the X-ray intensity produced on the substrate, the X-ray focal spot is determined in part by the point-like target rather than by the electron beam in the conventional X-ray tube. In theory, since it is able to reduce those unfavorable effects such as the electron beam trajectory swinging and the beam size changing for the microfocus X-ray tube, it could alleviate CT image artifacts caused by the X-ray focal spot shift and size change.
27249559	0	5	Study	T059	C0947630
27249559	13	23	Microfocus	T082	C0205234
27249559	24	34	X-Ray Tube	T074	C0184486
27249559	46	63	Point-Like Target	T169	C1521840
27249559	73	98	Micro-Computed Tomography	T060	C2350281
27249559	105	148	micro-Computed Tomography (Micro-CT) system	T060	C2350281
27249559	154	164	microfocus	T082	C0205234
27249559	165	175	X-ray tube	T074	C0184486
27249559	182	191	essential	T080	C0205224
27249559	214	221	spatial	T082	C1254362
27249559	222	232	resolution	T081	C1706463
27249559	236	238	CT	T060	C0040405
27249559	239	245	images	T170	C1704254
27249559	250	256	theory	T078	C0871935
27249559	286	290	size	T082	C0456389
27249559	295	304	stability	T080	C0205360
27249559	312	317	X-ray	T060	C0043299
27249559	318	328	focal spot	T082	C0205146
27249559	336	346	microfocus	T082	C0205234
27249559	347	357	X-ray tube	T074	C0184486
27249559	373	380	factors	T169	C1521761
27249559	392	399	voltage	T081	C0598352
27249559	400	412	fluctuations	T079	C0231241
27249559	414	424	mechanical	T070	C0376706
27249559	425	435	vibrations	T070	C0459800
27249559	441	460	temperature changes	T080	C0450031
27249559	466	471	cause	T078	C0085978
27249559	476	480	size	T082	C0456389
27249559	489	498	stability	T080	C0205360
27249559	506	511	X-ray	T060	C0043299
27249559	512	522	focal spot	T082	C0205146
27249559	526	533	degrade	T067	C1254366
27249559	541	551	microfocus	T082	C0205234
27249559	552	562	X-ray tube	T074	C0184486
27249559	574	597	point-like micro-target	T169	C1521840
27249559	611	616	X-ray	T060	C0043299
27249559	617	623	target	T169	C1521840
27249559	627	637	irradiated	T067	C1254366
27249559	656	669	electron beam	T073	C0013840
27249559	674	686	investigated	T169	C1292732
27249559	688	720	EGS4 Monte Carlo simulation code	T081	C0026507
27249559	742	753	calculation	T052	C1441506
27249559	761	766	X-ray	T060	C0043299
27249559	767	776	intensity	T070	C0596836
27249559	795	818	point-like micro-target	T169	C1521840
27249559	827	836	substrate	T167	C3891814
27249559	842	852	effects of	T080	C1704420
27249559	881	887	target	T169	C1521840
27249559	888	896	material	T167	C0520510
27249559	898	904	target	T169	C1521840
27249559	909	913	beam	T073	C0013840
27249559	914	918	size	T082	C0456389
27249559	924	931	studied	T059	C0947630
27249559	937	947	simulation	T062	C0679083
27249559	948	955	results	T169	C1274040
27249559	981	990	intensity	T070	C0596836
27249559	994	1000	X-rays	T060	C0043299
27249559	1001	1010	generated	T080	C2346631
27249559	1018	1035	point-like target	T169	C1521840
27249559	1039	1051	greater than	T081	C0439093
27249559	1064	1069	X-ray	T060	C0043299
27249559	1070	1079	intensity	T070	C0596836
27249559	1096	1105	substrate	T167	C3891814
27249559	1111	1116	X-ray	T060	C0043299
27249559	1117	1127	focal spot	T082	C0205146
27249559	1157	1174	point-like target	T169	C1521840
27249559	1194	1207	electron beam	T073	C0013840
27249559	1215	1227	conventional	T080	C0439858
27249559	1228	1238	X-ray tube	T074	C0184486
27249559	1243	1249	theory	T078	C0871935
27249559	1271	1277	reduce	T080	C0392756
27249559	1296	1303	effects	T080	C1280500
27249559	1316	1349	electron beam trajectory swinging	T033	C0243095
27249559	1358	1362	beam	T073	C0013840
27249559	1363	1367	size	T082	C0456389
27249559	1368	1376	changing	T169	C0392747
27249559	1385	1395	microfocus	T082	C0205234
27249559	1396	1406	X-ray tube	T074	C0184486
27249559	1417	1426	alleviate	T080	C0392756
27249559	1427	1429	CT	T060	C0040405
27249559	1430	1435	image	T170	C1704254
27249559	1436	1445	artifacts	T068	C0085089
27249559	1446	1452	caused	T078	C0085978
27249559	1460	1465	X-ray	T060	C0043299
27249559	1466	1476	focal spot	T082	C0205146
27249559	1477	1482	shift	T033	C3845720
27249559	1487	1498	size change	T081	C0541591

27250037|t|How variation between individuals affects species coexistence
27250037|a|Although the effects of variation between individuals within species are traditionally ignored in studies of species coexistence, the magnitude of intraspecific variation in nature is forcing ecologists to reconsider. Compelling intuitive arguments suggest that individual variation may provide a previously unrecognised route to diversity maintenance by blurring species - level competitive differences or substituting for species - level niche differences. These arguments, which are motivating a large body of empirical work, have rarely been evaluated with quantitative theory. Here we incorporate intraspecific variation into a common model of competition and identify three pathways by which this variation affects coexistence: (1) changes in competitive dynamics because of nonlinear averaging, (2) changes in species ' mean interaction strengths because of variation in underlying traits (also via nonlinear averaging) and (3) effects on stochastic demography. As a consequence of the first two mechanisms, we find that intraspecific variation in competitive ability increases the dominance of superior competitors, and intraspecific niche variation reduces species - level niche differentiation, both of which make coexistence more difficult. In addition, individual variation can exacerbate the effects of demographic stochasticity, and this further destabilises coexistence. Our work provides a theoretical foundation for emerging empirical interests in the effects of intraspecific variation on species diversity.
27250037	4	13	variation	T080	C0205419
27250037	14	21	between	T082	C0205103
27250037	22	33	individuals	T098	C0237401
27250037	34	41	affects	T080	C1280500
27250037	42	49	species	T185	C1705920
27250037	50	61	coexistence	T081	C1547035
27250037	75	82	effects	T080	C1280500
27250037	86	95	variation	T080	C0205419
27250037	96	103	between	T082	C0205103
27250037	104	115	individuals	T098	C0237401
27250037	123	130	species	T185	C1705920
27250037	135	148	traditionally	T169	C0443324
27250037	149	156	ignored	T078	C1554079
27250037	160	167	studies	T062	C2603343
27250037	171	178	species	T185	C1705920
27250037	179	190	coexistence	T081	C1547035
27250037	196	205	magnitude	T081	C1704240
27250037	209	222	intraspecific	T169	C0205245
27250037	223	232	variation	T080	C0205419
27250037	236	242	nature	T078	C0349590
27250037	246	253	forcing	T169	C0443221
27250037	254	264	ecologists	T097	C0259852
27250037	268	278	reconsider	T169	C0699752
27250037	291	300	intuitive	T055	C0021619
27250037	301	310	arguments	T054	C0680226
27250037	311	318	suggest	T078	C1705535
27250037	324	334	individual	T098	C0237401
27250037	335	344	variation	T080	C0205419
27250037	349	356	provide	T052	C1999230
27250037	383	388	route	T082	C0449444
27250037	392	401	diversity	T080	C0282469
27250037	402	413	maintenance	T052	C0024501
27250037	417	425	blurring	T080	C1511231
27250037	426	433	species	T185	C1705920
27250037	436	441	level	T080	C0441889
27250037	442	453	competitive	T054	C0679932
27250037	454	465	differences	T080	C1705242
27250037	469	481	substituting	T169	C0559956
27250037	486	493	species	T185	C1705920
27250037	496	501	level	T080	C0441889
27250037	502	507	niche	T169	C0205245
27250037	508	519	differences	T080	C1705242
27250037	527	536	arguments	T054	C0680226
27250037	548	558	motivating	T041	C0026605
27250037	561	566	large	T081	C0549177
27250037	567	571	body	T082	C0678594
27250037	575	584	empirical	T080	C1880496
27250037	585	589	work	T057	C0043227
27250037	596	602	rarely	T080	C0522498
27250037	608	617	evaluated	T081	C0034384
27250037	623	635	quantitative	T081	C0392762
27250037	636	642	theory	T078	C0871935
27250037	664	677	intraspecific	T169	C0205245
27250037	678	687	variation	T080	C0205419
27250037	695	701	common	T081	C0205214
27250037	702	707	model	T170	C3161035
27250037	711	722	competition	T054	C0679932
27250037	727	735	identify	T080	C0205396
27250037	742	750	pathways	T077	C1705987
27250037	765	774	variation	T080	C0205419
27250037	775	782	affects	T080	C1280500
27250037	783	794	coexistence	T081	C1547035
27250037	800	807	changes	T169	C0392747
27250037	811	822	competitive	T054	C0679932
27250037	823	831	dynamics	T170	C0206166
27250037	853	862	averaging	T081	C1510992
27250037	868	875	changes	T169	C0392747
27250037	879	886	species	T185	C1705920
27250037	889	893	mean	T081	C2347634
27250037	894	905	interaction	T169	C1704675
27250037	906	915	strengths	T078	C0808080
27250037	927	936	variation	T080	C0205419
27250037	951	957	traits	T032	C0599883
27250037	978	987	averaging	T081	C1510992
27250037	997	1004	effects	T080	C1280500
27250037	1008	1029	stochastic demography	T062	C0871922
27250037	1036	1050	consequence of	T169	C0686907
27250037	1065	1075	mechanisms	T169	C0441712
27250037	1080	1084	find	T033	C0243095
27250037	1090	1103	intraspecific	T169	C0205245
27250037	1104	1113	variation	T080	C0205419
27250037	1117	1128	competitive	T054	C0679932
27250037	1129	1136	ability	T032	C0085732
27250037	1137	1146	increases	T169	C0442805
27250037	1151	1160	dominance	T078	C0870441
27250037	1164	1172	superior	T080	C0205164
27250037	1173	1184	competitors	T098	C1257890
27250037	1190	1203	intraspecific	T169	C0205245
27250037	1204	1209	niche	T169	C0205245
27250037	1210	1219	variation	T080	C0205419
27250037	1220	1227	reduces	T080	C0392756
27250037	1228	1235	species	T185	C1705920
27250037	1238	1243	level	T080	C0441889
27250037	1244	1249	niche	T169	C0205245
27250037	1250	1265	differentiation	T169	C2945687
27250037	1267	1271	both	T080	C1706086
27250037	1286	1297	coexistence	T081	C1547035
27250037	1298	1302	more	T081	C0205172
27250037	1303	1312	difficult	T080	C0332218
27250037	1327	1337	individual	T098	C0237401
27250037	1338	1347	variation	T080	C0205419
27250037	1352	1362	exacerbate	T169	C0442805
27250037	1367	1374	effects	T080	C1280500
27250037	1378	1403	demographic stochasticity	T062	C0871922
27250037	1422	1434	destabilises	T169	C1883709
27250037	1435	1446	coexistence	T081	C1547035
27250037	1452	1456	work	T057	C0043227
27250037	1457	1465	provides	T052	C1999230
27250037	1468	1490	theoretical foundation	T062,T170	C0039778
27250037	1504	1513	empirical	T080	C1880496
27250037	1514	1523	interests	T041	C0543488
27250037	1531	1538	effects	T080	C1280500
27250037	1542	1555	intraspecific	T169	C0205245
27250037	1556	1565	variation	T080	C0205419
27250037	1569	1576	species	T185	C1705920
27250037	1577	1586	diversity	T080	C0282469

27250793|t|Intracellular Metabolism of Î±,Î²-Unsaturated Carbonyl Compounds, Acrolein, Crotonaldehyde and Methyl Vinyl Ketone, Active Toxicants in Cigarette Smoke: Participation of Glutathione Conjugation Ability and Aldehyde-Ketone Sensitive Reductase Activity
27250793|a|The major toxicants in cigarette smoke, Î±,Î²-unsaturated aldehydes, such as acrolein (ACR) and crotonaldehyde (CA), and Î±,Î²-unsaturated ketone, methyl vinyl ketone (MVK), are known to form Michael-type adducts with glutathione (GSH) and consequently cause intracellular GSH depletion, which is involved in cigarette smoke - induced cytotoxicity. We have previously clarified that exposure to cigarette smoke extract (CSE) of a mouse melanoma cell culture medium causes rapid reduction of intracellular GSH levels, and that the GSH - MVK adduct can be detected by LC/MS analysis while the GSH - CA adduct is hardly detected. In the present study, to clarify why the GSH - CA adduct is difficult to detect in the cell medium, we conducted detailed investigation of the structures of the reaction products of ACR, CA, MVK and CSE in the GSH solution or the cell culture medium. The mass spectra indicated that in the presence of the cells, the GSH - CA and GSH - ACR adducts were almost not detected while their corresponding alcohols were detected. On the other hand, both the GSH - MVK adducts and their reduced products were detected. In the absence of the cells, the reaction of GSH with all Î±,Î²-unsaturated carbonyls produced only their corresponding adducts. These results show that the GSH adducts of Î±,Î²-unsaturated aldehydes, CA and ACR, are quickly reduced by certain intracellular carbonyl reductase(s) and excreted from the cells, unlike the GSH adduct of Î±,Î²-unsaturated ketone, MVK. Such a difference in reactivity to the carbonyl reductase might be related to differences in the cytotoxicity of Î±,Î²-unsaturated aldehydes and ketones.
27250793	0	24	Intracellular Metabolism	T043	C1524026
27250793	28	62	Î±,Î²-Unsaturated Carbonyl Compounds	T109	C0596258
27250793	64	72	Acrolein	T109,T130	C0001204
27250793	74	88	Crotonaldehyde	T109,T131	C0045968
27250793	93	112	Methyl Vinyl Ketone	T109	C0047269
27250793	114	120	Active	T169	C0205177
27250793	121	130	Toxicants	T131	C0599787
27250793	134	149	Cigarette Smoke	T131	C0239059
27250793	168	179	Glutathione	T116,T123	C0017817
27250793	180	191	Conjugation	T044	C1148560
27250793	204	248	Aldehyde-Ketone Sensitive Reductase Activity	T044	C1151208
27250793	259	268	toxicants	T131	C0599787
27250793	272	287	cigarette smoke	T131	C0239059
27250793	289	314	Î±,Î²-unsaturated aldehydes	T109	C0001992
27250793	324	332	acrolein	T109,T130	C0001204
27250793	334	337	ACR	T109,T130	C0001204
27250793	343	357	crotonaldehyde	T109,T131	C0045968
27250793	359	361	CA	T109,T131	C0045968
27250793	368	390	Î±,Î²-unsaturated ketone	T109	C0022634
27250793	392	411	methyl vinyl ketone	T109	C0047269
27250793	413	416	MVK	T109	C0047269
27250793	437	457	Michael-type adducts	T104	C0596040
27250793	463	474	glutathione	T116,T123	C0017817
27250793	476	479	GSH	T116,T123	C0017817
27250793	504	517	intracellular	T082	C0178719
27250793	518	521	GSH	T116,T123	C0017817
27250793	522	531	depletion	T169	C0333668
27250793	554	569	cigarette smoke	T131	C0239059
27250793	572	579	induced	T169	C0205263
27250793	580	592	cytotoxicity	T049	C0596402
27250793	628	639	exposure to	T080	C0332157
27250793	640	663	cigarette smoke extract	T131	C0239059
27250793	665	668	CSE	T131	C0239059
27250793	675	680	mouse	T015	C0025929
27250793	681	694	melanoma cell	T025	C1513095
27250793	695	709	culture medium	T130	C0010454
27250793	723	732	reduction	T080	C0392756
27250793	736	749	intracellular	T082	C0178719
27250793	750	753	GSH	T116,T123	C0017817
27250793	754	760	levels	T080	C0441889
27250793	775	778	GSH	T116,T123	C0017817
27250793	781	784	MVK	T109	C0047269
27250793	785	791	adduct	T104	C0596040
27250793	799	807	detected	T033	C0442726
27250793	811	825	LC/MS analysis	T059	C0872318
27250793	836	839	GSH	T116,T123	C0017817
27250793	842	844	CA	T109,T131	C0045968
27250793	845	851	adduct	T104	C0596040
27250793	862	870	detected	T033	C0442726
27250793	887	892	study	T062	C2603343
27250793	913	916	GSH	T116,T123	C0017817
27250793	919	921	CA	T109,T131	C0045968
27250793	922	928	adduct	T104	C0596040
27250793	945	951	detect	T033	C0442726
27250793	959	963	cell	T025	C1513095
27250793	964	970	medium	T130	C0010454
27250793	994	1007	investigation	T169	C1292732
27250793	1015	1025	structures	T082	C0026377
27250793	1033	1050	reaction products	T104	C0596040
27250793	1054	1057	ACR	T109,T130	C0001204
27250793	1059	1061	CA	T109,T131	C0045968
27250793	1063	1066	MVK	T109	C0047269
27250793	1071	1074	CSE	T131	C0239059
27250793	1082	1085	GSH	T116,T123	C0017817
27250793	1086	1094	solution	T167	C0037633
27250793	1102	1106	cell	T025	C1513095
27250793	1107	1121	culture medium	T130	C0010454
27250793	1127	1139	mass spectra	T059	C0037813
27250793	1162	1170	presence	T080	C3854307
27250793	1178	1183	cells	T025	C1513095
27250793	1189	1192	GSH	T116,T123	C0017817
27250793	1195	1197	CA	T109,T131	C0045968
27250793	1202	1205	GSH	T116,T123	C0017817
27250793	1208	1211	ACR	T109,T130	C0001204
27250793	1212	1219	adducts	T104	C0596040
27250793	1236	1244	detected	T033	C0442726
27250793	1257	1279	corresponding alcohols	T109,T121	C0001975
27250793	1285	1293	detected	T033	C0442726
27250793	1323	1326	GSH	T116,T123	C0017817
27250793	1329	1332	MVK	T109	C0047269
27250793	1333	1340	adducts	T104	C0596040
27250793	1351	1367	reduced products	T071	C1514468
27250793	1373	1381	detected	T033	C0442726
27250793	1405	1410	cells	T025	C1513095
27250793	1416	1424	reaction	T169	C0443286
27250793	1428	1431	GSH	T116,T123	C0017817
27250793	1441	1466	Î±,Î²-unsaturated carbonyls	T109	C0596258
27250793	1501	1508	adducts	T104	C0596040
27250793	1516	1523	results	T169	C1274040
27250793	1538	1541	GSH	T116,T123	C0017817
27250793	1542	1549	adducts	T104	C0596040
27250793	1553	1578	Î±,Î²-unsaturated aldehydes	T109	C0001992
27250793	1580	1582	CA	T109,T131	C0045968
27250793	1587	1590	ACR	T109,T130	C0001204
27250793	1604	1611	reduced	T070	C0301630
27250793	1623	1636	intracellular	T082	C0178719
27250793	1637	1658	carbonyl reductase(s)	T116,T126	C1135630
27250793	1681	1686	cells	T025	C1513095
27250793	1699	1702	GSH	T116,T123	C0017817
27250793	1703	1709	adduct	T104	C0596040
27250793	1713	1735	Î±,Î²-unsaturated ketone	T109	C0022634
27250793	1737	1740	MVK	T109	C0047269
27250793	1763	1773	reactivity	T169	C0443286
27250793	1781	1799	carbonyl reductase	T044	C1151208
27250793	1839	1851	cytotoxicity	T049	C0596402
27250793	1855	1880	Î±,Î²-unsaturated aldehydes	T109	C0001992
27250793	1885	1892	ketones	T109	C0022634

27250823|t|Diagnostic utility of additional conventional techniques after endobronchial ultrasonography guidance during transbronchial biopsy
27250823|a|Endobronchial ultrasonography with a guide sheath transbronchial biopsy (EBUS - GS TBB) has been used to diagnose peripheral pulmonary lesions (PPLs). In this study, we evaluated the diagnostic utility of conventional TBB after EBUS - GS TBB. A retrospective analysis of patients who underwent conventional TBB after EBUS - GS TBB for PPL between August 1, 2012 and December 31, 2014. We performed multivariate analysis to examine the association of various clinical factors, including EBUS probe distance and sample size area, with diagnostic yield. Of 88 eligible patients, 57 (65%) were successfully diagnosed by EBUS - GS TBB. In 31 patients not diagnosed by EBUS - GS TBB, 15 (48%) were successfully diagnosed by additional conventional TBB. Ground glass opacity (GGO) was a significant factor associated with the diagnostic yield of additional conventional TBB following EBUS - GS TBB. Multivariate analysis and receiver operator curves revealed that distance between the PPL and the EBUS probe of less than 2.55 mm favored the utility of conventional TBB. Additional conventional TBB after EBUS - GS TBB could be a useful procedure for the diagnosis of ground glass opacity PPLs and in cases of a distance of less than 2.55 mm between the EBUS probe and the lesion.
27250823	0	10	Diagnostic	T169	C0348026
27250823	11	18	utility	T169	C0457083
27250823	33	45	conventional	T081	C0205214
27250823	46	56	techniques	T060	C0430022
27250823	63	92	endobronchial ultrasonography	T060	C2959489
27250823	93	101	guidance	T058	C0150600
27250823	109	130	transbronchial biopsy	T060	C0863477
27250823	131	160	Endobronchial ultrasonography	T060	C2959489
27250823	168	180	guide sheath	T074	C0025080
27250823	181	202	transbronchial biopsy	T060	C0863477
27250823	204	208	EBUS	T060	C2959489
27250823	211	213	GS	T074	C0025080
27250823	214	217	TBB	T060	C0863477
27250823	236	244	diagnose	T033	C0011900
27250823	245	273	peripheral pulmonary lesions	T033	C0577916
27250823	275	279	PPLs	T033	C0577916
27250823	290	295	study	T062	C2603343
27250823	314	324	diagnostic	T169	C0348026
27250823	325	332	utility	T169	C0457083
27250823	336	348	conventional	T081	C0205214
27250823	349	352	TBB	T060	C0863477
27250823	359	363	EBUS	T060	C2959489
27250823	366	368	GS	T074	C0025080
27250823	369	372	TBB	T060	C0863477
27250823	376	398	retrospective analysis	T062	C0035363
27250823	402	410	patients	T101	C0030705
27250823	425	437	conventional	T081	C0205214
27250823	438	441	TBB	T060	C0863477
27250823	448	452	EBUS	T060	C2959489
27250823	455	457	GS	T074	C0025080
27250823	458	461	TBB	T060	C0863477
27250823	466	469	PPL	T033	C0577916
27250823	529	550	multivariate analysis	T081	C0026777
27250823	566	577	association	T080	C0439849
27250823	589	597	clinical	T080	C0205210
27250823	598	605	factors	T169	C1521761
27250823	617	621	EBUS	T060	C2959489
27250823	622	627	probe	T074	C0182400
27250823	628	636	distance	T081	C0012751
27250823	641	652	sample size	T081	C0242618
27250823	653	657	area	T082	C0205146
27250823	664	680	diagnostic yield	T080	C0205556
27250823	697	705	patients	T101	C0030705
27250823	734	743	diagnosed	T033	C0011900
27250823	747	751	EBUS	T060	C2959489
27250823	754	756	GS	T074	C0025080
27250823	757	760	TBB	T060	C0863477
27250823	768	776	patients	T101	C0030705
27250823	781	790	diagnosed	T033	C0011900
27250823	794	798	EBUS	T060	C2959489
27250823	801	803	GS	T074	C0025080
27250823	804	807	TBB	T060	C0863477
27250823	836	845	diagnosed	T033	C0011900
27250823	860	872	conventional	T081	C0205214
27250823	873	876	TBB	T060	C0863477
27250823	878	898	Ground glass opacity	T033	C3827002
27250823	900	903	GGO	T033	C3827002
27250823	911	922	significant	T078	C0750502
27250823	923	929	factor	T169	C1521761
27250823	950	966	diagnostic yield	T080	C0205556
27250823	981	993	conventional	T081	C0205214
27250823	994	997	TBB	T060	C0863477
27250823	1008	1012	EBUS	T060	C2959489
27250823	1015	1017	GS	T074	C0025080
27250823	1018	1021	TBB	T060	C0863477
27250823	1023	1044	Multivariate analysis	T081	C0026777
27250823	1049	1073	receiver operator curves	T081	C0035787
27250823	1088	1096	distance	T081	C0012751
27250823	1109	1112	PPL	T033	C0577916
27250823	1121	1125	EBUS	T060	C2959489
27250823	1126	1131	probe	T074	C0182400
27250823	1165	1172	utility	T169	C0457083
27250823	1176	1188	conventional	T081	C0205214
27250823	1189	1192	TBB	T060	C0863477
27250823	1205	1217	conventional	T081	C0205214
27250823	1218	1221	TBB	T060	C0863477
27250823	1228	1232	EBUS	T060	C2959489
27250823	1235	1237	GS	T074	C0025080
27250823	1238	1241	TBB	T060	C0863477
27250823	1260	1269	procedure	T060	C0430022
27250823	1278	1287	diagnosis	T033	C0011900
27250823	1291	1311	ground glass opacity	T033	C3827002
27250823	1312	1316	PPLs	T033	C0577916
27250823	1324	1329	cases	T169	C0868928
27250823	1335	1343	distance	T081	C0012751
27250823	1377	1381	EBUS	T060	C2959489
27250823	1382	1387	probe	T074	C0182400
27250823	1396	1402	lesion	T033	C0577916

27250949|t|Strategies for Assaying Lysosomal Membrane Permeabilization
27250949|a|Late endosomal organelles have an acidic pH and contain hydrolytic enzymes to degrade cargo delivered either from the extracellular environment by endocytosis or from within the cell itself by autophagy. In the event of lysosomal membrane permeabilization (LMP), the contents of late endosomes and lysosomes can be released into the cytosol and then initiate apoptosis. Compounds that can trigger LMP are therefore candidates for the induction of apoptosis, in particular in anticancer therapy. Alternatively, drug-delivery systems, such as nanoparticles, can have side effects that can include LMP, which has toxic consequences for the cells. To determine when, to what extent, and with what consequences LMP occurs is therefore of paramount importance for the evaluation of new potentially LMP - inducing compounds. In this introduction, we provide an overview of some basic assays for assessing LMP, such as staining with lysosomotropic dyes and measurement of cysteine cathepsin activity, and discuss additional strategies for the detection of the release of endogenous lysosomal molecules or preloaded exogenous tracers into the cytosol.
27250949	0	10	Strategies	T061	C0184661
27250949	15	23	Assaying	T059	C1510438
27250949	24	42	Lysosomal Membrane	T026	C0230812
27250949	43	59	Permeabilization	T043	C0007613
27250949	60	74	Late endosomal	T026	C1166848
27250949	75	85	organelles	T026	C0029219
27250949	94	103	acidic pH	T081	C0020283
27250949	116	134	hydrolytic enzymes	T116,T126	C0020289
27250949	138	145	degrade	T169	C0243125
27250949	178	191	extracellular	T026	C0521119
27250949	192	203	environment	T082	C0014406
27250949	207	218	endocytosis	T043	C0014139
27250949	238	242	cell	T025	C0007634
27250949	253	262	autophagy	T043	C0004391
27250949	280	298	lysosomal membrane	T026	C0230812
27250949	299	315	permeabilization	T043	C0007613
27250949	317	320	LMP	T043	C0007613
27250949	339	353	late endosomes	T026	C1166848
27250949	358	367	lysosomes	T026	C0024369
27250949	393	400	cytosol	T026	C1383501
27250949	419	428	apoptosis	T043	C0162638
27250949	430	439	Compounds	T080	C0205198
27250949	457	460	LMP	T043	C0007613
27250949	494	503	induction	T169	C0205263
27250949	507	516	apoptosis	T043	C0162638
27250949	535	553	anticancer therapy	T061	C0920425
27250949	570	591	drug-delivery systems	T074	C0085104
27250949	601	614	nanoparticles	T073	C1450054
27250949	655	658	LMP	T043	C0007613
27250949	670	688	toxic consequences	T037	C0600688
27250949	697	702	cells	T025	C0007634
27250949	753	765	consequences	T078	C1547646
27250949	766	769	LMP	T043	C0007613
27250949	793	813	paramount importance	T080	C3898777
27250949	822	832	evaluation	T058	C0220825
27250949	836	839	new	T080	C0205314
27250949	840	851	potentially	T080	C3245505
27250949	852	855	LMP	T043	C0007613
27250949	858	876	inducing compounds	T080	C0205198
27250949	931	943	basic assays	T059	C1510438
27250949	948	957	assessing	T058	C0184514
27250949	958	961	LMP	T043	C0007613
27250949	985	1004	lysosomotropic dyes	T130	C0013343
27250949	1024	1032	cysteine	T116,T123	C0010654
27250949	1033	1042	cathepsin	T116,T126	C0007428
27250949	1043	1051	activity	T044	C0243102
27250949	1076	1086	strategies	T061	C0184661
27250949	1095	1104	detection	T061	C1511790
27250949	1112	1119	release	T169	C1283071
27250949	1123	1133	endogenous	T169	C0205227
27250949	1134	1143	lysosomal	T026	C0024369
27250949	1144	1153	molecules	T167	C0567416
27250949	1167	1176	exogenous	T169	C0205228
27250949	1177	1184	tracers	T130	C1522485
27250949	1194	1201	cytosol	T026	C1383501

27251117|t|Active diffusion and microtubule-based transport oppose myosin forces to position organelles in cells
27251117|a|Even distribution of peroxisomes (POs) and lipid droplets (LDs) is critical to their role in lipid and reactive oxygen species homeostasis. How even distribution is achieved remains elusive, but diffusive motion and directed motility may play a role. Here we show that in the fungus Ustilago maydis ~95% of POs and LDs undergo diffusive motions. These movements require ATP and involve bidirectional early endosome motility, indicating that microtubule - associated membrane trafficking enhances diffusion of organelles. When early endosome transport is abolished, POs and LDs drift slowly towards the growing cell end. This pole-ward drift is facilitated by anterograde delivery of secretory cargo to the cell tip by myosin-5. Modelling reveals that microtubule-based directed transport and active diffusion support distribution, mobility and mixing of POs. In mammalian COS-7 cells, microtubules and F-actin also counteract each other to distribute POs. This highlights the importance of opposing cytoskeletal forces in organelle positioning in eukaryotes.
27251117	0	6	Active	T169	C0205177
27251117	7	16	diffusion	T070	C0012222
27251117	21	48	microtubule-based transport	T043	C2755890
27251117	56	62	myosin	T116,T123	C0033684
27251117	63	69	forces	T067	C0441722
27251117	73	81	position	T082	C0733755
27251117	82	92	organelles	T026	C0029219
27251117	96	101	cells	T025	C0007634
27251117	107	119	distribution	T169	C1704711
27251117	123	134	peroxisomes	T026	C0752063
27251117	136	139	POs	T026	C0752063
27251117	145	159	lipid droplets	T026	C0230704
27251117	161	164	LDs	T026	C0230704
27251117	187	191	role	T077	C1705810
27251117	195	200	lipid	T109	C0023779
27251117	205	228	reactive oxygen species	T123,T196	C0162772
27251117	229	240	homeostasis	T038	C0019868
27251117	251	263	distribution	T169	C1704711
27251117	297	313	diffusive motion	T070	C0012222
27251117	327	335	motility	T040	C0007608
27251117	347	351	role	T077	C1705810
27251117	378	384	fungus	T004	C0016832
27251117	385	400	Ustilago maydis	T004	C0446013
27251117	409	412	POs	T026	C0752063
27251117	417	420	LDs	T026	C0230704
27251117	429	446	diffusive motions	T070	C0012222
27251117	454	463	movements	T040	C0007608
27251117	472	475	ATP	T114,T121,T123	C0001480
27251117	488	501	bidirectional	T080	C1706937
27251117	508	516	endosome	T026	C0034850
27251117	517	525	motility	T040	C0007608
27251117	543	554	microtubule	T026	C0026046
27251117	557	567	associated	T080	C0332281
27251117	568	576	membrane	T026	C0596901
27251117	577	588	trafficking	T043	C0599896
27251117	589	597	enhances	T052	C2349975
27251117	598	607	diffusion	T070	C0012222
27251117	611	621	organelles	T026	C0029219
27251117	634	652	endosome transport	T043	C1156042
27251117	667	670	POs	T026	C0752063
27251117	675	678	LDs	T026	C0230704
27251117	704	720	growing cell end	T026	C3159038
27251117	727	742	pole-ward drift	T043	C0007613
27251117	761	781	anterograde delivery	T043	C0598952
27251117	785	800	secretory cargo	T116,T123	C0597427
27251117	808	816	cell tip	T026	C1656978
27251117	820	828	myosin-5	T116,T126	C0969679
27251117	830	839	Modelling	T062	C0870071
27251117	853	889	microtubule-based directed transport	T043	C2755890
27251117	894	900	active	T169	C0205177
27251117	901	910	diffusion	T070	C0012222
27251117	919	931	distribution	T169	C1704711
27251117	933	941	mobility	T043	C1516353
27251117	956	959	POs	T026	C0752063
27251117	964	973	mammalian	T015	C0024660
27251117	974	985	COS-7 cells	T025	C1257858
27251117	987	999	microtubules	T026	C0026046
27251117	1004	1011	F-actin	T116,T123	C1180307
27251117	1042	1052	distribute	T169	C1704711
27251117	1053	1056	POs	T026	C0752063
27251117	1101	1113	cytoskeletal	T026	C0010853
27251117	1114	1120	forces	T067	C0441722
27251117	1124	1133	organelle	T026	C0029219
27251117	1134	1145	positioning	T082	C0733755
27251117	1149	1159	eukaryotes	T204	C0684063

27251157|t|Stimulation of cell proliferation by glutathione monoethyl ester in aged bone marrow stromal cells is associated with the assistance of TERT gene expression and telomerase activity
27251157|a|The proliferation and differentiation potential of aged bone marrow stromal cells (BMSCs) are significantly reduced. In order to improve the performance of the aged BMSCs, these cells were treated with 2 mM glutathione monoethyl ester (GSH-MEE) for 24 h. Proliferation rate, telomerase activity, telomere length, and differentiation to cholinergic neuron-like cells (CNLCs) were observed to increase. Though, the expression level of telomerase reverse transcriptase gene increased, but CTC1 and TEN1 genes from Ctc1-Stn1-Ten1 complex encoding proteins with regulatory function significantly decreased. Trypan blue exclusion assay was used to analyze the proliferation and, while telomere length, its several related gene expressions, and telomerase activity were measured using the real time reverse transcription-polymerase chain reaction and polymerase chain reaction enzyme-linked immunosorbent assay techniques, respectively. CNLCs differentiation potential was evaluated by estimating the percentage of choline acetyltransferase immunereactive cells .The results suggested that GSH-MEE could improve aged rat BMSC properties and would be of potential benefit for enhancing the performance of aged people's BMSCs.
27251157	0	11	Stimulation	T169	C1704686
27251157	15	33	cell proliferation	T043	C0596290
27251157	37	64	glutathione monoethyl ester	T116,T121	C0073870
27251157	68	98	aged bone marrow stromal cells	T025	C1640380
27251157	102	117	associated with	T080	C0332281
27251157	136	140	TERT	T028	C1367342
27251157	141	156	gene expression	T045	C0017262
27251157	161	180	telomerase activity	T045	C1148756
27251157	185	198	proliferation	T043	C0596290
27251157	203	218	differentiation	T043	C0007589
27251157	219	228	potential	T080	C3245505
27251157	232	262	aged bone marrow stromal cells	T025	C1640380
27251157	264	269	BMSCs	T025	C1640380
27251157	289	296	reduced	T080	C0392756
27251157	310	317	improve	T033	C0184511
27251157	341	345	aged	T032	C0001779
27251157	346	351	BMSCs	T025	C1640380
27251157	359	364	cells	T025	C0007634
27251157	370	377	treated	T169	C1522326
27251157	388	415	glutathione monoethyl ester	T116,T121	C0073870
27251157	417	424	GSH-MEE	T116,T121	C0073870
27251157	436	449	Proliferation	T043	C0596290
27251157	450	454	rate	T081	C1521828
27251157	456	475	telomerase activity	T045	C1148756
27251157	477	485	telomere	T026	C0085187
27251157	486	492	length	T081	C1444754
27251157	498	513	differentiation	T043	C0007589
27251157	517	546	cholinergic neuron-like cells	T025	C2333949
27251157	548	553	CNLCs	T025	C2333949
27251157	572	580	increase	T169	C0442805
27251157	594	610	expression level	T081	C3244092
27251157	614	651	telomerase reverse transcriptase gene	T028	C1367342
27251157	652	661	increased	T169	C0442805
27251157	667	671	CTC1	T028	C1824460
27251157	676	686	TEN1 genes	T028	C2751072
27251157	692	714	Ctc1-Stn1-Ten1 complex	T026	C0243092
27251157	715	723	encoding	T052	C2700640
27251157	724	732	proteins	T116,T123	C0033684
27251157	738	757	regulatory function	T045	C0017263
27251157	772	781	decreased	T081	C0205216
27251157	783	810	Trypan blue exclusion assay	T059	C0005507
27251157	835	848	proliferation	T043	C0596290
27251157	860	868	telomere	T026	C0085187
27251157	869	875	length	T081	C1444754
27251157	897	913	gene expressions	T045	C0017262
27251157	919	938	telomerase activity	T045	C1148756
27251157	963	1020	real time reverse transcription-polymerase chain reaction	T063	C0599161
27251157	1025	1050	polymerase chain reaction	T063	C0032520
27251157	1051	1095	enzyme-linked immunosorbent assay techniques	T059	C0014441
27251157	1111	1116	CNLCs	T025	C2333949
27251157	1117	1132	differentiation	T043	C0007589
27251157	1133	1142	potential	T080	C3245505
27251157	1189	1214	choline acetyltransferase	T028	C1413376
27251157	1215	1235	immunereactive cells	T025	C0007634
27251157	1264	1271	GSH-MEE	T116,T121	C0073870
27251157	1278	1285	improve	T033	C0184511
27251157	1291	1294	rat	T015	C0034721
27251157	1295	1299	BMSC	T025	C1640380
27251157	1300	1310	properties	T080	C0871161
27251157	1337	1344	benefit	T081	C0814225
27251157	1349	1358	enhancing	T052	C2349975
27251157	1378	1391	aged people's	T098	C0027361
27251157	1392	1397	BMSCs	T025	C1640380

27251364|t|Wild food plants and fungi used in the mycophilous Tibetan community of Zhagana (Tewo County, Gansu, China)
27251364|a|The aim of the study was to investigate knowledge and use of wild food plants and fungi in a highland valley in the Gannan Tibetan Autonomous Region on the north-eastern edges of the Tibetan Plateau. Field research was carried out in four neighbouring villages in a mountain valley of the Diebu (Tewo) county, surrounded by spruce forests. The study consisted of 30 interviews with single informants, or group interviews (altogether 63 informants). Apart from collecting voucher specimens, we also identified fungi using DNA barcoding. We recorded the use of 54 species of vascular plants. We also recorded the use of 22 mushroom taxa, which made up the largest category of wild foods. Fruits formed the largest category of food plants, with 21 species, larger than the wild greens category, which consisted of 20 species eaten after boiling or frying and 7 as raw snacks. We also recorded the alimentary use of 10 species of edible flowers and 3 species with underground edible organs. On average, 20.8 edible taxa were listed per interview (median - 21). The most listed category of wild foods was green vegetables (mean - 7.5 species, median - 8 species), but fruits and mushrooms were listed nearly as frequently (mean - 6.3, median - 6 and mean - 5.8, - median 6 respectively). Other category lists were very short, e.g., flowers (mean - 1.3, median - 1) and underground edible parts (mean - 0.7, median - 1). Wild vegetables are usually boiled and/or fried and served as side-dishes, or their green parts are eaten as snacks during mountain treks (e.g., peeled rhubarb shoots). Wild fruits are mainly collected by children and eaten raw, they are not stored for further use. The most widely used wild staple foods are Potetilla anserina roots, an important ceremonial food served on such occasions as New Year or at funerals. They are boiled and served with sugar and butter. The most important famine plants remembered by people are the aerial bulbils of Persicaria vivipara. Flowers are used as children's snacks - their nectar is sucked. The number of wild taxa eaten in the studied valley is similar to that of other Tibetan areas. The structure of wild food plant taxa is also very typical for Tibetan speaking areas (e.g., the use of rhubarb shoots, Potentilla anserina, Persicaria vivipara). The studied community show a high level of mycophilia.
27251364	0	16	Wild food plants	T168	C0032099
27251364	21	26	fungi	T004	C0016832
27251364	39	50	mycophilous	T168	C0678206
27251364	51	58	Tibetan	T083	C0040182
27251364	59	68	community	T096	C0009462
27251364	72	79	Zhagana	T083	C0017446
27251364	81	92	Tewo County	T083	C0017446
27251364	94	99	Gansu	T083	C0017446
27251364	101	106	China	T083	C0008115
27251364	123	128	study	T062	C2603343
27251364	136	147	investigate	T169	C1292732
27251364	148	157	knowledge	T170	C0376554
27251364	169	185	wild food plants	T168	C0032099
27251364	190	195	fungi	T004	C0016832
27251364	210	216	valley	T082	C0563004
27251364	224	256	Gannan Tibetan Autonomous Region	T083	C0017446
27251364	291	306	Tibetan Plateau	T083	C0040182
27251364	308	322	Field research	UnknownType	C0683945
27251364	360	368	villages	T083	C0562518
27251364	374	382	mountain	T083	C0442533
27251364	383	389	valley	T082	C0563004
27251364	397	416	Diebu (Tewo) county	T083	C0017446
27251364	432	446	spruce forests	T070	C0086312
27251364	452	457	study	T062	C2603343
27251364	474	484	interviews	T052	C0021822
27251364	497	507	informants	T169	C1550484
27251364	512	528	group interviews	T062	C0018260
27251364	544	554	informants	T169	C1550484
27251364	587	596	specimens	T167	C0370003
27251364	617	622	fungi	T004	C0016832
27251364	629	642	DNA barcoding	T062	C2936547
27251364	670	677	species	T185	C1705920
27251364	681	696	vascular plants	T002	C0682475
27251364	729	742	mushroom taxa	T168	C0678206
27251364	782	792	wild foods	T168	C0016452
27251364	794	800	Fruits	T168	C0016767
27251364	832	843	food plants	T168	C0032099
27251364	853	860	species	T185	C1705920
27251364	878	889	wild greens	T002	C0330098
27251364	922	929	species	T185	C1705920
27251364	930	935	eaten	T040	C0013470
27251364	942	949	boiling	T057	C0578393
27251364	953	959	frying	T057	C0578393
27251364	969	972	raw	T080	C1709843
27251364	973	979	snacks	T168	C0453863
27251364	1023	1030	species	T185	C1705920
27251364	1034	1048	edible flowers	T002	C0330090
27251364	1055	1062	species	T185	C1705920
27251364	1080	1093	edible organs	T168	C0032099
27251364	1112	1123	edible taxa	T168	C0032099
27251364	1140	1149	interview	T052	C0021822
27251364	1193	1203	wild foods	T168	C0016452
27251364	1208	1224	green vegetables	T168	C2348898
27251364	1237	1244	species	T185	C1705920
27251364	1257	1264	species	T185	C1705920
27251364	1271	1277	fruits	T168	C0016767
27251364	1282	1291	mushrooms	T168	C0678206
27251364	1435	1442	flowers	T002	C0330090
27251364	1484	1496	edible parts	T168	C0032099
27251364	1523	1538	Wild vegetables	T168	C0042440
27251364	1551	1557	boiled	T080	C0205556
27251364	1565	1570	fried	T080	C0205556
27251364	1575	1581	served	T057	C0578393
27251364	1607	1618	green parts	T002	C0032098
27251364	1623	1628	eaten	T040	C0013470
27251364	1632	1638	snacks	T168	C0453863
27251364	1646	1654	mountain	T083	C0442533
27251364	1655	1660	treks	T056	C2584300
27251364	1668	1689	peeled rhubarb shoots	T002	C2700376
27251364	1692	1703	Wild fruits	T168	C0016767
27251364	1728	1736	children	T100	C0008059
27251364	1741	1746	eaten	T040	C0013470
27251364	1747	1750	raw	T080	C1709843
27251364	1810	1827	wild staple foods	T168	C0016452
27251364	1832	1850	Potetilla anserina	T002	C1020468
27251364	1851	1856	roots	T002	C0242726
27251364	1871	1886	ceremonial food	T168	C0016452
27251364	1887	1893	served	T057	C0578393
27251364	1902	1911	occasions	T051	C0441471
27251364	1930	1938	funerals	T054	C0870591
27251364	1949	1955	boiled	T080	C0205556
27251364	1960	1966	served	T057	C0578393
27251364	1972	1977	sugar	T109,T121	C0242209
27251364	1982	1988	butter	T168	C0006494
27251364	2009	2015	famine	T067	C0015619
27251364	2016	2022	plants	T002	C0032098
27251364	2037	2043	people	T098	C0027361
27251364	2052	2066	aerial bulbils	T002	C0032098
27251364	2070	2089	Persicaria vivipara	T002	C1925203
27251364	2091	2098	Flowers	T002	C0330090
27251364	2111	2121	children's	T100	C0008059
27251364	2122	2128	snacks	T168	C0453863
27251364	2137	2143	nectar	T123	C2717960
27251364	2169	2178	wild taxa	T002	C0330098
27251364	2179	2184	eaten	T040	C0013470
27251364	2200	2206	valley	T082	C0563004
27251364	2235	2248	Tibetan areas	T083	C0040182
27251364	2267	2282	wild food plant	T168	C0032099
27251364	2313	2320	Tibetan	T171	C0040183
27251364	2330	2335	areas	T083	C0017446
27251364	2354	2368	rhubarb shoots	T002	C2700376
27251364	2370	2389	Potentilla anserina	T002	C1020468
27251364	2391	2410	Persicaria vivipara	T002	C1925203
27251364	2425	2434	community	T096	C0009462
27251364	2456	2466	mycophilia	T168	C0678206

27251800|t|Early assessment of bilateral inguinal hernia repair: A comparison between the laparoscopic total extraperitoneal and Stoppa approaches
27251800|a|The present clinical trial was designed to compare the results of bilateral inguinal hernia repair between patients who underwent the conventional Stoppa technique and laparoscopic total extraperitoneal repair (LTE) with a single mesh and without staple fixation. This controlled, randomised clinical trial was conducted at General Surgery and Trauma of the Clinics Hospital, Medical School, the University of SÎ³o Paulo between September 2010 and February 2011. Totally, 50 male patients, with a bilateral inguinal hernia, older than 25 years were considered eligible for the study. The following parameters were analysed during the early post-operative period: (1) The intensity of surgical trauma, operation time, C-reactive protein (CRP) levels, white blood cell count, bleeding and pain intensity; (2) quality of life assessment; and (3) post-operative complications. LTE procedure was longer than the Stoppa procedure (134.6 min Î 38.3 vs. 90.6 min Î 41.3; P < 0.05). The levels of CRP were higher in the Stoppa group (P < 0.05) but the number of leucocytes, haematocrit, and haemoglobin were similar between the groups (P > 0.05). There was no difference in pain during the 1 st and 7 th post-operative, physical functioning, physical limitation, the impact of pain on daily activities, and the Carolinas Comfort Scale during the 7 th and 15 th post-operative (P > 0.05). Complications occurred in 88% of Stoppa group (22 patients) and 64% in LTE group (16 patients) (P < 0.05). The comparative study between the Stoppa and LTE approaches for the bilateral inguinal hernia repair demonstrated that: (1) The LTE approach showed less surgical trauma despite the longer operation time; (2) Quality of life during the early post-operative period were similar; and (3) Complication rates were higher in the Stoppa group.
27251800	0	5	Early	T079	C1279919
27251800	6	16	assessment	T058	C0220825
27251800	20	52	bilateral inguinal hernia repair	T061	C0198737
27251800	56	66	comparison	T052	C1707455
27251800	79	113	laparoscopic total extraperitoneal	T061	C0087111
27251800	118	135	Stoppa approaches	T061	C0087111
27251800	140	147	present	T079	C0521116
27251800	148	162	clinical trial	T062	C0008976
27251800	179	186	compare	T052	C1707455
27251800	191	198	results	T169	C1274040
27251800	202	234	bilateral inguinal hernia repair	T061	C0198737
27251800	243	251	patients	T101	C0030705
27251800	270	282	conventional	T169	C0443177
27251800	283	299	Stoppa technique	T061	C0087111
27251800	304	345	laparoscopic total extraperitoneal repair	T061	C0521293
27251800	347	350	LTE	T061	C0521293
27251800	366	370	mesh	T074	C0181805
27251800	383	398	staple fixation	T061	C1293125
27251800	417	427	randomised	T062	C0034656
27251800	428	442	clinical trial	T062	C0008976
27251800	460	510	General Surgery and Trauma of the Clinics Hospital	T093	C1708333
27251800	512	526	Medical School	T093	C1708333
27251800	532	555	University of SÎ³o Paulo	T093	C1708333
27251800	610	614	male	T032	C0086582
27251800	615	623	patients	T101	C0030705
27251800	632	657	bilateral inguinal hernia	T190	C0267672
27251800	673	678	years	T079	C0439234
27251800	695	703	eligible	T080	C1548635
27251800	712	717	study	T062	C2603343
27251800	733	743	parameters	T077	C0549193
27251800	749	757	analysed	T062	C0936012
27251800	769	774	early	T079	C1279919
27251800	775	796	post-operative period	T079	C0032790
27251800	806	815	intensity	T080	C0522510
27251800	819	834	surgical trauma	T033	C4060629
27251800	836	850	operation time	T079	C3494201
27251800	852	870	C-reactive protein	T116,T129	C0006560
27251800	872	875	CRP	T116,T129	C0006560
27251800	877	883	levels	T080	C0441889
27251800	885	907	white blood cell count	T059	C0023508
27251800	909	917	bleeding	T046	C0019080
27251800	922	936	pain intensity	T201	C1320357
27251800	942	957	quality of life	T078	C0034380
27251800	958	968	assessment	T058	C0220825
27251800	978	1006	post-operative complications	T046	C0032787
27251800	1008	1021	LTE procedure	T061	C0521293
27251800	1026	1032	longer	T080	C0205166
27251800	1042	1058	Stoppa procedure	T061	C0087111
27251800	1113	1119	levels	T080	C0441889
27251800	1123	1126	CRP	T116,T129	C0006560
27251800	1132	1138	higher	T080	C0205250
27251800	1146	1152	Stoppa	T061	C0087111
27251800	1153	1158	group	T078	C0441833
27251800	1188	1198	leucocytes	T025	C0023516
27251800	1200	1211	haematocrit	T033	C0518014
27251800	1217	1228	haemoglobin	T116,T123	C0019046
27251800	1234	1241	similar	T080	C2348205
27251800	1254	1260	groups	T078	C0441833
27251800	1283	1296	no difference	T033	C3842396
27251800	1300	1304	pain	T184	C0030193
27251800	1330	1344	post-operative	T033	C0241311
27251800	1346	1366	physical functioning	T033	C0516981
27251800	1368	1387	physical limitation	T169	C0449295
27251800	1393	1399	impact	T080	C4049986
27251800	1403	1407	pain	T184	C0030193
27251800	1411	1427	daily activities	T056	C0871707
27251800	1437	1460	Carolinas Comfort Scale	T170	C0349674
27251800	1487	1501	post-operative	T033	C0241311
27251800	1514	1527	Complications	T046	C0009566
27251800	1547	1553	Stoppa	T061	C0087111
27251800	1554	1559	group	T078	C0441833
27251800	1564	1572	patients	T101	C0030705
27251800	1585	1588	LTE	T061	C0521293
27251800	1589	1594	group	T078	C0441833
27251800	1599	1607	patients	T101	C0030705
27251800	1625	1642	comparative study	T062	C1579762
27251800	1655	1661	Stoppa	T061	C0087111
27251800	1666	1669	LTE	T061	C0521293
27251800	1689	1721	bilateral inguinal hernia repair	T061	C0198737
27251800	1749	1752	LTE	T061	C0521293
27251800	1774	1789	surgical trauma	T033	C4060629
27251800	1802	1808	longer	T080	C0205166
27251800	1809	1823	operation time	T079	C3494201
27251800	1829	1844	Quality of life	T078	C0034380
27251800	1856	1861	early	T079	C1279919
27251800	1862	1883	post-operative period	T079	C0032790
27251800	1889	1896	similar	T080	C2348205
27251800	1906	1918	Complication	T046	C0009566
27251800	1919	1924	rates	T081	C1521828
27251800	1930	1936	higher	T080	C0205250
27251800	1944	1950	Stoppa	T061	C0087111
27251800	1951	1956	group	T078	C0441833

27251918|t|The role of catheter ablation in the management of atrial fibrillation
27251918|a|Atrial fibrillation is driven by spontaneous electrical activation emerging from the pulmonary veins. Catheter ablation using either radiofrequency or cryothermal energy electrically isolates these veins from the left atrium, both reducing the burden of atrial fibrillation episodes and improving the patient's symptoms. Catheter ablation is superior to antiarryhthmic drugs when patients are carefully selected. Underlying medical problems - including obesity, hypertension and obstructive sleep apnoea - should be optimally treated before considering ablation. Although this treatment has the potential to cure patients of their symptoms, they should be aware of the important associated procedural complications.
27251918	12	29	catheter ablation	T061	C0162563
27251918	37	47	management	T058	C0376636
27251918	51	70	atrial fibrillation	T047	C0004238
27251918	71	90	Atrial fibrillation	T047	C0004238
27251918	116	137	electrical activation	T040	C1658783
27251918	156	171	pulmonary veins	T023	C0034090
27251918	173	190	Catheter ablation	T061	C0162563
27251918	204	218	radiofrequency	T061	C0850292
27251918	222	240	cryothermal energy	T061	C0010412
27251918	241	253	electrically	T169	C0442828
27251918	254	262	isolates	T169	C0205409
27251918	269	274	veins	T023	C0034090
27251918	284	295	left atrium	T023	C0225860
27251918	302	310	reducing	T080	C0392756
27251918	315	321	burden	T078	C2828008
27251918	325	344	atrial fibrillation	T047	C0004238
27251918	345	353	episodes	T079	C1254367
27251918	372	381	patient's	T101	C0030705
27251918	382	390	symptoms	T184	C1457887
27251918	392	409	Catheter ablation	T061	C0162563
27251918	425	445	antiarryhthmic drugs	T121	C0003195
27251918	451	459	patients	T101	C0030705
27251918	495	511	medical problems	T201	C1715372
27251918	524	531	obesity	T047	C0028754
27251918	533	545	hypertension	T047	C0020538
27251918	550	574	obstructive sleep apnoea	T047	C0520679
27251918	597	604	treated	T169	C1522326
27251918	624	632	ablation	T061	C0547070
27251918	648	657	treatment	T061	C0087111
27251918	666	675	potential	T080	C3245505
27251918	679	683	cure	T077	C1880198
27251918	684	692	patients	T101	C0030705
27251918	702	710	symptoms	T184	C1457887
27251918	761	785	procedural complications	T033	C0742724

27252074|t|The Chinese Herbal Mixture Tien-Hsien Liquid Augments the Anticancer Immunity in Tumor Cell - Vaccinated Mice
27252074|a|Background The Chinese herbal mixture, Tien-Hsien liquid (THL), has been used as an anticancer dietary supplement for more than 20 years. Our previous studies have shown that THL can modulate immune response and inhibit tumor growth. In this study, we further evaluated the effect of THL on anticancer immune response in mice vaccinated with Î³-ray - irradiated tumor cells. Methods The antitumor effect of THL was determined in mice vaccinated with low-tumorigenic CT-26-low colon cancer cells or Î³-ray-irradiated high-tumorigenic CT-26-high colon cancer cells. The number of natural killer (NK) cells and T lymphocytes in the spleen was analyzed by flow cytometry. The tumor - killing activities of NK cells and cytotoxic T lymphocytes (CTLs) were analyzed by flow cytometry using YAC-1 and CT-26-high cells, respectively, as target cells. The levels of IFN-Î³, IL-2, and TNF-Î± were determined by ELISA. Results THL suppressed the growth of CT-26-high tumor in mice previously vaccinated with low-tumorigenic CT-26-low cells or Î³-irradiated CT-26-high cells. THL increased the populations of NK cells and CD4+ T lymphocytes in the spleen and enhanced the tumor - killing activities of NK cells and CTL in mice vaccinated with Î³-irradiated CT-26-high cells. THL increased the production of IFN-Î³, IL-2, and TNF-Î± in mice vaccinated with Î³-irradiated CT-26-high cells. Conclusion THL can enhance the antitumor immune responses in mice vaccinated with killed tumor cells. These results suggest that THL may be used as a complementary medicine for cancer patients previously treated with killed tumor cell vaccines, radiotherapy, or chemotherapy.
27252074	4	18	Chinese Herbal	T080	C3146288
27252074	19	26	Mixture	T167	C0439962
27252074	27	44	Tien-Hsien Liquid	T109,T121	C1528399
27252074	45	53	Augments	T081	C0205217
27252074	58	68	Anticancer	T080	C2986475
27252074	69	77	Immunity	T039	C0020964
27252074	81	91	Tumor Cell	T025	C0597032
27252074	94	104	Vaccinated	T033	C1116171
27252074	105	109	Mice	T015	C0025929
27252074	125	139	Chinese herbal	T080	C3146288
27252074	140	147	mixture	T167	C0439962
27252074	149	166	Tien-Hsien liquid	T109,T121	C1528399
27252074	168	171	THL	T109,T121	C1528399
27252074	194	204	anticancer	T080	C2986475
27252074	205	223	dietary supplement	T168	C0242295
27252074	241	246	years	T079	C0439234
27252074	252	260	previous	T079	C0205156
27252074	261	268	studies	T062	C2603343
27252074	285	288	THL	T109,T121	C1528399
27252074	293	301	modulate	T082	C0443264
27252074	302	317	immune response	T042	C0301872
27252074	322	329	inhibit	T052	C3463820
27252074	330	342	tumor growth	T191	C0598934
27252074	352	357	study	T062	C2603343
27252074	370	379	evaluated	T058	C0220825
27252074	384	390	effect	T080	C1280500
27252074	394	397	THL	T109,T121	C1528399
27252074	401	411	anticancer	T080	C2986475
27252074	412	427	immune response	T042	C0301872
27252074	431	435	mice	T015	C0025929
27252074	436	446	vaccinated	T033	C1116171
27252074	452	457	Î³-ray	T070	C0017011
27252074	460	470	irradiated	T070	C1282930
27252074	471	482	tumor cells	T025	C0597032
27252074	496	505	antitumor	T080	C2986475
27252074	506	512	effect	T080	C1280500
27252074	516	519	THL	T109,T121	C1528399
27252074	524	534	determined	T080	C0521095
27252074	538	542	mice	T015	C0025929
27252074	543	553	vaccinated	T033	C1116171
27252074	559	603	low-tumorigenic CT-26-low colon cancer cells	T025	C0085983
27252074	607	623	Î³-ray-irradiated	T061	C2985557
27252074	624	670	high-tumorigenic CT-26-high colon cancer cells	T025	C0085983
27252074	676	682	number	T081	C0237753
27252074	686	711	natural killer (NK) cells	T025	C0022688
27252074	716	729	T lymphocytes	T025	C0039194
27252074	737	743	spleen	T023	C0037993
27252074	748	756	analyzed	T062	C0936012
27252074	760	774	flow cytometry	T059	C0016263
27252074	780	785	tumor	T191	C0027651
27252074	788	795	killing	T043	C0599733
27252074	796	806	activities	T052	C0441655
27252074	810	818	NK cells	T025	C0022688
27252074	823	846	cytotoxic T lymphocytes	T025	C0039195
27252074	848	852	CTLs	T025	C0039195
27252074	859	867	analyzed	T062	C0936012
27252074	871	885	flow cytometry	T059	C0016263
27252074	892	897	YAC-1	T025	C0085983
27252074	902	918	CT-26-high cells	T025	C0085983
27252074	937	943	target	T169	C1521840
27252074	944	949	cells	T025	C0007634
27252074	955	961	levels	T080	C0441889
27252074	965	970	IFN-Î³	T116,T121,T129	C0021745
27252074	972	976	IL-2	T116,T129	C0021756
27252074	982	987	TNF-Î±	T116,T129	C1456820
27252074	993	1006	determined by	T080	C0521095
27252074	1007	1012	ELISA	T059	C0014441
27252074	1022	1025	THL	T109,T121	C1528399
27252074	1026	1036	suppressed	T169	C1260953
27252074	1041	1047	growth	T040	C0018270
27252074	1051	1067	CT-26-high tumor	T025	C0085983
27252074	1071	1075	mice	T015	C0025929
27252074	1087	1097	vaccinated	T033	C1116171
27252074	1103	1134	low-tumorigenic CT-26-low cells	T025	C0085983
27252074	1138	1150	Î³-irradiated	T061	C2985557
27252074	1151	1167	CT-26-high cells	T025	C0085983
27252074	1169	1172	THL	T109,T121	C1528399
27252074	1173	1182	increased	T081	C0205217
27252074	1202	1210	NK cells	T025	C0022688
27252074	1215	1233	CD4+ T lymphocytes	T025	C0039215
27252074	1241	1247	spleen	T023	C0037993
27252074	1252	1260	enhanced	T052	C2349975
27252074	1265	1270	tumor	T191	C0027651
27252074	1273	1280	killing	T043	C0599733
27252074	1281	1291	activities	T052	C0441655
27252074	1295	1303	NK cells	T025	C0022688
27252074	1308	1311	CTL	T025	C0039195
27252074	1315	1319	mice	T015	C0025929
27252074	1320	1330	vaccinated	T033	C1116171
27252074	1336	1348	Î³-irradiated	T061	C2985557
27252074	1349	1365	CT-26-high cells	T025	C0085983
27252074	1367	1370	THL	T109,T121	C1528399
27252074	1371	1380	increased	T081	C0205217
27252074	1385	1395	production	T169	C0205245
27252074	1399	1404	IFN-Î³	T116,T121,T129	C0021745
27252074	1406	1410	IL-2	T116,T129	C0021756
27252074	1416	1421	TNF-Î±	T116,T129	C1456820
27252074	1425	1429	mice	T015	C0025929
27252074	1430	1440	vaccinated	T033	C1116171
27252074	1446	1458	Î³-irradiated	T061	C2985557
27252074	1459	1475	CT-26-high cells	T025	C0085983
27252074	1488	1491	THL	T109,T121	C1528399
27252074	1496	1503	enhance	T052	C2349975
27252074	1508	1517	antitumor	T080	C2986475
27252074	1518	1534	immune responses	T042	C0301872
27252074	1538	1542	mice	T015	C0025929
27252074	1543	1553	vaccinated	T033	C1116171
27252074	1559	1565	killed	T169	C0205245
27252074	1566	1577	tumor cells	T025	C0597032
27252074	1585	1592	results	T169	C1274040
27252074	1606	1609	THL	T109,T121	C1528399
27252074	1627	1649	complementary medicine	T091	C1148474
27252074	1654	1660	cancer	T191	C0006826
27252074	1661	1669	patients	T101	C0030705
27252074	1670	1680	previously	T079	C0205156
27252074	1681	1688	treated	T169	C1522326
27252074	1694	1720	killed tumor cell vaccines	T116,T121,T129	C0376659
27252074	1722	1734	radiotherapy	T061	C1522449
27252074	1739	1751	chemotherapy	T061	C3665472

27252099|t|Comparison of Head Elevation Protocols Following Femoral Artery Sheath Removal After Coronary Angiography
27252099|a|To compare 2 standard protocols for head elevation following removal of a femoral artery sheath after coronary angiography and their effects on bleeding complications and reported levels of back pain. One protocol involved flat supine bed rest; the other allowed progressive head elevation. A prospective comparative study of 80 adult patients undergoing coronary angiography via the femoral approach. The Numeric Rating Scale was used as the measure of reported pain. No bleeding complications occurred in either group. Both groups had very low mean pain scores. Repeated- measures analysis demonstrated that the experience of pain differed significantly over time by location (F5,70 = 3.864, P = .004), with a notable decrease in pain scores more than 1 hour after sheath removal at the location that used the progressive head elevation protocol. Patients ' satisfaction scores after discharge did not differ significantly between the 2 groups. Patients with a history of chronic back pain had consistently higher pain scores, but those pain scores did not differ significantly by location (or protocol). It appears that using a progressive head - elevation protocol within the first 3 hours after diagnostic angiography is not associated with an increased risk of bleeding complications at the access site and warrants further exploration in the mitigation of back pain associated with prolonged supine bed rest.
27252099	0	10	Comparison	T052	C1707455
27252099	14	18	Head	T029	C0018670
27252099	19	38	Elevation Protocols	T061	C0439775
27252099	49	70	Femoral Artery Sheath	T023	C0015801
27252099	71	78	Removal	T061	C0015252
27252099	85	105	Coronary Angiography	T060	C0085532
27252099	109	116	compare	T052	C1707455
27252099	128	137	protocols	T061	C0008971
27252099	142	146	head	T029	C0018670
27252099	147	156	elevation	T061	C0439775
27252099	180	201	femoral artery sheath	T023	C0015801
27252099	208	228	coronary angiography	T060	C0085532
27252099	239	246	effects	T080	C1280500
27252099	250	258	bleeding	T046	C0019080
27252099	259	272	complications	T046	C0009566
27252099	296	305	back pain	T184	C0004604
27252099	311	319	protocol	T061	C0008971
27252099	334	340	supine	T082	C0038846
27252099	341	349	bed rest	T061	C0004910
27252099	381	385	head	T029	C0018670
27252099	386	395	elevation	T061	C0439775
27252099	411	428	comparative study	T062	C1579762
27252099	435	440	adult	T100	C0001675
27252099	441	449	patients	T101	C0030705
27252099	461	481	coronary angiography	T060	C0085532
27252099	490	497	femoral	T023	C0015811
27252099	498	506	approach	T082	C0449445
27252099	512	532	Numeric Rating Scale	T170	C4050142
27252099	549	556	measure	T081	C0079809
27252099	569	573	pain	T184	C0030193
27252099	578	586	bleeding	T046	C0019080
27252099	587	600	complications	T046	C0009566
27252099	620	625	group	T078	C0441833
27252099	632	638	groups	T078	C0441833
27252099	648	651	low	T080	C0205251
27252099	652	656	mean	T081	C0444504
27252099	657	668	pain scores	T033	C0582148
27252099	680	688	measures	T169	C1879489
27252099	689	697	analysis	T062	C0936012
27252099	734	738	pain	T184	C0030193
27252099	767	771	time	T079	C0040223
27252099	775	783	location	T029	C1515974
27252099	826	834	decrease	T081	C0547047
27252099	838	849	pain scores	T033	C0582148
27252099	862	866	hour	T079	C0439227
27252099	873	879	sheath	T023	C0015801
27252099	880	887	removal	T061	C0015252
27252099	895	903	location	T029	C1515974
27252099	930	934	head	T029	C0018670
27252099	935	953	elevation protocol	T061	C0439775
27252099	955	963	Patients	T101	C0030705
27252099	979	985	scores	T081	C0449820
27252099	1045	1051	groups	T078	C0441833
27252099	1053	1061	Patients	T101	C0030705
27252099	1069	1076	history	T033	C0262926
27252099	1080	1087	chronic	T079	C0205191
27252099	1088	1097	back pain	T184	C0004604
27252099	1122	1133	pain scores	T033	C0582148
27252099	1145	1156	pain scores	T033	C0582148
27252099	1189	1197	location	T029	C1515974
27252099	1202	1210	protocol	T061	C0008971
27252099	1249	1253	head	T029	C0018670
27252099	1256	1274	elevation protocol	T061	C0439775
27252099	1294	1299	hours	T079	C0439227
27252099	1306	1316	diagnostic	T169	C0348026
27252099	1317	1328	angiography	T060	C0002978
27252099	1365	1369	risk	T078	C0035647
27252099	1373	1381	bleeding	T046	C0019080
27252099	1382	1395	complications	T046	C0009566
27252099	1403	1414	access site	T082	C0589360
27252099	1455	1465	mitigation	T080	C0205556
27252099	1469	1478	back pain	T184	C0004604
27252099	1495	1504	prolonged	T079	C0439590
27252099	1505	1511	supine	T082	C0038846
27252099	1512	1520	bed rest	T061	C0004910

27252199|t|Morphological characteristics regulating phallic glans engorgement in the American alligator
27252199|a|The distal part of the crocodilian phallus consists of a bulbous glans containing well-developed vascular tissues that can inflate before or during sexual activity, enlarging and elaborating the glans into a complex, though still functionally undefined, copulatory structure. An enlarged glans putatively interacts with the female cloaca and may change the shape of her reproductive tract to facilitate insemination and increase the probability of fertilization. Here, we investigated the cellular-level properties of the glans and other inflatable phallic tissues associated with the sperm -conducting sulcus spermaticus in the American alligator (Alligator mississippiensis). Using histochemical staining, we visualized and defined collagen and elastin fiber densities and orientations in these tissues. Extracellular matrix architectures provided insights about phallic glans material properties and how they may affect tissue strength and flexibility during inflation and in response to copulatory forces. We also investigated the potential sources of fluids that induce inflation in alligator phalli. Combining serial sectioning and three-dimensional reconstruction, we identified a pair of supracrucal plexus vascular bodies at the proximal end of the alligator phallus that extend distally adjacent to ventro-medial sulcus tissues. Together, our gross and histological examination of the American alligator phallic glans suggests that its tissues are arranged in a manner that would allow vascular inflation to expand the glans to a specific and repeatable shape, and potentially release secretory products into the female reproductive tract. Both elements could play roles in postcopulatory sexual selection, by mechanically and/or chemically affecting female reproductive physiology.
27252199	0	13	Morphological	T082	C0543482
27252199	14	29	characteristics	T080	C1521970
27252199	41	54	phallic glans	T023	C0227948
27252199	55	66	engorgement	T047	C0020452
27252199	74	92	American alligator	T014	C0327167
27252199	97	108	distal part	T082	C0205108
27252199	116	127	crocodilian	T014	C0327160
27252199	128	135	phallus	T023	C0030851
27252199	150	163	bulbous glans	T023	C0227948
27252199	190	206	vascular tissues	T024	C1511228
27252199	241	256	sexual activity	T053	C0036864
27252199	258	267	enlarging	T080	C0442800
27252199	288	293	glans	T023	C1550261
27252199	301	308	complex	T080	C0439855
27252199	323	335	functionally	T169	C0205245
27252199	336	345	undefined	T078	C0750600
27252199	347	357	copulatory	T054	C1325873
27252199	372	380	enlarged	T080	C0442800
27252199	381	386	glans	T023	C1550261
27252199	398	407	interacts	T169	C1704675
27252199	417	423	female	T032	C0086287
27252199	424	430	cloaca	T023	C0008987
27252199	439	445	change	T169	C0392747
27252199	450	455	shape	T082	C0332479
27252199	459	481	her reproductive tract	T022	C0700038
27252199	496	508	insemination	T042	C0021586
27252199	513	521	increase	T169	C0442805
27252199	526	537	probability	T081	C0033204
27252199	541	554	fertilization	T040	C0015914
27252199	582	607	cellular-level properties	T043	C0007613
27252199	615	620	glans	T023	C1550261
27252199	631	657	inflatable phallic tissues	T024	C0040300
27252199	678	683	sperm	T025	C0037868
27252199	696	702	sulcus	T030	C1184482
27252199	703	714	spermaticus	T023	C0037855
27252199	722	740	American alligator	T014	C0327167
27252199	742	768	Alligator mississippiensis	T014	C0327167
27252199	777	799	histochemical staining	T059	C0200825
27252199	827	835	collagen	T116	C0009325
27252199	840	853	elastin fiber	T024	C0230899
27252199	854	863	densities	T081	C0178587
27252199	868	880	orientations	T082	C1704322
27252199	890	897	tissues	T024	C0040300
27252199	899	919	Extracellular matrix	T024	C0015350
27252199	958	971	phallic glans	T023	C0227948
27252199	1009	1015	affect	T169	C0392760
27252199	1016	1022	tissue	T024	C0040300
27252199	1023	1031	strength	T081	C0237897
27252199	1036	1047	flexibility	T080	C0242808
27252199	1084	1094	copulatory	T054	C1325873
27252199	1095	1101	forces	T067	C0441722
27252199	1128	1137	potential	T080	C3245505
27252199	1149	1155	fluids	T167	C0302908
27252199	1161	1167	induce	T169	C0205263
27252199	1181	1190	alligator	T014	C0002123
27252199	1191	1197	phalli	T023	C0030851
27252199	1209	1226	serial sectioning	T059	C0022885
27252199	1231	1263	three-dimensional reconstruction	T059	C0022885
27252199	1289	1316	supracrucal plexus vascular	T023	C0501402
27252199	1317	1323	bodies	T026	C1995017
27252199	1351	1360	alligator	T014	C0002123
27252199	1361	1368	phallus	T023	C0030851
27252199	1381	1398	distally adjacent	T082	C1254362
27252199	1402	1430	ventro-medial sulcus tissues	T024	C0040300
27252199	1446	1451	gross	T080	C0439806
27252199	1456	1480	histological examination	T033	C0449575
27252199	1488	1506	American alligator	T014	C0327167
27252199	1507	1520	phallic glans	T023	C0227948
27252199	1539	1546	tissues	T024	C0040300
27252199	1589	1597	vascular	T023	C0005847
27252199	1622	1627	glans	T023	C1550261
27252199	1657	1662	shape	T082	C0332479
27252199	1668	1679	potentially	T080	C3245505
27252199	1688	1706	secretory products	T026	C0243092
27252199	1716	1741	female reproductive tract	T022	C0700038
27252199	1777	1791	postcopulatory	T054	C1325873
27252199	1792	1808	sexual selection	T054	C1720879
27252199	1813	1825	mechanically	T169	C0443254
27252199	1844	1884	affecting female reproductive physiology	T039	C1517151

27252416|t|Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
27252416|a|To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686). We analyzed tumor biopsies from seven patients obtained before, during, and/or after treatment with AZD9291 or rociletinib (CO-1686). Targeted sequencing and FISH analyses were performed, and the relevance of candidate genes was functionally assessed in in vitro models. We found recurrent amplification of either MET or ERBB2 in tumors that were resistant or developed resistance to third-generation EGFR inhibitors and show that ERBB2 and MET activation can confer resistance to these compounds. Furthermore, we identified a KRAS(G12S) mutation in a patient with acquired resistance to AZD9291 as a potential driver of acquired resistance. Finally, we show that dual inhibition of EGFR /MEK might be a viable strategy to overcome resistance in EGFR-mutant cells expressing mutant KRAS CONCLUSIONS: Our data suggest that heterogeneous mechanisms of resistance can drive primary and acquired resistance to third-generation EGFR inhibitors and provide a rationale for potential combination strategies. Clin Cancer Res; 1-11. Â©2016 AACR.
27252416	0	24	Heterogeneous Mechanisms	T169	C0441712
27252416	28	59	Primary and Acquired Resistance	T038	C0013203
27252416	63	95	Third-Generation EGFR Inhibitors	T121	C1443775
27252416	114	138	mechanisms of resistance	T169	C0441712
27252416	128	138	resistance	T038	C0013203
27252416	142	174	third-generation EGFR inhibitors	T121	C1443775
27252416	178	186	patients	T101	C0030705
27252416	192	211	lung adenocarcinoma	T191	C0152013
27252416	234	241	therapy	T061	C0087111
27252416	254	261	AZD9291	T109,T121	C3896906
27252416	265	276	rociletinib	T109,T121	C4045493
27252416	278	285	CO-1686	T109,T121	C3275041
27252416	291	299	analyzed	T062	C0936012
27252416	300	314	tumor biopsies	T060	C0005558
27252416	320	325	seven	T081	C0205453
27252416	326	334	patients	T101	C0030705
27252416	373	382	treatment	T061	C0087111
27252416	388	395	AZD9291	T109,T121	C3896906
27252416	399	410	rociletinib	T109,T121	C4045493
27252416	412	419	CO-1686	T109,T121	C3275041
27252416	422	441	Targeted sequencing	T059	C1294197
27252416	446	459	FISH analyses	T063	C0162789
27252416	484	493	relevance	T080	C2347946
27252416	497	512	candidate genes	T028	C1332838
27252416	517	538	functionally assessed	T052	C1516048
27252416	542	557	in vitro models	T062	C1515654
27252416	568	591	recurrent amplification	T045	C0017256
27252416	602	605	MET	T028	C1417123
27252416	609	614	ERBB2	T028	C0242957
27252416	618	624	tumors	T191	C0027651
27252416	635	644	resistant	T038	C0013203
27252416	648	668	developed resistance	T038	C0013203
27252416	672	704	third-generation EGFR inhibitors	T121	C1443775
27252416	719	724	ERBB2	T045	C0017255
27252416	729	743	MET activation	T045	C0017255
27252416	755	765	resistance	T038	C0013203
27252416	769	784	these compounds	T121	C1443775
27252416	815	834	KRAS(G12S) mutation	T049	C3274036
27252416	840	847	patient	T101	C0030705
27252416	853	872	acquired resistance	T038	C0013203
27252416	876	883	AZD9291	T109,T121	C3896906
27252416	909	928	acquired resistance	T038	C0013203
27252416	952	967	dual inhibition	T052	C3463820
27252416	971	975	EGFR	T116,T126,T192	C0034802
27252416	971	980	EGFR /MEK	T116,T126	C0169101
27252416	992	1007	viable strategy	T041	C0679199
27252416	1020	1030	resistance	T038	C0013203
27252416	1034	1051	EGFR-mutant cells	T025	C0007634
27252416	1063	1074	mutant KRAS	T033	C2747837
27252416	1092	1096	data	T078	C1511726
27252416	1110	1148	heterogeneous mechanisms of resistance	T169	C0441712
27252416	1138	1148	resistance	T038	C0013203
27252416	1159	1190	primary and acquired resistance	T038	C0013203
27252416	1194	1226	third-generation EGFR inhibitors	T121	C1443775
27252416	1241	1250	rationale	T078	C2699007
27252416	1255	1264	potential	T080	C3245505
27252416	1265	1287	combination strategies	T061	C0013218

27252474|t|Nax signaling evoked by an increase in [Na+] in CSF induces water intake via EET -mediated TRPV4 activation
27252474|a|Water-intake behavior is under the control of brain systems that sense body-fluid conditions at sensory circumventricular organs (sCVOs); however, the underlying mechanisms have not yet been elucidated in detail. Nax is a sodium (Na(+)) level sensor in the brain, and the transient receptor potential vanilloid (TRPV) channels, TRPV1 and TRPV4, have been proposed to function as osmosensors. We herein investigated voluntary water intake immediately induced after an intracerebroventricular (icv) administration of a hypertonic NaCl solution in TRPV1-, TRPV4-, Nax-, and their double-gene knockout (KO) mice. The induction of water intake by TRPV1 - KO mice was normal, whereas that by TRPV4 - KO and Nax - KO mice was significantly less than that by WT mice. Water intake by Nax / TRPV4 - double KO mice was similar to that by the respective single KO mice. When TRPV4 activity was blocked with a specific antagonist HC-067047, water intake by WT mice was significantly reduced, whereas that by TRPV4 - KO and Nax - KO mice was not. Similar results were obtained with the administration of miconazole, which inhibits the biosynthesis of epoxyeicosatrienoic acids (EETs), endogenous agonists for TRPV4, from arachidonic acid (AA). Icv injection of hypertonic NaCl with AA or 5,6-EET restored water intake by Nax - KO mice to the WT level, but not that by TRPV4 - KO mice. These results suggest that the Na(+) signal generated in Nax - positive glial cells leads to the activation of TRPV4 - positive neurons in sCVOs in order to stimulate water intake by using EETs as gliotransmitters.
27252474	0	3	Nax	T116,T123	C1609241
27252474	4	13	signaling	T043	C0037083
27252474	14	23	evoked by	T080	C1444748
27252474	27	35	increase	T169	C0442805
27252474	40	43	Na+	T196	C0597484
27252474	48	51	CSF	T031	C0007806
27252474	52	59	induces	T169	C0205263
27252474	60	72	water intake	T040	C0013123
27252474	77	80	EET	T109	C1537011
27252474	91	96	TRPV4	T116,T123	C0962567
27252474	97	107	activation	T045	C0599177
27252474	108	120	Water-intake	T040	C0013123
27252474	143	150	control	T169	C2587213
27252474	154	167	brain systems	T023	C0006104
27252474	179	189	body-fluid	T031	C0005889
27252474	204	236	sensory circumventricular organs	T023	C3499120
27252474	238	243	sCVOs	T023	C3499120
27252474	270	280	mechanisms	T169	C0441712
27252474	321	324	Nax	T116,T123	C1609241
27252474	330	336	sodium	T196	C0597484
27252474	338	343	Na(+)	T196	C0597484
27252474	345	350	level	T080	C0441889
27252474	351	357	sensor	T044	C1152842
27252474	365	370	brain	T023	C0006104
27252474	380	434	transient receptor potential vanilloid (TRPV) channels	T116,T192	C0108303
27252474	436	441	TRPV1	T116,T192	C1259982
27252474	446	451	TRPV4	T116,T123	C0962567
27252474	463	471	proposed	T080	C1553874
27252474	475	483	function	T169	C0542341
27252474	487	498	osmosensors	T044	C1152842
27252474	510	522	investigated	T169	C1292732
27252474	523	532	voluntary	T055	C0439656
27252474	533	545	water intake	T040	C0013123
27252474	558	565	induced	T169	C0205263
27252474	575	598	intracerebroventricular	T082	C0595818
27252474	600	603	icv	T082	C0595818
27252474	605	619	administration	T061	C1533734
27252474	625	649	hypertonic NaCl solution	T121,T197	C0036085
27252474	653	659	TRPV1-	T028	C1421467
27252474	661	667	TRPV4-	T028	C1425291
27252474	669	673	Nax-	T028	C1419865
27252474	685	715	double-gene knockout (KO) mice	T015	C0206745
27252474	721	730	induction	T169	C0205263
27252474	734	746	water intake	T040	C0013123
27252474	750	755	TRPV1	T028	C1421467
27252474	758	765	KO mice	T015	C0206745
27252474	794	799	TRPV4	T028	C1425291
27252474	802	804	KO	T015	C0206745
27252474	809	812	Nax	T028	C1419865
27252474	815	822	KO mice	T015	C0206745
27252474	827	840	significantly	T078	C0750502
27252474	859	866	WT mice	T015	C1520150
27252474	868	880	Water intake	T040	C0013123
27252474	884	887	Nax	T028	C1419865
27252474	890	895	TRPV4	T028	C1425291
27252474	898	912	double KO mice	T015	C0206745
27252474	917	924	similar	T080	C2348205
27252474	951	957	single	T081	C0205171
27252474	958	965	KO mice	T015	C0206745
27252474	972	977	TRPV4	T116,T123	C1435011
27252474	978	986	activity	T044	C1537044
27252474	991	998	blocked	T169	C0332206
27252474	1006	1025	specific antagonist	T120	C0003139
27252474	1026	1035	HC-067047	T109,T121	C3493142
27252474	1037	1049	water intake	T040	C0013123
27252474	1053	1060	WT mice	T015	C1520150
27252474	1065	1078	significantly	T078	C0750502
27252474	1079	1086	reduced	T080	C0392756
27252474	1104	1109	TRPV4	T028	C1425291
27252474	1112	1114	KO	T015	C0206745
27252474	1119	1122	Nax	T028	C1419865
27252474	1125	1132	KO mice	T015	C0206745
27252474	1142	1149	Similar	T080	C2348205
27252474	1150	1157	results	T033	C0683954
27252474	1181	1195	administration	T061	C1533734
27252474	1199	1209	miconazole	T109,T121	C0025942
27252474	1217	1225	inhibits	T052	C3463820
27252474	1230	1242	biosynthesis	T169	C0005572
27252474	1246	1271	epoxyeicosatrienoic acids	T109	C1537011
27252474	1273	1277	EETs	T109	C1537011
27252474	1280	1290	endogenous	T169	C0205227
27252474	1291	1299	agonists	T121	C2987634
27252474	1304	1309	TRPV4	T116,T123	C1435011
27252474	1316	1332	arachidonic acid	T109	C0003695
27252474	1334	1336	AA	T109	C0003695
27252474	1339	1342	Icv	T082	C0595818
27252474	1343	1352	injection	T061	C1533685
27252474	1356	1371	hypertonic NaCl	T121,T197	C0036085
27252474	1377	1379	AA	T109	C0003695
27252474	1383	1390	5,6-EET	T109,T123	C0048925
27252474	1400	1412	water intake	T040	C0013123
27252474	1416	1419	Nax	T028	C1419865
27252474	1422	1429	KO mice	T015	C0206745
27252474	1437	1439	WT	T028	C1883559
27252474	1440	1445	level	T080	C0441889
27252474	1463	1468	TRPV4	T028	C1425291
27252474	1471	1478	KO mice	T015	C0206745
27252474	1486	1493	results	T033	C0683954
27252474	1511	1516	Na(+)	T196	C0597484
27252474	1517	1523	signal	T067	C1710082
27252474	1537	1540	Nax	T116,T123	C1609241
27252474	1543	1551	positive	T033	C1446409
27252474	1552	1563	glial cells	T025	C0027836
27252474	1577	1587	activation	T045	C0599177
27252474	1591	1596	TRPV4	T116,T123	C1435011
27252474	1599	1607	positive	T033	C1446409
27252474	1608	1615	neurons	T025	C0027882
27252474	1619	1624	sCVOs	T023	C3499120
27252474	1637	1646	stimulate	T061	C1292856
27252474	1647	1659	water intake	T040	C0013123
27252474	1669	1673	EETs	T109	C1537011
27252474	1677	1693	gliotransmitters	T123	C0027908

27252721|t|Timing of False Ring Formation in Pinus halepensis and Arbutus unedo in Southern Italy: Outlook from an Analysis of Xylogenesis and Tree-Ring Chronologies
27252721|a|Mediterranean tree rings are characterized by intra-annual density fluctuations (IADFs) due to partly climate-driven cambial activity. IADFs are used as structural signals to gain information on relations between environmental conditions and eco-physiological processes during xylogenesis, with intra-annual resolution. To reach an unbiased synchronization of the IADF position within tree rings and seasonal fluctuations in environmental conditions, it is necessary to know the timing of cambial activity and wood formation, which are species- and site-specific processes. We applied the microcoring technique to analyze xylogenesis in Pinus halepensis and Arbutus unedo. To the best of our knowledge, this is the first attempt to study xylogenesis in a hardwood species forming frequent IADFs. Both species co-occur at a site in southern Italy characterized by a Mediterranean climate. To facilitate tree-ring dating and identification of IADFs, we performed traditional dendroecological analysis. We analyzed xylogenesis during summer, which is considered a constraint for xylogenesis and a trigger for IADF formation. We followed the different phases of cell development in the current wood increment with the aim of evaluating whether and which type of IADFs were formed. We additionally analyzed the same phases again in September and in winter to verify the possible formation of IADFs in fall and whether cell production and differentiation was completed by the end of the calendar year. Both species formed the same type of IADFs (earlywood -like cells within latewood), due to temporary growth restoration triggered by rain events during the period of summer drought. At the end of the calendar year, no cells in the phases of enlargement and secondary cell wall deposition occurred. A. unedo was more sensitive than P. halepensis because IADF s were formed earlier in the season and were more frequent in the tree-ring series. The dendro-anatomical approach, combining analysis of tree-ring series and of xylogenesis, helped to detect the period of IADF formation in the two species. Results are discussed in functional terms, highlighting the environmental conditions triggering IADFs, and also in methodological terms, evaluating the applicability of xylogenesis analysis in Mediterranean woods, especially when the formation of IADFs is not uniform around the stem.
27252721	0	6	Timing	T079	C0449243
27252721	16	30	Ring Formation	T039	C0243056
27252721	34	50	Pinus halepensis	T002	C1028806
27252721	55	68	Arbutus unedo	T002	C1036425
27252721	72	80	Southern	T082	C1710133
27252721	81	86	Italy	T083	C0022277
27252721	88	95	Outlook	T201	C0420834
27252721	104	112	Analysis	T062	C0936012
27252721	116	127	Xylogenesis	T039	C0243056
27252721	132	141	Tree-Ring	T002	C0040811
27252721	142	154	Chronologies	T170	C0008717
27252721	155	168	Mediterranean	T083	C0282645
27252721	169	179	tree rings	T002	C0040811
27252721	184	197	characterized	T052	C1880022
27252721	201	234	intra-annual density fluctuations	T079	C0231241
27252721	236	241	IADFs	T079	C0231241
27252721	257	271	climate-driven	T070	C0008946
27252721	272	288	cambial activity	T039	C0243056
27252721	290	295	IADFs	T079	C0231241
27252721	308	318	structural	T082	C0678594
27252721	319	326	signals	T078	C0010439
27252721	335	346	information	T078	C1533716
27252721	350	359	relations	T080	C0439849
27252721	360	367	between	T082	C0205103
27252721	368	381	environmental	T082	C0014406
27252721	382	392	conditions	T080	C0348080
27252721	397	414	eco-physiological	T039	C0243056
27252721	415	424	processes	T067	C1522240
27252721	425	431	during	T079	C0347984
27252721	432	443	xylogenesis	T039	C0243056
27252721	450	462	intra-annual	T079	C0332181
27252721	463	473	resolution	T077	C2699488
27252721	487	495	unbiased	T062	C1711255
27252721	496	511	synchronization	T079	C0439580
27252721	519	523	IADF	T079	C0231241
27252721	524	532	position	T082	C0733755
27252721	540	544	tree	T002	C0040811
27252721	545	550	rings	T082	C0521164
27252721	555	563	seasonal	T079	C1254367
27252721	564	576	fluctuations	T184	C0231239
27252721	580	593	environmental	T082	C0014406
27252721	594	604	conditions	T080	C0348080
27252721	634	640	timing	T079	C0449243
27252721	644	660	cambial activity	T039	C0243056
27252721	665	669	wood	T167	C0043217
27252721	670	679	formation	T169	C1522492
27252721	691	699	species-	T080	C0205556
27252721	704	717	site-specific	T080	C0205556
27252721	718	727	processes	T067	C1522240
27252721	732	739	applied	T169	C4048755
27252721	744	765	microcoring technique	T169	C0449851
27252721	769	776	analyze	T062	C0936012
27252721	777	788	xylogenesis	T039	C0243056
27252721	792	808	Pinus halepensis	T002	C1028806
27252721	813	826	Arbutus unedo	T002	C1036425
27252721	876	883	attempt	T051	C1516084
27252721	887	892	study	T062	C2603343
27252721	893	904	xylogenesis	T039	C0243056
27252721	910	918	hardwood	T167	C0043217
27252721	919	926	species	T185	C1705920
27252721	935	943	frequent	T079	C0332183
27252721	944	949	IADFs	T079	C0231241
27252721	956	963	species	T185	C1705920
27252721	964	972	co-occur	T052	C1709305
27252721	978	982	site	T082	C0205145
27252721	986	994	southern	T082	C1710133
27252721	995	1000	Italy	T083	C0022277
27252721	1001	1014	characterized	T052	C1880022
27252721	1020	1033	Mediterranean	T083	C0282645
27252721	1034	1041	climate	T070	C0008946
27252721	1057	1073	tree-ring dating	T062	C2350279
27252721	1078	1092	identification	T080	C0205396
27252721	1096	1101	IADFs	T079	C0231241
27252721	1106	1115	performed	T169	C0884358
27252721	1116	1127	traditional	T169	C0443324
27252721	1128	1144	dendroecological	T080	C0205556
27252721	1145	1153	analysis	T062	C0936012
27252721	1158	1166	analyzed	T062	C0936012
27252721	1167	1178	xylogenesis	T039	C0243056
27252721	1179	1185	during	T079	C0347984
27252721	1186	1192	summer	T079	C0241301
27252721	1203	1213	considered	T078	C0750591
27252721	1216	1226	constraint	T169	C0443288
27252721	1231	1242	xylogenesis	T039	C0243056
27252721	1261	1265	IADF	T079	C0231241
27252721	1266	1275	formation	T169	C1522492
27252721	1293	1302	different	T080	C1705242
27252721	1303	1309	phases	T079	C0205390
27252721	1313	1329	cell development	T043	C0815089
27252721	1337	1344	current	T079	C0521116
27252721	1345	1349	wood	T167	C0043217
27252721	1350	1359	increment	T081	C1705117
27252721	1413	1418	IADFs	T079	C0231241
27252721	1424	1430	formed	T169	C0205431
27252721	1448	1456	analyzed	T062	C0936012
27252721	1466	1472	phases	T079	C0205390
27252721	1482	1491	September	T079	C3828193
27252721	1499	1505	winter	T079	C0241737
27252721	1509	1515	verify	T169	C1711411
27252721	1520	1528	possible	T033	C0332149
27252721	1529	1538	formation	T169	C1522492
27252721	1542	1547	IADFs	T079	C0231241
27252721	1551	1555	fall	T079	C0238715
27252721	1568	1572	cell	T025	C3178867
27252721	1573	1583	production	T039	C0243056
27252721	1588	1603	differentiation	T043	C0007589
27252721	1608	1617	completed	T080	C0205197
27252721	1636	1649	calendar year	T079	C0456586
27252721	1656	1663	species	T185	C1705920
27252721	1664	1670	formed	T169	C0205431
27252721	1688	1693	IADFs	T079	C0231241
27252721	1695	1704	earlywood	T167	C0043217
27252721	1711	1716	cells	T025	C3178867
27252721	1724	1732	latewood	T167	C0043217
27252721	1742	1751	temporary	T079	C0205374
27252721	1752	1758	growth	T067	C2911660
27252721	1759	1770	restoration	T033	C0243095
27252721	1771	1783	triggered by	T080	C1444748
27252721	1784	1788	rain	T070	C0034640
27252721	1789	1795	events	T051	C0441471
27252721	1796	1802	during	T079	C0347984
27252721	1807	1813	period	T079	C1948053
27252721	1817	1823	summer	T079	C0241301
27252721	1824	1831	drought	T070	C0013140
27252721	1851	1864	calendar year	T079	C0456586
27252721	1869	1874	cells	T025	C3178867
27252721	1882	1888	phases	T079	C0205390
27252721	1892	1903	enlargement	T080	C0442800
27252721	1908	1927	secondary cell wall	T026	C1167351
27252721	1928	1938	deposition	T169	C0333562
27252721	1939	1947	occurred	T052	C1709305
27252721	1949	1957	A. unedo	T002	C1036425
27252721	1967	1976	sensitive	T169	C0332324
27252721	1982	1995	P. halepensis	T002	C1028806
27252721	2004	2008	IADF	T079	C0231241
27252721	2016	2022	formed	T169	C0205431
27252721	2023	2030	earlier	T079	C1279919
27252721	2038	2044	season	T079	C0036497
27252721	2059	2067	frequent	T079	C0332183
27252721	2075	2084	tree-ring	T002	C0040811
27252721	2097	2114	dendro-anatomical	T080	C0205556
27252721	2135	2143	analysis	T062	C0936012
27252721	2147	2156	tree-ring	T002	C0040811
27252721	2171	2182	xylogenesis	T039	C0243056
27252721	2194	2200	detect	T033	C0442726
27252721	2205	2211	period	T079	C1948053
27252721	2215	2219	IADF	T079	C0231241
27252721	2220	2229	formation	T169	C1522492
27252721	2241	2248	species	T185	C1705920
27252721	2250	2257	Results	T169	C1274040
27252721	2275	2285	functional	T169	C0205245
27252721	2286	2291	terms	T078	C1705313
27252721	2310	2323	environmental	T082	C0014406
27252721	2324	2334	conditions	T080	C0348080
27252721	2335	2345	triggering	T080	C1444748
27252721	2346	2351	IADFs	T079	C0231241
27252721	2365	2379	methodological	UnknownType	C0815254
27252721	2380	2385	terms	T078	C1705313
27252721	2402	2415	applicability	T169	C4048755
27252721	2419	2430	xylogenesis	T039	C0243056
27252721	2431	2439	analysis	T062	C0936012
27252721	2443	2456	Mediterranean	T083	C0282645
27252721	2457	2462	woods	T167	C0043217
27252721	2484	2493	formation	T169	C1522492
27252721	2497	2502	IADFs	T079	C0231241
27252721	2510	2517	uniform	T080	C0205375
27252721	2529	2533	stem	T002	C0242767

27252817|t|An Accessible and Pragmatic Experimental Model of Nonalcoholic Fatty Liver Disease
27252817|a|BACKGROUND There is no convenient cheap pragmatic experimental model for Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH). Our objective was to create a pragmatic model of NAFLD / NASH. METHODS Sprague-Dawley rats were fed a high-fat, high sugar homemade diet ad libitum for seven weeks. The high-fat, high sugar diet included 59% of energy derived from fat, 30% from carbohydrates, and 11% from protein. Serum levels of fasting glucose, triglyceride, cholesterol, liver enzymes, insulin, and hepatic tumor necrosis factor-alpha (TNF-Î±) gene expression were determined. Hepatic histology was examined by H&E stain. RESULTS Rats fed the high-fat, high sugar diet developed hepatic steatosis, and a moderate inflammation, which was associated with increased serum levels of liver enzymes, glucose, insulin, triglyceride, cholesterol, and hepatic TNF-Î± gene expression. CONCLUSION This rat model resembles the key features of human NAFLD / NASH and provides a simple pragmatic experimental model for elucidating the disease prevention and treatment.
27252817	18	46	Pragmatic Experimental Model	T008	C0887965
27252817	50	82	Nonalcoholic Fatty Liver Disease	T047	C0400966
27252817	123	151	pragmatic experimental model	T008	C0887965
27252817	156	188	Nonalcoholic Fatty Liver Disease	T047	C0400966
27252817	190	195	NAFLD	T047	C0400966
27252817	198	226	Nonalcoholic Steatohepatitis	T047	C3241937
27252817	228	232	NASH	T047	C3241937
27252817	265	280	pragmatic model	T008	C0887965
27252817	284	289	NAFLD	T047	C0400966
27252817	292	296	NASH	T047	C3241937
27252817	306	325	Sprague-Dawley rats	T015	C0034715
27252817	337	345	high-fat	T061	C0521974
27252817	347	371	high sugar homemade diet	T061	C1445913
27252817	393	398	weeks	T079	C0439230
27252817	404	412	high-fat	T061	C0521974
27252817	414	429	high sugar diet	T061	C1445913
27252817	446	452	energy	T081	C1442080
27252817	466	469	fat	T109,T168	C0012171
27252817	480	493	carbohydrates	T168	C0453802
27252817	508	515	protein	T168	C0453858
27252817	517	548	Serum levels of fasting glucose	T059	C0583334
27252817	550	562	triglyceride	T059	C0542495
27252817	564	575	cholesterol	T059	C1445957
27252817	577	590	liver enzymes	T059	C0428321
27252817	592	599	insulin	T059	C0428357
27252817	605	612	hepatic	T029	C0205054
27252817	613	640	tumor necrosis factor-alpha	T116,T129	C1456820
27252817	642	647	TNF-Î±	T116,T129	C1456820
27252817	649	664	gene expression	T045	C0017262
27252817	682	689	Hepatic	T029	C0205054
27252817	690	699	histology	T059	C0344441
27252817	716	725	H&E stain	T059	C0523207
27252817	735	739	Rats	T015	C0034721
27252817	748	756	high-fat	T061	C0521974
27252817	758	773	high sugar diet	T061	C1445913
27252817	784	801	hepatic steatosis	T047	C0015695
27252817	809	830	moderate inflammation	T033	C0522568
27252817	858	897	increased serum levels of liver enzymes	T033	C0857093
27252817	899	906	glucose	T034	C0583332
27252817	908	915	insulin	T034	C1261415
27252817	917	929	triglyceride	T034	C1287372
27252817	931	942	cholesterol	T034	C1287371
27252817	948	955	hepatic	T029	C0205054
27252817	956	961	TNF-Î±	T116,T129	C1456820
27252817	962	977	gene expression	T045	C0017262
27252817	995	998	rat	T015	C0034721
27252817	999	1004	model	T008	C0887965
27252817	1035	1040	human	T016	C0086418
27252817	1041	1046	NAFLD	T047	C0400966
27252817	1049	1053	NASH	T047	C3241937
27252817	1076	1104	pragmatic experimental model	T008	C0887965
27252817	1125	1143	disease prevention	T061	C0679698
27252817	1148	1157	treatment	T061	C0087111

27252904|t|Comparison of the Effects of Subcutaneous Versus Continuous Infusion of Heparin on Key Inflammatory Parameters Following Sepsis
27252904|a|Sepsis is the result of the interaction between inflammatory mediators and coagulation pathway. Unfractionated heparin may play a role as an anti-inflammatory agent beyond its anticoagulatory effect in sepsis. As a result, it may cause reduction in organ failure rate in patients with sepsis due to its impact on both inflammatory and coagulation process. The aim of this study was to evaluate the anti-inflammatory effects of heparin in sepsis. Plasma plasminogen activator inhibitor-1 (PAI-1) as an inflammatory mediator and urinary necoutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney injury were investigated. This prospective, randomized controlled trial was conducted in a 32- bed intensive care unit. Thirty patients with sepsis were randomized to receive heparin infusion of 500 units/hour or 5000 units of heparin three times a day, subcutaneously. The plasma level of PAI-1 and urinary level of NGAL were determined at day 0, 2 and 7. The infusion group had a lower plasma PAI-1 level compared to the subcutaneous group at day 7 (11.3 Â± 1.6 vs. 16.5 Â± 4.2; P = 0.003). The urinary NGAL level was lower in the infusion group at day 2 (131.3 Â± 11.9 vs. 151.2 Â± 20.6; P = 0.014); however, at day 7 the NGAL level was decreased in the subcutaneous group as much as the infusion group and there was no significant difference between the two groups. There was no significant difference in the acute physiology and chronic health evaluation (APACHE) II and sequential organ failure assessment (SOFA) scores between the two groups at day 0, 2 and 7. Low-dose heparin infusion compared to subcutaneous heparin can decrease the plasma PAI-1 and urinary NGAL levels more rapidly. It can be related to anti-inflammatory effects of heparin, which may be more prominent in infusion route.
27252904	0	10	Comparison	T052	C1707455
27252904	18	28	Effects of	T080	C1704420
27252904	29	41	Subcutaneous	T061	C0576773
27252904	49	68	Continuous Infusion	T061	C0444889
27252904	72	79	Heparin	T109,T121,T123	C0019134
27252904	83	99	Key Inflammatory	T169	C0333348
27252904	100	110	Parameters	T077	C0549193
27252904	111	120	Following	T079	C0332282
27252904	121	127	Sepsis	T047	C0243026
27252904	128	134	Sepsis	T047	C0243026
27252904	142	148	result	T169	C1274040
27252904	156	167	interaction	T169	C1704675
27252904	176	198	inflammatory mediators	T121	C0243042
27252904	203	222	coagulation pathway	T044	C1704259
27252904	224	246	Unfractionated heparin	T121	C2825026
27252904	258	262	role	T077	C1705810
27252904	269	292	anti-inflammatory agent	T121	C0003209
27252904	304	326	anticoagulatory effect	T080	C1280500
27252904	330	336	sepsis	T047	C0243026
27252904	343	349	result	T169	C1274040
27252904	364	373	reduction	T080	C0392756
27252904	377	390	organ failure	T046	C0026766
27252904	391	395	rate	T081	C1521828
27252904	399	407	patients	T101	C0030705
27252904	413	419	sepsis	T047	C0243026
27252904	431	437	impact	T080	C4049986
27252904	446	458	inflammatory	T169	C0333348
27252904	463	482	coagulation process	T039	C1328723
27252904	488	491	aim	T078	C1947946
27252904	500	505	study	T062	C0681814
27252904	513	521	evaluate	T058	C0184514
27252904	526	551	anti-inflammatory effects	T080	C1515999
27252904	555	562	heparin	T109,T121,T123	C0019134
27252904	566	572	sepsis	T047	C0243026
27252904	574	580	Plasma	T031	C0032105
27252904	581	614	plasminogen activator inhibitor-1	T116,T123	C0030190
27252904	616	621	PAI-1	T116,T123	C0030190
27252904	629	650	inflammatory mediator	T121	C0243042
27252904	655	662	urinary	T080	C1524119
27252904	663	707	necoutrophil gelatinase-associated lipocalin	T116,T123	C2347341
27252904	709	713	NGAL	T116,T123	C2347341
27252904	720	726	marker	T201	C0005516
27252904	730	743	kidney injury	T037	C0160420
27252904	749	761	investigated	T169	C1292732
27252904	768	779	prospective	T062	C0033522
27252904	781	808	randomized controlled trial	T062	C0206035
27252904	832	835	bed	T082	C1547114
27252904	836	855	intensive care unit	T073,T093	C0021708
27252904	864	872	patients	T101	C0030705
27252904	878	884	sepsis	T047	C0243026
27252904	890	900	randomized	T062	C0034656
27252904	904	911	receive	T080	C1514756
27252904	912	919	heparin	T109,T121,T123	C0019134
27252904	920	928	infusion	T169	C1827465
27252904	936	946	units/hour	T081	C0456685
27252904	955	960	units	T081	C1519795
27252904	964	971	heparin	T109,T121,T123	C0019134
27252904	972	989	three times a day	T079	C0556984
27252904	991	1005	subcutaneously	T033	C1736929
27252904	1011	1017	plasma	T031	C0032105
27252904	1018	1023	level	T080	C0441889
27252904	1027	1032	PAI-1	T116,T123	C0030190
27252904	1037	1044	urinary	T080	C1524119
27252904	1045	1050	level	T080	C0441889
27252904	1054	1058	NGAL	T116,T123	C2347341
27252904	1078	1083	day 0	T033	C0243095
27252904	1085	1086	2	T033	C3842676
27252904	1091	1092	7	T033	C3842672
27252904	1098	1106	infusion	T169	C1827465
27252904	1107	1112	group	T078	C0441833
27252904	1119	1124	lower	T082	C0441994
27252904	1125	1131	plasma	T031	C0032105
27252904	1132	1137	PAI-1	T116,T123	C0030190
27252904	1138	1143	level	T080	C0441889
27252904	1144	1152	compared	T052	C1707455
27252904	1160	1178	subcutaneous group	T078	C0441833
27252904	1182	1187	day 7	T033	C3842672
27252904	1232	1239	urinary	T080	C1524119
27252904	1240	1244	NGAL	T116,T123	C2347341
27252904	1245	1250	level	T080	C0441889
27252904	1255	1260	lower	T082	C0441994
27252904	1268	1276	infusion	T169	C1827465
27252904	1277	1282	group	T078	C0441833
27252904	1286	1291	day 2	T033	C3842676
27252904	1348	1353	day 7	T033	C3842672
27252904	1358	1362	NGAL	T116,T123	C2347341
27252904	1363	1368	level	T080	C0441889
27252904	1373	1382	decreased	T081	C0205216
27252904	1390	1408	subcutaneous group	T078	C0441833
27252904	1424	1432	infusion	T169	C1827465
27252904	1433	1438	group	T078	C0441833
27252904	1453	1467	no significant	T080	C0205556
27252904	1468	1478	difference	T080	C1705242
27252904	1495	1501	groups	T078	C0441833
27252904	1513	1527	no significant	T080	C0205556
27252904	1528	1538	difference	T080	C1705242
27252904	1546	1604	acute physiology and chronic health evaluation (APACHE) II	T060	C0489438
27252904	1609	1658	sequential organ failure assessment (SOFA) scores	T033	C3494459
27252904	1675	1681	groups	T078	C0441833
27252904	1685	1690	day 0	T033	C0243095
27252904	1692	1693	2	T033	C3842676
27252904	1698	1699	7	T033	C3842672
27252904	1701	1709	Low-dose	T081	C0445550
27252904	1710	1717	heparin	T109,T121,T123	C0019134
27252904	1718	1726	infusion	T169	C1827465
27252904	1727	1735	compared	T052	C1707455
27252904	1739	1751	subcutaneous	T082	C0443315
27252904	1752	1759	heparin	T109,T121,T123	C0019134
27252904	1764	1772	decrease	T081	C0547047
27252904	1777	1783	plasma	T031	C0032105
27252904	1784	1789	PAI-1	T116,T123	C0030190
27252904	1794	1801	urinary	T080	C1524119
27252904	1802	1806	NGAL	T116,T123	C2347341
27252904	1807	1813	levels	T080	C0441889
27252904	1819	1826	rapidly	T080	C0456962
27252904	1838	1845	related	T080	C0439849
27252904	1849	1874	anti-inflammatory effects	T080	C1515999
27252904	1878	1885	heparin	T109,T121,T123	C0019134
27252904	1905	1914	prominent	T080	C0205402
27252904	1918	1932	infusion route	T169	C1827465

27253877|t|The Spreading of Social Energy: How Exposure to Positive and Negative Social News Affects Behavior
27253877|a|Social news, unlike video games or TV programs, conveys real-life interactions. Theoretically, social news in which people help or harm each other and violate rules should influence both prosocial and violation behaviors. In two experiments, we demonstrated the spreading effects of social news in a social interaction context emphasizing social conventions and a nonsocial interaction context emphasizing moral norms. Across the two studies, the results showed that positive social news increased cooperation (decreased defection) but had no effect on cheating, whereas negative social news increased cheating but with no change in cooperation (or defection). We conclude that there is a spreading impact of positive social news in the conventional norm domain and of negative social news in the moral norm domain.
27253877	4	13	Spreading	T080	C0332261
27253877	17	23	Social	T169	C0728831
27253877	24	30	Energy	T081	C1442080
27253877	36	47	Exposure to	T080	C0332157
27253877	48	56	Positive	T033	C1446409
27253877	61	69	Negative	T033	C0205160
27253877	70	76	Social	T169	C0728831
27253877	77	81	News	T170	C0282425
27253877	90	98	Behavior	T053	C0004927
27253877	99	105	Social	T169	C0728831
27253877	106	110	news	T170	C0282425
27253877	119	130	video games	T073	C0042649
27253877	134	145	TV programs	UnknownType	C0681283
27253877	155	164	real-life	T078	C0376558
27253877	165	177	interactions	T033	C0037420
27253877	194	200	social	T169	C0728831
27253877	201	205	news	T170	C0282425
27253877	215	221	people	T098	C0027361
27253877	222	226	help	T080	C1269765
27253877	230	245	harm each other	T054	C0037397
27253877	250	257	violate	T055	C0424347
27253877	258	263	rules	T089	C0023150
27253877	286	295	prosocial	T054	C0871164
27253877	300	319	violation behaviors	T055	C0424347
27253877	361	370	spreading	T080	C0332261
27253877	371	378	effects	T080	C1280500
27253877	382	388	social	T169	C0728831
27253877	389	393	news	T170	C0282425
27253877	399	417	social interaction	T033	C0037420
27253877	438	444	social	T169	C0728831
27253877	445	456	conventions	T068	C0086047
27253877	463	484	nonsocial interaction	T033	C1513916
27253877	505	510	moral	T078	C0026532
27253877	511	516	norms	T078	C0237750
27253877	533	540	studies	T062	C2603343
27253877	566	574	positive	T033	C1446409
27253877	575	581	social	T169	C0728831
27253877	582	586	news	T170	C0282425
27253877	597	608	cooperation	T054	C0392337
27253877	620	629	defection	T054	C0870406
27253877	639	641	no	T033	C1513916
27253877	642	648	effect	T080	C1280500
27253877	652	660	cheating	T055	C0683305
27253877	670	678	negative	T033	C0205160
27253877	679	685	social	T169	C0728831
27253877	686	690	news	T170	C0282425
27253877	701	709	cheating	T055	C0683305
27253877	719	721	no	T033	C1513916
27253877	722	728	change	T169	C0392747
27253877	732	743	cooperation	T054	C0392337
27253877	748	757	defection	T054	C0870406
27253877	788	797	spreading	T080	C0332261
27253877	798	804	impact	T080	C4049986
27253877	808	816	positive	T033	C1446409
27253877	817	823	social	T169	C0728831
27253877	824	828	news	T170	C0282425
27253877	836	848	conventional	T080	C0439858
27253877	849	860	norm domain	T078	C0237750
27253877	868	876	negative	T033	C0205160
27253877	877	883	social	T169	C0728831
27253877	884	888	news	T170	C0282425
27253877	896	901	moral	T078	C0026532
27253877	902	913	norm domain	T078	C0237750

27254091|t|Using Evolutionary Theory to Guide Mental Health Research
27254091|a|Evolutionary approaches to medicine can shed light on the origins and etiology of disease. Such an approach may be especially useful in psychiatry, which frequently addresses conditions with heterogeneous presentation and unknown causes. We review several previous applications of evolutionary theory that highlight the ways in which psychiatric conditions may persist despite and because of natural selection. One lesson from the evolutionary approach is that some conditions currently classified as disorders (because they cause distress and impairment) may actually be caused by functioning adaptations operating " normally " (as designed by natural selection). Such conditions suggest an alternative illness model that may generate alternative intervention strategies. Thus, the evolutionary approach suggests that psychiatry should sometimes think differently about distress and impairment. The complexity of the human brain, including normal functioning and potential for dysfunctions, has developed over evolutionary time and has been shaped by natural selection. Understanding the evolutionary origins of psychiatric conditions is therefore a crucial component to a complete understanding of etiology.
27254091	6	25	Evolutionary Theory	T170	C0237604
27254091	35	48	Mental Health	T041	C0025353
27254091	49	57	Research	T062	C0035168
27254091	58	81	Evolutionary approaches	T082	C0449445
27254091	85	93	medicine	T091	C0025118
27254091	98	108	shed light	T052	C2986669
27254091	116	123	origins	T079	C0439659
27254091	128	147	etiology of disease	T169	C1314792
27254091	157	165	approach	T082	C0449445
27254091	194	204	psychiatry	T058	C3526598
27254091	233	243	conditions	T080	C0348080
27254091	249	262	heterogeneous	T080	C0019409
27254091	280	294	unknown causes	T033	C3840856
27254091	299	305	review	T078	C1552617
27254091	323	335	applications	UnknownType	C0869019
27254091	339	358	evolutionary theory	T170	C0237604
27254091	392	414	psychiatric conditions	T047	C1718246
27254091	450	467	natural selection	T070	C0086685
27254091	489	510	evolutionary approach	T082	C0449445
27254091	524	534	conditions	T080	C0348080
27254091	545	555	classified	T185	C0008902
27254091	559	568	disorders	T048	C0004936
27254091	589	597	distress	T033	C0231303
27254091	602	612	impairment	T046	C0684336
27254091	640	651	functioning	T169	C0205245
27254091	652	663	adaptations	T038	C0392673
27254091	676	684	normally	T080	C0205307
27254091	703	720	natural selection	T070	C0086685
27254091	728	738	conditions	T080	C0348080
27254091	762	775	illness model	T050	C0684309
27254091	806	829	intervention strategies	T061	C0184661
27254091	841	862	evolutionary approach	T082	C0449445
27254091	877	887	psychiatry	T058	C3526598
27254091	911	922	differently	T080	C1705242
27254091	929	937	distress	T033	C0231303
27254091	942	952	impairment	T046	C0684336
27254091	958	968	complexity	T080	C0439855
27254091	976	981	human	T016	C0086418
27254091	982	987	brain	T023	C0006104
27254091	999	1005	normal	T080	C0205307
27254091	1006	1017	functioning	T042	C0678908
27254091	1022	1031	potential	T080	C3245505
27254091	1036	1048	dysfunctions	T047	C0262405
27254091	1069	1086	evolutionary time	T079	C0040223
27254091	1110	1127	natural selection	T070	C0086685
27254091	1147	1167	evolutionary origins	T079	C0439659
27254091	1171	1193	psychiatric conditions	T047	C1718246
27254091	1209	1216	crucial	T080	C1511545
27254091	1217	1226	component	T077	C1705248
27254091	1258	1266	etiology	T169	C1314792

27254783|t|Transcriptomic and Physiological Responses of the Green Microalga Chlamydomonas reinhardtii during Short-Term Exposure to Subnanomolar Methylmercury Concentrations
27254783|a|The effects of short-term exposure to subnanomolar methyl-mercury (MeHg) concentrations, representative of contaminated environments, on the microalga Chlamydomonas reinhardtii were assessed using both physiological end points and gene expression analysis. MeHg bioaccumulated and induced significant increase of the photosynthesis efficiency, while the algal growth, oxidative stress, and chlorophyll fluorescence were unaffected. At the molecular level, MeHg significantly dysregulated the expression of genes involved in motility, energy metabolism, lipid metabolism, metal transport, and antioxidant enzymes. Data suggest that the cells were able to cope with subnanomolar MeHg exposure, but this tolerance resulted in a significant cost to the cell energy and reserve metabolism as well as ample changes in the nutrition and motility of C. reinhardtii. The present results allowed gaining new insights on the effects and uptake mechanisms of MeHg at subnanomolar concentrations in aquatic primary producers.
27254783	0	14	Transcriptomic	T045	C0017262
27254783	19	42	Physiological Responses	T039	C0031843
27254783	50	65	Green Microalga	T204	C2936330
27254783	66	91	Chlamydomonas reinhardtii	T204	C0085356
27254783	110	121	Exposure to	T080	C0332157
27254783	122	134	Subnanomolar	T081	C0392762
27254783	135	148	Methylmercury	T109,T131	C0025794
27254783	149	163	Concentrations	T081	C1446561
27254783	179	189	short-term	T079	C0443303
27254783	190	201	exposure to	T080	C0332157
27254783	202	214	subnanomolar	T081	C0392762
27254783	215	229	methyl-mercury	T109,T131	C0025794
27254783	231	235	MeHg	T109,T131	C0025794
27254783	237	251	concentrations	T081	C1446561
27254783	271	283	contaminated	T169	C0205279
27254783	284	296	environments	T082	C0014406
27254783	305	314	microalga	T204	C2936330
27254783	315	340	Chlamydomonas reinhardtii	T204	C0085356
27254783	346	354	assessed	T052	C1516048
27254783	366	390	physiological end points	T039	C0031843
27254783	395	419	gene expression analysis	T063	C1880945
27254783	421	425	MeHg	T109,T131	C0025794
27254783	426	440	bioaccumulated	T042	C0311432
27254783	453	464	significant	T078	C0750502
27254783	465	473	increase	T169	C0442805
27254783	481	495	photosynthesis	T070	C0031764
27254783	496	506	efficiency	T081	C0013682
27254783	518	530	algal growth	T067	C0002035
27254783	532	548	oxidative stress	T049	C0242606
27254783	554	578	chlorophyll fluorescence	T043	C3548552
27254783	584	594	unaffected	T077	C2986417
27254783	620	624	MeHg	T109,T131	C0025794
27254783	639	651	dysregulated	T045	C0017263
27254783	656	675	expression of genes	T045	C0017262
27254783	688	696	motility	T040	C1510470
27254783	698	715	energy metabolism	T039	C0014272
27254783	717	733	lipid metabolism	T044	C0598783
27254783	735	750	metal transport	T043	C1159686
27254783	756	767	antioxidant	T121	C0003402
27254783	768	775	enzymes	T116,T126	C0014442
27254783	777	781	Data	T078	C1511726
27254783	799	804	cells	T025	C0007634
27254783	810	822	able to cope	T033	C2364069
27254783	828	840	subnanomolar	T081	C0392762
27254783	841	845	MeHg	T109,T131	C0025794
27254783	846	854	exposure	T080	C0332157
27254783	913	947	cell energy and reserve metabolism	T044	C1158282
27254783	980	989	nutrition	T040	C1442959
27254783	994	1002	motility	T040	C1510470
27254783	1006	1020	C. reinhardtii	T204	C0085356
27254783	1034	1041	results	T169	C1274040
27254783	1090	1107	uptake mechanisms	T039	C0243144
27254783	1111	1115	MeHg	T109,T131	C0025794
27254783	1119	1131	subnanomolar	T081	C0392762
27254783	1132	1146	concentrations	T081	C1446561
27254783	1150	1175	aquatic primary producers	T204	C2936330

27254792|t|Emergence of family medicine in Ethiopia [corrected]: an international collaborative education model
27254792|a|Family Medicine (FM) is a new specialty in Ethiopia. The first seven family physicians graduated in February 2016 from the inaugural residency programme at Addis Ababa University. Cooperation amongst Ethiopian and expatriate decision-makers and physicians was needed to begin the programme. Intentional replacement of expatriates with Ethiopian family physicians has begun. Barriers include lack of understanding of FM and the human and financial resources needed for scaling up the programme. Regular programme review with resident physician involvement has allowed the FM training programme to adapt and fit the Ethiopian context. Further successes will result from ongoing support and advocacy from the Federal Ministry of Health and other Ethiopian, African, and international primary care organisations.
27254792	0	9	Emergence	T080	C0205556
27254792	13	28	family medicine	T091	C0015607
27254792	32	40	Ethiopia	T083	C0015024
27254792	57	70	international	T078	C1512888
27254792	71	84	collaborative	T054	C0282116
27254792	85	100	education model	T170	C3161035
27254792	101	116	Family Medicine	T091	C0015607
27254792	118	120	FM	T091	C0015607
27254792	131	140	specialty	T091	C0037778
27254792	144	152	Ethiopia	T083	C0015024
27254792	158	187	first seven family physicians	T097	C1704221
27254792	188	197	graduated	T098	C0588053
27254792	201	209	February	T080	C3830166
27254792	234	243	residency	T065	C0035182
27254792	244	253	programme	T170	C0010478
27254792	257	279	Addis Ababa University	T073,T092	C0041740
27254792	281	292	Cooperation	T054	C0392337
27254792	301	310	Ethiopian	T098	C0239304
27254792	315	325	expatriate	T033	C3842568
27254792	326	341	decision-makers	T097	C0554244
27254792	346	356	physicians	T097	C0031831
27254792	371	376	begin	T079	C0439659
27254792	381	390	programme	T170	C0010478
27254792	392	403	Intentional	T078	C1512888
27254792	404	415	replacement	T169	C0559956
27254792	419	430	expatriates	T033	C3842568
27254792	436	445	Ethiopian	T098	C0239304
27254792	446	463	family physicians	T097	C1704221
27254792	468	473	begun	T079	C0439659
27254792	475	483	Barriers	T080	C0205556
27254792	492	499	lack of	T080	C0332268
27254792	500	513	understanding	T041	C0162340
27254792	517	519	FM	T091	C0015607
27254792	528	533	human	T169	C0024752
27254792	538	557	financial resources	T033	C0516918
27254792	569	579	scaling up	T081	C0392762
27254792	584	593	programme	T170	C0010478
27254792	595	602	Regular	T080	C0205272
27254792	603	612	programme	T170	C0010478
27254792	613	619	review	T080	C1704362
27254792	625	643	resident physician	T097	C1320928
27254792	644	655	involvement	T054	C0009476
27254792	672	674	FM	T091	C0015607
27254792	675	693	training programme	T065	C0040607
27254792	697	702	adapt	T080	C0205556
27254792	707	710	fit	T052	C2349186
27254792	715	724	Ethiopian	T098	C0239304
27254792	725	732	context	T078	C0449255
27254792	742	751	successes	T054	C0597535
27254792	757	763	result	T169	C1274040
27254792	777	784	support	T054	C0037438
27254792	789	797	advocacy	T054	C0150446
27254792	807	833	Federal Ministry of Health	T057	C0013562
27254792	844	853	Ethiopian	T098	C0239304
27254792	855	862	African	T098	C0027567
27254792	868	881	international	T078	C1512888
27254792	868	908	international primary care organisations	T093	C0596660

27255214|t|Hierarchical Targeting Strategy for Enhanced Tumor Tissue Accumulation / Retention and Cellular Internalization
27255214|a|Targeted delivery of therapeutic agents is an important way to improve the therapeutic index and reduce side effects. To design nanoparticles for targeted delivery, both enhanced tumor tissue accumulation / retention and enhanced cellular internalization should be considered simultaneously. So far, there have been very few nanoparticles with immutable structures that can achieve this goal efficiently. Hierarchical targeting, a novel targeting strategy based on stimuli responsiveness, shows good potential to enhance both tumor tissue accumulation / retention and cellular internalization. Here, the recent design and development of hierarchical targeting nanoplatforms, based on changeable particle sizes, switchable surface charges and activatable surface ligands, will be introduced. In general, the targeting moieties in these nanoplatforms are not activated during blood circulation for efficient tumor tissue accumulation, but re-activated by certain internal or external stimuli in the tumor microenvironment for enhanced cellular internalization.
27255214	0	22	Hierarchical Targeting	T169	C1521840
27255214	23	31	Strategy	T062	C0035171
27255214	36	44	Enhanced	T169	C0442805
27255214	45	57	Tumor Tissue	T024	C0475358
27255214	58	70	Accumulation	UnknownType	C0678759
27255214	73	82	Retention	T039	C0814008
27255214	87	111	Cellular Internalization	T043	C0014139
27255214	112	120	Targeted	T169	C1521840
27255214	121	129	delivery	T067	C1254366
27255214	133	151	therapeutic agents	T121	C1611640
27255214	158	167	important	T080	C3898777
27255214	168	171	way	T067	C1522240
27255214	175	182	improve	T080	C1272747
27255214	187	204	therapeutic index	T081	C0678793
27255214	209	215	reduce	T080	C0392756
27255214	216	228	side effects	T046	C0041755
27255214	233	239	design	T052	C1707689
27255214	240	253	nanoparticles	T073	C1450054
27255214	258	266	targeted	T169	C1521840
27255214	267	275	delivery	T067	C1254366
27255214	282	290	enhanced	T169	C0442805
27255214	291	303	tumor tissue	T024	C0475358
27255214	304	316	accumulation	UnknownType	C0678759
27255214	319	328	retention	T039	C0814008
27255214	333	341	enhanced	T169	C0442805
27255214	342	366	cellular internalization	T043	C0014139
27255214	377	387	considered	T078	C0750591
27255214	388	402	simultaneously	T079	C0521115
27255214	437	450	nanoparticles	T073	C1450054
27255214	466	476	structures	T082	C0678594
27255214	499	503	goal	T078	C1947946
27255214	504	515	efficiently	T080	C0442799
27255214	517	539	Hierarchical targeting	T169	C1521840
27255214	543	548	novel	T080	C0205314
27255214	549	558	targeting	T169	C1521840
27255214	559	567	strategy	T062	C0035171
27255214	577	584	stimuli	T067	C0234402
27255214	585	599	responsiveness	T032	C0871261
27255214	612	621	potential	T080	C3245505
27255214	625	632	enhance	T169	C0442805
27255214	638	650	tumor tissue	T024	C0475358
27255214	651	663	accumulation	UnknownType	C0678759
27255214	666	675	retention	T039	C0814008
27255214	680	704	cellular internalization	T043	C0014139
27255214	723	729	design	T052	C1707689
27255214	734	745	development	T169	C1527148
27255214	749	771	hierarchical targeting	T169	C1521840
27255214	796	806	changeable	T169	C0392747
27255214	807	821	particle sizes	T081	C0030608
27255214	823	833	switchable	T169	C0205245
27255214	834	849	surface charges	T080	C0205556
27255214	854	865	activatable	T169	C0205245
27255214	866	873	surface	T082	C0205148
27255214	874	881	ligands	T103	C0023688
27255214	891	901	introduced	T169	C1292748
27255214	919	928	targeting	T169	C1521840
27255214	929	937	moieties	T077	C3641152
27255214	979	985	during	T079	C0347984
27255214	986	1003	blood circulation	T039	C0005775
27255214	1008	1017	efficient	T080	C0442799
27255214	1018	1030	tumor tissue	T024	C0475358
27255214	1031	1043	accumulation	UnknownType	C0678759
27255214	1049	1061	re-activated	T169	C0205245
27255214	1073	1081	internal	T082	C0205102
27255214	1085	1093	external	T082	C0205101
27255214	1094	1101	stimuli	T067	C0234402
27255214	1109	1131	tumor microenvironment	T070	C2936626
27255214	1136	1144	enhanced	T169	C0442805
27255214	1145	1169	cellular internalization	T043	C0014139

27255399|t|Subsolid pulmonary nodule morphology and associated patient characteristics in a routine clinical population
27255399|a|To determine the presence and morphology of subsolid pulmonary nodules (SSNs) in a non-screening setting and relate them to clinical and patient characteristics. A total of 16,890 reports of clinically obtained chest CT (06/2011 to 11/2014, single-centre) were searched describing an SSN. Subjects with a visually confirmed SSN and at least two thin-slice CTs were included. Nodule volumes were measured. Progression was defined as volume increase exceeding the software interscan variation. Nodule morphology, location, and patient characteristics were evaluated. Fifteen transient and 74 persistent SSNs were included (median follow-up 19.6 [8.3-36.8] months). Subjects with an SSN were slightly older than those without (62 vs. 58 years; p = 0.01), but no gender predilection was found. SSNs were mostly located in the upper lobes. Women showed significantly more often persistent lesions than men (94 % vs. 69 %; p = 0.002). Part-solid lesions were larger (1638 vs. 383 mm(3); p < 0.001) and more often progressive (68 % vs. 38 %; p = 0.02), compared to pure ground-glass nodules. Progressive SSNs were rare under the age of 50 years. Logistic regression analysis did not identify additional nodule parameters of future progression, apart from part-solid nature. This study confirms previously reported characteristics of SSNs and associated factors in a European, routine clinical population. â¢ SSNs in women are significantly more often persistent compared to men. â¢ SSN persistence is not associated with age or prior malignancy. â¢ The majority of (persistent) SSNs are located in the upper lung lobes. â¢ A part-solid nature is associated with future nodule growth. â¢ Progressive solitary SSNs are rare under the age of 50 years.
27255399	0	25	Subsolid pulmonary nodule	T033	C0034079
27255399	26	36	morphology	T080	C0332437
27255399	52	75	patient characteristics	T201	C0815172
27255399	81	88	routine	T080	C0205547
27255399	89	97	clinical	T080	C0205210
27255399	98	108	population	T098	C1257890
27255399	126	134	presence	T080	C3854307
27255399	139	149	morphology	T080	C0332437
27255399	153	179	subsolid pulmonary nodules	T033	C0034079
27255399	181	185	SSNs	T033	C0034079
27255399	192	213	non-screening setting	T082	C3176918
27255399	233	241	clinical	T201	C0683325
27255399	246	269	patient characteristics	T201	C0815172
27255399	289	296	reports	T170	C0684224
27255399	300	310	clinically	T080	C0205210
27255399	320	328	chest CT	T060	C0202823
27255399	393	396	SSN	T033	C0034079
27255399	398	406	Subjects	T098	C0080105
27255399	414	422	visually	T169	C0234621
27255399	433	436	SSN	T033	C0034079
27255399	454	468	thin-slice CTs	T060	C0040405
27255399	484	490	Nodule	T020	C0028259
27255399	491	498	volumes	T081	C0449468
27255399	504	512	measured	T080	C0444706
27255399	514	525	Progression	T169	C0449258
27255399	541	547	volume	T081	C0449468
27255399	571	589	software interscan	T060	C0441633
27255399	590	599	variation	T080	C0205419
27255399	601	607	Nodule	T020	C0028259
27255399	608	618	morphology	T080	C0332437
27255399	620	628	location	T029	C1515974
27255399	634	657	patient characteristics	T201	C0815172
27255399	663	672	evaluated	T058	C0220825
27255399	682	691	transient	T079	C0205374
27255399	699	709	persistent	T079	C0205322
27255399	710	714	SSNs	T033	C0034079
27255399	737	746	follow-up	T058	C1522577
27255399	763	769	months	T079	C0439231
27255399	772	780	Subjects	T098	C0080105
27255399	789	792	SSN	T033	C0034079
27255399	843	848	years	T079	C0439234
27255399	868	874	gender	T032	C0079399
27255399	875	887	predilection	T078	C0242568
27255399	899	903	SSNs	T033	C0034079
27255399	916	923	located	T082	C0450429
27255399	931	942	upper lobes	T023	C0225756
27255399	944	949	Women	T098	C0043210
27255399	957	970	significantly	T078	C0750502
27255399	982	992	persistent	T079	C0205322
27255399	993	1000	lesions	T033	C0221198
27255399	1006	1009	men	T098	C0025266
27255399	1038	1056	Part-solid lesions	T033	C3826968
27255399	1116	1127	progressive	T169	C0205329
27255399	1172	1192	ground-glass nodules	T033	C3826968
27255399	1194	1205	Progressive	T169	C0205329
27255399	1206	1210	SSNs	T033	C0034079
27255399	1231	1234	age	T032	C0001779
27255399	1241	1246	years	T079	C0439234
27255399	1248	1276	Logistic regression analysis	UnknownType	C0681925
27255399	1305	1311	nodule	T020	C0028259
27255399	1312	1322	parameters	T033	C0449381
27255399	1333	1344	progression	T169	C0449258
27255399	1357	1374	part-solid nature	T080	C0449786
27255399	1381	1386	study	T062	C2603343
27255399	1416	1431	characteristics	T080	C1521970
27255399	1435	1439	SSNs	T033	C0034079
27255399	1455	1462	factors	T169	C1521761
27255399	1468	1476	European	T098	C0239307
27255399	1478	1485	routine	T080	C0205547
27255399	1486	1494	clinical	T080	C0205210
27255399	1495	1505	population	T098	C1257890
27255399	1509	1513	SSNs	T033	C0034079
27255399	1517	1522	women	T098	C0043210
27255399	1527	1540	significantly	T078	C0750502
27255399	1552	1562	persistent	T079	C0205322
27255399	1575	1578	men	T098	C0025266
27255399	1582	1585	SSN	T033	C0034079
27255399	1586	1597	persistence	T079	C0205322
27255399	1621	1624	age	T032	C0001779
27255399	1628	1633	prior	T079	C0332152
27255399	1634	1644	malignancy	T191	C4282132
27255399	1665	1675	persistent	T079	C0205322
27255399	1677	1681	SSNs	T033	C0034079
27255399	1701	1717	upper lung lobes	T023	C0225756
27255399	1723	1740	part-solid nature	T080	C0449786
27255399	1744	1759	associated with	T080	C0332281
27255399	1767	1773	nodule	T020	C0028259
27255399	1774	1780	growth	T042	C1621966
27255399	1784	1795	Progressive	T169	C0205329
27255399	1796	1809	solitary SSNs	T191	C2350019
27255399	1814	1818	rare	T080	C0522498
27255399	1829	1832	age	T032	C0001779
27255399	1839	1844	years	T079	C0439234

27255411|t|Dynamic CT myocardial perfusion imaging identifies early perfusion abnormalities in diabetes and hypertension: Insights from a multicenter registry
27255411|a|To identify patients with early signs of myocardial perfusion reduction, a reference base for perfusion measures is needed. To analyze perfusion parameters derived from dynamic computed tomography perfusion imaging (CTPI) in patients with suspected coronary artery disease (CAD), and relationship with risk factors. In this multicenter study, coronary CT angiography (cCTA) and dynamic CTPI were performed by second-generation dual-source CT in patients suspected of CAD. Risk factors were collected from hospital records. Patients with visual perfusion defects on CTPI, previous coronary intervention, or missing risk factor details were excluded. This analysis included 98 patients (mean age Â± standard deviation [SD], 59.0 Â± 8.6yrs; 73 male). Global measures of left ventricular myocardial blood flow (MBF), myocardial blood volume (MBV) and volume transfer constant (K(trans)) were calculated. Mean MBF was 139.3 Â± 31.4 mL/100 mL/min, MBV 19.1 Â± 2.7 mL/100 mL, and Ktrans 85.0 Â± 17.5 mL/100 mL/min. No significant differences in perfusion parameters were found by gender or age category. Hypertension and diabetes mellitus resulted in lower perfusion parameters (hypertension vs normotension: MBV 18.5 Â± 3.0 vs 19.7 Â± 2.3 mL/100 mL and K(trans) 82.0 Â± 18.0 vs 89.0 Â± 16.0, p < 0.05; diabetes vs no diabetes: MBF 128.5 Â± 31.5 vs 144.0 Â± 30.5 mL/100 mL/min and MBV 17.9 Â± 2.4 vs 19.4 Â± 2.8 mL/100 mL, p < 0.05). In patients with hyperlipidemia, MBF was higher (146.8 Â± 34.4 vs 130.7 Â± 24.3 mL/100 mL/min, p < 0.05). Smoking and family history did not show perfusion parameter differences. Dynamic CTPI identifies early perfusion disturbances in conditions like diabetes and hypertension. With further standardization, absolute perfusion measures may improve CAD risk stratification in patients without visual perfusion defects.
27255411	0	39	Dynamic CT myocardial perfusion imaging	T060	C3899514
27255411	51	56	early	T079	C1279919
27255411	57	66	perfusion	T042	C0599705
27255411	67	80	abnormalities	T033	C1704258
27255411	84	92	diabetes	T047	C0011847
27255411	97	109	hypertension	T047	C0020538
27255411	127	138	multicenter	T062	C1096776
27255411	139	147	registry	T170	C0034975
27255411	160	168	patients	T101	C0030705
27255411	174	185	early signs	T184	C0037088
27255411	189	209	myocardial perfusion	T032	C0428857
27255411	200	209	perfusion	T042	C0599705
27255411	210	219	reduction	T080	C0392756
27255411	242	251	perfusion	T042	C0599705
27255411	252	260	measures	T081	C0079809
27255411	283	292	perfusion	T042	C0599705
27255411	293	303	parameters	T033	C0449381
27255411	317	362	dynamic computed tomography perfusion imaging	T060	C3899514
27255411	345	354	perfusion	T042	C0599705
27255411	364	368	CTPI	T060	C3899514
27255411	373	381	patients	T101	C0030705
27255411	397	420	coronary artery disease	T047	C1956346
27255411	422	425	CAD	T047	C1956346
27255411	432	444	relationship	T080	C0439849
27255411	450	462	risk factors	T033	C0035648
27255411	472	489	multicenter study	T062	C1096776
27255411	491	514	coronary CT angiography	T060	C1634617
27255411	516	520	cCTA	T060	C1634617
27255411	526	538	dynamic CTPI	T060	C3899514
27255411	557	589	second-generation dual-source CT	T060	C0040405
27255411	593	601	patients	T101	C0030705
27255411	615	618	CAD	T047	C1956346
27255411	620	632	Risk factors	T033	C0035648
27255411	653	669	hospital records	T073,T170	C0019980
27255411	671	679	Patients	T101	C0030705
27255411	685	691	visual	T169	C0234621
27255411	692	701	perfusion	T042	C0599705
27255411	702	709	defects	T169	C1457869
27255411	713	717	CTPI	T060	C3899514
27255411	728	749	coronary intervention	T061	C0184661
27255411	762	773	risk factor	T033	C0035648
27255411	802	810	analysis	T062	C0936012
27255411	823	831	patients	T101	C0030705
27255411	887	891	male	T098	C0025266
27255411	901	909	measures	T081	C0079809
27255411	913	929	left ventricular	T023	C0225897
27255411	930	951	myocardial blood flow	T042	C2986786
27255411	953	956	MBF	T042	C2986786
27255411	959	982	myocardial blood volume	T201	C0005850
27255411	984	987	MBV	T201	C0005850
27255411	993	1017	volume transfer constant	T081	C2986811
27255411	1019	1027	K(trans)	T081	C2986811
27255411	1051	1054	MBF	T042	C2986786
27255411	1087	1090	MBV	T201	C0005850
27255411	1181	1190	perfusion	T042	C0599705
27255411	1191	1201	parameters	T033	C0449381
27255411	1216	1222	gender	T032	C0079399
27255411	1226	1229	age	T032	C0001779
27255411	1240	1252	Hypertension	T047	C0020538
27255411	1257	1274	diabetes mellitus	T047	C0011849
27255411	1293	1302	perfusion	T042	C0599705
27255411	1303	1313	parameters	T033	C0449381
27255411	1315	1327	hypertension	T047	C0020538
27255411	1331	1343	normotension	T033	C4068890
27255411	1345	1348	MBV	T201	C0005850
27255411	1388	1396	K(trans)	T081	C2986811
27255411	1435	1443	diabetes	T047	C0011847
27255411	1447	1458	no diabetes	T033	C0243095
27255411	1460	1463	MBF	T042	C2986786
27255411	1511	1514	MBV	T201	C0005850
27255411	1565	1573	patients	T101	C0030705
27255411	1579	1593	hyperlipidemia	T047	C0020473
27255411	1595	1598	MBF	T042	C2986786
27255411	1666	1673	Smoking	T055	C0037369
27255411	1678	1692	family history	T033	C0241889
27255411	1706	1715	perfusion	T042	C0599705
27255411	1716	1725	parameter	T033	C0449381
27255411	1739	1751	Dynamic CTPI	T060	C3899514
27255411	1769	1778	perfusion	T042	C0599705
27255411	1779	1791	disturbances	T080	C2699787
27255411	1811	1819	diabetes	T047	C0011847
27255411	1824	1836	hypertension	T047	C0020538
27255411	1851	1866	standardization	T062	C0038136
27255411	1877	1886	perfusion	T042	C0599705
27255411	1887	1895	measures	T081	C0079809
27255411	1908	1911	CAD	T047	C1956346
27255411	1912	1916	risk	T078	C0035647
27255411	1917	1931	stratification	T062	C1514983
27255411	1935	1943	patients	T101	C0030705
27255411	1952	1958	visual	T169	C0234621
27255411	1959	1968	perfusion	T042	C0599705
27255411	1969	1976	defects	T169	C1457869

27255600|t|Cognition Enhancing Activity of Sulforaphane Against Scopolamine Induced Cognitive Impairment in Zebra Fish (Danio rerio)
27255600|a|Several epidemiological studies have shown that consumption of large quantities of vegetables especially cruciferous vegetables (Broccoli and Brussels sprouts) can protect against chronic diseases. Sulforaphane, an isothiocynate found in cruciferous vegetables has been demonstrated to have neuroprotective effects in several experimental paradigms. This study was undertaken to examine the effect of sulforaphane on cognitive impairment in zebra fish model using a novel method of fear conditioning. Initially, the normal behaviour of zebra fishes was studied in light-dark tank for 10 min daily for 10 days. Fishes were then divided into seven groups of twelve in each. Group I served as normal, group II served as fear conditioned control, group III and group IV were sulforaphane (25 ÂµM/L) and piracetam (200 mg/L) treated respectively. Group V served as scopolamine (400 ÂµM/L) induced memory impairment fishes. Group VI and VII were sulforaphane (25 ÂµM/L) and piracetam (200 mg/L) treated scopolamine induced memory impairment groups respectively. In normal behavioural analysis, fishes preferred to stay in dark compartment. The average number of entries into the dark and time spent in dark were significantly more. Fishes in group II to VII were individually subjected to fear conditioning passive avoidance task and evaluated for learned task memory. It was observed that the average number of entries into dark and time spent in dark were significantly decreased. After exposure to respective treatment fishes in group III to VII were subjected to cognitive evaluation. There was no significant difference in cognition of group III and IV fishes exposed to sulforaphane and piracetam alone respectively. Fishes exposed to scopolamine showed a significant cognitive impairment. Sulforaphane exposure prior to scopolamine significantly retained the memory of learned task. These findings suggest that sulforaphane might be a promising therapeutic agent for cognitive enhancement in Alzheimer's disease.
27255600	0	9	Cognition	T041	C0009240
27255600	10	19	Enhancing	T052	C2349975
27255600	20	28	Activity	T078	C1561536
27255600	32	44	Sulforaphane	T109,T121	C0163159
27255600	45	52	Against	T080	C0521124
27255600	53	64	Scopolamine	T109,T121	C0036442
27255600	65	72	Induced	T169	C0205263
27255600	73	93	Cognitive Impairment	T048	C0338656
27255600	97	107	Zebra Fish	T013	C0043457
27255600	109	120	Danio rerio	T013	C0043457
27255600	122	129	Several	T081	C0443302
27255600	130	153	epidemiological studies	T062	C0002783
27255600	170	181	consumption	T052	C2983605
27255600	185	190	large	T081	C0549177
27255600	191	201	quantities	T081	C1265611
27255600	205	215	vegetables	T168	C0042440
27255600	227	249	cruciferous vegetables	T168	C0453113
27255600	251	259	Broccoli	T168	C0330499
27255600	264	280	Brussels sprouts	T168	C0330501
27255600	294	301	against	T080	C0521124
27255600	302	318	chronic diseases	T047	C0008679
27255600	320	332	Sulforaphane	T109,T121	C0163159
27255600	337	350	isothiocynate	T109	C0029224
27255600	351	356	found	T033	C0150312
27255600	360	382	cruciferous vegetables	T168	C0453113
27255600	413	436	neuroprotective effects	T169	C0815279
27255600	440	447	several	T081	C0443302
27255600	448	470	experimental paradigms	T062	C0681797
27255600	477	482	study	T062	C2603343
27255600	513	519	effect	T080	C1280500
27255600	523	535	sulforaphane	T109,T121	C0163159
27255600	539	559	cognitive impairment	T048	C0338656
27255600	563	573	zebra fish	T013	C0043457
27255600	574	579	model	T050	C0012644
27255600	588	593	novel	T080	C0205314
27255600	594	600	method	T170	C0025663
27255600	604	621	fear conditioning	T041	C0009649
27255600	638	644	normal	T080	C0205307
27255600	645	654	behaviour	T053	C0004927
27255600	658	670	zebra fishes	T013	C0043457
27255600	675	682	studied	T062	C2603343
27255600	686	701	light-dark tank	T073	C0337123
27255600	713	718	daily	T079	C0332173
27255600	726	730	days	T079	C0439228
27255600	732	738	Fishes	T013	C0043457
27255600	749	756	divided	T169	C0332849
27255600	762	767	seven	T081	C0205453
27255600	768	774	groups	UnknownType	C0681860
27255600	778	784	twelve	T081	C0205458
27255600	788	792	each	T081	C1457900
27255600	794	801	Group I	UnknownType	C0681860
27255600	812	818	normal	T080	C0205307
27255600	820	828	group II	UnknownType	C0681860
27255600	839	863	fear conditioned control	T041	C0009649
27255600	865	874	group III	UnknownType	C0681860
27255600	879	887	group IV	UnknownType	C0681860
27255600	893	905	sulforaphane	T109,T121	C0163159
27255600	920	929	piracetam	T109,T121	C0031977
27255600	941	948	treated	T169	C1522326
27255600	963	970	Group V	UnknownType	C0681860
27255600	981	992	scopolamine	T109,T121	C0036442
27255600	1004	1011	induced	T169	C0205263
27255600	1012	1029	memory impairment	T048	C0233794
27255600	1030	1036	fishes	T013	C0043457
27255600	1038	1046	Group VI	UnknownType	C0681860
27255600	1051	1054	VII	UnknownType	C0681860
27255600	1060	1072	sulforaphane	T109,T121	C0163159
27255600	1087	1096	piracetam	T109,T121	C0031977
27255600	1108	1115	treated	T169	C1522326
27255600	1116	1127	scopolamine	T109,T121	C0036442
27255600	1128	1135	induced	T169	C0205263
27255600	1136	1153	memory impairment	T048	C0233794
27255600	1154	1160	groups	UnknownType	C0681860
27255600	1178	1184	normal	T080	C0205307
27255600	1185	1205	behavioural analysis	T058	C1160858
27255600	1207	1213	fishes	T013	C0043457
27255600	1235	1239	dark	T080	C0332582
27255600	1240	1251	compartment	T082	C0449719
27255600	1257	1264	average	T081	C1510992
27255600	1265	1271	number	T081	C0237753
27255600	1275	1282	entries	T071	C1551338
27255600	1292	1296	dark	T080	C0332582
27255600	1301	1305	time	T079	C0040223
27255600	1315	1319	dark	T080	C0332582
27255600	1325	1343	significantly more	T081	C4055637
27255600	1345	1351	Fishes	T013	C0043457
27255600	1355	1363	group II	UnknownType	C0681860
27255600	1367	1370	VII	UnknownType	C0681860
27255600	1402	1419	fear conditioning	T041	C0009649
27255600	1420	1442	passive avoidance task	T060	C0683443
27255600	1447	1456	evaluated	T058	C0220825
27255600	1461	1480	learned task memory	T041	C0025260
27255600	1489	1497	observed	T169	C1441672
27255600	1507	1514	average	T081	C1510992
27255600	1515	1521	number	T081	C0237753
27255600	1525	1532	entries	T071	C1551338
27255600	1538	1542	dark	T080	C0332582
27255600	1547	1551	time	T079	C0040223
27255600	1561	1565	dark	T080	C0332582
27255600	1571	1584	significantly	T081	C0237881
27255600	1585	1594	decreased	T081	C0205216
27255600	1602	1613	exposure to	T080	C0332157
27255600	1625	1634	treatment	T169	C1522326
27255600	1635	1641	fishes	T013	C0043457
27255600	1645	1654	group III	UnknownType	C0681860
27255600	1658	1661	VII	UnknownType	C0681860
27255600	1680	1689	cognitive	T041	C0009240
27255600	1690	1700	evaluation	T058	C0220825
27255600	1712	1726	no significant	T033	C1273937
27255600	1727	1737	difference	T080	C1705242
27255600	1741	1750	cognition	T041	C0009240
27255600	1754	1763	group III	UnknownType	C0681860
27255600	1768	1770	IV	UnknownType	C0681860
27255600	1771	1777	fishes	T013	C0043457
27255600	1778	1788	exposed to	T080	C0332157
27255600	1789	1801	sulforaphane	T109,T121	C0163159
27255600	1806	1815	piracetam	T109,T121	C0031977
27255600	1836	1842	Fishes	T013	C0043457
27255600	1843	1853	exposed to	T080	C0332157
27255600	1854	1865	scopolamine	T109,T121	C0036442
27255600	1875	1886	significant	T081	C0237881
27255600	1887	1907	cognitive impairment	T048	C0338656
27255600	1909	1921	Sulforaphane	T109,T121	C0163159
27255600	1940	1951	scopolamine	T109,T121	C0036442
27255600	1952	1965	significantly	T081	C0237881
27255600	1979	1985	memory	T041	C0025260
27255600	1989	1996	learned	T041	C0023185
27255600	1997	2001	task	T169	C1317878
27255600	2009	2017	findings	T033	C0243095
27255600	2018	2025	suggest	T078	C1705535
27255600	2031	2043	sulforaphane	T109,T121	C0163159
27255600	2065	2082	therapeutic agent	T121	C1611640
27255600	2087	2096	cognitive	T041	C0009240
27255600	2097	2108	enhancement	T052	C2349975
27255600	2112	2131	Alzheimer's disease	T047	C0002395

27256046|t|Value of MDM2, CDK4 and SATB2 immunohistochemistry in histologic diagnosis of low-grade osteosarcoma
27256046|a|To investigate the value of combined application of MDM2, CDK4 and SATB2 immunohistochemistry in pathological diagnosis of low-grade osteosarcoma. Forty-seven cases of low grade osteosarcoma, including low grade central osteosarcoma (n=20) and parosteal osteosarcoma (n=27), were selected from Shanghai Jiaotong University Affiliated the Sixth People's Hospital. The clinical, radiography and histopathology were reviewed. The sensitivity and specificity of MDM2, CDK4 and SATB2 immunohistochemistry in the diagnosis of low-grade osteosarcoma were assessed along with an evaluation of their expressions in fibrous dysplasia, desmoplastic fibroma, low-grade fibrosarcoma and other fibrous tumors. Low-grade osteosarcoma had protracted clinical course, occurring mostly in elder adults and mainly involving long bones. Radiographic studies showed that low-grade central osteosarcoma had a mainly malignant lytic presentation, however about 5/18 of t umors overlapping with intermediate and benign bone diseases, while parosteal osteosarcoma was characterized by a densely sclerotic malignant appearance. Histologically, low-grade osteosarcoma s were characterized by well-differentiated spindle tumor cells, various mature tumor bones and an aggressive growth pattern. The positive expression rates of MDM2 and CDK4 in low-grade osteosarcoma were 74.5% and 55.3%, respectively. Eighty-three percent of low-grade osteosarcoma expressed one or both markers. Low-grade osteosarcoma and fibrous dysplasia were both positive for SATB2, while desmoplastic fibroma, low-grade fibrosacoma and other fibrous tumors were negative for SATB2. Accurate diagnosis of low-grade osteosarcoma should be based on combination of clinical presentation, imaging and histopathology, with immunohistochemistry as a diagnostic adjunct. Positive immunostaining for CDK4 and/or MDM2 supports the diagnosis of low-grade osteosarcoma, but the negative one does not rule out such lesion. The negative expression of SATB2 is helpful to exclude fibrous tumors originating from bone with the exception of fibrous dysplasia.
27256046	9	13	MDM2	T116,T123	C0127306
27256046	15	19	CDK4	T116,T126	C0246957
27256046	24	29	SATB2	T116,T123	C1958595
27256046	30	50	immunohistochemistry	T060	C0021044
27256046	54	64	histologic	T201	C0449574
27256046	65	74	diagnosis	T033	C0011900
27256046	78	87	low-grade	T033	C1962916
27256046	88	100	osteosarcoma	T191	C0029463
27256046	153	157	MDM2	T116,T123	C0127306
27256046	159	163	CDK4	T116,T126	C0246957
27256046	168	173	SATB2	T116,T123	C1958595
27256046	174	194	immunohistochemistry	T060	C0021044
27256046	198	210	pathological	T169	C1521733
27256046	211	220	diagnosis	T033	C0011900
27256046	224	233	low-grade	T033	C1962916
27256046	234	246	osteosarcoma	T191	C0029463
27256046	269	278	low grade	T033	C1962916
27256046	279	291	osteosarcoma	T191	C0029463
27256046	303	333	low grade central osteosarcoma	T191	C3814534
27256046	345	367	parosteal osteosarcoma	T191	C0206642
27256046	395	423	Shanghai Jiaotong University	T073,T092	C0041740
27256046	439	462	Sixth People's Hospital	T073,T093	C0019994
27256046	468	476	clinical	T080	C0205210
27256046	478	489	radiography	T060	C0043299
27256046	494	508	histopathology	T034	C0428093
27256046	514	522	reviewed	T080	C1709940
27256046	528	555	sensitivity and specificity	T081	C0036668
27256046	559	563	MDM2	T116,T123	C0127306
27256046	565	569	CDK4	T116,T126	C0246957
27256046	574	579	SATB2	T116,T123	C1958595
27256046	580	600	immunohistochemistry	T060	C0021044
27256046	608	617	diagnosis	T033	C0011900
27256046	621	630	low-grade	T033	C1962916
27256046	631	643	osteosarcoma	T191	C0029463
27256046	649	657	assessed	T058	C0220825
27256046	672	682	evaluation	T058	C0220825
27256046	692	703	expressions	T045	C1171362
27256046	707	724	fibrous dysplasia	T019	C0259779
27256046	726	746	desmoplastic fibroma	T191	C0206645
27256046	748	757	low-grade	T033	C1962916
27256046	758	770	fibrosarcoma	T191	C0016057
27256046	781	795	fibrous tumors	T191	C0206643
27256046	797	806	Low-grade	T033	C1962916
27256046	807	819	osteosarcoma	T191	C0029463
27256046	824	850	protracted clinical course	T033	C4228198
27256046	872	884	elder adults	T100	C0001675
27256046	906	910	long	T080	C0205166
27256046	911	916	bones	T023	C0262950
27256046	951	981	low-grade central osteosarcoma	T191	C3814534
27256046	995	1004	malignant	T080	C0205282
27256046	1005	1010	lytic	T080	C0439680
27256046	1011	1023	presentation	T078	C0449450
27256046	1049	1066	umors overlapping	T185	C1264754
27256046	1089	1095	benign	T080	C0205183
27256046	1096	1109	bone diseases	T047	C0005940
27256046	1117	1139	parosteal osteosarcoma	T191	C0206642
27256046	1171	1180	sclerotic	T169	C0334135
27256046	1181	1190	malignant	T080	C0205282
27256046	1191	1201	appearance	T080	C0700364
27256046	1203	1217	Histologically	T201	C0449574
27256046	1219	1228	low-grade	T033	C1962916
27256046	1229	1241	osteosarcoma	T191	C0029463
27256046	1286	1293	spindle	T025	C0682540
27256046	1294	1305	tumor cells	T025	C0597032
27256046	1315	1321	mature	T024	C0682560
27256046	1322	1333	tumor bones	T191	C0005967
27256046	1341	1351	aggressive	T079	C0580822
27256046	1352	1366	growth pattern	T033	C1156245
27256046	1372	1391	positive expression	T045	C1171362
27256046	1401	1405	MDM2	T116,T123	C0127306
27256046	1410	1414	CDK4	T116,T126	C0246957
27256046	1418	1427	low-grade	T033	C1962916
27256046	1428	1440	osteosarcoma	T191	C0029463
27256046	1501	1510	low-grade	T033	C1962916
27256046	1511	1523	osteosarcoma	T191	C0029463
27256046	1555	1564	Low-grade	T033	C1962916
27256046	1565	1577	osteosarcoma	T191	C0029463
27256046	1582	1599	fibrous dysplasia	T019	C0259779
27256046	1610	1618	positive	T033	C1514241
27256046	1623	1628	SATB2	T116,T123	C1958595
27256046	1636	1656	desmoplastic fibroma	T191	C0206645
27256046	1658	1667	low-grade	T033	C1962916
27256046	1668	1679	fibrosacoma	T191	C0016057
27256046	1690	1704	fibrous tumors	T191	C0206643
27256046	1710	1718	negative	T033	C1513916
27256046	1723	1728	SATB2	T116,T123	C1958595
27256046	1739	1748	diagnosis	T033	C0011900
27256046	1752	1761	low-grade	T033	C1962916
27256046	1762	1774	osteosarcoma	T191	C0029463
27256046	1794	1805	combination	T080	C0205195
27256046	1809	1830	clinical presentation	T170	C2708283
27256046	1832	1839	imaging	T060	C0011923
27256046	1844	1858	histopathology	T034	C0428093
27256046	1865	1885	immunohistochemistry	T060	C0021044
27256046	1891	1901	diagnostic	T169	C0348026
27256046	1902	1909	adjunct	T169	C1719882
27256046	1911	1934	Positive immunostaining	T059	C0487602
27256046	1939	1943	CDK4	T116,T126	C0246957
27256046	1951	1955	MDM2	T116,T123	C0127306
27256046	1969	1978	diagnosis	T033	C0011900
27256046	1982	1991	low-grade	T033	C1962916
27256046	1992	2004	osteosarcoma	T191	C0029463
27256046	2050	2056	lesion	T033	C0221198
27256046	2071	2081	expression	T045	C1171362
27256046	2085	2090	SATB2	T116,T123	C1958595
27256046	2113	2127	fibrous tumors	T191	C0206643
27256046	2145	2149	bone	T023	C0262950
27256046	2172	2189	fibrous dysplasia	T019	C0259779

27256126|t|Biobank and Genomic Research in Uganda: Are Extant Privacy and Confidentiality Regimes Adequate?
27256126|a|Not many African countries have been able to develop a robust system for regulating health research within their respective jurisdictions, particularly in the realm of biobanking and genomics. This is not without reason. Aside from underdevelopment and all that it entails or perhaps in consequence thereof, countries in the region have been unable to make significant strides in medical research. But there are exceptions. Amongst the few seeming success stories is Uganda. Nonetheless, although the country has developed what appears to be a functional framework to govern genomic research and biobanking, the consistency of key provisions with international standards, especially those pertaining to privacy of research participants and confidentiality of their health information, is not at all clear. Yet, making this determination - the main objective of this article - is critical in determining the adequacy of protection available to human research subjects in the country.
27256126	0	7	Biobank	T073	C1711176
27256126	12	19	Genomic	T091	C0887950
27256126	20	28	Research	T062	C0035168
27256126	32	38	Uganda	T083	C0041573
27256126	44	58	Extant Privacy	T078	C0080048
27256126	63	86	Confidentiality Regimes	T078	C0009669
27256126	87	95	Adequate	T080	C0205411
27256126	106	123	African countries	T083	C0001737
27256126	170	180	regulating	T064	C0851285
27256126	181	196	health research	T062	C0018757
27256126	221	234	jurisdictions	T170	C0680647
27256126	256	261	realm	T078	C3244047
27256126	265	275	biobanking	T073	C1711176
27256126	280	288	genomics	T091	C0887950
27256126	329	345	underdevelopment	UnknownType	C0681082
27256126	384	403	consequence thereof	T169	C0686907
27256126	405	414	countries	T083	C0454664
27256126	422	428	region	T083	C0017446
27256126	477	493	medical research	T062	C0079816
27256126	545	552	success	T054	C0597535
27256126	564	570	Uganda	T083	C0041573
27256126	598	619	country has developed	T080	C0282613
27256126	641	661	functional framework	T077	C1709697
27256126	672	679	genomic	T091	C0887950
27256126	680	688	research	T062	C0035168
27256126	693	703	biobanking	T073	C1711176
27256126	709	720	consistency	T080	C0332529
27256126	744	757	international	T078	C1512888
27256126	758	767	standards	T170	C0038137
27256126	800	807	privacy	T078	C0080048
27256126	811	819	research	T062	C0035168
27256126	820	832	participants	T098	C0679646
27256126	837	852	confidentiality	T078	C0009669
27256126	862	880	health information	T058	C0850397
27256126	945	954	objective	T170	C0018017
27256126	963	970	article	T170	C1706852
27256126	976	984	critical	T080	C1511545
27256126	1004	1012	adequacy	T080	C0205411
27256126	1016	1026	protection	T033	C1545588
27256126	1040	1045	human	T016	C0086418
27256126	1046	1063	research subjects	T098	C0080105
27256126	1071	1078	country	T083	C0454664

27256373|t|Impact of a Casino Opening on Gambling Behaviors of People Engaged in Methadone Maintenance
27256373|a|This study examined gambling behavior in the context of a newly opening casino, comparing disordered gamblers to non-disordered gamblers, in a population of individuals involved in methadone maintenance treatment. Disordered gamblers (N = 50) and non-disordered gamblers (N = 50) were surveyed before and after the opening of a new casino on gambling behaviors, substance use, and psychological symptoms. No statistically significant changes in gambling behaviors were observed for disordered gamblers or non-disordered gamblers across time points; however, non-disordered gamblers demonstrated non-significant increases in horse and dog race betting, electronic games, and casino table games. As expected, disordered gamblers were found to spend significantly more money on electronic games and casino table games (p < 0.05) and demonstrated higher rates of drug use and impulsivity than non-disordered gamblers. The introduction of a new casino did not appear to have a major impact on gambling behaviors of individuals attending methadone maintenance treatment, though the non-significant increases in gambling among non-disordered gamblers may indicate that this population is preferentially impacted by the opening of a new casino. Future investigation into the longer term effects of opening a new casino on this population may be warranted.
27256373	0	6	Impact	T080	C4049986
27256373	12	18	Casino	T073	C0442564
27256373	19	26	Opening	T082	C0175566
27256373	30	38	Gambling	T055	C0016995
27256373	39	48	Behaviors	T053	C0004927
27256373	52	58	People	T098	C0027361
27256373	70	79	Methadone	T109,T121	C0025605
27256373	80	91	Maintenance	T052	C0024501
27256373	112	120	gambling	T055	C0016995
27256373	121	129	behavior	T053	C0004927
27256373	156	163	opening	T082	C0175566
27256373	164	170	casino	T073	C0442564
27256373	172	181	comparing	T052	C1707455
27256373	182	201	disordered gamblers	T055	C0858352
27256373	205	228	non-disordered gamblers	T055	C0858352
27256373	235	245	population	T098	C1257890
27256373	249	260	individuals	T098	C0027361
27256373	273	304	methadone maintenance treatment	T061	C0746569
27256373	306	325	Disordered gamblers	T055	C0858352
27256373	339	362	non-disordered gamblers	T055	C0858352
27256373	377	385	surveyed	T062	C0178803
27256373	407	414	opening	T082	C0175566
27256373	424	430	casino	T073	C0442564
27256373	434	442	gambling	T055	C0016995
27256373	443	452	behaviors	T053	C0004927
27256373	454	467	substance use	T033	C0946431
27256373	473	495	psychological symptoms	T184	C0233397
27256373	497	533	No statistically significant changes	T033	C0243095
27256373	537	545	gambling	T055	C0016995
27256373	546	555	behaviors	T053	C0004927
27256373	574	593	disordered gamblers	T055	C0858352
27256373	597	620	non-disordered gamblers	T055	C0858352
27256373	650	673	non-disordered gamblers	T055	C0858352
27256373	687	712	non-significant increases	T033	C0243095
27256373	716	721	horse	T015	C0019944
27256373	716	742	horse and dog race betting	T055	C0016995
27256373	726	729	dog	T015	C0012984
27256373	744	760	electronic games	T073	C0042649
27256373	766	772	casino	T073	C0442564
27256373	773	784	table games	T170	C4288387
27256373	799	818	disordered gamblers	T055	C0858352
27256373	833	863	spend significantly more money	T033	C3842916
27256373	867	883	electronic games	T073	C0042649
27256373	888	894	casino	T073	C0442564
27256373	895	906	table games	T170	C4288387
27256373	951	959	drug use	T048	C0242510
27256373	964	975	impulsivity	T055	C0021125
27256373	981	1004	non-disordered gamblers	T055	C0858352
27256373	1032	1038	casino	T073	C0442564
27256373	1070	1076	impact	T080	C4049986
27256373	1080	1088	gambling	T055	C0016995
27256373	1089	1098	behaviors	T053	C0004927
27256373	1102	1113	individuals	T098	C0027361
27256373	1124	1155	methadone maintenance treatment	T061	C0746569
27256373	1168	1193	non-significant increases	T033	C0243095
27256373	1197	1205	gambling	T055	C0016995
27256373	1212	1235	non-disordered gamblers	T055	C0858352
27256373	1259	1269	population	T098	C1257890
27256373	1288	1296	impacted	T080	C4049986
27256373	1304	1311	opening	T082	C0175566
27256373	1321	1327	casino	T073	C0442564
27256373	1329	1335	Future	T079	C0016884
27256373	1336	1349	investigation	T169	C1292732
27256373	1359	1378	longer term effects	T067	C0023983
27256373	1382	1389	opening	T082	C0175566
27256373	1396	1402	casino	T073	C0442564
27256373	1411	1421	population	T098	C1257890

27256491|t|Association between Leukoaraiosis and Poor Outcome is not due to Reperfusion Inefficiency after Intravenous Thrombolysis
27256491|a|Leukoaraiosis (LA) is associated with structural and functional cerebrovascular impairment, which may compromise the capacity of ischemic tissue to maximize reperfusion after intravenous thrombolysis (IVT). We aimed to determine whether severe LA is correlated with reperfusion inefficiency, which contributes to infarct growth and poor functional outcome. We analyzed data from our consecutive acute ischemic stroke (AIS) patients who had acquired baseline and 24-h follow-up diffusion- and perfusion-weighted imaging. Reperfusion was defined as reduction of â¥70 % of hypoperfusion lesion at 24 h from baseline. Severe LA was defined as Fazekas score 2 or 3 on FLAIR images. We investigated the relationship between severity of LA and reperfusion status. Multivariate statistical analysis was carried out for modeling the independent predictors of reperfusion, infarct growth, and functional outcome. Finally, 79 patients were included, among them 30 (37.97 %) had severe LA. Reperfusion was observed in 41 (51.89 %) patients, the proportion of reperfusion was very similar in patients with and without severe LA (53.33 vs 51.02 %, p = 1.000). Large artery occlusion was the only independent unfavorable predictor for reperfusion (OR = 0.202, 95 % confidence interval, 0.060-0.673; p = 0.014). Multiple linear regression analysis revealed that severe LA was independently associated with infarct growth (standardized coefficients = 0.191, p = 0.040). Severe LA was also an independent predictor of poor outcome (mRS â¥ 3) (OR = 4.004, 95 % confidence interval, 1.267-12.656, p = 0.018) after adjusting for reperfusion and baseline severity of stroke. Severe LA was associated with infarct growth and poor outcome independent of reperfusion status, which may expand the notion that LA contributes the intrinsic vulnerability of brain tissue to acute ischemic insults. The burden of LA may not serve as an imaging indicator of reperfusion inefficiency after IVT for AIS patients.
27256491	0	11	Association	T080	C0439849
27256491	20	33	Leukoaraiosis	T046	C0948163
27256491	38	50	Poor Outcome	T033	C3806166
27256491	65	76	Reperfusion	T038	C0684253
27256491	77	89	Inefficiency	T033	C0231184
27256491	96	120	Intravenous Thrombolysis	T061	C0040044
27256491	121	134	Leukoaraiosis	T046	C0948163
27256491	136	138	LA	T046	C0948163
27256491	143	158	associated with	T080	C0332281
27256491	159	169	structural	T037	C0270611
27256491	174	211	functional cerebrovascular impairment	T037	C0270611
27256491	238	246	capacity	T081	C1516240
27256491	250	258	ischemic	T169	C0475224
27256491	259	265	tissue	T024	C0040300
27256491	278	289	reperfusion	T038	C0684253
27256491	296	320	intravenous thrombolysis	T061	C0040044
27256491	322	325	IVT	T061	C0040044
27256491	358	364	severe	T080	C0205082
27256491	365	367	LA	T046	C0948163
27256491	387	398	reperfusion	T038	C0684253
27256491	399	411	inefficiency	T033	C0231184
27256491	434	448	infarct growth	T067	C2911660
27256491	453	476	poor functional outcome	T033	C3806166
27256491	516	537	acute ischemic stroke	T047	C0948008
27256491	539	542	AIS	T047	C0948008
27256491	544	552	patients	T101	C0030705
27256491	570	578	baseline	T081	C1442488
27256491	588	597	follow-up	T058	C1522577
27256491	598	608	diffusion-	T060	C0598801
27256491	613	639	perfusion-weighted imaging	T060	C4287652
27256491	641	652	Reperfusion	T038	C0684253
27256491	668	677	reduction	T061	C0441610
27256491	690	703	hypoperfusion	T046	C0442856
27256491	704	710	lesion	T033	C0221198
27256491	724	732	baseline	T081	C1442488
27256491	734	740	Severe	T080	C0205082
27256491	741	743	LA	T046	C0948163
27256491	759	772	Fazekas score	T081	C0449820
27256491	783	795	FLAIR images	T060	C4285947
27256491	817	829	relationship	T080	C0439849
27256491	838	846	severity	T080	C0439793
27256491	850	852	LA	T046	C0948163
27256491	857	868	reperfusion	T038	C0684253
27256491	877	889	Multivariate	T081	C0026777
27256491	890	910	statistical analysis	T062	C0871424
27256491	931	939	modeling	T062	C0870071
27256491	956	966	predictors	T078	C2698872
27256491	970	981	reperfusion	T038	C0684253
27256491	983	997	infarct growth	T067	C2911660
27256491	1003	1021	functional outcome	T169	C1274040
27256491	1035	1043	patients	T101	C0030705
27256491	1087	1093	severe	T080	C0205082
27256491	1094	1096	LA	T046	C0948163
27256491	1098	1109	Reperfusion	T038	C0684253
27256491	1114	1122	observed	T169	C1441672
27256491	1139	1147	patients	T101	C0030705
27256491	1167	1178	reperfusion	T038	C0684253
27256491	1199	1207	patients	T101	C0030705
27256491	1225	1231	severe	T080	C0205082
27256491	1232	1234	LA	T046	C0948163
27256491	1272	1288	artery occlusion	T046	C0264995
27256491	1326	1335	predictor	T078	C2698872
27256491	1340	1351	reperfusion	T038	C0684253
27256491	1370	1389	confidence interval	T081	C0009667
27256491	1416	1451	Multiple linear regression analysis	T170	C0034980
27256491	1466	1472	severe	T080	C0205082
27256491	1473	1475	LA	T046	C0948163
27256491	1494	1509	associated with	T080	C0332281
27256491	1510	1524	infarct growth	T067	C2911660
27256491	1539	1551	coefficients	T081	C1707429
27256491	1573	1579	Severe	T080	C0205082
27256491	1580	1582	LA	T046	C0948163
27256491	1607	1616	predictor	T078	C2698872
27256491	1620	1632	poor outcome	T033	C3806166
27256491	1661	1680	confidence interval	T081	C0009667
27256491	1727	1738	reperfusion	T038	C0684253
27256491	1743	1751	baseline	T081	C1442488
27256491	1752	1760	severity	T080	C0439793
27256491	1764	1770	stroke	T047	C0038454
27256491	1772	1778	Severe	T080	C0205082
27256491	1779	1781	LA	T046	C0948163
27256491	1786	1801	associated with	T080	C0332281
27256491	1802	1816	infarct growth	T067	C2911660
27256491	1821	1833	poor outcome	T033	C3806166
27256491	1849	1860	reperfusion	T038	C0684253
27256491	1902	1904	LA	T046	C0948163
27256491	1921	1944	intrinsic vulnerability	T033	C1821973
27256491	1948	1960	brain tissue	T023	C0459385
27256491	1964	1986	acute ischemic insults	T046	C0022116
27256491	2002	2004	LA	T046	C0948163
27256491	2025	2042	imaging indicator	T169	C1522602
27256491	2046	2057	reperfusion	T038	C0684253
27256491	2058	2070	inefficiency	T033	C0231184
27256491	2077	2080	IVT	T061	C0040044
27256491	2085	2088	AIS	T047	C0948008
27256491	2089	2097	patients	T101	C0030705

27256947|t|The Experience of Women Veterans Coming Back from War
27256947|a|Issues surrounding mental health are common for women veterans who have served in Iraq and Afghanistan wars. The goal of this phenomenological study was to document themes in the stories gathered from eight women veterans who had come back from war. Themes in the stories were: arriving with mixed sentiments; evolving to a changed view of self; permeating aggravation; confounding broken relationships, frequent deployments, and change in military status; remembering war experiences; and seeking opportunity for what is possible. Mental health issues can be observed in the themes. Including story as part of the mental health visit with veterans may be beneficial to veterans as they deal with the transition of coming back.
27256947	4	14	Experience	T041	C0596545
27256947	18	23	Women	T098	C0043210
27256947	24	32	Veterans	T098	C0042610
27256947	50	53	War	T052	C0043027
27256947	54	86	Issues surrounding mental health	T048	C4061796
27256947	102	107	women	T098	C0043210
27256947	108	116	veterans	T098	C0042610
27256947	136	140	Iraq	T083	C0022066
27256947	145	156	Afghanistan	T083	C0001732
27256947	157	161	wars	T052	C0043027
27256947	180	196	phenomenological	T078	C0871071
27256947	197	202	study	T062	C2603343
27256947	210	218	document	T170	C1301746
27256947	219	225	themes	UnknownType	C0869035
27256947	233	240	stories	T170	C0282574
27256947	261	266	women	T098	C0043210
27256947	267	275	veterans	T098	C0042610
27256947	299	302	war	T052	C0043027
27256947	304	310	Themes	UnknownType	C0869035
27256947	318	325	stories	T170	C0282574
27256947	352	362	sentiments	T055	C0683293
27256947	378	385	changed	T169	C0392747
27256947	386	398	view of self	T041	C0242498
27256947	400	422	permeating aggravation	T033	C0243095
27256947	424	456	confounding broken relationships	T054	C2371543
27256947	458	478	frequent deployments	T033	C2321230
27256947	484	509	change in military status	T033	C1550416
27256947	511	522	remembering	T041	C0034770
27256947	523	526	war	T052	C0043027
27256947	527	538	experiences	T041	C0596545
27256947	544	584	seeking opportunity for what is possible	T033	C0243095
27256947	586	606	Mental health issues	T048	C4061796
27256947	630	636	themes	UnknownType	C0869035
27256947	648	653	story	T170	C0282574
27256947	669	682	mental health	T041	C0025353
27256947	694	702	veterans	T098	C0042610
27256947	724	732	veterans	T098	C0042610
27256947	755	780	transition of coming back	T052	C2700061

27257056|t|A novel role for poly(C) binding proteins in programmed ribosomal frameshifting
27257056|a|Translational control through programmed ribosomal frameshifting (PRF) is exploited widely by viruses and increasingly documented in cellular genes. Frameshifting is induced by mRNA secondary structures that compromise ribosome fidelity during decoding of a heptanucleotide 'slippery' sequence. The nsp2 PRF signal of porcine reproductive and respiratory syndrome virus is distinctive in directing both -2 and -1 PRF and in its requirement for a trans-acting protein factor, the viral replicase subunit nsp1Î². Here we show that the the trans-activation of frameshifting is carried out by a protein complex composed of nsp1Î² and a cellular poly(C) binding protein (PCBP). From the results of in vitro translation and electrophoretic mobility shift assays, we demonstrate that a PCBP / nsp1Î² complex binds to a C-rich sequence downstream of the slippery sequence and here mimics the activity of a structured mRNA stimulator of PRF. This is the first description of a role for a trans-acting cellular protein in PRF. The discovery broadens the repertoire of activities associated with poly(C) binding proteins and prototypes a new class of virus - host interactions.
27257056	8	12	role	T077	C1705810
27257056	17	41	poly(C) binding proteins	T116,T123	C0242210
27257056	45	79	programmed ribosomal frameshifting	T045	C0282572
27257056	80	93	Translational	T045	C1519614
27257056	94	101	control	T080	C0243148
27257056	110	144	programmed ribosomal frameshifting	T045	C0282572
27257056	146	149	PRF	T045	C0282572
27257056	174	181	viruses	T005	C0042776
27257056	213	221	cellular	T025	C0007634
27257056	222	227	genes	T028	C0017337
27257056	229	242	Frameshifting	T045	C0282572
27257056	246	253	induced	T169	C0205263
27257056	257	282	mRNA secondary structures	T114,T123	C0035696
27257056	299	307	ribosome	T026	C0035553
27257056	308	316	fidelity	T043	C0007613
27257056	324	332	decoding	T169	C0205245
27257056	338	373	heptanucleotide 'slippery' sequence	T086	C0004793
27257056	379	383	nsp2	T116,T123	C0033684
27257056	384	387	PRF	T045	C0282572
27257056	388	394	signal	T044	C0037080
27257056	398	449	porcine reproductive and respiratory syndrome virus	T005	C0376536
27257056	483	485	-2	T045	C0282572
27257056	490	496	-1 PRF	T045	C0282572
27257056	508	519	requirement	T169	C1514873
27257056	526	553	trans-acting protein factor	T116,T123	C0033684
27257056	559	564	viral	T005	C0042776
27257056	565	588	replicase subunit nsp1Î²	T116,T123	C0033684
27257056	616	632	trans-activation	T045	C0040624
27257056	636	649	frameshifting	T045	C0282572
27257056	670	685	protein complex	T116,T123	C1180347
27257056	698	703	nsp1Î²	T116,T123	C0033684
27257056	710	718	cellular	T025	C0007634
27257056	719	742	poly(C) binding protein	T116,T123	C0242210
27257056	744	748	PCBP	T116,T123	C0242210
27257056	771	779	in vitro	T080	C1533691
27257056	780	791	translation	T045	C1519614
27257056	796	833	electrophoretic mobility shift assays	T059	C0949632
27257056	857	861	PCBP	T116,T123	C0242210
27257056	864	869	nsp1Î²	T116,T123	C0033684
27257056	870	877	complex	T116,T123	C1180347
27257056	889	904	C-rich sequence	T086	C0004793
27257056	905	915	downstream	T082	C0522506
27257056	923	940	slippery sequence	T086	C0004793
27257056	961	969	activity	T052	C0441655
27257056	986	990	mRNA	T114,T123	C0035696
27257056	991	1001	stimulator	T123	C0574031
27257056	1005	1008	PRF	T045	C0282572
27257056	1045	1049	role	T077	C1705810
27257056	1056	1085	trans-acting cellular protein	T116,T123	C0033684
27257056	1089	1092	PRF	T045	C0282572
27257056	1135	1145	activities	T052	C0441655
27257056	1146	1161	associated with	T080	C0332281
27257056	1162	1186	poly(C) binding proteins	T116,T123	C0242210
27257056	1191	1201	prototypes	T080	C0205556
27257056	1217	1222	virus	T005	C0042776
27257056	1225	1229	host	T001	C1167395
27257056	1230	1242	interactions	T169	C1704675

27257063|t|RNA topoisomerase is prevalent in all domains of life and associates with polyribosomes in animals
27257063|a|DNA Topoisomerases are essential to resolve topological problems during DNA metabolism in all species. However, the prevalence and function of RNA topoisomerases remain uncertain. Here, we show that RNA topoisomerase activity is prevalent in Type IA topoisomerases from bacteria, archaea, and eukarya. Moreover, this activity always requires the conserved Type IA core domains and the same catalytic residue used in DNA topoisomerase reaction; however, it does not absolutely require the non-conserved carboxyl-terminal domain (CTD), which is necessary for relaxation reactions of supercoiled DNA. The RNA topoisomerase activity of human Top3Î² differs from that of Escherichia coli topoisomerase I in that the former but not the latter requires the CTD, indicating that topoisomerases have developed distinct mechanisms during evolution to catalyze RNA topoisomerase reactions. Notably, Top3Î² proteins from several animals associate with polyribosomes, which are units of mRNA translation, whereas the Top3 homologs from E. coli and yeast lack the association. The Top3Î² - polyribosome association requires TDRD3, which directly interacts with Top3Î² and is present in animals but not bacteria or yeast. We propose that RNA topoisomerases arose in the early RNA world, and that they are retained through all domains of DNA -based life, where they mediate mRNA translation as part of polyribosomes in animals.
27257063	0	17	RNA topoisomerase	T116,T126	C1336767
27257063	74	87	polyribosomes	T026	C0032592
27257063	91	98	animals	T008	C0003062
27257063	99	117	DNA Topoisomerases	T116,T126	C0949775
27257063	171	185	DNA metabolism	T045	C0683142
27257063	193	200	species	T185	C1705920
27257063	215	225	prevalence	T081	C0220900
27257063	230	238	function	T169	C0542341
27257063	242	260	RNA topoisomerases	T116,T126	C1336767
27257063	298	324	RNA topoisomerase activity	T045	C2257142
27257063	341	363	Type IA topoisomerases	T116,T126	C1336767
27257063	369	377	bacteria	T007	C0004611
27257063	379	386	archaea	T194	C0003732
27257063	392	399	eukarya	T204	C0684063
27257063	416	424	activity	T044	C1148560
27257063	445	475	conserved Type IA core domains	T086	C0009802
27257063	489	506	catalytic residue	T077	C1709915
27257063	515	541	DNA topoisomerase reaction	T045	C1150386
27257063	587	625	non-conserved carboxyl-terminal domain	T087	C1514562
27257063	627	630	CTD	T087	C1514562
27257063	656	676	relaxation reactions	T045	C0314627
27257063	680	695	supercoiled DNA	T114	C0012937
27257063	701	727	RNA topoisomerase activity	T045	C2257142
27257063	731	742	human Top3Î²	T116,T126	C1097583
27257063	764	780	Escherichia coli	T007	C0014834
27257063	781	796	topoisomerase I	T116,T126	C0012920
27257063	848	851	CTD	T087	C1514562
27257063	869	883	topoisomerases	T116,T126	C1336767
27257063	908	918	mechanisms	T169	C0441712
27257063	939	947	catalyze	T070	C0007382
27257063	948	965	RNA topoisomerase	T116,T126	C1336767
27257063	966	975	reactions	T067	C0596319
27257063	986	1000	Top3Î² proteins	T116,T126	C1097583
27257063	1014	1021	animals	T008	C0003062
27257063	1037	1050	polyribosomes	T026	C0032592
27257063	1071	1075	mRNA	T114,T123	C0035696
27257063	1076	1087	translation	T045	C1519614
27257063	1120	1127	E. coli	T007	C0014834
27257063	1132	1137	yeast	T004	C0043393
27257063	1164	1169	Top3Î²	T116,T126	C1097583
27257063	1172	1184	polyribosome	T026	C0032592
27257063	1185	1196	association	T067	C0596306
27257063	1206	1211	TDRD3	T116,T123	C2607057
27257063	1243	1248	Top3Î²	T116,T126	C1097583
27257063	1267	1274	animals	T008	C0003062
27257063	1283	1291	bacteria	T007	C0004611
27257063	1295	1300	yeast	T004	C0043393
27257063	1318	1336	RNA topoisomerases	T116,T126	C1336767
27257063	1356	1359	RNA	T114	C0035668
27257063	1385	1393	retained	T169	C0333118
27257063	1417	1420	DNA	T114,T123	C0012854
27257063	1428	1432	life	T078	C0376558
27257063	1453	1457	mRNA	T114,T123	C0035696
27257063	1458	1469	translation	T045	C1519614
27257063	1481	1494	polyribosomes	T026	C0032592
27257063	1498	1505	animals	T008	C0003062

27257207|t|First Draft Genome Sequence of Staphylococcus condimenti F-2T
27257207|a|This report describes the draft genome sequence of S. condimenti strain F-2(T) (DSM 11674), a potential starter culture. The genome assembly comprised 2,616,174 bp with 34.6% GC content. To the best of our knowledge, this is the first documentation that reports the whole-genome sequence of S. condimenti.
27257207	0	11	First Draft	T170	C1547277
27257207	12	27	Genome Sequence	T085	C2348746
27257207	31	61	Staphylococcus condimenti F-2T	T007	C1027928
27257207	67	73	report	T170	C0684224
27257207	88	93	draft	T170	C1547277
27257207	94	109	genome sequence	T085	C2348746
27257207	113	152	S. condimenti strain F-2(T) (DSM 11674)	T007	C1027928
27257207	156	165	potential	T080	C3245505
27257207	166	181	starter culture	T059	C0430402
27257207	187	202	genome assembly	T085	C2348746
27257207	203	212	comprised	T052	C2700400
27257207	223	225	bp	T044	C0600436
27257207	237	247	GC content	T081	C1135899
27257207	297	310	documentation	T170	C0920316
27257207	316	323	reports	T170	C0684224
27257207	328	349	whole-genome sequence	T085	C2348746
27257207	353	366	S. condimenti	T007	C1027928

27257353|t|Trajectories of Health and Behavioral Health Services Use among Community Corrections -Involved Rural Adults
27257353|a|This article seeks to establish time-based trajectories of health and behavioral health services utilization for community corrections-involved (CCI) adults and to examine demographic and clinical correlates associated with these trajectories. To accomplish this aim, the authors applied a latent class growth analysis (LCGA) to services use data from a sample of rural CCI adults who reported their medical, mental health, and substance use treatment utilization behavior every 60 days for 1.5 years. LCGA established 1.5-year trajectories and demographic correlates of health services among rural CCI adults. For medical services, three classes emerged (stable-low users, 13%; stable-intermediate users, 40%; and stable-high users, 47%). For mental health and substance use services, three classes emerged (stable-low, 69% and 61%, respectively; low-baseline-increase, 10% and 12%, respectively; high-baseline decline, 21% and 28%, respectively). Employment, gender, medication usage, and depression severity predicted membership across all services. Results underscore the importance of social workers and other community services providers aligning health services access with the needs of the CCI population, and highlight CCI adults as being at risk of underservice in critical prevention and intervention domains.
27257353	0	12	Trajectories	T082	C0205134
27257353	16	22	Health	T078	C0018684
27257353	27	53	Behavioral Health Services	T058	C0009472
27257353	54	57	Use	T169	C0457083
27257353	64	73	Community	T096	C0009462
27257353	74	85	Corrections	T169	C1947976
27257353	96	101	Rural	T033	C0240919
27257353	102	108	Adults	T100	C0001675
27257353	152	164	trajectories	T082	C0205134
27257353	168	174	health	T078	C0018684
27257353	179	205	behavioral health services	T058	C0009472
27257353	206	217	utilization	T169	C0457083
27257353	222	252	community corrections-involved	T078	C0009463
27257353	254	257	CCI	T078	C0009463
27257353	259	265	adults	T100	C0001675
27257353	281	292	demographic	T078	C0011292
27257353	297	305	clinical	T080	C0205210
27257353	339	351	trajectories	T082	C0205134
27257353	399	427	latent class growth analysis	T062	C0936012
27257353	429	433	LCGA	T062	C0936012
27257353	438	446	services	T058	C0009472
27257353	473	478	rural	T033	C0240919
27257353	479	482	CCI	T078	C0009463
27257353	483	489	adults	T100	C0001675
27257353	509	516	medical	T169	C0205476
27257353	518	531	mental health	T041	C0025353
27257353	537	550	substance use	T078	C1705534
27257353	551	572	treatment utilization	UnknownType	C0815187
27257353	573	581	behavior	T053	C0004927
27257353	591	595	days	T079	C0439228
27257353	604	609	years	T079	C0439234
27257353	611	615	LCGA	T062	C0936012
27257353	628	636	1.5-year	T079	C0439234
27257353	637	649	trajectories	T082	C0205134
27257353	654	665	demographic	T078	C0011292
27257353	680	695	health services	T058	C0018747
27257353	702	707	rural	T033	C0240919
27257353	708	711	CCI	T078	C0009463
27257353	712	718	adults	T100	C0001675
27257353	724	740	medical services	T058	C0199168
27257353	776	781	users	T098	C1706077
27257353	808	813	users	T098	C1706077
27257353	836	841	users	T098	C1706077
27257353	853	866	mental health	T041	C0025353
27257353	871	884	substance use	T078	C1705534
27257353	885	893	services	T058	C0009472
27257353	1058	1068	Employment	T080	C0014003
27257353	1070	1076	gender	T032	C0079399
27257353	1078	1094	medication usage	T033	C0240320
27257353	1100	1110	depression	T048	C0011570
27257353	1111	1119	severity	T080	C0439793
27257353	1130	1140	membership	T055	C0680038
27257353	1152	1160	services	T058	C0009472
27257353	1199	1213	social workers	T097	C0037444
27257353	1224	1242	community services	T058	C0009472
27257353	1243	1252	providers	T097	C0018724
27257353	1262	1277	health services	T058	C0018747
27257353	1307	1310	CCI	T078	C0009463
27257353	1337	1340	CCI	T078	C0009463
27257353	1341	1347	adults	T100	C0001675
27257353	1360	1364	risk	T078	C0035647
27257353	1393	1403	prevention	T061	C0199176
27257353	1408	1428	intervention domains	T061	C0184661

27257613|t|Data set of interactomes and metabolic pathways of proteins differentially expressed in brains with Alzheimer×³s disease
27257613|a|Alzheimer×³s disease is one of the main causes of dementia in the elderly and its frequency is on the rise worldwide. It is considered the result of complex interactions between genetic and environmental factors, being many of them unknown. Therefore, there is a dire necessity for the identification of novel molecular players for the understanding of this disease. In this data article we determined the protein expression profiles of whole protein extracts from cortex regions of brains from patients with Alzheimer×³s disease in comparison to a normal brain. We identified 721 iTRAQ-labeled polypeptides with more than 95% in confidence. We analyzed all proteins that changed in their expression level and located them in the KEGG metabolic pathways, as well as in the mitochondrial complexes of the electron transport chain and ATP synthase. In addition, we analyzed the over- and sub-expressed polypeptides through IPA software, specifically Core I and Biomarkers I modules. Data in this article is related to the research article "Identification of proteins that are differentially expressed in brains with Alzheimer's disease using iTRAQ labeling and tandem mass spectrometry " (Minjarez et al., 2016) [1].
27257613	0	8	Data set	T170	C0150098
27257613	12	24	interactomes	T044	C0872079
27257613	29	47	metabolic pathways	T169	C1291081
27257613	51	59	proteins	T116,T123	C0033684
27257613	75	84	expressed	T045	C1171362
27257613	88	94	brains	T023	C0006104
27257613	100	119	Alzheimer×³s disease	T047	C0002395
27257613	120	139	Alzheimer×³s disease	T047	C0002395
27257613	169	177	dementia	T048	C0497327
27257613	185	192	elderly	T098	C0001792
27257613	201	210	frequency	T079	C0439603
27257613	226	235	worldwide	T098	C2700280
27257613	268	275	complex	T080	C0439855
27257613	276	288	interactions	T169	C1704675
27257613	297	304	genetic	T080	C0814299
27257613	309	330	environmental factors	T080	C0686732
27257613	429	446	molecular players	T116,T123	C0033684
27257613	477	484	disease	T047	C0002395
27257613	494	498	data	T078	C1511726
27257613	499	506	article	T170	C1706852
27257613	525	543	protein expression	T045	C1171362
27257613	562	569	protein	T116,T123	C0033684
27257613	570	578	extracts	T167	C2828366
27257613	584	608	cortex regions of brains	T029	C0458324
27257613	614	622	patients	T101	C0030705
27257613	628	647	Alzheimer×³s disease	T047	C0002395
27257613	667	679	normal brain	T023	C0006104
27257613	684	694	identified	T080	C0205396
27257613	699	712	iTRAQ-labeled	T130	C2986808
27257613	713	725	polypeptides	T116	C1305923
27257613	763	771	analyzed	T062	C0936012
27257613	776	784	proteins	T116,T123	C0033684
27257613	807	823	expression level	T081	C3244092
27257613	848	871	KEGG metabolic pathways	T170	C3826812
27257613	891	946	mitochondrial complexes of the electron transport chain	T026	C1325653
27257613	951	963	ATP synthase	T116,T126	C0949692
27257613	981	989	analyzed	T062	C0936012
27257613	994	1030	over- and sub-expressed polypeptides	T116	C1305923
27257613	1039	1051	IPA software	T073,T170	C0037585
27257613	1066	1097	Core I and Biomarkers I modules	T170	C0037589
27257613	1099	1103	Data	T078	C1511726
27257613	1112	1119	article	T170	C1706852
27257613	1138	1146	research	T062	C0035168
27257613	1147	1154	article	T170	C1706852
27257613	1174	1182	proteins	T116,T123	C0033684
27257613	1207	1216	expressed	T045	C1171362
27257613	1220	1226	brains	T023	C0006104
27257613	1232	1251	Alzheimer's disease	T047	C0002395
27257613	1258	1272	iTRAQ labeling	T059	C0022885
27257613	1277	1301	tandem mass spectrometry	T063	C0599748

27257694|t|Emergency general surgery specific frailty index: A validation study
27257694|a|Assessment of operative risk in geriatric patients undergoing emergency general surgery (EGS) is challenging. Frailty is an established measure for risk assessment in surgical cases. The aim of our study was to validate a modified 15 variable emergency general surgery specific frailty index (EGSFI). We prospectively collected geriatric (age > 65) emergency general surgery patients for 1- year. Post-operative complications were collected. Frailty Index was calculated for 200 patients based on their pre-admission condition using 50- variable modified Rockwood Frailty Index (FI). EGSFI was developed based on the regression model for complications and the most significant factors in the FI. ROC curve analysis was performed to determine cutoff for frail status. We validated our results using 60 patients for predicting complications. A total of 260 patients (200 developing, 60 Validation) were enrolled in this study. Mean age was 71 Â± 11 years, and 33% developed complications. Most common complications were pneumonia (12%), UTI (9%), and wound infection (7%). Univariate analysis identified 15 variables significantly associated with complications that were used to develop the EGSFI. A cutoff frailty score of 0.325 was identified using ROC curve analysis for frail status .Sixty- patients (frail: 18, non-frail: 42) were enrolled in the validation cohort. Frail patients were more likely to have post-operative complications (47% vs. 20%, p < 0.001) compared to nonfrail patients. Frail status based on EGSFI was a significant predictor of post-operative complications (OR =7.3, 95% CI = 1.7 - 19.8; p=0.006). Age was not associated with postoperative complications (OR =0.99, 95% CI = 0.92 -1.06; p=0.86). The 15- variable validated EGSFI is a simple and reliable bedside tool to determine the frailty status of patients undergoing emergency general surgery. Frail status as determined by Abstract the EGSFI is an independent predictor of post-operative complications and mortality in geriatric emergency general surgery patients. Level II, Prognostic Studies - Investigating the Effect of a Patient Characteristic on the Outcome of Disease.
27257694	0	25	Emergency general surgery	T061	C2216322
27257694	26	48	specific frailty index	T170	C4075886
27257694	52	68	validation study	T062,T170	C0681836
27257694	69	79	Assessment	T058	C0220825
27257694	83	97	operative risk	T078	C0747003
27257694	101	119	geriatric patients	T101	C0870602
27257694	131	156	emergency general surgery	T061	C2216322
27257694	158	161	EGS	T061	C2216322
27257694	179	186	Frailty	T033	C0424594
27257694	205	212	measure	T081	C0079809
27257694	217	232	risk assessment	T058	C0086930
27257694	236	250	surgical cases	T077	C1706256
27257694	267	272	study	T062	C2603343
27257694	280	288	validate	T062	C1519941
27257694	303	311	variable	T080	C0439828
27257694	312	360	emergency general surgery specific frailty index	T058	C4075415
27257694	362	367	EGSFI	T058	C4075415
27257694	387	396	collected	T078	C1516695
27257694	397	406	geriatric	T080	C1704440
27257694	408	416	age > 65	T100	C0522003
27257694	418	443	emergency general surgery	T061	C2216322
27257694	444	452	patients	T101	C0870602
27257694	460	464	year	T079	C0439234
27257694	466	494	Post-operative complications	T046	C0032787
27257694	500	509	collected	T078	C1516695
27257694	511	524	Frailty Index	T170	C4075886
27257694	529	539	calculated	T059	C1443182
27257694	548	556	patients	T101	C0030705
27257694	572	585	pre-admission	T079	C0559269
27257694	586	595	condition	T080	C0348080
27257694	606	614	variable	T080	C0439828
27257694	624	646	Rockwood Frailty Index	T170	C4075886
27257694	648	650	FI	T170	C4075886
27257694	653	658	EGSFI	T058	C4075415
27257694	686	702	regression model	T170	C0034980
27257694	707	720	complications	T046	C0032787
27257694	761	763	FI	T170	C4075886
27257694	765	783	ROC curve analysis	T081	C0035787
27257694	811	817	cutoff	T169	C1442160
27257694	822	827	frail	T033	C0871754
27257694	828	834	status	T080	C0449438
27257694	839	848	validated	T062	C1519941
27257694	853	860	results	T169	C1274040
27257694	870	878	patients	T101	C0030705
27257694	883	893	predicting	T078	C0681842
27257694	894	907	complications	T046	C0032787
27257694	924	932	patients	T101	C0030705
27257694	953	963	Validation	T062	C1519941
27257694	970	978	enrolled	T058	C1516879
27257694	987	992	study	T062	C2603343
27257694	994	1002	Mean age	T032	C0001779
27257694	1015	1020	years	T079	C0439234
27257694	1040	1053	complications	T046	C0032787
27257694	1060	1066	common	T081	C0205214
27257694	1067	1080	complications	T046	C0032787
27257694	1086	1095	pneumonia	T047	C0032285
27257694	1103	1106	UTI	T047	C0042029
27257694	1117	1132	wound infection	T046	C0043241
27257694	1139	1158	Univariate analysis	T062	C0683962
27257694	1173	1182	variables	T080	C0439828
27257694	1197	1212	associated with	T080	C0332281
27257694	1213	1226	complications	T046	C0032787
27257694	1257	1262	EGSFI	T058	C4075415
27257694	1266	1272	cutoff	T169	C1442160
27257694	1273	1286	frailty score	T033	C4075885
27257694	1317	1335	ROC curve analysis	T081	C0035787
27257694	1340	1345	frail	T033	C0871754
27257694	1346	1352	status	T080	C0449438
27257694	1361	1369	patients	T101	C0030705
27257694	1371	1376	frail	T033	C0871754
27257694	1382	1391	non-frail	T033	C0871754
27257694	1402	1410	enrolled	T058	C1516879
27257694	1418	1428	validation	T062	C1519941
27257694	1429	1435	cohort	T098	C0599755
27257694	1437	1442	Frail	T033	C0871754
27257694	1443	1451	patients	T101	C0030705
27257694	1477	1505	post-operative complications	T046	C0032787
27257694	1543	1560	nonfrail patients	T101	C0870602
27257694	1562	1567	Frail	T033	C0871754
27257694	1568	1574	status	T080	C0449438
27257694	1584	1589	EGSFI	T058	C4075415
27257694	1596	1617	significant predictor	T078	C2698872
27257694	1621	1649	post-operative complications	T046	C0032787
27257694	1651	1653	OR	T081	C0028873
27257694	1664	1666	CI	T081	C0009667
27257694	1691	1694	Age	T032	C0001779
27257694	1703	1718	associated with	T080	C0332281
27257694	1719	1746	postoperative complications	T046	C0032787
27257694	1748	1750	OR	T081	C0028873
27257694	1762	1764	CI	T081	C0009667
27257694	1796	1804	variable	T080	C0439828
27257694	1805	1814	validated	T062	C1519941
27257694	1815	1820	EGSFI	T058	C4075415
27257694	1846	1858	bedside tool	T073	C4286058
27257694	1876	1890	frailty status	T033	C0424594
27257694	1894	1902	patients	T101	C0030705
27257694	1914	1939	emergency general surgery	T061	C2216322
27257694	1941	1946	Frail	T033	C0871754
27257694	1947	1953	status	T080	C0449438
27257694	1984	1989	EGSFI	T058	C4075415
27257694	1996	2017	independent predictor	T078	C2698872
27257694	2021	2049	post-operative complications	T046	C0032787
27257694	2054	2063	mortality	T081	C0205848
27257694	2067	2076	geriatric	T080	C1704440
27257694	2077	2102	emergency general surgery	T061	C2216322
27257694	2103	2111	patients	T101	C0870602
27257694	2123	2141	Prognostic Studies	T062	C0242481
27257694	2144	2157	Investigating	T169	C1292732
27257694	2162	2168	Effect	T080	C1280500
27257694	2174	2196	Patient Characteristic	T201	C1285579
27257694	2204	2222	Outcome of Disease	T033	C0679250

27257822|t|Comparative Epidemiologic Characteristics of Pertussis in 10 Central and Eastern European Countries, 2000-2013
27257822|a|We undertook an epidemiological survey of the annual incidence of pertussis reported from 2000 to 2013 in ten Central and Eastern European countries to ascertain whether increased pertussis reports in some countries share common underlying drivers or whether there are specific features in each country. The annual incidence of pertussis in the participating countries was obtained from relevant government institutions and/or national surveillance systems. We reviewed the changes in the pertussis incidence rates in each country to explore differences and/or similarities between countries in relation to pertussis surveillance; case definitions for detection and confirmation of pertussis; incidence and number of cases of pertussis by year, overall and by age group; population by year, overall and by age group; pertussis immunization schedule and coverage, and switch from whole-cell pertussis vaccines (wP) to acellular pertussis vaccines (aP). There was heterogeneity in the reported annual incidence rates and trends observed across countries. Reported pertussis incidence rates varied considerably, ranging from 0.01 to 96 per 100,000 population, with the highest rates generally reported in Estonia and the lowest in Hungary and Serbia. The greatest burden appears for the most part in infants (<1 year) in Bulgaria, Hungary, Latvia, Romania, and Serbia, but not in the other participating countries where the burden may have shifted to older children, though surveillance of adults may be inappropriate. There was no consistent pattern associated with the switch from wP to aP vaccines on reported pertussis incidence rates. The heterogeneity in reported data may be related to a number of factors including surveillance system characteristics or capabilities, different case definitions, type of pertussis confirmation tests used, public awareness of the disease, as well as real differences in the magnitude of the disease, or a combination of these factors. Our study highlights the need to standardize pertussis detection and confirmation in surveillance programs across Europe, complemented with carefully-designed seroprevalence studies using the same protocols and methodologies.
27257822	12	25	Epidemiologic	T169	C0014508
27257822	26	41	Characteristics	T080	C1521970
27257822	45	54	Pertussis	T047	C0043167
27257822	61	68	Central	T083	C0454714
27257822	73	99	Eastern European Countries	T083	C0015177
27257822	127	149	epidemiological survey	T062	C0376688
27257822	157	163	annual	T079	C0332181
27257822	164	173	incidence	T081	C0021149
27257822	177	186	pertussis	T047	C0043167
27257822	187	195	reported	T058	C0700287
27257822	221	228	Central	T083	C0454714
27257822	233	259	Eastern European countries	T083	C0015177
27257822	291	300	pertussis	T047	C0043167
27257822	301	308	reports	T170	C0025102
27257822	317	326	countries	T083	C0454664
27257822	389	397	features	T080	C2348519
27257822	406	413	country	T083	C0454664
27257822	419	425	annual	T079	C0332181
27257822	426	435	incidence	T081	C0021149
27257822	439	448	pertussis	T047	C0043167
27257822	470	479	countries	T083	C0454664
27257822	507	530	government institutions	T093	C2607850
27257822	538	567	national surveillance systems	T093	C1708333
27257822	572	580	reviewed	T080	C1709940
27257822	585	592	changes	T169	C0392747
27257822	600	609	pertussis	T047	C0043167
27257822	610	625	incidence rates	T081	C1708485
27257822	634	641	country	T083	C0454664
27257822	653	664	differences	T080	C1705242
27257822	672	684	similarities	T080	C2348205
27257822	693	702	countries	T083	C0454664
27257822	718	727	pertussis	T047	C0043167
27257822	728	740	surveillance	T169	C0220920
27257822	742	758	case definitions	T170	C0679227
27257822	763	772	detection	T033	C0442726
27257822	777	789	confirmation	T080	C0521091
27257822	793	802	pertussis	T047	C0043167
27257822	804	813	incidence	T081	C0021149
27257822	818	833	number of cases	T081	C0021149
27257822	837	846	pertussis	T047	C0043167
27257822	850	854	year	T079	C0439234
27257822	871	880	age group	T100	C0027362
27257822	882	892	population	T098	C1257890
27257822	896	900	year	T079	C0439234
27257822	917	926	age group	T100	C0027362
27257822	928	937	pertussis	T047	C0043167
27257822	938	959	immunization schedule	T061	C0020972
27257822	964	972	coverage	T169	C1999244
27257822	990	1019	whole-cell pertussis vaccines	T121,T129	C0031237
27257822	1021	1023	wP	T121,T129	C0031237
27257822	1028	1056	acellular pertussis vaccines	T121,T129	C0982332
27257822	1058	1060	aP	T121,T129	C0982332
27257822	1073	1086	heterogeneity	T080	C0019409
27257822	1094	1102	reported	T058	C0700287
27257822	1103	1109	annual	T079	C0332181
27257822	1110	1125	incidence rates	T081	C1708485
27257822	1153	1162	countries	T083	C0454664
27257822	1164	1172	Reported	T058	C0700287
27257822	1173	1182	pertussis	T047	C0043167
27257822	1183	1198	incidence rates	T081	C1708485
27257822	1256	1266	population	T098	C1257890
27257822	1277	1284	highest	T080	C1522410
27257822	1285	1290	rates	T081	C1521828
27257822	1301	1309	reported	T058	C0700287
27257822	1313	1320	Estonia	T083	C0014908
27257822	1329	1335	lowest	T080	C1708760
27257822	1339	1346	Hungary	T083	C0020174
27257822	1351	1357	Serbia	T083	C0036708
27257822	1372	1378	burden	T078	C2828008
27257822	1408	1415	infants	T100	C0021270
27257822	1420	1424	year	T079	C0439234
27257822	1429	1437	Bulgaria	T083	C0006368
27257822	1439	1446	Hungary	T083	C0020174
27257822	1448	1454	Latvia	T083	C0023128
27257822	1456	1463	Romania	T083	C0035826
27257822	1469	1475	Serbia	T083	C0036708
27257822	1512	1521	countries	T083	C0454664
27257822	1532	1538	burden	T078	C2828008
27257822	1559	1573	older children	T100	C0008059
27257822	1582	1594	surveillance	T169	C0220920
27257822	1598	1604	adults	T100	C0001675
27257822	1659	1674	associated with	T080	C0332281
27257822	1691	1693	wP	T121,T129	C0031237
27257822	1697	1708	aP vaccines	T121,T129	C0982332
27257822	1712	1720	reported	T058	C0700287
27257822	1721	1730	pertussis	T047	C0043167
27257822	1731	1746	incidence rates	T081	C1708485
27257822	1752	1765	heterogeneity	T080	C0019409
27257822	1769	1777	reported	T058	C0700287
27257822	1778	1782	data	T078	C1511726
27257822	1813	1820	factors	T169	C1521761
27257822	1831	1843	surveillance	T169	C0220920
27257822	1844	1850	system	T169	C0449913
27257822	1851	1866	characteristics	T080	C1521970
27257822	1870	1882	capabilities	T080	C2698977
27257822	1894	1910	case definitions	T170	C0679227
27257822	1912	1916	type	T080	C0332307
27257822	1920	1929	pertussis	T047	C0043167
27257822	1930	1948	confirmation tests	T059	C0022885
27257822	1955	1961	public	T092	C0678367
27257822	1962	1971	awareness	T033	C1328734
27257822	1979	1986	disease	T047	C0043167
27257822	2004	2015	differences	T081	C1705241
27257822	2023	2032	magnitude	T081	C1704240
27257822	2040	2047	disease	T047	C0043167
27257822	2075	2082	factors	T169	C1521761
27257822	2129	2138	pertussis	T047	C0043167
27257822	2139	2148	detection	T033	C0442726
27257822	2153	2165	confirmation	T080	C0521091
27257822	2169	2190	surveillance programs	T062	C1515095
27257822	2198	2204	Europe	T083	C0015176
27257822	2243	2265	seroprevalence studies	T062	C0600367
27257822	2281	2290	protocols	T170	C0442711
27257822	2295	2308	methodologies	T062	C0086912

27257836|t|Efficacy of a coaxial system with a compliant balloon catheter for navigation of the Penumbra reperfusion catheter in tortuous arteries: technique and case experience
27257836|a|OBJECTIVE The authors describe a method by which they easily and atraumatically navigate a large-bore reperfusion catheter of the Penumbra system to an embolus by using a coaxial system with a compliant balloon catheter in patients with tortuous arteries. METHODS A retrospective review of the prospective endovascular database was performed to identify cases in which a coaxial system with a compliant balloon catheter (Scepter C, MicroVention / Terumo; or TransForm C, Stryker Neurovascular) and a large-bore reperfusion catheter of the Penumbra system (Penumbra, Inc.) was used. The authors achieved a stable guiding sheath position and delivered the coaxial system with a compliant balloon catheter and a large-bore reperfusion catheter. Then, the balloon was inflated somewhat when the distal tip of the balloon was slightly advanced from the tip of the reperfusion catheter, and together the coaxial system was advanced to an embolus over a 0.014-in guidewire, even around the corner. When the distal tip of the balloon catheter reached the embolus, the authors deflated the balloon and navigated the large-bore reperfusion catheter to the embolus. Finally, the aspiration of the embolus with the Penumbra MAX pump was begun. RESULTS Between May 2014 and September 2015, the authors used this technique in 17 cases: 16 cases of middle cerebral artery occlusion (including 5 cases of internal carotid artery occlusion) and 1 case of basilar artery occlusion (age range 36-88 years, mean age 74.7 years, 13 men). For the reperfusion catheter of the Penumbra system, the 5MAX ACE was used in 15 cases, and the 5MAX was used in 2 cases. As a compliant balloon catheter, the Scepter C was used in 16 cases, and the TransForm C was used in 1 case. The technique was successful in 16 cases (94.1%). No parent artery dissections were noted in any cases. Catheter -induced vasospasm was noted in 1 case, but the vasospasm was transient. CONCLUSIONS A coaxial system with a compliant balloon catheter can help safely and easily to navigate the large-bore reperfusion catheter of the Penumbra system to an embolus in patients with tortuous arteries.
27257836	0	8	Efficacy	T080	C1280519
27257836	36	45	compliant	T080	C0566588
27257836	46	62	balloon catheter	T074	C0179734
27257836	67	77	navigation	T052	C2827562
27257836	85	93	Penumbra	T074	C0025080
27257836	94	105	reperfusion	T038	C0684253
27257836	106	114	catheter	T074	C0085590
27257836	118	135	tortuous arteries	T033	C1836791
27257836	137	146	technique	T169	C0449851
27257836	151	155	case	T169	C0868928
27257836	156	166	experience	T041	C0596545
27257836	167	176	OBJECTIVE	T170	C0018017
27257836	181	188	authors	T097	C3812881
27257836	200	206	method	T170	C0025663
27257836	221	227	easily	T033	C0332219
27257836	247	255	navigate	T052	C2827562
27257836	258	268	large-bore	T074	C1275738
27257836	269	280	reperfusion	T038	C0684253
27257836	281	289	catheter	T074	C0085590
27257836	297	312	Penumbra system	T074	C0025080
27257836	319	326	embolus	T033	C1704212
27257836	360	369	compliant	T080	C0566588
27257836	370	386	balloon catheter	T074	C0179734
27257836	390	398	patients	T101	C0030705
27257836	404	421	tortuous arteries	T033	C1836791
27257836	423	430	METHODS	T170	C0025663
27257836	433	453	retrospective review	T062	C0035363
27257836	473	485	endovascular	T029	C0524425
27257836	486	494	database	T170	C0242356
27257836	512	520	identify	T080	C0205396
27257836	521	526	cases	T169	C0868928
27257836	560	569	compliant	T080	C0566588
27257836	570	586	balloon catheter	T074	C0179734
27257836	588	597	Scepter C	T074	C0025080
27257836	599	611	MicroVention	T074	C0025080
27257836	614	620	Terumo	T074	C1655965
27257836	625	636	TransForm C	T074	C0025080
27257836	638	645	Stryker	T074	C0025080
27257836	646	659	Neurovascular	T023	C0824497
27257836	667	677	large-bore	T074	C1275738
27257836	678	689	reperfusion	T038	C0684253
27257836	690	698	catheter	T074	C0085590
27257836	706	721	Penumbra system	T074	C0025080
27257836	723	737	Penumbra, Inc.	T170	C1552679
27257836	753	760	authors	T097	C3812881
27257836	772	778	stable	T080	C0205360
27257836	779	786	guiding	T074	C0221799
27257836	787	793	sheath	T024	C0027807
27257836	794	802	position	T082	C0733755
27257836	807	816	delivered	T169	C1705822
27257836	843	852	compliant	T080	C0566588
27257836	853	869	balloon catheter	T074	C0179734
27257836	876	886	large-bore	T074	C1275738
27257836	887	898	reperfusion	T038	C0684253
27257836	899	907	catheter	T074	C0085590
27257836	919	926	balloon	T074	C0179734
27257836	958	964	distal	T082	C0205108
27257836	965	968	tip	T080	C3282898
27257836	976	983	balloon	T074	C0179734
27257836	997	1005	advanced	T080	C0205179
27257836	1015	1018	tip	T080	C3282898
27257836	1026	1037	reperfusion	T038	C0684253
27257836	1038	1046	catheter	T074	C0085590
27257836	1052	1060	together	T080	C1883357
27257836	1084	1092	advanced	T080	C0205179
27257836	1099	1106	embolus	T033	C1704212
27257836	1123	1132	guidewire	T073	C1708264
27257836	1150	1156	corner	T082	C1254362
27257836	1167	1173	distal	T082	C0205108
27257836	1174	1177	tip	T080	C3282898
27257836	1185	1201	balloon catheter	T074	C0179734
27257836	1214	1221	embolus	T033	C1704212
27257836	1227	1234	authors	T097	C3812881
27257836	1248	1255	balloon	T074	C0179734
27257836	1260	1269	navigated	T052	C2827562
27257836	1274	1284	large-bore	T074	C1275738
27257836	1285	1296	reperfusion	T038	C0684253
27257836	1297	1305	catheter	T074	C0085590
27257836	1313	1320	embolus	T033	C1704212
27257836	1335	1345	aspiration	T061	C0349707
27257836	1353	1360	embolus	T033	C1704212
27257836	1370	1378	Penumbra	T074	C0025080
27257836	1379	1387	MAX pump	T074	C0025080
27257836	1399	1406	RESULTS	T169	C1274040
27257836	1448	1455	authors	T097	C3812881
27257836	1466	1475	technique	T169	C0449851
27257836	1482	1487	cases	T169	C0868928
27257836	1492	1497	cases	T169	C0868928
27257836	1501	1533	middle cerebral artery occlusion	T020	C0740391
27257836	1547	1552	cases	T169	C0868928
27257836	1556	1589	internal carotid artery occlusion	T047	C0149853
27257836	1597	1601	case	T169	C0868928
27257836	1605	1629	basilar artery occlusion	T190	C0265098
27257836	1631	1634	age	T032	C0001779
27257836	1635	1640	range	T081	C1514721
27257836	1654	1658	mean	T081	C2348143
27257836	1659	1662	age	T032	C0001779
27257836	1678	1681	men	T098	C0025266
27257836	1692	1703	reperfusion	T038	C0684253
27257836	1704	1712	catheter	T074	C0085590
27257836	1720	1735	Penumbra system	T074	C0025080
27257836	1741	1749	5MAX ACE	T074	C0025080
27257836	1765	1770	cases	T169	C0868928
27257836	1780	1784	5MAX	T074	C0025080
27257836	1799	1804	cases	T169	C0868928
27257836	1811	1820	compliant	T080	C0566588
27257836	1821	1837	balloon catheter	T074	C0179734
27257836	1843	1852	Scepter C	T074	C0025080
27257836	1868	1873	cases	T169	C0868928
27257836	1883	1894	TransForm C	T074	C0025080
27257836	1909	1913	case	T169	C0868928
27257836	1919	1928	technique	T169	C0449851
27257836	1933	1943	successful	T080	C1272703
27257836	1950	1955	cases	T169	C0868928
27257836	1965	1967	No	T169	C0332197
27257836	1968	1974	parent	T099	C0030551
27257836	1975	1993	artery dissections	T047	C0002949
27257836	1999	2004	noted	T080	C4288581
27257836	2012	2017	cases	T169	C0868928
27257836	2019	2027	Catheter	T074	C0085590
27257836	2037	2046	vasospasm	T046	C0085616
27257836	2051	2056	noted	T080	C4288581
27257836	2062	2066	case	T169	C0868928
27257836	2076	2085	vasospasm	T046	C0085616
27257836	2090	2099	transient	T079	C0205374
27257836	2101	2112	CONCLUSIONS	T078	C1707478
27257836	2137	2146	compliant	T080	C0566588
27257836	2147	2163	balloon catheter	T074	C0179734
27257836	2184	2190	easily	T033	C0332219
27257836	2194	2202	navigate	T052	C2827562
27257836	2207	2217	large-bore	T074	C1275738
27257836	2218	2229	reperfusion	T038	C0684253
27257836	2230	2238	catheter	T074	C0085590
27257836	2246	2261	Penumbra system	T074	C0025080
27257836	2268	2275	embolus	T033	C1704212
27257836	2279	2287	patients	T101	C0030705
27257836	2293	2310	tortuous arteries	T033	C1836791

27258136|t|Hepatic and renal toxicological evaluations of an industrial ovotoxic chemical, 4-vinylcyclohexene diepoxide, in both sexes of Wistar rats
27258136|a|4-Vinylcyclohexene diepoxide (VCD) is an industrial occupational health hazard chemical because it induces ovotoxicity in rodents. The current study investigated the impacts of VCD on selected hepatic and renal markers of oxidative stress and inflammation in both sexes of Wistar rats. Thus, male and female rats were randomly distributed into four groups of ten rats per group, and dosed orally with VCD for 28 days. The control male and female groups of rats received corn oil only, while each of the three remaining groups of both sexes of rats received VCD (100, 250 and 500 mg/kg BW) respectively. Thereafter, biomarkers of hepatic and renal oxidative damage, inflammation and immunohistochemical expressions of iNOS, COX-2, caspase-9 and caspase-3 were evaluated. The results revealed that VCD increased markers of liver and kidney functions, oxidative damage and inflammation, and disrupted the antioxidant homeostasis of the rats (p<0.05). Lastly, VCD enhanced the immunohistochemical expressions of iNOS, COX-2, caspase-9 and caspase-3 in the liver of the rats. Thus, our data imply that VCD induced toxicity in the liver and kidney of rats via the combined impacts of oxidative damage and inflammation.
27258136	0	7	Hepatic	T029	C0205054
27258136	12	17	renal	T023	C0022646
27258136	18	31	toxicological	T169	C0205472
27258136	32	43	evaluations	T058	C0220825
27258136	50	60	industrial	T169	C0205245
27258136	61	78	ovotoxic chemical	T131	C0032346
27258136	80	108	4-vinylcyclohexene diepoxide	T109,T131	C0048737
27258136	118	123	sexes	T032	C1522384
27258136	127	138	Wistar rats	T015	C0034716
27258136	139	167	4-Vinylcyclohexene diepoxide	T109,T131	C0048737
27258136	169	172	VCD	T109,T131	C0048737
27258136	180	190	industrial	T169	C0205245
27258136	191	203	occupational	T169	C0521127
27258136	204	226	health hazard chemical	T131	C0079483
27258136	238	245	induces	T169	C0205263
27258136	246	257	ovotoxicity	T037	C0600688
27258136	261	268	rodents	T015	C0035804
27258136	282	287	study	T062	C2603343
27258136	288	300	investigated	T169	C1292732
27258136	316	319	VCD	T109,T131	C0048737
27258136	332	339	hepatic	T029	C0205054
27258136	344	349	renal	T023	C0022646
27258136	350	357	markers	T201	C0005516
27258136	361	377	oxidative stress	T049	C0242606
27258136	382	394	inflammation	T046	C0021368
27258136	403	408	sexes	T032	C1522384
27258136	412	423	Wistar rats	T015	C0034716
27258136	431	435	male	T032	C0086582
27258136	440	446	female	T032	C0086287
27258136	447	451	rats	T015	C0034716
27258136	457	465	randomly	T080	C0439605
27258136	466	477	distributed	T169	C1704711
27258136	488	494	groups	T078	C0441833
27258136	502	506	rats	T015	C0034716
27258136	511	516	group	T078	C0441833
27258136	522	527	dosed	T081	C0178602
27258136	528	534	orally	T169	C1527415
27258136	540	543	VCD	T109,T131	C0048737
27258136	551	555	days	T079	C0439228
27258136	561	568	control	T096	C0009932
27258136	569	573	male	T032	C0086582
27258136	578	584	female	T032	C0086287
27258136	585	591	groups	T078	C0441833
27258136	595	599	rats	T015	C0034716
27258136	600	608	received	T080	C1514756
27258136	609	617	corn oil	T109,T168	C0010029
27258136	648	657	remaining	T080	C1527428
27258136	658	664	groups	T078	C0441833
27258136	673	678	sexes	T032	C1522384
27258136	682	686	rats	T015	C0034716
27258136	687	695	received	T080	C1514756
27258136	696	699	VCD	T109,T131	C0048737
27258136	718	726	mg/kg BW	T081	C0560741
27258136	754	764	biomarkers	T201	C0005516
27258136	768	775	hepatic	T046	C0151763
27258136	780	802	renal oxidative damage	T033	C1408258
27258136	804	816	inflammation	T046	C0021368
27258136	821	852	immunohistochemical expressions	T059	C0022885
27258136	856	860	iNOS	T116,T126	C0132555
27258136	862	867	COX-2	T116,T126	C0387583
27258136	869	878	caspase-9	T116,T126	C0910167
27258136	883	892	caspase-3	T116,T126	C0291573
27258136	898	907	evaluated	T058	C0220825
27258136	921	929	revealed	T080	C0443289
27258136	935	938	VCD	T109,T131	C0048737
27258136	939	948	increased	T081	C0205217
27258136	949	956	markers	T201	C0005516
27258136	960	965	liver	T042	C0232741
27258136	970	986	kidney functions	T042	C0232804
27258136	988	1004	oxidative damage	T037	C0178314
27258136	1009	1021	inflammation	T046	C0021368
27258136	1027	1036	disrupted	T080	C0332454
27258136	1041	1064	antioxidant homeostasis	T038	C0019868
27258136	1072	1076	rats	T015	C0034716
27258136	1095	1098	VCD	T109,T131	C0048737
27258136	1112	1143	immunohistochemical expressions	T059	C0022885
27258136	1147	1151	iNOS	T116,T126	C0132555
27258136	1153	1158	COX-2	T116,T126	C0387583
27258136	1160	1169	caspase-9	T116,T126	C0910167
27258136	1174	1183	caspase-3	T116,T126	C0291573
27258136	1191	1196	liver	T023	C0023884
27258136	1204	1208	rats	T015	C0034716
27258136	1220	1224	data	T078	C1511726
27258136	1236	1239	VCD	T109,T131	C0048737
27258136	1240	1247	induced	T169	C0205263
27258136	1248	1256	toxicity	T037	C0600688
27258136	1264	1269	liver	T023	C0023884
27258136	1274	1280	kidney	T023	C0022646
27258136	1284	1288	rats	T015	C0034716
27258136	1297	1305	combined	T080	C0205195
27258136	1306	1313	impacts	T080	C4049986
27258136	1317	1333	oxidative damage	T037	C0178314
27258136	1338	1350	inflammation	T046	C0021368

27258690|t|Combinatorial Library Screening Coupled to Mass Spectrometry to Identify Valuable Cyclic Peptides
27258690|a|Combinatorial library screening coupled to mass spectrometry (MS) analysis is a practical approach to identify useful peptides. Cyclic peptides can have high biological activity, selectivity, and affinity for target proteins, and high stability against proteolytic degradation. Here we describe two strategies to prepare combinatorial libraries suitable for MS analysis to accelerate the discovery of cyclic peptide structures. Both approaches use ChemMatrix resin and the linker 4-hydroxymethylbenzoic acid. One strategy involves the synthesis of a one-bead-two-peptides library in which each bead contains both the cyclic peptide and its linear counterpart to facilitate MS analysis. The other protocol is based on the synthesis of a cyclic depsipeptide library in which a glycolamidic ester group is incorporated by adding glycolic acid. After library screening, the ring is opened and the peptide is released simultaneously for subsequent MS analysis. Â© 2016 by John Wiley & Sons, Inc.
27258690	0	21	Combinatorial Library	T116,T130	C0376433
27258690	22	31	Screening	T169	C1305399
27258690	43	60	Mass Spectrometry	T059	C0037813
27258690	82	97	Cyclic Peptides	T116	C0030957
27258690	98	119	Combinatorial library	T116,T130	C0376433
27258690	120	129	screening	T169	C1305399
27258690	141	172	mass spectrometry (MS) analysis	T059	C0037813
27258690	188	196	approach	T082	C0449445
27258690	216	224	peptides	T116	C0030956
27258690	226	241	Cyclic peptides	T116	C0030957
27258690	256	275	biological activity	T038	C3714634
27258690	277	288	selectivity	T081	C0038592
27258690	294	302	affinity	T070	C1510827
27258690	314	322	proteins	T116,T123	C0033684
27258690	333	342	stability	T080	C0205360
27258690	351	374	proteolytic degradation	T044	C0597304
27258690	419	442	combinatorial libraries	T116,T130	C0376433
27258690	456	467	MS analysis	T059	C0037813
27258690	486	495	discovery	T062	C2827399
27258690	499	513	cyclic peptide	T116	C0030957
27258690	514	524	structures	T082	C0678594
27258690	531	541	approaches	T082	C0449445
27258690	546	562	ChemMatrix resin	T109	C0029224
27258690	578	605	4-hydroxymethylbenzoic acid	T109	C0029224
27258690	633	642	synthesis	T052	C1883254
27258690	648	677	one-bead-two-peptides library	T116,T130	C0376436
27258690	715	729	cyclic peptide	T116	C0030957
27258690	771	782	MS analysis	T059	C0037813
27258690	819	828	synthesis	T052	C1883254
27258690	834	861	cyclic depsipeptide library	T116,T130	C0376436
27258690	873	897	glycolamidic ester group	T120	C1254355
27258690	924	937	glycolic acid	T109	C1533643
27258690	945	952	library	T116,T130	C0376436
27258690	953	962	screening	T169	C1305399
27258690	991	998	peptide	T116	C0030956
27258690	1041	1052	MS analysis	T059	C0037813

27258956|t|Women's Sexual Issues After Myocardial Infarction: A Literature Review
27258956|a|Sexual activity after myocardial infarction (MI) is a concern for patients and often a challenge for health care professionals to address. It is widely recognized that most patients, of both sexes, report sexual problems or concerns after MI. However, there are reported differences between men and women. Women with sexual concerns may seek less help from health care providers and are more inclined to conceal them because of cultural barriers. The aim of the current study is to present a comprehensive review of the literature describing women's sexual issues after MI. A systematic search of the relevant literature was performed within international databases, including PubMed / Medline, Scopus, ScienceDirect, and ProQuest, as well as Google Scholar using relevant keywords. Also, Persian electronic databases such as Magiran, Scientific Information Databases, and Iran Medex were searched from the inception to October 2014. Articles focusing on the sexual issues after MI only in women, as well as articles on both sexes where women's results could be separated, were included in this review. A total of 8 articles were included in the final dataset. The main themes of women's sexual concerns after MI were " loss or decrease of sexual activity ," " dissatisfaction of sexual relationship ," " doubt about resumption time of sexual activity ," " fear of reinfarction or sudden death during sexual activity after MI ," " knowledge deficit regarding sexual activity after MI ," and " poor performance of health care providers in sexual counseling ." The results of this review demonstrate that women's post- MI sexual activity is affected by many concerns. The concerns may be a knowledge deficit related to not receiving necessary consultation on this topic. Nurses, as first-line care givers, can provide appropriate consultation and education for patients post- MI. As a result, breaking taboo imposed by cultural barriers, personal assumptions, or lack of confidence on giving sexual consultation may ultimately help patients to improve their quality of life.
27258956	0	7	Women's	T098	C0043210
27258956	8	21	Sexual Issues	T169	C2362503
27258956	28	49	Myocardial Infarction	T047	C0027051
27258956	53	70	Literature Review	T170	C0282441
27258956	71	86	Sexual activity	T053	C0036864
27258956	93	114	myocardial infarction	T047	C0027051
27258956	116	118	MI	T047	C0027051
27258956	125	132	concern	T078	C2699424
27258956	137	145	patients	T101	C0030705
27258956	172	197	health care professionals	T097	C1704312
27258956	244	252	patients	T101	C0030705
27258956	262	267	sexes	T032	C1522384
27258956	276	291	sexual problems	T047	C0856619
27258956	295	303	concerns	T078	C2699424
27258956	310	312	MI	T047	C0027051
27258956	362	365	men	T098	C0025266
27258956	370	375	women	T098	C0043210
27258956	377	382	Women	T098	C0043210
27258956	388	403	sexual concerns	T078	C2699424
27258956	428	449	health care providers	T097	C0018724
27258956	475	482	conceal	T080	C0443189
27258956	499	516	cultural barriers	T033	C1948141
27258956	522	525	aim	T078	C1947946
27258956	533	546	current study	T062	C2603343
27258956	577	601	review of the literature	T170	C0282441
27258956	613	620	women's	T098	C0043210
27258956	621	634	sexual issues	T169	C2362503
27258956	641	643	MI	T047	C0027051
27258956	681	691	literature	T170	C0023866
27258956	713	736	international databases	T170	C0242356
27258956	748	754	PubMed	T170	C1138432
27258956	757	764	Medline	T170	C0025141
27258956	766	772	Scopus	T170	C0282574
27258956	774	787	ScienceDirect	T170	C0282574
27258956	793	801	ProQuest	T170	C0282574
27258956	814	828	Google Scholar	T170	C0282574
27258956	844	852	keywords	T170	C1708608
27258956	860	888	Persian electronic databases	T170	C3841595
27258956	897	904	Magiran	T170	C0282574
27258956	906	938	Scientific Information Databases	T170	C0282574
27258956	944	954	Iran Medex	T170	C0282574
27258956	1005	1013	Articles	T170	C1706852
27258956	1030	1043	sexual issues	T169	C2362503
27258956	1050	1052	MI	T047	C0027051
27258956	1061	1066	women	T098	C0043210
27258956	1079	1087	articles	T170	C1706852
27258956	1096	1101	sexes	T032	C1522384
27258956	1108	1115	women's	T098	C0043210
27258956	1166	1172	review	T058	C1273406
27258956	1187	1195	articles	T170	C1706852
27258956	1223	1230	dataset	T170	C0150098
27258956	1251	1258	women's	T098	C0043210
27258956	1259	1274	sexual concerns	T078	C2699424
27258956	1281	1283	MI	T047	C0027051
27258956	1291	1295	loss	T081	C1517945
27258956	1299	1307	decrease	T081	C0547047
27258956	1311	1326	sexual activity	T053	C0036864
27258956	1332	1370	dissatisfaction of sexual relationship	T033	C0237211
27258956	1376	1381	doubt	T041	C0870444
27258956	1388	1403	resumption time	T033	C1821070
27258956	1407	1422	sexual activity	T053	C0036864
27258956	1428	1432	fear	T041	C0015726
27258956	1436	1448	reinfarction	T047	C0348593
27258956	1452	1464	sudden death	T046	C0011071
27258956	1472	1487	sexual activity	T053	C0036864
27258956	1494	1496	MI	T047	C0027051
27258956	1502	1519	knowledge deficit	T033	C1998986
27258956	1530	1545	sexual activity	T053	C0036864
27258956	1552	1554	MI	T047	C0027051
27258956	1564	1568	poor	T080	C0542537
27258956	1569	1580	performance	T055	C0597198
27258956	1584	1605	health care providers	T097	C0018724
27258956	1609	1626	sexual counseling	T058	C0036870
27258956	1650	1656	review	T058	C1273406
27258956	1674	1681	women's	T098	C0043210
27258956	1688	1690	MI	T047	C0027051
27258956	1691	1706	sexual activity	T053	C0036864
27258956	1727	1735	concerns	T078	C2699424
27258956	1741	1749	concerns	T078	C2699424
27258956	1759	1776	knowledge deficit	T033	C1998986
27258956	1812	1824	consultation	T058	C0009818
27258956	1840	1846	Nurses	T097	C0028661
27258956	1851	1873	first-line care givers	T097	C0085537
27258956	1899	1911	consultation	T058	C0009818
27258956	1930	1938	patients	T101	C0030705
27258956	1945	1947	MI	T047	C0027051
27258956	1971	1976	taboo	T078	C0039227
27258956	1988	2005	cultural barriers	T033	C1948141
27258956	2032	2050	lack of confidence	T033	C0558092
27258956	2061	2080	sexual consultation	T058	C0009818
27258956	2101	2109	patients	T101	C0030705
27258956	2127	2142	quality of life	T078	C0034380

27259186|t|Effect of autohydrolysis on the wettability, absorbility and further alkali impregnation of poplar wood chips
27259186|a|Autohydrolysis with different severity factors was performed on poplar wood chips prior to pulping, and the wettability, absorbility and the following impregnation of NaOH solution for the poplar wood chips were then investigated. The results showed that after autohydrolysis pretreatment the porosity, shrinkage and fiber saturation point (FSP) of the poplar wood chips were increased, while the surface contact angle decreased as the severity factor was increased. The autohydrolyzed chips absorbed more NaOH in impregnation that resulted in a low NaOH concentration in the bulk impregnation liquor (i.e., the impregnation liquor outside wood chips), while the concentration in the entrapped liquor (i.e., the impregnation liquor inside wood chips) was increased. Autohydrolysis substantially improved the effectiveness of alkali impregnation.
27259186	10	24	autohydrolysis	T070	C0020291
27259186	32	43	wettability	T080	C0162598
27259186	45	56	absorbility	T070	C0000854
27259186	69	75	alkali	T197	C0002055
27259186	76	88	impregnation	T067	C1522240
27259186	92	98	poplar	T002	C0522458
27259186	99	109	wood chips	T167	C0043217
27259186	110	124	Autohydrolysis	T070	C0020291
27259186	140	148	severity	T080	C0439793
27259186	149	156	factors	T080	C0205556
27259186	174	180	poplar	T002	C0522458
27259186	181	191	wood chips	T167	C0043217
27259186	201	208	pulping	T067	C1522240
27259186	218	229	wettability	T080	C0162598
27259186	231	242	absorbility	T070	C0000854
27259186	261	273	impregnation	T067	C1522240
27259186	277	281	NaOH	T131,T197	C0037517
27259186	282	290	solution	T167	C0037633
27259186	299	305	poplar	T002	C0522458
27259186	306	316	wood chips	T167	C0043217
27259186	327	339	investigated	T169	C1292732
27259186	371	385	autohydrolysis	T070	C0020291
27259186	386	398	pretreatment	T052	C3539076
27259186	403	411	porosity	T080	C0080037
27259186	413	422	shrinkage	T169	C0332513
27259186	427	449	fiber saturation point	T033	C0243095
27259186	451	454	FSP	T033	C0243095
27259186	463	469	poplar	T002	C0522458
27259186	470	480	wood chips	T167	C0043217
27259186	486	495	increased	T081	C0205217
27259186	507	528	surface contact angle	T080	C0205556
27259186	546	554	severity	T080	C0439793
27259186	555	561	factor	T080	C0205556
27259186	566	575	increased	T081	C0205217
27259186	581	595	autohydrolyzed	T070	C0020291
27259186	596	601	chips	T167	C0043217
27259186	602	610	absorbed	T070	C0000854
27259186	616	620	NaOH	T131,T197	C0037517
27259186	624	636	impregnation	T067	C1522240
27259186	660	664	NaOH	T131,T197	C0037517
27259186	665	678	concentration	T081	C1446561
27259186	691	703	impregnation	T067	C1522240
27259186	704	710	liquor	T167	C0439861
27259186	722	734	impregnation	T067	C1522240
27259186	735	741	liquor	T167	C0439861
27259186	750	760	wood chips	T167	C0043217
27259186	773	786	concentration	T081	C1446561
27259186	794	803	entrapped	T033	C0243095
27259186	804	810	liquor	T167	C0439861
27259186	822	834	impregnation	T067	C1522240
27259186	835	841	liquor	T167	C0439861
27259186	849	859	wood chips	T167	C0043217
27259186	865	874	increased	T081	C0205217
27259186	876	890	Autohydrolysis	T070	C0020291
27259186	905	913	improved	T033	C0184511
27259186	918	931	effectiveness	T080	C1280519
27259186	935	941	alkali	T197	C0002055
27259186	942	954	impregnation	T067	C1522240

27259326|t|Effect of Transcatheter Arterial Chemoembolization Combined with Argon-Helium Cryosurgery System on the Changes of NK Cells and T Cell Subsets in Peripheral Blood of Hepatocellular Carcinoma Patients
27259326|a|Hepatocellular carcinoma (HCC) is one of the most aggressive tumors in humans. T lymphocytes and natural killer (NK) cells are the body's first line of defense to prevent tumor cell growth. Previous studies have demonstrated that transcatheter arterial chemoembolization (TACE) combined with argon-helium cryosurgery system (AHCS) can effectively treat liver cancer. However, the mechanism of the treatment is unclear yet. In the current study, we investigated the effects of TACE combined with AHCS on the changes of T cell subsets and NK cells in peripheral blood of HCC. Our data show that alpha-fetoprotein (AFP) levels in peripheral blood were significantly up-regulated in HCC patients before treatment when compared with healthy people and reduced after TACE combined with AHCS treatment (P < 0.01). In addition, we found that CD4+ cells and NK cells decreased (P < 0.05) and CD8+ cells increased (P < 0.05) in HCC patients when compared with healthy people. After treatment, the CD4+ cells, CD4+ / CD8+ ratio, and NK cells were dramatically increased in HCC patients (P < 0.05). In contrast, CD8+ cells were significantly decreased (P < 0.05). TACE combined with AHCS treatment significantly prolonged 1- year survival rate of HCC patients and did not show significant side effects. Taken together, our data indicate that TACE combined with AHCS treatment improves patients ' immune system. It is a feasible and effective therapeutic method for HCC patients.
27259326	0	6	Effect	T080	C1280500
27259326	10	50	Transcatheter Arterial Chemoembolization	T061	C3888803
27259326	65	96	Argon-Helium Cryosurgery System	T061	C0010408
27259326	104	111	Changes	T169	C0392747
27259326	115	123	NK Cells	T025	C0022688
27259326	128	142	T Cell Subsets	T025	C0080202
27259326	146	162	Peripheral Blood	T031	C0229664
27259326	166	190	Hepatocellular Carcinoma	T191	C2239176
27259326	191	199	Patients	T101	C0030705
27259326	200	224	Hepatocellular carcinoma	T191	C2239176
27259326	226	229	HCC	T191	C2239176
27259326	250	260	aggressive	T080	C1550594
27259326	261	267	tumors	T191	C0027651
27259326	271	277	humans	T016	C0086418
27259326	279	292	T lymphocytes	T025	C0039194
27259326	297	311	natural killer	T025	C2709199
27259326	313	315	NK	T025	C2709199
27259326	317	322	cells	T025	C0007634
27259326	331	337	body's	T016	C0242821
27259326	352	359	defense	T042	C0520990
27259326	363	370	prevent	T080	C2700409
27259326	371	381	tumor cell	T025	C0597032
27259326	382	388	growth	T043	C0007595
27259326	390	406	Previous studies	T062	C2603343
27259326	430	470	transcatheter arterial chemoembolization	T061	C3888803
27259326	472	476	TACE	T061	C3888803
27259326	492	523	argon-helium cryosurgery system	T061	C0010408
27259326	525	529	AHCS	T061	C0010408
27259326	525	529	AHCS	T061	C0010408
27259326	535	546	effectively	T080	C1704419
27259326	547	552	treat	T061	C0087111
27259326	553	565	liver cancer	T191	C0345904
27259326	580	589	mechanism	T169	C0441712
27259326	597	606	treatment	T061	C0087111
27259326	610	617	unclear	T033	C3845108
27259326	638	643	study	T062	C2603343
27259326	648	660	investigated	T169	C1292732
27259326	665	675	effects of	T080	C1704420
27259326	676	680	TACE	T061	C3888803
27259326	695	699	AHCS	T061	C0010408
27259326	707	714	changes	T169	C0392747
27259326	718	732	T cell subsets	T025	C0080202
27259326	737	745	NK cells	T025	C0022688
27259326	749	765	peripheral blood	T031	C0229664
27259326	769	772	HCC	T191	C2239176
27259326	778	782	data	T078	C1511726
27259326	793	810	alpha-fetoprotein	T116,T123	C0002210
27259326	812	815	AFP	T116,T123	C0002210
27259326	817	823	levels	T080	C0441889
27259326	827	843	peripheral blood	T031	C0229664
27259326	863	875	up-regulated	T044	C0041904
27259326	879	882	HCC	T191	C2239176
27259326	883	891	patients	T101	C0030705
27259326	899	908	treatment	T061	C0087111
27259326	914	922	compared	T052	C1707455
27259326	928	935	healthy	T080	C3898900
27259326	936	942	people	T098	C0027361
27259326	947	954	reduced	T080	C0392756
27259326	961	965	TACE	T061	C3888803
27259326	980	984	AHCS	T061	C0010408
27259326	985	994	treatment	T061	C0087111
27259326	1034	1044	CD4+ cells	T025	C0039215
27259326	1049	1057	NK cells	T025	C0022688
27259326	1058	1067	decreased	T081	C0205216
27259326	1083	1093	CD8+ cells	T025	C0242629
27259326	1094	1103	increased	T081	C0205217
27259326	1118	1121	HCC	T191	C2239176
27259326	1122	1130	patients	T101	C0030705
27259326	1136	1144	compared	T052	C1707455
27259326	1150	1157	healthy	T080	C3898900
27259326	1158	1164	people	T098	C0027361
27259326	1172	1181	treatment	T061	C0087111
27259326	1187	1197	CD4+ cells	T025	C0039215
27259326	1199	1203	CD4+	T025	C0039215
27259326	1206	1210	CD8+	T025	C0242629
27259326	1211	1216	ratio	T081	C0456603
27259326	1222	1230	NK cells	T025	C0022688
27259326	1249	1258	increased	T081	C0205217
27259326	1262	1265	HCC	T191	C2239176
27259326	1266	1274	patients	T101	C0030705
27259326	1300	1310	CD8+ cells	T025	C0242629
27259326	1330	1339	decreased	T081	C0205216
27259326	1352	1356	TACE	T061	C3888803
27259326	1371	1375	AHCS	T061	C0010408
27259326	1376	1385	treatment	T061	C0087111
27259326	1413	1417	year	T079	C0439234
27259326	1418	1431	survival rate	T081	C0038954
27259326	1435	1438	HCC	T191	C2239176
27259326	1439	1447	patients	T101	C0030705
27259326	1477	1489	side effects	T046	C0879626
27259326	1511	1515	data	T078	C1511726
27259326	1530	1534	TACE	T061	C3888803
27259326	1549	1553	AHCS	T061	C0010408
27259326	1554	1563	treatment	T061	C0087111
27259326	1564	1572	improves	T033	C0184511
27259326	1573	1581	patients	T101	C0030705
27259326	1584	1597	immune system	T022	C0020962
27259326	1620	1629	effective	T080	C1704419
27259326	1630	1648	therapeutic method	T061	C0087111
27259326	1653	1656	HCC	T191	C2239176
27259326	1657	1665	patients	T101	C0030705

27259362|t|Identification and characterization of Dichelobacter nodosus serogroup H from ovine footrot in India
27259362|a|A total of 56 foot swabs were collected from inter digital spaces of sheep with footrot lesions were screened for 16 rRNA of Dichelobacter nodosus by PCR. Out of the 56 samples, 38(67.85%) were found to be positive. All the positive samples were subjected to multiplex PCR targeting fimA gene for identification of serogroups of D. nodosus. Serogroup H was found along with serogroup B in 12 (55.26%) samples and with serogroup I in 8 (22.2%) samples. The serogroup H was identified for the first time from the Indian subcontinent. The phylogenetic analysis of the present sequence with the available serogroup H sequences of GenBank revealed to be in close association with the serotype H1.
27259362	0	14	Identification	T080	C0205396
27259362	19	35	characterization	T052	C1880022
27259362	39	60	Dichelobacter nodosus	T007	C0314932
27259362	61	72	serogroup H	T170	C0449555
27259362	78	83	ovine	T015	C1123019
27259362	84	91	footrot	T047	C0016513
27259362	95	100	India	T083	C0021201
27259362	115	125	foot swabs	T167	C0183753
27259362	146	166	inter digital spaces	T030	C0230506
27259362	170	175	sheep	T015	C0036945
27259362	181	188	footrot	T047	C0016513
27259362	189	196	lesions	T033	C0221198
27259362	202	210	screened	T060	C1710031
27259362	218	222	rRNA	T114,T123	C0035701
27259362	226	247	Dichelobacter nodosus	T007	C0314932
27259362	251	254	PCR	T063	C0032520
27259362	270	277	samples	T077	C2347026
27259362	307	315	positive	T033	C1514241
27259362	325	333	positive	T033	C1514241
27259362	334	341	samples	T077	C2347026
27259362	360	373	multiplex PCR	T063	C3179032
27259362	374	393	targeting fimA gene	T063	C0242613
27259362	398	412	identification	T080	C0205396
27259362	416	426	serogroups	T170	C0449543
27259362	430	440	D. nodosus	T007	C0314932
27259362	442	453	Serogroup H	T170	C0449555
27259362	475	486	serogroup B	T170	C0456771
27259362	502	509	samples	T077	C2347026
27259362	519	530	serogroup I	T170	C0449543
27259362	544	551	samples	T077	C2347026
27259362	557	568	serogroup H	T170	C0449555
27259362	573	583	identified	T080	C0205396
27259362	612	631	Indian subcontinent	T083	C0454693
27259362	637	658	phylogenetic analysis	T062	C1519068
27259362	674	682	sequence	T086	C0004793
27259362	702	713	serogroup H	T170	C0449555
27259362	714	723	sequences	T086	C0004793
27259362	727	734	GenBank	T170	C0598211
27259362	780	791	serotype H1	T170	C0449943

27259647|t|Production of bioactive conjugated linoleic acid by the multifunctional enolase from Lactobacillus plantarum
27259647|a|Lactobacillus plantarum Î±-enolase, a multifunctional -anchorless- surface protein belonging to the conserved family of enolases with a central role in glycolytic metabolism, was characterized to have a side role in the intricate metabolism of biohydrogenation of linoleic acid, catalyzing the formation of bioactive 9-cis-11-trans-CLA through dehydration and isomerization of 10-hydroxy-12-cis-octadecenoic acid. The identity of the enolase was confirmed through mass spectrometric analysis that showed the characteristic 442 amino acid sequence with a molecular mass of 48.03 kDa. The enolase was not capable of using linoleic acid directly as a substrate but instead uses its hydroxyl derivative 10-hydroxi-12-cis-octadecenoic acid to finally form bioactive conjugated linoleic acid. Biochemical optimization studies were carried out to elucidate the conditions for maximum production of 9-cis-11-trans-CLA and maximum stability of Î±-enolase when catalyzing this reaction. Furthermore, through structural analysis of the protein, we propose the binding sites of substrate and product molecules that were characterized as two hydrophobic superficial pockets located at opposite ends of the enolase connected through a channel where the catalysis of dehydration and isomerization might occur. These results prove that multifunctional Î±-enolase also plays a role in cell detoxification from polyunsaturated fatty acids such as linoleic acid, along with the linoleate isomerase complex.
27259647	14	23	bioactive	T167	C3714412
27259647	24	48	conjugated linoleic acid	T109,T121	C1257880
27259647	56	71	multifunctional	T116,T126	C3658346
27259647	72	79	enolase	T116,T126	C0031691
27259647	85	108	Lactobacillus plantarum	T007	C0317608
27259647	109	132	Lactobacillus plantarum	T007	C0317608
27259647	133	142	Î±-enolase	T116,T126	C2364020
27259647	146	161	multifunctional	T116,T126	C3658346
27259647	175	190	surface protein	T116,T123	C0025252
27259647	228	236	enolases	T116,T126	C0031691
27259647	260	270	glycolytic	T044	C0017952
27259647	271	281	metabolism	T040	C0025519
27259647	287	300	characterized	T052	C1880022
27259647	328	348	intricate metabolism	T040	C0025519
27259647	352	368	biohydrogenation	T070	C0020286
27259647	372	385	linoleic acid	T109,T121,T123	C0023749
27259647	387	397	catalyzing	T070	C0007382
27259647	402	411	formation	T169	C1522492
27259647	415	424	bioactive	T167	C3714412
27259647	425	443	9-cis-11-trans-CLA	T109	C1609806
27259647	452	463	dehydration	T067	C0598133
27259647	468	481	isomerization	T044	C0596342
27259647	485	520	10-hydroxy-12-cis-octadecenoic acid	T109	C0620518
27259647	542	549	enolase	T116,T126	C0031691
27259647	572	599	mass spectrometric analysis	T059	C0037813
27259647	635	654	amino acid sequence	T087	C0002518
27259647	662	676	molecular mass	T081	C3152252
27259647	686	689	kDa	T081	C1532717
27259647	695	702	enolase	T116,T126	C0031691
27259647	728	741	linoleic acid	T109,T121,T123	C0023749
27259647	756	765	substrate	T167	C3891814
27259647	787	795	hydroxyl	T197	C0700307
27259647	796	806	derivative	T169	C1527240
27259647	807	842	10-hydroxi-12-cis-octadecenoic acid	T109	C0620518
27259647	859	868	bioactive	T167	C3714412
27259647	869	893	conjugated linoleic acid	T109	C0050156
27259647	895	906	Biochemical	T169	C0205474
27259647	907	919	optimization	T052	C2698650
27259647	920	927	studies	T062	C2603343
27259647	999	1017	9-cis-11-trans-CLA	T109	C1609806
27259647	1030	1039	stability	T044	C0014439
27259647	1043	1052	Î±-enolase	T116,T126	C2364020
27259647	1058	1068	catalyzing	T070	C0007382
27259647	1074	1082	reaction	T067	C0596319
27259647	1105	1124	structural analysis	T061	C0204514
27259647	1132	1139	protein	T116,T123	C0033684
27259647	1156	1169	binding sites	T192	C0005456
27259647	1173	1182	substrate	T167	C3891814
27259647	1187	1194	product	T071	C1514468
27259647	1195	1204	molecules	T167	C0567416
27259647	1215	1228	characterized	T052	C1880022
27259647	1236	1247	hydrophobic	T080	C0598629
27259647	1300	1307	enolase	T116,T126	C0031691
27259647	1328	1335	channel	T116,T123	C0022009
27259647	1346	1355	catalysis	T070	C0007382
27259647	1359	1370	dehydration	T067	C0598133
27259647	1375	1388	isomerization	T044	C0596342
27259647	1427	1442	multifunctional	T116,T126	C3658346
27259647	1443	1452	Î±-enolase	T116,T126	C2364020
27259647	1474	1493	cell detoxification	T043	C4235382
27259647	1499	1526	polyunsaturated fatty acids	T109,T123	C0032615
27259647	1535	1548	linoleic acid	T109,T121,T123	C0023749
27259647	1565	1584	linoleate isomerase	T116,T126	C0312354
27259647	1585	1592	complex	T104	C1704241

27259677|t|The "tight orbit": Incidence and management of the orbital compartment syndrome
27259677|a|The orbital compartment syndrome (OCS) constitutes a severe emergency, requiring immediate clinical diagnosis and surgical decompression. The key symptom is progressive visual impairment caused by an increase in intraorbital pressure, impairing the perfusion of relevant neurovascular and neurosensory structures. Intraorbital bleeding due to trauma and surgical intervention is known to be the main etiological factor. A retrospective analysis of all patients affected by an OCS between January 1, 2012, and May 31, 2015, was performed. Patients' records were reviewed with regard to etiology, initial ophthalmologic status, fracture pattern, concomitant medication, surgical management, and postoperative outcome. The incidence of OCS was calculated based on the total number of craniomaxillofacial (CMF) emergencies. Within 3.5 years, a total of 18,093 CMF emergencies were registered. In 16 patients, an OCS was documented, corresponding to an incidence of 0.088%. The mean patient age was 67.31 Â± 23.86 years, ranging from 22 to 102 years. The etiology varied, but trauma with subsequent intraorbital bleeding was the main cause. The use of anticoagulative medication was documented in 50% of the cases. In 14 patients, immediate surgical orbital decompression was performed: in 10 patients, vision could be preserved; in three patients, blindness resulted; and one patient was lost to follow-up. Two patients were managed without surgery. With regard to the total number of CMF emergencies, OCS is a rare condition. Early clinical diagnosis and surgical decompression are required to prevent permanent vision impairment. Anticoagulative medication must be considered as a predisposing factor for an orbital compartment syndrome in patients affected by periorbital trauma.
27259677	19	28	Incidence	T081	C0021149
27259677	33	43	management	T058	C0376636
27259677	51	79	orbital compartment syndrome	T047	C0009492
27259677	84	112	orbital compartment syndrome	T047	C0009492
27259677	114	117	OCS	T047	C0009492
27259677	140	149	emergency	T067	C0013956
27259677	161	170	immediate	T079	C0205253
27259677	171	189	clinical diagnosis	T060	C0332140
27259677	194	216	surgical decompression	T061	C0376530
27259677	226	233	symptom	T184	C1457887
27259677	237	266	progressive visual impairment	T033	C1839364
27259677	280	288	increase	T169	C0442805
27259677	292	313	intraorbital pressure	T042	C0021888
27259677	315	324	impairing	T169	C0221099
27259677	329	338	perfusion	T061	C0031001
27259677	342	350	relevant	T080	C2347946
27259677	351	364	neurovascular	T023	C2338723
27259677	369	392	neurosensory structures	T023	C0446849
27259677	394	415	Intraorbital bleeding	T046	C0019080
27259677	423	429	trauma	T037	C3714660
27259677	434	455	surgical intervention	T033	C0549433
27259677	502	515	retrospective	T080	C1514923
27259677	516	524	analysis	T062	C0936012
27259677	532	540	patients	T101	C0030705
27259677	541	549	affected	T169	C0392760
27259677	556	559	OCS	T047	C0009492
27259677	607	616	performed	T169	C0884358
27259677	618	627	Patients'	T101	C0030705
27259677	628	635	records	T170	C0034869
27259677	641	649	reviewed	T080	C1709940
27259677	665	673	etiology	T169	C1314792
27259677	675	682	initial	T079	C0205265
27259677	683	697	ophthalmologic	T169	C0205481
27259677	698	704	status	T080	C0449438
27259677	706	722	fracture pattern	T033	C0243095
27259677	724	746	concomitant medication	T078	C2347852
27259677	748	767	surgical management	T058	C1515089
27259677	773	786	postoperative	T079	C0032790
27259677	787	794	outcome	T169	C1274040
27259677	800	809	incidence	T081	C0021149
27259677	813	816	OCS	T047	C0009492
27259677	821	831	calculated	T052	C1441506
27259677	845	857	total number	T081	C4288115
27259677	861	880	craniomaxillofacial	T029	C0005898
27259677	882	885	CMF	T029	C0005898
27259677	887	898	emergencies	T046	C2745965
27259677	911	916	years	T079	C0439234
27259677	936	939	CMF	T029	C0005898
27259677	940	951	emergencies	T046	C2745965
27259677	957	967	registered	T058	C1514821
27259677	975	983	patients	T101	C0030705
27259677	988	991	OCS	T047	C0009492
27259677	996	1006	documented	T058	C1301725
27259677	1028	1037	incidence	T081	C0021149
27259677	1053	1057	mean	T081	C0444504
27259677	1058	1065	patient	T101	C0030705
27259677	1066	1069	age	T032	C0001779
27259677	1088	1093	years	T079	C0439234
27259677	1095	1102	ranging	T081	C1514721
27259677	1118	1123	years	T079	C0439234
27259677	1129	1137	etiology	T169	C1314792
27259677	1150	1156	trauma	T037	C3714660
27259677	1173	1194	intraorbital bleeding	T046	C0019080
27259677	1208	1213	cause	T033	C0552510
27259677	1226	1252	anticoagulative medication	T061	C0003281
27259677	1257	1267	documented	T058	C1301725
27259677	1282	1287	cases	T169	C0868928
27259677	1295	1303	patients	T101	C0030705
27259677	1305	1314	immediate	T079	C0205253
27259677	1315	1345	surgical orbital decompression	T061	C3267044
27259677	1350	1359	performed	T169	C0884358
27259677	1367	1375	patients	T101	C0030705
27259677	1377	1383	vision	T040	C0042789
27259677	1393	1402	preserved	T059	C0033085
27259677	1413	1421	patients	T101	C0030705
27259677	1423	1432	blindness	T033	C0456909
27259677	1433	1441	resulted	T169	C1274040
27259677	1451	1458	patient	T101	C0030705
27259677	1463	1467	lost	T169	C0745777
27259677	1471	1480	follow-up	T058	C1522577
27259677	1486	1494	patients	T101	C0030705
27259677	1516	1523	surgery	T061	C0543467
27259677	1544	1556	total number	T081	C4288115
27259677	1560	1563	CMF	T029	C0005898
27259677	1564	1575	emergencies	T046	C2745965
27259677	1577	1580	OCS	T047	C0009492
27259677	1586	1590	rare	T080	C0522498
27259677	1591	1600	condition	T080	C0348080
27259677	1602	1607	Early	T079	C1279919
27259677	1608	1626	clinical diagnosis	T060	C0332140
27259677	1631	1653	surgical decompression	T061	C0376530
27259677	1658	1666	required	T169	C1514873
27259677	1670	1677	prevent	T080	C2700409
27259677	1678	1687	permanent	T079	C0205355
27259677	1688	1705	vision impairment	T033	C3665347
27259677	1707	1733	Anticoagulative medication	T061	C0003281
27259677	1758	1777	predisposing factor	T079	C0032946
27259677	1785	1813	orbital compartment syndrome	T047	C0009492
27259677	1817	1825	patients	T101	C0030705
27259677	1826	1834	affected	T169	C0392760
27259677	1838	1856	periorbital trauma	UnknownType	C0747513

27260358|t|Ammonia as an In Situ Sanitizer: Influence of Virus Genome Type on Inactivation
27260358|a|Treatment of human excreta and animal manure (HEAM) is key in controlling the spread of persistent enteric pathogens, such as viruses. The extent of virus inactivation during HEAM storage and treatment appears to vary with virus genome type, although the reasons for this variability are not clear. Here, we investigated the inactivation of viruses of different genome types under conditions representative of HEAM storage or mesophilic digestion. The goals were to characterize the influence of HEAM solution conditions on inactivation and to determine the potential mechanisms involved. Specifically, eight viruses representing the four viral genome types (single-stranded RNA [ssRNA], double-stranded RNA [dsRNA], single-stranded DNA [ssDNA], and double-stranded DNA [dsDNA]) were exposed to synthetic solutions with well-controlled temperature (20 to 35Â°C), pH (8 to 9), and ammonia (NH3) concentrations (0 to 40 mmol liter(-1)). DNA and dsRNA viruses were considerably more resistant than ssRNA viruses, resulting in up to 1,000-fold-longer treatment times to reach a 4-log inactivation. The apparently slower inactivation of DNA viruses was rationalized by the higher stability of DNA than that of ssRNA in HEAM. Pushing the system toward harsher pH (>9) and temperature (>35Â°C) conditions, such as those encountered in thermophilic digestion and alkaline treatments, led to more consistent inactivation kinetics among ssRNA and other viruses. This suggests that the dependence of inactivation on genome type disappeared in favor of protein -mediated inactivation mechanisms common to all viruses. Finally, we recommend the use of MS2 as a conservative indicator to assess the inactivation of ssRNA viruses and the stable Î¦X174 or dsDNA phages as indicators for persistent viruses. Viruses are among the most environmentally persistent pathogens. They can be present in high concentrations in human excreta and animal manure (HEAM). Therefore, appropriate treatment of HEAM is important prior to its reuse or discharge into the environment. Here, we investigated the factors that determine the persistence of viruses in HEAM, and we determined the main mechanisms that lead to their inactivation. Unlike other organisms, viruses can have four different genome types (double- or single-stranded RNA or DNA), and the viruses studied herein represent all four types. Genome type appeared to be the major determinant for persistence. Single-stranded RNA viruses are the most labile, because this genome type is susceptible to degradation in HEAM. In contrast, the other genome types are more stable; therefore, inactivation is slower and mainly driven by the degradation of viral proteins. Overall, this study allows us to better understand the behavior of viruses in HEAM.
27260358	0	7	Ammonia	T121,T197	C0002607
27260358	14	21	In Situ	T082	C0444498
27260358	22	31	Sanitizer	T074	C0183086
27260358	33	42	Influence	T077	C4054723
27260358	46	51	Virus	T005	C0042776
27260358	52	63	Genome Type	T028	C0017428
27260358	67	79	Inactivation	T169	C0544461
27260358	80	89	Treatment	T169	C1522326
27260358	93	98	human	T016	C0086418
27260358	99	106	excreta	T031	C0504085
27260358	111	117	animal	T008	C0003062
27260358	118	124	manure	T167	C0024765
27260358	126	130	HEAM	T031	C0504085
27260358	142	153	controlling	T067	C2239193
27260358	168	178	persistent	T079	C0205322
27260358	179	186	enteric	T082	C1304890
27260358	187	196	pathogens	T001	C0450254
27260358	206	213	viruses	T005	C0042776
27260358	219	225	extent	T082	C0439792
27260358	229	247	virus inactivation	T059	C0599953
27260358	255	259	HEAM	T031	C0504085
27260358	260	267	storage	T169	C1698986
27260358	272	281	treatment	T169	C1522326
27260358	303	308	virus	T005	C0042776
27260358	309	320	genome type	T028	C0017428
27260358	352	363	variability	T077	C2827666
27260358	388	400	investigated	T169	C1292732
27260358	405	417	inactivation	T169	C0544461
27260358	421	428	viruses	T005	C0042776
27260358	432	441	different	T080	C1705242
27260358	442	454	genome types	T028	C0017428
27260358	461	471	conditions	T080	C0348080
27260358	490	494	HEAM	T031	C0504085
27260358	495	502	storage	T169	C1698986
27260358	517	526	digestion	T040	C0012238
27260358	563	572	influence	T077	C4054723
27260358	576	580	HEAM	T031	C0504085
27260358	590	600	conditions	T080	C0348080
27260358	604	616	inactivation	T169	C0544461
27260358	638	647	potential	T080	C3245505
27260358	648	658	mechanisms	T169	C0441712
27260358	689	696	viruses	T005	C0042776
27260358	719	737	viral genome types	T028	C0042720
27260358	739	758	single-stranded RNA	T114	C3272452
27260358	760	765	ssRNA	T114	C3272452
27260358	768	787	double-stranded RNA	T114,T123	C0035693
27260358	789	794	dsRNA	T114,T123	C0035693
27260358	797	816	single-stranded DNA	T114	C0012935
27260358	818	823	ssDNA	T114	C0012935
27260358	830	849	double-stranded DNA	T114,T123	C0311474
27260358	851	856	dsDNA	T114,T123	C0311474
27260358	864	874	exposed to	T080	C0332157
27260358	875	894	synthetic solutions	T167	C0037633
27260358	900	915	well-controlled	T169	C3853142
27260358	916	927	temperature	T081	C0039476
27260358	942	944	pH	T081	C0020283
27260358	959	966	ammonia	T121,T197	C0002607
27260358	968	971	NH3	T121,T197	C0002607
27260358	973	987	concentrations	T081	C1446561
27260358	1014	1017	DNA	T114,T123	C0012854
27260358	1022	1027	dsRNA	T114,T123	C0035693
27260358	1028	1035	viruses	T005	C0042776
27260358	1059	1068	resistant	T169	C0332325
27260358	1074	1087	ssRNA viruses	T005	C1911773
27260358	1089	1101	resulting in	T169	C0332294
27260358	1126	1135	treatment	T169	C1522326
27260358	1159	1171	inactivation	T169	C0544461
27260358	1195	1207	inactivation	T169	C0544461
27260358	1211	1222	DNA viruses	T005	C0012923
27260358	1254	1263	stability	T060	C0796351
27260358	1267	1270	DNA	T114,T123	C0012854
27260358	1284	1289	ssRNA	T114	C3272452
27260358	1293	1297	HEAM	T031	C0504085
27260358	1325	1332	harsher	T033	C4068826
27260358	1333	1335	pH	T081	C0020283
27260358	1345	1356	temperature	T081	C0039476
27260358	1365	1375	conditions	T080	C0348080
27260358	1406	1418	thermophilic	T070	C0018837
27260358	1419	1428	digestion	T040	C0012238
27260358	1433	1441	alkaline	T080	C1979842
27260358	1442	1452	treatments	T169	C1522326
27260358	1477	1489	inactivation	T169	C0544461
27260358	1490	1498	kinetics	T070	C0022702
27260358	1505	1510	ssRNA	T114	C3272452
27260358	1521	1528	viruses	T005	C0042776
27260358	1535	1543	suggests	T078	C1705535
27260358	1567	1579	inactivation	T169	C0544461
27260358	1583	1594	genome type	T028	C0017428
27260358	1619	1626	protein	T116,T123	C0033684
27260358	1637	1649	inactivation	T169	C0544461
27260358	1650	1660	mechanisms	T169	C0441712
27260358	1675	1682	viruses	T005	C0042776
27260358	1717	1720	MS2	T005	C0206390
27260358	1739	1748	indicator	T169	C1522602
27260358	1763	1775	inactivation	T169	C0544461
27260358	1779	1792	ssRNA viruses	T005	C1911773
27260358	1808	1813	Î¦X174	T005	C0031303
27260358	1817	1822	dsDNA	T114,T123	C0311474
27260358	1823	1829	phages	T005	C0004651
27260358	1833	1843	indicators	T169	C1522602
27260358	1848	1858	persistent	T079	C0205322
27260358	1859	1866	viruses	T005	C0042776
27260358	1868	1875	Viruses	T005	C0042776
27260358	1895	1910	environmentally	T082	C0014406
27260358	1911	1921	persistent	T079	C0205322
27260358	1922	1931	pathogens	T001	C0450254
27260358	1945	1952	present	T033	C0150312
27260358	1961	1975	concentrations	T081	C1446561
27260358	1979	1984	human	T016	C0086418
27260358	1985	1992	excreta	T031	C0504085
27260358	1997	2003	animal	T008	C0003062
27260358	2004	2010	manure	T167	C0024765
27260358	2012	2016	HEAM	T031	C0504085
27260358	2030	2041	appropriate	T080	C1548787
27260358	2042	2051	treatment	T169	C1522326
27260358	2055	2059	HEAM	T031	C0504085
27260358	2095	2104	discharge	T031	C2926602
27260358	2114	2125	environment	T082	C0014406
27260358	2136	2148	investigated	T169	C1292732
27260358	2153	2160	factors	T169	C1521761
27260358	2195	2202	viruses	T005	C0042776
27260358	2206	2210	HEAM	T031	C0504085
27260358	2239	2249	mechanisms	T169	C0441712
27260358	2269	2281	inactivation	T169	C0544461
27260358	2296	2305	organisms	T001	C0029235
27260358	2307	2314	viruses	T005	C0042776
27260358	2329	2338	different	T080	C1705242
27260358	2339	2351	genome types	T028	C0017428
27260358	2364	2383	single-stranded RNA	T114	C3272452
27260358	2387	2390	DNA	T114,T123	C0012854
27260358	2401	2408	viruses	T005	C0042776
27260358	2450	2461	Genome type	T028	C0017428
27260358	2516	2543	Single-stranded RNA viruses	T005	C1911773
27260358	2578	2589	genome type	T028	C0017428
27260358	2608	2619	degradation	T169	C0243125
27260358	2623	2627	HEAM	T031	C0504085
27260358	2652	2664	genome types	T028	C0017428
27260358	2693	2705	inactivation	T169	C0544461
27260358	2741	2752	degradation	T169	C0243125
27260358	2756	2770	viral proteins	T116,T123	C0042736
27260358	2827	2835	behavior	T053	C0004927
27260358	2839	2846	viruses	T005	C0042776
27260358	2850	2854	HEAM	T031	C0504085

27260450|t|An electrochemical genosensor for Leishmania major detection based on dual effect of immobilization and electrocatalysis of cobalt-zinc ferrite quantum dots
27260450|a|Identification of Leishmania parasites is important in diagnosis and clinical studies of leishmaniasis. Although epidemiological and clinical methods are available, they are not sufficient for identification of causative agents of leishmaniasis. In the present study, quantum dots of magnetic cobalt-zinc ferrite (Co0.5Zn0.5Fe2O4) were synthesized and characterized by physicochemical methods. The quantum dots were then employed as an electrode modifier to immobilize a 24-mer specific single stranded DNA probe, and fabrication of a label-free, PCR-free and signal-on electrochemical genosensor for the detection of Leishmania major. Hybridization of the complementary single stranded DNA sequence with the probe under the selected conditions was explored using methylene blue as a redox marker, utilizing the electrocatalytic effect of the quantum dots on the methylene blue electroreduction process. The genosensor could detect a synthetic single stranded DNA target in a range of 1.0Ã10(-11) to 1.0Ã10(-18)molL(-1) with a limit of detection of 2.0Ã10(-19)molL(-1), and genomic DNA in a range of 7.31Ã10(-14) to 7.31Ã10(-6)ngÎ¼L(-1) with a limit of detection of 1.80Ã10(-14)ngÎ¼L(-1) with a high selectivity and sensitivity.
27260450	3	18	electrochemical	T059	C2350499
27260450	19	29	genosensor	T075	C0600364
27260450	34	50	Leishmania major	T204	C0023276
27260450	51	60	detection	T061	C1511790
27260450	75	81	effect	T080	C1280500
27260450	85	99	immobilization	T059	C4048292
27260450	104	120	electrocatalysis	T070	C0007382
27260450	124	143	cobalt-zinc ferrite	T197	C0021521
27260450	144	156	quantum dots	T073	C1258084
27260450	157	171	Identification	T080	C0205396
27260450	175	185	Leishmania	T204	C0023270
27260450	186	195	parasites	T204	C0030498
27260450	212	221	diagnosis	T033	C0011900
27260450	226	242	clinical studies	T062	C0008972
27260450	246	259	leishmaniasis	T047	C0023281
27260450	270	285	epidemiological	T062	C0014503
27260450	290	298	clinical	T080	C0205210
27260450	299	306	methods	T170	C0025663
27260450	335	345	sufficient	T080	C0205410
27260450	350	364	identification	T080	C0205396
27260450	368	384	causative agents	T033	C0449411
27260450	388	401	leishmaniasis	T047	C0023281
27260450	418	423	study	T062	C0008972
27260450	425	437	quantum dots	T073	C1258084
27260450	441	449	magnetic	T070	C0563532
27260450	450	469	cobalt-zinc ferrite	T197	C0021521
27260450	471	486	Co0.5Zn0.5Fe2O4	T197	C0021521
27260450	493	504	synthesized	T052	C1883254
27260450	509	522	characterized	T052	C1880022
27260450	526	549	physicochemical methods	T070	C2350462
27260450	555	567	quantum dots	T073	C1258084
27260450	593	602	electrode	T074	C0013812
27260450	603	611	modifier	T074	C0810640
27260450	615	625	immobilize	T169	C0221099
27260450	644	659	single stranded	T114	C0012935
27260450	660	669	DNA probe	T114,T130	C0012893
27260450	727	742	electrochemical	T059	C2350499
27260450	743	753	genosensor	T075	C0600364
27260450	762	771	detection	T061	C1511790
27260450	775	791	Leishmania major	T204	C0023276
27260450	793	806	Hybridization	T063	C0221902
27260450	814	827	complementary	T114	C0006556
27260450	828	843	single stranded	T114	C0012935
27260450	844	856	DNA sequence	T086	C0162326
27260450	866	871	probe	T114,T130	C0012893
27260450	882	890	selected	T052	C1707391
27260450	891	901	conditions	T080	C0348080
27260450	921	935	methylene blue	T109,T121,T130	C0025746
27260450	941	953	redox marker	T201	C0005516
27260450	969	985	electrocatalytic	T070	C0007382
27260450	986	992	effect	T080	C1280500
27260450	1000	1012	quantum dots	T073	C1258084
27260450	1020	1034	methylene blue	T109,T121,T130	C0025746
27260450	1035	1051	electroreduction	T070	C0301630
27260450	1052	1059	process	T067	C1522240
27260450	1065	1075	genosensor	T075	C0600364
27260450	1082	1088	detect	T061	C1511790
27260450	1091	1127	synthetic single stranded DNA target	T114	C0598279
27260450	1133	1138	range	T081	C1514721
27260450	1184	1202	limit of detection	T081	C2718050
27260450	1231	1242	genomic DNA	T114	C3272453
27260450	1248	1253	range	T081	C1514721
27260450	1300	1318	limit of detection	T081	C2718050
27260450	1350	1354	high	T080	C0205250
27260450	1355	1366	selectivity	T080	C2828393
27260450	1371	1382	sensitivity	T169	C0332324

27260627|t|Associations of Body Mass Index and Physical Activity With Sexual Dysfunction in Breast Cancer Survivors
27260627|a|Sexual dysfunction is a common and distressing consequence of breast cancer (BC) treatment. In the present study, we investigated the sexual functioning of BC patients and its association with women's personal characteristics and cancer treatments. In this cross-sectional study, sexual function was assessed using the Female Sexual Function Index (FSFI). The health-related quality of life (HRQOL) was measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and its breast module BR-23. Of the 235 participants approached, 216 participants were included in the study. Of these, 63 patients reported no sexual activity in the last month and thus were analyzed only in relation to the sexual desire domain of FSFI. A total of 154 (71.3 %) patients were classified with hypoactive sexual desire disorder (HSDD). From those patients reporting sexual activity in the last month, 63.3 % (97 out of 153) were classified with sexual dysfunction. Using hierarchical logistic regression, the variance explained (change in R (2)) by the addition of body mass index (BMI) and mild to moderate physical activity in the prediction models of sexual dysfunction and HSDD were 6.8 and 7.2 %, respectively. Age, BMI, and physical activity were independently associated with sexual dysfunction and HSDD. Additionally, BC patients with sexual dysfunction reported lower scores on global HRQOL, role functioning, and fatigue. Based on our findings, BC survivors should be encouraged to practice regular physical activity and to lose weight in order to avoid sexual dysfunction. However, future clinical trials are needed to confirm these findings.
27260627	0	12	Associations	T080	C0439849
27260627	16	31	Body Mass Index	T201	C1305855
27260627	36	53	Physical Activity	T056	C0026606
27260627	59	77	Sexual Dysfunction	T047	C0549622
27260627	81	94	Breast Cancer	T191	C0678222
27260627	95	104	Survivors	T101	C0206194
27260627	105	123	Sexual dysfunction	T047	C0549622
27260627	140	151	distressing	T033	C0231303
27260627	152	166	consequence of	T169	C0686907
27260627	167	180	breast cancer	T191	C0678222
27260627	182	184	BC	T191	C0678222
27260627	186	195	treatment	T061	C0087111
27260627	212	217	study	T062	C2603343
27260627	239	257	sexual functioning	T040	C0278092
27260627	261	263	BC	T191	C0678222
27260627	264	272	patients	T101	C0030705
27260627	281	292	association	T041	C0004083
27260627	298	305	women's	T098	C0043210
27260627	306	314	personal	T032	C1519021
27260627	315	330	characteristics	T080	C1521970
27260627	335	352	cancer treatments	T061	C0920425
27260627	362	383	cross-sectional study	T062	C0010362
27260627	385	400	sexual function	T040	C0278092
27260627	424	452	Female Sexual Function Index	T170	C4289276
27260627	454	458	FSFI	T170	C4289276
27260627	465	495	health-related quality of life	T078	C4279947
27260627	497	502	HRQOL	T078	C4279947
27260627	527	585	European Organization for Research and Treatment of Cancer	T093	C1516985
27260627	587	592	EORTC	T093	C1516985
27260627	594	601	QLQ-C30	T170	C3641780
27260627	610	629	breast module BR-23	T170	C0282574
27260627	642	654	participants	T098	C0679646
27260627	671	683	participants	T098	C0679646
27260627	725	733	patients	T101	C0030705
27260627	743	761	no sexual activity	T033	C3840693
27260627	774	779	month	T079	C0439231
27260627	827	840	sexual desire	T041	C0023618
27260627	841	847	domain	T169	C1880389
27260627	851	855	FSFI	T170	C4289276
27260627	881	889	patients	T101	C0030705
27260627	911	944	hypoactive sexual desire disorder	T048	C0020594
27260627	946	950	HSDD	T048	C0020594
27260627	964	972	patients	T101	C0030705
27260627	983	998	sexual activity	T053	C0036864
27260627	1011	1016	month	T079	C0439231
27260627	1062	1080	sexual dysfunction	T047	C0549622
27260627	1088	1120	hierarchical logistic regression	T062	C0206031
27260627	1182	1197	body mass index	T201	C1305855
27260627	1199	1202	BMI	T201	C1305855
27260627	1225	1242	physical activity	T056	C0026606
27260627	1250	1260	prediction	T078	C0681842
27260627	1261	1267	models	T170	C3161035
27260627	1271	1289	sexual dysfunction	T047	C0549622
27260627	1294	1298	HSDD	T048	C0020594
27260627	1333	1336	Age	T032	C0001779
27260627	1338	1341	BMI	T201	C1305855
27260627	1347	1364	physical activity	T056	C0026606
27260627	1400	1418	sexual dysfunction	T047	C0549622
27260627	1423	1427	HSDD	T048	C0020594
27260627	1443	1445	BC	T191	C0678222
27260627	1446	1454	patients	T101	C0030705
27260627	1460	1478	sexual dysfunction	T047	C0549622
27260627	1488	1493	lower	T081	C1611820
27260627	1494	1500	scores	T081	C0449820
27260627	1511	1516	HRQOL	T078	C4279947
27260627	1523	1534	functioning	T169	C0205245
27260627	1540	1547	fatigue	T184	C0015672
27260627	1562	1570	findings	T033	C0243095
27260627	1572	1574	BC	T191	C0678222
27260627	1575	1584	survivors	T101	C0206194
27260627	1609	1617	practice	T041	C0032893
27260627	1626	1643	physical activity	T056	C0026606
27260627	1651	1662	lose weight	UnknownType	C0418839
27260627	1681	1699	sexual dysfunction	T047	C0549622
27260627	1717	1732	clinical trials	T062	C0008976
27260627	1761	1769	findings	T033	C0243095

27261525|t|The N-Methyl d-Aspartate Glutamate Receptor Antagonist Ketamine Disrupts the Functional State of the Corticothalamic Pathway
27261525|a|The non-competitive N-methyl d-aspartate glutamate receptor (NMDAR) antagonist ketamine elicits a brain state resembling high-risk states for developing psychosis and early stages of schizophrenia characterized by sensory and cognitive deficits and aberrant ongoing gamma oscillations (30-80 Hz)in cortical and subcortical structures, including the thalamus. The underlying mechanisms are unknown. The goal of the present study was to determine whether a ketamine - induced psychotic - relevant state disturbs the functional state of the corticothalamic (CT) pathway. Multisite field recordings were performed in the somatosensory CT system of the sedated rat. Baseline activity was challenged by activation of vibrissa - related prethalamic inputs. The sensory - evoked thalamic response was characterized by a short - latency (â¼4 ms) prethalamic -mediated negative sharp potential and a longer latency (â¼10 ms) CT -mediated negative potential. Following a single subcutaneous injection of ketamine (2.5 mg/kg), spontaneously occurring and sensory - evoked thalamic gamma oscillations increased and decreased in power, respectively. The power of the sensory -related gamma oscillations was positively correlated with both the amplitude and the area under the curve of the corresponding CT potential but not with the prethalamic potential. The present results show that the layer VI CT pathway significantly contributes in thalamic gamma oscillations, and they support the hypothesis that reduced NMDAR activation disturbs the functional state of CT and corticocortical networks.
27261525	4	54	N-Methyl d-Aspartate Glutamate Receptor Antagonist	T121	C0598695
27261525	55	63	Ketamine	T109,T121	C0022614
27261525	64	72	Disrupts	T080	C0332454
27261525	77	87	Functional	T169	C0205245
27261525	88	93	State	T169	C1442792
27261525	101	116	Corticothalamic	T023	C1184631
27261525	117	124	Pathway	T077	C1705987
27261525	129	144	non-competitive	UnknownType	C0815027
27261525	145	203	N-methyl d-aspartate glutamate receptor (NMDAR) antagonist	T121	C0598695
27261525	204	212	ketamine	T109,T121	C0022614
27261525	223	228	brain	T023	C0006104
27261525	229	234	state	T169	C1442792
27261525	246	255	high-risk	T033	C0332167
27261525	256	262	states	T169	C1442792
27261525	278	287	psychosis	T048	C0033975
27261525	292	304	early stages	T079	C2363430
27261525	308	321	schizophrenia	T048	C0036341
27261525	322	335	characterized	T052	C1880022
27261525	339	346	sensory	T047	C0748618
27261525	351	369	cognitive deficits	T048	C0009241
27261525	383	390	ongoing	T078	C0549178
27261525	391	409	gamma oscillations	T042	C0678909
27261525	423	431	cortical	T023	C0007776
27261525	436	447	subcortical	T029	C0815275
27261525	448	458	structures	T082	C0678594
27261525	474	482	thalamus	T023	C0039729
27261525	499	509	mechanisms	T169	C0441712
27261525	514	521	unknown	T080	C0439673
27261525	527	531	goal	T170	C0018017
27261525	539	546	present	T079	C0521116
27261525	547	552	study	T062	C2603343
27261525	580	588	ketamine	T109,T121	C0022614
27261525	591	598	induced	T169	C0205263
27261525	599	608	psychotic	T048	C0033975
27261525	611	619	relevant	T080	C2347946
27261525	620	625	state	T169	C1442792
27261525	626	634	disturbs	T080	C2699787
27261525	639	649	functional	T169	C0205245
27261525	650	655	state	T169	C1442792
27261525	663	678	corticothalamic	T023	C1184631
27261525	680	682	CT	T023	C1184631
27261525	684	691	pathway	T077	C1705987
27261525	693	719	Multisite field recordings	T060	C0430022
27261525	725	734	performed	T169	C0884358
27261525	742	765	somatosensory CT system	T022	C0682661
27261525	773	780	sedated	T033	C0235195
27261525	781	784	rat	T015	C0034721
27261525	786	794	Baseline	T081	C1442488
27261525	795	803	activity	T052	C0441655
27261525	822	832	activation	T052	C1879547
27261525	836	844	vibrissa	T023	C0042640
27261525	847	854	related	T080	C0439849
27261525	855	866	prethalamic	T029	C0152349
27261525	867	873	inputs	T077	C1708517
27261525	879	886	sensory	T080	C0445254
27261525	889	913	evoked thalamic response	T042	C0015214
27261525	918	931	characterized	T052	C1880022
27261525	937	942	short	T081	C1806781
27261525	945	952	latency	T080	C0205275
27261525	961	972	prethalamic	T029	C0152349
27261525	983	991	negative	T080	C2825491
27261525	998	1007	potential	T043	C0001272
27261525	1014	1020	longer	T080	C0205166
27261525	1021	1028	latency	T080	C0205275
27261525	1038	1040	CT	T023	C1184631
27261525	1051	1059	negative	T080	C2825491
27261525	1060	1069	potential	T043	C0001272
27261525	1083	1089	single	T081	C0205171
27261525	1090	1112	subcutaneous injection	T169	C0021499
27261525	1116	1124	ketamine	T109,T121	C0022614
27261525	1138	1151	spontaneously	T169	C0205359
27261525	1166	1173	sensory	T080	C0445254
27261525	1176	1210	evoked thalamic gamma oscillations	T042	C0015214
27261525	1211	1220	increased	T081	C0205217
27261525	1225	1234	decreased	T081	C0205216
27261525	1238	1243	power	T081	C3854080
27261525	1263	1268	power	T081	C3854080
27261525	1276	1283	sensory	T080	C0445254
27261525	1293	1311	gamma oscillations	T042	C0678909
27261525	1316	1326	positively	T033	C1446409
27261525	1327	1337	correlated	T080	C1707520
27261525	1352	1361	amplitude	T082	C2346753
27261525	1370	1390	area under the curve	T081	C0376690
27261525	1412	1414	CT	T023	C1184631
27261525	1415	1424	potential	T043	C0001272
27261525	1442	1453	prethalamic	T029	C0152349
27261525	1454	1463	potential	T043	C0001272
27261525	1469	1476	present	T079	C0521116
27261525	1477	1484	results	T169	C1274040
27261525	1499	1507	layer VI	T023	C2322689
27261525	1508	1510	CT	T023	C1184631
27261525	1511	1518	pathway	T077	C1705987
27261525	1533	1544	contributes	T052	C1880177
27261525	1548	1556	thalamic	T023	C0039729
27261525	1557	1575	gamma oscillations	T042	C0678909
27261525	1598	1608	hypothesis	T078	C1512571
27261525	1614	1621	reduced	T080	C0392756
27261525	1622	1627	NMDAR	T116,T192	C0080093
27261525	1628	1638	activation	T043	C1514758
27261525	1639	1647	disturbs	T080	C2699787
27261525	1652	1662	functional	T169	C0205245
27261525	1663	1668	state	T169	C1442792
27261525	1672	1674	CT	T023	C1184631
27261525	1679	1694	corticocortical	T023	C0007776
27261525	1695	1703	networks	T040	C0598941

27261587|t|Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin - induced diabetic model
27261587|a|Diabetic nephropathy (DN) is a leading cause of end-stage renal disease in the world. Several signaling pathways are involved in the pathogenesis of DN including elevation in level of angiotensin II, formation of advanced glycation end products (AGE), activation of protein kinase c (PKC), and lipid accumulation. These pathways activate one another mutually leading to oxidative stress, increasing expression of transforming growth factor beta-1 (TGF-Î² 1) and release of interleukins and adhesion molecules, so the aim of this study is to interrupt more than pathogenic pathway to ameliorate the progression of DN. In the present study, white male rats (N=48) were divided into six groups (8 rats each), the first two groups served as normal control and a control vehicle group while the remaining four groups were rendered diabetic by a single intraperitoneal injection of Streptozotocin (STZ) and being left for 4 weeks to develop DN. Thereafter, the rats were divided into DN group, DN group receiving Telmisartan or Sildenafil or Telmisartan Sildenafil combination. After the specified treatment period, urine samples were collected (using metabolic cages) to measure proteinuria, animals were then euthanized, blood and tissue samples were collected for measurement of Blood glucose, BUN, S.Cr, LDL, NO, TGF-Î²1, IL-1Î², AGEPs, and SOD. The combination therapy showed significant decrease in BUN, S.Cr, LDL, TGF-Î²1, IL-1Î², Proteinuria and AGEPs and significant increase in SOD and NO. The findings showed that combination therapy was able to ameliorate DN and that the effects were superior to the single drugs alone.
27261587	0	11	Combination	T121	C0013162
27261587	15	26	telmisartan	T109,T121	C0248719
27261587	32	42	sildenafil	T109,T121	C0529793
27261587	43	53	ameliorate	T080	C0205556
27261587	54	65	progression	T046	C0242656
27261587	69	89	diabetic nephropathy	T047	C0011881
27261587	93	107	streptozotocin	T109,T195	C0038432
27261587	110	117	induced	T169	C0205263
27261587	118	126	diabetic	T033	C0241863
27261587	133	153	Diabetic nephropathy	T047	C0011881
27261587	155	157	DN	T047	C0011881
27261587	181	204	end-stage renal disease	T047	C0022661
27261587	227	245	signaling pathways	T044	C0037080
27261587	266	278	pathogenesis	T046	C0699748
27261587	282	284	DN	T047	C0011881
27261587	295	304	elevation	T082	C0702240
27261587	317	331	angiotensin II	T116,T121,T123	C0003009
27261587	333	342	formation	T169	C1522492
27261587	346	377	advanced glycation end products	T109,T123	C0162574
27261587	379	382	AGE	T109,T123	C0162574
27261587	385	395	activation	T043	C1819041
27261587	399	415	protein kinase c	T116,T126	C0033634
27261587	417	420	PKC	T116,T126	C0033634
27261587	427	445	lipid accumulation	T033	C0333574
27261587	453	461	pathways	T044	C0037080
27261587	462	470	activate	T052	C1879547
27261587	503	519	oxidative stress	T049	C0242606
27261587	532	542	expression	T045	C1171362
27261587	546	579	transforming growth factor beta-1	T116,T121,T123	C1704256
27261587	581	588	TGF-Î² 1	T116,T121,T123	C1704256
27261587	594	601	release	T169	C1283071
27261587	605	617	interleukins	T116,T129	C0021764
27261587	622	640	adhesion molecules	T116,T123	C0007578
27261587	693	703	pathogenic	T033	C3816499
27261587	704	711	pathway	T077	C1705987
27261587	715	725	ameliorate	T080	C0205556
27261587	730	741	progression	T046	C0242656
27261587	745	747	DN	T047	C0011881
27261587	764	769	study	T062	C0008972
27261587	771	786	white male rats	T015	C0684072
27261587	826	830	rats	T015	C0684072
27261587	869	883	normal control	T096	C0009932
27261587	890	911	control vehicle group	T096	C0009932
27261587	958	966	diabetic	T033	C0241863
27261587	979	1004	intraperitoneal injection	T061	C0021493
27261587	1008	1022	Streptozotocin	T109,T195	C0038432
27261587	1024	1027	STZ	T109,T195	C0038432
27261587	1067	1069	DN	T047	C0011881
27261587	1087	1091	rats	T015	C0684072
27261587	1110	1112	DN	T047	C0011881
27261587	1120	1122	DN	T047	C0011881
27261587	1139	1150	Telmisartan	T109,T121	C0248719
27261587	1154	1164	Sildenafil	T109,T121	C0529793
27261587	1168	1179	Telmisartan	T109,T121	C0248719
27261587	1180	1190	Sildenafil	T109,T121	C0529793
27261587	1191	1202	combination	T121	C0013162
27261587	1214	1223	specified	T080	C0205369
27261587	1224	1233	treatment	T169	C0039798
27261587	1234	1240	period	T079	C1948053
27261587	1242	1255	urine samples	T031	C1610733
27261587	1261	1270	collected	T078	C1516695
27261587	1278	1293	metabolic cages	T073	C3273359
27261587	1306	1317	proteinuria	T033	C0033687
27261587	1319	1326	animals	T008	C0003062
27261587	1337	1347	euthanized	T054	C0162665
27261587	1349	1354	blood	T031	C0178913
27261587	1359	1373	tissue samples	T024	C1292533
27261587	1379	1388	collected	T078	C1516695
27261587	1393	1421	measurement of Blood glucose	T059	C0392201
27261587	1423	1426	BUN	T059	C0005845
27261587	1428	1432	S.Cr	T059	C0201976
27261587	1434	1437	LDL	T059	C0202117
27261587	1439	1441	NO	T059	C3810607
27261587	1443	1449	TGF-Î²1	T059	C3889969
27261587	1451	1456	IL-1Î²	T059	C3815172
27261587	1458	1463	AGEPs	T059	C0022885
27261587	1469	1472	SOD	T059	C0022885
27261587	1478	1497	combination therapy	T061	C0013218
27261587	1529	1532	BUN	T123,T197	C0600137
27261587	1534	1538	S.Cr	T109,T123	C0010294
27261587	1540	1543	LDL	T109,T123	C0023823
27261587	1545	1551	TGF-Î²1	T116,T121,T123	C1704256
27261587	1553	1558	IL-1Î²	T116,T129	C0021753
27261587	1560	1571	Proteinuria	T033	C0033687
27261587	1576	1581	AGEPs	T109,T123	C0162574
27261587	1610	1613	SOD	T116,T121,T126	C0038838
27261587	1618	1620	NO	T121,T123,T197	C0028128
27261587	1647	1666	combination therapy	T061	C0013218
27261587	1679	1689	ameliorate	T080	C0205556
27261587	1690	1692	DN	T047	C0011881
27261587	1719	1727	superior	T080	C0205556
27261587	1742	1747	drugs	T121	C0013227

27261783|t|Analysis of Low-Biomass Microbial Communities in the Deep Biosphere
27261783|a|Over the past few decades, the subseafloor biosphere has been explored by scientific ocean drilling to depths of about 2.5km below the seafloor. Although organic-rich anaerobic sedimentary habitats in the ocean margins harbor large numbers of microbial cells, microbial populations in ultraoligotrophic aerobic sedimentary habitats in the open ocean gyres are several orders of magnitude less abundant. Despite advances in cultivation-independent molecular ecological techniques, exploring the low-biomass environment remains technologically challenging, especially in the deep subseafloor biosphere. Reviewing the historical background of deep-biosphere analytical methods, the importance of obtaining clean samples and tracing contamination, as well as methods for detecting microbial life, technological aspects of molecular microbiology, and detecting subseafloor metabolic activity will be discussed.
27261783	0	8	Analysis	T062	C0936012
27261783	12	23	Low-Biomass	T081	C0005535
27261783	24	45	Microbial Communities	T001	C0445623
27261783	53	67	Deep Biosphere	UnknownType	C0681784
27261783	82	93	few decades	T081	C2981279
27261783	99	120	subseafloor biosphere	UnknownType	C0681784
27261783	142	167	scientific ocean drilling	T169	C0205245
27261783	171	177	depths	T082	C0205125
27261783	203	211	seafloor	UnknownType	C0681784
27261783	222	265	organic-rich anaerobic sedimentary habitats	T082	C0871648
27261783	273	293	ocean margins harbor	T082	C1254362
27261783	311	326	microbial cells	T001	C0445623
27261783	328	349	microbial populations	T001	C0445623
27261783	353	399	ultraoligotrophic aerobic sedimentary habitats	T082	C0871648
27261783	412	423	ocean gyres	T169	C0205245
27261783	446	455	magnitude	T081	C1704240
27261783	461	469	abundant	T080	C2346714
27261783	491	546	cultivation-independent molecular ecological techniques	T169	C0449851
27261783	562	573	low-biomass	T081	C0005535
27261783	574	585	environment	T082	C0014406
27261783	594	621	technologically challenging	T080	C0332218
27261783	641	667	deep subseafloor biosphere	UnknownType	C0681784
27261783	669	678	Reviewing	T080	C1704362
27261783	683	704	historical background	T170	C1552723
27261783	708	722	deep-biosphere	UnknownType	C0681784
27261783	723	741	analytical methods	T170	C0178476
27261783	747	757	importance	T080	C3898777
27261783	771	784	clean samples	T167	C0370003
27261783	789	796	tracing	T033	C0243095
27261783	797	810	contamination	T078	C2349974
27261783	823	830	methods	T170	C0025663
27261783	835	844	detecting	T033	C0243095
27261783	845	854	microbial	T001	C0599840
27261783	855	859	life	T078	C0376558
27261783	861	882	technological aspects	UnknownType	C0681539
27261783	886	908	molecular microbiology	T091	C0025952
27261783	914	923	detecting	T033	C0243095
27261783	924	935	subseafloor	UnknownType	C0681784
27261783	936	954	metabolic activity	T040	C0025519

27262143|t|Novel immunotherapeutic strategies to target alloantibody -producing B and plasma cells in transplantation
27262143|a|There is an unmet need for immunotherapeutic agents that target humoral alloimmunity in solid organ transplantation. This includes sensitized patients with preformed donor -specific human leucocyte antigen antibodies and patients who develop de-novo donor -specific antibodies, both of which are associated with acute and chronic antibody-mediated rejection and allograft loss. In this review, we discuss recent progress in the generation of B-cell and plasma cell -targeted therapeutics, with an emphasis on novel agents. To deplete or inhibit B cells, B-cell -specific mAbs have been developed, including CD20, CD22, CD19 and bi-specific antibodies that target two B-cell antigens. In addition, inhibition of B-cell - activating cytokines, such as B cell-activating factor, may also reduce allo-B-cell activation. Plasma cells remain a difficult therapeutic target, but inhibition of germinal centre responses via costimulatory blockade or IL21 neutralization, induction of plasma cell apoptosis using proteasome inhibitors or disruption of the plasma cell niche are potential avenues being explored. The ultimate aim of these animal and human studies is to develop agents that efficiently target humoral effectors, whilst sparing B and plasma cells with a regulatory capacity to promote long-term allograft survival, but we remain some distance away from this goal.
27262143	0	5	Novel	T080	C0205314
27262143	6	34	immunotherapeutic strategies	T061	C0021083
27262143	38	44	target	T169	C1521840
27262143	45	57	alloantibody	T129	C0022144
27262143	69	70	B	T025	C0004561
27262143	75	87	plasma cells	T025	C0032112
27262143	91	106	transplantation	T061	C0040732
27262143	134	158	immunotherapeutic agents	T121,T129	C0876248
27262143	164	170	target	T169	C1521840
27262143	171	191	humoral alloimmunity	T042	C0598604
27262143	195	222	solid organ transplantation	T061	C0029216
27262143	238	257	sensitized patients	T101	C0030705
27262143	273	278	donor	T098	C0029206
27262143	289	312	human leucocyte antigen	T116,T129	C0019721
27262143	313	323	antibodies	T116,T129	C0003241
27262143	328	336	patients	T101	C0030705
27262143	349	356	de-novo	T078	C1515568
27262143	357	362	donor	T098	C0029206
27262143	373	383	antibodies	T116,T129	C0003241
27262143	403	418	associated with	T080	C0332281
27262143	419	424	acute	T079	C0205178
27262143	429	436	chronic	T079	C0205191
27262143	437	464	antibody-mediated rejection	T046	C1608421
27262143	469	478	allograft	T061	C0040739
27262143	479	483	loss	T081	C1517945
27262143	493	499	review	T170	C0282443
27262143	519	527	progress	T169	C1280477
27262143	535	545	generation	T052	C3146294
27262143	549	555	B-cell	T025	C0004561
27262143	560	571	plasma cell	T025	C0032112
27262143	582	594	therapeutics	T061	C0087111
27262143	616	621	novel	T080	C0205314
27262143	622	628	agents	T120	C0450442
27262143	633	640	deplete	T169	C0333668
27262143	644	651	inhibit	T052	C3463820
27262143	652	659	B cells	T025	C0004561
27262143	661	667	B-cell	T025	C0004561
27262143	678	682	mAbs	T116,T129	C0003250
27262143	714	718	CD20	T116,T129	C0054946
27262143	720	724	CD22	T116,T129	C0054947
27262143	726	730	CD19	T116,T129	C0108748
27262143	747	757	antibodies	T116,T129	C0003241
27262143	763	769	target	T169	C1521840
27262143	774	780	B-cell	T025	C0004561
27262143	781	789	antigens	T129	C0003320
27262143	804	814	inhibition	T052	C3463820
27262143	818	824	B-cell	T025	C0004561
27262143	827	837	activating	T043	C1326120
27262143	838	847	cytokines	T116,T129	C0079189
27262143	857	881	B cell-activating factor	T116,T123	C1682317
27262143	899	921	allo-B-cell activation	T043	C2259068
27262143	923	935	Plasma cells	T025	C0032112
27262143	955	966	therapeutic	T061	C0087111
27262143	967	973	target	T169	C1521840
27262143	979	989	inhibition	T052	C3463820
27262143	993	1008	germinal centre	T024	C0282491
27262143	1009	1018	responses	T032	C0871261
27262143	1037	1045	blockade	T169	C0332206
27262143	1049	1053	IL21	T116,T129	C0962190
27262143	1054	1068	neutralization	T169	C2987668
27262143	1070	1079	induction	T169	C0205263
27262143	1083	1094	plasma cell	T025	C0032112
27262143	1095	1104	apoptosis	T043	C0162638
27262143	1111	1132	proteasome inhibitors	T121	C1443643
27262143	1136	1146	disruption	T169	C0332453
27262143	1154	1165	plasma cell	T025	C0032112
27262143	1223	1226	aim	T078	C1947946
27262143	1236	1242	animal	T008	C0003062
27262143	1247	1260	human studies	T062	C0178693
27262143	1299	1305	target	T169	C1521840
27262143	1306	1323	humoral effectors	T025	C0312740
27262143	1340	1341	B	T025	C0004561
27262143	1346	1358	plasma cells	T025	C0032112
27262143	1366	1376	regulatory	T077	C1704735
27262143	1377	1385	capacity	T033	C0518031
27262143	1407	1416	allograft	T061	C0040739
27262143	1417	1425	survival	T042	C0018131
27262143	1470	1474	goal	T170	C0018017

27262362|t|Survival status and functional outcome of children who required prolonged intensive care after cardiac surgery
27262362|a|Children who require prolonged intensive care after cardiac surgery are at risk of high mortality. The long-term survival and functional outcome of these children have not been studied in detail. Children who stayed in intensive care for >28 days after cardiac surgery from 1997 to 2012 were studied in a single institution. A total of 116 patients were identified; 107 (92%) were <1 year of age and 63 (54%) had univentricular physiology. The incidence of children requiring prolonged intensive care increased from 1.01/100 undergoing cardiac surgery in 1997 to 2000 to 2.66/100 in 2009 to 2012 (P trend = .002). This increase coincided with an increase in the number of children with hypoplastic left heart syndrome having prolonged intensive care during the same period (0.13/100 in 1997-2000 to 1.0/100 in 2009-2012; P trend = .001). Survival to pediatric intensive care unit (PICU) discharge was 74% (95% confidence interval [CI], 65-82) and 51% (95% CI, 41-59) at 3 years. Factors associated with mortality were univentricular repair (hazard ratio [HR], 2.12; 95% CI, 1.21-3.70; P = .008) and acute renal failure (HR, 3.01; 95% CI, 1.77-5.12; P < .001), but era did not influence mortality (1997-2005 vs 2006-2012; log-rank P = .66). Among PICU survivors, 3- year survival in those who did not need early reoperation was 81% (95% CI, 66-90), compared with 58% (95% CI, 42-71) in those who required early reoperation (log-rank P = .01). Among survivors, 36% had either moderate or severe disability and 13% had poor quality of life. The incidence of children requiring prolonged intensive care after cardiac surgery has increase d in our institution. Our data suggest that the long-term outcome for most of these children is poor, especially after univentricular repair.
27262362	0	15	Survival status	T033	C1148433
27262362	20	30	functional	T169	C0205245
27262362	31	38	outcome	T169	C1274040
27262362	42	50	children	T100	C0008059
27262362	55	63	required	T169	C1514873
27262362	64	73	prolonged	T079	C0439590
27262362	74	88	intensive care	T058	C0085559
27262362	95	110	cardiac surgery	T061	C0018821
27262362	111	119	Children	T100	C0008059
27262362	132	141	prolonged	T079	C0439590
27262362	142	156	intensive care	T058	C0085559
27262362	163	178	cardiac surgery	T061	C0018821
27262362	183	190	at risk	T080	C1444641
27262362	194	208	high mortality	T081	C0205848
27262362	214	223	long-term	T079	C0443252
27262362	224	232	survival	T033	C1148433
27262362	237	247	functional	T169	C0205245
27262362	248	255	outcome	T169	C1274040
27262362	265	273	children	T100	C0008059
27262362	299	305	detail	T080	C1522508
27262362	307	315	Children	T100	C0008059
27262362	320	326	stayed	T033	C2706919
27262362	330	344	intensive care	T058	C0085559
27262362	353	357	days	T079	C0439228
27262362	364	379	cardiac surgery	T061	C0018821
27262362	423	434	institution	T093	C2607850
27262362	451	459	patients	T101	C0030705
27262362	465	475	identified	T080	C0205396
27262362	495	506	year of age	T079	C1510829
27262362	524	549	univentricular physiology	T019,T047	C2959602
27262362	555	564	incidence	T081	C0021149
27262362	568	576	children	T100	C0008059
27262362	587	596	prolonged	T079	C0439590
27262362	597	611	intensive care	T058	C0085559
27262362	612	621	increased	T081	C0205217
27262362	647	662	cardiac surgery	T061	C0018821
27262362	730	738	increase	T169	C0442805
27262362	730	738	increase	T169	C0442805
27262362	757	765	increase	T169	C0442805
27262362	773	779	number	T081	C0237753
27262362	783	791	children	T100	C0008059
27262362	797	828	hypoplastic left heart syndrome	T047	C0152101
27262362	836	845	prolonged	T079	C0439590
27262362	846	860	intensive care	T058	C0085559
27262362	877	883	period	T079	C1948053
27262362	949	957	Survival	T033	C1148433
27262362	961	990	pediatric intensive care unit	T073,T093	C0021710
27262362	992	996	PICU	T073,T093	C0021710
27262362	998	1007	discharge	T058	C0030685
27262362	1021	1040	confidence interval	T081	C0009667
27262362	1042	1044	CI	T081	C0009667
27262362	1067	1069	CI	T081	C0009667
27262362	1083	1088	years	T079	C0439234
27262362	1090	1097	Factors	T169	C1521761
27262362	1098	1113	associated with	T080	C0332281
27262362	1114	1123	mortality	T081	C0205848
27262362	1129	1150	univentricular repair	T061	C1961051
27262362	1152	1164	hazard ratio	T081	C2985465
27262362	1166	1168	HR	T081	C2985465
27262362	1181	1183	CI	T081	C0009667
27262362	1210	1229	acute renal failure	T047	C0022660
27262362	1231	1233	HR	T081	C2985465
27262362	1245	1247	CI	T081	C0009667
27262362	1287	1296	influence	T077	C4054723
27262362	1297	1306	mortality	T081	C0205848
27262362	1357	1361	PICU	T073,T093	C0021710
27262362	1362	1371	survivors	T101	C0206194
27262362	1376	1380	year	T079	C0439234
27262362	1381	1389	survival	T033	C1148433
27262362	1416	1421	early	T079	C1279919
27262362	1422	1433	reoperation	T061	C0035110
27262362	1447	1449	CI	T081	C0009667
27262362	1459	1467	compared	T052	C1707455
27262362	1482	1484	CI	T081	C0009667
27262362	1506	1514	required	T169	C1514873
27262362	1515	1520	early	T079	C1279919
27262362	1521	1532	reoperation	T061	C0035110
27262362	1559	1568	survivors	T101	C0206194
27262362	1585	1593	moderate	T033	C0424989
27262362	1597	1614	severe disability	T033	C0424990
27262362	1627	1647	poor quality of life	T033	C3686815
27262362	1653	1662	incidence	T081	C0021149
27262362	1666	1674	children	T100	C0008059
27262362	1685	1694	prolonged	T079	C0439590
27262362	1695	1709	intensive care	T058	C0085559
27262362	1716	1731	cardiac surgery	T061	C0018821
27262362	1736	1744	increase	T169	C0442805
27262362	1754	1765	institution	T093	C2607850
27262362	1771	1775	data	T078	C1511726
27262362	1776	1783	suggest	T078	C1705535
27262362	1793	1802	long-term	T079	C0443252
27262362	1803	1810	outcome	T169	C1274040
27262362	1829	1837	children	T100	C0008059
27262362	1841	1845	poor	T080	C2700379
27262362	1864	1885	univentricular repair	T061	C1961051

27263085|t|Haptic feedback helps bipedal coordination
27263085|a|The present study investigated whether special haptic or visual feedback would facilitate the coordination of in-phase, cyclical feet movements of different amplitudes. Seventeen healthy participants sat with their feet on sliding panels that were moved externally over the same or different amplitudes. The participants were asked to generate simultaneous knee flexion-extension movements, or to let their feet be dragged, resulting in reference foot displacements of 150 mm and experimental foot displacements of 150, 120, or 90 mm. Four types of feedback were given: (1) special haptic feedback, involving actively following the motions of the sliders manipulated by two confederates, (2) haptic feedback resulting from passive motion, (3) veridical visual feedback, and (4) enhanced visual feedback. Both with respect to amplitude assimilation effects, correlations and standard deviation of relative phase, the results showed that enhanced visual feedback did not facilitate bipedal independence, but haptic feedback with active movement did. Implications of the findings for movement rehabilitation contexts are discussed.
27263085	0	6	Haptic	T042	C0871762
27263085	7	15	feedback	T041	C2911691
27263085	22	29	bipedal	T023	C0016504
27263085	30	42	coordination	T039	C0242414
27263085	55	60	study	T062	C2603343
27263085	61	73	investigated	T169	C1292732
27263085	82	89	special	T080	C0205555
27263085	90	96	haptic	T042	C0871762
27263085	100	115	visual feedback	T041	C2936181
27263085	137	149	coordination	T039	C0242414
27263085	153	161	in-phase	T082	C1254362
27263085	163	171	cyclical	T079	C0439596
27263085	172	176	feet	T023	C0016504
27263085	177	186	movements	T040	C0026649
27263085	190	199	different	T080	C1705242
27263085	200	210	amplitudes	T082	C2346753
27263085	222	242	healthy participants	T098	C1708335
27263085	258	262	feet	T023	C0016504
27263085	266	273	sliding	T169	C0332246
27263085	274	280	panels	T073	C1706365
27263085	291	296	moved	T169	C1269909
27263085	297	307	externally	T082	C0205101
27263085	325	334	different	T080	C1705242
27263085	335	345	amplitudes	T082	C2346753
27263085	351	363	participants	T098	C0679646
27263085	378	386	generate	T052	C3146294
27263085	387	399	simultaneous	T079	C0521115
27263085	400	404	knee	T023	C0022742
27263085	405	422	flexion-extension	T082	C0444509
27263085	423	432	movements	T040	C0026649
27263085	450	454	feet	T023	C0016504
27263085	458	465	dragged	T033	C0243095
27263085	467	479	resulting in	T169	C0332294
27263085	480	489	reference	T081	C0034925
27263085	490	494	foot	T023	C0016504
27263085	495	508	displacements	T061	C0441526
27263085	523	535	experimental	T080	C1517586
27263085	536	540	foot	T023	C0016504
27263085	541	554	displacements	T061	C0441526
27263085	592	600	feedback	T041	C2911691
27263085	617	624	special	T080	C0205555
27263085	625	631	haptic	T041	C0870771
27263085	632	640	feedback	T041	C2911691
27263085	642	651	involving	T169	C1314939
27263085	661	670	following	T079	C0332282
27263085	675	682	motions	T169	C0687704
27263085	690	697	sliders	T074	C0025080
27263085	698	709	manipulated	T061	C0947647
27263085	717	729	confederates	T098	C1257890
27263085	735	741	haptic	T041	C0870771
27263085	742	750	feedback	T041	C2911691
27263085	766	780	passive motion	T042	C0079991
27263085	786	795	veridical	T080	C0205556
27263085	796	811	visual feedback	T041	C2936181
27263085	821	829	enhanced	T052	C2349975
27263085	830	845	visual feedback	T041	C2936181
27263085	868	877	amplitude	T082	C2346753
27263085	878	890	assimilation	T041	C1999057
27263085	891	898	effects	T080	C1280500
27263085	900	912	correlations	T080	C1707520
27263085	917	935	standard deviation	T081	C0871420
27263085	939	947	relative	T080	C0205345
27263085	948	953	phase	T079	C0205390
27263085	959	966	results	T034	C0456984
27263085	979	987	enhanced	T052	C2349975
27263085	988	1003	visual feedback	T041	C2936181
27263085	1023	1030	bipedal	T023	C0016504
27263085	1031	1043	independence	T078	C0085862
27263085	1049	1055	haptic	T041	C0870771
27263085	1056	1064	feedback	T041	C2911691
27263085	1070	1085	active movement	T040	C0231481
27263085	1111	1119	findings	T033	C0243095
27263085	1124	1132	movement	T040	C0026649
27263085	1133	1147	rehabilitation	T033	C0007237
27263085	1148	1156	contexts	T078	C0449255

27264279|t|Synthesis and in vitro bone cell activity of analogues of the cyclohexapeptide dianthin G
27264279|a|The cyclohexapeptide natural product dianthin G promotes osteoblast (bone-forming cell) proliferation in vitro at nanomolar concentrations, and is therefore considered a promising candidate for the treatment of osteoporosis. An N(Î±)-methyl amide bond scan of dianthin G was performed to probe the effect of modifying amide bonds on osteoblast proliferation. In addition, to provide greater structural diversity, a series of dicarba dianthin G analogues was synthesised using ring closing metathesis. Dianthin G and one novel dicarba analogue increased the number of human osteoblasts and importantly they did not increase osteoclast (bone-resorbing cell) differentiation in bone marrow cells.
27264279	0	9	Synthesis	T052	C1883254
27264279	14	22	in vitro	T080	C1533691
27264279	23	32	bone cell	T025	C0029432
27264279	33	41	activity	T052	C0441655
27264279	45	54	analogues	T104	C0002776
27264279	62	89	cyclohexapeptide dianthin G	T121	C1254351
27264279	94	137	cyclohexapeptide natural product dianthin G	T121	C1254351
27264279	138	146	promotes	T052	C0033414
27264279	147	191	osteoblast (bone-forming cell) proliferation	T043	C2247140
27264279	192	200	in vitro	T080	C1533691
27264279	204	228	nanomolar concentrations	T081	C0457929
27264279	288	297	treatment	T169	C1522326
27264279	301	313	osteoporosis	T047	C0029456
27264279	318	340	N(Î±)-methyl amide bond	T104	C1254350
27264279	349	359	dianthin G	T121	C1254351
27264279	364	373	performed	T169	C0884358
27264279	377	382	probe	T169	C1292732
27264279	387	393	effect	T080	C1280500
27264279	407	418	amide bonds	T104	C1254350
27264279	422	446	osteoblast proliferation	T043	C2247140
27264279	480	490	structural	T082	C0678594
27264279	491	500	diversity	T080	C1880371
27264279	514	542	dicarba dianthin G analogues	T104	C0002776
27264279	547	558	synthesised	T052	C1883254
27264279	565	588	ring closing metathesis	T067	C0596319
27264279	590	600	Dianthin G	T121	C1254351
27264279	609	614	novel	T080	C0205314
27264279	615	631	dicarba analogue	T104	C0002776
27264279	632	641	increased	T081	C0205217
27264279	656	661	human	T016	C0086418
27264279	662	673	osteoblasts	T025	C0029418
27264279	703	711	increase	T081	C0205217
27264279	712	760	osteoclast (bone-resorbing cell) differentiation	T043	C1159978
27264279	764	781	bone marrow cells	T025	C0005955

27265179|t|Effects of grazing cow diet on volatile compounds as well as physicochemical and sensory characteristics of 12- month - ripened Montasio cheese
27265179|a|The aim of this study was to evaluate the effects of pasture type and cow feeding supplementation level on a 12- mo - ripened Montasio protected designation of origin (PDO) cheese, which is one of the most important PDO cheeses produced in northeast Italy. Cheeses were characterized for volatile compounds, color, mechanical variables, and sensory descriptors. Pasture type significantly affected most of the instrumental variables considered and, as a consequence, sensory properties were affected as well. Cheeses from the pasture characterized by a nutrient-rich vegetation type were higher in protein and lower in fat content. Furthermore, such cheeses, evaluated by a sensory panel, were more intense in color with a more pungent and less cow-like odor, in agreement with what found through instrumental analyses. Supplementation level resulted in less pronounced effects, limited to volatile compounds and texture properties, which were not detected by sensory analysis. The characterization of the 12- mo ripened Montasio cheese reported here is an important step for the valorization of this PDO product.
27265179	0	7	Effects	T080	C1280500
27265179	11	22	grazing cow	T040	C3178952
27265179	23	27	diet	T168	C0012155
27265179	31	49	volatile compounds	T120	C0443769
27265179	61	76	physicochemical	T070	C2350462
27265179	81	88	sensory	T080	C0445254
27265179	89	104	characteristics	T080	C1521970
27265179	112	117	month	T079	C0439231
27265179	120	143	ripened Montasio cheese	T168	C0007968
27265179	160	165	study	T062	C2603343
27265179	173	181	evaluate	T058	C0220825
27265179	186	193	effects	T080	C1280500
27265179	197	204	pasture	T082	C0442534
27265179	214	217	cow	T015	C0007452
27265179	218	225	feeding	T052	C2987508
27265179	226	241	supplementation	T168	C0242295
27265179	257	259	mo	T079	C0439231
27265179	262	278	ripened Montasio	T168	C0007968
27265179	279	310	protected designation of origin	T170	C1519193
27265179	312	315	PDO	T170	C1519193
27265179	317	323	cheese	T168	C0007968
27265179	360	363	PDO	T170	C1519193
27265179	364	371	cheeses	T168	C0007968
27265179	384	399	northeast Italy	T083	C0022277
27265179	401	408	Cheeses	T168	C0007968
27265179	414	427	characterized	T052	C1880022
27265179	432	450	volatile compounds	T120	C0443769
27265179	452	457	color	T080	C0009393
27265179	459	479	mechanical variables	T080	C0439828
27265179	485	492	sensory	T080	C0445254
27265179	493	504	descriptors	T170	C0282354
27265179	506	513	Pasture	T082	C0442534
27265179	519	532	significantly	T078	C0750502
27265179	533	541	affected	T169	C0392760
27265179	554	566	instrumental	T081	C1704339
27265179	567	576	variables	T080	C0439828
27265179	611	618	sensory	T080	C0445254
27265179	635	643	affected	T169	C0392760
27265179	653	660	Cheeses	T168	C0007968
27265179	670	677	pasture	T082	C0442534
27265179	678	691	characterized	T052	C1880022
27265179	697	710	nutrient-rich	T168	C0678695
27265179	711	721	vegetation	T168	C0032099
27265179	742	749	protein	T116,T123	C0033684
27265179	763	766	fat	T109,T168	C0012171
27265179	794	801	cheeses	T168	C0007968
27265179	803	812	evaluated	T058	C0220825
27265179	818	831	sensory panel	T097	C0027363
27265179	843	850	intense	T080	C0522510
27265179	854	859	color	T080	C0009393
27265179	872	879	pungent	T070	C0028884
27265179	889	902	cow-like odor	T070	C0028884
27265179	941	953	instrumental	T081	C1704339
27265179	954	962	analyses	T062	C0936012
27265179	964	979	Supplementation	T168	C0242295
27265179	1014	1021	effects	T080	C1280500
27265179	1034	1052	volatile compounds	T120	C0443769
27265179	1057	1064	texture	T080	C0449582
27265179	1104	1111	sensory	T080	C0445254
27265179	1112	1120	analysis	T062	C0936012
27265179	1126	1142	characterization	T052	C1880022
27265179	1154	1156	mo	T079	C0439231
27265179	1157	1180	ripened Montasio cheese	T168	C0007968
27265179	1224	1236	valorization	T081	C0600618
27265179	1245	1248	PDO	T170	C1519193
27265179	1249	1256	product	T071	C1514468

27265654|t|Conservation education and habitat restoration for the endangered Sagalla caecilian (Boulengerula niedeni) in Sagalla Hill, Kenya
27265654|a|The Sagalla caecilian (Boulengerula niedeni) is an endangered amphibian endemic to Sagalla Hill in the Taita Hills. This burrowing worm -like species prefers soft soil with high moisture and organic matter. The major threats to the Sagalla caecilian are soil erosion caused by steep slopes, bare ground and water siphoning / soil hardening from exotic eucalyptus trees. The purpose of this study was to get a better understanding of the local people's attitude towards this species and how they can contribute to its continued conservation through restoration of its remaining habitat. In this study, it was found that 96% of Sagalla people are aware of the species, its habits and its association with soils high in organic matter. It was also found that 96% of Sagalla people use organic manure from cow dung in their farms. Habitat restoration through planting of indigenous plants was found to be ongoing, especially on compounds of public institutions as well as on private lands. Although drought was found to be a challenge for seedlings development especially on the low elevation sites, destruction by livestock especially during the dry season is also a major threat. In this study, it was recommended that any future habitat restoration initiative should include strong chain-link fencing to protect the seedlings from livestock activity. Recognizing that the preferred habitats for the species are in the valleys, systematic planting of keystone plant species such as fig trees (Ficus) creates the best microhabitats. These are better than general woodlots of indigenous trees.
27265654	0	22	Conservation education	T065	C0013652
27265654	27	34	habitat	T082	C0871648
27265654	35	46	restoration	T169	C0205245
27265654	55	65	endangered	T098	C2717882
27265654	66	83	Sagalla caecilian	T011	C2999417
27265654	85	105	Boulengerula niedeni	T011	C2999417
27265654	110	122	Sagalla Hill	T083	C0022558
27265654	124	129	Kenya	T083	C0022558
27265654	134	151	Sagalla caecilian	T011	C2999417
27265654	153	173	Boulengerula niedeni	T011	C2999417
27265654	181	191	endangered	T098	C2717882
27265654	192	201	amphibian	T011	C0002668
27265654	202	209	endemic	UnknownType	C0681784
27265654	213	225	Sagalla Hill	T083	C0022558
27265654	233	244	Taita Hills	T083	C0022558
27265654	251	265	burrowing worm	T204	C0018893
27265654	272	279	species	T185	C1705920
27265654	288	292	soft	T080	C0205358
27265654	293	297	soil	T167	C0037592
27265654	303	307	high	T080	C0205250
27265654	308	316	moisture	T167	C0868994
27265654	321	335	organic matter	T167	C0439861
27265654	341	346	major	T080	C0205164
27265654	347	354	threats	T078	C0749385
27265654	362	379	Sagalla caecilian	T011	C2999417
27265654	384	396	soil erosion	T070	C1254365
27265654	397	403	caused	T169	C0678227
27265654	407	419	steep slopes	T082	C1254362
27265654	426	432	ground	T083	C0242744
27265654	437	452	water siphoning	T067	C1254366
27265654	455	469	soil hardening	T067	C1254366
27265654	475	498	exotic eucalyptus trees	T002	C0015148
27265654	520	525	study	T062	C2603343
27265654	539	545	better	T080	C0332272
27265654	546	559	understanding	T041	C0162340
27265654	567	572	local	T082	C0205276
27265654	573	581	people's	T098	C0027361
27265654	582	590	attitude	T041	C0004271
27265654	604	611	species	T185	C1705920
27265654	629	639	contribute	T052	C1880177
27265654	647	656	continued	T078	C0549178
27265654	657	669	conservation	T080	C2347858
27265654	678	689	restoration	T169	C0205245
27265654	697	706	remaining	T080	C1527428
27265654	707	714	habitat	T082	C0871648
27265654	724	729	study	T062	C2603343
27265654	738	743	found	T033	C0150312
27265654	756	763	Sagalla	T083	C0022558
27265654	764	770	people	T098	C0027361
27265654	775	780	aware	T041	C0004448
27265654	788	795	species	T185	C1705920
27265654	801	807	habits	T055	C0018464
27265654	833	838	soils	T167	C0037592
27265654	839	843	high	T080	C0205250
27265654	847	861	organic matter	T167	C0439861
27265654	875	880	found	T033	C0150312
27265654	893	900	Sagalla	T083	C0022558
27265654	901	907	people	T098	C0027361
27265654	912	919	organic	T080	C0747055
27265654	920	926	manure	T167	C0024765
27265654	932	935	cow	T015	C0007452
27265654	936	940	dung	T031	C0015733
27265654	950	955	farms	T082	C0557759
27265654	957	964	Habitat	T082	C0871648
27265654	965	976	restoration	T169	C0205245
27265654	985	993	planting	T052	C0441655
27265654	997	1007	indigenous	T082	C0205276
27265654	1008	1014	plants	T002	C0032098
27265654	1019	1024	found	T033	C0150312
27265654	1031	1038	ongoing	T078	C0549178
27265654	1040	1050	especially	T080	C0205555
27265654	1054	1063	compounds	T103	C1706082
27265654	1067	1086	public institutions	T092	C1552744
27265654	1101	1114	private lands	UnknownType	C0681784
27265654	1125	1132	drought	T070	C0013140
27265654	1137	1142	found	T033	C0150312
27265654	1165	1174	seedlings	T002	C0242437
27265654	1175	1186	development	T169	C1527148
27265654	1205	1208	low	T080	C0205251
27265654	1209	1218	elevation	T082	C0702240
27265654	1219	1224	sites	T082	C0205145
27265654	1226	1237	destruction	T052	C1948029
27265654	1241	1250	livestock	T008	C2936506
27265654	1262	1268	during	T079	C0347984
27265654	1273	1276	dry	T080	C0205222
27265654	1277	1283	season	T079	C0036497
27265654	1294	1299	major	T080	C0205164
27265654	1300	1306	threat	T078	C0749385
27265654	1316	1321	study	T062	C2603343
27265654	1330	1341	recommended	T078	C0034866
27265654	1351	1357	future	T079	C0016884
27265654	1358	1365	habitat	T082	C0871648
27265654	1366	1377	restoration	T169	C0205245
27265654	1378	1388	initiative	T041	C0424093
27265654	1396	1403	include	T169	C0332257
27265654	1404	1410	strong	T080	C0442821
27265654	1411	1421	chain-link	T073	C3273359
27265654	1422	1429	fencing	T052	C0441655
27265654	1445	1454	seedlings	T002	C0242437
27265654	1460	1469	livestock	T008	C2936506
27265654	1470	1478	activity	T052	C0441655
27265654	1501	1510	preferred	T078	C0558295
27265654	1511	1519	habitats	T082	C0871648
27265654	1528	1535	species	T185	C1705920
27265654	1547	1554	valleys	T082	C0563004
27265654	1556	1566	systematic	T169	C0220922
27265654	1567	1575	planting	T052	C0441655
27265654	1579	1593	keystone plant	T002	C0032098
27265654	1594	1601	species	T185	C1705920
27265654	1610	1619	fig trees	T002	C0969754
27265654	1621	1626	Ficus	T002	C0969754
27265654	1628	1635	creates	T052	C1706214
27265654	1645	1658	microhabitats	T082	C0871648
27265654	1670	1676	better	T080	C0332272
27265654	1682	1689	general	T082	C0205246
27265654	1690	1698	woodlots	T082	C1254362
27265654	1702	1712	indigenous	T082	C0205276
27265654	1713	1718	trees	T002	C0040811

27266283|t|The sensitivity and specifity of DR-70 immunoassay as a tumor marker for non-small cell lung cancer
27266283|a|Lung cancer is the most important causes of the cancer related mortality. Patients with lung cancer are usually diagnosed at advanced or locally advanced stage, for this reason early diagnosis of lung cancer is very important. For early detection of lung cancer some methods are emphasized such as low-dose computed tomography or tumor biomarkers. In this study we aimed to evaluate DR-70 sensitivity and specificity as a tumor marker in detection of non-small cell lung cancers. Between May 2013 and April 2014, the serum samples from 88 non lung cancer patients, 86 patients with chronic obstructive pulmonary disesase were obtained. Blood samples from each participant were analyzed for DR-70 level. Totally 174 patients were enrolled to the study (152 male, 22 female). Histopathologically 47(53.4%) patients were diagnosed with squamous cell lung cancer, 34 (38.6%) with adenocarcinoma, and 7 (8%) with non-small cell lung cancer. The mean serum DR-70 levels in lung cancer patients (2.43 Â± 1.82 Âµg/mL) was significantly higher compared to the 86 non-cancerous subjects (1.15 Â± 0.70 Âµg/mL) (p< 0.01). DR-70 exhibited clinical sensitivity and specificity of 54.5 and 83.7%, respectively, at an optimal cut off at 1.98 Âµg/mL. It could be said that the risk of the presence of the disease is 6.171 times higher in the cases where DR-70 level is 1.98 Âµg/mL and higher. DR-70, a marker used to measure fibrin degradation products, generated by all major cancers, may helps to find high risk lung cancer patients.
27266283	4	29	sensitivity and specifity	T081	C0036668
27266283	33	38	DR-70	T123	C0041365
27266283	39	50	immunoassay	T059	C0020980
27266283	56	68	tumor marker	T123	C0041365
27266283	73	99	non-small cell lung cancer	T191	C0007131
27266283	100	111	Lung cancer	T191	C0242379
27266283	148	172	cancer related mortality	T081	C1516192
27266283	174	182	Patients	T101	C0030705
27266283	188	199	lung cancer	T191	C0242379
27266283	212	221	diagnosed	T060	C0430022
27266283	225	233	advanced	T029	C0005898
27266283	237	259	locally advanced stage	T029	C0005898
27266283	277	292	early diagnosis	T060	C0596473
27266283	296	307	lung cancer	T191	C0242379
27266283	331	346	early detection	T060	C0596473
27266283	350	361	lung cancer	T191	C0242379
27266283	398	426	low-dose computed tomography	T060	C0040405
27266283	430	446	tumor biomarkers	T123	C0041366
27266283	474	482	evaluate	T058	C0220825
27266283	483	488	DR-70	T123	C0041365
27266283	489	516	sensitivity and specificity	T081	C0036668
27266283	522	534	tumor marker	T123	C0041365
27266283	538	547	detection	T061	C1511790
27266283	551	578	non-small cell lung cancers	T191	C0007131
27266283	588	591	May	T079	C3812381
27266283	601	606	April	T079	C3715024
27266283	617	630	serum samples	T031	C1550100
27266283	639	654	non lung cancer	T191	C0006826
27266283	655	663	patients	T101	C0030705
27266283	668	676	patients	T101	C0030705
27266283	682	720	chronic obstructive pulmonary disesase	T047	C0024117
27266283	736	749	Blood samples	T031	C0178913
27266283	760	771	participant	T098	C0679646
27266283	777	785	analyzed	T062	C0936012
27266283	790	795	DR-70	T123	C0041365
27266283	796	801	level	T080	C0441889
27266283	815	823	patients	T101	C0030705
27266283	845	850	study	T062	C2603343
27266283	856	860	male	T098	C0025266
27266283	865	871	female	T098	C0043210
27266283	874	893	Histopathologically	T169	C0243140
27266283	904	912	patients	T101	C0030705
27266283	918	927	diagnosed	T060	C0430022
27266283	933	958	squamous cell lung cancer	T191	C0149782
27266283	976	990	adenocarcinoma	T191	C0001418
27266283	1008	1034	non-small cell lung cancer	T191	C0007131
27266283	1040	1056	mean serum DR-70	T123	C0041365
27266283	1057	1063	levels	T080	C0441889
27266283	1067	1078	lung cancer	T191	C0242379
27266283	1079	1087	patients	T101	C0030705
27266283	1112	1132	significantly higher	T033	C0243095
27266283	1133	1141	compared	T052	C1707455
27266283	1152	1165	non-cancerous	T033	C0243095
27266283	1166	1174	subjects	T098	C2349001
27266283	1206	1211	DR-70	T123	C0041365
27266283	1222	1230	clinical	T080	C0205210
27266283	1231	1258	sensitivity and specificity	T081	C0036668
27266283	1298	1305	optimal	T080	C2698651
27266283	1306	1313	cut off	T169	C1442160
27266283	1383	1390	disease	T047	C0012634
27266283	1432	1437	DR-70	T123	C0041365
27266283	1438	1443	level	T080	C0441889
27266283	1470	1475	DR-70	T123	C0041365
27266283	1479	1485	marker	T123	C0041365
27266283	1494	1501	measure	T081	C0079809
27266283	1502	1529	fibrin degradation products	T116,T123	C0163275
27266283	1554	1561	cancers	T191	C0006826
27266283	1581	1590	high risk	T033	C0332167
27266283	1591	1602	lung cancer	T191	C0242379
27266283	1603	1611	patients	T101	C0030705

27266322|t|The biological effect of metal ions on the granulation of aerobic granular activated sludge
27266322|a|As a special biofilm structure, microbial attachment is believed to play an important role in the granulation of aerobic granular activated sludge (AGAS). This experiment was to investigate the biological effect of Ca(2+), Mg(2+), Cu(2+), Fe(2+), Zn(2+), and K(+) which are the most common ions present in biological wastewater treatment systems, on the microbial attachment of AGAS and flocculent activated sludge (FAS), from which AGAS is always derived, in order to provide a new strategy for the rapid cultivation and stability control of AGAS. The result showed that attachment biomass of AGAS was about 300% higher than that of FAS without the addition of metal ions. Different metal ions had different effects on the process of microbial attachment. FAS and AGAS reacted differently to the metal ions as well, and in fact, AGAS was more sensitive to the metal ions. Specifically, Ca(2+), Mg(2+), and K(+) could increase the microbial attachment ability of both AGAS and FAS under appropriate concentrations, Cu(2+), Fe(2+), and Zn(2+) were also beneficial to the microbial attachment of FAS at low concentrations, but Cu(2+), Fe(2+), and Zn(2+) greatly inhibited the attachment process of AGAS even at extremely low concentrations. In addition, the acylated homoserine lactone (AHL)-based quorum sensing system, the content of extracellular polymeric substances and the relative hydrophobicity of the sludges were greatly influenced by metal ions. As all these parameters had close relationships with the microbial attachment process, the microbial attachment may be affected by changes of these parameters.
27266322	4	14	biological	T080	C0205460
27266322	15	21	effect	T080	C1280500
27266322	25	30	metal	T197	C0025552
27266322	31	35	ions	T196	C0022023
27266322	43	54	granulation	T059	C4281706
27266322	58	65	aerobic	T080	C1510824
27266322	66	74	granular	T080	C0205248
27266322	75	84	activated	T052	C1879547
27266322	85	91	sludge	T069	C0282346
27266322	105	112	biofilm	T007	C0081786
27266322	124	133	microbial	T001	C0599840
27266322	134	144	attachment	T052	C1947904
27266322	190	201	granulation	T059	C4281706
27266322	213	221	granular	T080	C0205248
27266322	222	231	activated	T052	C1879547
27266322	232	238	sludge	T069	C0282346
27266322	240	244	AGAS	T069	C0282346
27266322	270	281	investigate	T169	C1292732
27266322	286	296	biological	T080	C0205460
27266322	297	303	effect	T080	C1280500
27266322	307	314	Ca(2+),	T121,T196	C0596235
27266322	315	321	Mg(2+)	T121,T196	C2346927
27266322	323	329	Cu(2+)	T121,T197	C1177210
27266322	331	337	Fe(2+)	T196	C2346592
27266322	339	345	Zn(2+)	T121,T196	C2346521
27266322	351	355	K(+)	T121,T196	C0597277
27266322	382	386	ions	T196	C0022023
27266322	398	408	biological	T080	C0205460
27266322	409	419	wastewater	T069	C3494254
27266322	420	429	treatment	T057	C0597684
27266322	446	455	microbial	T001	C0599840
27266322	456	466	attachment	T052	C1947904
27266322	470	474	AGAS	T069	C0282346
27266322	479	489	flocculent	T043	C0016243
27266322	490	499	activated	T052	C1879547
27266322	500	506	sludge	T069	C0282346
27266322	508	511	FAS	T069	C0282346
27266322	525	529	AGAS	T069	C0282346
27266322	592	597	rapid	T080	C0456962
27266322	598	609	cultivation	T169	C0220814
27266322	614	623	stability	T080	C0205360
27266322	624	631	control	T080	C0243148
27266322	635	639	AGAS	T069	C0282346
27266322	664	674	attachment	T052	C1947904
27266322	675	682	biomass	T081	C0005535
27266322	686	690	AGAS	T069	C0282346
27266322	726	729	FAS	T069	C0282346
27266322	754	759	metal	T197	C0025552
27266322	760	764	ions	T196	C0022023
27266322	776	781	metal	T197	C0025552
27266322	782	786	ions	T196	C0022023
27266322	801	808	effects	T080	C1280500
27266322	816	823	process	T067	C1522240
27266322	827	836	microbial	T001	C0599840
27266322	837	847	attachment	T052	C1947904
27266322	849	852	FAS	T069	C0282346
27266322	857	861	AGAS	T069	C0282346
27266322	889	894	metal	T197	C0025552
27266322	895	899	ions	T196	C0022023
27266322	922	926	AGAS	T069	C0282346
27266322	936	945	sensitive	T169	C0332324
27266322	953	958	metal	T197	C0025552
27266322	959	963	ions	T196	C0022023
27266322	979	985	Ca(2+)	T121,T196	C0596235
27266322	987	993	Mg(2+)	T121,T196	C2346927
27266322	999	1003	K(+)	T121,T196	C0597277
27266322	1023	1032	microbial	T001	C0599840
27266322	1033	1043	attachment	T052	C1947904
27266322	1060	1064	AGAS	T069	C0282346
27266322	1069	1072	FAS	T069	C0282346
27266322	1079	1090	appropriate	T080	C1548787
27266322	1091	1105	concentrations	T081	C1446561
27266322	1107	1113	Cu(2+)	T121,T197	C1177210
27266322	1115	1121	Fe(2+)	T196	C2346592
27266322	1127	1133	Zn(2+)	T121,T196	C2346521
27266322	1162	1171	microbial	T001	C0599840
27266322	1172	1182	attachment	T052	C1947904
27266322	1186	1189	FAS	T069	C0282346
27266322	1193	1196	low	T080	C0205251
27266322	1197	1211	concentrations	T081	C1446561
27266322	1217	1223	Cu(2+)	T121,T197	C1177210
27266322	1225	1231	Fe(2+)	T196	C2346592
27266322	1237	1243	Zn(2+)	T121,T196	C2346521
27266322	1266	1284	attachment process	T052	C1947904
27266322	1288	1292	AGAS	T069	C0282346
27266322	1301	1310	extremely	T080	C0205403
27266322	1311	1314	low	T080	C0205251
27266322	1315	1329	concentrations	T081	C1446561
27266322	1348	1375	acylated homoserine lactone	T109	C1313745
27266322	1377	1380	AHL	T109	C1313745
27266322	1388	1409	quorum sensing system	T043	C1154599
27266322	1426	1439	extracellular	T026	C0521119
27266322	1440	1460	polymeric substances	T104,T122	C0032521
27266322	1478	1492	hydrophobicity	T080	C0598629
27266322	1500	1507	sludges	T069	C0282346
27266322	1535	1540	metal	T197	C0025552
27266322	1541	1545	ions	T196	C0022023
27266322	1560	1570	parameters	T077	C0549193
27266322	1604	1613	microbial	T001	C0599840
27266322	1614	1632	attachment process	T052	C1947904
27266322	1638	1647	microbial	T001	C0599840
27266322	1648	1658	attachment	T052	C1947904
27266322	1678	1685	changes	T169	C0392747
27266322	1695	1705	parameters	T077	C0549193

27266753|t|The clinical and economic burden of significant bleeding during lung resection surgery: A retrospective matched cohort analysis of real - world data
27266753|a|The objective of this retrospective study was to quantify the clinical and economic burden of significant bleeding in lung resection surgery in the US. This study utilized 2009-2012 data from the Premier Perspective Database(TM). Adult patients with primary pulmonary lobectomy or segmentectomy procedures were categorized by the surgical approach (VATS vs open) and primary diagnosis (primary or metastatic lung cancer vs non-lung cancer). Patients requiring â¥3 units of blood products with at least 1 unit of PRBCs: " significant bleeding " cohort; those requiring <3 units: " non-significant bleeding " cohort; and those not requiring blood products: " no bleeding " cohort. A matched cohort analysis was performed between the " significant bleeding " and the " no bleeding cohort " using matching variables: hospital, lung cancer diagnosis, year of surgery, APR-DRG severity score, procedure type and approach, age, and gender. The " All - patient " cohort comprised 21,429 patients: 213 " significant bleeding "; 2,780 " non-significant bleeding "; and 18,436 " no bleeding ". Overall incidence of significant chest bleeding was 0.99%. Patients from " significant bleeding " cohort and " non-significant bleeding " cohort had 2.5 days and 2 days (p < 0.0001) longer length of stay in the hospital compared to those in the " no bleeding " cohort, respectively. Overall, hospital costs for " significant bleeding " cohort were higher than " no bleeding " cohort for those who were covered under Medicare ($59,871 vs $23,641), were â¥76 years of age ($64,010 vs $24,243), had greater severity of illness ($97,813 vs $51,871) and underwent open segmentectomy ($74,220 vs $21,903). Hospital costs for " significant bleeding " cohort and " non-significant bleeding " were significantly higher ($11,589 and $5,280, respectively, p < 0.0001) than no bleeding cohort. Although significant bleeding during lung resection surgery is rare, patients with such complication could stay longer at the hospital and cost an average of $13,103 more than those without.
27266753	4	12	clinical	T080	C0205210
27266753	17	25	economic	T169	C0013557
27266753	26	32	burden	T078	C2828008
27266753	36	47	significant	T078	C0750502
27266753	48	56	bleeding	T046	C0019080
27266753	57	63	during	T079	C0347984
27266753	64	86	lung resection surgery	T061	C0396565
27266753	90	127	retrospective matched cohort analysis	T062	C2985505
27266753	131	135	real	T080	C0205238
27266753	138	143	world	T098	C2700280
27266753	144	148	data	T078	C1511726
27266753	153	162	objective	T080	C1571702
27266753	171	190	retrospective study	T062	C0035363
27266753	198	206	quantify	T081	C1709793
27266753	211	219	clinical	T080	C0205210
27266753	224	232	economic	T169	C0013557
27266753	233	239	burden	T078	C2828008
27266753	243	254	significant	T078	C0750502
27266753	255	263	bleeding	T046	C0019080
27266753	267	289	lung resection surgery	T061	C0396565
27266753	297	299	US	T083	C0041703
27266753	306	311	study	T062	C2603343
27266753	312	320	utilized	T169	C1524063
27266753	331	335	data	T078	C1511726
27266753	345	377	Premier Perspective Database(TM)	T170	C0242356
27266753	379	384	Adult	T100	C0001675
27266753	385	393	patients	T101	C0030705
27266753	399	426	primary pulmonary lobectomy	T061	C0189497
27266753	430	454	segmentectomy procedures	T061	C0189488
27266753	460	471	categorized	T052	C0871968
27266753	479	496	surgical approach	T169	C0449446
27266753	498	502	VATS	T061	C0752151
27266753	506	510	open	T061	C4283938
27266753	516	533	primary diagnosis	T080	C0332137
27266753	535	542	primary	T060	C0920688
27266753	546	568	metastatic lung cancer	T060	C0920688
27266753	572	587	non-lung cancer	T060	C0430022
27266753	590	598	Patients	T101	C0030705
27266753	612	617	units	T081	C0439148
27266753	621	635	blood products	T121	C0456388
27266753	641	649	at least	T080	C1524031
27266753	652	656	unit	T081	C0439148
27266753	660	665	PRBCs	T116,T121	C2316467
27266753	669	680	significant	T078	C0750502
27266753	681	689	bleeding	T046	C0019080
27266753	692	698	cohort	T098	C0599755
27266753	719	724	units	T081	C0439148
27266753	728	743	non-significant	T033	C1273937
27266753	744	752	bleeding	T046	C0019080
27266753	755	761	cohort	T098	C0599755
27266753	787	801	blood products	T121	C0456388
27266753	805	807	no	T169	C1518422
27266753	808	816	bleeding	T046	C0019080
27266753	819	825	cohort	T098	C0599755
27266753	837	852	cohort analysis	T062	C0086027
27266753	857	866	performed	T169	C0884358
27266753	881	892	significant	T078	C0750502
27266753	893	901	bleeding	T046	C0019080
27266753	914	916	no	T169	C1518422
27266753	917	925	bleeding	T046	C0019080
27266753	926	932	cohort	T098	C0599755
27266753	941	959	matching variables	UnknownType	C0815175
27266753	961	969	hospital	T073,T093	C0019994
27266753	971	992	lung cancer diagnosis	T060	C0920688
27266753	994	1009	year of surgery	T079	C0439234
27266753	1011	1033	APR-DRG severity score	T081	C0457451
27266753	1035	1049	procedure type	T201	C0944777
27266753	1054	1062	approach	T169	C0449446
27266753	1064	1067	age	T032	C0001779
27266753	1073	1079	gender	T032	C0079399
27266753	1087	1090	All	T081	C0444868
27266753	1093	1100	patient	T101	C0030705
27266753	1103	1109	cohort	T098	C0599755
27266753	1127	1135	patients	T101	C0030705
27266753	1143	1154	significant	T078	C0750502
27266753	1155	1163	bleeding	T046	C0019080
27266753	1175	1190	non-significant	T033	C1273937
27266753	1191	1199	bleeding	T046	C0019080
27266753	1216	1218	no	T169	C1518422
27266753	1219	1227	bleeding	T046	C0019080
27266753	1231	1238	Overall	T080	C1561607
27266753	1239	1248	incidence	T081	C0021149
27266753	1252	1263	significant	T078	C0750502
27266753	1264	1269	chest	T029	C0817096
27266753	1270	1278	bleeding	T046	C0019080
27266753	1290	1298	Patients	T101	C0030705
27266753	1306	1317	significant	T078	C0750502
27266753	1318	1326	bleeding	T046	C0019080
27266753	1329	1335	cohort	T098	C0599755
27266753	1342	1357	non-significant	T033	C1273937
27266753	1358	1366	bleeding	T046	C0019080
27266753	1369	1375	cohort	T098	C0599755
27266753	1384	1388	days	T079	C0439228
27266753	1395	1399	days	T079	C0439228
27266753	1413	1419	longer	T080	C0205166
27266753	1420	1434	length of stay	T079	C0023303
27266753	1442	1450	hospital	T073,T093	C0019994
27266753	1451	1459	compared	T052	C1707455
27266753	1478	1480	no	T169	C1518422
27266753	1481	1489	bleeding	T046	C0019080
27266753	1492	1498	cohort	T098	C0599755
27266753	1514	1521	Overall	T080	C1561607
27266753	1523	1537	hospital costs	T081	C0206174
27266753	1544	1555	significant	T078	C0750502
27266753	1556	1564	bleeding	T046	C0019080
27266753	1567	1573	cohort	T098	C0599755
27266753	1579	1585	higher	T080	C0205250
27266753	1593	1595	no	T169	C1518422
27266753	1596	1604	bleeding	T046	C0019080
27266753	1607	1613	cohort	T098	C0599755
27266753	1633	1640	covered	T169	C0439844
27266753	1647	1655	Medicare	T064	C0018717
27266753	1687	1699	years of age	T079	C1510829
27266753	1726	1733	greater	T081	C1704243
27266753	1734	1753	severity of illness	T080	C0521117
27266753	1794	1807	segmentectomy	T061	C2987624
27266753	1830	1844	Hospital costs	T081	C0206174
27266753	1851	1862	significant	T078	C0750502
27266753	1863	1871	bleeding	T046	C0019080
27266753	1874	1880	cohort	T098	C0599755
27266753	1887	1902	non-significant	T033	C1273937
27266753	1903	1911	bleeding	T046	C0019080
27266753	1919	1932	significantly	T078	C0750502
27266753	1933	1939	higher	T080	C0205250
27266753	1992	1994	no	T169	C1518422
27266753	1995	2003	bleeding	T046	C0019080
27266753	2004	2010	cohort	T098	C0599755
27266753	2021	2032	significant	T078	C0750502
27266753	2033	2041	bleeding	T046	C0019080
27266753	2042	2048	during	T079	C0347984
27266753	2049	2071	lung resection surgery	T061	C0396565
27266753	2075	2079	rare	T080	C0522498
27266753	2081	2089	patients	T101	C0030705
27266753	2100	2112	complication	T046	C0009566
27266753	2119	2123	stay	T079	C3489408
27266753	2124	2130	longer	T080	C0205166
27266753	2138	2146	hospital	T073,T093	C0019994
27266753	2151	2155	cost	T081	C0206174

27266840|t|Laceration of a branch of the profunda femoris artery caused by a spike of the displaced lesser trochanter in an inter-trochanteric femoral fracture. A case report
27266840|a|Injury of femoral vessels is an extremely rare complication in intertrochanteric femoral fractures. In most cases reported, the vascular lesion involves the superficial femoral artery, whereas in very few cases does it involve the profunda femoris artery. We report a case of acute bleeding due to laceration of a perforating branch of the profunda femoris artery caused by a sharp fragment of the displaced lesser trochanter in an intertrochanteric femoral fracture; the lesion was treated by transcatheter embolization. The arterial injury may be iatrogenic, occurring during intramedullary internal fixation, or less frequently, the injury may be due to the fracture itself, caused by a sharp bone fragment that damages the profunda femoris artery or one of its perforating branches. We believe that intertrochanteric femoral fractures with avulsed lesser trochanter are at risk for femoral vessel injuries caused by the displaced bone spike, and we advise meticulous clinical and laboratory monitoring pre- and post-operatively to prevent serious complications.
27266840	0	10	Laceration	T037	C0043246
27266840	16	25	branch of	T082	C1253959
27266840	30	53	profunda femoris artery	T023	C0226455
27266840	54	60	caused	T169	C0678227
27266840	66	71	spike	T033	C0243095
27266840	79	88	displaced	T082	C0012727
27266840	89	106	lesser trochanter	T023	C0223866
27266840	113	131	inter-trochanteric	T030	C0229984
27266840	132	148	femoral fracture	T037	C0015802
27266840	152	163	case report	T170	C0007320
27266840	164	170	Injury	T037	C3263722
27266840	174	189	femoral vessels	T023	C1116455
27266840	196	205	extremely	T080	C0205403
27266840	206	210	rare	T080	C0522498
27266840	211	223	complication	T046	C0009566
27266840	227	244	intertrochanteric	T030	C0229984
27266840	245	262	femoral fractures	T037	C0015802
27266840	272	277	cases	T169	C0220856
27266840	278	286	reported	T058	C0700287
27266840	292	307	vascular lesion	T047	C1402315
27266840	308	316	involves	T169	C1314939
27266840	321	347	superficial femoral artery	T023	C0447106
27266840	369	374	cases	T169	C0220856
27266840	383	390	involve	T169	C1314939
27266840	395	418	profunda femoris artery	T023	C0226455
27266840	423	429	report	T170	C0684224
27266840	432	436	case	T169	C0220856
27266840	440	454	acute bleeding	T046	C0333276
27266840	462	472	laceration	T037	C0043246
27266840	478	489	perforating	T033	C0549099
27266840	490	499	branch of	T082	C1253959
27266840	504	527	profunda femoris artery	T023	C0226455
27266840	528	534	caused	T169	C0678227
27266840	540	545	sharp	T033	C1444775
27266840	546	557	fragment of	T169	C0332255
27266840	562	571	displaced	T082	C0012727
27266840	572	589	lesser trochanter	T023	C0223866
27266840	596	613	intertrochanteric	T030	C0229984
27266840	614	630	femoral fracture	T037	C0015802
27266840	636	642	lesion	T033	C0221198
27266840	647	654	treated	T169	C1522326
27266840	658	684	transcatheter embolization	T061	C0203006
27266840	690	705	arterial injury	T037	C0340652
27266840	713	723	iatrogenic	T080	C0439669
27266840	725	734	occurring	T052	C1709305
27266840	742	756	intramedullary	T082	C2732619
27266840	757	774	internal fixation	T061	C0016642
27266840	784	794	frequently	T079	C0332183
27266840	800	806	injury	T037	C3263722
27266840	825	833	fracture	T037	C0016658
27266840	842	848	caused	T169	C0678227
27266840	854	859	sharp	T033	C1444775
27266840	860	873	bone fragment	T037	C3698366
27266840	879	886	damages	T169	C1883709
27266840	891	914	profunda femoris artery	T023	C0226455
27266840	929	940	perforating	T033	C0549099
27266840	941	949	branches	T082	C1253959
27266840	967	984	intertrochanteric	T030	C0229984
27266840	985	1002	femoral fractures	T037	C0015802
27266840	1008	1015	avulsed	T037	C0262386
27266840	1016	1033	lesser trochanter	T023	C0223866
27266840	1038	1045	at risk	T080	C1444641
27266840	1050	1064	femoral vessel	T023	C1116455
27266840	1065	1073	injuries	T037	C3263722
27266840	1074	1080	caused	T169	C0678227
27266840	1088	1097	displaced	T082	C0012727
27266840	1098	1102	bone	T023	C0262950
27266840	1103	1108	spike	T033	C0243095
27266840	1124	1134	meticulous	T080	C0205556
27266840	1135	1143	clinical	T080	C0205210
27266840	1148	1169	laboratory monitoring	T058	C3165364
27266840	1170	1174	pre-	T079	C0445204
27266840	1179	1195	post-operatively	T079	C0032790
27266840	1199	1228	prevent serious complications	T061	C0547286

27266878|t|Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China
27266878|a|China is actively promoting regulation of rare diseases, rare disease and orphan drugs have been formally incorporated into the national planning. However, few studies have been done to evaluate the affordability of rare disease patients in China. This study aims to provide policy recommendations for the establishment of social security mechanism for rare diseases in China, so as to address the problem of poverty caused by these diseases. A total of 7 rare diseases were selected by Delphi method. Affordability of treatment for the 7 rare diseases was assessed through annual per capital income, catastrophic expenditure and impoverishment expenditure among urban and rural residents in China. Assessed through annual per capital income, health expenditure for the 7 rare diseases are all rather high. The highest health expenditure is equivalent to income of 69.34 years of one urban resident, and the burden is heavier for rural residents. Through catastrophic expenditure assessment, proportions of the population experiencing catastrophic expenditure caused by the 7 rare diseases are all under 0.167 â°. However, once one is ill and taking medications, he will suffer from catastrophic health expenditure. Through impoverishment expenditure assessment, the proportions of impoverishment payment are low among both urban and rural residents, but the 7 rare diseases could lead nearly 4.6 million people into poverty on a national scale. The affordability of treatment for rare disease as well as orphan drugs is rather poor. Residents of different income levels all have difficulties to afford the treatment for rare diseases, so poverty caused by rare diseases is quite widespread. Therefore, social security mechanism for rare disease patients should be established and specific payment pattern for orphan drugs should be set up.
27266878	0	24	Catastrophic expenditure	T081	C0015318
27266878	29	43	impoverishment	T081	C0392762
27266878	47	55	patients	T101	C0030705
27266878	70	83	rare diseases	T047	C0678236
27266878	87	92	China	T083	C0008115
27266878	93	98	China	T083	C0008115
27266878	111	120	promoting	T052	C0033414
27266878	135	148	rare diseases	T047	C0678236
27266878	150	162	rare disease	T047	C0678236
27266878	167	179	orphan drugs	T121	C0013232
27266878	221	238	national planning	UnknownType	C0679910
27266878	253	260	studies	T062	C2603343
27266878	292	305	affordability	T081	C0814630
27266878	309	321	rare disease	T047	C0678236
27266878	322	330	patients	T101	C0030705
27266878	334	339	China	T083	C0008115
27266878	368	374	policy	T170	C0242456
27266878	375	390	recommendations	T078	C0034866
27266878	399	412	establishment	T080	C0443211
27266878	416	441	social security mechanism	T170	C0282574
27266878	446	459	rare diseases	T047	C0678236
27266878	463	468	China	T083	C0008115
27266878	502	509	poverty	T102	C0032854
27266878	526	534	diseases	T047	C0012634
27266878	549	562	rare diseases	T047	C0678236
27266878	580	593	Delphi method	T062	C0011216
27266878	595	608	Affordability	T081	C0814630
27266878	612	621	treatment	T061	C0087111
27266878	632	645	rare diseases	T047	C0678236
27266878	650	658	assessed	T052	C1516048
27266878	667	692	annual per capital income	T081	C0021162
27266878	694	718	catastrophic expenditure	T081	C0015318
27266878	723	737	impoverishment	T081	C0392762
27266878	738	749	expenditure	T081	C0015316
27266878	756	761	urban	T098	C1257890
27266878	766	781	rural residents	T098	C1257890
27266878	785	790	China	T083	C0008115
27266878	792	800	Assessed	T052	C1516048
27266878	809	834	annual per capital income	T081	C0021162
27266878	836	854	health expenditure	T081	C0015318
27266878	865	878	rare diseases	T047	C0678236
27266878	912	930	health expenditure	T081	C0015318
27266878	948	954	income	T081	C0021162
27266878	964	969	years	T079	C0439234
27266878	977	991	urban resident	T098	C1257890
27266878	1023	1038	rural residents	T098	C1257890
27266878	1048	1072	catastrophic expenditure	T081	C0015318
27266878	1073	1083	assessment	T052	C1516048
27266878	1085	1096	proportions	T081	C1709707
27266878	1104	1114	population	T098	C1257890
27266878	1128	1152	catastrophic expenditure	T081	C0015318
27266878	1169	1182	rare diseases	T047	C0678236
27266878	1227	1230	ill	T184	C0221423
27266878	1242	1253	medications	T170	C4284232
27266878	1275	1306	catastrophic health expenditure	T081	C0015318
27266878	1316	1330	impoverishment	T081	C0392762
27266878	1331	1342	expenditure	T081	C0015316
27266878	1343	1353	assessment	T052	C1516048
27266878	1359	1370	proportions	T081	C1709707
27266878	1374	1388	impoverishment	T081	C0392762
27266878	1389	1396	payment	T081	C0680264
27266878	1416	1421	urban	T098	C1257890
27266878	1426	1441	rural residents	T098	C1257890
27266878	1453	1466	rare diseases	T047	C0678236
27266878	1497	1503	people	T098	C1257890
27266878	1509	1516	poverty	T102	C0032854
27266878	1542	1555	affordability	T081	C0814630
27266878	1559	1568	treatment	T061	C0087111
27266878	1573	1585	rare disease	T047	C0678236
27266878	1597	1609	orphan drugs	T121	C0013232
27266878	1620	1624	poor	T080	C0542537
27266878	1626	1635	Residents	T098	C2347958
27266878	1649	1662	income levels	T080	C0870689
27266878	1699	1708	treatment	T061	C0087111
27266878	1713	1726	rare diseases	T047	C0678236
27266878	1731	1738	poverty	T102	C0032854
27266878	1749	1762	rare diseases	T047	C0678236
27266878	1772	1782	widespread	T082	C0205391
27266878	1795	1820	social security mechanism	T170	C0282574
27266878	1825	1837	rare disease	T047	C0678236
27266878	1838	1846	patients	T101	C0030705
27266878	1882	1889	payment	T081	C0680264
27266878	1902	1914	orphan drugs	T121	C0013232

27267054|t|Rh(III) - Catalyzed Oxidative Annulation Leading to Substituted Indolizines by Cleavage of C(sp(2))-H/C(sp(3))-H Bonds
27267054|a|Rhodium(III) - catalyzed oxidative annulation reactions of pyridinium trifluoromethanesulfonate salts with alkynes leading to substituted indolizines by cleavage of C(sp(2))-H/C(sp(3))-H bonds are developed. The starting materials are readily available, and the reactions have a broad substrate scope. This reaction overcomes some drawbacks of the previous indolizine synthetic methods and provides a new efficient route to indolizine derivatives.
27267054	0	7	Rh(III)	T104	C0303636
27267054	10	19	Catalyzed	T070	C0007382
27267054	20	40	Oxidative Annulation	T067	C0596319
27267054	52	75	Substituted Indolizines	T109	C0021243
27267054	79	87	Cleavage	T067	C0596311
27267054	91	118	C(sp(2))-H/C(sp(3))-H Bonds	T070	C0596391
27267054	119	131	Rhodium(III)	T104	C0303636
27267054	134	143	catalyzed	T070	C0007382
27267054	144	174	oxidative annulation reactions	T067	C0596319
27267054	178	220	pyridinium trifluoromethanesulfonate salts	T109	C0034256
27267054	226	233	alkynes	T109	C0002078
27267054	245	268	substituted indolizines	T109	C0021243
27267054	272	280	cleavage	T067	C0596311
27267054	284	311	C(sp(2))-H/C(sp(3))-H bonds	T070	C0596391
27267054	331	349	starting materials	T167	C3891814
27267054	362	371	available	T169	C0470187
27267054	381	390	reactions	T067	C0596319
27267054	398	403	broad	T082	C0332464
27267054	404	413	substrate	T167	C3891814
27267054	414	419	scope	T077	C1710028
27267054	426	434	reaction	T067	C0596319
27267054	435	444	overcomes	T052	C2983310
27267054	450	459	drawbacks	T169	C0449295
27267054	476	486	indolizine	T109	C0021243
27267054	487	504	synthetic methods	T070	C0007987
27267054	524	533	efficient	T080	C0442799
27267054	534	539	route	T082	C0449444
27267054	543	565	indolizine derivatives	T109	C0021243

27267338|t|Pyomyositis in childhood - systemic lupus erythematosus
27267338|a|Pyomyositis is a pyogenic infection of skeletal muscle that arises from hematogenous spread and usually presents with localized abscess. This muscle infection has been rarely reported in adult-onset systemic lupus erythematous and, to the best of our knowledge, has not been diagnosed in pediatric lupus population. Among our childhood-onset systemic lupus erythematous population, including 289 patients, one presented pyomyositis. This patient was diagnosed with childhood-onset systemic lupus erythematous at the age of 10 years-old. After six years, while being treated with prednisone, azathioprine and hydroxychloroquine, she was hospitalized due to a 30-day history of insidious pain in the left thigh and no apparent trauma or fever were reported. Her physical examination showed muscle tenderness and woody induration. Laboratory tests revealed anemia, increased acute phase reactants and normal muscle enzymes. Computer tomography of the left thigh showed collection on the middle third of the vastus intermedius, suggesting purulent stage of pyomyositis. Treatment with broad-spectrum antibiotic was initiated, leading to a complete clinical resolution. In conclusion, we described the first case of pyomyositis during childhood in pediatric lupus population. This report reinforces that the presence of localized muscle pain in immunocompromised patients, even without elevation of muscle enzymes, should raise the suspicion of pyomyositis. A prompt antibiotic therapy is strongly recommended.
27267338	0	11	Pyomyositis	T047	C1704275
27267338	15	24	childhood	T079	C0231335
27267338	27	55	systemic lupus erythematosus	T047	C0024141
27267338	56	67	Pyomyositis	T047	C1704275
27267338	73	91	pyogenic infection	T047	C0858906
27267338	95	110	skeletal muscle	T024	C0242692
27267338	128	147	hematogenous spread	T033	C0796572
27267338	174	183	localized	T082	C0392752
27267338	184	191	abscess	T047	C0000833
27267338	198	214	muscle infection	T047	C1400686
27267338	243	254	adult-onset	T033	C1853562
27267338	255	282	systemic lupus erythematous	T047	C0024141
27267338	318	340	has not been diagnosed	T033	C0686906
27267338	344	353	pediatric	T080	C1521725
27267338	354	370	lupus population	T098	C1257890
27267338	382	397	childhood-onset	T033	C1837352
27267338	398	425	systemic lupus erythematous	T047	C0024141
27267338	426	436	population	T098	C1257890
27267338	452	460	patients	T101	C0030705
27267338	476	487	pyomyositis	T047	C1704275
27267338	494	501	patient	T101	C0030705
27267338	506	515	diagnosed	T033	C0011900
27267338	521	536	childhood-onset	T033	C1837352
27267338	537	564	systemic lupus erythematous	T047	C0024141
27267338	572	575	age	T032	C0001779
27267338	635	645	prednisone	T109,T121,T125	C0032952
27267338	647	659	azathioprine	T109,T121,T131	C0004482
27267338	664	682	hydroxychloroquine	T109,T121	C0020336
27267338	692	704	hospitalized	T033	C0701159
27267338	732	746	insidious pain	UnknownType	C0747146
27267338	754	764	left thigh	T023	C0230426
27267338	781	787	trauma	T037	C3714660
27267338	791	796	fever	T184	C0015967
27267338	816	836	physical examination	T058	C0031809
27267338	844	861	muscle tenderness	T184	C0240419
27267338	866	882	woody induration	T046	C0332534
27267338	884	900	Laboratory tests	T059	C0022885
27267338	910	916	anemia	T047	C0002871
27267338	928	949	acute phase reactants	T116,T123	C0001347
27267338	954	975	normal muscle enzymes	T033	C1141893
27267338	977	1014	Computer tomography of the left thigh	T029	C4284993
27267338	1040	1052	middle third	T082	C0442050
27267338	1060	1078	vastus intermedius	T023	C0224448
27267338	1091	1099	purulent	T080	C0439665
27267338	1100	1105	stage	T079	C0205390
27267338	1109	1120	pyomyositis	T047	C1704275
27267338	1122	1131	Treatment	T061	C0087111
27267338	1137	1162	broad-spectrum antibiotic	T195	C0003232
27267338	1200	1208	clinical	T080	C0205210
27267338	1209	1219	resolution	T077	C2699488
27267338	1267	1278	pyomyositis	T047	C1704275
27267338	1286	1295	childhood	T079	C0231335
27267338	1299	1308	pediatric	T080	C1521725
27267338	1309	1325	lupus population	T098	C1257890
27267338	1332	1338	report	T170	C0085973
27267338	1371	1392	localized muscle pain	T184	C1504509
27267338	1396	1422	immunocompromised patients	T033	C0085393
27267338	1429	1436	without	T080	C0332288
27267338	1437	1446	elevation	T080	C3163633
27267338	1450	1464	muscle enzymes	T059	C1141895
27267338	1483	1492	suspicion	T041	C0242114
27267338	1496	1507	pyomyositis	T047	C1704275
27267338	1518	1536	antibiotic therapy	T061	C0338237

27267388|t|Quantitative fetal fibronectin and cervical length to predict preterm birth in asymptomatic women with previous cervical surgery
27267388|a|Quantitative fetal fibronectin testing has demonstrated accuracy for prediction of spontaneous preterm birth in asymptomatic women with a history of preterm birth. Predictive accuracy in women with previous cervical surgery (a potentially different risk mechanism) is not known. We sought to compare the predictive accuracy of cervicovaginal fluid quantitative fetal fibronectin and cervical length testing in asymptomatic women with previous cervical surgery to that in women with 1 previous preterm birth. We conducted a prospective blinded secondary analysis of a larger observational study of cervicovaginal fluid quantitative fetal fibronectin concentration in asymptomatic women measured with a Hologic 10Q system (Hologic, Marlborough, MA). Prediction of spontaneous preterm birth (<30, <34, and <37 weeks) with cervicovaginal fluid quantitative fetal fibronectin concentration in primiparous women who had undergone at least 1 invasive cervical procedure (n = 473) was compared with prediction in women who had previous spontaneous preterm birth, preterm prelabor rupture of membranes, or late miscarriage (n = 821). Relationship with cervical length was explored. The rate of spontaneous preterm birth <34 weeks in the cervical surgery group was 3% compared with 9% in previous spontaneous preterm birth group. Receiver operating characteristic curves comparing quantitative fetal fibronectin for prediction at all 3 gestational end points were comparable between the cervical surgery and previous spontaneous preterm birth groups (34 weeks: area under the curve, 0.78 [95% confidence interval 0.64-0.93] vs 0.71 [95% confidence interval 0.64-0.78]; P = .39). Prediction of spontaneous preterm birth using cervical length compared with quantitative fetal fibronectin for prediction of preterm birth <34 weeks of gestation offered similar prediction (area under the curve, 0.88 [95% confidence interval 0.79-0.96] vs 0.77 [95% confidence interval 0.62-0.92], P = .12 in the cervical surgery group; and 0.77 [95% confidence interval 0.70-0.84] vs 0.74 [95% confidence interval 0.67-0.81], P = .32 in the previous spontaneous preterm birth group). Prediction of spontaneous preterm birth using cervicovaginal fluid quantitative fetal fibronectin in asymptomatic women with cervical surgery is valid, and has comparative accuracy to that in women with a history of spontaneous preterm birth.
27267388	0	30	Quantitative fetal fibronectin	T059	C3837520
27267388	35	50	cervical length	T060	C1956055
27267388	54	61	predict	T078	C0681842
27267388	62	75	preterm birth	T033	C0151526
27267388	79	91	asymptomatic	T033	C0231221
27267388	92	97	women	T098	C0043210
27267388	112	128	cervical surgery	T061	C2044988
27267388	129	167	Quantitative fetal fibronectin testing	T059	C3837520
27267388	172	184	demonstrated	T060	C2729318
27267388	185	193	accuracy	T080	C0443131
27267388	198	208	prediction	T078	C0681842
27267388	212	237	spontaneous preterm birth	T033	C3827961
27267388	241	253	asymptomatic	T033	C0231221
27267388	254	259	women	T098	C0043210
27267388	267	274	history	T033	C0262926
27267388	278	291	preterm birth	T033	C0151526
27267388	293	303	Predictive	T080	C0681890
27267388	304	312	accuracy	T080	C0443131
27267388	316	321	women	T098	C0043210
27267388	336	352	cervical surgery	T061	C2044988
27267388	433	443	predictive	T080	C0681890
27267388	444	452	accuracy	T080	C0443131
27267388	456	476	cervicovaginal fluid	T031	C0392908
27267388	477	507	quantitative fetal fibronectin	T059	C3837520
27267388	512	535	cervical length testing	T060	C1956055
27267388	539	551	asymptomatic	T033	C0231221
27267388	552	557	women	T098	C0043210
27267388	572	588	cervical surgery	T061	C2044988
27267388	600	605	women	T098	C0043210
27267388	622	635	preterm birth	T033	C0151526
27267388	652	663	prospective	T062	C0033522
27267388	664	671	blinded	T062	C0150108
27267388	682	690	analysis	T062	C0936012
27267388	703	722	observational study	T062	C1518527
27267388	726	746	cervicovaginal fluid	T031	C0392908
27267388	747	777	quantitative fetal fibronectin	T059	C3837520
27267388	778	791	concentration	T081	C1446561
27267388	795	807	asymptomatic	T033	C0231221
27267388	808	813	women	T098	C0043210
27267388	830	848	Hologic 10Q system	T170	C0282574
27267388	850	857	Hologic	T170	C0947322
27267388	859	870	Marlborough	T083	C0017446
27267388	872	874	MA	T083	C0024874
27267388	877	887	Prediction	T078	C0681842
27267388	891	916	spontaneous preterm birth	T033	C3827961
27267388	936	941	weeks	T079	C0439230
27267388	948	968	cervicovaginal fluid	T031	C0392908
27267388	969	999	quantitative fetal fibronectin	T059	C3837520
27267388	1000	1013	concentration	T081	C1446561
27267388	1017	1028	primiparous	T033	C0033150
27267388	1029	1034	women	T098	C0043210
27267388	1064	1072	invasive	T080	C0205281
27267388	1073	1091	cervical procedure	T060	C0195314
27267388	1120	1130	prediction	T078	C0681842
27267388	1134	1139	women	T098	C0043210
27267388	1157	1182	spontaneous preterm birth	T033	C3827961
27267388	1184	1221	preterm prelabor rupture of membranes	T046	C0015944
27267388	1226	1242	late miscarriage	T046	C0000786
27267388	1272	1280	cervical	T082	C0205064
27267388	1281	1287	length	T081	C1444754
27267388	1314	1339	spontaneous preterm birth	T033	C3827961
27267388	1344	1349	weeks	T079	C0439230
27267388	1357	1373	cervical surgery	T061	C2044988
27267388	1374	1379	group	T078	C0441833
27267388	1416	1441	spontaneous preterm birth	T033	C3827961
27267388	1442	1447	group	T078	C0441833
27267388	1449	1489	Receiver operating characteristic curves	T081	C0035787
27267388	1500	1530	quantitative fetal fibronectin	T059	C3837520
27267388	1535	1545	prediction	T078	C0681842
27267388	1555	1566	gestational	T079	C0439671
27267388	1567	1577	end points	T080	C2349179
27267388	1606	1622	cervical surgery	T061	C2044988
27267388	1636	1661	spontaneous preterm birth	T033	C3827961
27267388	1662	1668	groups	T078	C0441833
27267388	1673	1678	weeks	T079	C0439230
27267388	1680	1700	area under the curve	T081	C0376690
27267388	1712	1731	confidence interval	T081	C0009667
27267388	1756	1775	confidence interval	T081	C0009667
27267388	1798	1808	Prediction	T078	C0681842
27267388	1812	1837	spontaneous preterm birth	T033	C3827961
27267388	1844	1859	cervical length	T060	C1956055
27267388	1874	1904	quantitative fetal fibronectin	T059	C3837520
27267388	1909	1919	prediction	T078	C0681842
27267388	1923	1936	preterm birth	T033	C0151526
27267388	1941	1946	weeks	T079	C0439230
27267388	1950	1959	gestation	T040	C0032961
27267388	1976	1986	prediction	T078	C0681842
27267388	1988	2008	area under the curve	T081	C0376690
27267388	2020	2039	confidence interval	T081	C0009667
27267388	2064	2083	confidence interval	T081	C0009667
27267388	2111	2127	cervical surgery	T061	C2044988
27267388	2128	2133	group	T078	C0441833
27267388	2149	2168	confidence interval	T081	C0009667
27267388	2193	2212	confidence interval	T081	C0009667
27267388	2249	2274	spontaneous preterm birth	T033	C3827961
27267388	2275	2280	group	T078	C0441833
27267388	2283	2293	Prediction	T078	C0681842
27267388	2297	2322	spontaneous preterm birth	T033	C3827961
27267388	2329	2349	cervicovaginal fluid	T031	C0392908
27267388	2350	2380	quantitative fetal fibronectin	T059	C3837520
27267388	2384	2396	asymptomatic	T033	C0231221
27267388	2397	2402	women	T098	C0043210
27267388	2408	2424	cervical surgery	T061	C2044988
27267388	2455	2463	accuracy	T080	C0443131
27267388	2475	2480	women	T098	C0043210
27267388	2488	2495	history	T033	C0262926
27267388	2499	2524	spontaneous preterm birth	T033	C3827961

27267564|t|Proteome changes in rat serum after a chronic ingestion of enriched uranium: Toward a biological signature of internal contamination and radiological effect
27267564|a|The civilian and military use of uranium results in an increased risk of human exposure. The toxicity of uranium results from both its chemical and radiological properties that vary with isotopic composition. Validated biomarkers of health effects associated with exposure to uranium are neither sensitive nor specific to uranium radiotoxicity and/or radiological effect. This study aimed at investigating if serum proteins could be useful as biomarkers of both uranium exposure and radiological effect. Male Sprague-Dawley rats were chronically exposed through drinking water to low levels (40mg/L, corresponding to 1mg of uranium per animal per day) of either 4% (235) U-enriched uranium (EU) or 12% EU during 6 weeks. A proteomics approach based on two-dimensional electrophoresis (2D-DIGE) and mass spectrometry (MS) was used to establish protein expression profiles that could be relevant for discriminating between groups, and to identify some differentially expressed proteins following uranium ingestion. It demonstrated that the expressions of 174 protein spots over 1045 quantified spots were altered after uranium exposure (p<0.05). Using both inferential and non-supervised multivariate statistics, we show sets of spots features that lead to a clear discrimination between controls and EU exposed groups on the one hand (21 spots), and between 4% EU and 12% EU on the other hand (7 spots), showing that investigation of the serum proteome may possibly be of relevance to address both uranium contamination and radiological effect. Finally, using bioinformatics tools, pathway analyses of differentially expressed MS - identified proteins find that acute phase, inflammatory and immune responses as well as oxidative stress are likely involved in the response to contamination, suggesting a physiological perturbation, but that does not necessarily lead to a toxic effect.
27267564	0	8	Proteome	T116,T123	C0751973
27267564	9	16	changes	T169	C0392747
27267564	20	23	rat	T015	C0034721
27267564	24	29	serum	T031	C0229671
27267564	38	55	chronic ingestion	T038	C0232478
27267564	68	75	uranium	T196	C0041928
27267564	86	106	biological signature	T201	C0005516
27267564	110	132	internal contamination	T078	C2349974
27267564	137	156	radiological effect	T080	C1280500
27267564	161	169	civilian	T098	C0680413
27267564	174	182	military	T097	C3245458
27267564	183	189	use of	T169	C1524063
27267564	190	197	uranium	T196	C0041928
27267564	212	221	increased	T081	C0205217
27267564	222	226	risk	T078	C0035647
27267564	230	235	human	T016	C0086418
27267564	236	244	exposure	T080	C0332157
27267564	250	258	toxicity	T037	C0600688
27267564	262	269	uranium	T196	C0041928
27267564	292	300	chemical	T070	C0243178
27267564	305	328	radiological properties	T080	C0871161
27267564	344	352	isotopic	T080	C4038403
27267564	353	364	composition	T201	C0486616
27267564	376	386	biomarkers	T201	C0005516
27267564	390	396	health	T078	C0018684
27267564	397	404	effects	T080	C1280500
27267564	405	420	associated with	T080	C0332281
27267564	421	432	exposure to	T080	C0332157
27267564	433	440	uranium	T196	C0041928
27267564	453	462	sensitive	T169	C0332324
27267564	479	486	uranium	T196	C0041928
27267564	487	500	radiotoxicity	T037	C2747839
27267564	508	527	radiological effect	T080	C1280500
27267564	566	580	serum proteins	T116,T123	C0036825
27267564	600	610	biomarkers	T201	C0005516
27267564	619	635	uranium exposure	T051	C4316579
27267564	640	659	radiological effect	T080	C1280500
27267564	666	685	Sprague-Dawley rats	T015	C2699239
27267564	691	710	chronically exposed	T080	C0332157
27267564	719	733	drinking water	T167	C0599638
27267564	737	740	low	T080	C0205251
27267564	741	747	levels	T080	C0441889
27267564	781	788	uranium	T196	C0041928
27267564	793	799	animal	T008	C0003062
27267564	804	807	day	T079	C0439228
27267564	828	846	U-enriched uranium	T196	C0041928
27267564	848	850	EU	T196	C0041928
27267564	859	861	EU	T196	C0041928
27267564	871	876	weeks	T079	C0439230
27267564	880	890	proteomics	T091	C0872252
27267564	891	899	approach	T169	C1292724
27267564	909	940	two-dimensional electrophoresis	UnknownType	C0678632
27267564	942	949	2D-DIGE	T059	C2936240
27267564	955	972	mass spectrometry	T059	C0037813
27267564	974	976	MS	T059	C0037813
27267564	1000	1018	protein expression	T045	C1171362
27267564	1019	1027	profiles	T059	C1979963
27267564	1078	1084	groups	T078	C0441833
27267564	1122	1140	expressed proteins	T045	C1171362
27267564	1151	1158	uranium	T196	C0041928
27267564	1159	1168	ingestion	T038	C0232478
27267564	1195	1206	expressions	T045	C1171362
27267564	1214	1227	protein spots	T116,T123	C0033684
27267564	1238	1248	quantified	T081	C1709793
27267564	1249	1254	spots	T116,T123	C0033684
27267564	1274	1290	uranium exposure	T051	C4316579
27267564	1312	1323	inferential	T081	C2828391
27267564	1328	1366	non-supervised multivariate statistics	T062,T170	C0010101
27267564	1384	1389	spots	T116,T123	C0033684
27267564	1390	1398	features	T080	C2348519
27267564	1443	1451	controls	T096	C0009932
27267564	1456	1473	EU exposed groups	T078	C0441833
27267564	1494	1499	spots	T116,T123	C0033684
27267564	1517	1519	EU	T196	C0041928
27267564	1528	1530	EU	T196	C0041928
27267564	1552	1557	spots	T116,T123	C0033684
27267564	1573	1586	investigation	T169	C1292732
27267564	1594	1599	serum	T031	C0229671
27267564	1600	1608	proteome	T116,T123	C0751973
27267564	1628	1637	relevance	T080	C2347946
27267564	1654	1661	uranium	T196	C0041928
27267564	1662	1675	contamination	T078	C2349974
27267564	1680	1699	radiological effect	T080	C1280500
27267564	1738	1754	pathway analyses	T170	C0868995
27267564	1773	1782	expressed	T045	C1171362
27267564	1783	1785	MS	T059	C0037813
27267564	1788	1798	identified	T080	C0205396
27267564	1799	1807	proteins	T116,T123	C0033684
27267564	1818	1829	acute phase	T079	C0439557
27267564	1831	1843	inflammatory	T169	C0333348
27267564	1848	1864	immune responses	T042	C0301872
27267564	1876	1892	oxidative stress	T049	C0242606
27267564	1932	1945	contamination	T078	C2349974
27267564	1960	1986	physiological perturbation	T169	C0332453
27267564	2028	2040	toxic effect	T037	C0600688

27267962|t|Prediction of extravasation in pelvic fracture using coagulation biomarkers
27267962|a|To evaluate the usefulness of coagulation biomarkers, which are easy and quick to analyze in emergency settings, for prediction of arterial extravasation due to pelvic fracture. The medical records of pelvic fracture patients transferred to the emergency department of Gunma University Hospital between December 2009 and May 2015 were reviewed. Patients were divided into two groups, those with (Extra(+)) and without (Extra(-)) arterial extravasation on enhanced CT or angiography. Levels of fibrin degradation products (FDP), D-dimer, fibrinogen, the ratio of FDP to fibrinogen, the ratio of D-dimer to fibrinogen, systolic blood pressure, heart rate, the Glasgow Coma Scale, pH, base excess, hemoglobin and lactate levels, the pattern of pelvic injury, and injury severity score were measured at hospital admission, and compared between the two groups. Parameters with a significant difference between the two groups were used to construct receiver operating characteristic (ROC) curves. The study included 29 patients with pelvic fracture. FDP, D-dimer, the ratio of FDP to fibrinogen and the ratio of D-dimer to fibrinogen were the most useful parameters for predicting arterial extravasation due to pelvic fracture. FDP, D-dimer, the ratio of FDP to fibrinogen, the ratio of D-dimer to fibrinogen, and hemoglobin and lactate levels were significantly higher in the Extra(+) group than in the Extra(-) group (FDP, 354.8Î¼g/mL [median] versus 96.6Î¼g/mL; D-dimer, 122.3Î¼g/mL versus 42.1Î¼g/mL; the ratio of FDP to fibrinogen, 3.39 versus 0.42; the ratio of D-dimer to fibrinogen, 1.14 versus 0.18; hemoglobin, 10.5g/dL versus 13.5g/dL; lactate, 3.5mmol/L versus 1.7mmol/L). The area under the ROC curves for FDP, D-dimer, the ratio of FDP to fibrinogen, the ratio of D-dimer to fibrinogen, hemoglobin and lactate levels were 0.900, 0.882, 0.918, 0.900, 0.815 and 0.765, respectively. Coagulation biomarkers, and hemoglobin and lactate levels could be useful to predict the existence of arterial extravasation due to pelvic fracture. The ratio of FDP to fibrinogen and the ratio of D-dimer to fibrinogen were the most accurate markers. Coagulation biomarkers may enable more rapid and specific treatment for pelvic fracture.
27267962	0	10	Prediction	T078	C0681842
27267962	14	27	extravasation	T046	C0015376
27267962	31	46	pelvic fracture	T037	C0149531
27267962	53	64	coagulation	T039	C1328723
27267962	65	75	biomarkers	T201	C0005516
27267962	92	102	usefulness	T080	C3827682
27267962	106	117	coagulation	T039	C1328723
27267962	118	128	biomarkers	T201	C0005516
27267962	169	187	emergency settings	T067	C0013956
27267962	193	203	prediction	T078	C0681842
27267962	207	215	arterial	T023	C0003842
27267962	216	229	extravasation	T046	C0015376
27267962	237	252	pelvic fracture	T037	C0149531
27267962	258	273	medical records	T170	C0025102
27267962	277	292	pelvic fracture	T037	C0149531
27267962	293	301	patients	T101	C0030705
27267962	421	429	Patients	T101	C0030705
27267962	448	458	two groups	T078	C0441833
27267962	472	480	Extra(+)	T033	C1446409
27267962	495	503	Extra(-)	T033	C0205160
27267962	505	513	arterial	T023	C0003842
27267962	514	527	extravasation	T046	C0015376
27267962	540	542	CT	T060	C0040405
27267962	546	557	angiography	T060	C0002978
27267962	559	565	Levels	T080	C0441889
27267962	569	596	fibrin degradation products	T059	C0200453
27267962	598	601	FDP	T059	C0200453
27267962	604	611	D-dimer	T059	C0200462
27267962	613	623	fibrinogen	T059	C0337428
27267962	629	655	ratio of FDP to fibrinogen	T059	C1261161
27267962	661	691	ratio of D-dimer to fibrinogen	T059	C1261161
27267962	693	716	systolic blood pressure	T201	C0871470
27267962	718	728	heart rate	T201	C0018810
27267962	734	752	Glasgow Coma Scale	T170	C0017594
27267962	754	756	pH	T081	C0020283
27267962	758	769	base excess	T059	C0201985
27267962	771	781	hemoglobin	T059	C0518015
27267962	786	793	lactate	T059	C0202115
27267962	794	800	levels	T080	C0441889
27267962	817	830	pelvic injury	T037	C0149531
27267962	836	857	injury severity score	T170	C0021504
27267962	875	893	hospital admission	T058	C0184666
27267962	920	930	two groups	T078	C0441833
27267962	985	995	two groups	T078	C0441833
27267962	1019	1052	receiver operating characteristic	T081	C0034772
27267962	1053	1065	(ROC) curves	T081	C0035787
27267962	1089	1097	patients	T101	C0030705
27267962	1103	1118	pelvic fracture	T037	C0149531
27267962	1120	1123	FDP	T116,T123	C0163275
27267962	1125	1132	D-dimer	T116,T123	C0060323
27267962	1138	1164	ratio of FDP to fibrinogen	T081	C0456603
27267962	1173	1203	ratio of D-dimer to fibrinogen	T081	C0456603
27267962	1240	1250	predicting	T078	C0681842
27267962	1251	1259	arterial	T023	C0003842
27267962	1260	1273	extravasation	T046	C0015376
27267962	1281	1296	pelvic fracture	T037	C0149531
27267962	1298	1301	FDP	T116,T123	C0163275
27267962	1303	1310	D-dimer	T116,T123	C0060323
27267962	1316	1342	ratio of FDP to fibrinogen	T081	C0456603
27267962	1348	1378	ratio of D-dimer to fibrinogen	T081	C0456603
27267962	1384	1394	hemoglobin	T034	C0019029
27267962	1399	1413	lactate levels	T034	C1304767
27267962	1419	1439	significantly higher	T081	C4055637
27267962	1447	1455	Extra(+)	T033	C1446409
27267962	1474	1482	Extra(-)	T033	C0205160
27267962	1490	1493	FDP	T116,T123	C0163275
27267962	1533	1540	D-dimer	T116,T123	C0060323
27267962	1575	1601	ratio of FDP to fibrinogen	T081	C0456603
27267962	1625	1655	ratio of D-dimer to fibrinogen	T081	C0456603
27267962	1675	1685	hemoglobin	T034	C0019029
27267962	1713	1720	lactate	T034	C1304767
27267962	1770	1780	ROC curves	T081	C0035787
27267962	1785	1788	FDP	T116,T123	C0163275
27267962	1790	1797	D-dimer	T116,T123	C0060323
27267962	1803	1829	ratio of FDP to fibrinogen	T081	C0456603
27267962	1835	1865	ratio of D-dimer to fibrinogen	T081	C0456603
27267962	1867	1877	hemoglobin	T034	C0019029
27267962	1882	1896	lactate levels	T034	C1304767
27267962	1961	1972	Coagulation	T039	C1328723
27267962	1973	1983	biomarkers	T201	C0005516
27267962	1989	1999	hemoglobin	T034	C0019029
27267962	2004	2018	lactate levels	T034	C1304767
27267962	2028	2034	useful	T080	C3827682
27267962	2038	2045	predict	T078	C0681842
27267962	2050	2059	existence	T033	C0150312
27267962	2063	2071	arterial	T023	C0003842
27267962	2072	2085	extravasation	T046	C0015376
27267962	2093	2108	pelvic fracture	T037	C0149531
27267962	2114	2140	ratio of FDP to fibrinogen	T081	C0456603
27267962	2149	2179	ratio of D-dimer to fibrinogen	T081	C0456603
27267962	2194	2210	accurate markers	T074	C2745888
27267962	2212	2223	Coagulation	T039	C1328723
27267962	2224	2234	biomarkers	T201	C0005516
27267962	2270	2279	treatment	T169	C1522326
27267962	2284	2299	pelvic fracture	T037	C0149531

27268023|t|Social security status and mortality in Belgian and Spanish male workers
27268023|a|To assess differences in mortality rates between social security statuses in two independent samples of Belgian and Spanish male workers. Study of two retrospective cohorts (Belgium, n=23,607; Spain, n=44,385) of 50-60 year old male employees with 4 years of follow-up. Mortality rate ratios (MRR) were estimated using Poisson regression models. Mortality for subjects with permanent disability was higher than for the employed, for both Belgium [MRR =4.56 (95% CI: 2.88-7.21)] and Spain [MRR =7.15 (95% CI: 5.37-9.51)]. For the unemployed / early retirees, mortality was higher in Spain [MRR =1.64 (95% CI: 1.24-2.17)] than in Belgium [MRR =0.88 (95% CI: 0.46-1.71)]. MRR differences between Belgium and Spain for unemployed workers could be partly explained because of differences between the two social security systems. Future studies should further explore mortality differences between countries with different social security systems.
27268023	0	15	Social security	T064	C0037435
27268023	16	22	status	T080	C0449438
27268023	27	36	mortality	T033	C1306577
27268023	40	47	Belgian	T098	C0337797
27268023	52	59	Spanish	T098	C3161473
27268023	60	64	male	T098	C0025266
27268023	65	72	workers	T098	C1527116
27268023	76	82	assess	T058	C0184514
27268023	83	94	differences	T080	C1705242
27268023	98	113	mortality rates	T081	C0205848
27268023	122	137	social security	T064	C0037435
27268023	138	146	statuses	T080	C0449438
27268023	166	173	samples	T098	C1257890
27268023	177	184	Belgian	T098	C0337797
27268023	189	196	Spanish	T098	C3161473
27268023	197	201	male	T098	C0025266
27268023	202	209	workers	T098	C1527116
27268023	211	245	Study of two retrospective cohorts	T062	C2985505
27268023	247	254	Belgium	T083	C0004950
27268023	266	271	Spain	T083	C0037747
27268023	301	305	male	T098	C0025266
27268023	306	315	employees	T097	C0599987
27268023	323	328	years	T079	C0439234
27268023	332	341	follow-up	T058	C1522577
27268023	343	364	Mortality rate ratios	T081	C0392762
27268023	366	369	MRR	T081	C0392762
27268023	376	385	estimated	T081	C0750572
27268023	392	410	Poisson regression	T170	C0034980
27268023	411	417	models	T170	C3161035
27268023	419	428	Mortality	T033	C1306577
27268023	433	441	subjects	T098	C2349001
27268023	447	456	permanent	T079	C0205355
27268023	457	467	disability	T033	C0231170
27268023	472	478	higher	T080	C0205250
27268023	492	500	employed	T033	C0557351
27268023	511	518	Belgium	T083	C0004950
27268023	520	523	MRR	T081	C0392762
27268023	535	537	CI	T081	C0009667
27268023	555	560	Spain	T083	C0037747
27268023	562	565	MRR	T081	C0392762
27268023	577	579	CI	T081	C0009667
27268023	602	612	unemployed	T033	C0041674
27268023	615	620	early	T079	C1279919
27268023	621	629	retirees	T098	C0815271
27268023	631	640	mortality	T033	C1306577
27268023	645	651	higher	T080	C0205250
27268023	655	660	Spain	T083	C0037747
27268023	662	665	MRR	T081	C0392762
27268023	677	679	CI	T081	C0009667
27268023	701	708	Belgium	T083	C0004950
27268023	710	713	MRR	T081	C0392762
27268023	725	727	CI	T081	C0009667
27268023	742	745	MRR	T081	C0392762
27268023	746	757	differences	T080	C1705242
27268023	766	773	Belgium	T083	C0004950
27268023	778	783	Spain	T083	C0037747
27268023	788	798	unemployed	T033	C0041674
27268023	799	806	workers	T098	C1527116
27268023	844	855	differences	T080	C1705242
27268023	872	895	social security systems	T064	C2371809
27268023	897	903	Future	T079	C0016884
27268023	904	911	studies	T062	C2603343
27268023	935	944	mortality	T033	C1306577
27268023	945	956	differences	T080	C1705242
27268023	965	974	countries	T083	C0454664
27268023	980	989	different	T080	C1705242
27268023	990	1013	social security systems	T064	C2371809

27270311|t|Direct contact with perivascular tumor cells enhances integrin Î±vÎ²3 signaling and migration of endothelial cells
27270311|a|The secretion of soluble pro-angiogenic factors by tumor cells and stromal cells in the perivascular niche promotes the aggressive angiogenesis that is typical of glioblastoma (GBM). Here, we show that angiogenesis also can be promoted by a direct interaction between brain tumor cells, including tumor cells with cancer stem -like properties (CSCs), and endothelial cells (ECs). As shown in vitro, this direct interaction is mediated by binding of integrin Î±vÎ²3 expressed on ECs to the RGD-peptide in L1CAM expressed on CSCs. It promotes both EC network formation and enhances directed migration toward basic fibroblast growth factor. Activation of Î±vÎ²3 and bone marrow tyrosine kinase on chromosome X (BMX) is required for migration stimulated by direct binding but not for migration stimulated by soluble factors. RGD-peptide treatment of mice with established intracerebral GBM xenografts significantly reduced the percentage of Sox2 -positive tumor cells and CSCs in close proximity to ECs, decreased integrin Î±vÎ²3 and BMX activation and p130CAS phosphorylation in the ECs, and reduced the vessel surface area. These results reveal a previously unrecognized aspect of the regulation of angiogenesis in GBM that can impact therapeutic anti-angiogenic targeting.
27270311	20	32	perivascular	T023	C0005847
27270311	33	44	tumor cells	T025	C0597032
27270311	54	67	integrin Î±vÎ²3	T116,T192	C1138427
27270311	68	77	signaling	T044	C1514762
27270311	82	91	migration	T043	C1622501
27270311	95	112	endothelial cells	T025	C0225336
27270311	117	126	secretion	T043	C1327616
27270311	138	160	pro-angiogenic factors	T123	C0002976
27270311	164	175	tumor cells	T025	C0597032
27270311	180	193	stromal cells	T025	C0162597
27270311	201	213	perivascular	T023	C0005847
27270311	233	256	aggressive angiogenesis	T191	C1519670
27270311	276	288	glioblastoma	T191	C0017636
27270311	290	293	GBM	T191	C0017636
27270311	315	327	angiogenesis	T191	C1519670
27270311	381	386	brain	T023	C0006104
27270311	387	398	tumor cells	T025	C0597032
27270311	410	421	tumor cells	T025	C0597032
27270311	427	438	cancer stem	T025	C1956422
27270311	457	461	CSCs	T025	C1956422
27270311	468	485	endothelial cells	T025	C0225336
27270311	487	490	ECs	T025	C0225336
27270311	502	510	in vitro	T080	C1533691
27270311	551	558	binding	T044	C0597358
27270311	562	575	integrin Î±vÎ²3	T116,T192	C1138427
27270311	576	585	expressed	T045	C0597360
27270311	589	592	ECs	T025	C0225336
27270311	600	611	RGD-peptide	T116,T123	C0052350
27270311	615	620	L1CAM	T116,T123	C0950625
27270311	621	630	expressed	T045	C1171362
27270311	634	638	CSCs	T025	C1956422
27270311	657	659	EC	T025	C0225336
27270311	660	677	network formation	T043	C0007613
27270311	700	709	migration	T043	C1622501
27270311	723	747	fibroblast growth factor	T116,T123	C0016026
27270311	749	759	Activation	T052	C1879547
27270311	763	767	Î±vÎ²3	T116,T192	C1138427
27270311	772	815	bone marrow tyrosine kinase on chromosome X	T116,T126	C1384557
27270311	817	820	BMX	T116,T126	C1453891
27270311	838	847	migration	T043	C1622501
27270311	869	876	binding	T044	C0597358
27270311	889	898	migration	T043	C1622501
27270311	930	941	RGD-peptide	T116,T123	C0052350
27270311	942	951	treatment	T169	C1522326
27270311	955	959	mice	T015	C0025929
27270311	977	990	intracerebral	T082	C0442111
27270311	991	994	GBM	T191	C0017636
27270311	995	1005	xenografts	T122	C0522537
27270311	1046	1050	Sox2	T116,T123	C0300483
27270311	1061	1072	tumor cells	T025	C0597032
27270311	1077	1081	CSCs	T025	C1956422
27270311	1104	1107	ECs	T025	C0225336
27270311	1119	1132	integrin Î±vÎ²3	T116,T192	C1138427
27270311	1137	1140	BMX	T116,T126	C1453891
27270311	1156	1163	p130CAS	T116,T123	C1451358
27270311	1164	1179	phosphorylation	T044	C1158886
27270311	1187	1190	ECs	T025	C0225336
27270311	1208	1214	vessel	T023	C0005847
27270311	1215	1227	surface area	T082	C0205146
27270311	1290	1300	regulation	T038	C1327622
27270311	1304	1316	angiogenesis	T191	C1519670
27270311	1320	1323	GBM	T191	C0017636
27270311	1340	1351	therapeutic	T169	C0302350
27270311	1352	1367	anti-angiogenic	T121,T123	C0596087

27270538|t|Evaluation of the Prostate Imaging Reporting and Data System for Magnetic Resonance Imaging Diagnosis of Prostate Cancer in Patients with Prostate-specific Antigen <20 ng/ml
27270538|a|The European Society of Urogenital Radiology has built the Prostate Imaging Reporting and Data System (PI-RADS) for standardizing the diagnosis of prostate cancer (PCa). This study evaluated the PI-RADS diagnosis method in patients with prostate-specific antigen (PSA) <20 ng/ml. A total of 133 patients with PSA <20 ng/ml were prospectively recruited. T2-weighted (T2WI) and diffusion-weighted (DWI) magnetic resonance images of the prostate were acquired before a 12-core transrectal prostate biopsy. Each patient's peripheral zone was divided into six regions on the images; each region corresponded to two of the 12 biopsy cores. T2WI, DWI, and T2WI + DWI scores were computed according to PI-RADS. The diagnostic accuracy of the PI-RADS score was evaluated using histopathology of prostate biopsies as the reference standard. PCa was histologically diagnosed in 169 (21.2%) regions. Increased PI-RADS score correlated positively with increased cancer detection rate. The cancer detection rate for scores 1 to 5 was 2.8%, 15.0%, 34.6%, 52.6%, and 88.9%, respectively, using T2WI and 12.0%, 20.2%, 48.0%, 85.7%, and 93.3%, respectively, using DWI. For T2WI + DWI, the cancer detection rate was 1.5% (score 2), 13.5% (scores 3-4), 41.3% (scores 5-6), 75.9% (scores 7-8), and 92.3% (scores 9-10). The area under the curve for cancer detection was 0.700 (T2WI), 0.735 (DWI) and 0.749 (T2WI + DWI). The sensitivity and specificity were 53.8% and 89.2%, respectively, when using scores 5-6 as the cutoff value for T2WI + DWI. The PI-RADS score correlates with the PCa detection rate in patients with PSA <20 ng/ml. The summed score of T2WI + DWI has the highest accuracy in detection of PCa. However, the sensitivity should be further improved.
27270538	18	60	Prostate Imaging Reporting and Data System	T170	C4284879
27270538	65	91	Magnetic Resonance Imaging	T060	C0024485
27270538	92	101	Diagnosis	T062	C1704656
27270538	105	120	Prostate Cancer	T191	C0376358
27270538	124	132	Patients	T101	C0030705
27270538	138	163	Prostate-specific Antigen	T116,T126,T129	C0138741
27270538	178	218	European Society of Urogenital Radiology	T093	C1708333
27270538	233	275	Prostate Imaging Reporting and Data System	T170	C4284879
27270538	277	284	PI-RADS	T170	C4284879
27270538	308	317	diagnosis	T062	C1704656
27270538	321	336	prostate cancer	T191	C0376358
27270538	338	341	PCa	T191	C0376358
27270538	349	354	study	T062	C2603343
27270538	369	376	PI-RADS	T170	C4284879
27270538	377	393	diagnosis method	T060	C0430022
27270538	397	405	patients	T101	C0030705
27270538	411	436	prostate-specific antigen	T116,T126,T129	C0138741
27270538	438	441	PSA	T116,T126,T129	C0138741
27270538	469	477	patients	T101	C0030705
27270538	483	486	PSA	T116,T126,T129	C0138741
27270538	527	538	T2-weighted	T060	C0011923
27270538	540	544	T2WI	T060	C0011923
27270538	550	600	diffusion-weighted (DWI) magnetic resonance images	T060	C0598801
27270538	608	616	prostate	T023	C0033572
27270538	640	675	12-core transrectal prostate biopsy	T060	C0401641
27270538	682	691	patient's	T101	C0030705
27270538	692	707	peripheral zone	T029	C0458696
27270538	744	750	images	T170	C1704254
27270538	794	806	biopsy cores	T060	C3846093
27270538	808	812	T2WI	T060	C0011923
27270538	814	817	DWI	T060	C0598801
27270538	823	827	T2WI	T060	C0011923
27270538	830	833	DWI	T060	C0598801
27270538	834	840	scores	T081	C0449820
27270538	868	875	PI-RADS	T170	C4284879
27270538	881	900	diagnostic accuracy	T080	C0598285
27270538	908	915	PI-RADS	T170	C4284879
27270538	916	921	score	T081	C0449820
27270538	942	956	histopathology	T091	C0677043
27270538	960	977	prostate biopsies	T060	C0194804
27270538	1005	1008	PCa	T191	C0376358
27270538	1013	1037	histologically diagnosed	UnknownType	C0679557
27270538	1072	1079	PI-RADS	T170	C4284879
27270538	1080	1085	score	T081	C0449820
27270538	1123	1139	cancer detection	T058	C1516193
27270538	1140	1144	rate	T081	C1521828
27270538	1150	1166	cancer detection	T058	C1516193
27270538	1167	1171	rate	T081	C1521828
27270538	1176	1182	scores	T081	C0449820
27270538	1252	1256	T2WI	T060	C0011923
27270538	1320	1323	DWI	T060	C0598801
27270538	1329	1333	T2WI	T060	C0011923
27270538	1336	1339	DWI	T060	C0598801
27270538	1345	1361	cancer detection	T058	C1516193
27270538	1362	1366	rate	T081	C1521828
27270538	1377	1382	score	T081	C0449820
27270538	1394	1400	scores	T081	C0449820
27270538	1414	1420	scores	T081	C0449820
27270538	1434	1440	scores	T081	C0449820
27270538	1458	1464	scores	T081	C0449820
27270538	1501	1517	cancer detection	T058	C1516193
27270538	1529	1533	T2WI	T060	C0011923
27270538	1543	1546	DWI	T060	C0598801
27270538	1559	1563	T2WI	T060	C0011923
27270538	1566	1569	DWI	T060	C0598801
27270538	1651	1657	scores	T081	C0449820
27270538	1686	1690	T2WI	T060	C0011923
27270538	1693	1696	DWI	T060	C0598801
27270538	1702	1709	PI-RADS	T170	C4284879
27270538	1710	1715	score	T081	C0449820
27270538	1736	1749	PCa detection	T061	C0281186
27270538	1750	1754	rate	T081	C1521828
27270538	1758	1766	patients	T101	C0030705
27270538	1772	1775	PSA	T116,T126,T129	C0138741
27270538	1798	1803	score	T081	C0449820
27270538	1807	1811	T2WI	T060	C0011923
27270538	1814	1817	DWI	T060	C0598801
27270538	1859	1862	PCa	T191	C0376358

27270753|t|The use of Ocimum americanum essential oil against the pathogens Aeromonas hydrophila and Gyrodactylus sp. in silver catfish (Rhamdia quelen)
27270753|a|The bactericidal activity (MIC-test) of Ocimum americanum (inflorescences) essential oil (OAEO) against Aeromonas hydrophila was determined in this study. It was also investigated the potential of OAEO and the main compound found in the oil (linalool) at subinhibitory concentrations to be inhibitors of hemolysis caused by Aer. hydrophila in fish erythrocytes. An in vivo experiment was conducted to evaluate survival of fish (Rhamdia quelen) experimentally infected with Aer. hydrophila and exposed to OAEO. A second experiment was conducted to evaluate the in vitro and in vivo activity of OAEO (mix from inflorescences and leaves) against the parasite Gyrodactylus sp. The OAEO showed weak in vitro activity against Aer. hydrophila (6400 Î¼g ml(-1)). At subinhibitory concentrations OAEO (100 Î¼g ml(-1)) inhibited hemolysis (90%) caused by Aer. hydrophila in fish erythrocytes, however, linalool did not present hemolysis inhibition activity. At low concentrations (10 and 20 mg l(-1)) added to the water OAEO promoted survival of experimentally infected fish with Aer. hydrophila. Lastly, OAEO -mix (50 mg l(-1)) was effective against Gyrodactylus sp. significantly reducing (60%) the number of parasites in the fish. This article is protected by copyright. All rights reserved.
27270753	11	28	Ocimum americanum	T002	C1483717
27270753	29	42	essential oil	T109	C0028910
27270753	55	64	pathogens	T001	C0450254
27270753	65	85	Aeromonas hydrophila	T007	C0085491
27270753	90	106	Gyrodactylus sp.	T204	C1211435
27270753	110	124	silver catfish	T013	C1939719
27270753	126	140	Rhamdia quelen	T013	C1194855
27270753	146	167	bactericidal activity	T034	C1271650
27270753	169	177	MIC-test	T059	C0427978
27270753	182	199	Ocimum americanum	T002	C1483717
27270753	201	215	inflorescences	T002	C2697680
27270753	217	230	essential oil	T109	C0028910
27270753	232	236	OAEO	T109	C0028910
27270753	246	266	Aeromonas hydrophila	T007	C0085491
27270753	339	343	OAEO	T109	C0028910
27270753	357	365	compound	T080	C0205198
27270753	379	382	oil	T109	C0028908
27270753	384	392	linalool	T109,T121	C0064997
27270753	432	442	inhibitors	T120	C0243077
27270753	446	455	hemolysis	T046	C0019054
27270753	466	481	Aer. hydrophila	T007	C0085491
27270753	485	489	fish	T013	C1939719
27270753	490	502	erythrocytes	T025	C0014792
27270753	507	525	in vivo experiment	T062	C0681829
27270753	552	560	survival	T052	C0038952
27270753	564	568	fish	T013	C0016163
27270753	570	584	Rhamdia quelen	T013	C1194855
27270753	586	600	experimentally	T062	C0681814
27270753	601	609	infected	T033	C0439663
27270753	615	630	Aer. hydrophila	T007	C0085491
27270753	635	642	exposed	T080	C0332157
27270753	646	650	OAEO	T109	C0028910
27270753	661	671	experiment	T062	C0681814
27270753	702	710	in vitro	T062	C0681828
27270753	715	722	in vivo	T062	C0681829
27270753	735	739	OAEO	T109	C0028910
27270753	750	764	inflorescences	T002	C2697680
27270753	769	775	leaves	T002	C0242724
27270753	789	814	parasite Gyrodactylus sp.	T204	C1211435
27270753	819	823	OAEO	T109	C0028910
27270753	831	835	weak	T080	C1762617
27270753	836	844	in vitro	T062	C0681828
27270753	862	877	Aer. hydrophila	T007	C0085491
27270753	928	932	OAEO	T109	C0028910
27270753	949	958	inhibited	T052	C3463820
27270753	959	968	hemolysis	T046	C0019054
27270753	985	1000	Aer. hydrophila	T007	C0085491
27270753	1004	1008	fish	T013	C1939719
27270753	1009	1021	erythrocytes	T025	C0014792
27270753	1032	1040	linalool	T109,T121	C0064997
27270753	1045	1056	not present	T169	C0332197
27270753	1057	1066	hemolysis	T046	C0019054
27270753	1067	1086	inhibition activity	T052	C3463820
27270753	1144	1149	water	T121,T197	C0043047
27270753	1150	1154	OAEO	T109	C0028910
27270753	1155	1163	promoted	T052	C0033414
27270753	1164	1172	survival	T052	C0038952
27270753	1191	1199	infected	T033	C0439663
27270753	1200	1204	fish	T013	C1939719
27270753	1210	1225	Aer. hydrophila	T007	C0085491
27270753	1235	1239	OAEO	T109	C0028910
27270753	1263	1272	effective	T080	C1704419
27270753	1281	1297	Gyrodactylus sp.	T204	C1211435
27270753	1298	1320	significantly reducing	T081	C4055638
27270753	1341	1350	parasites	T204	C0030498
27270753	1358	1362	fish	T013	C1939719

27271087|t|Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6- week, placebo-controlled study
27271087|a|Asenapine is a second generation anti-psychotic approved in the USA in 2009 for the treatment of schizophrenia, but its efficacy has not been proven in Asian patients. The objectives of this study are to evaluate the efficacy and tolerability of asenapine in Asian patients experiencing an acute exacerbation of schizophrenia. In this prospective, double-blind study, patients in Japan, Korea, and Taiwan were randomized (1:1:1) to asenapine 5 mg twice daily (bid), 10 mg bid or placebo for 6 weeks after a 3- to 7- day washout / screening period. The primary endpoint was the mean change in the positive and negative syndrome scale (PANSS) total score from baseline to day 42/ treatment end. Of the 532 participants randomized, 530 received treatment. The primary endpoint was significantly greater with asenapine 5 and 10 mg bid than with placebo (-12.24 and -14.17 vs. -0.95; p < 0.0001). The results of secondary endpoints including PANSS negative subscale scores and PANSS responders at the end of treatment supported the results of the primary endpoint. There were no significant differences in the incidence of treatment -emergent adverse events reported with asenapine 5 and 10 mg bid and placebo (84.6, 80.7, and 81.6 %). There was a mean (Â± standard deviation) change in weight of -1.76 Â± 2.45 kg for placebo, +0.42 Â± 2.65 kg for asenapine 5 mg bid, and +0.81 Â± 2.89 kg for asenapine 10 mg bid group. Asenapine was effective and generally well tolerated when used for the treatment of acute exacerbations of schizophrenia in Asian patients.
27271087	0	8	Efficacy	T080	C1280519
27271087	13	19	safety	T080	C0678800
27271087	23	32	asenapine	T109,T121	C2000088
27271087	36	41	Asian	T098	C0078988
27271087	42	50	patients	T101	C0030705
27271087	59	77	acute exacerbation	T033	C0743630
27271087	81	94	schizophrenia	T048	C0036341
27271087	98	109	multicentre	T062	C0206012
27271087	111	121	randomized	T062,T170	C0206034
27271087	123	135	double-blind	T062	C0013072
27271087	140	144	week	T079	C0439230
27271087	146	170	placebo-controlled study	T062,T170	C0599724
27271087	171	180	Asenapine	T109,T121	C2000088
27271087	204	218	anti-psychotic	T121	C0040615
27271087	235	238	USA	T083	C0041703
27271087	255	264	treatment	T061	C0087111
27271087	268	281	schizophrenia	T048	C0036341
27271087	291	299	efficacy	T080	C1280519
27271087	323	328	Asian	T098	C0078988
27271087	329	337	patients	T101	C0030705
27271087	343	353	objectives	T170	C0018017
27271087	362	367	study	T062	C2603343
27271087	388	396	efficacy	T080	C1280519
27271087	401	413	tolerability	T080	C1704410
27271087	417	426	asenapine	T109,T121	C2000088
27271087	430	435	Asian	T098	C0078988
27271087	436	444	patients	T101	C0030705
27271087	461	479	acute exacerbation	T033	C0743630
27271087	483	496	schizophrenia	T048	C0036341
27271087	519	537	double-blind study	T062	C0013072
27271087	539	547	patients	T101	C0030705
27271087	551	556	Japan	T083	C0022341
27271087	558	563	Korea	T083	C0022771
27271087	569	575	Taiwan	T083	C0039260
27271087	581	591	randomized	T062	C0034656
27271087	603	612	asenapine	T109,T121	C2000088
27271087	618	629	twice daily	T079	C0585361
27271087	631	634	bid	T079	C0585361
27271087	643	646	bid	T079	C0585361
27271087	650	657	placebo	T062	C1706408
27271087	664	669	weeks	T079	C0439230
27271087	687	690	day	T079	C0439228
27271087	691	698	washout	T079	C1710661
27271087	701	717	screening period	T079	C1948053
27271087	723	739	primary endpoint	T130	C2986535
27271087	767	803	positive and negative syndrome scale	T170	C0451383
27271087	805	810	PANSS	T170	C0451383
27271087	818	823	score	T081	C0449820
27271087	829	837	baseline	T081	C1442488
27271087	841	844	day	T079	C0439228
27271087	849	858	treatment	T061	C0087111
27271087	875	887	participants	T098	C0679646
27271087	888	898	randomized	T062	C0034656
27271087	913	922	treatment	T061	C0087111
27271087	928	944	primary endpoint	T130	C2986535
27271087	976	985	asenapine	T109,T121	C2000088
27271087	998	1001	bid	T079	C0585361
27271087	1012	1019	placebo	T062	C1706408
27271087	1067	1074	results	T169	C1274040
27271087	1078	1097	secondary endpoints	T080	C2349179
27271087	1108	1113	PANSS	T170	C0451383
27271087	1114	1138	negative subscale scores	T081	C0449820
27271087	1143	1148	PANSS	T170	C0451383
27271087	1174	1183	treatment	T061	C0087111
27271087	1198	1205	results	T169	C1274040
27271087	1213	1229	primary endpoint	T130	C2986535
27271087	1276	1285	incidence	T081	C0021149
27271087	1289	1298	treatment	T061	C0087111
27271087	1289	1308	treatment -emergent	T078	C0750573
27271087	1309	1323	adverse events	T046	C0877248
27271087	1338	1347	asenapine	T109,T121	C2000088
27271087	1360	1363	bid	T079	C0585361
27271087	1368	1375	placebo	T062	C1706408
27271087	1422	1440	standard deviation	T081	C0871420
27271087	1482	1489	placebo	T062	C1706408
27271087	1511	1520	asenapine	T109,T121	C2000088
27271087	1526	1529	bid	T079	C0585361
27271087	1555	1564	asenapine	T109,T121	C2000088
27271087	1571	1574	bid	T079	C0585361
27271087	1582	1591	Asenapine	T109,T121	C2000088
27271087	1596	1605	effective	T080	C1704419
27271087	1625	1634	tolerated	T080	C1704410
27271087	1653	1662	treatment	T061	C0087111
27271087	1666	1685	acute exacerbations	T033	C0743630
27271087	1689	1702	schizophrenia	T048	C0036341
27271087	1706	1711	Asian	T098	C0078988
27271087	1712	1720	patients	T101	C0030705

27271770|t|Interleukin-1Î² induced Stress Granules Sequester COX-2 mRNA and Regulates its Stability and Translation in Human OA Chondrocytes
27271770|a|Enhanced and immediate expression of cyclooxygenase-2 (COX-2) mRNA is observed in IL-1Î² - stimulated OA chondrocytes but the synthesis of protein found significantly delayed. Here we investigated the role of stress granules (SGs), ribonucleoprotein complexes that regulate mRNA translation, in the delayed translation of COX-2 mRNAs in IL-1Î² - stimulated OA chondrocytes. Stimulation of human chondrocytes with IL-1Î² activated the stress response genes and the phosphorylation of eIF2Î± that triggered the assembly of SGs. Using combined immunofluorescence staining of SGs markers and COX-2 protein, RNA fluorescence in situ hybridization and RNA immunoprecipitation, the COX-2 mRNAs were found sequestered in SGs in IL-1Î² - stimulated OA chondrocytes. No increase in COX-2 protein expression was observed during the persistence of SGs but enhanced expression of COX-2 protein was noted upon clearance of the SGs. Inhibition of SGs clearance blocked COX-2 mRNA translation whereas blocking the assembly of SGs by TIA-1 depletion resulted in rapid and increased production of COX-2 and PGE2. Our findings show for the first time assembly of SGs and sequestration of COX-2 mRNAs in human OA chondrocytes under pathological conditions. Post-transcriptional regulation of COX-2 mRNAs translation by SGs indicates a role in IL-1Î² -mediated catabolic response that could be therapeutically targeted in OA.
27271770	0	14	Interleukin-1Î²	T116,T129	C0021753
27271770	23	38	Stress Granules	T026	C1325596
27271770	39	48	Sequester	T169	C0333312
27271770	49	54	COX-2	T116,T126	C0387583
27271770	55	59	mRNA	T114,T123	C0035696
27271770	64	73	Regulates	T038	C1327622
27271770	78	87	Stability	T080	C2350440
27271770	92	103	Translation	UnknownType	C0678935
27271770	107	112	Human	T016	C0086418
27271770	113	115	OA	T047	C0029408
27271770	116	128	Chondrocytes	T025	C0225369
27271770	129	137	Enhanced	T052	C2349975
27271770	152	162	expression	T045	C0017262
27271770	166	182	cyclooxygenase-2	T028	C1367485
27271770	184	189	COX-2	T028	C1367485
27271770	191	195	mRNA	T114,T123	C0035696
27271770	211	216	IL-1Î²	T116,T129	C0021753
27271770	219	229	stimulated	T061	C1292856
27271770	230	232	OA	T047	C0029408
27271770	233	245	chondrocytes	T025	C0225369
27271770	254	274	synthesis of protein	T044	C0597295
27271770	295	302	delayed	T079	C0205421
27271770	337	352	stress granules	T026	C1325596
27271770	354	357	SGs	T026	C1325596
27271770	360	387	ribonucleoprotein complexes	T026	C1167298
27271770	393	401	regulate	T038	C1327622
27271770	402	418	mRNA translation	UnknownType	C0678935
27271770	427	434	delayed	T079	C0205421
27271770	435	446	translation	UnknownType	C0678935
27271770	450	455	COX-2	T028	C1367485
27271770	456	461	mRNAs	T114,T123	C0035696
27271770	465	470	IL-1Î²	T116,T129	C0021753
27271770	473	483	stimulated	T061	C1292856
27271770	484	486	OA	T047	C0029408
27271770	487	499	chondrocytes	T025	C0225369
27271770	501	512	Stimulation	T061	C1292856
27271770	516	521	human	T016	C0086418
27271770	522	534	chondrocytes	T025	C0225369
27271770	540	545	IL-1Î²	T116,T129	C0021753
27271770	560	575	stress response	T039	C0149784
27271770	576	581	genes	T028	C0017337
27271770	590	605	phosphorylation	T044	C1158886
27271770	609	614	eIF2Î±	T116,T123	C0013733
27271770	620	629	triggered	T080	C1444748
27271770	634	649	assembly of SGs	T045	C2247634
27271770	666	693	immunofluorescence staining	T059	C0079603
27271770	697	700	SGs	T026	C1325596
27271770	701	708	markers	T201	C0005516
27271770	713	726	COX-2 protein	T116,T126	C0387583
27271770	728	731	RNA	T114	C0035668
27271770	732	766	fluorescence in situ hybridization	T063	C0162789
27271770	771	774	RNA	T114	C0035668
27271770	775	794	immunoprecipitation	T059	C0021069
27271770	800	805	COX-2	T028	C1367485
27271770	806	811	mRNAs	T114,T123	C0035696
27271770	823	834	sequestered	T169	C0333312
27271770	838	841	SGs	T026	C1325596
27271770	845	850	IL-1Î²	T116,T129	C0021753
27271770	853	863	stimulated	T061	C1292856
27271770	864	866	OA	T047	C0029408
27271770	867	879	chondrocytes	T025	C0225369
27271770	881	883	No	T033	C1513916
27271770	884	892	increase	T169	C0442805
27271770	896	901	COX-2	T116,T126	C0387583
27271770	902	920	protein expression	T045	C1171362
27271770	945	956	persistence	T079	C0439590
27271770	960	963	SGs	T026	C1325596
27271770	968	976	enhanced	T052	C2349975
27271770	977	987	expression	T045	C1171362
27271770	991	1004	COX-2 protein	T116,T126	C0387583
27271770	1020	1029	clearance	T080	C0449297
27271770	1037	1040	SGs	T026	C1325596
27271770	1042	1052	Inhibition	T052	C3463820
27271770	1056	1059	SGs	T026	C1325596
27271770	1060	1069	clearance	T080	C0449297
27271770	1070	1077	blocked	T169	C0332206
27271770	1078	1083	COX-2	T028	C1367485
27271770	1084	1088	mRNA	T114,T123	C0035696
27271770	1089	1100	translation	UnknownType	C0678935
27271770	1109	1117	blocking	T169	C0332206
27271770	1122	1137	assembly of SGs	T045	C2247634
27271770	1141	1146	TIA-1	T116,T129	C1429678
27271770	1147	1156	depletion	T169	C0333668
27271770	1179	1188	increased	T081	C0205217
27271770	1189	1199	production	T169	C0005572
27271770	1203	1208	COX-2	T116,T126	C0387583
27271770	1213	1217	PGE2	T109,T121,T125	C0012472
27271770	1256	1271	assembly of SGs	T045	C2247634
27271770	1276	1289	sequestration	T169	C0333312
27271770	1293	1298	COX-2	T028	C1367485
27271770	1299	1304	mRNAs	T114,T123	C0035696
27271770	1308	1313	human	T016	C0086418
27271770	1314	1316	OA	T047	C0029408
27271770	1317	1329	chondrocytes	T025	C0225369
27271770	1336	1359	pathological conditions	T184	C0039058
27271770	1361	1392	Post-transcriptional regulation	T045	C1514248
27271770	1396	1401	COX-2	T028	C1367485
27271770	1402	1419	mRNAs translation	UnknownType	C0678935
27271770	1423	1426	SGs	T026	C1325596
27271770	1447	1452	IL-1Î²	T116,T129	C0021753
27271770	1463	1472	catabolic	T169	C0311402
27271770	1473	1481	response	T032	C0871261
27271770	1496	1511	therapeutically	T061	C0087111
27271770	1524	1526	OA	T047	C0029408

27271775|t|Effect of target animacy on hand preference in Sichuan snub-nosed monkeys (Rhinopithecus roxellana)
27271775|a|Twenty-eight captive Sichuan snub-nosed monkeys (Rhinopithecus roxellana) were involved in the current study. Many individuals showed handedness, with a modest tendency toward left-hand use especially for animate targets, although no group-level handedness was found. There was no significant gender difference in the direction and strength of hand preference for both targets. Females showed a significantly higher overall rate of actions toward animate targets than inanimate targets for both hands, whereas males displayed almost the reversed pattern. There were no significant interactions between lateral hand use and target animacy for either males or females. Most individuals showed rightward or leftward laterality shift trends between inanimate and animate targets. These findings to some extent support the existence of a potential trend concerning a categorical neural distinction between targets demanding functional manipulation (inanimate objects) and those demanding social manipulation (animate objects), even though specialized hand preference based on target animacy has not been fully established in this arboreal Old World monkey species.
27271775	0	6	Effect	T080	C1280500
27271775	10	16	target	T169	C1521840
27271775	28	43	hand preference	T033	C0422881
27271775	47	73	Sichuan snub-nosed monkeys	T015	C1022940
27271775	75	98	Rhinopithecus roxellana	T015	C1022940
27271775	100	112	Twenty-eight	T081	C4283787
27271775	121	147	Sichuan snub-nosed monkeys	T015	C1022940
27271775	149	172	Rhinopithecus roxellana	T015	C1022940
27271775	179	187	involved	T169	C1314939
27271775	203	208	study	T062	C2603343
27271775	234	244	handedness	T032	C0023114
27271775	276	289	left-hand use	T033	C0234418
27271775	305	320	animate targets	T169	C1521840
27271775	346	356	handedness	T032	C0023114
27271775	361	366	found	T033	C0150312
27271775	378	392	no significant	T033	C1273937
27271775	393	410	gender difference	T032	C0036866
27271775	418	427	direction	T082	C0449738
27271775	432	440	strength	T081	C0237897
27271775	444	459	hand preference	T033	C0422881
27271775	464	468	both	T080	C1706086
27271775	469	476	targets	T169	C1521840
27271775	478	485	Females	T032	C0086287
27271775	495	508	significantly	T078	C0750502
27271775	509	515	higher	T080	C0205250
27271775	516	523	overall	T080	C1561607
27271775	524	528	rate	T081	C1521828
27271775	532	539	actions	T052	C3266814
27271775	540	546	toward	T169	C1280477
27271775	547	562	animate targets	T169	C1521840
27271775	568	585	inanimate targets	T169	C1521840
27271775	590	594	both	T080	C1706086
27271775	595	600	hands	T023	C0018563
27271775	610	615	males	T032	C0086582
27271775	616	625	displayed	T169	C0870432
27271775	626	632	almost	T080	C3828842
27271775	637	645	reversed	T169	C1555029
27271775	666	680	no significant	T033	C1273937
27271775	681	693	interactions	T169	C1704675
27271775	702	709	lateral	T082	C0205093
27271775	710	718	hand use	T040	C0562230
27271775	723	729	target	T169	C1521840
27271775	742	748	either	T033	C3844638
27271775	749	754	males	T032	C0086582
27271775	758	765	females	T032	C0086287
27271775	824	829	shift	T169	C0333051
27271775	830	836	trends	T079	C1521798
27271775	859	874	animate targets	T169	C1521840
27271775	882	890	findings	T033	C0243095
27271775	891	905	to some extent	T080	C1555600
27271775	906	913	support	T077	C1521721
27271775	918	927	existence	T077	C2987476
27271775	933	942	potential	T080	C3245505
27271775	943	948	trend	T079	C1521798
27271775	974	980	neural	T169	C3714606
27271775	981	992	distinction	T080	C1705242
27271775	1001	1008	targets	T169	C1521840
27271775	1019	1029	functional	T169	C0205245
27271775	1030	1042	manipulation	T033	C1832073
27271775	1044	1061	inanimate objects	T072	C0347997
27271775	1083	1089	social	T169	C0728831
27271775	1090	1102	manipulation	T033	C1832073
27271775	1104	1119	animate objects	T072	C0347997
27271775	1134	1145	specialized	T077	C1704211
27271775	1146	1161	hand preference	T033	C0422881
27271775	1171	1185	target animacy	T169	C1521840
27271775	1205	1216	established	T080	C0443211
27271775	1225	1258	arboreal Old World monkey species	T015	C1022940

27271951|t|Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
27271951|a|Paraneoplastic encephalitides usually precede a diagnosis of cancer and are often refractory to immunosuppressive therapy. Conversely, autoimmune encephalitides are reversible conditions that can occur in the presence or absence of cancer. To report the induction of autoimmune encephalitis in 2 patients after treatment of metastatic cancer with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab. A retrospective case study was conducted of the clinical and management course of 2 patients with progressive, treatment - refractory metastatic cancer who were treated with a single dose each (concomitantly) of the immune checkpoint inhibitors nivolumab, 1 mg/kg, and ipilimumab, 3 mg/kg. Nivolumab and ipilimumab. The clinical response to immunosuppressive therapy in suspected autoimmune encephalitis in the setting of immune checkpoint inhibitor use. Autoantibody testing confirmed identification of anti-N-methyl-D-aspartate receptor antibodies in the cerebrospinal fluid of 1 patient. Withdrawal of immune checkpoint inhibitors and initiation of immunosuppressive therapy, consisting of intravenous methylprednisolone sodium succinate equivalent to 1000 mg of methylprednisolone for 5 days, 0.4 mg/kg/d of intravenous immunoglobulin for 5 days, and 2 doses of rituximab, 1000 mg, in 1 patient and oral prednisone, 60 mg/d, in the other patient, resulted in improved neurologic symptoms. Immune checkpoint inhibition may favor the development of immune responses against neuronal antigens, leading to autoimmune encephalitis. Early recognition and treatment of autoimmune encephalitis in patients receiving immune checkpoint blockade therapy will likely be essential for maximizing clinical recovery and minimizing the effect of drug-related toxic effects. The mechanisms by which immune checkpoint inhibition may contribute to autoimmune encephalitis require further study.
27271951	0	11	Association	T080	C0439849
27271951	15	38	Autoimmune Encephalitis	T047	C0393639
27271951	53	80	Immune Checkpoint Inhibitor	T121	C1254351
27271951	81	90	Treatment	T169	C0039798
27271951	95	112	Metastatic Cancer	T191	C0027627
27271951	113	142	Paraneoplastic encephalitides	T047	C0338430
27271951	161	180	diagnosis of cancer	T060	C0920688
27271951	195	205	refractory	T169	C0205269
27271951	209	234	immunosuppressive therapy	T061	C0021079
27271951	248	273	autoimmune encephalitides	T047	C0393639
27271951	278	288	reversible	T169	C0205343
27271951	289	299	conditions	T080	C0348080
27271951	309	314	occur	T052	C1709305
27271951	322	330	presence	T033	C0150312
27271951	334	341	absence	T169	C0332197
27271951	345	351	cancer	T191	C0006826
27271951	367	376	induction	T169	C0205263
27271951	380	403	autoimmune encephalitis	T047	C0393639
27271951	409	417	patients	T101	C0030705
27271951	424	433	treatment	T169	C0039798
27271951	437	454	metastatic cancer	T191	C0027627
27271951	462	473	combination	T080	C0205195
27271951	481	509	immune checkpoint inhibitors	T121	C1254351
27271951	510	519	nivolumab	T116,T121,T129	C3657270
27271951	524	534	ipilimumab	T116,T121,T129	C1367202
27271951	538	562	retrospective case study	T062	C0035363
27271951	584	607	clinical and management	T058	C1516615
27271951	608	614	course	T079	C0750729
27271951	620	628	patients	T101	C0030705
27271951	634	645	progressive	T169	C0205329
27271951	647	656	treatment	T169	C0039798
27271951	659	687	refractory metastatic cancer	T191	C0677936
27271951	697	709	treated with	T061	C0332293
27271951	712	723	single dose	T081	C0869039
27271951	730	743	concomitantly	T079	C0521115
27271951	752	780	immune checkpoint inhibitors	T121	C1254351
27271951	781	790	nivolumab	T116,T121,T129	C3657270
27271951	805	815	ipilimumab	T116,T121,T129	C1367202
27271951	826	835	Nivolumab	T116,T121,T129	C3657270
27271951	840	850	ipilimumab	T116,T121,T129	C1367202
27271951	856	873	clinical response	T033	C4055223
27271951	877	902	immunosuppressive therapy	T061	C0021079
27271951	906	915	suspected	T080	C0332147
27271951	916	939	autoimmune encephalitis	T047	C0393639
27271951	958	985	immune checkpoint inhibitor	T121	C1254351
27271951	991	1011	Autoantibody testing	T059	C1272321
27271951	1012	1021	confirmed	T033	C0750484
27271951	1022	1036	identification	T080	C0205396
27271951	1040	1085	anti-N-methyl-D-aspartate receptor antibodies	T116,T129	C3203613
27271951	1093	1112	cerebrospinal fluid	T031	C0007806
27271951	1118	1125	patient	T101	C0030705
27271951	1127	1137	Withdrawal	T052	C2349954
27271951	1141	1169	immune checkpoint inhibitors	T121	C1254351
27271951	1174	1184	initiation	T169	C1704686
27271951	1188	1213	immunosuppressive therapy	T061	C0021079
27271951	1229	1240	intravenous	T169	C0013153
27271951	1241	1320	methylprednisolone sodium succinate equivalent to 1000 mg of methylprednisolone	T200	C4083084
27271951	1327	1331	days	T079	C0439228
27271951	1348	1374	intravenous immunoglobulin	T116,T121,T129	C0085297
27271951	1381	1385	days	T079	C0439228
27271951	1393	1398	doses	T081	C0178602
27271951	1402	1411	rituximab	T116,T121,T129	C0393022
27271951	1427	1434	patient	T101	C0030705
27271951	1439	1454	oral prednisone	T200	C0305834
27271951	1478	1485	patient	T101	C0030705
27271951	1499	1507	improved	T033	C0184511
27271951	1508	1527	neurologic symptoms	T184	C0235031
27271951	1529	1557	Immune checkpoint inhibition	T040	C2255931
27271951	1572	1583	development	T169	C1527148
27271951	1587	1603	immune responses	T042	C0301872
27271951	1612	1629	neuronal antigens	T129	C0521390
27271951	1642	1665	autoimmune encephalitis	T047	C0393639
27271951	1667	1684	Early recognition	T061	C0814435
27271951	1689	1698	treatment	T169	C0039798
27271951	1702	1725	autoimmune encephalitis	T047	C0393639
27271951	1729	1737	patients	T101	C0030705
27271951	1748	1782	immune checkpoint blockade therapy	T061	C0021079
27271951	1798	1807	essential	T080	C0205224
27271951	1823	1831	clinical	T080	C0205210
27271951	1832	1840	recovery	T052	C0237820
27271951	1870	1896	drug-related toxic effects	T033	C1408407
27271951	1922	1950	immune checkpoint inhibition	T040	C2255931
27271951	1969	1992	autoimmune encephalitis	T047	C0393639

27271969|t|Spatio-Temporal Distribution of Bark and Ambrosia Beetles in a Brazilian Tropical Dry Forest
27271969|a|Bark and the ambrosia beetles dig into host plants and live most of their lives in concealed tunnels. We assessed beetle community dynamics in tropical dry forest sites in early, intermediate, and late successional stages, evaluating the influence of resource availability and seasonal variations in guild structure. We collected a total of 763 beetles from 23 species, including 14 bark beetle species, and 9 ambrosia beetle species. Local richness of bark and ambrosia beetles was estimated at 31 species. Bark and ambrosia composition was similar over the successional stages gradient, and beta diversity among sites was primarily determined by species turnover, mainly in the bark beetle community. Bark beetle richness and abundance were higher at intermediate stages; availability of wood was the main spatial mechanism. Climate factors were effectively non-seasonal. Ambrosia beetles were not influenced by successional stages, however the increase in wood resulted in increased abundance. We found higher richness at the end of the dry and wet seasons, and abundance increased with air moisture and decreased with higher temperatures and greater rainfall. In summary, bark beetle species accumulation was higher at sites with better wood production, while the needs of fungi (host and air moisture), resulted in a favorable conditions for species accumulation of ambrosia. The overall biological pattern among guilds differed from tropical rain forests, showing patterns similar to dry forest areas.
27271969	0	28	Spatio-Temporal Distribution	T169	C1704711
27271969	32	36	Bark	T002	C0949119
27271969	41	49	Ambrosia	T002	C0331432
27271969	50	57	Beetles	T204	C0009276
27271969	63	72	Brazilian	T083	C0006137
27271969	73	92	Tropical Dry Forest	T070	C0086312
27271969	93	97	Bark	T002	C0949119
27271969	106	114	ambrosia	T002	C0331432
27271969	115	122	beetles	T204	C0009276
27271969	132	143	host plants	UnknownType	C0868970
27271969	186	193	tunnels	T082	C1116506
27271969	198	206	assessed	T052	C1516048
27271969	207	213	beetle	T204	C0009276
27271969	214	223	community	T096	C0009462
27271969	224	232	dynamics	T102	C0237587
27271969	236	255	tropical dry forest	T070	C0086312
27271969	256	261	sites	T082	C0205145
27271969	265	270	early	T079	C1279919
27271969	272	284	intermediate	T079	C1254367
27271969	290	294	late	T079	C0205087
27271969	295	314	successional stages	T079	C1306673
27271969	344	352	resource	T078	C0035201
27271969	353	365	availability	T169	C0470187
27271969	370	389	seasonal variations	T079	C0036496
27271969	393	408	guild structure	T080	C0205556
27271969	413	422	collected	T078	C1516695
27271969	438	445	beetles	T204	C0009276
27271969	454	461	species	T185	C1705920
27271969	476	480	bark	T002	C0949119
27271969	481	487	beetle	T204	C0009276
27271969	488	495	species	T185	C1705920
27271969	503	511	ambrosia	T002	C0331432
27271969	512	518	beetle	T204	C0009276
27271969	519	526	species	T185	C1705920
27271969	528	533	Local	T082	C0205276
27271969	534	542	richness	T080	C0205556
27271969	546	550	bark	T002	C0949119
27271969	555	563	ambrosia	T002	C0331432
27271969	564	571	beetles	T204	C0009276
27271969	592	599	species	T185	C1705920
27271969	601	605	Bark	T002	C0949119
27271969	610	618	ambrosia	T002	C0331432
27271969	619	630	composition	T078	C1254370
27271969	652	671	successional stages	T079	C1306673
27271969	672	680	gradient	T081	C0812409
27271969	686	700	beta diversity	T080	C1880371
27271969	707	712	sites	T082	C0205145
27271969	741	748	species	T185	C1705920
27271969	773	777	bark	T002	C0949119
27271969	778	784	beetle	T204	C0009276
27271969	785	794	community	T096	C0009462
27271969	796	800	Bark	T002	C0949119
27271969	801	807	beetle	T204	C0009276
27271969	808	816	richness	T080	C0205556
27271969	821	830	abundance	T080	C2346714
27271969	846	865	intermediate stages	T079	C1306673
27271969	867	882	availability of	T169	C0470187
27271969	883	887	wood	T167	C0043217
27271969	901	918	spatial mechanism	T169	C0441712
27271969	920	927	Climate	T070	C0008946
27271969	928	935	factors	T169	C1521761
27271969	953	965	non-seasonal	T080	C0205556
27271969	967	975	Ambrosia	T002	C0331432
27271969	976	983	beetles	T204	C0009276
27271969	1007	1026	successional stages	T079	C1306673
27271969	1040	1048	increase	T169	C0442805
27271969	1052	1056	wood	T167	C0043217
27271969	1069	1078	increased	T081	C0205217
27271969	1079	1088	abundance	T080	C2346714
27271969	1106	1114	richness	T080	C0205556
27271969	1133	1136	dry	T079	C0036497
27271969	1141	1152	wet seasons	T079	C0036497
27271969	1158	1167	abundance	T080	C2346714
27271969	1168	1177	increased	T081	C0205217
27271969	1183	1186	air	T167	C0001861
27271969	1187	1195	moisture	T167	C0868994
27271969	1222	1234	temperatures	T081	C0039476
27271969	1247	1255	rainfall	T070	C0034640
27271969	1269	1273	bark	T002	C0949119
27271969	1274	1280	beetle	T204	C0009276
27271969	1281	1288	species	T185	C1705920
27271969	1289	1301	accumulation	T169	C0205245
27271969	1316	1321	sites	T082	C0205145
27271969	1334	1338	wood	T167	C0043217
27271969	1339	1349	production	T052	C0441655
27271969	1370	1375	fungi	T004	C0016832
27271969	1377	1381	host	UnknownType	C0868970
27271969	1386	1389	air	T167	C0001861
27271969	1390	1398	moisture	T167	C0868994
27271969	1425	1435	conditions	T080	C0348080
27271969	1440	1447	species	T185	C1705920
27271969	1448	1460	accumulation	T169	C0205245
27271969	1464	1472	ambrosia	T002	C0331432
27271969	1486	1496	biological	T080	C0205460
27271969	1497	1504	pattern	T080	C0205556
27271969	1532	1553	tropical rain forests	T070	C0086312
27271969	1583	1599	dry forest areas	T070	C0086312

27272523|t|Intron Derived Size Polymorphism in the Mitochondrial Genomes of Closely Related Chrysoporthe Species
27272523|a|In this study, the complete mitochondrial (mt) genomes of Chrysoporthe austroafricana (190,834 bp), C. cubensis (89,084 bp) and C. deuterocubensis (124,412 bp) were determined. Additionally, the mitochondrial genome of another member of the Cryphonectriaceae, namely Cryphonectria parasitica (158,902 bp), was retrieved and annotated for comparative purposes. These genomes showed high levels of synteny, especially in regions including genes involved in oxidative phosphorylation and electron transfer, unique open reading frames (uORFs), ribosomal RNAs (rRNAs) and transfer RNAs (tRNAs), as well as intron positions. Comparative analyses revealed signatures of duplication events, intron number and length variation, and varying intronic ORFs which highlighted the genetic diversity of mt genomes among the Cryphonectriaceae. These mt genomes showed remarkable size polymorphism. The size polymorphism in the mt genomes of these closely related Chrysoporthe species was attributed to the varying number and length of introns, coding sequences and to a lesser extent, intergenic sequences. Compared to publicly available fungal mt genomes, the C. austroafricana mt genome is the second largest in the Ascomycetes thus far.
27272523	0	6	Intron	T114,T123	C0021920
27272523	7	14	Derived	T080	C1441547
27272523	15	19	Size	T082	C0456389
27272523	20	32	Polymorphism	T045	C0032529
27272523	40	61	Mitochondrial Genomes	T028	C1819716
27272523	65	80	Closely Related	T080	C0439849
27272523	81	101	Chrysoporthe Species	T004	C1633289
27272523	121	129	complete	T080	C0205197
27272523	130	156	mitochondrial (mt) genomes	T028	C1819716
27272523	160	187	Chrysoporthe austroafricana	T004	C1907678
27272523	202	213	C. cubensis	T004	C1641019
27272523	230	248	C. deuterocubensis	T004	C3717325
27272523	267	277	determined	T080	C0521095
27272523	297	317	mitochondrial genome	T028	C1819716
27272523	343	360	Cryphonectriaceae	T004	C1947056
27272523	369	393	Cryphonectria parasitica	T004	C0997457
27272523	412	421	retrieved	T080	C0205556
27272523	426	435	annotated	T080	C1552720
27272523	440	460	comparative purposes	T062	C0683941
27272523	468	475	genomes	T028	C0017428
27272523	498	505	synteny	T044	C0314656
27272523	521	528	regions	T082	C1254362
27272523	529	538	including	T169	C0332257
27272523	539	544	genes	T028	C0017337
27272523	545	556	involved in	T169	C1314939
27272523	557	582	oxidative phosphorylation	T044	C0030013
27272523	587	604	electron transfer	T044	C0013846
27272523	606	632	unique open reading frames	T028	C0079941
27272523	633	640	(uORFs)	T028	C0079941
27272523	642	656	ribosomal RNAs	T114,T123	C0035701
27272523	657	664	(rRNAs)	T114,T123	C0035701
27272523	669	682	transfer RNAs	T114,T123	C0035711
27272523	683	690	(tRNAs)	T114,T123	C0035711
27272523	703	709	intron	T114,T123	C0021920
27272523	710	719	positions	T082	C0733755
27272523	721	741	Comparative analyses	T062	C0683941
27272523	742	750	revealed	T080	C0443289
27272523	751	761	signatures	T169	C1708225
27272523	765	776	duplication	T045	C0017261
27272523	777	783	events	T051	C0441471
27272523	785	791	intron	T114,T123	C0021920
27272523	792	819	number and length variation	T070	C0042333
27272523	825	832	varying	T070	C0042333
27272523	833	841	intronic	T114,T123	C0021920
27272523	842	846	ORFs	T028	C0079941
27272523	869	886	genetic diversity	T070	C0042333
27272523	890	900	mt genomes	T028	C1819716
27272523	911	928	Cryphonectriaceae	T004	C1947056
27272523	936	946	mt genomes	T028	C1819716
27272523	965	969	size	T082	C0456389
27272523	970	982	polymorphism	T045	C0032529
27272523	988	992	size	T082	C0456389
27272523	993	1005	polymorphism	T045	C0032529
27272523	1013	1023	mt genomes	T028	C1819716
27272523	1033	1048	closely related	T080	C0439849
27272523	1049	1069	Chrysoporthe species	T004	C1633289
27272523	1092	1117	varying number and length	T070	C0042333
27272523	1121	1128	introns	T114,T123	C0021920
27272523	1130	1146	coding sequences	T028	C0079941
27272523	1156	1162	lesser	T080	C0547044
27272523	1163	1169	extent	T082	C0439792
27272523	1171	1191	intergenic sequences	T114,T123	C0887857
27272523	1193	1201	Compared	T052	C1707455
27272523	1224	1230	fungal	T169	C0521033
27272523	1231	1241	mt genomes	T028	C1819716
27272523	1247	1264	C. austroafricana	T004	C1907678
27272523	1265	1274	mt genome	T028	C1819716
27272523	1289	1296	largest	T081	C0443228
27272523	1304	1315	Ascomycetes	T004	C1960228

27272784|t|Detection and Characterization of Flat Aberrant Crypt Foci (Flat ACF) in the Novel A/J Min/+ Mouse
27272784|a|Flat aberrant crypt foci (flat ACF) and mucin-depleted foci (MDF) have previously been described as preneoplastic colonic lesions. We used the novel A/J Min/+ mouse model, that demonstrates extensive spontaneous colon carcinogenesis to refine the method of detection of flat ACF and further characterize and define them as early lesions by histological examination and comparison with MDF. Colons were stained with methylene blue (MB) for flat ACF detection and restained with high-iron diamine-alcian blue (HID-AB) for MDF detection. Optimal flat ACF recognition required at least 24 h of storage post- MB staining and adherence to a set of characteristics. The fraction of flat ACF corresponding with MDF was 93%. Flat ACF / MDF displayed the same picture of severe dysplasia, lack of mucus and goblet cells and accumulation of cytoplasmic Î²-catenin. The easily detectable flat ACF are reliable surface biomarkers of Apc -driven colon carcinogenesis.
27272784	0	9	Detection	T061	C1511790
27272784	34	69	Flat Aberrant Crypt Foci (Flat ACF)	T047	C1510713
27272784	83	98	A/J Min/+ Mouse	T050	C2986594
27272784	99	123	Flat aberrant crypt foci	T047	C1510713
27272784	125	133	flat ACF	T047	C1510713
27272784	139	158	mucin-depleted foci	T047	C3828884
27272784	160	163	MDF	T047	C3828884
27272784	199	228	preneoplastic colonic lesions	T047	C1514395
27272784	248	269	A/J Min/+ mouse model	T050	C2986594
27272784	311	331	colon carcinogenesis	T191	C0699790
27272784	356	365	detection	T061	C1511790
27272784	369	377	flat ACF	T047	C1510713
27272784	428	435	lesions	T033	C0221198
27272784	439	463	histological examination	T059	C0019637
27272784	484	487	MDF	T047	C3828884
27272784	489	495	Colons	T023	C0009368
27272784	501	528	stained with methylene blue	T059	C1319310
27272784	530	532	MB	T109,T121,T130	C0025746
27272784	538	546	flat ACF	T047	C1510713
27272784	547	556	detection	T061	C1511790
27272784	561	570	restained	T059	C0487602
27272784	576	605	high-iron diamine-alcian blue	T109	C0062712
27272784	607	613	HID-AB	T109	C0062712
27272784	619	622	MDF	T047	C3828884
27272784	623	632	detection	T061	C1511790
27272784	642	650	flat ACF	T047	C1510713
27272784	703	714	MB staining	T059	C1319310
27272784	762	773	fraction of	T081	C1264633
27272784	774	782	flat ACF	T047	C1510713
27272784	802	805	MDF	T047	C3828884
27272784	815	823	Flat ACF	T047	C1510713
27272784	826	829	MDF	T047	C3828884
27272784	860	876	severe dysplasia	T049	C0334048
27272784	878	885	lack of	T080	C0332268
27272784	886	891	mucus	T025	C1513729
27272784	896	908	goblet cells	T025	C0014597
27272784	913	925	accumulation	T033	C4055506
27272784	929	940	cytoplasmic	T026	C0521449
27272784	941	950	Î²-catenin	T116,T123	C0105770
27272784	974	982	flat ACF	T047	C1510713
27272784	996	1003	surface	T026	C0699040
27272784	1004	1014	biomarkers	T201	C0005516
27272784	1018	1021	Apc	T028	C0162832
27272784	1030	1050	colon carcinogenesis	T191	C0699790

27273075|t|The flavivirus dengue induces hypertrophy of white matter astrocytes
27273075|a|Flaviviruses, including Zika and dengue (DENV), pose a serious global threat to human health. Of the 50+ million humans infected with DENV annually, approximately 1-3 % progress to severe disease manifestations, dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). Several factors are suspected to mediate the course of infection and pathogenesis of DENV infection. DHF and DSS are associated with vascular leakage and neurological sequelae. Our hypothesis was that altered astrocyte activation and morphology would alter the dynamics of the extracellular space and hence, neuronal and vascular function. We investigated the mechanisms of neuropathogenesis DENV infection in rhesus macaques. There were decreased numbers of GFAP immunopositive astrocytes per unit area, although those that remained had increased arbor length and complexity. This was combined with structural hypertrophy of white matter astrocytes in the absence of increased vascular leakage. Combined, these studies show how even low-grade infection with DENV induces measurable changes within the parenchyma of infected individuals.
27273075	4	14	flavivirus	T005	C0016215
27273075	15	21	dengue	T005	C0011315
27273075	30	41	hypertrophy	T046	C0020564
27273075	45	57	white matter	T024	C0682708
27273075	58	68	astrocytes	T025	C0004112
27273075	69	81	Flaviviruses	T005	C0016215
27273075	93	97	Zika	T005	C0318793
27273075	102	108	dengue	T005	C0011315
27273075	110	114	DENV	T005	C0011315
27273075	124	131	serious	T080	C0205404
27273075	132	138	global	T080	C2348867
27273075	139	145	threat	T078	C0749385
27273075	149	154	human	T016	C0086418
27273075	155	161	health	T078	C0018684
27273075	182	188	humans	T016	C0086418
27273075	189	197	infected	T033	C0439663
27273075	203	207	DENV	T005	C0011315
27273075	250	279	severe disease manifestations	T070	C1373233
27273075	281	305	dengue hemorrhagic fever	T047	C0019100
27273075	307	310	DHF	T047	C0019100
27273075	315	336	dengue shock syndrome	T047	C0376300
27273075	338	341	DSS	T047	C0376300
27273075	399	408	infection	T033	C0439663
27273075	413	425	pathogenesis	T046	C0699748
27273075	429	433	DENV	T005	C0011315
27273075	434	443	infection	T033	C0439663
27273075	445	448	DHF	T047	C0019100
27273075	453	456	DSS	T047	C0376300
27273075	461	476	associated with	T080	C0332281
27273075	477	493	vascular leakage	T046	C1400957
27273075	498	519	neurological sequelae	T046	C1285433
27273075	525	535	hypothesis	T078	C1512571
27273075	545	552	altered	T169	C0392747
27273075	553	573	astrocyte activation	T043	C1326121
27273075	578	588	morphology	T080	C0332437
27273075	595	600	alter	T169	C0392747
27273075	605	613	dynamics	T070	C3826426
27273075	621	640	extracellular space	T030	C0015352
27273075	652	660	neuronal	T039	C1254359
27273075	665	682	vascular function	T201	C0232337
27273075	718	735	neuropathogenesis	T047	C1518296
27273075	736	740	DENV	T005	C0011315
27273075	741	750	infection	T033	C0439663
27273075	754	769	rhesus macaques	T015	C0024400
27273075	782	799	decreased numbers	T033	C0243095
27273075	803	807	GFAP	T116,T129	C0486835
27273075	808	833	immunopositive astrocytes	T025	C0004112
27273075	882	891	increased	T081	C0205217
27273075	892	897	arbor	T082	C1254362
27273075	898	904	length	T081	C1444754
27273075	909	919	complexity	T033	C0243095
27273075	930	938	combined	T080	C0205195
27273075	944	954	structural	T082	C0678594
27273075	955	966	hypertrophy	T046	C0020564
27273075	970	982	white matter	T024	C0682708
27273075	983	993	astrocytes	T025	C0004112
27273075	1001	1008	absence	T169	C0332197
27273075	1012	1021	increased	T081	C0205217
27273075	1022	1038	vascular leakage	T046	C1400957
27273075	1040	1048	Combined	T080	C0205195
27273075	1078	1087	low-grade	T080	C1282907
27273075	1088	1097	infection	T033	C0439663
27273075	1103	1107	DENV	T005	C0011315
27273075	1116	1134	measurable changes	T169	C0392747
27273075	1146	1156	parenchyma	T023	C0933845
27273075	1160	1168	infected	T033	C0439663
27273075	1169	1180	individuals	T098	C0237401

27273160|t|Transcriptional enhancement of Smn levels in motoneurons is crucial for proper axon morphology in zebrafish
27273160|a|An unresolved mystery in the field of spinal muscular atrophy (SMA) is why a reduction of the ubiquitously expressed Smn protein causes defects mostly in motoneurons. We addressed the possibility that this restricted vulnerability stems from elevated Smn expression in motoneurons. To explore this, we established an ex vivo zebrafish culture system of GFP - marked motoneurons to quantitatively measure Smn protein and smn mRNA levels as well as promoter activity in motoneurons versus other cell types. Importantly, we uncovered that Smn levels are elevated in motoneurons by means of transcriptional activation. In addition, we identified the ETS family transcription factor Etv5b to be responsible for increased smn transcription in motoneurons. Moreover, we established that the additional supply of Smn protein in motoneurons is necessary for proper axonogenesis in a cell-autonomous manner. These findings demonstrate the reliance of motoneurons on more Smn, thereby adding a novel piece of evidence for their increased vulnerability under SMA conditions.
27273160	0	27	Transcriptional enhancement	T045	C0162493
27273160	31	34	Smn	T028	C1420257
27273160	35	41	levels	T034	C0428479
27273160	45	56	motoneurons	T025	C0026609
27273160	79	83	axon	T026	C0004461
27273160	84	94	morphology	T080	C0332437
27273160	98	107	zebrafish	T013	C0043457
27273160	146	169	spinal muscular atrophy	T047	C0026847
27273160	171	174	SMA	T047	C0026847
27273160	225	236	Smn protein	T116,T123	C1571507
27273160	244	251	defects	T033	C0241225
27273160	262	273	motoneurons	T025	C0026609
27273160	359	373	Smn expression	T045	C1171362
27273160	377	388	motoneurons	T025	C0026609
27273160	425	457	ex vivo zebrafish culture system	T074	C4305352
27273160	433	442	zebrafish	T013	C0043457
27273160	461	464	GFP	T116,T130	C0120285
27273160	467	473	marked	T080	C1708632
27273160	474	485	motoneurons	T025	C0026609
27273160	512	523	Smn protein	T034	C0428479
27273160	528	536	smn mRNA	T114,T123	C0035696
27273160	537	543	levels	T081	C0392762
27273160	576	587	motoneurons	T025	C0026609
27273160	601	605	cell	T025	C0007634
27273160	644	654	Smn levels	T034	C0428479
27273160	671	682	motoneurons	T025	C0026609
27273160	695	721	transcriptional activation	T045	C0162493
27273160	754	791	ETS family transcription factor Etv5b	T116,T123	C0919488
27273160	824	841	smn transcription	T045	C0040649
27273160	845	856	motoneurons	T025	C0026609
27273160	913	924	Smn protein	T116,T123	C1571507
27273160	928	939	motoneurons	T025	C0026609
27273160	964	976	axonogenesis	T042	C1160337
27273160	982	1004	cell-autonomous manner	T043	C0007613
27273160	1012	1020	findings	T034	C0587081
27273160	1049	1060	motoneurons	T025	C0026609
27273160	1069	1072	Smn	T116,T123	C1571507
27273160	1106	1114	evidence	T078	C3887511
27273160	1125	1134	increased	T081	C0205217
27273160	1135	1148	vulnerability	T201	C0012655
27273160	1155	1169	SMA conditions	T047	C0026847

27273231|t|Experimental study in pulmonary artery sealing with a vessel-sealing device
27273231|a|The development of vessel-sealing devices will facilitate safety in video-assisted thoracoscopic surgery. Our objective was to evaluate the feasibility and safety of sealing pulmonary arteries with the Enseal tissue-sealing device. Pulmonary arteries from beagle dogs (mean body weight 13.1 kg, range 10.5-15.4 kg) were divided into 3 groups according to the in-vivo sealing method used (Enseal, ligation, and proximal ligation plus distal Enseal) and extracted to evaluate the pressure tolerance up to 75 mm Hg at the sealed end. A left lower lobectomy was performed to evaluate chronic-phase durability of the sealed stumps in a survival model. Two or three branches of the pulmonary arteries in each dog were allocated to each of the 3 groups. After the scheduled survival period, the pulmonary arteries were sampled. Pressure tolerance at the sealed end was evaluated in 91 pulmonary artery sections. All sealed ends showed pressure tolerance >75 mm Hg. A left lower lobectomy was performed in 13 dogs in which 35 pulmonary artery sections had been allocated into the 3 groups. No sealing failure was found, and pathological findings showed healing and persistent hemostasis at all sealed ends of the pulmonary arteries after 2 and 4 weeks of the survival period. Pulmonary arteries sealed in vivo with the Enseal device showed pressure tolerance >75 mm Hg in the acute phase, and persistent hemostasis after 2 or 4 weeks. Pulmonary artery sealing with the Enseal device is feasible and safe in thoracic surgery settings.
27273231	0	18	Experimental study	T062	C0681814
27273231	22	38	pulmonary artery	T023	C0034052
27273231	39	46	sealing	T061	C1963784
27273231	54	75	vessel-sealing device	T074	C0025080
27273231	95	117	vessel-sealing devices	T074	C0025080
27273231	134	140	safety	T068	C0036043
27273231	144	180	video-assisted thoracoscopic surgery	T061	C0752151
27273231	216	227	feasibility	T080	C0205556
27273231	232	238	safety	T068	C0036043
27273231	242	249	sealing	T061	C1963784
27273231	250	268	pulmonary arteries	T023	C0034052
27273231	278	306	Enseal tissue-sealing device	T074	C0025080
27273231	308	326	Pulmonary arteries	T023	C0034052
27273231	332	343	beagle dogs	T015	C1296765
27273231	411	417	groups	T096	C1642385
27273231	435	442	in-vivo	T082	C1515655
27273231	443	457	sealing method	T170	C0449371
27273231	464	470	Enseal	T074	C0025080
27273231	472	480	ligation	T061	C0189722
27273231	486	494	proximal	T082	C0205107
27273231	495	503	ligation	T061	C0189722
27273231	509	515	distal	T082	C0205108
27273231	516	522	Enseal	T074	C0025080
27273231	554	562	pressure	T067	C0033095
27273231	563	572	tolerance	T080	C1704410
27273231	595	601	sealed	T169	C0587267
27273231	602	605	end	T082	C0444930
27273231	620	629	lobectomy	T061	C0023928
27273231	656	669	chronic-phase	T079	C0457343
27273231	688	701	sealed stumps	T074	C0025080
27273231	707	721	survival model	T008	C0599779
27273231	752	770	pulmonary arteries	T023	C0034052
27273231	779	782	dog	T015	C0012984
27273231	815	821	groups	T096	C1642385
27273231	843	851	survival	T052	C0038952
27273231	852	858	period	T079	C1948053
27273231	864	882	pulmonary arteries	T023	C0034052
27273231	897	905	Pressure	T067	C0033095
27273231	906	915	tolerance	T080	C1704410
27273231	923	929	sealed	T169	C0587267
27273231	930	933	end	T082	C0444930
27273231	954	970	pulmonary artery	T023	C0034052
27273231	985	991	sealed	T169	C0587267
27273231	992	996	ends	T082	C0444930
27273231	1004	1012	pressure	T067	C0033095
27273231	1013	1022	tolerance	T080	C1704410
27273231	1047	1056	lobectomy	T061	C0023928
27273231	1077	1081	dogs	T015	C0012984
27273231	1094	1110	pulmonary artery	T023	C0034052
27273231	1150	1156	groups	T096	C1642385
27273231	1158	1160	No	T033	C1513916
27273231	1161	1168	sealing	T061	C1963784
27273231	1169	1176	failure	T169	C0231174
27273231	1192	1204	pathological	T169	C1521733
27273231	1205	1213	findings	T033	C0243095
27273231	1221	1228	healing	T040	C0043240
27273231	1233	1243	persistent	T079	C0205322
27273231	1244	1254	hemostasis	T042	C0019116
27273231	1262	1268	sealed	T169	C0587267
27273231	1269	1273	ends	T082	C0444930
27273231	1281	1299	pulmonary arteries	T023	C0034052
27273231	1314	1319	weeks	T079	C0439230
27273231	1327	1335	survival	T052	C0038952
27273231	1336	1342	period	T079	C1948053
27273231	1344	1362	Pulmonary arteries	T023	C0034052
27273231	1363	1369	sealed	T169	C0587267
27273231	1370	1377	in vivo	T082	C1515655
27273231	1387	1400	Enseal device	T074	C0025080
27273231	1408	1416	pressure	T067	C0033095
27273231	1417	1426	tolerance	T080	C1704410
27273231	1444	1455	acute phase	T079	C0439557
27273231	1461	1471	persistent	T079	C0205322
27273231	1472	1482	hemostasis	T042	C0019116
27273231	1496	1501	weeks	T079	C0439230
27273231	1503	1519	Pulmonary artery	T023	C0034052
27273231	1520	1527	sealing	T061	C1963784
27273231	1537	1550	Enseal device	T074	C0025080
27273231	1554	1562	feasible	T080	C0205556
27273231	1567	1571	safe	T068	C0036043
27273231	1575	1591	thoracic surgery	T061	C0524832

27273307|t|Pathophysiology, treatment and prevention of ovarian hyperstimulation syndrome
27273307|a|Severe ovarian hyperstimulation syndrome (OHSS) is an iatrogenic condition that affects 1% of women that undergo treatment with assisted reproductive technology. The review aims to summarize recent evidence on pathophysiology, treatment, and prevention of OHSS. The pathophysiology is still not completely understood; however, vascular endothelial growth factor is likely to be an important mediator. Human chorionic gonadotropin was previously thought to be necessary for OHSS to occur; however, recent case reports have proven otherwise. The contribution of an attenuated anti-Mullerian hormone signalling pathway and CD11c + HLA-DR + dendritic cells and associated interleukins has been explored recently as contributors to pathogenesis. Treatment is largely supportive and is based mainly on consensus statements rather than evidence. Therefore, it is important to prevent this condition by identifying women at risk, allowing the clinician to implement preventive strategies, including the use of GnRH antagonist cycles with agonist triggers. More research is required to elucidate the pathophysiology behind the condition. Clinicians should employ strategies to prevent OHSS.
27273307	0	15	Pathophysiology	T169	C0031847
27273307	17	26	treatment	T061	C0087111
27273307	31	41	prevention	T061	C0199176
27273307	45	78	ovarian hyperstimulation syndrome	T047	C0085083
27273307	79	85	Severe	T080	C0205082
27273307	86	119	ovarian hyperstimulation syndrome	T047	C0085083
27273307	121	125	OHSS	T047	C0085083
27273307	133	143	iatrogenic	T080	C0439669
27273307	144	153	condition	T080	C0348080
27273307	159	166	affects	T077	C4054723
27273307	173	178	women	T098	C0043210
27273307	192	201	treatment	T061	C0087111
27273307	207	239	assisted reproductive technology	T061	C0872104
27273307	245	251	review	T170	C0282443
27273307	252	256	aims	T078	C1947946
27273307	260	269	summarize	T170	C1706244
27273307	270	276	recent	T079	C0332185
27273307	277	285	evidence	T078	C3887511
27273307	289	304	pathophysiology	T169	C0031847
27273307	306	315	treatment	T061	C0087111
27273307	321	331	prevention	T061	C0199176
27273307	335	339	OHSS	T047	C0085083
27273307	345	360	pathophysiology	T169	C0031847
27273307	374	384	completely	T080	C0205197
27273307	385	395	understood	T041	C0162340
27273307	406	440	vascular endothelial growth factor	T116,T123	C0078058
27273307	460	469	important	T080	C3898777
27273307	480	508	Human chorionic gonadotropin	T116,T121,T125	C1141639
27273307	524	531	thought	T041	C0039869
27273307	552	556	OHSS	T047	C0085083
27273307	560	565	occur	T052	C1709305
27273307	576	595	recent case reports	T170	C0007320
27273307	601	607	proven	T080	C0456369
27273307	623	635	contribution	T052	C1880177
27273307	642	652	attenuated	T052	C0599946
27273307	653	675	anti-Mullerian hormone	T116,T121,T125	C0066928
27273307	676	694	signalling pathway	T043	C0037083
27273307	699	704	CD11c	T116,T129,T192	C0023395
27273307	707	713	HLA-DR	T116,T129	C0019764
27273307	716	731	dendritic cells	T025	C0011306
27273307	736	746	associated	T080	C0332281
27273307	747	759	interleukins	T116,T129	C0021764
27273307	778	786	recently	T079	C0332185
27273307	790	802	contributors	T052	C1880177
27273307	806	818	pathogenesis	T046	C0699748
27273307	820	829	Treatment	T061	C0087111
27273307	841	851	supportive	T061	C0344211
27273307	859	864	based	T078	C1705938
27273307	875	884	consensus	T054	C0376298
27273307	885	895	statements	T078	C1710187
27273307	908	916	evidence	T078	C3887511
27273307	935	944	important	T080	C3898777
27273307	948	955	prevent	T169	C1292733
27273307	961	970	condition	T080	C0348080
27273307	974	985	identifying	T058	C1269815
27273307	986	991	women	T098	C0043210
27273307	992	999	at risk	T080	C1444641
27273307	1001	1009	allowing	T054	C0683607
27273307	1014	1023	clinician	T097	C0871685
27273307	1027	1036	implement	T052	C1708476
27273307	1037	1058	preventive strategies	T170	C0679716
27273307	1060	1069	including	T169	C0332257
27273307	1081	1096	GnRH antagonist	T121,T125	C1268855
27273307	1097	1103	cycles	T079	C0001289
27273307	1109	1116	agonist	T121	C2987634
27273307	1132	1140	research	T062	C0035168
27273307	1144	1152	required	T169	C1514873
27273307	1170	1185	pathophysiology	T169	C0031847
27273307	1197	1206	condition	T080	C0348080
27273307	1208	1218	Clinicians	T097	C0871685
27273307	1226	1232	employ	T169	C0457083
27273307	1233	1243	strategies	T041	C0679199
27273307	1247	1254	prevent	T061	C0679698
27273307	1255	1259	OHSS	T047	C0085083

27273918|t|A DANGEROUS MUDDYING OF THE WATERS? THE ' SIGNIFICANT HARM ' OF RE B AND G (CHILDREN) (CARE PROCEEDINGS)[2015] EWFC 3
27273918|a|The academic debate rages on as to whether male circumcision really is in the best interests of the child or if it constitutes an abusive practice. This commentary discusses the recent case of Re B and G (children) (care proceedings) [2015] EWFC 3, delivered by the current President of the Family Division of the High court, Sir James Munby. Two key issues are raised by this judgment. First, that President Munby's obiter comments constitute an attack on the legally accepted act of male circumcision by suggesting a similar nature between the illegal act of female genital mutilation (FGM) and that of male circumcision as well as the suggestion that male circumcision can be classed as a significant harm. Second, that this case reflects the woefully unprepared condition of the UK medical profession in dealing with FGM.
27273918	42	53	SIGNIFICANT	T078	C0750502
27273918	54	58	HARM	UnknownType	C0680558
27273918	64	84	RE B AND G (CHILDREN	T100	C0008059
27273918	87	103	CARE PROCEEDINGS	T057	C0584988
27273918	122	130	academic	UnknownType	C0683838
27273918	131	137	debate	T052	C0870392
27273918	138	143	rages	T041	C0034634
27273918	161	178	male circumcision	T061	C0008819
27273918	196	200	best	T080	C1522427
27273918	201	210	interests	T041	C0543488
27273918	218	223	child	T100	C0008059
27273918	248	255	abusive	T051	C1546935
27273918	256	264	practice	T080	C0475222
27273918	271	281	commentary	T170	C0282411
27273918	282	291	discusses	T054	C2584313
27273918	296	302	recent	T079	C0332185
27273918	303	307	case	T169	C0868928
27273918	311	332	Re B and G (children)	T100	C0008059
27273918	334	350	care proceedings	T057	C0584988
27273918	384	391	current	T079	C0521116
27273918	392	401	President	T097	C0679924
27273918	409	442	Family Division of the High court	T092	C0029246
27273918	469	475	issues	T033	C0033213
27273918	480	486	raised	T080	C0442818
27273918	495	503	judgment	T033	C1287392
27273918	517	526	President	T097	C0679924
27273918	542	550	comments	T170	C0947611
27273918	565	571	attack	T054	C1261512
27273918	579	586	legally	T169	C1301860
27273918	587	595	accepted	T080	C1272684
27273918	596	599	act	T052	C3266814
27273918	603	620	male circumcision	T061	C0008819
27273918	637	644	similar	T080	C2348205
27273918	645	651	nature	T169	C1262865
27273918	664	671	illegal	T078	C3242151
27273918	672	675	act	T052	C3266814
27273918	679	704	female genital mutilation	T054	C0403893
27273918	706	709	FGM	T054	C0403893
27273918	723	740	male circumcision	T061	C0008819
27273918	756	766	suggestion	T078	C1705535
27273918	772	789	male circumcision	T061	C0008819
27273918	810	821	significant	T078	C0750502
27273918	822	826	harm	UnknownType	C0680558
27273918	846	850	case	T169	C0868928
27273918	851	859	reflects	T041	C0558058
27273918	873	883	unprepared	T185	C4082133
27273918	884	893	condition	T080	C0348080
27273918	901	903	UK	T083	C0041700
27273918	904	922	medical profession	T091	C0814933
27273918	939	942	FGM	T054	C0403893

27274087|t|Zinc transporter ZIP10 forms a heteromer with ZIP6 which regulates embryonic development and cell migration
27274087|a|There is growing evidence that zinc and its transporters are involved in cell migration during development and in cancer. In the present study, we show that zinc transporter ZIP10 (SLC39A10) stimulates cell motility and proliferation, both in mammalian cells and in the zebrafish embryo. This is associated with inactivation of GSK-3Î± and -3Ã and downregulation of E-cadherin (CDH1). Morpholino -mediated knock-down of zip10 causes delayed epiboly and deformities of the head, eye, heart and tail. Furthermore, zip10 deficiency results in overexpression of cdh1, zip6 and stat3, the latter gene product driving transcription of both zip6 and zip10 The non-reduntant requirement of Zip6 and Zip10 for epithelial to mesenchymal transition (EMT) is consistent with our finding that they exist as a heteromer. We postulate that a subset of ZIPs carrying PrP-like ectodomains, including ZIP6 and ZIP10, are integral to cellular pathways and plasticity programs, such as EMT.
27274087	0	16	Zinc transporter	T116,T123	C1608304
27274087	17	22	ZIP10	T116,T123	C1957162
27274087	46	50	ZIP6	T116,T123	C1432030
27274087	57	66	regulates	T038	C1327622
27274087	67	88	embryonic development	T042	C0013936
27274087	93	107	cell migration	T043	C1622501
27274087	125	133	evidence	T078	C3887511
27274087	139	143	zinc	T121,T123,T196	C0043481
27274087	152	164	transporters	T116,T123	C1608304
27274087	169	177	involved	T169	C1314939
27274087	181	195	cell migration	T043	C1622501
27274087	196	202	during	T079	C0347984
27274087	203	214	development	T040	C0678723
27274087	222	228	cancer	T191	C0006826
27274087	245	250	study	T062	C2603343
27274087	265	281	zinc transporter	T116,T123	C1608304
27274087	282	287	ZIP10	T116,T123	C1957162
27274087	289	297	SLC39A10	T116,T123	C1957162
27274087	299	309	stimulates	T070	C1948023
27274087	310	323	cell motility	T040	C0007608
27274087	328	341	proliferation	T043	C0596290
27274087	351	366	mammalian cells	T025	C1512977
27274087	378	387	zebrafish	T013	C0043457
27274087	388	394	embryo	T018	C0013935
27274087	404	419	associated with	T080	C0332281
27274087	420	432	inactivation	T044	C0314679
27274087	436	442	GSK-3Î±	T116,T126	C3853562
27274087	447	450	-3Ã	T116,T126	C4283740
27274087	455	469	downregulation	T044	C0013081
27274087	473	483	E-cadherin	T116,T123	C0042172
27274087	485	489	CDH1	T116,T123	C1739912
27274087	492	502	Morpholino	T114	C1881903
27274087	513	523	knock-down	T063	C2350567
27274087	527	532	zip10	T028	C1427168
27274087	540	547	delayed	T079	C0205421
27274087	548	555	epiboly	T042	C3548582
27274087	560	571	deformities	T080	C1527361
27274087	579	583	head	T029	C0018670
27274087	585	588	eye	T023	C0015392
27274087	590	595	heart	T023	C0018787
27274087	600	604	tail	T023	C0039259
27274087	619	624	zip10	T116,T123	C1957162
27274087	625	635	deficiency	T169	C0011155
27274087	647	661	overexpression	T045	C1514559
27274087	665	669	cdh1	T116,T123	C1739912
27274087	671	675	zip6	T116,T123	C1432030
27274087	680	685	stat3	T116,T123	C0253050
27274087	698	710	gene product	T116,T123	C0033684
27274087	719	732	transcription	T045	C0040649
27274087	741	745	zip6	T116,T123	C1432030
27274087	750	755	zip10	T116,T123	C1957162
27274087	774	785	requirement	T169	C1514873
27274087	789	793	Zip6	T116,T123	C1432030
27274087	798	803	Zip10	T116,T123	C1957162
27274087	808	844	epithelial to mesenchymal transition	T043	C1523298
27274087	846	849	EMT	T043	C1523298
27274087	854	869	consistent with	T078	C0332290
27274087	874	881	finding	T033	C0243095
27274087	892	897	exist	T077	C2987476
27274087	934	940	subset	T185	C1515021
27274087	944	948	ZIPs	T116,T123	C2934441
27274087	958	978	PrP-like ectodomains	T087	C1514562
27274087	980	989	including	T169	C0332257
27274087	990	994	ZIP6	T116,T123	C1432030
27274087	999	1004	ZIP10	T116,T123	C1957162
27274087	1010	1018	integral	T081	C0443238
27274087	1022	1030	cellular	T059	C0178539
27274087	1031	1039	pathways	T044	C1704259
27274087	1044	1054	plasticity	T043	C4042875
27274087	1055	1063	programs	T169	C3484370
27274087	1073	1076	EMT	T043	C1523298

27274281|t|Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma
27274281|a|Axitinib, a selective and potent tyrosine kinase inhibitor of vascular endothelial growth factor receptors, was available to patients from Canada and Australia, prior to regulatory approval of axitinib in these countries, for treatment of clear-cell metastatic renal cell carcinoma (mRCC) after failure of one prior systemic regimen. This single-arm, open-label study of axitinib evaluated the efficacy, safety, and quality of life (QoL) in patients with mRCC whose disease progressed after one prior systemic first-line regimen. Primary objective was objective response rate evaluated per Response Evaluation Criteria in Solid Tumors (RECIST) and Choi criteria. Progression-free survival, overall survival, safety, and QoL were secondary end points. Due to the small study size, analyses comprised of descriptive statistics. Fifteen patients were recruited, five from Canada and ten from Australia, over a limited recruitment period. Thirteen patients received sunitinib as prior therapy. All patients had clear-cell carcinoma, eleven had prior nephrectomy. Liver, lung, and lymph nodes were the most frequent sites of metastases; one patient had brain metastasis. Median time on axitinib was 118.0 days (range: 3.5-645.0 days); estimated survival probability at 12 months was 57.8%. Two (13.3%) patients had objective responses per RECIST versus nine (60.0%) per Choi criteria. Six patients had progressive disease based on RECIST versus three per Choi criteria. Nine (60.0%) events of progression or death occurred by the end of study, and three patients continued to receive the study drug. Fatigue (33%) and diarrhea (20%) were the most common grade â¥3 all-causality, treatment -emergent adverse events. The mean change in European Quality of Life - 5 Dimensions score from baseline to end of treatment was -0.0837. The small number of patients and lack of a comparator arm limit the ability to draw definitive conclusions; however, safety and efficacy profiles of axitinib were consistent with reports from previous studies in patients with mRCC, and patients generally maintained QoL. The sizeable difference observed in objective response rate by RECIST versus Choi criteria merits further research.
27274281	0	10	Evaluation	T058	C0220825
27274281	28	36	axitinib	T109,T121	C1700874
27274281	41	85	Response Evaluation Criteria in Solid Tumors	T170	C1709926
27274281	93	106	Choi criteria	T170	C0935549
27274281	121	128	treated	T033	C0332154
27274281	129	137	patients	T101	C0030705
27274281	143	174	metastatic renal cell carcinoma	T191	C0278678
27274281	175	183	Axitinib	T109,T121	C1700874
27274281	208	233	tyrosine kinase inhibitor	T121	C1268567
27274281	237	281	vascular endothelial growth factor receptors	T116,T126,T192	C0148199
27274281	300	308	patients	T101	C0030705
27274281	314	320	Canada	T083	C0006823
27274281	325	334	Australia	T083	C0004340
27274281	356	364	approval	T170	C2346845
27274281	368	376	axitinib	T109,T121	C1700874
27274281	386	395	countries	T083	C0454664
27274281	401	410	treatment	T061	C0087111
27274281	414	456	clear-cell metastatic renal cell carcinoma	T191	C2931852
27274281	458	462	mRCC	T191	C2931852
27274281	500	507	regimen	T061	C0040808
27274281	514	524	single-arm	T062	C2826346
27274281	526	542	open-label study	T062	C1709323
27274281	546	554	axitinib	T109,T121	C1700874
27274281	569	577	efficacy	T062	C1707887
27274281	579	585	safety	T062	C1705187
27274281	591	606	quality of life	T078	C0034380
27274281	608	611	QoL	T078	C0034380
27274281	616	624	patients	T101	C0030705
27274281	630	634	mRCC	T191	C2931852
27274281	641	648	disease	T047	C0012634
27274281	649	659	progressed	T046	C0242656
27274281	685	703	first-line regimen	T061	C1708063
27274281	737	750	response rate	T079	C0237629
27274281	751	760	evaluated	T058	C0220825
27274281	765	809	Response Evaluation Criteria in Solid Tumors	T170	C1709926
27274281	811	817	RECIST	T170	C1709926
27274281	823	836	Choi criteria	T170	C0935549
27274281	838	863	Progression-free survival	T081	C0242792
27274281	865	881	overall survival	T081	C4086681
27274281	883	889	safety	T062	C1705187
27274281	895	898	QoL	T078	C0034380
27274281	943	948	study	T062	C2603343
27274281	989	999	statistics	T062	C2717898
27274281	1009	1017	patients	T101	C0030705
27274281	1044	1050	Canada	T083	C0006823
27274281	1064	1073	Australia	T083	C0004340
27274281	1119	1127	patients	T101	C0030705
27274281	1137	1146	sunitinib	T109,T121	C1176020
27274281	1156	1163	therapy	T061	C0087111
27274281	1169	1177	patients	T101	C0030705
27274281	1182	1202	clear-cell carcinoma	T191	C0206681
27274281	1221	1232	nephrectomy	T061	C0027695
27274281	1234	1239	Liver	T023	C0023884
27274281	1241	1245	lung	T023	C0024109
27274281	1251	1262	lymph nodes	T023	C0024204
27274281	1295	1305	metastases	T191	C0027627
27274281	1311	1318	patient	T101	C0030705
27274281	1323	1339	brain metastasis	T191	C0220650
27274281	1341	1347	Median	T081	C0876920
27274281	1356	1364	axitinib	T109,T121	C1700874
27274281	1375	1379	days	T079	C0439228
27274281	1381	1386	range	T081	C1514721
27274281	1398	1402	days	T079	C0439228
27274281	1415	1423	survival	T052	C0038952
27274281	1442	1448	months	T079	C0439231
27274281	1472	1480	patients	T101	C0030705
27274281	1495	1504	responses	T032	C0871261
27274281	1509	1515	RECIST	T170	C1709926
27274281	1540	1553	Choi criteria	T170	C0935549
27274281	1559	1567	patients	T101	C0030705
27274281	1572	1583	progressive	T046	C0242656
27274281	1584	1591	disease	T047	C0012634
27274281	1601	1607	RECIST	T170	C1709926
27274281	1625	1638	Choi criteria	T170	C0935549
27274281	1663	1674	progression	T046	C0242656
27274281	1678	1683	death	T040	C0011065
27274281	1707	1712	study	T062	C2603343
27274281	1724	1732	patients	T101	C0030705
27274281	1758	1763	study	T062	C2603343
27274281	1764	1768	drug	T121	C1254351
27274281	1770	1777	Fatigue	T184	C0015672
27274281	1788	1796	diarrhea	T184	C0011991
27274281	1848	1857	treatment	T061	C0087111
27274281	1868	1882	adverse events	T046	C0877248
27274281	1888	1892	mean	T081	C0444504
27274281	1903	1911	European	T083	C0015176
27274281	1912	1927	Quality of Life	T078	C0034380
27274281	1943	1948	score	T081	C0449820
27274281	1954	1962	baseline	T081	C1442488
27274281	1973	1982	treatment	T061	C0087111
27274281	2016	2024	patients	T101	C0030705
27274281	2080	2090	definitive	T079	C0443196
27274281	2091	2102	conclusions	T078	C1707478
27274281	2113	2119	safety	T062	C1705187
27274281	2124	2132	efficacy	T062	C1707887
27274281	2145	2153	axitinib	T109,T121	C1700874
27274281	2197	2204	studies	T062	C2603343
27274281	2208	2216	patients	T101	C0030705
27274281	2222	2226	mRCC	T191	C2931852
27274281	2232	2240	patients	T101	C0030705
27274281	2262	2265	QoL	T078	C0034380
27274281	2313	2326	response rate	T079	C0237629
27274281	2330	2336	RECIST	T170	C1709926
27274281	2344	2357	Choi criteria	T170	C0935549
27274281	2373	2381	research	T062	C0008972

27274417|t|Demographics, Health, and Risk Behaviors of Young Adults Who Drink Energy Drinks and Coffee Beverages
27274417|a|Objective: The present study investigates risk behaviors, sleep habits, and mental health factors associated with caffeinated beverage use in young adults. Materials and Methods: Students from a midsize private university (n = 159) completed a 15- minute anonymous questionnaire, including questions on risk behaviors, sleep habits, alcohol, and caffeine consumption. We compared behaviors between the top â¼15% ("high end") of energy drink users (â¥3/ month) and coffee users (â¥16/ month) to those with less frequent or no caffeine consumption. Results: Caffeine consumption was frequent among young adults. In the last month, 36% of students had an energy drink, 69% had coffee or espresso, and 86% reported having any caffeine; however, the majority of students were unaware of the caffeine content in these beverages. High-end energy drink consumers reported more risk-taking behaviors (increased drug and alcohol use and less frequent seat belt use), sleep disturbances (later bedtimes, harder time falling asleep, and more all-nighters), and higher frequency of mental illness diagnoses than those who consumed fewer energy drinks. In contrast, the frequency of most risk behaviors, sleep disturbances, and mental illness diagnoses was not significantly different between the high-end and general population of coffee drinkers. Conclusion: Students with delayed sleep patterns, mental illness, and higher frequency of substance use and risk behaviors were more likely to be regular energy drink users but not regular coffee drinkers. It is unclear whether the psychoactive content in energy drinks results in different behavioral effects than just caffeine in coffee, and/or different personality / health populations are drawn to the two types of beverages.
27274417	0	12	Demographics	T090	C0011298
27274417	14	20	Health	T055	C0018687
27274417	26	40	Risk Behaviors	T055	C0086931
27274417	44	56	Young Adults	T100	C0238598
27274417	61	66	Drink	T168	C0452428
27274417	67	80	Energy Drinks	T168	C3179078
27274417	85	91	Coffee	T168	C0009237
27274417	92	101	Beverages	T168	C0005329
27274417	102	111	Objective	T170	C0018017
27274417	117	124	present	T033	C0150312
27274417	125	130	study	T062	C2603343
27274417	131	143	investigates	T169	C1292732
27274417	144	158	risk behaviors	T055	C0086931
27274417	160	172	sleep habits	T033	C2133558
27274417	178	199	mental health factors	T033	C4035943
27274417	200	215	associated with	T080	C0332281
27274417	216	236	caffeinated beverage	T168	C0678438
27274417	244	256	young adults	T100	C0238598
27274417	258	267	Materials	T167	C0520510
27274417	272	279	Methods	T170	C0025663
27274417	281	289	Students	T098	C0038492
27274417	297	323	midsize private university	T073,T092	C0041740
27274417	350	356	minute	T079	C0439232
27274417	357	366	anonymous	T080	C2346787
27274417	367	380	questionnaire	T170	C0034394
27274417	392	401	questions	T078	C0681799
27274417	405	419	risk behaviors	T055	C0086931
27274417	421	433	sleep habits	T033	C2133558
27274417	435	442	alcohol	T055	C0001948
27274417	448	468	caffeine consumption	T054	C0948365
27274417	473	481	compared	T052	C1707455
27274417	482	491	behaviors	T053	C0004927
27274417	529	541	energy drink	T168	C3179078
27274417	542	547	users	T098	C1706077
27274417	553	558	month	T079	C0439231
27274417	564	570	coffee	T168	C0009237
27274417	571	576	users	T098	C1706077
27274417	583	588	month	T079	C0439231
27274417	604	617	less frequent	T079	C1254367
27274417	624	644	caffeine consumption	T054	C0948365
27274417	646	653	Results	T033	C0683954
27274417	655	675	Caffeine consumption	T054	C0948365
27274417	680	688	frequent	T079	C0332183
27274417	695	707	young adults	T100	C0238598
27274417	721	726	month	T079	C0439231
27274417	735	743	students	T098	C0038492
27274417	751	763	energy drink	T168	C3179078
27274417	773	779	coffee	T168	C0009237
27274417	783	791	espresso	T168	C0016452
27274417	821	829	caffeine	T109,T121	C0006644
27274417	844	852	majority	T054	C0680220
27274417	856	864	students	T098	C0038492
27274417	870	877	unaware	T062	C0150114
27274417	885	893	caffeine	T109,T121	C0006644
27274417	894	901	content	T077	C0456205
27274417	911	920	beverages	T168	C0005329
27274417	931	943	energy drink	T168	C3179078
27274417	944	953	consumers	T098	C1257890
27274417	968	989	risk-taking behaviors	T055	C0683303
27274417	991	1005	increased drug	T033	C1821939
27274417	1010	1021	alcohol use	T055	C0001948
27274417	1026	1039	less frequent	T079	C1254367
27274417	1040	1053	seat belt use	T033	C1303116
27274417	1056	1074	sleep disturbances	T184	C0037317
27274417	1076	1081	later	T079	C0205087
27274417	1082	1090	bedtimes	T079	C0521112
27274417	1092	1118	harder time falling asleep	T048	C0393760
27274417	1129	1141	all-nighters	T079	C1254367
27274417	1155	1164	frequency	T079	C0439603
27274417	1168	1182	mental illness	T048	C0004936
27274417	1183	1192	diagnoses	T033	C0011900
27274417	1208	1216	consumed	T033	C3173371
27274417	1223	1236	energy drinks	T168	C3179078
27274417	1241	1249	contrast	T080	C1979874
27274417	1255	1264	frequency	T079	C0439603
27274417	1273	1287	risk behaviors	T055	C0086931
27274417	1289	1307	sleep disturbances	T184	C0037317
27274417	1313	1327	mental illness	T048	C0004936
27274417	1328	1337	diagnoses	T033	C0011900
27274417	1382	1413	high-end and general population	T098	C1257890
27274417	1417	1423	coffee	T168	C0009237
27274417	1424	1432	drinkers	T033	C0556338
27274417	1434	1444	Conclusion	T078	C1707478
27274417	1446	1454	Students	T098	C0038492
27274417	1460	1467	delayed	T079	C0205421
27274417	1468	1482	sleep patterns	T033	C1849174
27274417	1484	1498	mental illness	T048	C0004936
27274417	1511	1520	frequency	T079	C0439603
27274417	1524	1537	substance use	T048	C0237123
27274417	1542	1556	risk behaviors	T055	C0086931
27274417	1588	1600	energy drink	T168	C3179078
27274417	1601	1606	users	T098	C1706077
27274417	1615	1638	regular coffee drinkers	T033	C0554771
27274417	1646	1653	unclear	T033	C3845108
27274417	1666	1678	psychoactive	T121	C0033978
27274417	1679	1686	content	T077	C0456205
27274417	1690	1703	energy drinks	T168	C3179078
27274417	1704	1711	results	T169	C1274040
27274417	1725	1743	behavioral effects	T053	C0004927
27274417	1754	1762	caffeine	T109,T121	C0006644
27274417	1766	1772	coffee	T168	C0009237
27274417	1791	1802	personality	T041	C0031208
27274417	1805	1823	health populations	T098	C1257890
27274417	1854	1863	beverages	T168	C0005329

27274524|t|Eosinophilic Gastroenteritis as a Rare Cause of Recurrent Epigastric Pain
27274524|a|Eosinophilic gastroenteritis (EGE) is a rare inflammatory disorder of gastrointestinal tract characterized by eosinophilic infiltration of the bowel wall. It can mimic many gastrointestinal disorders due to its wide spectrum of presentations. Diagnose is mostly based on excluding other disorders and a high suspicion. Here we report a case of 26 year old man with a history of sever epigastric pain followed by nausea, vomiting since a few days before admission with final diagnosis of EGE.
27274524	0	28	Eosinophilic Gastroenteritis	T047	C1262481
27274524	34	38	Rare	T080	C0522498
27274524	39	44	Cause	T169	C0015127
27274524	48	73	Recurrent Epigastric Pain	UnknownType	C0743544
27274524	74	102	Eosinophilic gastroenteritis	T047	C1262481
27274524	104	107	EGE	T047	C1262481
27274524	119	140	inflammatory disorder	T047	C1290884
27274524	144	166	gastrointestinal tract	T022	C0017189
27274524	167	180	characterized	T052	C1880022
27274524	184	209	eosinophilic infiltration	T046	C0333390
27274524	217	227	bowel wall	T023	C0021853
27274524	247	273	gastrointestinal disorders	T047	C0017178
27274524	285	315	wide spectrum of presentations	T033	C0243095
27274524	317	325	Diagnose	T033	C0011900
27274524	345	354	excluding	T169	C0332196
27274524	355	360	other	T080	C0205394
27274524	361	370	disorders	T047	C0012634
27274524	377	381	high	T080	C0205250
27274524	382	391	suspicion	T041	C0242114
27274524	401	414	report a case	T170	C0007320
27274524	421	425	year	T079	C0439234
27274524	426	429	old	T079	C0580836
27274524	430	433	man	T098	C0025266
27274524	441	448	history	T033	C0262926
27274524	452	473	sever epigastric pain	T184	C0232493
27274524	486	492	nausea	T184	C0027497
27274524	494	502	vomiting	T184	C0042963
27274524	511	514	few	T081	C0205388
27274524	515	519	days	T079	C0439228
27274524	520	526	before	T079	C0332152
27274524	527	536	admission	T058	C0030673
27274524	548	557	diagnosis	T033	C0011900
27274524	561	564	EGE	T047	C1262481

27274541|t|Biochemical characteristics of AtFAR2, a fatty acid reductase from Arabidopsis thaliana that reduces fatty acyl-CoA and - ACP substrates into fatty alcohols
27274541|a|Fatty alcohols and derivatives are important for proper deposition of a functional pollen wall. Mutations in specific genes encoding fatty acid reductases (FAR) responsible for fatty alcohol production cause abnormal development of pollen. A disrupted AtFAR2 (MS2) gene in Arabidopsis thaliana results in pollen developing an abnormal exine layer and a reduced fertility phenotype. AtFAR2 has been shown to be targeted to chloroplasts and in a purified form to be specific for acyl-ACP substrates. Here, we present data on the in vitro and in planta characterizations of AtFAR2 from A. thaliana and show that this enzyme has the ability to use both, C16:0-ACP and C16:0-CoA, as substrates to produce C16:0-alcohol. Our results further show that AtFAR2 is highly similar in properties and substrate specificity to AtFAR6 for which in vitro data has been published, and which is also a chloroplast localized enzyme. This suggests that although AtFAR2 is the major enzyme responsible for exine layer functionality, AtFAR6 might provide functional redundancy to AtFAR2.
27274541	0	11	Biochemical	T169	C0205474
27274541	12	27	characteristics	T080	C1521970
27274541	31	37	AtFAR2	T116,T126	C4307379
27274541	41	61	fatty acid reductase	T116,T126	C0060094
27274541	67	87	Arabidopsis thaliana	T002	C0162740
27274541	101	115	fatty acyl-CoA	T114,T123	C0001374
27274541	122	136	ACP substrates	T116,T123	C0001369
27274541	142	156	fatty alcohols	T109	C0015694
27274541	157	171	Fatty alcohols	T109	C0015694
27274541	176	187	derivatives	T104	C0243072
27274541	192	201	important	T080	C3898777
27274541	213	223	deposition	T169	C0333562
27274541	229	239	functional	T169	C0205245
27274541	240	251	pollen wall	T026	C1820005
27274541	253	262	Mutations	T045	C0596611
27274541	275	280	genes	T028	C0017337
27274541	290	311	fatty acid reductases	T116,T126	C0060094
27274541	313	316	FAR	T116,T126	C0060094
27274541	334	347	fatty alcohol	T109	C0015694
27274541	348	358	production	T169	C0205245
27274541	365	373	abnormal	T033	C0205161
27274541	374	385	development	T169	C1527148
27274541	389	395	pollen	T002	C0032385
27274541	399	408	disrupted	T080	C0332454
27274541	409	426	AtFAR2 (MS2) gene	T028	C1428496
27274541	430	450	Arabidopsis thaliana	T002	C0162740
27274541	451	458	results	T169	C1274040
27274541	462	468	pollen	T002	C0032385
27274541	469	479	developing	T169	C1527148
27274541	483	491	abnormal	T033	C0205161
27274541	492	503	exine layer	T026	C1820006
27274541	510	527	reduced fertility	T033	C0243095
27274541	528	537	phenotype	T032	C0031437
27274541	539	545	AtFAR2	T116,T126	C4307379
27274541	567	575	targeted	T169	C1521840
27274541	579	591	chloroplasts	T026	C0008266
27274541	601	614	purified form	T080	C0348078
27274541	621	629	specific	T080	C0205369
27274541	634	653	acyl-ACP substrates	T116,T123	C0001369
27274541	672	676	data	T078	C1511726
27274541	684	692	in vitro	T080	C1533691
27274541	700	706	planta	T002	C0032098
27274541	707	724	characterizations	T052	C1880022
27274541	728	734	AtFAR2	T116,T126	C4307379
27274541	740	751	A. thaliana	T002	C0162740
27274541	771	777	enzyme	T116,T126	C0014442
27274541	807	816	C16:0-ACP	T116,T123	C0001369
27274541	821	830	C16:0-CoA	T114,T123	C0030239
27274541	835	845	substrates	T120	C0178623
27274541	857	870	C16:0-alcohol	T109,T122	C0055152
27274541	902	908	AtFAR2	T116,T126	C4307379
27274541	930	940	properties	T080	C0205556
27274541	945	954	substrate	T120	C0178623
27274541	955	966	specificity	T081	C0037791
27274541	970	976	AtFAR6	T116,T126	C0060094
27274541	987	995	in vitro	T080	C1533691
27274541	996	1000	data	T078	C1511726
27274541	1041	1052	chloroplast	T026	C0008266
27274541	1053	1062	localized	T082	C0392752
27274541	1063	1069	enzyme	T116,T126	C0014442
27274541	1099	1105	AtFAR2	T116,T126	C4307379
27274541	1119	1125	enzyme	T116,T126	C0014442
27274541	1142	1153	exine layer	T026	C1820006
27274541	1154	1167	functionality	T169	C0542341
27274541	1169	1175	AtFAR6	T116,T126	C0060094
27274541	1190	1200	functional	T169	C0205245
27274541	1201	1211	redundancy	T169	C1313915
27274541	1215	1221	AtFAR2	T116,T126	C4307379

27274791|t|Comparing Time Perception among Morphine - Derived Drugs Addicts and Controls
27274791|a|The aim of the present study is to compare time perception among drug addicts and controls. 30 drug addicts were selected, and 30 non-addict individuals were selected as the control group. The two groups performed three tests of time reproduction, time estimation, and time discrimination. There was a significant difference between the addicts group and the control group regarding the error of time reproduction and time estimation. The addict group in comparison to the control group had a lower under- reproduction and a higher over- reproduction error, and also a lower under- estimation and higher over- estimation error. However, regarding time discrimination, no significant difference was observed between the errors committed by both groups. On the other hand, when showing images of drug consumption tools and normal images with same durations, the normal group believed that the images related to drug consumption tools were shown for a shorter period of time. Time perception is different between morphine - derived drugs addicts and controls.
27274791	0	9	Comparing	T052	C1707455
27274791	10	25	Time Perception	T041	C0040226
27274791	32	40	Morphine	T109,T121	C0026549
27274791	43	50	Derived	T080	C1441547
27274791	51	56	Drugs	T121	C0013227
27274791	57	64	Addicts	T101	C0858354
27274791	69	77	Controls	T096	C0009932
27274791	82	85	aim	T078	C1947946
27274791	101	106	study	T062	C2603343
27274791	113	120	compare	T052	C1707455
27274791	121	136	time perception	T041	C0040226
27274791	143	155	drug addicts	T033	C0700285
27274791	160	168	controls	T096	C0009932
27274791	173	185	drug addicts	T033	C0700285
27274791	191	199	selected	T052	C1707391
27274791	208	230	non-addict individuals	T098	C0237401
27274791	236	244	selected	T052	C1707391
27274791	252	265	control group	T096	C0009932
27274791	275	281	groups	T078	C0441833
27274791	298	303	tests	T170	C0392366
27274791	307	311	time	T079	C0040223
27274791	312	324	reproduction	T040	C0035150
27274791	326	341	time estimation	T079	C0871937
27274791	347	351	time	T079	C0040223
27274791	352	366	discrimination	T041	C0012632
27274791	380	391	significant	T078	C0750502
27274791	392	402	difference	T080	C1705242
27274791	415	422	addicts	T101	C0858354
27274791	423	428	group	T078	C0441833
27274791	437	450	control group	T096	C0009932
27274791	465	470	error	T080	C0743559
27274791	474	478	time	T079	C0040223
27274791	479	491	reproduction	T040	C0035150
27274791	496	511	time estimation	T079	C0871937
27274791	517	523	addict	T101	C0858354
27274791	524	529	group	T078	C0441833
27274791	533	543	comparison	T052	C1707455
27274791	551	564	control group	T096	C0009932
27274791	571	576	lower	T052	C2003888
27274791	584	596	reproduction	T040	C0035150
27274791	603	609	higher	T080	C0205250
27274791	616	628	reproduction	T040	C0035150
27274791	629	634	error	T080	C0743559
27274791	647	652	lower	T052	C2003888
27274791	660	670	estimation	T041	C0680844
27274791	675	681	higher	T080	C0205250
27274791	688	698	estimation	T041	C0680844
27274791	699	704	error	T080	C0743559
27274791	725	729	time	T079	C0040223
27274791	730	744	discrimination	T041	C0012632
27274791	749	760	significant	T078	C0750502
27274791	761	771	difference	T080	C1705242
27274791	797	803	errors	T080	C0743559
27274791	822	828	groups	T078	C0441833
27274791	862	868	images	T170	C1704922
27274791	872	888	drug consumption	UnknownType	C0678263
27274791	889	894	tools	T073	C0336791
27274791	899	905	normal	T080	C0205307
27274791	906	912	images	T170	C1704922
27274791	923	932	durations	T079	C0449238
27274791	938	944	normal	T080	C0205307
27274791	945	950	group	T078	C0441833
27274791	969	975	images	T170	C1704922
27274791	987	1003	drug consumption	UnknownType	C0678263
27274791	1004	1009	tools	T073	C0336791
27274791	1027	1034	shorter	T081	C1806781
27274791	1035	1041	period	T079	C1948053
27274791	1045	1049	time	T079	C0040223
27274791	1051	1066	Time perception	T041	C0040226
27274791	1070	1079	different	T080	C1705242
27274791	1088	1096	morphine	T109,T121	C0026549
27274791	1099	1106	derived	T080	C1441547
27274791	1107	1112	drugs	T121	C0013227
27274791	1113	1120	addicts	T101	C0858354
27274791	1125	1133	controls	T096	C0009932

27274893|t|Comparison of sonoelastography with sonourethrography and retrograde urethrography in the evaluation of male anterior urethral strictures
27274893|a|Retrograde urethrography (RUG) is the most common and preferred imaging modality for imaging of the anterior urethral strictures despite its well-known limitations and disadvantages. Sonourethrography (SUG) was introduced in 1988 to overcome the limitations of RUG and to provide more accurate results. As proper selection of imaging modality is very important for planning the treatment, various advances in this area are required. One of the major factors for recurrence of stricture disease is spongiofibrosis. Sonoelastography (SE) is a newer technique, tried in various other pathologies. In this study, we have used this technique for the first time to assess its efficacy in the evaluation of anterior urethral stricture disease by comparison with RUG and SUG. Between August 2014 and May 2015, 77 patients with clinical features of anterior urethral stricture disease were included in the study and evaluated by RUG followed by SUG and SE for stricture location, length, depth of spongiofibrosis and periurethral pathologies. The results were then correlated with operative and histopathological findings. Overall diagnostic accuracy of SE, SUG, and RGU for the estimation of stricture location, and length were estimated 92.68% vs. 91.54%, 79% vs. 78.87% and 80.48% vs. 43.66%, respectively, while for depth of spongiofibrosis SE, and SUG had accuracy rates of 87.3%, 48%, respectively. The mean length measured on SE was nearest to the mean intra-operative stricture length (21.34+11.8 mm). SE findings significantly correlated with the colour of bladder mucosa on cystoscopic examination (p=0.003) whereas the association was non-significant (p=0.127) for difficulty in incision. While a nonsignificant correlation existed between SUG findings related both to the colour of the bladder mucosa and difficulty in incision on cystoscopy, SE findings had a significant association (p<0.001) with histopathology findings for severe degree of fibrosis. Sonoelastography estimates stricture site and length better in comparison with RUG and SUG. It estimates degree of spongiofibrosis which serves as an important prognostic factor for stricture recurrence more accurately than SUG.
27274893	14	30	sonoelastography	T060	C1955929
27274893	36	53	sonourethrography	T060	C0581495
27274893	58	82	retrograde urethrography	T060	C0845989
27274893	90	100	evaluation	T058	C0220825
27274893	104	108	male	T032	C0086582
27274893	109	137	anterior urethral strictures	T190	C1720814
27274893	138	162	Retrograde urethrography	T060	C0845989
27274893	164	167	RUG	T060	C0845989
27274893	202	218	imaging modality	T169	C1275506
27274893	223	230	imaging	T060	C0011923
27274893	238	266	anterior urethral strictures	T190	C1720814
27274893	290	301	limitations	T169	C0449295
27274893	321	338	Sonourethrography	T060	C0581495
27274893	340	343	SUG	T060	C0581495
27274893	371	379	overcome	T052	C2983310
27274893	384	395	limitations	T169	C0449295
27274893	399	402	RUG	T060	C0845989
27274893	423	439	accurate results	T080	C0598285
27274893	464	480	imaging modality	T169	C1275506
27274893	503	525	planning the treatment	T170	C0599880
27274893	600	610	recurrence	T067	C0034897
27274893	614	631	stricture disease	T047	C0041974
27274893	635	650	spongiofibrosis	T046	C0016059
27274893	652	668	Sonoelastography	T060	C1955929
27274893	670	672	SE	T060	C1955929
27274893	679	694	newer technique	T062	C1519842
27274893	719	730	pathologies	T091	C0030664
27274893	808	816	efficacy	T080	C2348251
27274893	838	873	anterior urethral stricture disease	T190	C1720814
27274893	893	896	RUG	T060	C0845989
27274893	901	904	SUG	T060	C0581495
27274893	943	951	patients	T101	C0030705
27274893	978	1013	anterior urethral stricture disease	T190	C1720814
27274893	1058	1061	RUG	T060	C0845989
27274893	1074	1077	SUG	T060	C0581495
27274893	1082	1084	SE	T060	C1955929
27274893	1089	1098	stricture	T047	C1389955
27274893	1099	1107	location	T082	C0450429
27274893	1109	1115	length	T081	C1444754
27274893	1117	1122	depth	T201	C1827571
27274893	1126	1141	spongiofibrosis	T046	C0016059
27274893	1146	1158	periurethral	T029	C3828581
27274893	1159	1170	pathologies	T091	C0030664
27274893	1224	1250	histopathological findings	T169	C0243140
27274893	1260	1279	diagnostic accuracy	T080	C0598285
27274893	1283	1285	SE	T060	C1955929
27274893	1287	1290	SUG	T060	C0581495
27274893	1296	1299	RGU	T060	C0845989
27274893	1322	1331	stricture	T047	C1389955
27274893	1332	1340	location	T082	C0450429
27274893	1346	1352	length	T081	C1444754
27274893	1449	1454	depth	T201	C1827571
27274893	1458	1473	spongiofibrosis	T046	C0016059
27274893	1474	1476	SE	T060	C1955929
27274893	1482	1485	SUG	T060	C0581495
27274893	1490	1504	accuracy rates	T080	C0443131
27274893	1562	1564	SE	T060	C1955929
27274893	1589	1604	intra-operative	T079	C0456904
27274893	1605	1614	stricture	T047	C1389955
27274893	1615	1621	length	T081	C1444754
27274893	1639	1641	SE	T060	C1955929
27274893	1685	1709	colour of bladder mucosa	T033	C0475705
27274893	1713	1736	cystoscopic examination	T060	C0401483
27274893	1819	1827	incision	T061	C0184898
27274893	1880	1883	SUG	T060	C0581495
27274893	1913	1941	colour of the bladder mucosa	T033	C0475705
27274893	1960	1968	incision	T061	C0184898
27274893	1972	1982	cystoscopy	T060	C0010702
27274893	1984	1986	SE	T060	C1955929
27274893	2041	2064	histopathology findings	T169	C0243140
27274893	2076	2094	degree of fibrosis	T060	C4285457
27274893	2096	2112	Sonoelastography	T060	C1955929
27274893	2123	2148	stricture site and length	T082	C1254362
27274893	2175	2178	RUG	T060	C0845989
27274893	2183	2186	SUG	T060	C0581495
27274893	2211	2226	spongiofibrosis	T046	C0016059
27274893	2256	2273	prognostic factor	T201	C1514474
27274893	2278	2298	stricture recurrence	T067	C0034897
27274893	2304	2314	accurately	T080	C0443131
27274893	2320	2323	SUG	T060	C0581495

27275025|t|Phytoplankton production and taxon - specific growth rates in the Costa Rica Dome
27275025|a|During summer 2010, we investigated phytoplankton production and growth rates at 19 stations in the eastern tropical Pacific, where winds and strong opposing currents generate the Costa Rica Dome (CRD), an open - ocean upwelling feature. Primary production ((14)C - incorporation) and group-specific growth and net growth rates (two-treatment seawater dilution method) were estimated from samples incubated in situ at eight depths. Our cruise coincided with a mild El NiÃ±o event, and only weak upwelling was observed in the CRD. Nevertheless, the highest phytoplankton abundances were found near the dome center. However, mixed-layer growth rates were lowest in the dome center (â¼0.5-0.9 day(-1)), but higher on the edge of the dome (â¼0.9-1.0 day(-1)) and in adjacent coastal waters (0.9-1.3 day(-1)). We found good agreement between independent methods to estimate growth rates. Mixed-layer growth rates of Prochlorococcus and Synechococcus were largely balanced by mortality, whereas eukaryotic phytoplankton showed positive net growth (â¼0.5-0.6 day(-1)), that is, growth available to support larger (mesozooplankton) consumer biomass. These are the first group-specific phytoplankton rate estimates in this region, and they demonstrate that integrated primary production is high, exceeding 1 g C m(-2) day(-1) on average, even during a period of reduced upwelling.
27275025	0	13	Phytoplankton	T002	C0031865
27275025	14	24	production	T169	C1522492
27275025	29	34	taxon	T077	C1515221
27275025	37	45	specific	T080	C0205369
27275025	46	58	growth rates	T079	C0449249
27275025	66	81	Costa Rica Dome	T083	C0010182
27275025	89	95	summer	T079	C0241301
27275025	105	117	investigated	T169	C1292732
27275025	118	131	phytoplankton	T002	C0031865
27275025	132	142	production	T169	C1522492
27275025	147	159	growth rates	T079	C0449249
27275025	166	206	stations in the eastern tropical Pacific	UnknownType	C0681784
27275025	214	219	winds	T070	C0043187
27275025	224	230	strong	T080	C0442821
27275025	231	248	opposing currents	T070	C1254365
27275025	249	257	generate	T052	C3146294
27275025	262	277	Costa Rica Dome	T083	C0010182
27275025	279	282	CRD	T083	C0010182
27275025	288	292	open	T082	C0175566
27275025	295	300	ocean	T083	C0028814
27275025	301	318	upwelling feature	T070	C1254365
27275025	320	327	Primary	T080	C0205225
27275025	328	338	production	T169	C1522492
27275025	340	345	(14)C	T130,T196	C0302945
27275025	348	361	incorporation	T169	C0243126
27275025	367	381	group-specific	T078	C3858709
27275025	382	388	growth	T040	C0597252
27275025	393	409	net growth rates	T079	C0449249
27275025	411	424	two-treatment	T169	C1522326
27275025	425	433	seawater	T167	C0036499
27275025	434	449	dilution method	T059	C0079240
27275025	456	465	estimated	T081	C0750572
27275025	471	478	samples	T002	C0032098
27275025	479	488	incubated	T059	C1439852
27275025	489	496	in situ	T082	C0444498
27275025	506	512	depths	T082	C0205125
27275025	542	546	mild	T080	C2945599
27275025	547	554	El NiÃ±o	T070	C2936615
27275025	555	560	event	T051	C0441471
27275025	566	570	only	T081	C0205171
27275025	571	575	weak	T080	C1762617
27275025	576	585	upwelling	T070	C1254365
27275025	590	598	observed	T169	C1441672
27275025	606	609	CRD	T083	C0010182
27275025	629	636	highest	T080	C1522410
27275025	637	650	phytoplankton	T002	C0031865
27275025	651	661	abundances	T080	C2346714
27275025	682	686	dome	UnknownType	C0681784
27275025	687	693	center	T082	C0205099
27275025	704	715	mixed-layer	T082	C1883067
27275025	716	728	growth rates	T079	C0449249
27275025	734	740	lowest	T080	C1708760
27275025	748	752	dome	UnknownType	C0681784
27275025	753	759	center	T082	C0205099
27275025	784	790	higher	T080	C0205250
27275025	798	802	edge	T082	C1254362
27275025	810	814	dome	UnknownType	C0681784
27275025	841	849	adjacent	T082	C0205117
27275025	850	864	coastal waters	T083	C0442542
27275025	893	897	good	T080	C0205170
27275025	898	907	agreement	T080	C0332529
27275025	916	927	independent	T078	C0085862
27275025	928	947	methods to estimate	T081	C2825570
27275025	948	960	growth rates	T079	C0449249
27275025	962	973	Mixed-layer	T082	C1883067
27275025	974	986	growth rates	T079	C0449249
27275025	990	1005	Prochlorococcus	T007	C0995582
27275025	1010	1023	Synechococcus	T007	C0995533
27275025	1049	1058	mortality	T081	C0205848
27275025	1068	1092	eukaryotic phytoplankton	T002	C0031865
27275025	1100	1108	positive	T033	C1446409
27275025	1109	1119	net growth	T040	C0018270
27275025	1149	1155	growth	T040	C0597252
27275025	1156	1165	available	T169	C0470187
27275025	1177	1183	larger	T081	C0549177
27275025	1185	1200	mesozooplankton	T204	C0043530
27275025	1202	1210	consumer	T080	C0205556
27275025	1211	1218	biomass	T081	C0005535
27275025	1234	1239	first	T080	C1279901
27275025	1240	1254	group-specific	T078	C3858709
27275025	1255	1268	phytoplankton	T002	C0031865
27275025	1269	1273	rate	T081	C1521828
27275025	1274	1283	estimates	T081	C0750572
27275025	1292	1298	region	T083	C0017446
27275025	1337	1344	primary	T080	C0205225
27275025	1345	1355	production	T169	C1522492
27275025	1359	1363	high	T080	C0205250
27275025	1398	1405	average	T081	C1510992
27275025	1421	1427	period	T079	C1948053
27275025	1431	1438	reduced	T080	C0392756
27275025	1439	1448	upwelling	T070	C1254365

27275298|t|Incidence and Impact of Patient - Prosthesis Mismatch in Isolated Aortic Valve Surgery
27275298|a|The mains topics of this work are the incidence of patient - prosthesis mismatch and the influence in the early results of isolated aortic valve surgery. In 193 patients isolated aortic valve surgery was performed. The study population was divided in three subgroups: 20 patients with severe, 131 patients with moderate and 42 patients without patient - prosthesis mismatch. The indexed effective orifice area was used to define the subgroups. Operative mortality and perioperative complications were considered the indicators of the early results of aortic valve surgery. The incidence of severe and moderate patient - prosthesis mismatch was respectively 10.3% and 67.8%. Hospital mortality and perioperative complications were: mortality 5% vs. 3.1% vs. 2.4% (p = 0.855), low cardiac output 5% vs. 6.9% vs. 4.8% (p = 0.861); pulmonary complications 5% vs. 3.1 vs. 0.0% (p = 0.430); exploration for bleeding 5% vs. 0.8% vs. 2.4% (p = 0.319); atrial fibrillation 30% vs. 19.8% vs. 11.9% (p = 0.225); wound infection 5% vs. 0.8% vs. 0.00% (p = 0.165), respectively for the group with severe, moderate and without patient - prosthesis mismatch. Patient - prosthesis mismatch is a common occurrence in aortic valve surgery. This phenomenon does not affect the early results of aortic valve surgery.
27275298	0	9	Incidence	T081	C0021149
27275298	14	20	Impact	T080	C4049986
27275298	24	31	Patient	T101	C0030705
27275298	34	44	Prosthesis	T074	C0175649
27275298	45	53	Mismatch	T080	C1881865
27275298	57	86	Isolated Aortic Valve Surgery	T061	C0003506
27275298	125	134	incidence	T081	C0021149
27275298	138	145	patient	T101	C0030705
27275298	148	158	prosthesis	T074	C0175649
27275298	159	167	mismatch	T080	C1881865
27275298	176	185	influence	T077	C4054723
27275298	193	198	early	T079	C1279919
27275298	199	206	results	T169	C1274040
27275298	210	239	isolated aortic valve surgery	T061	C0003506
27275298	248	256	patients	T101	C0030705
27275298	257	286	isolated aortic valve surgery	T061	C0003506
27275298	291	300	performed	T169	C0884358
27275298	306	322	study population	T098	C2348561
27275298	327	334	divided	T169	C0332849
27275298	344	353	subgroups	T185	C1515021
27275298	358	366	patients	T101	C0030705
27275298	372	378	severe	T080	C0205082
27275298	384	392	patients	T101	C0030705
27275298	398	406	moderate	T080	C0205081
27275298	414	422	patients	T101	C0030705
27275298	423	430	without	T080	C0332288
27275298	431	438	patient	T101	C0030705
27275298	441	451	prosthesis	T074	C0175649
27275298	452	460	mismatch	T080	C1881865
27275298	466	473	indexed	T170	C0918012
27275298	474	496	effective orifice area	T201	C4267733
27275298	501	505	used	T169	C1524063
27275298	520	529	subgroups	T185	C1515021
27275298	531	540	Operative	T079	C1882154
27275298	541	550	mortality	T081	C0205848
27275298	555	582	perioperative complications	T046	C0021890
27275298	588	598	considered	T078	C0750591
27275298	603	616	indicators of	T078	C0392360
27275298	621	626	early	T079	C1279919
27275298	627	634	results	T169	C1274040
27275298	638	658	aortic valve surgery	T061	C0003506
27275298	664	673	incidence	T081	C0021149
27275298	677	683	severe	T080	C0205082
27275298	688	696	moderate	T080	C0205081
27275298	697	704	patient	T101	C0030705
27275298	707	717	prosthesis	T074	C0175649
27275298	718	726	mismatch	T080	C1881865
27275298	761	779	Hospital mortality	T080	C0085556
27275298	784	811	perioperative complications	T046	C0021890
27275298	818	827	mortality	T080	C0085556
27275298	862	880	low cardiac output	T033	C0007166
27275298	915	938	pulmonary complications	T046	C0281169
27275298	972	983	exploration	T061	C1280903
27275298	988	996	bleeding	T046	C0019080
27275298	1031	1050	atrial fibrillation	T047	C0004238
27275298	1088	1103	wound infection	T046	C0043241
27275298	1160	1165	group	UnknownType	C0681860
27275298	1171	1177	severe	T080	C0205082
27275298	1179	1187	moderate	T080	C0205081
27275298	1192	1199	without	T080	C0332288
27275298	1200	1207	patient	T101	C0030705
27275298	1210	1220	prosthesis	T074	C0175649
27275298	1221	1229	mismatch	T080	C1881865
27275298	1231	1238	Patient	T101	C0030705
27275298	1241	1251	prosthesis	T074	C0175649
27275298	1252	1260	mismatch	T080	C1881865
27275298	1266	1272	common	T081	C0205214
27275298	1273	1283	occurrence	T079	C2745955
27275298	1287	1307	aortic valve surgery	T061	C0003506
27275298	1314	1324	phenomenon	T067	C1882365
27275298	1325	1333	does not	T080	C1299585
27275298	1334	1340	affect	T080	C1280500
27275298	1345	1350	early	T079	C1279919
27275298	1351	1358	results	T169	C1274040
27275298	1362	1382	aortic valve surgery	T061	C0003506

27275827|t|Nutrient Intakes in Early Life and Risk of Obesity
27275827|a|There is increasing evidence that environmental factors in early life predict later health. The early adiposity rebound recorded in most obese subjects suggests that factors promoting body fat development have operated in the first years of life. Birth weight, growth velocity and body mass index (BMI) trajectories seem to be highly sensitive to the environmental conditions present during pregnancy and in early life ("The first 1000 days "). Particularly, nutritional exposure can have a long-term effect on health in adulthood. The high protein-low fat diet often recorded in young children may have contributed to the rapid rise of childhood obesity prevalence during the last decades. Metabolic programming by early nutrition could explain the development of later obesity and adult diseases.
27275827	0	16	Nutrient Intakes	T081	C0006777
27275827	20	25	Early	T079	C1279919
27275827	26	30	Life	T078	C0376558
27275827	35	42	Risk of	T078	C0035647
27275827	43	50	Obesity	T047	C0028754
27275827	60	70	increasing	T169	C0442808
27275827	71	79	evidence	T078	C3887511
27275827	85	106	environmental factors	T169	C1516998
27275827	110	115	early	T079	C1279919
27275827	116	120	life	T078	C0376558
27275827	129	134	later	T079	C0205087
27275827	135	141	health	T078	C0018684
27275827	147	152	early	T079	C1279919
27275827	153	170	adiposity rebound	T080	C0205556
27275827	188	193	obese	T047	C0028754
27275827	194	202	subjects	T098	C2349001
27275827	217	224	factors	T169	C1521761
27275827	225	234	promoting	T052	C0033414
27275827	235	243	body fat	T201	C0344335
27275827	244	255	development	T039	C0243107
27275827	283	288	years	T079	C0439234
27275827	292	296	life	T078	C0376558
27275827	298	310	Birth weight	T032	C0005612
27275827	312	327	growth velocity	T033	C2012658
27275827	332	347	body mass index	T201	C1305855
27275827	349	352	BMI	T201	C1305855
27275827	378	394	highly sensitive	T080	C0439822
27275827	402	415	environmental	T082	C0014406
27275827	416	426	conditions	T080	C0348080
27275827	427	434	present	T033	C0150312
27275827	435	441	during	T079	C0347984
27275827	442	451	pregnancy	T040	C0032961
27275827	459	464	early	T079	C1279919
27275827	465	469	life	T078	C0376558
27275827	487	491	days	T079	C0439228
27275827	510	521	nutritional	T080	C1521739
27275827	522	530	exposure	T080	C0332157
27275827	542	558	long-term effect	T067	C0023983
27275827	562	568	health	T078	C0018684
27275827	572	581	adulthood	T079	C0700597
27275827	587	612	high protein-low fat diet	T168	C0012155
27275827	631	636	young	T079	C0332239
27275827	637	645	children	T100	C0008059
27275827	674	679	rapid	T080	C0456962
27275827	688	697	childhood	T079	C0231335
27275827	698	705	obesity	T047	C0028754
27275827	706	716	prevalence	T081	C0220900
27275827	717	723	during	T079	C0347984
27275827	733	740	decades	T081	C2981279
27275827	742	751	Metabolic	T169	C0311400
27275827	752	763	programming	T090	C1518533
27275827	767	772	early	T079	C1279919
27275827	773	782	nutrition	T040	C1442959
27275827	801	812	development	T039	C0243107
27275827	816	821	later	T079	C0205087
27275827	822	829	obesity	T047	C0028754
27275827	834	848	adult diseases	T047	C0277562

27275849|t|Characteristics of the fibroplasia and collagen expression in the abdominal wall after implant of the polypropylene mesh and polypropylene / polyglecaprone mesh in rats
27275849|a|To compare fibroplasia and the resistance of the abdominal wall when polypropylene meshes and polypropylene / poliglecaprone are used. Seventy-seven male Wistar rats were divided into three groups: Control Group (for resistance); Group E (polypropylene mesh); and Group U (polypropylene / poliglecaprone mesh). The animals in Groups E and U had a standard muscular and aponeurotic defect, with integral peritoneum, and correction with the mesh. Measurements were taken 4, 7, 14, 28 and 56 days after surgery. The resistance, and collagen density were studied. Resistance on the 56th day was similar in both meshes. The gain in resistance described an ascending curve for the polypropylene mesh and was irregular in the case of the polypropylene / poliglecaprone. Fibroplasia showed a gain in type I and type III collagen in both groups (p<0.001). Collagen III stabilized in the 14th day and collagen I continued to ascend. The gain in resistance of the polypropylene mesh is regular and ascending, whereas the polypropylene / poliglecaprone is not regular. The final resistance of both meshes is similar; the collagen density increases over time, and show the same inflammatory potential.
27275849	0	15	Characteristics	T080	C1521970
27275849	23	34	fibroplasia	T067	C4049604
27275849	39	47	collagen	T116	C0009325
27275849	48	58	expression	T045	C1171362
27275849	66	80	abdominal wall	T023	C0836916
27275849	87	94	implant	T061	C0021107
27275849	102	120	polypropylene mesh	T109,T122	C1321585
27275849	125	138	polypropylene	T109,T122	C1321585
27275849	141	160	polyglecaprone mesh	T109,T122	C0381199
27275849	164	168	rats	T015	C0034693
27275849	180	191	fibroplasia	T067	C4049604
27275849	200	210	resistance	T039	C1514892
27275849	218	232	abdominal wall	T023	C0836916
27275849	238	258	polypropylene meshes	T109,T122	C1321585
27275849	263	276	polypropylene	T109,T122	C1321585
27275849	279	293	poliglecaprone	T109,T122	C0381199
27275849	318	322	male	T032	C0086582
27275849	323	334	Wistar rats	T015	C0034716
27275849	359	365	groups	T098	C2348561
27275849	367	380	Control Group	T096	C0009932
27275849	386	396	resistance	T039	C1514892
27275849	399	406	Group E	T098	C2348561
27275849	408	426	polypropylene mesh	T109,T122	C1321585
27275849	433	440	Group U	T098	C2348561
27275849	442	455	polypropylene	T109,T122	C1321585
27275849	458	477	poliglecaprone mesh	T109,T122	C0381199
27275849	484	491	animals	T008	C0003062
27275849	495	503	Groups E	T098	C2348561
27275849	508	509	U	T098	C2348561
27275849	525	533	muscular	T024	C0026845
27275849	538	549	aponeurotic	T029	C0521343
27275849	550	556	defect	T169	C1457869
27275849	563	571	integral	T082	C0205102
27275849	572	582	peritoneum	T024	C0031153
27275849	588	598	correction	T169	C1947976
27275849	608	612	mesh	T074	C0038930
27275849	658	662	days	T079	C0439228
27275849	669	676	surgery	T061	C0543467
27275849	682	692	resistance	T039	C1514892
27275849	698	706	collagen	T116	C0009325
27275849	707	714	density	T081	C0178587
27275849	720	727	studied	T062	C2603343
27275849	729	739	Resistance	T039	C1514892
27275849	752	755	day	T079	C0439228
27275849	776	782	meshes	T074	C0038930
27275849	788	792	gain	T081	C1517378
27275849	796	806	resistance	T039	C1514892
27275849	820	829	ascending	T169	C1962987
27275849	830	835	curve	T082	C0205134
27275849	844	862	polypropylene mesh	T109,T122	C1321585
27275849	871	880	irregular	T080	C0205271
27275849	900	913	polypropylene	T109,T122	C1321585
27275849	916	930	poliglecaprone	T109,T122	C0381199
27275849	932	943	Fibroplasia	T067	C4049604
27275849	953	957	gain	T081	C1517378
27275849	961	967	type I	T116,T123	C0041455
27275849	972	989	type III collagen	T116,T123	C0009332
27275849	998	1004	groups	T098	C2348561
27275849	1016	1028	Collagen III	T116,T123	C0009332
27275849	1029	1039	stabilized	T033	C0184512
27275849	1052	1055	day	T079	C0439228
27275849	1060	1070	collagen I	T116,T123	C0041455
27275849	1084	1090	ascend	T169	C1962987
27275849	1096	1100	gain	T081	C1517378
27275849	1104	1114	resistance	T039	C1514892
27275849	1122	1140	polypropylene mesh	T109,T122	C1321585
27275849	1156	1165	ascending	T169	C1962987
27275849	1179	1192	polypropylene	T109,T122	C1321585
27275849	1195	1209	poliglecaprone	T109,T122	C0381199
27275849	1236	1246	resistance	T039	C1514892
27275849	1255	1261	meshes	T074	C0038930
27275849	1278	1286	collagen	T116	C0009325
27275849	1287	1294	density	T081	C0178587
27275849	1334	1346	inflammatory	T169	C0333348
27275849	1347	1356	potential	T080	C3245505

27277750|t|Co-delivery of pemetrexed and miR-21 antisense oligonucleotide by lipid - polymer hybrid nanoparticles and effects on glioblastoma cells
27277750|a|Combination therapy using anticancer drugs and nucleic acid is a more promising strategy to overcome multidrug resistance in cancer and to enhance apoptosis. In this study, lipid - polymer hybrid nanoparticles (LPNs), which contain both pemetrexed and miR-21 antisense oligonucleotide (anti-miR-21), have been developed for treatment of glioblastoma, the most aggressive type of brain tumor. Prepared LPNs have been well characterized by particle size distribution and zeta potential measurements, determination of encapsulation efficiency, and in vitro release experiments. Morphology of LPNs was determined by transmission electron microscopy. LPNs had a hydrodynamic size below 100 nm and exhibited sustained release of pemetrexed up to 10 h. Encapsulation of pemetrexed in LPNs increased cellular uptake from 6% to 78%. Results of confocal microscopy analysis have shown that co-delivery of anti-miR-21 significantly improved accumulation of LPNs in the nucleus of U87MG cells. Nevertheless, more effective cytotoxicity results could not be obtained due to low concentration of anti-miR-21, loaded in LPNs. We expect that the effective drug delivery systems can be obtained with higher concentration of anti-miR-21 for the treatment of glioblastoma.
27277750	0	11	Co-delivery	T169	C1705822
27277750	15	25	pemetrexed	T109,T121	C0210657
27277750	30	62	miR-21 antisense oligonucleotide	T114,T123,T130	C0079925
27277750	66	71	lipid	T109	C0023779
27277750	74	81	polymer	T104,T122	C0032521
27277750	82	102	hybrid nanoparticles	T073	C1450054
27277750	107	114	effects	T080	C1280500
27277750	118	130	glioblastoma	T191	C0017636
27277750	131	136	cells	T025	C0007634
27277750	137	156	Combination therapy	T061	C0009429
27277750	163	179	anticancer drugs	T109,T121	C0003392
27277750	184	196	nucleic acid	T114,T123	C0028606
27277750	238	258	multidrug resistance	T032	C0242640
27277750	262	268	cancer	T191	C0027651
27277750	284	293	apoptosis	T043	C0162638
27277750	303	308	study	T062	C2603343
27277750	310	315	lipid	T109	C0023779
27277750	318	325	polymer	T104,T122	C0032521
27277750	326	346	hybrid nanoparticles	T073	C1450054
27277750	348	352	LPNs	T122	C1713964
27277750	374	384	pemetrexed	T109,T121	C0210657
27277750	389	421	miR-21 antisense oligonucleotide	T114,T123,T130	C0079925
27277750	423	434	anti-miR-21	T114,T123,T130	C0079925
27277750	461	470	treatment	T169	C1522326
27277750	474	486	glioblastoma	T191	C0017636
27277750	497	507	aggressive	T191	C2945759
27277750	516	527	brain tumor	T191	C0006118
27277750	538	542	LPNs	T122	C1713964
27277750	575	588	particle size	T081	C0030608
27277750	589	601	distribution	T169	C1704711
27277750	606	620	zeta potential	T067	C0597697
27277750	621	633	measurements	T169	C0242485
27277750	652	665	encapsulation	T067	C2348438
27277750	666	676	efficiency	T081	C0013682
27277750	682	690	in vitro	T080	C1533691
27277750	691	710	release experiments	T062	C0681814
27277750	712	722	Morphology	T080	C0332437
27277750	726	730	LPNs	T122	C1713964
27277750	749	781	transmission electron microscopy	T059	C0678118
27277750	783	787	LPNs	T122	C1713964
27277750	794	806	hydrodynamic	T070	C2936194
27277750	807	811	size	T082	C0456389
27277750	839	856	sustained release	T169	C0391871
27277750	860	870	pemetrexed	T109,T121	C0210657
27277750	883	896	Encapsulation	T067	C2348438
27277750	900	910	pemetrexed	T109,T121	C0210657
27277750	914	918	LPNs	T122	C1713964
27277750	929	944	cellular uptake	T043	C0007613
27277750	972	1000	confocal microscopy analysis	T059	C0242842
27277750	1017	1028	co-delivery	T169	C1705822
27277750	1032	1043	anti-miR-21	T114,T123,T130	C0079925
27277750	1067	1079	accumulation	T033	C4055506
27277750	1083	1087	LPNs	T122	C1713964
27277750	1095	1102	nucleus	T026	C0007610
27277750	1106	1117	U87MG cells	T025	C0007634
27277750	1148	1160	cytotoxicity	T049	C0596402
27277750	1161	1168	results	T169	C1274040
27277750	1202	1215	concentration	UnknownType	C0678563
27277750	1219	1230	anti-miR-21	T114,T123,T130	C0079925
27277750	1242	1246	LPNs	T122	C1713964
27277750	1277	1298	drug delivery systems	T074	C0085104
27277750	1327	1340	concentration	UnknownType	C0678563
27277750	1344	1355	anti-miR-21	T114,T123,T130	C0079925
27277750	1364	1373	treatment	T061	C0087111
27277750	1377	1389	glioblastoma	T191	C0017636

27278134|t|Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction
27278134|a|The protective effect of dual antiplatelet therapy (DAPT) following acute coronary syndrome is undisputed, but its duration is subject of debate. Several studies show that prolonged therapy provides a clinical benefit in patients following acute coronary syndrome. The aim of this position paper authored by Austrian experts is to outline the current evidence and provide an overview of recent studies. It is also intended to serve as a practical guide to identify those patients who may benefit from prolonged DAPT.
27278134	0	6	Expert	T097	C1522486
27278134	7	21	position paper	T170	C0282574
27278134	25	34	prolonged	T079	C0439590
27278134	35	60	dual antiplatelet therapy	T061	C1096021
27278134	64	84	secondary prevention	T061	C0679699
27278134	95	116	myocardial infarction	T047	C0027051
27278134	121	138	protective effect	T080	C1280500
27278134	142	167	dual antiplatelet therapy	T061	C1096021
27278134	169	173	DAPT	T061	C1096021
27278134	185	208	acute coronary syndrome	T047	C0948089
27278134	232	240	duration	T079	C0449238
27278134	255	261	debate	T052	C0870392
27278134	271	278	studies	T062	C2603343
27278134	289	298	prolonged	T079	C0439590
27278134	299	306	therapy	T061	C0087111
27278134	318	326	clinical	T080	C0205210
27278134	327	334	benefit	T081	C0814225
27278134	338	346	patients	T101	C0030705
27278134	357	380	acute coronary syndrome	T047	C0948089
27278134	398	412	position paper	T170	C0282574
27278134	425	433	Austrian	T098	C0337795
27278134	434	441	experts	T097	C1522486
27278134	460	467	current	T079	C0521116
27278134	468	476	evidence	T078	C3887511
27278134	511	518	studies	T062	C2603343
27278134	554	569	practical guide	T170	C0681467
27278134	588	596	patients	T101	C0030705
27278134	605	612	benefit	T081	C0814225
27278134	618	627	prolonged	T079	C0439590
27278134	628	632	DAPT	T061	C1096021

27279849|t|Clinical evaluation of the AutoPulse automated chest compression device for out-of-hospital cardiac arrest in the northern district of Shanghai, China
27279849|a|Whether the AutoPulse automated chest compression device is worthy of clinical use for out-of-hospital cardiac arrest (OHCA) remains controversial. A prospective controlled study was conducted to evaluate the effect of AutoPulse versus manual chest compression for cardiopulmonary resuscitation (CPR) of OHCA patients in the northern district of Shanghai, China. A total of 133 patients with OHCA who were treated at the Emergency Medical Center of the Tenth People's Hospital Affiliated with Tongji University between March 2011 and March 2012 were included. The patients were randomly assigned to the Manual CPR (n = 64) and AutoPulse CPR groups (n = 69) in accordance with the approach of chest compression received. The primary outcome measure was return of spontaneous circulation (ROSC), and the secondary outcome measures included 24-h survival rate, hospital discharge rate, and neurological prognosis at hospital discharge. The ROSC rate of patients with OHCA was significantly higher in the AutoPulse CPR group than in the Manual CPR group (44.9% vs. 23.4%; p = 0.009). The 24-h survival rate of OHCA patients was significantly higher in the AutoPulse CPR group than in the Manual CPR group (39.1% vs. 21.9%; p = 0.03). The hospital discharge rate of the patients with OHCA was significantly higher in the AutoPulse CPR group than in the Manual CPR group (18.8% vs. 6.3%; p = 0.03). The proportion of patients with OHCA and a cerebral performance category score of 1 or 2 points at hospital discharge was higher in the AutoPulse CPR group than in the Manual CPR group, but the difference was not statistically significant (16.2% vs. 13.4%, p = 1.00). Use of the AutoPulse increases CPR success and survival rates in patients with OHCA, but its ability to improve cerebral performance requires further evaluation.
27279849	0	19	Clinical evaluation	T058	C4084924
27279849	27	36	AutoPulse	T074	C0183001
27279849	37	71	automated chest compression device	T074	C0183001
27279849	76	106	out-of-hospital cardiac arrest	T046	C2936490
27279849	114	122	northern	T082	C1709269
27279849	135	143	Shanghai	T083	C0017446
27279849	145	150	China	T083	C0008115
27279849	163	172	AutoPulse	T074	C0183001
27279849	173	207	automated chest compression device	T074	C0183001
27279849	221	229	clinical	T080	C0205210
27279849	230	233	use	T169	C0457083
27279849	238	268	out-of-hospital cardiac arrest	T046	C2936490
27279849	270	274	OHCA	T046	C2936490
27279849	301	329	prospective controlled study	T062	C0033522
27279849	347	355	evaluate	T058	C0220825
27279849	360	369	effect of	T080	C1704420
27279849	370	379	AutoPulse	T074	C0183001
27279849	387	393	manual	T169	C0175674
27279849	394	399	chest	T029	C0817096
27279849	400	411	compression	T061	C0565514
27279849	416	445	cardiopulmonary resuscitation	T061	C0007203
27279849	447	450	CPR	T061	C0007203
27279849	455	459	OHCA	T046	C2936490
27279849	460	468	patients	T101	C0030705
27279849	476	484	northern	T082	C1709269
27279849	497	505	Shanghai	T083	C0017446
27279849	507	512	China	T083	C0008115
27279849	529	537	patients	T101	C0030705
27279849	543	547	OHCA	T046	C2936490
27279849	557	564	treated	T169	C1522326
27279849	572	627	Emergency Medical Center of the Tenth People's Hospital	T073,T093	C0019994
27279849	628	638	Affiliated	T080	C1510826
27279849	644	661	Tongji University	T073,T093	C0020028
27279849	715	723	patients	T101	C0030705
27279849	729	737	randomly	T080	C0439605
27279849	738	746	assigned	T169	C1516050
27279849	754	760	Manual	T169	C0175674
27279849	761	764	CPR	T061	C0007203
27279849	778	787	AutoPulse	T074	C0183001
27279849	788	791	CPR	T061	C0007203
27279849	792	798	groups	T078	C0441833
27279849	808	826	in accordance with	T169	C4281991
27279849	843	848	chest	T029	C0817096
27279849	849	860	compression	T061	C0565514
27279849	861	869	received	T080	C1514756
27279849	875	882	primary	T080	C0205225
27279849	883	898	outcome measure	T081	C0086749
27279849	903	936	return of spontaneous circulation	T033	C3258122
27279849	938	942	ROSC	T033	C3258122
27279849	953	962	secondary	T081	C0205436
27279849	963	979	outcome measures	T081	C0086749
27279849	994	1007	survival rate	T081	C0038954
27279849	1009	1032	hospital discharge rate	T081	C0598611
27279849	1038	1050	neurological	T080	C0205494
27279849	1051	1060	prognosis	T058	C0033325
27279849	1064	1082	hospital discharge	T058	C0586003
27279849	1088	1092	ROSC	T033	C3258122
27279849	1093	1097	rate	T081	C1521828
27279849	1101	1109	patients	T101	C0030705
27279849	1115	1119	OHCA	T046	C2936490
27279849	1124	1144	significantly higher	T081	C4055637
27279849	1152	1161	AutoPulse	T074	C0183001
27279849	1162	1165	CPR	T061	C0007203
27279849	1166	1171	group	T078	C0441833
27279849	1184	1190	Manual	T169	C0175674
27279849	1191	1194	CPR	T061	C0007203
27279849	1195	1200	group	T078	C0441833
27279849	1240	1253	survival rate	T081	C0038954
27279849	1257	1261	OHCA	T046	C2936490
27279849	1262	1270	patients	T101	C0030705
27279849	1275	1295	significantly higher	T081	C4055637
27279849	1303	1312	AutoPulse	T074	C0183001
27279849	1313	1316	CPR	T061	C0007203
27279849	1317	1322	group	T078	C0441833
27279849	1335	1341	Manual	T169	C0175674
27279849	1342	1345	CPR	T061	C0007203
27279849	1346	1351	group	T078	C0441833
27279849	1385	1408	hospital discharge rate	T081	C0598611
27279849	1416	1424	patients	T101	C0030705
27279849	1430	1434	OHCA	T046	C2936490
27279849	1439	1459	significantly higher	T081	C4055637
27279849	1467	1476	AutoPulse	T074	C0183001
27279849	1477	1480	CPR	T061	C0007203
27279849	1481	1486	group	T078	C0441833
27279849	1499	1505	Manual	T169	C0175674
27279849	1506	1509	CPR	T061	C0007203
27279849	1510	1515	group	T078	C0441833
27279849	1548	1558	proportion	T081	C1709707
27279849	1562	1570	patients	T101	C0030705
27279849	1576	1580	OHCA	T046	C2936490
27279849	1587	1622	cerebral performance category score	T081	C0449820
27279849	1643	1661	hospital discharge	T058	C0586003
27279849	1666	1672	higher	T080	C0205250
27279849	1680	1689	AutoPulse	T074	C0183001
27279849	1690	1693	CPR	T061	C0007203
27279849	1694	1699	group	T078	C0441833
27279849	1712	1718	Manual	T169	C0175674
27279849	1719	1722	CPR	T061	C0007203
27279849	1723	1728	group	T078	C0441833
27279849	1738	1748	difference	T081	C1705241
27279849	1753	1756	not	T169	C1518422
27279849	1757	1782	statistically significant	T081	C0237881
27279849	1812	1815	Use	T169	C0457083
27279849	1823	1832	AutoPulse	T074	C0183001
27279849	1833	1842	increases	T081	C0205217
27279849	1843	1846	CPR	T061	C0007203
27279849	1847	1854	success	T081	C0392762
27279849	1859	1873	survival rates	T081	C0038954
27279849	1877	1885	patients	T101	C0030705
27279849	1891	1895	OHCA	T046	C2936490
27279849	1916	1923	improve	T033	C0184511
27279849	1924	1932	cerebral	T023	C0006104
27279849	1933	1944	performance	T052	C1882330
27279849	1962	1972	evaluation	T058	C0220825

27279861|t|Medulloblastoma: molecular pathways and histopathological classification
27279861|a|Malignant brain tumors are the leading cause of cancer death among pediatric patients, and medulloblastoma constitutes 20% of them. Currently, the treatment is risk-adapted. Maximum surgical resection is recommended, always followed by chemotherapy and neuroaxis radiotherapy. In spite of the improving survival rate, survivors succumb to treatment - induced side effects. To reduce toxic effects, molecular-targeted treatment is proposed. Medulloblastoma research is very robust, and new articles on the subject are published daily. In the current review we have tried to bring together molecular pathophysiology of the neoplasm and current pathological classification, thus making an effort to relate tumor biology and the histological picture.
27279861	0	15	Medulloblastoma	T191	C0025149
27279861	17	35	molecular pathways	T044	C1704259
27279861	40	57	histopathological	T169	C0243140
27279861	58	72	classification	T185	C0008902
27279861	73	95	Malignant brain tumors	T191	C0153633
27279861	104	111	leading	T169	C1522538
27279861	112	117	cause	T169	C0015127
27279861	121	127	cancer	T191	C0006826
27279861	128	133	death	T033	C1306577
27279861	140	149	pediatric	T080	C1521725
27279861	150	158	patients	T101	C0030705
27279861	164	179	medulloblastoma	T191	C0025149
27279861	220	229	treatment	T061	C0087111
27279861	255	273	surgical resection	T061	C0015252
27279861	277	288	recommended	T078	C0034866
27279861	309	321	chemotherapy	T061	C3665472
27279861	326	335	neuroaxis	T022	C3714787
27279861	336	348	radiotherapy	T061	C1522449
27279861	366	375	improving	T080	C1272745
27279861	376	389	survival rate	T081	C0038954
27279861	391	400	survivors	T101	C0206194
27279861	412	421	treatment	T061	C0087111
27279861	424	431	induced	T169	C0205263
27279861	432	444	side effects	T046	C0879626
27279861	449	455	reduce	T080	C0392756
27279861	456	469	toxic effects	T037	C0600688
27279861	471	499	molecular-targeted treatment	T061	C2699893
27279861	513	528	Medulloblastoma	T191	C0025149
27279861	529	537	research	T062	C0035168
27279861	546	552	robust	T080	C2986815
27279861	562	570	articles	T170	C1706852
27279861	590	599	published	T057	C0034037
27279861	622	628	review	T170	C0282443
27279861	661	670	molecular	T080	C1521991
27279861	671	686	pathophysiology	T169	C0031847
27279861	694	702	neoplasm	T191	C0027651
27279861	715	727	pathological	T169	C1521733
27279861	728	742	classification	T185	C0008902
27279861	776	789	tumor biology	T062	C1519672
27279861	798	818	histological picture	T201	C1301121

27279981|t|Expression of the Mir-133 and Bcl-2 could be affected by swimming training in the heart of ovariectomized rats
27279981|a|The beneficial and more potent role of exercise to prevent heart apoptosis in ovariectomized rats has been known. The aim of this study was to examine the effects of swimming training on cardiac expression of Bcl-2, and Mir-133 levels and glycogen changes in the myocyte. Forty animals were separated into four groups as control, sham, ovariectomy (OVX) and ovariectomized group with 8 weeks swimming training (OVX.E). Training effects were evaluated by measuring lipid profiles, Bcl-2 and Mir-133 expression levels in the cardiac tissue. Grafts were analyzed by reverse transcription-polymerase chain reaction for Bcl-2 mRNA and Mir-133 and by Western blot for Bcl-2 protein. Ovariectomy down-regulated Bcl-2 and Mir-133 expression levels in the cardiac tissue, and swimming training up-regulated their expression significantly (P<0.05). Our results showed that regular exercise as a physical replacement therapy could prevent and improve the effects of estrogen deficiency in the cardia.
27279981	0	10	Expression	T045	C1171362
27279981	18	25	Mir-133	T114	C2934005
27279981	30	35	Bcl-2	T116,T123	C1528442
27279981	57	65	swimming	T056	C0039003
27279981	66	74	training	T065	C0220931
27279981	82	87	heart	T023	C0018787
27279981	91	110	ovariectomized rats	T015	C0034693
27279981	142	146	role	T077	C1705810
27279981	150	158	exercise	T056	C0015259
27279981	162	169	prevent	T080	C2700409
27279981	170	175	heart	T023	C0018787
27279981	176	185	apoptosis	T043	C0162638
27279981	189	208	ovariectomized rats	T015	C0034693
27279981	266	276	effects of	T080	C1704420
27279981	277	285	swimming	T056	C0039003
27279981	286	294	training	T065	C0220931
27279981	298	305	cardiac	T023	C0018787
27279981	306	316	expression	T045	C1171362
27279981	320	325	Bcl-2	T116,T123	C1528442
27279981	331	338	Mir-133	T114	C2934005
27279981	339	345	levels	T080	C0441889
27279981	350	358	glycogen	T109,T123	C0017911
27279981	359	366	changes	T169	C0392747
27279981	374	381	myocyte	T025	C0225828
27279981	389	396	animals	T008	C0003062
27279981	422	428	groups	T078	C0441833
27279981	432	439	control	T096	C0009932
27279981	441	445	sham	T078	C0441833
27279981	447	458	ovariectomy	T078	C0441833
27279981	460	463	OVX	T078	C0441833
27279981	469	489	ovariectomized group	T078	C0441833
27279981	497	502	weeks	T079	C0439230
27279981	503	511	swimming	T056	C0039003
27279981	512	520	training	T065	C0220931
27279981	530	538	Training	T065	C0220931
27279981	539	546	effects	T080	C1280500
27279981	575	589	lipid profiles	T059	C0022885
27279981	591	596	Bcl-2	T116,T123	C1528442
27279981	601	608	Mir-133	T114	C2934005
27279981	609	626	expression levels	T081	C3244092
27279981	634	648	cardiac tissue	T024	C1272575
27279981	650	656	Grafts	T024	C0332835
27279981	674	721	reverse transcription-polymerase chain reaction	T063	C0599161
27279981	726	736	Bcl-2 mRNA	T028	C0376515
27279981	741	748	Mir-133	T028	C2825314
27279981	756	768	Western blot	T059,T063	C0005863
27279981	773	786	Bcl-2 protein	T116,T123	C1528442
27279981	788	799	Ovariectomy	T061	C0029936
27279981	800	814	down-regulated	T044	C0013081
27279981	815	820	Bcl-2	T116,T123	C1528442
27279981	825	832	Mir-133	T114	C2934005
27279981	833	850	expression levels	T081	C3244092
27279981	858	872	cardiac tissue	T024	C1272575
27279981	878	886	swimming	T056	C0039003
27279981	887	895	training	T065	C0220931
27279981	896	908	up-regulated	T044	C0041904
27279981	915	925	expression	T045	C1171362
27279981	982	990	exercise	T056	C0015259
27279981	996	1024	physical replacement therapy	T061	C0279033
27279981	1031	1038	prevent	T080	C2700409
27279981	1055	1065	effects of	T080	C1704420
27279981	1066	1085	estrogen deficiency	T047	C0853662
27279981	1093	1099	cardia	T023	C0018787

27280034|t|Changes in risk factors for young male suicide in Newcastle upon Tyne, 1961-2009
27280034|a|Aims and method To ascertain differences in patterns of suicide in young men over three decades (1960s, 1990s and 2000s) and discuss implications for suicide prevention. Data on suicides and open verdicts in men aged 15-34 were obtained from coroner's records in Newcastle upon Tyne and analysed using SPSS software. Results An increase in suicide rates from the first to the second decade was followed by a fall in the third decade. This was associated with an increasing proportion of single men, those living alone, unemployment, consumption of alcohol, use of hanging, previous suicide attempt and history of treatment for mental illness. Clinical implications This study highlights the need for more interventions and focus to be given to young males in the suicide prevention area and is of high importance in the field of public health. Areas that could be tackled include reducing access to means of suicide, reducing alcohol use, support for relationship difficulties, engagement with mental health services and management of chronic illness.
27280034	0	7	Changes	T169	C0392747
27280034	11	23	risk factors	T033	C0035648
27280034	28	33	young	T079	C0332239
27280034	34	38	male	T032	C0086582
27280034	39	46	suicide	T033	C0038661
27280034	50	69	Newcastle upon Tyne	T083	C0017446
27280034	81	85	Aims	T078	C1947946
27280034	90	96	method	T170	C0025663
27280034	110	121	differences	T080	C1705242
27280034	125	144	patterns of suicide	T033	C0038661
27280034	148	153	young	T079	C0332239
27280034	154	157	men	T098	C0025266
27280034	169	176	decades	T081	C2981279
27280034	214	226	implications	T080	C0205556
27280034	231	238	suicide	T033	C0038661
27280034	239	249	prevention	T080	C2700409
27280034	251	255	Data	T078	C1511726
27280034	259	267	suicides	T033	C0038661
27280034	272	285	open verdicts	T064	C0680738
27280034	289	292	men	T098	C0025266
27280034	323	340	coroner's records	T170	C0282574
27280034	344	363	Newcastle upon Tyne	T083	C0017446
27280034	368	376	analysed	T062	C0936012
27280034	383	396	SPSS software	T073,T170	C0037585
27280034	398	405	Results	T169	C1274040
27280034	409	417	increase	T169	C0442805
27280034	421	434	suicide rates	T033	C1822575
27280034	464	470	decade	T081	C2981279
27280034	507	513	decade	T081	C2981279
27280034	524	539	associated with	T080	C0332281
27280034	543	553	increasing	T169	C0442808
27280034	554	564	proportion	T081	C1709707
27280034	568	574	single	T081	C0205171
27280034	575	578	men	T098	C0025266
27280034	586	598	living alone	T033	C0260794
27280034	600	612	unemployment	T033	C0041674
27280034	614	636	consumption of alcohol	T055	C0001948
27280034	645	652	hanging	T037	C0544691
27280034	654	662	previous	T079	C0205156
27280034	663	678	suicide attempt	T033	C0038663
27280034	683	703	history of treatment	UnknownType	C0814462
27280034	708	722	mental illness	T048	C0004936
27280034	724	732	Clinical	T080	C0205210
27280034	733	745	implications	T080	C0205556
27280034	751	756	study	T062	C2603343
27280034	786	799	interventions	T061	C0184661
27280034	804	809	focus	T041	C0589098
27280034	825	830	young	T079	C0332239
27280034	831	836	males	T032	C0086582
27280034	844	851	suicide	T033	C0038661
27280034	852	867	prevention area	T080	C2700409
27280034	901	923	field of public health	T170	C3244304
27280034	961	969	reducing	T080	C0392756
27280034	970	976	access	T082	C0444454
27280034	980	985	means	T077	C1704970
27280034	989	996	suicide	T033	C0038661
27280034	998	1006	reducing	T080	C0392756
27280034	1007	1018	alcohol use	T055	C0001948
27280034	1020	1027	support	T077	C1521721
27280034	1032	1044	relationship	T080	C0439849
27280034	1045	1057	difficulties	T080	C0332218
27280034	1059	1069	engagement	T058	C3508152
27280034	1075	1097	mental health services	T058	C0025355
27280034	1102	1112	management	T058	C0376636
27280034	1116	1131	chronic illness	T047	C0008679

27280293|t|Spatio-Temporal History of HIV-1 CRF35_AD in Afghanistan and Iran
27280293|a|HIV-1 Circulating Recombinant Form 35_AD (CRF35_AD) has an important position in the epidemiological profile of Afghanistan and Iran. Despite the presence of this clade in Afghanistan and Iran for over a decade, our understanding of its origin and dissemination patterns is limited. In this study, we performed a Bayesian phylogeographic analysis to reconstruct the spatio-temporal dispersion pattern of this clade using eligible CRF35_AD gag and pol sequences available in the Los Alamos HIV database (432 sequences available from Iran, 16 sequences available from Afghanistan, and a single CRF35_AD -like pol sequence available from USA). Bayesian Markov Chain Monte Carlo algorithm was implemented in BEAST v1.8.1. Between-country dispersion rates were tested with Bayesian stochastic search variable selection method and were considered significant where Bayes factor values were greater than three. The findings suggested that CRF35_AD sequences were genetically similar to parental sequences from Kenya and Uganda, and to a set of subtype A1 sequences available from Afghan refugees living in Pakistan. Our results also showed that across all phylogenies, Afghan and Iranian CRF35_AD sequences formed a monophyletic cluster (posterior clade credibility> 0.7). The divergence date of this cluster was estimated to be between 1990 and 1992. Within this cluster, a bidirectional dispersion of the virus was observed across Afghanistan and Iran. We could not clearly identify if Afghanistan or Iran first established or received this epidemic, as the root location of this cluster could not be robustly estimated. Three CRF35_AD sequences from Afghan refugees living in Pakistan nested among Afghan and Iranian CRF35_AD branches. However, the CRF35_AD -like sequence available from USA diverged independently from Kenyan subtype A1 sequences, suggesting it not to be a true CRF35_AD lineage. Potential factors contributing to viral exchange between Afghanistan and Iran could be injection drug networks and mass migration of Afghan refugees and labours to Iran, which calls for extensive preventive efforts.
27280293	0	23	Spatio-Temporal History	T062	C3494293
27280293	27	41	HIV-1 CRF35_AD	T034	C3656358
27280293	45	56	Afghanistan	T083	C0001732
27280293	61	65	Iran	T083	C0022065
27280293	66	106	HIV-1 Circulating Recombinant Form 35_AD	T005	C0019704
27280293	108	116	CRF35_AD	T034	C3656358
27280293	151	166	epidemiological	T091	C0014507
27280293	167	174	profile	T169	C2003903
27280293	178	189	Afghanistan	T083	C0001732
27280293	194	198	Iran	T083	C0022065
27280293	229	234	clade	T001	C0029235
27280293	238	249	Afghanistan	T083	C0001732
27280293	254	258	Iran	T083	C0022065
27280293	314	327	dissemination	T080	C0332261
27280293	379	412	Bayesian phylogeographic analysis	T081	C0242196
27280293	432	466	spatio-temporal dispersion pattern	T080	C0332261
27280293	475	480	clade	T001	C0029235
27280293	496	504	CRF35_AD	T034	C3656358
27280293	505	526	gag and pol sequences	T086	C0004793
27280293	544	554	Los Alamos	T083	C3829256
27280293	555	567	HIV database	T170	C0950132
27280293	573	582	sequences	T086	C0004793
27280293	598	602	Iran	T083	C0022065
27280293	607	616	sequences	T086	C0004793
27280293	632	643	Afghanistan	T083	C0001732
27280293	658	666	CRF35_AD	T034	C3656358
27280293	673	685	pol sequence	T086	C0004793
27280293	701	704	USA	T083	C0041703
27280293	707	750	Bayesian Markov Chain Monte Carlo algorithm	T170	C0002045
27280293	770	782	BEAST v1.8.1	T073,T170	C0037585
27280293	834	886	Bayesian stochastic search variable selection method	T170	C0034980
27280293	925	944	Bayes factor values	T081	C1553908
27280293	998	1006	CRF35_AD	T034	C3656358
27280293	1007	1016	sequences	T086	C0004793
27280293	1045	1063	parental sequences	T086	C0004793
27280293	1069	1074	Kenya	T083	C0022558
27280293	1079	1085	Uganda	T083	C0041573
27280293	1103	1113	subtype A1	T034	C3656358
27280293	1114	1123	sequences	T086	C0004793
27280293	1139	1145	Afghan	T083	C0001732
27280293	1146	1154	refugees	T098	C0034961
27280293	1165	1173	Pakistan	T083	C0030211
27280293	1215	1226	phylogenies	T078	C0031797
27280293	1228	1234	Afghan	T083	C0001732
27280293	1239	1246	Iranian	T083	C0022065
27280293	1247	1255	CRF35_AD	T034	C3656358
27280293	1256	1265	sequences	T086	C0004793
27280293	1275	1295	monophyletic cluster	T081	C1704332
27280293	1360	1367	cluster	T081	C1704332
27280293	1423	1430	cluster	T081	C1704332
27280293	1434	1447	bidirectional	T080	C1706937
27280293	1448	1458	dispersion	T080	C0332261
27280293	1466	1471	virus	T005	C0042776
27280293	1492	1503	Afghanistan	T083	C0001732
27280293	1508	1512	Iran	T083	C0022065
27280293	1547	1558	Afghanistan	T083	C0001732
27280293	1562	1566	Iran	T083	C0022065
27280293	1602	1610	epidemic	T047	C0277548
27280293	1641	1648	cluster	T081	C1704332
27280293	1688	1696	CRF35_AD	T034	C3656358
27280293	1697	1706	sequences	T086	C0004793
27280293	1712	1718	Afghan	T083	C0001732
27280293	1719	1727	refugees	T098	C0034961
27280293	1728	1737	living in	T082	C0337646
27280293	1738	1746	Pakistan	T083	C0030211
27280293	1760	1766	Afghan	T083	C0001732
27280293	1771	1778	Iranian	T083	C0022065
27280293	1779	1787	CRF35_AD	T034	C3656358
27280293	1811	1819	CRF35_AD	T034	C3656358
27280293	1826	1834	sequence	T086	C0004793
27280293	1850	1853	USA	T083	C0041703
27280293	1882	1888	Kenyan	T083	C0022558
27280293	1889	1899	subtype A1	T034	C3656358
27280293	1900	1909	sequences	T086	C0004793
27280293	1942	1950	CRF35_AD	T034	C3656358
27280293	1960	1969	Potential	T080	C3245505
27280293	1970	1977	factors	T169	C1521761
27280293	1994	1999	viral	T005	C0042776
27280293	2017	2028	Afghanistan	T083	C0001732
27280293	2033	2037	Iran	T083	C0022065
27280293	2075	2089	mass migration	T054	C0600210
27280293	2093	2099	Afghan	T083	C0001732
27280293	2100	2108	refugees	T098	C0034961
27280293	2113	2120	labours	T055	C0022867
27280293	2124	2128	Iran	T083	C0022065
27280293	2146	2155	extensive	T080	C0205231
27280293	2156	2166	preventive	T080	C1456501

27280485|t|Hepatitis E virus in donor plasma collected in Japan
27280485|a|Human hepatitis E virus (HEV) is prevalent worldwide. Iatrogenic HEV has recently been identified based on the reports of transfusion-transmitted cases. The detection rate of HEV-RNA and seroprevalence of HEV-IgG / IgM have been regionally evaluated in Japan, and donor plasma collected in Hokkaido is currently screened by nucleic acid amplification testing. However, the detection rate of HEV-RNA in blood donors in Japan outside of Hokkaido has not been reported. A total of 620 140 qualified donor plasma samples from Japanese regions excluding Hokkaido were tested for HEV-RNA (pools of 50 or 500) between 2004 and 2014. HEV-RNA-positive plasma bags were identified, and the HEV viral load, genotype and anti-HEV immunoglobulin (Ig)G/IgM were evaluated. The detection rate of HEV-RNA (pools of 50) was 1/15 075 and higher in eastern than in western Japan. All 36 HEV-RNA-positive samples were genotype 3 with viral load ranging from <1Â·69 to 7Â·22 log10 copies/ml. Our detection rate of HEV-RNA in donor populations in Japan outside Hokkaido (1/15 075 donations) is generally lower than reported in Europe and lower than previously reported for Hokkaido (1/8173 donations). As methods varied, we cannot exclude that these differences are reflective of differing RNA detection limits. In contrast to Hokkaido where genotype 4 has been reported among blood donations, all our positive donations were genotype 3, which is less pathogenic.
27280485	0	17	Hepatitis E virus	T005	C0085294
27280485	21	26	donor	T098	C0013018
27280485	27	33	plasma	T031	C0032105
27280485	47	52	Japan	T083	C0022341
27280485	53	58	Human	T016	C0086418
27280485	59	76	hepatitis E virus	T005	C0085294
27280485	78	81	HEV	T005	C0085294
27280485	86	105	prevalent worldwide	T033	C0243095
27280485	107	117	Iatrogenic	T080	C0439669
27280485	118	121	HEV	T005	C0085294
27280485	140	150	identified	T080	C0205396
27280485	164	171	reports	T170	C0684224
27280485	175	204	transfusion-transmitted cases	T169	C0868928
27280485	210	224	detection rate	T081	C1521828
27280485	228	235	HEV-RNA	T114	C3263637
27280485	240	254	seroprevalence	T062	C0600367
27280485	258	265	HEV-IgG	T116,T129	C0806349
27280485	268	271	IgM	T116,T129	C0806350
27280485	282	302	regionally evaluated	T058	C0220825
27280485	306	311	Japan	T083	C0022341
27280485	317	322	donor	T098	C0013018
27280485	323	329	plasma	T031	C0032105
27280485	343	351	Hokkaido	T083	C0454745
27280485	365	373	screened	T169	C1305399
27280485	377	411	nucleic acid amplification testing	T059	C0200932
27280485	426	440	detection rate	T081	C1521828
27280485	444	451	HEV-RNA	T114	C3263637
27280485	455	467	blood donors	T098	C0005795
27280485	471	476	Japan	T083	C0022341
27280485	488	496	Hokkaido	T083	C0454745
27280485	549	554	donor	T098	C0013018
27280485	555	569	plasma samples	T031	C0444263
27280485	575	591	Japanese regions	T083	C0022341
27280485	602	610	Hokkaido	T083	C0454745
27280485	616	622	tested	T169	C0039593
27280485	627	634	HEV-RNA	T114	C3263637
27280485	679	695	HEV-RNA-positive	T114	C3263637
27280485	696	707	plasma bags	T031	C1292468
27280485	713	723	identified	T080	C0205396
27280485	733	736	HEV	T005	C0085294
27280485	737	747	viral load	T059	C1261478
27280485	749	757	genotype	T032	C0017431
27280485	762	795	anti-HEV immunoglobulin (Ig)G/IgM	T116,T129	C0312636
27280485	816	830	detection rate	T081	C1521828
27280485	834	841	HEV-RNA	T114	C3263637
27280485	883	890	eastern	T083	C0022341
27280485	899	912	western Japan	T083	C0022341
27280485	921	937	HEV-RNA-positive	T114	C3263637
27280485	938	945	samples	T031	C0444263
27280485	951	961	genotype 3	T032	C0017431
27280485	967	977	viral load	T033	C0376705
27280485	1026	1040	detection rate	T081	C1521828
27280485	1044	1051	HEV-RNA	T114	C3263637
27280485	1055	1072	donor populations	T098	C0013018
27280485	1076	1081	Japan	T083	C0022341
27280485	1090	1098	Hokkaido	T083	C0454745
27280485	1109	1118	donations	T058	C0005794
27280485	1156	1162	Europe	T083	C0015176
27280485	1202	1210	Hokkaido	T083	C0454745
27280485	1219	1228	donations	T058	C0005794
27280485	1319	1322	RNA	T114	C0035668
27280485	1323	1339	detection limits	T081	C2718050
27280485	1356	1364	Hokkaido	T083	C0454745
27280485	1371	1381	genotype 4	T032	C0017431
27280485	1406	1421	blood donations	T058	C0005794
27280485	1431	1439	positive	T033	C1446409
27280485	1440	1449	donations	T058	C0005794
27280485	1455	1465	genotype 3	T032	C0017431
27280485	1481	1491	pathogenic	T033	C3816499

27280525|t|Social cognition in schizophrenia: Factor structure of emotion processing and theory of mind
27280525|a|Factor analytic studies examining social cognition in schizophrenia have yielded inconsistent results most likely due to the varying number and quality of measures. With the recent conclusion of Phase 3 of the Social Cognition Psychometric Evaluation (SCOPE) Study, the most psychometrically sound measures of social cognition have been identified. Therefore, the aims of the present study were to: 1) examine the factor structure of social cognition in schizophrenia through the utilization of psychometrically sound measures, 2) examine the stability of the factor structure across two study visits, 3) compare the factor structure of social cognition in schizophrenia to that in healthy controls, and 4) examine the relationship between the factors and relevant outcome measures including social functioning and symptoms. Results supported a one-factor model for the patient and healthy control samples at both visits. This single factor was significantly associated with negative symptoms in the schizophrenia sample and with social functioning in both groups at both study visits.
27280525	0	16	Social cognition	T054	C0871381
27280525	20	33	schizophrenia	T048	C0036341
27280525	35	51	Factor structure	T081	C0870541
27280525	55	62	emotion	T041	C0013987
27280525	63	73	processing	T041	C0025361
27280525	78	92	theory of mind	T078	C0935573
27280525	93	116	Factor analytic studies	T081	C0085801
27280525	127	143	social cognition	T054	C0871381
27280525	147	160	schizophrenia	T048	C0036341
27280525	187	194	results	T169	C1274040
27280525	237	256	quality of measures	T170	C3242457
27280525	288	295	Phase 3	T079	C0439561
27280525	303	319	Social Cognition	T054	C0871381
27280525	320	357	Psychometric Evaluation (SCOPE) Study	T060	C0033920
27280525	368	384	psychometrically	T060	C0033920
27280525	385	399	sound measures	T060	C0430022
27280525	403	419	social cognition	T054	C0871381
27280525	477	482	study	T062	C2603343
27280525	495	502	examine	T033	C0332128
27280525	507	523	factor structure	T081	C0870541
27280525	527	543	social cognition	T054	C0871381
27280525	547	560	schizophrenia	T048	C0036341
27280525	588	604	psychometrically	T060	C0033920
27280525	605	619	sound measures	T060	C0430022
27280525	624	631	examine	T033	C0332128
27280525	636	645	stability	T080	C0205360
27280525	653	669	factor structure	T081	C0870541
27280525	681	686	study	T062	C2603343
27280525	710	726	factor structure	T081	C0870541
27280525	730	746	social cognition	T054	C0871381
27280525	750	763	schizophrenia	T048	C0036341
27280525	775	791	healthy controls	T080	C2986479
27280525	800	807	examine	T033	C0332128
27280525	837	844	factors	T081	C0870541
27280525	858	874	outcome measures	T081	C0086749
27280525	885	903	social functioning	T054	C0037395
27280525	908	916	symptoms	T184	C1457887
27280525	918	925	Results	T169	C1274040
27280525	938	954	one-factor model	T170	C0282574
27280525	963	970	patient	T101	C0030705
27280525	975	990	healthy control	T080	C2986479
27280525	1007	1013	visits	T058	C1512346
27280525	1007	1013	visits	T058	C1512346
27280525	1052	1067	associated with	T080	C0332281
27280525	1068	1085	negative symptoms	T184	C1457887
27280525	1093	1106	schizophrenia	T048	C0036341
27280525	1107	1113	sample	T167	C0370003
27280525	1123	1141	social functioning	T054	C0037395
27280525	1150	1156	groups	T098	C1257890
27280525	1165	1170	study	T062	C2603343
27280525	1171	1177	visits	T058	C1512346

27282214|t|Individual differences in behavioral activation and cardiac vagal control influence affective startle modification
27282214|a|The startle response (SR) has a close relationship with stress responses. Startle modification (SRM) has been widely used to study stress disorders (e.g., posttraumatic stress disorder). The framework of the behavioral inhibition and activation systems (BIS / BAS) has been thought to correspond with withdrawal and approach motivational processes underlying affective SRM and can influence stress reactivity. Vagally-mediated cardiac activity as indexed by heart rate variability (HRV) has been associated with SRM and regulatory processes during stress. In the present study, the influence of individual differences in the BIS / BAS and resting HRV on affective SRM were examined. Eighty-six subjects viewed affective pictures while acoustic SR stimuli were delivered. Individual differences in motivation were measured by the BIS/BAS scales. The magnitude of SR was assessed as electromyographic activity of the SR eyeblink during pictures of different valences. Resting HRV was derived from electrocardiography. In contrast to previous studies, the present results showed that startle inhibition and potentiation were related to BAS and HRV, but not to BIS. There was also an interaction of BAS and HRV, indicating that the relationship between HRV and SRM strengthened as BAS scores decreased. The present findings suggest that BAS may relate to both withdrawal and approach, and trait stress reactivity is influence d by BAS and cardiac vagal activity. In addition, BAS moderates the relationship between cardiac vagal activity and SRM. These findings have both theoretical and practical implications for the study of SRM, stress disorders, and health.
27282214	0	22	Individual differences	T054	C0021228
27282214	26	47	behavioral activation	T040	C2253866
27282214	52	73	cardiac vagal control	T044	C1148560
27282214	74	83	influence	T077	C4054723
27282214	94	114	startle modification	T169	C0449851
27282214	119	135	startle response	T040	C0038186
27282214	137	139	SR	T040	C0038186
27282214	153	165	relationship	T080	C0439849
27282214	171	187	stress responses	T039	C0149784
27282214	189	209	Startle modification	T169	C0449851
27282214	211	214	SRM	T169	C0449851
27282214	246	262	stress disorders	T048	C0004936
27282214	270	299	posttraumatic stress disorder	T048	C0038436
27282214	323	344	behavioral inhibition	T041	C0039474
27282214	369	372	BIS	T041	C0039474
27282214	440	462	motivational processes	T041	C0026605
27282214	484	487	SRM	T169	C0449851
27282214	496	505	influence	T077	C4054723
27282214	506	523	stress reactivity	T039	C2350025
27282214	525	558	Vagally-mediated cardiac activity	T033	C0443168
27282214	562	569	indexed	T170	C0918012
27282214	573	595	heart rate variability	T033	C0243095
27282214	597	600	HRV	T033	C0243095
27282214	611	626	associated with	T080	C0332281
27282214	627	630	SRM	T169	C0449851
27282214	635	655	regulatory processes	T038	C1327622
27282214	663	669	stress	T033	C0038435
27282214	697	706	influence	T077	C4054723
27282214	710	732	individual differences	T054	C0021228
27282214	740	743	BIS	T041	C0039474
27282214	762	765	HRV	T033	C0243095
27282214	779	782	SRM	T169	C0449851
27282214	788	796	examined	T033	C0332128
27282214	798	817	Eighty-six subjects	T096	C0681850
27282214	835	843	pictures	T073	C0441469
27282214	850	869	acoustic SR stimuli	T070	C0683110
27282214	886	908	Individual differences	T054	C0021228
27282214	912	922	motivation	T041	C0026605
27282214	928	936	measured	T080	C0444706
27282214	944	958	BIS/BAS scales	T170	C0282574
27282214	964	973	magnitude	T081	C1704240
27282214	977	979	SR	T040	C0038186
27282214	984	992	assessed	T052	C1516048
27282214	996	1013	electromyographic	T060	C0013839
27282214	1014	1022	activity	T052	C0441655
27282214	1030	1032	SR	T040	C0038186
27282214	1033	1041	eyeblink	T042	C0005757
27282214	1049	1057	pictures	T073	C0441469
27282214	1071	1079	valences	T080	C0205556
27282214	1089	1092	HRV	T033	C0243095
27282214	1110	1129	electrocardiography	T060	C1623258
27282214	1176	1183	results	T169	C1274040
27282214	1196	1214	startle inhibition	T044	C1148560
27282214	1219	1231	potentiation	T044	C1148560
27282214	1256	1259	HRV	T033	C0243095
27282214	1272	1275	BIS	T041	C0039474
27282214	1295	1306	interaction	T169	C1704675
27282214	1318	1321	HRV	T033	C0243095
27282214	1343	1355	relationship	T080	C0439849
27282214	1364	1367	HRV	T033	C0243095
27282214	1372	1375	SRM	T169	C0449851
27282214	1396	1402	scores	T081	C0449820
27282214	1426	1434	findings	T033	C0243095
27282214	1500	1505	trait	T032	C0599883
27282214	1506	1523	stress reactivity	T039	C2350025
27282214	1527	1536	influence	T077	C4054723
27282214	1550	1572	cardiac vagal activity	T033	C0443168
27282214	1605	1617	relationship	T080	C0439849
27282214	1626	1648	cardiac vagal activity	T033	C0443168
27282214	1653	1656	SRM	T169	C0449851
27282214	1664	1672	findings	T033	C0243095
27282214	1683	1721	theoretical and practical implications	T169	C0205245
27282214	1739	1742	SRM	T169	C0449851
27282214	1744	1760	stress disorders	T048	C0004936
27282214	1766	1772	health	T078	C0018684

27282236|t|Efficient patient modeling for visuo - haptic VR simulation using a generic patient atlas
27282236|a|This work presents a new time-saving virtual patient modeling system by way of example for an existing visuo - haptic training and planning virtual reality (VR) system for percutaneous transhepatic cholangio-drainage (PTCD). Our modeling process is based on a generic patient atlas to start with. It is defined by organ - specific optimized models, method modules and parameters, i.e. mainly individual segmentation masks, transfer functions to fill the gaps between the masks and intensity image data. In this contribution, we show how generic patient atlases can be generalized to new patient data. The methodology consists of patient - specific, locally-adaptive transfer functions and dedicated modeling methods such as multi-atlas segmentation, vessel filtering and spline-modeling. Our full image volume segmentation algorithm yields median DICE coefficients of 0.98, 0.93, 0.82, 0.74, 0.51 and 0.48 regarding soft-tissue, liver, bone, skin, blood and bile vessels for ten test patients and three selected reference patients. Compared to standard slice-wise manual contouring time saving is remarkable. Our segmentation process shows out efficiency and robustness for upper abdominal puncture simulation systems. This marks a significant step toward establishing patient - specific training and hands-on planning systems in a clinical environment.
27282236	10	17	patient	T101	C0030705
27282236	18	26	modeling	T062	C0870071
27282236	31	36	visuo	T169	C0234621
27282236	39	45	haptic	T042	C0871762
27282236	46	59	VR simulation	T066	C0871582
27282236	76	83	patient	T101	C0030705
27282236	84	89	atlas	T073,T170	C0004171
27282236	127	134	virtual	T066	C0871582
27282236	135	142	patient	T101	C0030705
27282236	143	158	modeling system	T062	C0870071
27282236	193	198	visuo	T169	C0234621
27282236	201	207	haptic	T042	C0871762
27282236	208	216	training	T065	C0220931
27282236	230	257	virtual reality (VR) system	T066	C0871582
27282236	262	306	percutaneous transhepatic cholangio-drainage	T061	C1504490
27282236	308	312	PTCD	T061	C1504490
27282236	319	335	modeling process	T062	C0870071
27282236	358	365	patient	T101	C0030705
27282236	366	371	atlas	T073,T170	C0004171
27282236	404	409	organ	T023	C0178784
27282236	412	420	specific	T080	C0205369
27282236	421	430	optimized	T052	C2698650
27282236	431	437	models	T170	C3161035
27282236	439	453	method modules	T170	C0025663
27282236	458	468	parameters	T077	C0549193
27282236	493	505	segmentation	T066	C2697664
27282236	506	511	masks	T080	C2346471
27282236	513	531	transfer functions	T066	C0024931
27282236	544	548	gaps	T082	C3887622
27282236	561	566	masks	T080	C2346471
27282236	571	586	intensity image	T080	C2346471
27282236	587	591	data	T078	C1511726
27282236	635	642	patient	T101	C0030705
27282236	643	650	atlases	T073,T170	C0004171
27282236	677	689	patient data	T170	C2707520
27282236	719	726	patient	T101	C0030705
27282236	729	737	specific	T080	C0205369
27282236	756	774	transfer functions	T066	C0024931
27282236	789	805	modeling methods	T062	C0870071
27282236	814	838	multi-atlas segmentation	T066	C2697664
27282236	840	856	vessel filtering	T170	C0025663
27282236	861	876	spline-modeling	T170	C0025663
27282236	887	912	image volume segmentation	T066	C2697664
27282236	913	922	algorithm	T170	C0002045
27282236	930	954	median DICE coefficients	T081	C0392762
27282236	1006	1017	soft-tissue	T024	C0225317
27282236	1019	1024	liver	T023	C0023884
27282236	1026	1030	bone	T024	C0005931
27282236	1032	1036	skin	T022	C1123023
27282236	1038	1043	blood	T023	C0005847
27282236	1048	1060	bile vessels	T031	C0005388
27282236	1074	1082	patients	T101	C0030705
27282236	1112	1120	patients	T101	C0030705
27282236	1143	1171	slice-wise manual contouring	T066	C2697664
27282236	1203	1223	segmentation process	T066	C2697664
27282236	1234	1244	efficiency	T081	C0013682
27282236	1249	1259	robustness	T080	C2986815
27282236	1270	1288	abdominal puncture	T037	C2089285
27282236	1289	1307	simulation systems	T066	C0009609
27282236	1322	1333	significant	T078	C0750502
27282236	1359	1366	patient	T101	C0030705
27282236	1369	1377	specific	T080	C0205369
27282236	1378	1386	training	T065	C0220931
27282236	1422	1442	clinical environment	T061	C0008971

27282265|t|The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study
27282265|a|To investigate the effects of esomeprazole and rebamipide combination therapy on symptomatic improvement in patients with reflux esophagitis. A total of 501 patients with reflux esophagitis were randomized into one of the following two treatment regimens: 40 mg esomeprazole plus 300 mg rebamipide daily (combination therapy group) or 40 mg esomeprazole daily (monotherapy group). We used a symptom questionnaire that evaluated heartburn, acid regurgitation, and four upper gastrointestinal symptoms. The primary efficacy end point was the mean decrease in the total symptom score. The mean decreases in the total symptom score at 4 weeks were estimated to be -18.1Â±13.8 in the combination therapy group and -15.1Â±11.9 in the monotherapy group (p=0.011). Changes in reflux symptom s from baseline after 4 weeks of treatment were -8.4Â±6.6 in the combination therapy group and -6.8Â±5.9 in the monotherapy group (p=0.009). Over a 4- week treatment course, esomeprazole and rebamipide combination therapy was more effective in decreasing the symptoms of reflux esophagitis than esomeprazole monotherapy.
27282265	4	12	Benefits	T081	C0814225
27282265	16	35	Combination Therapy	T061	C0009429
27282265	41	53	Esomeprazole	T109,T121	C0937846
27282265	58	68	Rebamipide	T109,T121	C0069562
27282265	72	79	Symptom	T184	C1457887
27282265	80	91	Improvement	T077	C2986411
27282265	95	113	Reflux Esophagitis	T047	C0014869
27282265	118	131	International	T078	C1512888
27282265	132	149	Multicenter Study	T062	C1096776
27282265	153	164	investigate	T169	C1292732
27282265	169	176	effects	T080	C1280500
27282265	180	192	esomeprazole	T109,T121	C0937846
27282265	197	207	rebamipide	T109,T121	C0069562
27282265	208	227	combination therapy	T061	C0009429
27282265	231	242	symptomatic	T184	C1457887
27282265	243	254	improvement	T077	C2986411
27282265	258	266	patients	T101	C0030705
27282265	272	290	reflux esophagitis	T047	C0014869
27282265	307	315	patients	T101	C0030705
27282265	321	339	reflux esophagitis	T047	C0014869
27282265	345	355	randomized	T062,T170	C0206034
27282265	386	404	treatment regimens	T061	C0040808
27282265	412	424	esomeprazole	T109,T121	C0937846
27282265	437	447	rebamipide	T109,T121	C0069562
27282265	448	453	daily	T079	C0332173
27282265	455	474	combination therapy	T061	C0009429
27282265	475	480	group	T078	C0441833
27282265	491	503	esomeprazole	T109,T121	C0937846
27282265	504	509	daily	T079	C0332173
27282265	511	522	monotherapy	T061	C0087111
27282265	523	528	group	T078	C0441833
27282265	541	548	symptom	T184	C1457887
27282265	549	562	questionnaire	T170	C0034394
27282265	568	577	evaluated	T169	C1292732
27282265	578	587	heartburn	T184	C0018834
27282265	589	607	acid regurgitation	T184	C0849747
27282265	618	649	upper gastrointestinal symptoms	T047	C0857493
27282265	663	671	efficacy	T080	C1280519
27282265	695	703	decrease	T081	C0547047
27282265	717	730	symptom score	T033	C3476546
27282265	741	750	decreases	T081	C0547047
27282265	764	777	symptom score	T033	C3476546
27282265	783	788	weeks	T079	C0439230
27282265	828	847	combination therapy	T061	C0009429
27282265	848	853	group	T078	C0441833
27282265	876	887	monotherapy	T061	C0087111
27282265	888	893	group	T078	C0441833
27282265	916	922	reflux	T047	C0014869
27282265	923	930	symptom	T184	C1457887
27282265	938	946	baseline	T081	C1442488
27282265	955	960	weeks	T079	C0439230
27282265	964	973	treatment	T061	C0087111
27282265	995	1014	combination therapy	T061	C0009429
27282265	1015	1020	group	T078	C0441833
27282265	1041	1052	monotherapy	T061	C0087111
27282265	1053	1058	group	T078	C0441833
27282265	1080	1084	week	T079	C0439230
27282265	1085	1094	treatment	T061	C0087111
27282265	1103	1115	esomeprazole	T109,T121	C0937846
27282265	1120	1130	rebamipide	T109,T121	C0069562
27282265	1131	1150	combination therapy	T061	C0009429
27282265	1160	1169	effective	T080	C1704419
27282265	1173	1183	decreasing	T033	C0442797
27282265	1188	1196	symptoms	T184	C1457887
27282265	1200	1218	reflux esophagitis	T047	C0014869
27282265	1224	1236	esomeprazole	T109,T121	C0937846
27282265	1237	1248	monotherapy	T061	C0087111

27282454|t|Achilles tendon material properties are greater in the jump leg of jumping athletes
27282454|a|The Achilles tendon (AT) must adapt to meet changes in demands. This study explored AT adaptation by comparing properties within the jump and non-jump legs of jumping athletes. Non-jumping control athletes were included to control limb dominance effects. AT properties were assessed in the preferred (jump) and non-preferred (lead) jumping legs of male collegiate-level long and/or high jump (jumpers; n=10) and cross-country (controls; n=10) athletes. Cross-sectional area (CSA), elongation, and force during isometric contractions were used to estimate the morphological, mechanical and material properties of the ATs bilaterally. Jumpers exposed their ATs to more force and stress than controls (all pâ¤0.03). AT force and stress were also greater in the jump leg of both jumpers and controls than in the lead leg (all p<0.05). Jumpers had 17.8% greater AT stiffness and 24.4% greater Young's modulus in their jump leg compared to lead leg (all p<0.05). There were no jump versus lead leg differences in AT stiffness or Young's modulus within controls (all p>0.05). ATs chronically exposed to elevated mechanical loading were found to exhibit greater mechanical (stiffness) and material (Young's modulus) properties.
27282454	0	15	Achilles tendon	T023	C0001074
27282454	16	35	material properties	T070	C3658372
27282454	40	47	greater	T081	C1704243
27282454	55	63	jump leg	T023	C1140621
27282454	67	74	jumping	T056	C0221189
27282454	75	83	athletes	T097	C0238703
27282454	88	103	Achilles tendon	T023	C0001074
27282454	105	107	AT	T023	C0001074
27282454	123	127	meet	T067	C1550543
27282454	128	135	changes	T169	C0392747
27282454	139	146	demands	T078	C0699784
27282454	168	170	AT	T023	C0001074
27282454	171	181	adaptation	T040	C0000934
27282454	185	194	comparing	T052	C1707455
27282454	195	205	properties	T080	C0871161
27282454	217	221	jump	T056	C0221189
27282454	226	234	non-jump	T033	C0243095
27282454	235	239	legs	T023	C1140621
27282454	243	250	jumping	T056	C0221189
27282454	251	259	athletes	T097	C0238703
27282454	261	272	Non-jumping	T033	C0243095
27282454	273	289	control athletes	T097	C0238703
27282454	295	303	included	T169	C0332257
27282454	307	314	control	T080	C0243148
27282454	315	319	limb	T023	C0015385
27282454	320	329	dominance	T078	C0870441
27282454	330	337	effects	T080	C1280500
27282454	339	341	AT	T023	C0001074
27282454	342	352	properties	T080	C0871161
27282454	358	366	assessed	T052	C1516048
27282454	374	383	preferred	T078	C0558295
27282454	385	389	jump	T056	C0221189
27282454	395	408	non-preferred	T033	C0243095
27282454	416	423	jumping	T056	C0221189
27282454	424	428	legs	T023	C1140621
27282454	432	436	male	T032	C0086582
27282454	437	453	collegiate-level	T080	C0441889
27282454	454	458	long	T080	C0205166
27282454	466	470	high	T080	C0205250
27282454	471	475	jump	T056	C0221189
27282454	477	484	jumpers	T098	C1257890
27282454	496	509	cross-country	T083	C0454664
27282454	511	519	controls	T097	C0238703
27282454	527	535	athletes	T097	C0238703
27282454	537	557	Cross-sectional area	T082	C0205146
27282454	559	562	CSA	T082	C0205146
27282454	565	575	elongation	T067	C1254366
27282454	581	586	force	T067	C0441722
27282454	594	616	isometric contractions	T042	C0022205
27282454	630	638	estimate	T081	C0750572
27282454	643	656	morphological	T082	C0543482
27282454	658	668	mechanical	T070	C3658372
27282454	673	692	material properties	T070	C3658372
27282454	700	703	ATs	T023	C0001074
27282454	704	715	bilaterally	T082	C0238767
27282454	717	724	Jumpers	T098	C1257890
27282454	725	732	exposed	T080	C0332157
27282454	739	742	ATs	T023	C0001074
27282454	751	756	force	T067	C0441722
27282454	761	767	stress	T033	C0038435
27282454	773	781	controls	T097	C0238703
27282454	796	798	AT	T023	C0001074
27282454	799	804	force	T067	C0441722
27282454	809	815	stress	T033	C0038435
27282454	826	833	greater	T081	C1704243
27282454	841	845	jump	T056	C0221189
27282454	846	849	leg	T023	C1140621
27282454	858	865	jumpers	T098	C1257890
27282454	870	878	controls	T097	C0238703
27282454	891	899	lead leg	T023	C1140621
27282454	914	921	Jumpers	T098	C1257890
27282454	932	939	greater	T081	C1704243
27282454	940	942	AT	T023	C0001074
27282454	943	952	stiffness	T184	C0427008
27282454	963	970	greater	T081	C1704243
27282454	971	986	Young's modulus	T081	C2350289
27282454	996	1000	jump	T056	C0221189
27282454	1001	1004	leg	T023	C1140621
27282454	1005	1013	compared	T052	C1707455
27282454	1017	1025	lead leg	T023	C1140621
27282454	1054	1058	jump	T056	C0221189
27282454	1066	1074	lead leg	T023	C1140621
27282454	1075	1086	differences	T080	C1705242
27282454	1090	1092	AT	T023	C0001074
27282454	1093	1102	stiffness	T184	C0427008
27282454	1106	1121	Young's modulus	T081	C2350289
27282454	1129	1137	controls	T097	C0238703
27282454	1152	1155	ATs	T023	C0001074
27282454	1156	1167	chronically	T079	C0205191
27282454	1168	1175	exposed	T080	C0332157
27282454	1179	1187	elevated	T080	C3163633
27282454	1188	1206	mechanical loading	T067	C0563538
27282454	1229	1236	greater	T081	C1704243
27282454	1237	1247	mechanical	T070	C3658372
27282454	1249	1258	stiffness	T184	C0427008
27282454	1264	1272	material	T070	C3658372
27282454	1274	1289	Young's modulus	T081	C2350289
27282454	1291	1301	properties	T080	C0871161

27282845|t|Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes
27282845|a|Assessment of residual disease after neoadjuvant therapy for breast cancer is an ongoing challenge of breast imaging. This study evaluates the accuracy of a novel dedicated system for molecular breast imaging (MBI) composed of the new generation of cadmium zinc telluride detectors in assessing residual disease after neoadjuvant therapy in patients with breast cancer. Clinical data, imaging, surgical, and pathological findings of 51 women with breast cancer undergoing neoadjuvant therapy were recorded. MBI findings were correlated with surgical pathology results. Accuracy of MBI in predicting complete pathological response and size of residual disease was assessed according to molecular subtypes. The size of the largest focus of uptake on MBI correlated with the largest dimension measured on pathology (r = 0.55; P < .001). This correlation was stronger for triple negative and HER2/neu positive subtypes (r = 0.92 and 0.62, respectively). Sixteen patients (31%) had complete pathological response. The sensitivity and specificity of MBI for detecting residual disease were 83% (95% confidence interval [CI], 66-93) and 69% (95% CI, 42-88), respectively. For triple negative or HER2/neu positive disease the sensitivity and specificity were 88% (95% CI, 62-98) and 75% (95% CI, 43-93), respectively. The accuracy of MBI in assessing residual disease after neoadjuvant treatment might be related to the molecular subtype. Accuracy is highest in the triple negative and HER2/neu positive subtypes.
27282845	0	10	Assessment	T058	C0220825
27282845	14	30	Residual Disease	T191	C0543478
27282845	36	60	Molecular Breast Imaging	T060	C2985547
27282845	64	72	Patients	T101	C0030705
27282845	84	103	Neoadjuvant Therapy	T061	C0600558
27282845	122	131	Molecular	T080	C1521991
27282845	132	140	Subtypes	T185	C0449560
27282845	141	151	Assessment	T058	C0220825
27282845	155	171	residual disease	T191	C0543478
27282845	178	197	neoadjuvant therapy	T061	C0600558
27282845	202	215	breast cancer	T191	C0006142
27282845	243	249	breast	T023	C0006141
27282845	250	257	imaging	T060	C0011923
27282845	264	269	study	T062	C2603343
27282845	270	279	evaluates	T058	C0220825
27282845	284	292	accuracy	T080	C0443131
27282845	325	349	molecular breast imaging	T060	C2985547
27282845	351	354	MBI	T060	C2985547
27282845	390	412	cadmium zinc telluride	T197	C1258740
27282845	413	422	detectors	T073	C0180392
27282845	436	452	residual disease	T191	C0543478
27282845	459	478	neoadjuvant therapy	T061	C0600558
27282845	482	490	patients	T101	C0030705
27282845	496	509	breast cancer	T191	C0006142
27282845	511	524	Clinical data	T170	C1516606
27282845	526	533	imaging	T060	C0011923
27282845	535	543	surgical	T169	C0038895
27282845	549	561	pathological	T169	C1521733
27282845	562	570	findings	T033	C0243095
27282845	577	582	women	T098	C0043210
27282845	588	601	breast cancer	T191	C0006142
27282845	613	632	neoadjuvant therapy	T061	C0600558
27282845	648	651	MBI	T060	C2985547
27282845	652	660	findings	T033	C0243095
27282845	666	676	correlated	T080	C1707520
27282845	682	708	surgical pathology results	T170	C1710255
27282845	710	718	Accuracy	T080	C0443131
27282845	722	725	MBI	T060	C2985547
27282845	740	770	complete pathological response	T033	C4050242
27282845	775	779	size	T082	C0456389
27282845	783	799	residual disease	T191	C0543478
27282845	826	835	molecular	T080	C1521991
27282845	836	844	subtypes	T185	C0449560
27282845	850	854	size	T082	C0456389
27282845	889	892	MBI	T060	C2985547
27282845	893	903	correlated	T080	C1707520
27282845	943	952	pathology	T169	C0205469
27282845	980	991	correlation	T080	C1707520
27282845	1009	1024	triple negative	T191	C3539878
27282845	1029	1046	HER2/neu positive	T201	C2348909
27282845	1047	1055	subtypes	T185	C0449560
27282845	1099	1107	patients	T101	C0030705
27282845	1118	1148	complete pathological response	T033	C4050242
27282845	1154	1165	sensitivity	T081	C1511883
27282845	1170	1181	specificity	T081	C0037791
27282845	1185	1188	MBI	T060	C2985547
27282845	1203	1219	residual disease	T191	C0543478
27282845	1234	1253	confidence interval	T081	C0009667
27282845	1255	1257	CI	T081	C0009667
27282845	1280	1282	CI	T081	C0009667
27282845	1310	1325	triple negative	T191	C3539878
27282845	1329	1346	HER2/neu positive	T201	C2348909
27282845	1359	1370	sensitivity	T081	C1511883
27282845	1375	1386	specificity	T081	C0037791
27282845	1401	1403	CI	T081	C0009667
27282845	1425	1427	CI	T081	C0009667
27282845	1455	1463	accuracy	T080	C0443131
27282845	1467	1470	MBI	T060	C2985547
27282845	1484	1500	residual disease	T191	C0543478
27282845	1507	1528	neoadjuvant treatment	T061	C0600558
27282845	1553	1562	molecular	T080	C1521991
27282845	1563	1570	subtype	T185	C0449560
27282845	1572	1580	Accuracy	T080	C0443131
27282845	1599	1614	triple negative	T191	C3539878
27282845	1619	1636	HER2/neu positive	T201	C2348909
27282845	1637	1645	subtypes	T185	C0449560

27283081|t|Sinus augmentation using a histone deacetylase inhibitor in a calcium sulfate carrier in rabbit: A pilot study
27283081|a|Histone deacetylase inhibitors such as sodium butyrate (SB) have been suggested to be promising candidate small molecules for bone regeneration. In this study, the capacity of SB loaded onto calcium sulfate (CaS) to enhance bone formation was investigated in a rabbit sinus model. Following preparation of the sinus access window on a randomly selected side, SB loaded onto CaS (CaS / SB) was grafted in five rabbits, and CaS alone (control) was grafted in another five rabbits. The animals were euthanized after 4 weeks for radiographic, histometric, and immunohistochemical analyses. There was a statistically significant difference in the total augmented volume between the groups in the radiographic analysis (158.22 Â± 39.31 mm(3) and 107.09 Â± 39.69 mm(3), respectively, p = 0.040). The CaS / SB group showed a larger portion of mature lamellar bone and a higher level of mineralization of bone trabeculae, characterized by more intense labeling with osteocalcin compared with the control group in the immunohistochemical analysis. The number of osteocalcin-positive cells within the central area of the augmented sinus was significantly higher in the CaS / SB group than in the control group (179 Â± 26.0 mm(2) and 123 Â± 33.2 mm(2), respectively, p = 0.027). In conclusion, CaS / SB exhibited superior osteogenic potential, especially in the central portion of the augmented sinus as well as improvement of the volume maintenance for sinus augmentation. Â© 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2016.
27283081	0	18	Sinus augmentation	T061	C2236586
27283081	27	56	histone deacetylase inhibitor	T116,T121,T126	C1512474
27283081	62	77	calcium sulfate	T121,T122,T197	C0006720
27283081	78	85	carrier	T122	C0013161
27283081	89	95	rabbit	T015	C3887509
27283081	99	110	pilot study	T062	C0031928
27283081	111	141	Histone deacetylase inhibitors	T116,T121,T126	C1512474
27283081	150	165	sodium butyrate	T109,T121	C0142812
27283081	167	169	SB	T109,T121	C0142812
27283081	207	232	candidate small molecules	T121	C1254351
27283081	237	254	bone regeneration	T042	C0005972
27283081	275	283	capacity	T081	C1516240
27283081	287	289	SB	T109,T121	C0142812
27283081	290	296	loaded	T052	C1708715
27283081	302	317	calcium sulfate	T121,T122,T197	C0006720
27283081	319	322	CaS	T121,T122,T197	C0006720
27283081	327	334	enhance	T052	C2349975
27283081	335	349	bone formation	T042	C0029433
27283081	372	390	rabbit sinus model	T008	C0599779
27283081	421	426	sinus	T030	C0030471
27283081	427	433	access	T169	C1554204
27283081	464	468	side	T082	C0441987
27283081	470	472	SB	T109,T121	C0142812
27283081	473	479	loaded	T052	C1708715
27283081	485	488	CaS	T121,T122,T197	C0006720
27283081	490	493	CaS	T121,T122,T197	C0006720
27283081	496	498	SB	T109,T121	C0142812
27283081	504	511	grafted	T061	C1961139
27283081	520	527	rabbits	T015	C3887509
27283081	533	536	CaS	T121,T122,T197	C0006720
27283081	544	551	control	T096	C0009932
27283081	557	564	grafted	T061	C1961139
27283081	581	588	rabbits	T015	C3887509
27283081	594	601	animals	T008	C0003062
27283081	607	617	euthanized	T058	C1136183
27283081	636	648	radiographic	T060	C1962945
27283081	650	661	histometric	T059	C0344441
27283081	667	686	immunohistochemical	T059	C1441616
27283081	687	695	analyses	T062	C0936012
27283081	709	734	statistically significant	T081	C0237881
27283081	759	768	augmented	T081	C0205217
27283081	769	775	volume	T082	C0456389
27283081	788	794	groups	T078	C0441833
27283081	802	823	radiographic analysis	T060	C1962945
27283081	902	905	CaS	T121,T122,T197	C0006720
27283081	908	910	SB	T109,T121	C0142812
27283081	911	916	group	T078	C0441833
27283081	926	932	larger	T081	C0549177
27283081	933	940	portion	T082	C0449719
27283081	944	950	mature	T079	C0205286
27283081	951	964	lamellar bone	T024	C0682560
27283081	987	1001	mineralization	T042	C2350989
27283081	1005	1020	bone trabeculae	T024	C2826619
27283081	1052	1060	labeling	T059	C0887853
27283081	1066	1077	osteocalcin	T116,T123	C0029419
27283081	1096	1109	control group	T096	C0009932
27283081	1117	1136	immunohistochemical	T059	C1441616
27283081	1137	1145	analysis	T062	C0936012
27283081	1161	1181	osteocalcin-positive	T116,T123	C0029419
27283081	1182	1187	cells	T025	C0007634
27283081	1199	1211	central area	T082	C0205099
27283081	1219	1228	augmented	T081	C0205217
27283081	1229	1234	sinus	T030	C0030471
27283081	1253	1259	higher	T080	C0205250
27283081	1267	1270	CaS	T121,T122,T197	C0006720
27283081	1273	1275	SB	T109,T121	C0142812
27283081	1276	1281	group	T078	C0441833
27283081	1294	1307	control group	T096	C0009932
27283081	1389	1392	CaS	T121,T122,T197	C0006720
27283081	1395	1397	SB	T109,T121	C0142812
27283081	1408	1416	superior	T080	C0205250
27283081	1417	1437	osteogenic potential	T042	C0029433
27283081	1457	1472	central portion	T082	C0449719
27283081	1480	1489	augmented	T081	C0205217
27283081	1490	1495	sinus	T030	C0030471
27283081	1507	1518	improvement	T077	C2986411
27283081	1526	1532	volume	T082	C0456389
27283081	1533	1544	maintenance	T052	C0024501
27283081	1549	1567	sinus augmentation	T061	C2236586

27283167|t|Integrating Palliative Care in Pediatric Oncology: Evidence for an Evolving Paradigm for Comprehensive Cancer Care
27283167|a|The demonstrated benefit of integrating palliative care (PC) into cancer treatment has triggered an increased need for PC services. The trajectory of integrating PC in comprehensive cancer centers, particularly pediatric centers, is unknown. We describe our 8- year experience of initiating and establishing PC with the Quality of Life Service (QoLS) at St. Jude Children's Research Hospital. We retrospectively reviewed records of patients seen by the QoLS (n=615) from March 2007 to December 2014. Variables analyzed for each year, using descriptive statistics, included diagnostic groups, QoLS encounters, goals of care, duration of survival, and location of death. Total QoLS patient encounters increased from 58 (2007) to 1,297 (2014), new consults increased from 17 (2007) to 115 (2014), and mean encounters per patient increased from 5.06 (2007) to 16.11 (2014). Goal of care at initial consultation shifted from primarily comfort to an increasing goal of cure. The median number of days from initial consult to death increased from 52 days (2008) to 223 days (2014). A trend toward increased outpatient location of death was noted with 42% outpatient deaths in 2007, increasing to a majority in each subsequent year (range, 51%-74%). Hospital-wide, patients receiving PC services before death increased from approximately 50% to nearly 100%. Since its inception, the QoLS experienced a dramatic increase in referrals and encounters per patient, increased use by all clinical services, a trend toward earlier consultation and longer term follow-up, increasing outpatient location of death, and near- universal PC involvement at the end-of-life. The successful integration of PC in a comprehensive cancer center, and the resulting potential for improved care provision over time, can serve as a model for other programs on a broad scale.
27283167	0	11	Integrating	T080	C0205195
27283167	12	27	Palliative Care	T091	C0030231
27283167	31	49	Pediatric Oncology	T091	C1518931
27283167	67	75	Evolving	T169	C0332253
27283167	76	84	Paradigm	T062	C0681797
27283167	89	102	Comprehensive	T058	C0009586
27283167	103	114	Cancer Care	T061	C0920687
27283167	143	154	integrating	T080	C0205195
27283167	155	170	palliative care	T091	C0030231
27283167	172	174	PC	T091	C0030231
27283167	181	197	cancer treatment	T061	C0920425
27283167	215	224	increased	T081	C0205217
27283167	234	236	PC	T091	C0030231
27283167	265	276	integrating	T080	C0205195
27283167	277	279	PC	T091	C0030231
27283167	283	296	comprehensive	T058	C0009586
27283167	297	312	cancer centers,	T073,T093	C1516604
27283167	326	343	pediatric centers	T093	C0020017
27283167	376	380	year	T079	C0439234
27283167	410	422	establishing	T080	C0443211
27283167	423	425	PC	T091	C0030231
27283167	435	458	Quality of Life Service	T058	C0008079
27283167	460	464	QoLS	T058	C0008079
27283167	469	506	St. Jude Children's Research Hospital	T093	C1519168
27283167	536	555	records of patients	T170	C0025102
27283167	568	572	QoLS	T058	C0008079
27283167	586	591	March	T079	C3829202
27283167	600	608	December	T080	C3830550
27283167	615	624	Variables	T081	C1705098
27283167	643	647	year	T079	C0439234
27283167	667	677	statistics	T081	C1456551
27283167	688	705	diagnostic groups	T170	C0011928
27283167	707	711	QoLS	T058	C0008079
27283167	712	722	encounters	T058	C1512346
27283167	724	737	goals of care	T058	C2930505
27283167	739	759	duration of survival	T201	C2919551
27283167	765	782	location of death	T082	C2924451
27283167	790	794	QoLS	T058	C0008079
27283167	795	802	patient	T101	C0030705
27283167	803	813	encounters	T058	C1512346
27283167	814	823	increased	T081	C0205217
27283167	860	868	consults	T058	C0009818
27283167	869	878	increased	T081	C0205217
27283167	918	928	encounters	T058	C1512346
27283167	933	940	patient	T101	C0030705
27283167	941	950	increased	T081	C0205217
27283167	985	997	Goal of care	T058	C2930505
27283167	1001	1021	initial consultation	T058	C2065349
27283167	1045	1052	comfort	T041	C1331418
27283167	1059	1069	increasing	T169	C0442808
27283167	1070	1082	goal of cure	T170	C3897861
27283167	1115	1130	initial consult	T058	C2065349
27283167	1134	1139	death	T033	C1306577
27283167	1140	1149	increased	T081	C0205217
27283167	1205	1214	increased	T081	C0205217
27283167	1215	1225	outpatient	T101	C0029921
27283167	1226	1243	location of death	T082	C2924451
27283167	1263	1273	outpatient	T101	C0029921
27283167	1274	1280	deaths	T033	C1306577
27283167	1290	1300	increasing	T169	C0442808
27283167	1306	1314	majority	T080	C0205164
27283167	1334	1338	year	T079	C0439234
27283167	1357	1370	Hospital-wide	T080	C1510665
27283167	1372	1380	patients	T101	C0030705
27283167	1391	1393	PC	T091	C0030231
27283167	1410	1415	death	T033	C1306577
27283167	1416	1425	increased	T081	C0205217
27283167	1431	1444	approximately	T080	C0332232
27283167	1490	1494	QoLS	T058	C0008079
27283167	1518	1526	increase	T081	C0205217
27283167	1530	1539	referrals	T058	C0034927
27283167	1544	1554	encounters	T058	C1512346
27283167	1559	1566	patient	T101	C0030705
27283167	1568	1577	increased	T081	C0205217
27283167	1589	1606	clinical services	T058	C1704289
27283167	1623	1630	earlier	T079	C1279919
27283167	1631	1643	consultation	T058	C0009818
27283167	1648	1659	longer term	T079	C0443252
27283167	1660	1669	follow-up	T058	C1522577
27283167	1671	1681	increasing	T169	C0442808
27283167	1682	1692	outpatient	T101	C0029921
27283167	1693	1710	location of death	T082	C2924451
27283167	1722	1731	universal	T080	C0175671
27283167	1732	1734	PC	T091	C0030231
27283167	1754	1765	end-of-life	T058	C0039548
27283167	1782	1793	integration	T080	C0205195
27283167	1797	1799	PC	T091	C0030231
27283167	1805	1818	comprehensive	T058	C0009586
27283167	1819	1832	cancer center	T073,T093	C1516604
27283167	1875	1889	care provision	T058	C3244104
27283167	1895	1899	time	T079	C0040223
27283167	1916	1921	model	T170	C3161035
27283167	1932	1940	programs	T058	C0679897

27283994|t|Juglone ameliorates skin wound healing by promoting skin cell migration through Rac1 / Cdc42 / PAK pathway
27283994|a|Skin cell regeneration and wound healing are key processes in the recovery from skin injuries. Rapid cell migration and regeneration of skin cells lead to faster and better healing of wounded skin. In the present study, we aimed to investigate the wound healing potential of juglone, a naturally occurring Pin1 inhibitor found in walnuts. Cultured skin cells (NHDF and HaCaT) and hairless mice were treated with juglone after wound creation to examine its effects on cell migration and wound healing rate. The expressions of cell migration related proteins (Rac1, Cdc42, and Î±-PAK), collagen deposition, and angiogenesis were analyzed. Juglone treatment resulted in faster rate of growth and migration and recovered cell morphology, particularly at a concentration of 5 ÂµM, in skin cells compared to the untreated group. In vivo experiments showed that mice treated with juglone showed faster wound healing rate with better skin morphology and collagen deposition than the vehicle group. Furthermore, juglone increased the activation and/or expression of Cdc42, Rac1, and Î±-pak in HaCaT cells, and resulted in enhanced angiogenesis in endothelial cells (HUVECs). Juglone also activated MAPKs signaling by activation of ERK, JNK, and p38 proteins. Taken together, these data suggest that juglone may be a potential candidate for wound healing and skin regeneration which ameliorates wound healing mainly by promoting skin cell migration through Rac1 / Cdc42 / PAK pathway.
27283994	0	7	Juglone	T109,T121	C0064170
27283994	8	19	ameliorates	T080	C0205556
27283994	20	24	skin	T022	C1123023
27283994	25	38	wound healing	T040	C0043240
27283994	42	51	promoting	T052	C0033414
27283994	52	56	skin	T022	C1123023
27283994	57	71	cell migration	T043	C1622501
27283994	80	84	Rac1	T116,T126	C0139880
27283994	87	92	Cdc42	T116,T126	C0082645
27283994	95	98	PAK	T116,T126	C0072402
27283994	99	106	pathway	T043	C0037083
27283994	107	116	Skin cell	T025	C0814995
27283994	117	129	regeneration	T042	C0034963
27283994	134	147	wound healing	T040	C0043240
27283994	173	181	recovery	T040	C2004454
27283994	187	200	skin injuries	T037	C0281980
27283994	202	207	Rapid	T080	C0456962
27283994	208	222	cell migration	T043	C1622501
27283994	227	239	regeneration	T042	C0034963
27283994	243	253	skin cells	T025	C0814995
27283994	280	287	healing	T040	C0043240
27283994	291	298	wounded	T033	C0332797
27283994	299	303	skin	T022	C1123023
27283994	339	350	investigate	T169	C1292732
27283994	355	368	wound healing	T040	C0043240
27283994	369	378	potential	T080	C3245505
27283994	382	389	juglone	T109,T121	C0064170
27283994	413	417	Pin1	T116,T126	C1453967
27283994	418	427	inhibitor	T121	C0014432
27283994	437	444	walnuts	T168	C0993635
27283994	446	465	Cultured skin cells	T025	C0007635
27283994	467	471	NHDF	T025	C0007634
27283994	476	481	HaCaT	T025	C0007634
27283994	487	500	hairless mice	T015	C0025924
27283994	506	518	treated with	T061	C0332293
27283994	519	526	juglone	T109,T121	C0064170
27283994	574	588	cell migration	T043	C1622501
27283994	617	628	expressions	T045	C1171362
27283994	632	646	cell migration	T043	C1622501
27283994	655	663	proteins	T116,T123	C0033684
27283994	665	669	Rac1	T116,T126	C0139880
27283994	671	676	Cdc42	T116,T126	C0082645
27283994	682	687	Î±-PAK	T116,T126	C0299856
27283994	690	698	collagen	T116	C0009325
27283994	699	709	deposition	T169	C0333562
27283994	715	727	angiogenesis	T042	C0302600
27283994	733	741	analyzed	T062	C0936012
27283994	743	750	Juglone	T109,T121	C0064170
27283994	751	760	treatment	T061	C0087111
27283994	788	794	growth	T043	C0007595
27283994	799	808	migration	T043	C1622501
27283994	823	838	cell morphology	T201	C1521816
27283994	858	871	concentration	T081	C1446561
27283994	884	894	skin cells	T025	C0814995
27283994	911	920	untreated	T033	C0332155
27283994	921	926	group	T098	C1257890
27283994	928	935	In vivo	T082	C1515655
27283994	936	947	experiments	T062	C0681814
27283994	960	964	mice	T015	C0026809
27283994	965	977	treated with	T061	C0332293
27283994	978	985	juglone	T109,T121	C0064170
27283994	1000	1013	wound healing	T040	C0043240
27283994	1031	1035	skin	T022	C1123023
27283994	1036	1046	morphology	T080	C0332437
27283994	1051	1059	collagen	T116	C0009325
27283994	1060	1070	deposition	T169	C0333562
27283994	1080	1093	vehicle group	T096	C0009932
27283994	1108	1115	juglone	T109,T121	C0064170
27283994	1130	1140	activation	T044	C3822610
27283994	1148	1158	expression	T045	C1171362
27283994	1162	1167	Cdc42	T116,T126	C0082645
27283994	1169	1173	Rac1	T116,T126	C0139880
27283994	1179	1184	Î±-pak	T116,T126	C0299856
27283994	1188	1199	HaCaT cells	T025	C0007634
27283994	1217	1225	enhanced	T052	C2349975
27283994	1226	1238	angiogenesis	T042	C0302600
27283994	1242	1259	endothelial cells	T025	C0225336
27283994	1261	1267	HUVECs	T025	C3179121
27283994	1270	1277	Juglone	T109,T121	C0064170
27283994	1293	1308	MAPKs signaling	T044	C0752320
27283994	1312	1322	activation	T044	C3822610
27283994	1326	1329	ERK	T116,T126	C0600388
27283994	1331	1334	JNK	T116,T126	C0248813
27283994	1340	1343	p38	T116,T126	C1120843
27283994	1344	1352	proteins	T116,T123	C0033684
27283994	1394	1401	juglone	T109,T121	C0064170
27283994	1435	1448	wound healing	T040	C0043240
27283994	1453	1457	skin	T022	C1123023
27283994	1458	1470	regeneration	T042	C0034963
27283994	1477	1488	ameliorates	T080	C0205556
27283994	1489	1502	wound healing	T040	C0043240
27283994	1513	1522	promoting	T052	C0033414
27283994	1523	1527	skin	T022	C1123023
27283994	1528	1542	cell migration	T043	C1622501
27283994	1551	1555	Rac1	T116,T126	C0139880
27283994	1558	1563	Cdc42	T116,T126	C0082645
27283994	1566	1569	PAK	T116,T126	C0072402
27283994	1570	1577	pathway	T043	C0037083

27284118|t|Tibia stress fracture secondary to obsessive compulsive disorder
27284118|a|Obsessive compulsive disorder (OCD) is a chronic psychiatric disorder characterized by obsessions and compulsions. Early-onset OCD is one of the most common mental illnesses of children and adolescents, with a prevalence of 1% to 3%. It is related to worse lifespan symptoms and prognosis. Therefore, the treatment of OCD in children and adolescent has gained importance. If it is not treated successfully, the compulsive behaviors may cause extreme stress for children and their parents. Although minor complications of OCD are commonly observed, major complications are considerably rare due to the nature of compulsive behaviors. Apparently, loss of vision, autocastration, rectal prolapse are examples of major complications secondary to OCD. As far as we know, it is the first case of tibia stress fracture secondary to OCD. In the present case report, we will discuss tibia stress fracture developing secondary to compulsive behavior due to OCD.
27284118	0	21	Tibia stress fracture	T037	C2711399
27284118	35	64	obsessive compulsive disorder	T048	C0028768
27284118	65	94	Obsessive compulsive disorder	T048	C0028768
27284118	96	99	OCD	T048	C0028768
27284118	106	134	chronic psychiatric disorder	T048	C0870281
27284118	152	162	obsessions	T048	C0233697
27284118	167	178	compulsions	T048	C0600104
27284118	180	191	Early-onset	T033	C1833334
27284118	192	195	OCD	T048	C0028768
27284118	222	238	mental illnesses	T048	C0004936
27284118	242	250	children	T100	C0008059
27284118	255	266	adolescents	T100	C0205653
27284118	275	285	prevalence	T081	C0033105
27284118	322	330	lifespan	T102	C0870809
27284118	331	339	symptoms	T184	C1457887
27284118	344	353	prognosis	T058	C0033325
27284118	370	379	treatment	T061	C0087111
27284118	383	386	OCD	T048	C0028768
27284118	390	398	children	T100	C0008059
27284118	403	413	adolescent	T100	C0205653
27284118	450	457	treated	T169	C1522326
27284118	476	496	compulsive behaviors	T048	C0600104
27284118	515	521	stress	T048	C0038443
27284118	526	534	children	T100	C0008059
27284118	545	552	parents	T099	C0030551
27284118	569	582	complications	T078	C2362589
27284118	586	589	OCD	T048	C0028768
27284118	619	632	complications	T078	C2362589
27284118	650	654	rare	T080	C0522498
27284118	676	696	compulsive behaviors	T048	C0600104
27284118	710	724	loss of vision	T047	C1398668
27284118	726	740	autocastration	T037	C0178314
27284118	742	757	rectal prolapse	T047	C0034888
27284118	780	793	complications	T078	C2362589
27284118	807	810	OCD	T048	C0028768
27284118	855	876	tibia stress fracture	T037	C2711399
27284118	890	893	OCD	T048	C0028768
27284118	910	921	case report	T170	C0085973
27284118	939	960	tibia stress fracture	T037	C2711399
27284118	985	1004	compulsive behavior	T048	C0600104
27284118	1012	1015	OCD	T048	C0028768

27284491|t|Mutation profiles of synchronous colorectal cancers from a patient with Lynch syndrome suggest distinct oncogenic pathways
27284491|a|Patients with Lynch syndrome often present with multiple synchronous or metachronous colorectal cancers (CRCs). The presence of multiple CRCs with distinct genetic profiles and driver mutations could complicate treatment as each cancer may respond differently to therapy. Studies of sporadic CRCs suggested that synchronous tumors have distinct etiologies, but could not rule out differences in genetic background. The presence of multiple cancers in a patient with a predisposing mutation provides an opportunity to profile synchronous cancers in the same genetic background. Here, we describe the case of a patient with Lynch syndrome that presented with six synchronous CRCs. Microsatellite instability (MSI) and genomic profiling indicated that each lesion had a unique pattern of instability and a distinct profile of affected genes. These findings support the idea that in Lynch syndrome, synchronous CRCs can develop in parallel with distinct mutation profiles and that these differences may inform treatment decisions.
27284491	0	8	Mutation	T045	C0026882
27284491	9	17	profiles	T169	C2003903
27284491	21	32	synchronous	T191	C0027663
27284491	33	51	colorectal cancers	T191	C1527249
27284491	59	66	patient	T101	C0030705
27284491	72	86	Lynch syndrome	T191	C1333990
27284491	104	113	oncogenic	T191	C0596263
27284491	114	122	pathways	T077	C1705987
27284491	123	131	Patients	T101	C0030705
27284491	137	151	Lynch syndrome	T191	C1333990
27284491	171	191	multiple synchronous	T191	C0027663
27284491	195	207	metachronous	T191	C1334703
27284491	208	226	colorectal cancers	T191	C1527249
27284491	228	232	CRCs	T191	C1527249
27284491	251	259	multiple	T081	C0439064
27284491	260	264	CRCs	T191	C1527249
27284491	279	295	genetic profiles	T059	C2986505
27284491	307	316	mutations	T045	C0026882
27284491	323	333	complicate	T169	C0231242
27284491	334	343	treatment	T169	C0039798
27284491	352	358	cancer	T191	C0006826
27284491	363	370	respond	T032	C0871261
27284491	371	382	differently	T080	C1705242
27284491	386	393	therapy	T061	C0087111
27284491	406	414	sporadic	T033	C1853237
27284491	415	419	CRCs	T191	C1527249
27284491	435	453	synchronous tumors	T191	C0027663
27284491	459	478	distinct etiologies	T169	C0015127
27284491	518	536	genetic background	T032	C4042916
27284491	554	570	multiple cancers	T191	C0346429
27284491	576	583	patient	T101	C0030705
27284491	591	603	predisposing	T169	C0231203
27284491	604	612	mutation	T045	C0026882
27284491	625	636	opportunity	T062	C0683937
27284491	640	647	profile	T169	C2003903
27284491	648	667	synchronous cancers	T191	C0027663
27284491	680	698	genetic background	T032	C4042916
27284491	732	739	patient	T101	C0030705
27284491	745	759	Lynch syndrome	T191	C1333990
27284491	784	795	synchronous	T191	C0027663
27284491	796	800	CRCs	T191	C1527249
27284491	802	828	Microsatellite instability	T046	C0920269
27284491	830	833	MSI	T046	C0920269
27284491	839	856	genomic profiling	T059	C2986505
27284491	877	883	lesion	T033	C0221198
27284491	890	896	unique	T080	C1710548
27284491	897	904	pattern	T082	C0449774
27284491	908	919	instability	T033	C1444783
27284491	926	942	distinct profile	T169	C2003903
27284491	946	960	affected genes	T028	C0017337
27284491	968	976	findings	T169	C2607943
27284491	1002	1016	Lynch syndrome	T191	C1333990
27284491	1018	1034	synchronous CRCs	T191	C0027663
27284491	1073	1081	mutation	T045	C0026882
27284491	1082	1090	profiles	T169	C2003903
27284491	1129	1148	treatment decisions	T033	C4061230

27284493|t|Sensitization to the motor stimulant effects of 3,4-methylenedioxypyrovalerone (MDPV) and cross-sensitization to methamphetamine in rats
27284493|a|In recent years, there has been a dramatic increase in abuse of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV), often in combination with other illicit stimulants. We sought to determine if repeated exposure to MDPV would produce sensitization to the motor stimulant effects of the drug, and whether cross-sensitization would develop with the stimulant effects of methamphetamine (METH). Male Sprague-Dawley rats were administered MDPV (1 or 5 mg/kg) or saline once daily for 5 days at 24 hour intervals, or were administered MDPV (1 mg/kg) or saline once daily for 5 days at 48 hour intervals. For cross-sensitization experiments, rats were administered METH (1 mg/kg) or MDPV (1 or 5 mg/kg) once daily for 5 days at 48 hour intervals, and following a 5 day incubation period, were given an acute challenge injection of either MDPV (0.5 mg/kg) or METH (0.5 mg/kg), respectively. Rats repeatedly administered MDPV (1 mg/kg) every 48 hours, but not every 24 hours, demonstrated increased motor activity when given either a subsequent challenge of MDPV (0.5 mg/kg i.p.) or METH (0.5 mg/kg), indicating the development of behavioral sensitization and cross-sensitization, respectively. Moreover, rats repeatedly administered METH (1 mg/kg) every 48 hours did not exhibit cross-sensitization to the motor stimulating effects of a subsequent challenge with MDPV (0.5 mg/kg). These results suggest that specific patterns of MDPV administration may lead to lasting changes in behavioral responses to subsequent METH exposure.
27284493	0	13	Sensitization	T040	C1325847
27284493	21	26	motor	T025	C0026609
27284493	27	36	stimulant	T121	C0304402
27284493	37	44	effects	T080	C1280500
27284493	48	78	3,4-methylenedioxypyrovalerone	T109	C2974592
27284493	80	84	MDPV	T109	C2974592
27284493	90	109	cross-sensitization	T040	C1325847
27284493	113	128	methamphetamine	T109,T131	C0025611
27284493	132	136	rats	T015	C0086893
27284493	147	152	years	T079	C0439234
27284493	180	188	increase	T081	C0205217
27284493	192	197	abuse	T048	C0013146
27284493	205	224	synthetic cathinone	T109,T121	C0054876
27284493	225	255	3,4-methylenedioxypyrovalerone	T109	C2974592
27284493	257	261	MDPV	T109	C2974592
27284493	273	284	combination	T080	C0205195
27284493	296	303	illicit	T169	C0332266
27284493	304	314	stimulants	T121	C0304402
27284493	342	350	repeated	T169	C0205341
27284493	351	362	exposure to	T080	C0332157
27284493	363	367	MDPV	T109	C2974592
27284493	382	395	sensitization	T040	C1325847
27284493	403	408	motor	T025	C0026609
27284493	409	418	stimulant	T121	C0304402
27284493	419	426	effects	T080	C1280500
27284493	434	438	drug	T121	C0013227
27284493	452	471	cross-sensitization	T040	C1325847
27284493	478	485	develop	T169	C1527148
27284493	495	504	stimulant	T121	C0304402
27284493	505	512	effects	T080	C1280500
27284493	516	531	methamphetamine	T109,T131	C0025611
27284493	533	537	METH	T109,T131	C0025611
27284493	540	544	Male	T032	C0086582
27284493	545	564	Sprague-Dawley rats	T015	C0034715
27284493	570	582	administered	T081	C0001555
27284493	583	587	MDPV	T109	C2974592
27284493	606	612	saline	T167	C0036082
27284493	613	623	once daily	T079	C0556983
27284493	630	634	days	T079	C0439228
27284493	641	645	hour	T079	C0439227
27284493	646	655	intervals	T079	C1272706
27284493	665	677	administered	T081	C0001555
27284493	678	682	MDPV	T109	C2974592
27284493	696	702	saline	T167	C0036082
27284493	703	713	once daily	T079	C0556983
27284493	720	724	days	T079	C0439228
27284493	731	735	hour	T079	C0439227
27284493	736	745	intervals	T079	C1272706
27284493	751	770	cross-sensitization	T040	C1325847
27284493	771	782	experiments	T062	C0205664
27284493	784	788	rats	T015	C0034715
27284493	794	806	administered	T081	C0001555
27284493	807	811	METH	T109,T131	C0025611
27284493	825	829	MDPV	T109	C2974592
27284493	845	855	once daily	T079	C0556983
27284493	862	866	days	T079	C0439228
27284493	873	877	hour	T079	C0439227
27284493	878	887	intervals	T079	C1272706
27284493	907	910	day	T079	C0439228
27284493	911	928	incubation period	T033	C1320226
27284493	960	969	injection	T122	C1272883
27284493	980	984	MDPV	T109	C2974592
27284493	1000	1004	METH	T109,T131	C0025611
27284493	1032	1036	Rats	T015	C0034715
27284493	1037	1047	repeatedly	T169	C0205341
27284493	1048	1060	administered	T081	C0001555
27284493	1061	1065	MDPV	T109	C2974592
27284493	1085	1090	hours	T079	C0439227
27284493	1109	1114	hours	T079	C0439227
27284493	1129	1138	increased	T081	C0205217
27284493	1139	1153	motor activity	T033	C0243095
27284493	1198	1202	MDPV	T109	C2974592
27284493	1223	1227	METH	T109,T131	C0025611
27284493	1256	1281	development of behavioral	T040	C2825534
27284493	1282	1295	sensitization	T040	C1325847
27284493	1300	1319	cross-sensitization	T040	C1325847
27284493	1345	1349	rats	T015	C0034715
27284493	1361	1373	administered	T081	C0001555
27284493	1374	1378	METH	T109,T131	C0025611
27284493	1398	1403	hours	T079	C0439227
27284493	1420	1439	cross-sensitization	T040	C1325847
27284493	1447	1452	motor	T025	C0026609
27284493	1453	1464	stimulating	T070	C1948023
27284493	1465	1472	effects	T080	C1280500
27284493	1504	1508	MDPV	T109	C2974592
27284493	1528	1535	results	T169	C1274040
27284493	1558	1566	patterns	T082	C0449774
27284493	1570	1574	MDPV	T109	C2974592
27284493	1575	1589	administration	T081	C0001555
27284493	1621	1631	behavioral	T053	C0004927
27284493	1632	1641	responses	T032	C0871261
27284493	1656	1660	METH	T109,T131	C0025611
27284493	1661	1669	exposure	T080	C0332157

27284958|t|Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies
27284958|a|Activating, nonamplification ERBB2 mutations (ERBB2mut) are not detected by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), but are detected by DNA sequencing and may predict clinical responses to human epidermal growth factor receptor (HER2)- targeted therapy. The authors queried 5605 advanced/metastatic breast cancers (mBC) to uncover the frequency of ERBB2mut genomic alterations. Clinical responses to anti-HER2 therapeutics were identified. DNA was extracted from 40 Âµm of formalin-fixed paraffin-embedded (FFPE) sections. Comprehensive genomic profiling (CGP) was used to evaluate up to 315 genes (592Ã mean coverage depth). Results were analyzed for base substitutions, short indels, copy number changes, and selected rearrangements. Of 5605 cases, 698 (12.5%) featured ERBB2 alterations, including 596 (10.6%) ERBB2 amplifications (ERBB2amp) and 138 (2.4%) ERBB2mut; 38 cases (0.7%) had co-occurring ERBB2amp and ERBB2mut. ERBB2mut predominantly affected the kinase (124 cases; 90%) or extracellular (15 cases; 11%) domains. Both primary BC (52 cases; 38%) and metastatic site biopsies (86 cases; 62%) were found to harbor ERBB2mut, which were distributed across carcinoma not otherwise specified (NOS) (69 cases; 50%), invasive ductal carcinoma (IDC) (40 cases; 29%), invasive lobular carcinoma (ILC) (27 cases; 20%), and mucinous mBC (2 cases; 1%). Genes commonly coaltered with ERBB2 were tumor protein 53 (TP53) (49%); phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) (42%); cadherin 1, type 1 (CDH1) (37%); MYC (17%); and cyclin D1 protein (CCND1) (16%). CDH1 mutations were enriched in ERBB2mut mBC (P<0.0006) and associated with recurrent mBC. Selected patients with ERBB2mut, without ERBB2amp, who responded to anti-HER2 targeted therapies are presented herein. Within this large series, 1.8% of cases harbored ERBB2mut, which are undetectable by standard-of-care IHC or FISH tests. Metastatic BC driven by ERBB2mut respond to anti-HER2 targeted therapies, and expanding clinical trials designed to detect ERBB2mut by CGP and optimize targeted treatments are warranted. Cancer 2016. Â© 2016 American Cancer Society. Cancer 2016;122:2654-2662. Â© 2016 American Cancer Society.
27284958	0	16	Nonamplification	T033	C0243095
27284958	17	22	ERBB2	T028	C0242957
27284958	23	42	genomic alterations	T045	C0596611
27284958	51	56	cases	T169	C0868928
27284958	60	69	recurrent	T191	C0278493
27284958	74	98	metastatic breast cancer	T191	C0278488
27284958	128	137	anti-HER2	T033	C0243095
27284958	138	156	targeted therapies	T061	C3854476
27284958	169	185	nonamplification	T033	C0243095
27284958	186	191	ERBB2	T028	C0242957
27284958	192	201	mutations	T045	C0596611
27284958	203	211	ERBB2mut	T028	C0678941
27284958	233	253	immunohistochemistry	T060	C0021044
27284958	255	258	IHC	T060	C0021044
27284958	263	297	fluorescence in situ hybridization	T063	C0162789
27284958	299	303	FISH	T063	C0162789
27284958	326	340	DNA sequencing	T059	C1294197
27284958	357	375	clinical responses	T033	C4055223
27284958	379	417	human epidermal growth factor receptor	T116,T126,T192	C1702024
27284958	419	423	HER2	T116,T126,T192	C1702024
27284958	426	442	targeted therapy	T061	C3854476
27284958	469	503	advanced/metastatic breast cancers	T191	C0278488
27284958	505	508	mBC	T191	C0278488
27284958	525	534	frequency	T079	C0439603
27284958	538	546	ERBB2mut	T028	C0678941
27284958	547	566	genomic alterations	T045	C0596611
27284958	568	586	Clinical responses	T033	C4055223
27284958	590	599	anti-HER2	T033	C0243095
27284958	600	612	therapeutics	T061	C0087111
27284958	618	628	identified	T080	C0205396
27284958	630	633	DNA	T114,T123	C0012854
27284958	662	710	formalin-fixed paraffin-embedded (FFPE) sections	T024	C2711483
27284958	712	743	Comprehensive genomic profiling	T059	C0022885
27284958	745	748	CGP	T059	C0022885
27284958	781	786	genes	T028	C0017337
27284958	815	822	Results	T169	C1274040
27284958	841	859	base substitutions	T045	C1158746
27284958	861	873	short indels	T045	C1956002
27284958	875	894	copy number changes	T045	C2717926
27284958	900	923	selected rearrangements	T045	C0017287
27284958	933	938	cases	T169	C0868928
27284958	961	966	ERBB2	T028	C0242957
27284958	967	978	alterations	T045	C0596611
27284958	1002	1007	ERBB2	T028	C0242957
27284958	1008	1022	amplifications	T045	C0017256
27284958	1024	1032	ERBB2amp	T045	C0017256
27284958	1049	1057	ERBB2mut	T028	C0678941
27284958	1062	1067	cases	T169	C0868928
27284958	1092	1100	ERBB2amp	T045	C0017256
27284958	1105	1113	ERBB2mut	T028	C0678941
27284958	1115	1123	ERBB2mut	T028	C0678941
27284958	1151	1157	kinase	T116,T126	C0031727
27284958	1163	1168	cases	T169	C0868928
27284958	1178	1191	extracellular	T026	C0521119
27284958	1208	1215	domains	T082	C1517050
27284958	1222	1232	primary BC	T191	C0678222
27284958	1237	1242	cases	T169	C0868928
27284958	1253	1268	metastatic site	T033	C0280457
27284958	1269	1277	biopsies	T060	C0005558
27284958	1282	1287	cases	T169	C0868928
27284958	1315	1323	ERBB2mut	T028	C0678941
27284958	1355	1364	carcinoma	T191	C0007097
27284958	1399	1404	cases	T169	C0868928
27284958	1412	1437	invasive ductal carcinoma	T191	C1134719
27284958	1439	1442	IDC	T191	C1134719
27284958	1448	1453	cases	T169	C0868928
27284958	1461	1487	invasive lobular carcinoma	T191	C0279565
27284958	1489	1492	ILC	T191	C0279565
27284958	1498	1503	cases	T169	C0868928
27284958	1515	1527	mucinous mBC	T191	C1334807
27284958	1531	1536	cases	T169	C0868928
27284958	1543	1548	Genes	T028	C0017337
27284958	1573	1578	ERBB2	T028	C0242957
27284958	1584	1600	tumor protein 53	T028	C0079419
27284958	1602	1606	TP53	T028	C0079419
27284958	1615	1668	phosphatidylinositol 3-kinase catalytic subunit alpha	T028	C1335212
27284958	1670	1676	PIK3CA	T028	C1335212
27284958	1685	1703	cadherin 1, type 1	T028	C0694872
27284958	1705	1709	CDH1	T028	C0694872
27284958	1718	1721	MYC	T028	C0086661
27284958	1733	1750	cyclin D1 protein	T028	C1413172
27284958	1752	1757	CCND1	T028	C1413172
27284958	1766	1770	CDH1	T028	C0694872
27284958	1771	1780	mutations	T045	C0596611
27284958	1798	1806	ERBB2mut	T028	C0678941
27284958	1807	1810	mBC	T191	C0278488
27284958	1826	1841	associated with	T080	C0332281
27284958	1842	1855	recurrent mBC	UnknownType	C0741681
27284958	1866	1874	patients	T101	C0030705
27284958	1880	1888	ERBB2mut	T028	C0678941
27284958	1898	1906	ERBB2amp	T045	C0017256
27284958	1925	1934	anti-HER2	T033	C0243095
27284958	1935	1953	targeted therapies	T061	C3854476
27284958	2010	2015	cases	T169	C0868928
27284958	2025	2033	ERBB2mut	T028	C0678941
27284958	2061	2077	standard-of-care	T061	C2936643
27284958	2078	2081	IHC	T060	C0021044
27284958	2085	2095	FISH tests	T063	C0162789
27284958	2097	2110	Metastatic BC	T191	C0278488
27284958	2121	2129	ERBB2mut	T028	C0678941
27284958	2141	2150	anti-HER2	T033	C0243095
27284958	2151	2169	targeted therapies	T061	C3854476
27284958	2185	2200	clinical trials	T062	C0008976
27284958	2220	2228	ERBB2mut	T028	C0678941
27284958	2232	2235	CGP	T059	C0022885
27284958	2249	2268	targeted treatments	T061	C3854476

27285457|t|PROTECTIVE EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON PROGRESSION OF DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES
27285457|a|To investigate the effects of dipeptidyl peptidase-4 inhibitors (DPP4) on the progression of diabetic retinopathy (DR) in patients with Type 2 diabetes based on the DR severity scale. The medical records of 82 patients with Type 2 diabetes enrolled from 2005 to 2015 were retrospectively reviewed. Fundus photographs were graded using Early Treatment Diabetic Retinopathy Study methods. The associations between baseline risk factors and progression of DR were investigated. Seven of 28 patients treated with DPP4 inhibitors and 26 of 54 treated with other hypoglycemic agents showed progression of retinopathy, defined as one or more steps on the Early Treatment Diabetic Retinopathy Study scale (P = 0.043). Only treatment with DPP4 inhibitors significantly reduced the progression of DR in patients after propensity score matching (P = 0.009). Treatment with DPP4 inhibitors was associated with a lower risk of DR progression (P = 0.011). Treatment with DPP4 inhibitors was the independent protective factor against the progression of DR, aside from improving glycemic control. This is the first study to show the benefits of DPP4 inhibitors in reducing DR progression, and provides encouraging preliminary data for further evaluation of DPP4 inhibitors in the progression of DR in a randomized, double-blind, placebo-controlled trial.
27285457	0	21	PROTECTIVE EFFECTS OF	T080	C1704420
27285457	22	55	DIPEPTIDYL PEPTIDASE-4 INHIBITORS	T121	C1827106
27285457	59	70	PROGRESSION	T046	C0242656
27285457	74	94	DIABETIC RETINOPATHY	T047	C0011884
27285457	98	106	PATIENTS	T101	C0030705
27285457	112	127	TYPE 2 DIABETES	T047	C0011860
27285457	131	142	investigate	T169	C1292732
27285457	147	157	effects of	T080	C1704420
27285457	158	191	dipeptidyl peptidase-4 inhibitors	T121	C1827106
27285457	193	197	DPP4	T121	C1827106
27285457	206	217	progression	T046	C0242656
27285457	221	241	diabetic retinopathy	T047	C0011884
27285457	243	245	DR	T047	C0011884
27285457	250	258	patients	T101	C0030705
27285457	264	279	Type 2 diabetes	T047	C0011860
27285457	293	295	DR	T047	C0011884
27285457	296	310	severity scale	T081	C0392762
27285457	316	331	medical records	T170	C0025102
27285457	338	346	patients	T101	C0030705
27285457	352	367	Type 2 diabetes	T047	C0011860
27285457	400	415	retrospectively	T080	C1514923
27285457	416	424	reviewed	T080	C1709940
27285457	426	444	Fundus photographs	T060	C0200189
27285457	450	456	graded	T185	C0441800
27285457	463	513	Early Treatment Diabetic Retinopathy Study methods	T170	C3899277
27285457	519	531	associations	T080	C0332281
27285457	540	548	baseline	T081	C1442488
27285457	549	561	risk factors	T033	C0035648
27285457	566	577	progression	T046	C0242656
27285457	581	583	DR	T047	C0011884
27285457	589	601	investigated	T169	C1292732
27285457	615	623	patients	T101	C0030705
27285457	624	631	treated	T169	C1522326
27285457	637	652	DPP4 inhibitors	T121	C1827106
27285457	666	673	treated	T169	C1522326
27285457	685	704	hypoglycemic agents	T121	C0020616
27285457	712	723	progression	T046	C0242656
27285457	727	738	retinopathy	T047	C0011884
27285457	776	824	Early Treatment Diabetic Retinopathy Study scale	T081	C0392762
27285457	843	852	treatment	T169	C1522326
27285457	858	873	DPP4 inhibitors	T121	C1827106
27285457	888	895	reduced	T080	C0392756
27285457	900	911	progression	T046	C0242656
27285457	915	917	DR	T047	C0011884
27285457	921	929	patients	T101	C0030705
27285457	936	952	propensity score	T081	C2718044
27285457	975	984	Treatment	T169	C1522326
27285457	990	1005	DPP4 inhibitors	T121	C1827106
27285457	1010	1025	associated with	T080	C0332281
27285457	1028	1033	lower	T052	C2003888
27285457	1034	1038	risk	T078	C0035647
27285457	1042	1044	DR	T047	C0011884
27285457	1045	1056	progression	T046	C0242656
27285457	1070	1079	Treatment	T169	C1522326
27285457	1085	1100	DPP4 inhibitors	T121	C1827106
27285457	1109	1120	independent	T078	C0085862
27285457	1121	1138	protective factor	T169	C1521761
27285457	1151	1162	progression	T046	C0242656
27285457	1166	1168	DR	T047	C0011884
27285457	1181	1207	improving glycemic control	T033	C0243095
27285457	1245	1253	benefits	T081	C0814225
27285457	1257	1272	DPP4 inhibitors	T121	C1827106
27285457	1276	1284	reducing	T080	C0392756
27285457	1285	1287	DR	T047	C0011884
27285457	1288	1299	progression	T046	C0242656
27285457	1326	1337	preliminary	T079	C0439611
27285457	1338	1342	data	T078	C1511726
27285457	1355	1365	evaluation	T058	C0220825
27285457	1369	1384	DPP4 inhibitors	T121	C1827106
27285457	1392	1403	progression	T046	C0242656
27285457	1407	1409	DR	T047	C0011884
27285457	1415	1425	randomized	T062	C0034656
27285457	1427	1439	double-blind	T062	C0013072
27285457	1441	1465	placebo-controlled trial	T062,T170	C0599724

27285494|t|Parasympathetic Activity and Bronchial Hyperresponsiveness in Athletes
27285494|a|A high prevalence of asthma and bronchial hyperresponsiveness (BHR) is reported in swimmers and cross-country skiers. It has been suggested that increased parasympathetic nervous activity is involved in asthma development in endurance athletes. We aimed to assess the associations of BHR to parasympathetic activity in healthy and asthmatic swimmers and cross-country skiers and healthy non athletes. Parasympathetic activity was measured by pupillometry and heart rate variability at the onset of exercise with the cardiac vagal index calculated in 28 cross-country skiers (â18/â10), 29 swimmers (â17/â12), and 30 healthy nonathlete controls (â14/â16) on two different days. All subjects performed a methacholine bronchial challenge with the provocation dose causing 20% decrease in the forced expiratory volume in 1 s calculated (PD20met). Data were analyzed by robust regression analysis and presented as Î² coefficients with 95% confidence intervals (CI). PD20met was negatively associated with cardiac vagal index (-13.9, 95% CI = -26.8 to -1.0) in all subjects. When adjusted to the type of sport, this association was stronger in swimmers (-8.3, 95% CI = -13.0 to -3.6) as compared with controls and nonsignificant in cross-country skiers. Percent pupil constriction was significantly associated with PD20met in swimmers (-9.4, 95% CI = -15.4 to -3.4) only after adjusting for the type of sport. Fourteen swimmers (48%) and 16 cross-country skiers (57%) had doctor-diagnosed asthma in combination with current BHR and/or current use of asthma drugs. Seventy-two percent swimmers, 44% cross-country skiers, and 39% controls had a PD20met â¤8 Î¼mol (P = 0.015). Fourteen swimmers had a PD20met â¤2 Î¼mol as compared with one cross-country skier (P < 0.001). Parasympathetic activity measured in the heart is more closely related to BHR as compared with parasympathetic activity measured in the pupils. The type of sport influences BHR severity and its relationship to parasympathetic activity.
27285494	0	15	Parasympathetic	T023	C0459522
27285494	16	24	Activity	T043	C0234075
27285494	29	58	Bronchial Hyperresponsiveness	T047	C0085129
27285494	62	70	Athletes	T097	C0238703
27285494	73	88	high prevalence	T081	C1512456
27285494	92	98	asthma	T047	C0004096
27285494	103	132	bronchial hyperresponsiveness	T047	C0085129
27285494	134	137	BHR	T047	C0085129
27285494	154	162	swimmers	T098	C0450068
27285494	167	187	cross-country skiers	T033	C0425040
27285494	216	225	increased	T081	C0205217
27285494	226	241	parasympathetic	T023	C0459522
27285494	242	258	nervous activity	T043	C0234075
27285494	274	280	asthma	T047	C0004096
27285494	296	305	endurance	T033	C0518031
27285494	306	314	athletes	T097	C0238703
27285494	328	334	assess	T058	C0184514
27285494	355	358	BHR	T047	C0085129
27285494	362	377	parasympathetic	T023	C0459522
27285494	378	386	activity	T043	C0234075
27285494	390	397	healthy	T080	C3898900
27285494	402	411	asthmatic	T047	C0004096
27285494	412	420	swimmers	T098	C0450068
27285494	425	445	cross-country skiers	T033	C0425040
27285494	450	457	healthy	T080	C3898900
27285494	462	470	athletes	T097	C0238703
27285494	472	487	Parasympathetic	T023	C0459522
27285494	488	496	activity	T043	C0234075
27285494	501	509	measured	T080	C0444706
27285494	513	525	pupillometry	T060	C0260180
27285494	530	540	heart rate	T201	C0018810
27285494	541	552	variability	T077	C2827666
27285494	560	568	onset of	T080	C0332162
27285494	569	577	exercise	T056	C0015259
27285494	587	606	cardiac vagal index	T081	C0392762
27285494	624	644	cross-country skiers	T033	C0425040
27285494	772	784	methacholine	T109,T121	C0600370
27285494	785	804	bronchial challenge	T060	C2061924
27285494	814	825	provocation	T067	C0449428
27285494	826	830	dose	T081	C0178602
27285494	891	901	calculated	T052	C1441506
27285494	903	910	PD20met	T121	C1254351
27285494	913	917	Data	T078	C1511726
27285494	923	931	analyzed	T062	C0936012
27285494	935	941	robust	T080	C2986815
27285494	942	961	regression analysis	T170	C0034980
27285494	1003	1023	confidence intervals	T081	C0009667
27285494	1025	1027	CI	T081	C0009667
27285494	1030	1037	PD20met	T121	C1254351
27285494	1053	1068	associated with	T080	C0332281
27285494	1069	1088	cardiac vagal index	T081	C0392762
27285494	1101	1103	CI	T081	C0009667
27285494	1128	1136	subjects	T098	C0080105
27285494	1167	1172	sport	T056	C0038039
27285494	1207	1215	swimmers	T098	C0450068
27285494	1227	1229	CI	T081	C0009667
27285494	1264	1272	controls	T096	C0009932
27285494	1295	1315	cross-country skiers	T033	C0425040
27285494	1325	1343	pupil constriction	T047	C0026205
27285494	1362	1377	associated with	T080	C0332281
27285494	1378	1385	PD20met	T121	C1254351
27285494	1389	1397	swimmers	T098	C0450068
27285494	1409	1411	CI	T081	C0009667
27285494	1466	1471	sport	T056	C0038039
27285494	1482	1490	swimmers	T098	C0450068
27285494	1504	1524	cross-country skiers	T033	C0425040
27285494	1535	1558	doctor-diagnosed asthma	T047	C3843752
27285494	1587	1590	BHR	T047	C0085129
27285494	1613	1619	asthma	T047	C0004096
27285494	1620	1625	drugs	T121	C1254351
27285494	1647	1655	swimmers	T098	C0450068
27285494	1661	1681	cross-country skiers	T033	C0425040
27285494	1691	1699	controls	T096	C0009932
27285494	1706	1713	PD20met	T121	C1254351
27285494	1744	1752	swimmers	T098	C0450068
27285494	1759	1766	PD20met	T121	C1254351
27285494	1796	1815	cross-country skier	T033	C0425040
27285494	1829	1844	Parasympathetic	T023	C0459522
27285494	1845	1853	activity	T043	C0234075
27285494	1854	1862	measured	T080	C0444706
27285494	1870	1875	heart	T023	C0018787
27285494	1903	1906	BHR	T047	C0085129
27285494	1924	1939	parasympathetic	T023	C0459522
27285494	1940	1948	activity	T043	C0234075
27285494	1949	1957	measured	T080	C0444706
27285494	1965	1971	pupils	T023	C0034121
27285494	1985	1990	sport	T056	C0038039
27285494	2002	2005	BHR	T047	C0085129
27285494	2039	2054	parasympathetic	T023	C0459522
27285494	2055	2063	activity	T043	C0234075

27286118|t|The relationship between histological prostatitis and lower urinary tract symptoms and sexual function
27286118|a|This prospective analysis assessed the effect of histological prostatitis on lower urinary tract functions and sexual function. The patients were separated into two groups as histologically observed prostatitis (Group A) and no prostatitis (Group B) according to the biopsy outcomes. International prostate symptom score, international index of erectile function-5 scores, maximal and average flow rate, and residual urine volumes were compared statistically between groups. There was no significant difference (P>0.05) in baseline age (t=0.64), body mass index value (t=0.51), prostate volume (t=0.87), prostate-specific antigen levels (t=0.43), maximal (t=0.84) and average flow rate (t=0.59), and post-void residual urine volume (t=0.71). Mean international prostate symptom score in patients with prostatitis was numerically but not significantly higher than that in those without prostatitis (t=0.794, P=0.066). Mean international index of erectile function-5 score in the prostatitis group was significantly lower than that in those without prostatitis (t=1.854, P=0.013). Histological prostatitis notably affected sexual function of patients and may serve as a major risk factor for sexual dysfunction while having little effect on lower urinary tract symptoms.
27286118	4	16	relationship	T080	C0439849
27286118	25	37	histological	T169	C0205462
27286118	38	49	prostatitis	T047	C0033581
27286118	54	82	lower urinary tract symptoms	T184	C0574785
27286118	87	102	sexual function	T040	C0278092
27286118	108	128	prospective analysis	T062	C0033522
27286118	129	137	assessed	T052	C1516048
27286118	142	148	effect	T080	C1280500
27286118	152	164	histological	T169	C0205462
27286118	165	176	prostatitis	T047	C0033581
27286118	180	199	lower urinary tract	T022	C0729866
27286118	200	209	functions	T169	C0542341
27286118	214	229	sexual function	T040	C0278092
27286118	235	243	patients	T101	C0030705
27286118	249	258	separated	T080	C0443299
27286118	268	274	groups	T078	C0441833
27286118	278	292	histologically	T169	C0205462
27286118	293	301	observed	T169	C1441672
27286118	302	313	prostatitis	T047	C0033581
27286118	315	322	Group A	T078	C0441833
27286118	328	342	no prostatitis	T033	C0243095
27286118	344	351	Group B	T078	C0441833
27286118	370	376	biopsy	T060	C0005558
27286118	377	385	outcomes	T169	C1274040
27286118	387	423	International prostate symptom score	T170	C1998280
27286118	425	474	international index of erectile function-5 scores	T201	C2959364
27286118	476	483	maximal	T033	C0429784
27286118	488	505	average flow rate	T033	C0429785
27286118	511	533	residual urine volumes	T033	C0429774
27286118	539	547	compared	T052	C1707455
27286118	570	576	groups	T078	C0441833
27286118	591	602	significant	T081	C0237881
27286118	603	613	difference	T080	C1705242
27286118	626	634	baseline	T081	C1442488
27286118	635	638	age	T032	C0001779
27286118	649	670	body mass index value	T201	C1305855
27286118	681	696	prostate volume	T081	C1441416
27286118	707	739	prostate-specific antigen levels	T059	C0201544
27286118	750	757	maximal	T033	C0429784
27286118	771	788	average flow rate	T033	C0429785
27286118	803	812	post-void	T079	C1439885
27286118	813	834	residual urine volume	T033	C0429774
27286118	845	849	Mean	T081	C0444504
27286118	850	886	international prostate symptom score	T170	C1998280
27286118	890	898	patients	T101	C0030705
27286118	904	915	prostatitis	T047	C0033581
27286118	920	931	numerically	T081	C0243174
27286118	940	960	significantly higher	T081	C4055637
27286118	980	987	without	T080	C0332288
27286118	988	999	prostatitis	T047	C0033581
27286118	1020	1024	Mean	T081	C0444504
27286118	1025	1073	international index of erectile function-5 score	T201	C2959364
27286118	1081	1092	prostatitis	T047	C0033581
27286118	1093	1098	group	T078	C0441833
27286118	1103	1122	significantly lower	T081	C4055638
27286118	1142	1149	without	T080	C0332288
27286118	1150	1161	prostatitis	T047	C0033581
27286118	1182	1194	Histological	T169	C0205462
27286118	1195	1206	prostatitis	T047	C0033581
27286118	1215	1223	affected	T169	C0392760
27286118	1224	1239	sexual function	T040	C0278092
27286118	1243	1251	patients	T101	C0030705
27286118	1271	1276	major	T080	C0205164
27286118	1277	1288	risk factor	T033	C0035648
27286118	1293	1311	sexual dysfunction	T047	C0549622
27286118	1332	1338	effect	T080	C1280500
27286118	1342	1370	lower urinary tract symptoms	T184	C0574785

27286174|t|Beyond " Median Waiting Time ": Development and Validation of a Competing Risk Model to Predict Outcomes on the Kidney Transplant Waiting List
27286174|a|Median historical time to kidney transplant is misleading because it does not convey the competing risks of death or removal from the waiting list. We developed and validated a competing risk model to calculate likelihood of outcomes for kidney transplant candidates and demonstrate how this information differs from median time to transplant. Data were obtained from the US Scientific Registry of Transplant Recipients. The retrospective cohort included 163 636 adults listed for kidney transplant before December 31, 2011. Predictors were age, sex, blood type, calculated panel-reactive antibodies, donation service area, dialysis duration, comorbid conditions, and body mass index. Outcomes were deceased or living donor transplant, death or removal from the list due to deteriorating medical condition, or removal due to other reasons. We calculated hazards for the possible outcomes, then the cumulative incidence function for a given candidate using competing risk methodology. Discrimination and calibration were assessed through C statistics and calibration plots for each cause - specific Cox proportional hazard model. C statistics ranged from 0.64 to 0.73. Calibration plots showed good calibration. The competing risk model shows probability of all possible outcomes for up to 12 years given a candidate's characteristics, contrasted with the median waiting time for that candidate's donation service area. A competing risk model conveys more relevant information than the median waiting time for a given transplant center. This model will be updated to create a calculator reflecting the most recent outcomes and changes in allocation policy. It illustrates the conversations that should be initiated with transplant candidates.
27286174	9	15	Median	T081	C0876920
27286174	16	28	Waiting Time	T079	C0814636
27286174	32	43	Development	T169	C1527148
27286174	48	58	Validation	T062	C1519941
27286174	74	84	Risk Model	UnknownType	C0679713
27286174	88	95	Predict	T078	C0681842
27286174	96	104	Outcomes	T169	C1274040
27286174	112	118	Kidney	T023	C0022646
27286174	119	142	Transplant Waiting List	T170	C3272315
27286174	143	149	Median	T081	C0876920
27286174	150	160	historical	T079	C0019659
27286174	161	165	time	T079	C0040223
27286174	169	186	kidney transplant	T061	C0022671
27286174	242	247	risks	T078	C0035647
27286174	251	256	death	T040	C0011065
27286174	260	289	removal from the waiting list	T033	C0420299
27286174	330	340	risk model	UnknownType	C0679713
27286174	344	353	calculate	T052	C1441506
27286174	368	376	outcomes	T080	C0085415
27286174	381	398	kidney transplant	T061	C0022671
27286174	399	409	candidates	T098	C0524355
27286174	435	446	information	T078	C1533716
27286174	447	454	differs	T080	C1705242
27286174	460	466	median	T081	C0876920
27286174	467	471	time	T079	C0814636
27286174	475	485	transplant	T061	C0022671
27286174	487	491	Data	T078	C1511726
27286174	497	505	obtained	T169	C1301820
27286174	515	537	US Scientific Registry	T170	C0034975
27286174	541	562	Transplant Recipients	T101	C0376387
27286174	568	588	retrospective cohort	T062	C2985505
27286174	606	612	adults	T100	C0001675
27286174	624	641	kidney transplant	T061	C0022671
27286174	668	678	Predictors	T033	C0035648
27286174	684	687	age	T032	C0001779
27286174	689	692	sex	T032	C0079399
27286174	694	704	blood type	T201	C1383165
27286174	706	716	calculated	T059	C1443182
27286174	717	742	panel-reactive antibodies	T059	C1141951
27286174	744	752	donation	T061	C0411257
27286174	753	765	service area	T083	C0007403
27286174	767	775	dialysis	T061	C0011946
27286174	776	784	duration	T079	C0449238
27286174	786	805	comorbid conditions	T033	C1275743
27286174	811	826	body mass index	T201	C1305855
27286174	828	836	Outcomes	T080	C0085415
27286174	854	866	living donor	T098	C0348050
27286174	867	877	transplant	T061	C0022671
27286174	879	884	death	T040	C0011065
27286174	888	909	removal from the list	T033	C0420299
27286174	910	916	due to	T169	C0678226
27286174	917	930	deteriorating	T080	C0332271
27286174	931	938	medical	T169	C0205476
27286174	939	948	condition	T080	C0348080
27286174	953	960	removal	T033	C0420299
27286174	961	967	due to	T169	C0678226
27286174	968	981	other reasons	T033	C3840932
27286174	986	996	calculated	T169	C0444686
27286174	997	1004	hazards	T080	C0598697
27286174	1013	1021	possible	T033	C0332149
27286174	1022	1030	outcomes	T080	C0085415
27286174	1041	1051	cumulative	T080	C1511559
27286174	1052	1061	incidence	T081	C0021149
27286174	1062	1070	function	T039	C0031843
27286174	1083	1092	candidate	T098	C0524355
27286174	1109	1113	risk	T078	C0035647
27286174	1114	1125	methodology	T078	C3266812
27286174	1127	1141	Discrimination	T041	C0012632
27286174	1146	1157	calibration	T081	C0006751
27286174	1163	1171	assessed	T052	C1516048
27286174	1172	1179	through	T169	C0332273
27286174	1180	1192	C statistics	UnknownType	C0681933
27286174	1197	1208	calibration	T081	C0006751
27286174	1209	1214	plots	T169	C1301732
27286174	1219	1223	each	T081	C1457900
27286174	1224	1229	cause	T169	C0015127
27286174	1232	1240	specific	T080	C0205369
27286174	1241	1270	Cox proportional hazard model	T081,T170	C0018623
27286174	1272	1284	C statistics	UnknownType	C0681933
27286174	1311	1322	Calibration	T081	C0006751
27286174	1323	1328	plots	T169	C1301732
27286174	1336	1340	good	T080	C0205170
27286174	1341	1352	calibration	T081	C0006751
27286174	1368	1378	risk model	UnknownType	C0679713
27286174	1385	1396	probability	T081	C0033204
27286174	1404	1412	possible	T033	C0332149
27286174	1413	1421	outcomes	T080	C0085415
27286174	1432	1440	12 years	T079	C0439234
27286174	1449	1460	candidate's	T098	C0524355
27286174	1461	1476	characteristics	T080	C1521970
27286174	1498	1504	median	T081	C0876920
27286174	1505	1517	waiting time	T079	C0814636
27286174	1527	1538	candidate's	T098	C0524355
27286174	1539	1547	donation	T061	C0411257
27286174	1548	1560	service area	T083	C0007403
27286174	1574	1584	risk model	UnknownType	C0679713
27286174	1598	1606	relevant	T080	C2347946
27286174	1607	1618	information	T078	C1533716
27286174	1628	1634	median	T081	C0876920
27286174	1635	1647	waiting time	T079	C0814636
27286174	1654	1659	given	T077	C1442162
27286174	1660	1677	transplant center	T093	C1708333
27286174	1684	1689	model	T081	C0033204
27286174	1698	1705	updated	T079	C1519814
27286174	1709	1715	create	T052	C1706214
27286174	1749	1755	recent	T079	C0332185
27286174	1756	1764	outcomes	T080	C0085415
27286174	1769	1776	changes	T169	C0392747
27286174	1780	1790	allocation	T052	C1706778
27286174	1791	1797	policy	T170	C0242456
27286174	1818	1831	conversations	T054	C0871703
27286174	1847	1856	initiated	T169	C1704686
27286174	1862	1872	transplant	T061	C0022671
27286174	1873	1883	candidates	T098	C0524355

27286333|t|Chemical Composition and Biological Activity of Essential Oils from Different Species of Piper from Panama
27286333|a|The chemical composition of leaf essential oils from 11 species of Piper from Panama was analyzed by a combination GC-FID and GC-MS procedures. Six of them had sesquiterpene hydrocarbons as major constituents, three were characterized by monoterpene hydrocarbons, one by a diterpene, and one by a phenylpropanoid, dillapiole. The main components identified in each species were: cembratrienol (25.4 %) in Piper augustum; Î²-pinene (26.6 %) in Piper corrugatum; Î±-pinene (19.4 %) in Piper curtispicum; trans-Î²-farnesene (63.7 %) in Piper darienense; p-cymene (43.9 %) in Piper grande; dillapiole (57.7 %) in Piper hispidum; linalool (14.5 %), Î±-phellandrene (13.8 %), and limonene (12.2 %) in Piper jacquemontianum; Î²-caryophyllene (45.2 %) in Piper longispicum; linalool (16.5 %), Î±-phellandrene (11.8 %), limonene (11.4 %), and p-cymene (9.0 %) in Piper multiplinervium; Î²-selinene (19.0 %), Î²-elemene (16.1 %), and Î±-selinene (15.5 %) in Piper reticulatum; and germacrene D (19.7 %) in Piper trigonum. The essential oils of P. hispidum and P. longispicum at a concentration of 250 Âµg/mL showed larvicidal activity against Aedes aegypti, while the oils from P. curtispicum, P. multiplinervium, P. reticulatum, and P. trigonum were inactive (LC100 â¥ 500 Âµg/mL). The essential oils of P. grande, P. jacquemontianum, and P. multiplinervium showed no significant antifungal activity (MIC > 250 Âµg/mL) against several yeasts and filamentous fungal strains.
27286333	0	20	Chemical Composition	T070	C0243176
27286333	25	44	Biological Activity	T052	C0441655
27286333	48	62	Essential Oils	T109	C0028910
27286333	78	85	Species	T185	C1705920
27286333	89	94	Piper	T002	C0330232
27286333	100	106	Panama	T083	C0030266
27286333	111	131	chemical composition	T070	C0243176
27286333	135	139	leaf	T002	C0242724
27286333	140	154	essential oils	T109	C0028910
27286333	163	170	species	T185	C1705920
27286333	174	179	Piper	T002	C0330232
27286333	185	191	Panama	T083	C0030266
27286333	210	221	combination	T080	C0205195
27286333	222	228	GC-FID	T059	C0201752
27286333	233	249	GC-MS procedures	T059	C0024868
27286333	267	280	sesquiterpene	T109	C0036847
27286333	281	293	hydrocarbons	T109	C0020242
27286333	297	315	major constituents	T167	C0729650
27286333	328	341	characterized	T052	C1880022
27286333	345	356	monoterpene	T109	C0682997
27286333	357	369	hydrocarbons	T109	C0020242
27286333	380	389	diterpene	T109	C0012780
27286333	404	419	phenylpropanoid	T109	C0029224
27286333	421	431	dillapiole	T109,T123	C1567161
27286333	472	479	species	T185	C1705920
27286333	486	499	cembratrienol	T109	C0029224
27286333	512	526	Piper augustum	T002	C1062974
27286333	528	536	Î²-pinene	T109	C0076109
27286333	549	565	Piper corrugatum	T002	C0330232
27286333	567	575	Î±-pinene	T109,T130	C0051459
27286333	588	605	Piper curtispicum	T002	C2642369
27286333	607	624	trans-Î²-farnesene	T109	C0053429
27286333	637	653	Piper darienense	T002	C1062985
27286333	655	663	p-cymene	T109,T121	C0048220
27286333	676	688	Piper grande	T002	C2642388
27286333	690	700	dillapiole	T109,T123	C1567161
27286333	713	727	Piper hispidum	T002	C1062989
27286333	729	737	linalool	T109,T121	C0064997
27286333	748	762	Î±-phellandrene	T109	C0602210
27286333	777	785	limonene	T109,T121	C0064992
27286333	798	819	Piper jacquemontianum	T002	C2272006
27286333	821	836	Î²-caryophyllene	T109,T121	C0525503
27286333	849	866	Piper longispicum	T002	C1469484
27286333	868	876	linalool	T109,T121	C0064997
27286333	887	901	Î±-phellandrene	T109	C0602210
27286333	912	920	limonene	T109,T121	C0064992
27286333	935	943	p-cymene	T109,T121	C0048220
27286333	955	976	Piper multiplinervium	T002	C1090358
27286333	978	988	Î²-selinene	T109	C0256149
27286333	999	1008	Î²-elemene	T109,T123	C1101268
27286333	1023	1033	Î±-selinene	T109	C2714569
27286333	1046	1063	Piper reticulatum	T002	C1062997
27286333	1069	1081	germacrene D	T109	C0119091
27286333	1094	1108	Piper trigonum	T002	C2642474
27286333	1114	1128	essential oils	T109	C0028910
27286333	1132	1143	P. hispidum	T002	C1062989
27286333	1148	1162	P. longispicum	T002	C1469484
27286333	1168	1181	concentration	T081	C1446561
27286333	1202	1221	larvicidal activity	T033	C2825141
27286333	1230	1243	Aedes aegypti	T204	C0322859
27286333	1255	1259	oils	T109	C0028910
27286333	1265	1279	P. curtispicum	T002	C2642369
27286333	1281	1299	P. multiplinervium	T002	C1090358
27286333	1301	1315	P. reticulatum	T002	C1062997
27286333	1321	1332	P. trigonum	T002	C2642474
27286333	1338	1346	inactive	T081	C1705605
27286333	1372	1386	essential oils	T109	C0028910
27286333	1390	1399	P. grande	T002	C2642388
27286333	1401	1419	P. jacquemontianum	T002	C2272006
27286333	1425	1443	P. multiplinervium	T002	C1090358
27286333	1466	1485	antifungal activity	T044	C1321381
27286333	1520	1526	yeasts	T004	C0043393
27286333	1531	1557	filamentous fungal strains	T004	C0369241

27286759|t|Spatial analysis of drug poisoning deaths in the American West, particularly Utah
27286759|a|Most states in the Western US have high rates of drug poisoning death (DPD), especially New Mexico, Nevada, Arizona and Utah (UT). This seems paradoxical in UT where illicit drug use, smoking and drinking rates are low. To investigate this, spatial analysis of county level DPD data and other relevant factors in the Western US and UT was undertaken. Poisson kriging was used to smooth the DPD data, populate data gaps and improve the reliability of rates recorded in sparsely populated counties. Links between DPD and economic, environmental, health, lifestyle, and demographic factors were investigated at four scales using multiple linear regression. LDS church membership and altitude, factors not previously considered, were included. Spatial change in the strength and sign of relationships was investigated using geographically weighted regression and significant DPD clusters were identified using the Local Moran's I. Economic factors, like the sharp social gradient between rural and urban areas were important to DPD throughout the west. Higher DPD rates were also found in areas of higher elevation and the desert rural areas in the south. The unique characteristics of DPD in UT in terms of health and lifestyle factors, as well as the demographic structure of DPD in the most LDS populous states (UT, Idaho, Wyoming), suggest that high DPD in heavily LDS areas are predominantly prescription opioid related whereas in other Western states a larger proportion of DPD might come from illicit drugs. Drug policies need to be adapted to the geographical differences in the dominant type of drug causing death. Educational materials need to be marketed to the demographic groups at greatest risk and take into account differences in population characteristics between and within States. Some suggestions about how such adaptations can be made are given and future research needs outlined.
27286759	0	16	Spatial analysis	T062	C0814926
27286759	20	34	drug poisoning	T037	C0013221
27286759	35	41	deaths	T040	C0011065
27286759	49	62	American West	T083	C0041703
27286759	77	81	Utah	T083	C0042124
27286759	87	93	states	T083	C1301808
27286759	101	111	Western US	T083	C0041703
27286759	122	127	rates	T081	C0205848
27286759	131	145	drug poisoning	T037	C0013221
27286759	146	151	death	T040	C0011065
27286759	153	156	DPD	T040	C0011065
27286759	170	180	New Mexico	T083	C0027972
27286759	182	188	Nevada	T083	C0027951
27286759	190	197	Arizona	T083	C0003787
27286759	202	206	Utah	T083	C0042124
27286759	208	210	UT	T083	C0042124
27286759	224	235	paradoxical	T080	C0205310
27286759	239	241	UT	T083	C0042124
27286759	248	264	illicit drug use	T055	C0281875
27286759	266	273	smoking	T055	C0037369
27286759	278	292	drinking rates	T055	C0001948
27286759	297	300	low	T080	C0205251
27286759	323	339	spatial analysis	T062	C0814926
27286759	343	349	county	T083	C0079170
27286759	356	359	DPD	T040	C0011065
27286759	360	364	data	T078	C1511726
27286759	375	383	relevant	T080	C2347946
27286759	384	391	factors	T169	C1521761
27286759	399	409	Western US	T083	C0041703
27286759	414	416	UT	T083	C0042124
27286759	433	448	Poisson kriging	T062	C3494287
27286759	472	475	DPD	T040	C0011065
27286759	476	480	data	T078	C1511726
27286759	491	495	data	T078	C1511726
27286759	517	528	reliability	T081	C2347947
27286759	532	537	rates	T081	C0205848
27286759	550	577	sparsely populated counties	T083	C0079170
27286759	593	596	DPD	T040	C0011065
27286759	601	609	economic	T081	C0205749
27286759	611	624	environmental	T169	C1516998
27286759	626	632	health	T078	C0018684
27286759	634	643	lifestyle	T054	C0023676
27286759	649	668	demographic factors	T078	C0011292
27286759	708	734	multiple linear regression	T081	C0023733
27286759	736	757	LDS church membership	UnknownType	C0683988
27286759	762	770	altitude	T081	C0002349
27286759	772	779	factors	T169	C1521761
27286759	822	836	Spatial change	T082	C0012727
27286759	844	852	strength	T078	C0808080
27286759	865	878	relationships	T080	C0439849
27286759	902	936	geographically weighted regression	T081	C4046053
27286759	953	956	DPD	T040	C0011065
27286759	957	965	clusters	T081	C1704332
27286759	992	1007	Local Moran's I	T062	C3825653
27286759	1009	1025	Economic factors	T081	C0205749
27286759	1042	1048	social	T169	C0728831
27286759	1049	1057	gradient	T081	C0812409
27286759	1066	1071	rural	T082	C0178837
27286759	1076	1087	urban areas	T082	C0178876
27286759	1106	1109	DPD	T040	C0011065
27286759	1131	1137	Higher	T080	C0205250
27286759	1138	1147	DPD rates	T081	C0205848
27286759	1167	1172	areas	T082	C0205146
27286759	1176	1182	higher	T080	C0205250
27286759	1183	1192	elevation	T082	C0702240
27286759	1201	1219	desert rural areas	T082	C0178837
27286759	1227	1232	south	T082	C1710133
27286759	1245	1260	characteristics	T080	C1521970
27286759	1264	1267	DPD	T040	C0011065
27286759	1271	1273	UT	T083	C0042124
27286759	1286	1292	health	T033	C0810377
27286759	1297	1306	lifestyle	T054	C0023676
27286759	1331	1352	demographic structure	T102	C0683970
27286759	1356	1359	DPD	T040	C0011065
27286759	1372	1391	LDS populous states	T083	C1301808
27286759	1393	1395	UT	T083	C0042124
27286759	1397	1402	Idaho	T083	C0020787
27286759	1404	1411	Wyoming	T083	C0043287
27286759	1432	1435	DPD	T040	C0011065
27286759	1439	1456	heavily LDS areas	T083	C0017446
27286759	1488	1494	opioid	T109,T121,T131	C0242402
27286759	1520	1534	Western states	T083	C0041703
27286759	1558	1561	DPD	T040	C0011065
27286759	1578	1591	illicit drugs	T131	C0086190
27286759	1593	1606	Drug policies	UnknownType	C0683727
27286759	1633	1657	geographical differences	T033	C0935553
27286759	1665	1673	dominant	T169	C1527180
27286759	1682	1686	drug	T121	C0013227
27286759	1695	1700	death	T040	C0011065
27286759	1702	1723	Educational materials	T065	C2919937
27286759	1735	1743	marketed	T080	C3640197
27286759	1751	1769	demographic groups	T078	C0441833
27286759	1773	1781	greatest	T081	C0205393
27286759	1782	1786	risk	T078	C0035647
27286759	1809	1820	differences	T080	C1705242
27286759	1824	1850	population characteristics	T102	C0032661
27286759	1870	1876	States	T083	C1301808
27286759	1883	1894	suggestions	T078	C1705535

27287100|t|Electrochemically assisted deposition of strontium modified magnesium phosphate on titanium surfaces
27287100|a|Electrochemically assisted deposition was utilized to produce ceramic coatings on the basis of magnesium ammonium phosphate (struvite) on corundum - blasted titanium surfaces. By the addition of defined concentrations of strontium nitrate to the coating electrolyte Sr(2+) ions were successfully incorporated into the struvite matrix. By variation of deposition parameters it was possible to fabricate coatings with different kinetics of Sr(2+) into physiological media, whereas the release of therapeutically relevant strontium doses could be sustained over several weeks. Morphological and crystallographic examinations of the immersed coatings revealed that the degradation of struvite and the release of Sr(2+) ions were accompanied by a transformation of the coating to a calcium phosphate based phase similar to low-crystalline hydroxyapatite. These findings showed that strontium doped struvite coatings may provide a promising degradable coating system for the local application of strontium or other biologically active metal ions in the implant-bone interface.
27287100	0	37	Electrochemically assisted deposition	T169	C0333562
27287100	41	50	strontium	T196	C0038467
27287100	60	79	magnesium phosphate	T121,T197	C0065527
27287100	83	91	titanium	T196	C0040302
27287100	92	100	surfaces	T082	C0205148
27287100	101	138	Electrochemically assisted deposition	T169	C0333562
27287100	163	170	ceramic	T073	C0007742
27287100	171	179	coatings	T080	C1522408
27287100	196	224	magnesium ammonium phosphate	T123,T197	C0126771
27287100	226	234	struvite	T123,T197	C0075338
27287100	239	247	corundum	T197	C0086065
27287100	250	257	blasted	T070	C0337026
27287100	258	266	titanium	T196	C0040302
27287100	267	275	surfaces	T082	C0205148
27287100	322	339	strontium nitrate	T121,T197	C0536786
27287100	347	354	coating	T080	C1522408
27287100	355	366	electrolyte	T121,T197	C0013832
27287100	367	378	Sr(2+) ions	T196	C0038467
27287100	397	409	incorporated	T169	C0243126
27287100	419	427	struvite	T123,T197	C0075338
27287100	428	434	matrix	T109,T121	C4050026
27287100	452	462	deposition	T169	C0333562
27287100	463	473	parameters	T077	C0549193
27287100	503	511	coatings	T080	C1522408
27287100	527	535	kinetics	T070	C0022702
27287100	539	545	Sr(2+)	T196	C0038467
27287100	595	610	therapeutically	T169	C0302350
27287100	611	619	relevant	T080	C2347946
27287100	620	629	strontium	T196	C0038467
27287100	630	635	doses	T081	C0178602
27287100	668	673	weeks	T079	C0439230
27287100	675	688	Morphological	T082	C0543482
27287100	693	722	crystallographic examinations	T059	C0022885
27287100	730	738	immersed	T080	C0205556
27287100	739	747	coatings	T080	C1522408
27287100	766	777	degradation	T169	C0243125
27287100	781	789	struvite	T123,T197	C0075338
27287100	798	805	release	T169	C0391871
27287100	809	820	Sr(2+) ions	T196	C0038467
27287100	843	857	transformation	T039	C3714584
27287100	865	872	coating	T080	C1522408
27287100	878	895	calcium phosphate	T121,T197	C0006711
27287100	919	949	low-crystalline hydroxyapatite	T197	C0020326
27287100	957	965	findings	T169	C2607943
27287100	978	987	strontium	T196	C0038467
27287100	994	1002	struvite	T123,T197	C0075338
27287100	1003	1011	coatings	T080	C1522408
27287100	1036	1046	degradable	T169	C0243125
27287100	1047	1054	coating	T080	C1522408
27287100	1055	1061	system	T169	C0449913
27287100	1091	1100	strontium	T196	C0038467
27287100	1110	1129	biologically active	T123	C0566267
27287100	1130	1140	metal ions	T197	C0025552
27287100	1148	1170	implant-bone interface	T030	C4042803

27287247|t|Inflamed skin predisposes to sensitization to less potent allergens
27287247|a|Irritant dermatitis, caused by genetic barrier dysfunction in atopic dermatitis or wet work in hand dermatitis, induces innate immune response that might predispose to allergic contact sensitization to less potent sensitizers. We sought to determine if positive patch test results to less potent allergens are more prevalent in patients with a history of childhood flexural dermatitis or current wet work. We examined our database of patients presenting to a contact dermatitis clinic tested to potential contact allergens as indicated by their history. Allergens from our most recent standard were studied if they could be classified as weak, moderate, or strong sensitizers based on published data from the local lymph node assay. Patients were stratified by a history of childhood - onset flexural dermatitis as a proxy for atopic dermatitis and by occupation. History of childhood - onset dermatitis predisposed to contact allergy to weak sensitizers and wet work to medium - potency sensitizers. Neither predisposed to contact allergy from strong sensitizers. Association cannot prove causation. We conclude that strong sensitizers do not require wet work or atopy to cause sensitization. Barrier defects associated with childhood eczema and wet work may promote sensitization to weak antigens.
27287247	0	8	Inflamed	T169	C0333348
27287247	9	13	skin	T022	C1123023
27287247	14	25	predisposes	T169	C0231203
27287247	29	42	sensitization	T040	C1325847
27287247	46	50	less	T080	C0205251
27287247	51	57	potent	T077	C4054723
27287247	58	67	allergens	T129	C0002092
27287247	68	87	Irritant dermatitis	T047	C0162823
27287247	99	114	genetic barrier	T169	C0314603
27287247	115	126	dysfunction	T077	C3887504
27287247	130	147	atopic dermatitis	T047	C0011615
27287247	151	159	wet work	T057	C0443352
27287247	163	178	hand dermatitis	T047	C0239816
27287247	180	187	induces	T169	C0205263
27287247	188	210	innate immune response	T032	C0020969
27287247	222	232	predispose	T169	C0231203
27287247	236	252	allergic contact	T047	C0162820
27287247	253	266	sensitization	T040	C1325847
27287247	270	274	less	T080	C0205251
27287247	275	281	potent	T077	C4054723
27287247	282	293	sensitizers	T129	C0002092
27287247	321	340	positive patch test	T034	C0856592
27287247	341	348	results	T169	C1274040
27287247	352	356	less	T080	C0205251
27287247	357	363	potent	T077	C4054723
27287247	364	373	allergens	T129	C0002092
27287247	378	392	more prevalent	T081	C1512456
27287247	396	404	patients	T101	C0030705
27287247	412	432	history of childhood	T033	C0489532
27287247	433	452	flexural dermatitis	T047	C0263224
27287247	456	472	current wet work	T057	C0443352
27287247	490	498	database	T170	C0242356
27287247	502	510	patients	T101	C0030705
27287247	527	545	contact dermatitis	T047	C0011616
27287247	546	552	clinic	T073,T093	C0442592
27287247	553	559	tested	T169	C0039593
27287247	563	572	potential	T080	C3245505
27287247	573	590	contact allergens	T129	C1320247
27287247	613	620	history	T058	C0679831
27287247	622	631	Allergens	T129	C0002092
27287247	653	661	standard	T080	C1442989
27287247	667	674	studied	T062	C2603343
27287247	706	710	weak	T080	C1762617
27287247	712	720	moderate	T080	C0205081
27287247	725	731	strong	T080	C0442821
27287247	732	743	sensitizers	T129	C0002092
27287247	753	767	published data	T170	C0993637
27287247	777	799	local lymph node assay	T081	C0887969
27287247	801	809	Patients	T169	C0314603
27287247	815	825	stratified	T080	C0205363
27287247	831	851	history of childhood	T033	C0489532
27287247	854	879	onset flexural dermatitis	T047	C0263224
27287247	895	912	atopic dermatitis	T047	C0011615
27287247	920	930	occupation	T033	C0421456
27287247	932	952	History of childhood	T033	C0489532
27287247	955	971	onset dermatitis	T047	C0011615
27287247	972	983	predisposed	T169	C0231203
27287247	987	1002	contact allergy	T047	C0162820
27287247	1006	1010	weak	T080	C1762617
27287247	1011	1022	sensitizers	T129	C0002092
27287247	1027	1035	wet work	T057	C0443352
27287247	1039	1045	medium	T081	C0439536
27287247	1048	1055	potency	T077	C4054723
27287247	1056	1067	sensitizers	T129	C0002092
27287247	1077	1088	predisposed	T169	C0231203
27287247	1092	1107	contact allergy	T047	C0162820
27287247	1113	1119	strong	T080	C0442821
27287247	1120	1131	sensitizers	T129	C0002092
27287247	1133	1144	Association	T080	C0439849
27287247	1158	1167	causation	T078	C0085978
27287247	1186	1192	strong	T080	C0442821
27287247	1193	1204	sensitizers	T129	C0002092
27287247	1220	1228	wet work	T057	C0443352
27287247	1232	1237	atopy	T046	C0392707
27287247	1247	1260	sensitization	T040	C1325847
27287247	1262	1277	Barrier defects	T169	C1457869
27287247	1278	1293	associated with	T080	C0332281
27287247	1294	1310	childhood eczema	T047	C1276071
27287247	1315	1323	wet work	T057	C0443352
27287247	1328	1335	promote	T052	C0033414
27287247	1336	1349	sensitization	T040	C1325847
27287247	1353	1357	weak	T080	C1762617
27287247	1358	1366	antigens	T129	C0003320

27288403|t|Transcription rate and transcript length drive formation of chromosomal interaction domain boundaries
27288403|a|Chromosomes in all organisms are highly organized and divided into multiple chromosomal interaction domains, or topological domains. Regions of active, high transcription help establish and maintain domain boundaries, but precisely how this occurs remains unclear. Here, using fluorescence microscopy and chromosome conformation capture in conjunction with deep sequencing (Hi-C), we show that in Caulobacter crescentus, both transcription rate and transcript length, independent of concurrent translation, drive the formation of domain boundaries. We find that long, highly expressed genes do not form topological boundaries simply through the inhibition of supercoil diffusion. Instead, our results support a model in which long, active regions of transcription drive local decompaction of the chromosome, with these more open regions of the chromosome forming spatial gaps in vivo that diminish contacts between DNA in neighboring domains. These insights into the molecular forces responsible for domain formation in Caulobacter likely generalize to other bacteria and possibly eukaryotes.
27288403	0	13	Transcription	T045	C0040649
27288403	14	18	rate	T081	C1521828
27288403	23	33	transcript	T114	C1519595
27288403	34	40	length	T081	C1444754
27288403	47	56	formation	T169	C1522492
27288403	60	101	chromosomal interaction domain boundaries	T026	C1953345
27288403	102	113	Chromosomes	T026	C0008633
27288403	121	130	organisms	T001	C0029235
27288403	142	151	organized	T169	C1300196
27288403	156	163	divided	T169	C0332849
27288403	169	177	multiple	T081	C0439064
27288403	178	209	chromosomal interaction domains	T026	C1953345
27288403	214	233	topological domains	T026	C1953345
27288403	259	272	transcription	T045	C0040649
27288403	301	318	domain boundaries	T026	C1953345
27288403	358	365	unclear	T033	C3845108
27288403	379	402	fluorescence microscopy	T059	C0026022
27288403	459	474	deep sequencing	T063	C2936624
27288403	499	521	Caulobacter crescentus	T007	C0085449
27288403	528	541	transcription	T045	C0040649
27288403	542	546	rate	T081	C1521828
27288403	551	561	transcript	T114	C1519595
27288403	562	568	length	T081	C1444754
27288403	570	584	independent of	T169	C0332291
27288403	596	607	translation	T045	C1519614
27288403	619	628	formation	T169	C1522492
27288403	632	649	domain boundaries	T026	C1953345
27288403	687	692	genes	T028	C0017337
27288403	705	727	topological boundaries	T026	C1953345
27288403	747	757	inhibition	T052	C3463820
27288403	813	818	model	T170	C0026343
27288403	852	865	transcription	T045	C0040649
27288403	931	956	regions of the chromosome	T026	C1953345
27288403	965	977	spatial gaps	T082	C3887622
27288403	978	985	in vivo	T082	C1515655
27288403	1017	1020	DNA	T114,T123	C0012854
27288403	1036	1043	domains	T026	C1953345
27288403	1069	1085	molecular forces	T067	C0441722
27288403	1102	1108	domain	T026	C1953345
27288403	1109	1118	formation	T169	C1522492
27288403	1122	1133	Caulobacter	T007	C0085448
27288403	1161	1169	bacteria	T007	C0004611
27288403	1183	1193	eukaryotes	T204	C0684063